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“Life is not easy for any of us. But what of that? We must have perseverance and above all 
confidence in ourselves. We must believe that we are gifted for something and that this thing must be 
attained”. 
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Marie Curie 
 
 
“Above all, don’t fear difficult moments. The best comes from them”.  
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Neurogenesis is a multiple step process that must be tightly regulated or otherwise results in 
pathological events. Therefore, a deep characterization of the molecular mechanisms that control the 
biology of neural stem/progenitor cells (NSPCs) will provide a better understanding of the role of 
neurogenic niches and new therapeutic strategies for neurodegenerative diseases and brain tumours. 
In this thesis we have analyzed the regulation of NSCs fate by the transcription factor Nuclear 
factor (erythroid-derived 2)-like 2 (NRF2), which is considered a master regulator of cellular 
homeostasis, and the Transcriptional co-activator with PDZ-binding motif (TAZ), a major effector of the 
Hippo pathway. NRF2 controls the expression of a wide battery of cytoprotective genes that have a 
tremendous impact on physiological responses such as inflammation, senescence or metabolism. 
However, its relevance in neurogenesis is just starting to be unveiled. On the other hand, TAZ is a major 
effector of the Hippo pathway, which plays a key role in tissue homeostasis and organ size control by 
regulating tissue-specific stem cells. However, the implication of TAZ in neurogenesis has not been 
analyzed. 
In this study, we have identified NRF2 as a regulator of hippocampal NSCs self-renewal and 
differentiation. We show that genetic manipulation of NRF2 results in the modulation of NSPCs 
differentiation and proliferation capacity. To assess the functional relevance of NRF2 in neurogenesis 
under pathological conditions, we analyzed the impact of NRF2 deficiency in neurogenesis of the 
subgranular zone (SGZ) of the hippocampus in a mouse model of Alzheimer´s Disease (AD). We found 
that NRF2 deficiency results in an accelerated loss of NSCs, loss of synaptic plasticity measured as long 
term potentiation (LTP) and impaired the execution of cognitive tasks. 
At the molecular level, we have identified NRF2 enhancer sequences, termed Antioxidant 
Response Elements (AREs), in the promoter region of the TAZ coding gene. Consequently, we show that 
genetic and pharmacological manipulation of NRF2 results in the modulation of TAZ gene expression in 
NSPCs. These findings open a new window to understand the molecular mechanisms underlying NRF2 
function in stemness. 
We have also established a novel role of TAZ as repressor of neuronal differentiation, based on 
the transcriptional repression of SOX2 and the basic helix-loop-helix (bHLH) factors ASCL1, 
NEUROG2 and NEUROD1. Data mining of The Cancer Genome Atlas showed a negative correlation 
between TAZ and the expression of these proneurogenic factors in lower grade gliomas and 
glioblastomas. We found that TAZ favours glioblastoma CSCs tumorigenic capacity and that genetic 
modulation of TAZ in these cells inversely correlated with proneurogenic genes expression. Due to the 
relevance of these proneurogenic factors in the ablation of glioblastoma cancer stem cells (CSCs), this 
novel TAZ/proneurogenic factors axis may have important implications in the development of this type 
of brain tumours.  
The characterization of molecular mechanism governing NSPCs fate provides new insights to 
harness these cells for brain repair. Overall, this thesis describes a novel role of NRF2 and TAZ in the 
control of neural stem cell fate, suggesting a new strategy to combat brain pathology. 
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La neurogénesis es un proceso con varias etapas que debe estar estrictamente regulado, en caso 
contrario, conllevaría una serie de procesos patológicos. De esta manera, una caracterización profunda de 
los mecanismos moleculares que controlan la biología de las células troncales/progenitores neurales 
(NSPCs) nos permitirá conocer mejor el papel de los nichos neurogénicos y las implicaciones en el 
desarrollo de nuevas terapias en enfermedades neurodegenerativas y tumores cerebrales.  
En esta tesis, hemos estudiado el papel del Nuclear factor (erythroid-derived 2)-like 2 (NRF2), 
considerado el maestro regulador de la homeostasis celular, y del Transcriptional co-activator with PDZ-
binding motif (TAZ), uno de los mayores efectores de la vía Hippo, en el destino de las NSPCs. NRF2 
controla la expresión de genes citoprotectores con un enorme impacto en respuestas fisiológicas como 
inflamación, senescencia o metabolismo. Sin embargo, su importancia en neurogénesis está empezando 
a ser estudiada. Por su parte, TAZ es uno de los mayores efectores de la vía Hippo, con un papel 
fundamental en la homeostasis tisular y en el control del crecimiento de los órganos, mediante la 
regulación de las células mesenquimales específicas de tejido. Sin embargo, ningún estudio previo ha 
abordado la importancia de TAZ en neurogénesis.  
En este estudio, identificamos a NRF2 como un regulador de la capacidad de auto-renovación y 
diferenciación de las NSPCs hipocampales. Mostramos cómo la manipulación genética de NRF2 conduce 
a una modulación estas capacidades en las NSPCs. Para abordar la relevancia funcional del papel que 
NRF2 juega en neurogénesis en condiciones patológicas, analizamos el impacto de NRF2 en la 
neurogénesis hipocampal del giro dentado en modelos murinos de la enfermedad de Alzhéimer. La 
ausencia de NRF2 conlleva una pérdida acelerada de NSPCs y a un deterioro de la plasticidad sináptica 
y las capacidades cognitivas. A nivel molecular, hemos identificado elementos de respuesta a NRF2, 
llamados elementos de respuesta antioxidante (AREs), en la región promotora del gen que codifica a 
TAZ. Además, la manipulación genética y farmacológica de NRF2 modula la expresión génica de TAZ 
en NSPCs. Estas observaciones abren una nueva vía para entender los mecanismos moleculares que se 
encuentran tras la función de NRF2 en el control de las células troncales. También hemos establecido un 
nuevo papel del TAZ como represor de la diferenciación neuronal, basada en la represión transcripcional 
de SOX2 y los factores hélice-bucle-hélice básica (bHLH) ASCL1, NEUROG2 y NEUROD1. Los datos 
de The Cancer Genome Atlas, muestran una correlación negativa entre TAZ y la expresión de estos 
factores proneurogénicos en gliomas de bajo grado y glioblastomas. Encontramos que TAZ favorece la 
capacidad tumorigénica en las células mesenquimales de cáncer (CSCs) en glioblastoma y que la 
modulación genética de TAZ correlaciona inversamente con la expresión de los factores proneurogénicos. 
Debido a la relevancia de estos factores proneurogénicos en la supresión de las CSCs, este nuevo eje 
TAZ/factores proneurogénicos puede tener importantes implicaciones en el desarrollo de estos tumores 
cerebrales. La caracterización de los mecanismos moleculares que gobiernan el destino de las NSPCs 
ofrece nuevas posibilidades para sacar partido a estas células en la reparación cerebral. De manera global, 
esta tesis describe un nuevo papel de NRF2 y TAZ en el control del destino de las NSPCs, ofreciendo 
una nueva estrategia para combatir la patología cerebral.  
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AcH3 Acetylated lysine 9 in histone 3. 
ACTB Actin beta. 
AD Alzheimer´s disease. 
Akt Protein kinase B. 
APC Adenomatous Polyposis Coli. 
ApoE4 Apolipoprotein E4. 
APP Amyloid precursor protein. 
ARE Antioxidant response element. 
ASCL1 Achaete-scute like 1. 
ASCL1 Human gene encoding ASCL1. 
AT APPV717I/TAUP301L. 
Aβ Amyloid beta. 
BACH1 Bric-a-brac homodimerization domain and cap ‘n’ collar homolog 1. 
BDNF Brain-derived neurotrophic factor. 
bFGF Basic fibroblast growth factor. 
bHLH Basic helix-loop-helix. 
BIRC5 Baculoviral IAP Repeat Containing 5, also known as Survivin. 
BIRC5 Human gene encoding BIRC5. 
BLBP Brain lipid-binding protein. 
BMP Bone morphogenetic protein. 
β-TrCP β-Transducing repeat-containing protein. 
BrdU 5-bromo-2'-deoxyuridine. 
Brg1 Brahma-related gene-1. 
BSA Bovine serum albumin. 
BTB Bric-a-brac homodimerization domain. 
bZIP Basic-leucine-zipper. 
CA1 Area 1 of the Cornu Ammonis. 
CA3 Area 3 of the Cornu Ammonis. 
CHD4 Chromodomain-helicase-DNA-binding protein 4. 
ChIP Chromatin immunoprecipitation assay. 
CK1 Casein kinase 1. 
CNC Cap ‘n’ collar. 
CNS Central nervous system. 
CSC Cancer stem cell. 
CSF Cerebral spinal fluid. 
CT Control. 
CTGF Connective tissue growth factor. 
CTGF Human gene encoding CTGF. 
Ctgf Murine gene encoding CTGF. 
CUL3 Cullin3. 
CYR61 Cysteine-rich, angiogenic inducer 61. 
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CYR61 Human gene encoding CYR61. 
DAB 3´-3´-diaminobenzidine tetrahydrochloride. 
DAPI 4’,6-diamidino-2-phenylindole. 
DCX Doublecortin. 
DDIT4 DNA damage inducible transcript 4. 
DG Dentate gyrus. 
Dll1 Delta-like protein 1. 
DMEM Dulbecco’s modified Eagle medium. 
DNA Deoxyribonucleic acid. 
EC Entorhinal cortex. 
ECL Enhanced chemiluminiscence. 
EDTA Ethylene diamine tetraacetic acid. 
EdU 5-ethynyl-2'-deoxyuridine. 
EGF Epidermal growth factor. 
EGTA Ethylene glycol tetraacetic acid. 
EMT Epithelial–mesenchymal transition. 
ENCODE Encyclopedia of DNA elements at the University of California Santa Cruz. 
ER Endoplasmic reticulum. 
ESC Embryonic stem cell. 
FBS Fetal bovine serum. 
fEPSP Field excitatory post-synaptic potential. 
FGF-2 Fibroblast growth factor-2. 
GABA Gamma-Aminobutyric acid. 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase. 
GB Glioblastoma. 
GBM Glioblastoma multiforme. 
GBMLGG Lower grade glioma and glioblastoma. 
GC Granular cell. 
GCL Granular cell layer. 
GCLC Glutamate-cysteine ligase catalytic subunit. 
GCLM Glutamate-cysteine ligase modifier subunit. 
GFAP Glial-fibrillary acidic protein. 
GFP Green fluorescent protein. 
GLAST Astrocytic glutamate aspartate transporter. 
GLI Glioma-associated oncogene homolog (Zinc Finger Protein). 
GSH Glutathione. 
GSK-3β Glycogen-synthetase-kinase-3 beta. 
H3 Histone 3. 
H3K27ac Acetylation at lysine 27 of histone 3. 
HBSS Hank’s balanced salt solution. 
hEGF Human epidermal growth factor. 
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HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid. 
Hes Hairy enhancer of split. 
hFGF Human fibroblast growth factor. 
HMG High-mobility group. 
HMOX1 Human gene encoding HO1. 
HO1 Heme oxygenase 1. 
HRD1 Inositol requiring enzyme/E3 ubiquitin ligase synoviolin. 
HRP Horseradish peroxidase. 
ICC Immunocytochemistry. 
IF Immunofluorescence. 
IGF-1 Insulin-like growth factor-1. 
IHC-Fr Immunohistochemistry on frozen slices. 
IHC-p Immunohistochemistry on paraffin slices. 
IPC Intermediate progenitor cell. 
IRE1 Inositol requiring enzyme. 
KDM3A Lysine demethylase 3A. 
KEAP1 Kelch-like ECH-associated protein 1. 
LATS1/2 Large tumour suppressor kinase 1/2. 
LB Luria-Bertani medium. 
LRP5/6 Low-density lipoprotein receptor related protein 5/6. 
LTP Long-term potentiation. 
MAF Small muscle aponeurosis fibromatosis. 
MAP2 Microtubule associated protein- 2. 
MOB1 Mps one binder 1. 
MPP Medial perforant path. 
MPTP 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. 
MST1/2 Serine/threonine kinases mammalian Ste20-like kinases. 
MWM Morris water maze. 
NADP Nicotinamide adenine dinucleotide phosphate. 
NDP52 Nuclear dot protein 52 kDa. 
Neh NRF2 − ECH homology. 
Nestin Neuroectodermal stem cell marker. 
NeuN Neuron nuclear protein. 
NEUROD1 Neuronal differentiation 1. 
NEUROD1 Human gene encoding NEUROD1. 
NEUROG2 Neurogenin 2. 
NEUROG2 Human gene encoding NEUROG2. 
NF2 Neurofibromin 2. 
NFE2L2 Human gene encoding NRF2. 
Nfe2l2 Murine gene encoding NRF2. 
NICD Notch intracellular domain. 
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NPC Neural progenitor cell. 
NQO1 NAD(P)H quinone dehydrogenase 1. 
NQO1 Human gene encoding NQO1. 
Nqo1 Murine gene encoding NQO1. 
NRF2 Nuclear factor (erythroid-derived 2)-like 2. 
NSC Neural stem cell. 
NSPC Neural stem/progenitor cell. 
NuRD Nucleosome remodelling and histone deacetylase. 
OB Olfactory bulb. 
PAX3 Paired box protein 3. 
PAX6 Paired box protein 6. 
PBS Phosphate buffered saline. 
PCR Polymerase chain reaction. 
PCR2 Polycomb repressive complex 2. 
PDGF-β Platelet-derived growth factor β. 
PFA Paraformaldehyde. 
PI3K Phosphoinositide 3-kinase. 
PMSF Phenylmethylsulfonyl fluoride. 
PROX1 Prospero homeobox protein 1. 
PS Presenilin. 
PSA-NCAM Polysialylated neural cell adhesion molecule. 
PSSM Position-specific scoring matrix. 
QNP Quiescent neural progenitor. 
qRT-PCR Quantitative real time polymerase chain reaction. 
RA Retinoic acid. 
RBPJ Recombining binding protein suppressor of hairless. 
RBX1 RING-box protein 1. 
RG Radial glia. 
RGL Radial glial-like cell. 
RMS Rostral migratory stream. 
RMST Rhabdomyosarcoma 2-associated transcript. 
RNA Ribonucleic acid. 
RNA Pol II RNA polymerase II. 
ROS Reactive oxygen species. 
RUNX2 Runt-related transcription factor 2. 
RXR Retinoid X receptor. 
S100β S100 calcium-binding protein B. 
SAV1 Salvador family WW domain containing protein 1. 
SCF S-phase kinase-associated protein 1–CUL1–F box containing complex. 
S.D. Standard deviation. 
SDS Sodium dodecyl sulfate. 
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SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
SEM Standard error of the mean. 
SFN R,S-sulforaphane. 
SGZ Subgranular zone. 
Shh Sonic hedgehog. 
SKP1 S-phase kinase-associated protein. 
SMAD2/3/4 Mothers against decapentaplegic homolog 2, 3 and 4. 
SOD Superoxide dismutase. 
SOX2 Sex determining region Y (SRY)-Box 2. 
SOX2 Human gene encoding SOX2. 
SV40 Simian virus 40. 
SVZ Subventricular zone. 
TAE Tris base, acetic acid and EDTA buffer. 
TAP Transit-amplifying precursor. 
TAU Neuronal microtubule associated protein. 
TAZ Transcriptional co-activator with PDZ-binding motif. 
TBP TATA box binding protein. 
TBS Tris buffered saline. 
TBX5 T-box transcription factor 5. 
TCF/LEF T-cell factor/lymphoid enhancer-binding factor. 
TCGA The cancer genome atlas. 
TE Tris-EDTA buffer. 
TEAD Transcriptional enhancer factor TEF-1. 
TEMED N N N′N′-Tetramethylethylenediamine. 
TF Transcription factor. 
TGF-β Transforming growth factor β. 
TIR TAZ interacting region. 
Trb2 T-box brain protein 2. 
TTBS Tris buffered saline with Tween 20. 
TUBB3 β-III-tubulin. 
UCSC University of California, Santa Cruz. 
VEGF Vascular endothelial growth factor. 
V-SVZ Ventricular-subventricular zone. 
VZ Ventricular zone. 
WB Western blot. 
Wnt Wingless and integrated or int-1. 
WWTR1 WW-domain containing transcriptional regulator 1. 
WWTR1 Human gene encoding TAZ. 
Wwtr1 Murine gene encoding TAZ. 
YAP Yes-associated protein. 
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1. Neurogenesis. 
 
Neurogenesis is the formation of newborn neurons derived from neural stem cells (NSCs). NSCs 
are multipotent cells with self-renewal capacity which give rise to several cell types in the central nervous 
system (CNS): astrocytes, oligodendrocytes and neurons (Kriegstein and Alvarez-Buylla, 2009). 
Although initially it was postulated that the CNS lacks regenerative capacity in adults, during the last 
decades, this idea has been questioned by several studies. In the 60s, it was probed that the formation of 
newborn neurons occurs in distinct region of the brain as the hippocampus, olfactory bulb (OB) and cortex 
in mammals (Altman, 1962; Altman J Fau - Das and Das, 1965), and songbirds (Paton and Nottebohm, 
1984; Burd and Nottebohm, 1985). During the 90s, NSCs from adult mammalian brains were isolated, 
propagated in vitro and differentiated into neurons and glia (Reynolds and Weiss, 1992; Richards et al., 
1992; Gage et al., 1995).  
 
2. Neurogenic niches. 
 
In the adult mammalian brain, NSCs are restricted to specialized brain regions known as 
neurogenic niches. The main neurogenic niches are the subventricular zone (SVZ) of the lateral walls of 
the I and II ventricles (Alvarez-Buylla and Garcia-Verdugo, 2002) and the subgranular zone (SGZ) of the 
dentate gyrus (DG) of the hippocampus (Doetsch et al., 1997). The presence of NSCs in other regions of 
the adult brain, such the neocortex and the hypothalamus, is still under controversy (Ernst et al., 2014; 
Ernst and Frisen, 2015; Magnusson and Frisen, 2016; Gould, 2007) (Fig. 1). 
 
 
Figure 1. Neurogenic regions in the adult murine and human brain. Green areas correspond to the best-characterized 
neurogenic niches. Yellow areas indicate regions that respond to injury. Red areas indicate regions with weak evidence of 
neurogenic activity (modified from Magnusson and Frisen, 2016). 
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2.1. Subventricular zone (SVZ). 
 
In the adult mouse brain, the largest germinal niche is the subventricular zone (SVZ), also known 
as ventricular-subventricular zone (V-SVZ). This neurogenic niche comprises several cell types. First, 
the NSCs named B1 cells are largely quiescent with astrocytic properties, expressing glial-fibrillary acidic 
protein (GFAP), astrocytic glutamate aspartate transporter (GLAST) and brain lipid-binding protein 
(BLBP) and possess an end-feet on blood vessels (Hartfuss et al., 2001; Malatesta et al., 2000). Type B1 
cells could be in activated or inactivated state (Codega et al., 2014; Mich et al., 2014). Active B1 cells 
express Nestin and the transcription factor Sex Determining Region Y (SRY)-Box 2 (SOX2) and divide 
asymmetrically to generate one B1 daughter cell and a transit-amplifying precursor (TAP, type C cell or 
neural progenitor cell (NPC)) (Ortega et al., 2013b; Ortega et al., 2013a). Type C cells are more 
committed neuronal progenitors that express transcription factors such as proneural basic-helix loop helix 
(bHLH) Achaete-scute like 1 (Ascl1), and Neurogenin 2 (Neurog2) (Brill et al., 2009), and are more 
proliferative than B1 cells, dividing several times symmetrically before finally converting into 
neuroblasts (type A cells) (Ponti et al., 2013). Type A cells express basic helix-loop-helix (bHLH) factors 
Neurog2 (Brill et al., 2009), Neuronal Differentiation 1 (NeuroD1), ß-III-tubulin (Tubb3), doublecortin 
(DCX) and polysialylated neural cell adhesion molecule (PSA-NCAM) (Hsieh, 2012; Brown et al., 2003) 
and form a network of migrating neurons within an astrocytic sheath that coalesces to form the rostral 
migratory stream (RMS) towards the olfactory bulb (OB) (Doetsch and Alvarez-Buylla, 1996) (Fig. 2). 
In the OB, A cells migrate radially outward from the RMS, integrate into the existing circuitry and mature 
into gamma-aminobutyric acid (GABA)-ergic and dopaminergic interneurons. The newborn neurons 
express the neuron nuclear protein NeuN and the microtubule associated protein- 2 (MAP2). Newborn 
neurons have several functions facilitating fine-odor discrimination (Li et al., 2018; Lledo and 
Saghatelyan, 2005; Cecchi et al., 2001) and odor-reward association during adaptive learning (Grelat et 
al., 2018). 
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Figure 2. Schematic overview of the cells types in the SVZ neurogenic niche. Adult neural stem cells in the SVZ (B1 cells) 
differentiate into mature neurons in the OB. Specific markers and transcription factors are indicated below each cell type. SVZ: 
subventricular zone; RMS: rostral migratory stream; OB: olfactory bulb. 
 
B1 cells generate neurons and, to a lesser extent, new oligodendrocytes (Menn et al., 2006; Nait-
Oumesmar et al., 1999; Picard-Riera et al., 2002) and astrocytes (Benner et al., 2013). 
The SVZ presents a specific cytoarchitecture: B1 cells have their small apical surface in contact 
with the cerebrospinal fluid (CSF) in the ventricle, surrounding the ependymal cells in a pinwheel-like 
architecture (Mirzadeh et al., 2008). The contact with the CSF, which contains soluble factors related to 
bone morphogenetic proteins (BMPs), Wnts, Sonic hedgehog (Shh) and retinoic acid (RA), and the basal 
contact with the blood vessels modulates B1 cells responses (Huang et al., 2010; Lehtinen and Walsh, 
2011; Lehtinen et al., 2011). C cells are located at the SVZ and close to their progenitors and the blood 
vessels (Tavazoie et al., 2008).  
Here, we have described the SVZ in rodents, but this region presents anatomical and proliferative 
differences between species (Perez-Martin et al., 2000; Kornack and Rakic, 2001; Luzzati et al., 2006; 
Sawamoto et al., 2011). In humans, NSCs can be isolated from the SVZ and proliferate in vitro forming 
clonal aggregates named “neurospheres” (Kukekov et al., 1999; Sanai et al., 2004), but their proliferative 
capacity is significantly lower than the rates observed in mice, and there has been an extensive debate 
about the levels of newborn neurons incorporated into the human OB (Sanai et al., 2007; Sanai et al., 
2004; Quinones-Hinojosa et al., 2006; Curtis et al., 2007). Some studies suggest that the highest neuronal 
production takes place in the fetal brain (Guerrero-Cazares et al., 2011), while in the adult, low numbers 
of neurons are born in the OB under physiological conditions (Kempermann, 2013; Sanai et al., 2004; 
Ihrie and Alvarez-Buylla, 2011). 
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2.2. Subgranular zone of the dentate gyrus (SGZ). 
 
Active neurogenesis in the adult subgranular zone (SGZ) of the DG of the hippocampus in rodents 
has been described by several studies (Kempermann et al., 1997; Kuhn et al., 1996; Seki and Arai, 1999). 
Here, the NSCs are known as Type 1 cells, Radial glial-like cells (RGLs), radial astrocytes, or quiescent 
neural progenitors (QNPs). In this study, we refer them as neural stem cells (NSCs). NSCs are a 
heterogenic population (Jhaveri et al., 2015; Lacar et al., 2016; Shin et al., 2015) which express the 
astrocytic markers GFAP and vimentin, and the transcription factor SOX2, but contrary to astrocytes, 
also Nestin (Kempermann et al., 2004; Kriegstein and Alvarez-Buylla, 2009). NSCs have a low 
proliferative rate and present a long process that crosses the granular cell layer (GCL) towards the 
molecular layer and is in contact with the basal vasculature of the SGZ.  
When NSCs undergo asymmetric division, they generate transient amplifying progenitors (type 
2a and 2b cells, also known as intermediate progenitor cells (IPCs)), positive for Nestin, Ascl1, Neurog2 
and SOX2 (Hsieh, 2012), but not for GFAP (Gebara et al., 2016). In this study, these cells are named 
neural progenitor cells (NPCs). NPCs cells are highly proliferative, lack ramifications (Suh et al., 2007; 
Steiner et al., 2006) and remain in the SGZ (Encinas et al., 2011) until they turn into neuroblasts (type 3) 
(Kempermann et al., 2004) expressing DCX, PSA-NCAM, and NeuroD1. Neuroblasts finally 
differentiate into glutamatergic excitatory granular cell (GC) neurons that integrate into the GCL 
(Bonaguidi et al., 2011; Bonaguidi et al., 2012; Lugert et al., 2010; Suh et al., 2007; Sun et al., 2013). 
Immature neurons express DCX and PSA-NCAM and undergo a phase of increased synaptic plasticity, 
being responsible for inducing long-term potentiation (LTP) rather than the mature granule cells (Wang 
et al., 2000; Schmidt-Hieber et al., 2004). In fact, the only LTP measurable from the DG under normal 
conditions originates from the immature neurons (Saxe et al., 2006; Garthe et al., 2009). Mature GCs 
express NeuN, MAP2 and the calcium-binding protein calbindin. GCs project out a large dendritic tree 
into the adjacent molecular layer and axons that innervate target cells in the hilus and area 3 of the cornu 
Ammonis (CA3). These cells receive GABAergic inputs from the entorhinal cortex (Zhao et al., 2006; 
Toni et al., 2008) (Fig. 3). 
Hippocampal neurogenesis has been associated to learning and memory (Deng et al., 2010). 
Increased levels of neurogenesis correlate with improved performance in hippocampus-dependent 
learning and memory tasks, such as the Morris water maze (MWM) (Kempermann et al., 1997; van Praag 
et al., 1999). Other studies relate hippocampal neurogenesis to spatial and object recognition memory 
(Jessberger et al., 2009), fear conditioning and synaptic plasticity (Saxe et al., 2006) and pattern 
discrimination (Clelland et al., 2009; Sahay et al., 2011; Nakashiba et al., 2012; Danielson et al., 2016; 
Aizawa et al., 2009). 
In addition to neurons, adult NSCs in the rodent SGZ give rise to a small population of astrocytes 
(Encinas et al., 2011; van Praag et al., 1999), but apparently they do not form oligodendrocytes (Steiner 
et al., 2004). 
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In humans, the existence of hippocampal neurogenesis is still under controversy. Although several 
studies describe the existence of lifelong hippocampal neurogenesis in humans (Bergmann et al., 2015; 
Eriksson et al., 1998; Knoth et al., 2010; Roy et al., 2000; Spalding et al., 2013; Boldrini et al., 2018; 
Moreno-Jimenez et al., 2019; Tobin et al., 2019), recently, some studies concluded that hippocampal 
neurogenesis drops to undetectable amounts during childhood (Sorrells et al., 2018). The inability to reach 
a consensus is due, at least in part, to the lack of standardized protocols in tissue processing and the 
reduced number of marker studies. The development of methods to follow the hippocampal neurogenesis 
in vivo would help to assess the impact of lifelong neurogenesis in humans. 
 
Figure 3. Schematic overview of the hippocampal neurogenic niche. Adult NSCs in the hippocampus (radial glia-like cells, 
type 1 cells) and their differentiation in the SGZ of the DG. Below each cell type it is indicated its specific cell markers and 
transcription factors. ML: molecular layer; GCL: granular cell layer; SGZ: subgranular zone. 
 
In this thesis, we will refer sometimes, to simplify, altogether to the population of neural stem 
cells and neural progenitor cells as neural stem/progenitor cells (NSPCs). 
 
 
3. Regulation of adult neurogenesis. 
 
Adult neurogenesis is an orchestrated multistep process, which comprises: 1) maintenance and 
proliferation of NSCs, 2) fate specification, 3) differentiation, maturation, and survival of neurons and 4) 
integration into existing brain circuits. The progression of neurogenesis is dynamically coordinated by 
extrinsic as well as intrinsic factors, such as microenvironment-derived signals and coordinated by precise 
changes in the pattern of gene expression (Zhao et al., 2008b; Suh et al., 2009; Ming and Song, 2011; 
Beckervordersandforth et al., 2015). 
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3.1. Signaling pathways. 
 
A variety of signaling pathways triggered at the plasma membrane are known to act during the 
process of neurogenesis by the control of different key transcription factors. Many of the signaling 
pathways have an effect on NSC proliferation and undergo considerable crosstalk. 
 
Notch. - The Notch signaling pathway, maintains the proliferative and undifferentiated stages of 
both embryonic and adult NPCs (Pleasure et al., 2000; Breunig et al., 2007; Lavado and Oliver, 2014). 
Upon Notch signaling, the expression of bHLH transcription factors, such as Hairy enhancer of split 
(Hes), is induced (Bray and Bernard, 2010). Hes represses the expression of proneural genes, such as 
Ascl1 and Neurog2, thus enabling maintenance of the NSCs pool (Hatakeyama et al., 2004; Imayoshi et 
al., 2008). The specific context in which Notch signaling is activated dictates the particular downstream 
process that is triggered: proliferation, fate specification, or apoptosis. 
 
Wnt. - Wnt/β-catenin signaling is important for proliferation and differentiation in the developing 
cortex and hippocampus (Zechner et al., 2003), but also in postnatal and adult neurogenesis (Zhang et al., 
2011; Ortiz-Matamoros et al., 2013; Varela-Nallar and Inestrosa, 2013). Wnt ligands are a family of auto- 
and paracrine glycoproteins secreted by astrocytes and NSCs (Lie et al., 2005; Qu et al., 2010; Okamoto 
et al., 2011). After Wnt signaling activation, cytoplasmic β-catenin is stabilized and translocates to the 
nucleus where it binds T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factor 
and drives the expression of neurogenic genes such as Neurog2 and Neurod1 (Gao et al., 2009; Kuwabara 
et al., 2009; Lavado et al., 2010). In the absence of Wnt ligand, glycogen-synthetase-kinase-3 beta 
(GSK3β), a key modulator of the Wnt pathway, forms a degradation complex, comprising Axin, 
Adenomatous Polyposis Coli (APC), and β-Transducing repeat- Containing Protein (β-TrCP), that leads 
to phosphorylation and ubiquitination of β-catenin and subsequent degradation by the proteasome (Chen 
et al., 2000). 
Wnt plays dual roles during neurogenesis. On one hand, it promotes self-renewal and maintains 
RG during early neurogenesis (Wrobel et al., 2007; Zhou et al., 2004). On the other, it induces the 
proliferation of hippocampal progenitors (Varela-Nallar and Inestrosa, 2013) and neuronal differentiation 
during mid and late neurogenesis (Kuwabara et al., 2009; Lie et al., 2005) through epigenetic modification 
of targeted genes by context- and cell-type-dependent mechanisms. 
 
Shh. - The Sonic hedgehog (Shh) signaling cascade is essential for the expansion and establishment 
of postnatal hippocampal progenitors (Breunig et al., 2008; Amador-Arjona et al., 2011; Han et al., 2008). 
During neurogenesis, active Shh signaling decreases, whereas the activity of the zinc finger protein GLI 
repressor increases (Fuccillo et al., 2006; Philipp and Caron, 2009), being necessary for production of 
progenitors and for neuronal differentiation (Wang et al., 2011).   
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3.2. Neurotrophic and growth factors. 
 
Neurotrophic factors are extracellular signaling proteins that play important roles in both the 
developing and the adult CNS (Glebova and Ginty, 2005; Lu et al., 2005). One neurotrophic factor is 
brain-derived neurotrophic factor (BDNF), which favours neurogenesis both in the SGZ and the SVZ 
(Scharfman et al., 2005; Zigova et al., 1998; Benraiss et al., 2001).   
Growth factors are extracellular proteins that promote cell growth and maintenance on the 
neurogenic niches (Bottcher and Niehrs, 2005; Guillemot and Zimmer, 2011). Regarding neurogenesis, 
fibroblast growth factor-2 (FGF-2), also known as basic FGF (bFGF), is related with an increase in the 
number of newly born cells in the adult rat hippocampus (Rai et al., 2007). Another cytokine implicated 
in neurogenesis is the epidermal growth factor (EGF). EGF administration into lateral ventricles leads to 
significant upregulation of cell proliferation within the SVZ (Morshead et al., 2003; Okano et al., 1996). 
Moreover, NPCs express receptors for FGF-2 and EGF (Gritti et al., 1999). Thus, FGF-2 and EGF are 
used to promote cell proliferation and survival of NSPCs grown in culture as neurospheres (Pincus et al., 
1998; Tropepe et al., 1999) and are used in this study to maintain stem cells in vitro. Other trophic factors 
important in neurogenesis are vascular endothelial growth factor (VEGF), insulin-like growth factor-1 
(IGF-1) and transforming growth factor β (TGF-β) (Brooker et al., 2000; Aberg et al., 2003; Aberg et al., 
2000; Yasuhara et al., 2004; Khaibullina et al., 2004; Cao et al., 2004; Funa and Sasahara, 2014). 
 
3.3. Redox control of neurogenesis. 
 
Changes in environmental and intracellular redox status are crucial for the fate of NSPCs 
(Madhavan, 2015; Dickinson et al., 2011; Tsatmali et al., 2005; Yuan et al., 2015). Recent studies indicate 
that a reducing environment favours cell proliferation, whereas an oxidizing environment favours cell 
differentiation (Schafer and Buettner, 2001). Furthermore, a more oxidized environment favours 
differentiation towards astroglia, whereas a more reduced environment favours the neuronal lineage 
(Prozorovski et al., 2008). At the intracellular level, as the stem cells are stimulated, either by tissue 
injury, inflammation, or growth factors, low levels of reactive oxygen species (ROS) are produced, which 
activate redox-sensitive signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt signaling that 
favours cell proliferation (Smith et al., 2000; Yoneyama et al., 2010; Le Belle et al., 2011). When ROS 
levels increase, the rate of proliferation slows down and in turn the intracellular environment favours 
differentiation (Smith et al., 2000; Yoneyama et al., 2010; Le Belle et al., 2011). Thus, a delicate redox 
balance needs to be achieved in neurogenesis because its perturbation in NSPCs or within the neurogenic 
microenvironment can lead to changes in the production, functional integration, and long-term survival 
of new neurons. 
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3.4. Transcriptional regulation of neurogenesis. 
 
The changes in gene expression point transcriptions factors as central coordinators of the 
development of new functional neurons from NSCs. 
 
3.4.1. SOX2. 
 
Sex determining region Y (SRY)-box 2 (SOX2) is a homeobox transcription factor of the SOX 
family characterized by a highly conserved DNA binding domain known as high-mobility group (HMG). 
SOX2 is highly expressed in NSCs and NPCs (Steiner et al., 2006) and controls their multipotency and 
proliferative capacities (Favaro et al., 2009; Steiner et al., 2006; Ferri et al., 2004) as well as proper 
neuronal differentiation and maturation (Cavallaro et al., 2008). SOX2 is regulated by Notch signaling 
(Ehm et al., 2010) and is able to modulate Shh signaling by controlling the expression of Shh (Favaro et 
al., 2009). Recently, SOX2 has been described as an epigenetic regulator of the bHLH genes Neurog2 
and Neurod1, preventing excessive activity of Polycomb Repressive Complex 2 (PRC2). Thus, SOX2 
favours a permissive epigenetic state in NPCs, appropriate for the activation of the differentiation 
program upon exposure to a neurogenic stimulus (Amador-Arjona et al., 2015) (Fig. 4A). SOX2 interacts 
with the long non-coding RNA RMST (rhabdomyosarcoma 2-associated transcript). In the onset of 
neurogenesis in human NSCs, the complex RMST-SOX2 regulates a large pool of downstream genes 
including ASCL1 and NEUROG2 (Ng et al., 2013) (Fig. 4B). The implication of SOX2 in neurogenesis 
has also been described in the acquisition of neuronal fates in sensory ganglia (Cimadamore et al., 2011).  
 
 
Figure 4. Schematic view of SOX2 mechanisms involved in the regulation of neurogenesis. (A) SOX2 inhibits PCR2 activity 
favouring a permissive epigenetic state of NPCs for neuronal differentiation. (B) SOX2 interacts with RMST in the onset of 
neurogenesis driving the expression of proneural factors.  
 
SOX2 gene expression is activated by several signaling pathways, including Shh, Wnt, FGF and 
TGF-β (Manoranjan et al., 2012), but few studies have analyzed which transcription factors are involved. 
For example, SOX2 is positively regulated in NSPCs by transcription factors that are expressed at 
considerably high levels during early neural development and differentiation such as prospero homeobox 
protein 1 (PROX1) and paired box protein 6 (PAX6) (Lengler et al., 2005; Chen et al., 2008b). 
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3.4.2. Basic helix-loop-helix (bHLH) transcription factors. 
 
The basic helix-loop-helix (bHLH) transcription factors are essential regulators of NSCs fate 
specification and differentiation in embryonic development and adult neurogenesis (Bertrand et al., 2002; 
Ross et al., 2003; Imayoshi and Kageyama, 2014) and have emerged as potential candidates for 
transcription factor-based neural cell reprogramming.  
The structure of bHLH transcription factors is comprised by two alpha-helices connected by a 
non-conserved loop region for dimerization and a basic domain for DNA binding (Fig. 5A). After 
dimerization with ubiquitously expressed bHLH E proteins, bHLH transcription factors bind the 
consensus E-box sequence (CANNTG) (Bertrand et al., 2002). bHLH are classified based on their pattern 
of expression. In this section, we will focus on the Class II proneural factors that are expressed in the 
CNS, such as Ascl1, Neurog2 and NeuroD1. These factors regulate the expression of neuron-specific 
genes and those encoding Notch ligands, such as Delta-like protein 1 (Dll1), which activates Notch 
signaling in neighbouring cells contributing to NPC maintenance (Castro et al., 2006; Henke et al., 2009). 
Achaete-scute like 1 (Ascl1) is expressed in NPCs (Uda et al., 2007) and has several roles, 
regulating the expression of genes related to cell-cycle exit, neuronal components of the cytoskeleton (as 
Dcx and Tubb3), neurotransmitter biosynthesis, and neurite outgrowth, but also other genes related with 
cell-cycle progression (Castro et al., 2011). In the SVZ, Ascl1 expression is restricted to TAPs destined 
to differentiate into GABAergic interneurons of the OB. In the adult hippocampus, Ascl1 is transiently 
expressed by NPCs that subsequently develop into glutamatergic granule cell neurons (Kim et al., 2007). 
During neuronal differentiation, Ascl1 promotes chromatin accessibility, which may be important to 
allow subsequent regulation by other transcription factors. Thus, Aslc1 acts as a pioneer factor during 
neuronal fate (Raposo et al., 2015) (Fig. 5B). 
Neurogenin 2 (Neurog2) is another proneural bHLH factor expressed in NPCs. In the adult SVZ, 
in contrast to Ascl1, Neurog2 is expressed by a subset of NPCs that differentiate into glutamatergic 
interneurons (Brill et al., 2009). Neurog2 is also expressed transiently by NPCs in the SGZ (Hodge et al., 
2008). Neurog2 remodels the closed chromatin of its target genes by binding to histone acetyltransferases, 
such as the H3K9 demethylase known as KDM3A (lysine demethylase 3A) (Lin et al., 2017) or the 
chromatin remodelling protein Brahma-related gene-1 (Brg1) (Seo et al., 2005). These interactions 
facilitate Neurog2 binding to the regulatory regions of neuronal differentiation genes such as Neurod1 
and Tubb3 (Ma et al., 1996; Sommer et al., 1996; Lin et al., 2017) (Fig. 5C). 
 Neurogenic Differentiation 1 (NeuroD1) is a bHLH factor which plays an important role during 
neuronal differentiation and is expressed transiently in committed progenitors and neuroblasts and 
declines in immature neurons (Gao et al., 2009; Hevner et al., 2006; Aprea et al., 2014). NeuroD1 is 
crucial for the survival and differentiation of newborn neurons in the adult SGZ and SVZ (Gao et al., 
2009; Schwab et al., 2000). NeuroD1 confers transcriptional competence, acting as a precursor factor 
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during neuronal differentiation and favouring chromatin accessibility, which is epigenetically maintained 
even after NeuroD1 disappearance during neurogenesis (Pataskar et al., 2016) (Fig. 6). 
The general mode of proneural gene function has thus been elucidated. However, the regulatory 
mechanisms that spatially and temporally control proneural gene function are only beginning to be 
deciphered. 
 
 
Figure 5. Proneural basic helix-loop-helix structure and epigenetic mechanism. (A) Structure of basic helix-loop-helix 
(bHLH) factors. bHLH transcription factors present two alpha-helices connected by a non-conserved loop region for dimerization 
and a basic domain to bind E-box sequence in the DNA. (B) Ascl1 is a pioneer transcription factor which induces chromatin 
opening of target neuronal genes. (C) Neurog2 binds lysine demethylase 3A (KDM3A) to demethylate H3K9me2 at repressive 
sites, allowing for new chromatin modifications that open the chromatin (eg. H3K37ac3). Neurog2 also binds Brg1, a chromatin 
remodeler, to directly open the chromatin.   
 
 
Figure 6. NeuroD1 acts as a pioneer factor during neuronal program. NeuroD1 reprograms chromatin by loss of inactive 
(H3K27me3) and gain of active (H3K27Ac) histone marks, leading to increased chromatin acessibility for RNA polymerase II 
(Pol II) recruitment, followed by neuronal gene expression. 
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Due to their neurogenic functions, proneural bHLH factors are key players in the neuronal 
reprogramming of somatic cells. Ascl1 directly reprogram fibroblasts, astrocytes and pericytes (combined 
with SOX2) to induce neuronal differentiation (Chanda et al., 2014; Wapinski et al., 2013; Karow et al., 
2012; Vierbuchen et al., 2010). Neurog2 can induce glutamatergic neurons from postnatal astrocytes 
(Berninger et al., 2007; Heinrich et al., 2010) and motor neurons from fibroblasts (Liu et al., 2013). Forced 
NeuroD1 expression reprograms astrocytes towards functional neurons (Guo et al., 2014). Recently, 
neuronal conversion from mouse microglia by NeuroD1 has been reported (Matsuda et al., 2019). Despite 
these intensive studies, the generation of induced neurons nowadays is still little efficient.  
In this thesis, we will simplify the way to refer altogether to SOX2 and proneural bHLH factors 
ASCL1, NEUROG2 and NEUROD1 as proneurogenic factors, based on their implication in the neuronal 
differentiation of NSPCs (Colasante et al., 2019). A better understanding of how proneurogenic genes are 
regulated will allow a more efficient use in regenerative medicine based on neuronal reprogramming. 
 
There are other factors related with regulation of neurogenesis that will not be addressed in the 
present study. These include intrinsic factors which can modulate neurogenesis as inflammation state, 
hormones and neurotransmitters (Kohman and Rhodes, 2013; Trivino-Paredes et al., 2016), and extrinsic 
factors such as enriched environment (Kempermann et al., 1997), calorie restriction (Murphy et al., 2014) 
and exercise (Trivino-Paredes et al., 2016; van Praag et al., 1999).  
 
4. Deregulation of neurogenesis. 
 
Adult neurogenesis is emerging as an important player in brain homeostasis. Alterations in the 
proper course of neurogenesis have been described in aging and several CNS diseases, such as major 
depression, epilepsy, Alzheimer´s disease (AD) and glioblastomas (GB) (Sahay and Hen, 2007; Parent 
and Murphy, 2008; Alcantara Llaguno and Parada, 2016). Aging, AD and cancer are analyzed in this 
work as three examples of deregulation of neurogenesis. 
 
4.1. Aging. 
 
Aging is one of the most significant risk factors for cognitive decline and neurodegenerative 
disorders and leads to a progressive decay in adult neurogenesis. During aging, neurogenesis declines 
both the DG and the SVZ of rodents, non-human primates and humans (Apple et al., 2017; Luo et al., 
2006; Kuhn et al., 1996; Spalding et al., 2013; Encinas et al., 2011; Aizawa et al., 2009; Amrein et al., 
2011; Dennis et al., 2016). Furthermore, the age-related decline in neurogenesis has been correlated with 
cognitive impairment. In the SVZ, the decrease in newborn neurons in the OB is observed behaviourally 
by olfactory deficits in aged rodents (Enwere et al., 2004; Rochefort et al., 2002). On the other hand, the 
progressive loss of hippocampal neurogenesis correlates with deficits in hippocampal functions of 
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learning and spatial memory in old rats as measured by the MWM and visual pattern discrimination tests 
(Drapeau et al., 2003; Driscoll et al., 2006). Identifying the mechanisms involved in the depletion of the 
NSPCs pool with aging may reveal therapeutic targets for increasing the neurogenic response and 
improving the cognitive functions of the elderly. 
 
4.2. Alzheimer´s disease (AD). 
 
Aging is the main risk factor for AD. AD is characterized by progressive neuronal loss, followed 
by memory loss and cognitive impairment (Goedert and Spillantini, 2006). The main neuropathological 
hallmarks of AD are the neurofibrillary tangles of hyperphosphorylated neuronal microtubule associated 
TAU protein (Geschwind, 2003) and senile plaques formed by the deposition of β-amyloid (Aβ) (Selkoe, 
2001; Nicolas and Hassan, 2014). Aβ1–40 and Aβ1–42 are released from amyloid precursor protein (APP) 
by β and γ secretases, the presenilins 1 and 2 (PS1 and PS2, respectively) (Selkoe, 2001; Nicolas and 
Hassan, 2014). The genes encoding APP, PS1 and PS2 are involved in familiar AD, and mutations in 
these genes can increase the production of Aβ1–42 (Lithner et al., 2011). Furthermore, PS1 is expressed in 
the adult hippocampus (Page et al., 1996; Boissiere et al., 1996), including the NPCs of the SGZ (Wen et 
al., 2002). Indeed, PS1 plays a role in regulating Notch signaling, and is responsible for maturation of 
glia and neurons (Gaiano and Fishell, 2002) by cleavage of Notch intracellular domain (NICD) (Kojro 
and Fahrenholz, 2005). On the other hand, hyperphosphorilation of TAU has been related with an over 
activation of GSK3β in AD (Leroy et al., 2007; Blalock et al., 2004; Hooper et al., 2008). GSK3 was 
identified as a master regulator of NSCs homeostasis with impact in Wnt, Shh and Notch signaling in the 
mammalian brain development (Kim et al., 2009). Even more, small GSK3 inhibitors elicit an increase 
of NPCs (Lange et al., 2011). 
 The relevance of neurogenesis in AD differs among several mouse models (Lazarov and Marr, 
2010; Mu and Gage, 2011). For example, transgenic mice with mutant APP/PS1 exhibit impaired 
neurogenesis at both the SVZ and SGZ even earlier than the appearance of Aβ deposits and memory loss, 
suggesting that impaired neurogenesis may partly initiate the neuropathology of AD (Demars et al., 
2010). The double knockout of PS1 and PS2 apparently enhances neurogenesis at first steps but in term 
leads to exhaustion of the neurogenic niche (Chen et al., 2008a). Moreover, transgenic mice with mutant 
APP exhibit increased proliferation and differentiation of NPCs in the SGZ (Jin et al., 2004). The triple 
transgenic mice (3xTg-AD) harbouring three mutant genes (APPK595N/M596L, PS1M146V and TAUP301L) show 
temporal and region-specific Aβ and TAU pathology, accompanied by cognitive deficits, including 
reduced LTP (Oddo et al., 2003a; Oddo et al., 2003b). The neurogenic niches of these mice present an 
accelerated age-related reduction in proliferating cells, committed progenitors and newborn neurons prior 
to the development of amyloid plaques or neurofibrillary tangles, thus, indicating again that loss of adult 
neurogenesis may be partly the cause of the premature cognitive decline in AD (Rodriguez et al., 2008b; 
Rodriguez et al., 2009; Hamilton et al., 2010). In addition, apolipoprotein E4 (ApoE4), the major known 
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risk factor for AD, inhibits hippocampal neurogenesis by impairing the functions of GABAergic 
interneurons (Li et al., 2009). As it happens with AD animal models, hippocampal neurogenesis is 
controversial in AD patients. Some studies have reported that adult hippocampal neurogenesis is inhibited 
in AD patients, whereas gliogenesis is increased (Boekhoorn et al., 2006; Crews and Masliah, 2010; 
Moreno-Jimenez et al., 2019; Tobin et al., 2019), meanwhile other studies have reported an increase in 
adult hippocampal neurogenesis in AD patients (Jin et al., 2004). These discrepancies may reflect 
different stages of AD or the heterogeneous nature of AD pathology.   
The characterization of factors that modulate NSPCs will allow us to understand the implication of 
neurogenesis in AD and its therapeutic implication. 
 
4.3.  Glioblastomas. 
 
Glioblastoma multiforme (GBM) is a highly aggressive grade IV tumour based on the criteria of 
The World Health Organisation. GBM is the most prevalent glial tumour, with the worst prognosis, lowest 
rate of patient’s survival and with a poor response to current therapies (Wen and Kesari, 2008; Stupp et 
al., 2009). One of the most significant questions in GBM research is its cellular origin. GBM comprises 
a heterogeneous population of cells ranging from highly tumorigenic stem-like cells to more 
differentiated cancerous cells (Singh et al., 2004). The cancer stem cell (CSC) model suggests that only 
a small group of cells have quiescence and self-renewal capacity within the tumour bulk, and that those 
are responsible for tumour maintenance and recurrence (Pattabiraman and Weinberg, 2014). Although 
there is controversy about which cell types in the CNS contribute to GBM formation, recent studies 
suggest that deregulation of proliferation or oncogenic mutations within NSPCs could lead to brain 
tumour formation, pointing to the transformation of NSPCs to CSCs in gliomas (Swartling et al., 2014; 
Zheng et al., 2008; Alcantara Llaguno et al., 2009; Jacques et al., 2010; Sanai et al., 2005; Lee et al., 
2018; Altmann et al., 2019; Chen et al., 2012; Holland et al., 2000). Indeed, NSPCs harbouring driver 
mutations have been highlighted as potential targets for preventing the recurrence of GBM (Zong et al., 
2015; Chen et al., 2013; Khalifa et al., 2017; Visvader, 2011).  
In GBM, the limited therapeutic options increase the pressure to discover new genetic and 
molecular targets. Recent studies based on the forced expression of the proneurogenic bHLH factors, as 
NEUROG2 (Su et al., 2014), ASCL1 (Park et al., 2017) and NEUROD1 (Guichet et al., 2013) showed a 
reduction in the tumorigenic properties of GBM cells and enhanced neuronal differentiation. Thus, 
identification of factors that could control the expression of these proneurogenic factors opens a new 
window in the therapeutic treatment of GBM. 
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5. Transcription factor NRF2. 
 
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a protein that belongs to the cap ‘n’ collar 
(CNC) family of transcription factors, encoded by the NFE2L2 gene. At the C-terminus, NRF2 contains 
a basic leucine-zipper (bZip) domain that participates in the formation of heterodimers with other bZip 
proteins, like small muscle aponeurosis fibromatosis (MAF) K, G and F (Ma, 2013; Hayes and Dinkova-
Kostova, 2014). These heterodimers bind to the regulatory enhancer sequence termed Antioxidant 
Response Element (ARE; 5′-TGACNNNGC-3′) (Moi et al., 1994; Venugopal and Jaiswal, 1996). NRF2 
regulates more than 250 genes that participate in multiple homeostatic functions including regulation of 
inflammation, redox metabolism, cell survival and proteostasis (Wild et al., 1999; Rushmore et al., 1991, 
Rushmore and Pickett, 1990; Lee et al., 2005; Thimmulappa et al., 2002; Pajares et al., 2017; Pajares et 
al., 2016; Rojo de la Vega et al., 2018; Rojo de la Vega et al., 2016). Thus, NRF2 is considered a master 
regulator of cellular homeostasis. 
 
5.1.  NRF2 structure and regulation. 
 
Human NRF2 comprises 605 aminoacids (597 in the mouse) organized in seven regions, called 
NRF2 − ECH homology (Neh) domains 1–7 (Fig. 7). Neh1, Neh3, Neh4 and Neh5 regions are required 
for transactivation activity (Hayes and McMahon, 2009; Hirotsu et al., 2012; Kim et al., 2013). The Neh1 
domain comprises the CNC-bZIP region that dimerizes with the small MAF proteins and binds DNA 
(Hirotsu et al., 2012).  
 
 
Figure 7.  NRF2 structure. NRF2 possesses seven regions called NRF2-ECH homology (Neh) domains. The functional role of 
the main Neh domains is specified.  Residue numbers are shown for the human protein. 
 
Neh2 and Neh6 regions contain several destruction motifs and are related with NRF2 instability. 
The Neh2 region comprises the DLG and ETGE motifs which recruit Kelch-like ECH-associated protein  
(KEAP1) (Tong et al., 2006; McMahon et al., 2006). KEAP1 presents NRF2 for ubiquitination to the E3 
ligase complex formed by Cullin3 and RING-box protein 1 (CUL3/RBX1) (Tong et al., 2007), resulting 
in subsequent NRF2 degradation by the proteasome 26S (Suzuki et al., 2013; Hayes and Dinkova-
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Kostova, 2014). ROS, electrophiles or many xenobiotics induce NRF2 accumulation through 
modifications of key cysteine residues in KEAP1. They cause a conformational change in the NRF2-
KEAP1 complex by promoting the formation of adducts or oxidation of sulfhydryl groups in some of the 
Cys residues of KEAP1 (mainly Cys-151, Cys-273 and Cys-288). This conformational change prevents 
NRF2 ubiquitination and subsequent proteasomal degradation (Zhang and Hannink, 2003) and results in 
NRF2 stabilization, translocation to the nucleus and activation of its transcriptional activity (Itoh et al., 
1997) (Fig. 8). 
The Neh6 region comprises the DSGIS and DSAPGS motifs. DSGIS is phosphorylated by the 
serine/threonine protein kinase GSK3β. This phosphodomain recruits β-TrCP (Rada et al., 2011; Rada et 
al., 2012), a substrate adaptor for the S-phase kinase-associated protein 1 (SKP1)–CUL1–F box 
containing complex (SCF) (SCF/β-TrCP) (Suzuki et al., 2000; Wu et al., 2003). Thus, GSK3/β-TrCP 
targets NRF2 for ubiquitin-proteasome degradation and links NRF2 regulation with signaling responses 
such as Wnt and Shh (Cuadrado, 2015). β-TrCP also recognizes the DSAPGS motif in the Neh6 which 
seems to be constitutively phosphorylated (Chowdhry et al., 2013) (Fig. 8). 
The Neh7 domain mediates repression of NRF2 by the retinoid X receptor (RXR)α through 
physical association of the two proteins (Wang et al., 2013). Additional degradative systems regulate 
NRF2 at post-transcriptional level, such as the inositol requiring enzyme (IRE1)/E3 ubiquitin ligase 
synoviolin (HRD1) under endoplasmic reticulum (ER) stress (Wu et al., 2014) (Fig. 8). 
 
 
Figure 8.  Molecular mechanisms of NRF2 regulation. Under basal conditions, NRF2 is bound to KEAP1 and undergoes rapid 
proteasomal degradation. Upon induction, cysteine residues in KEAP1 are modified, the E3 ubiquitin ligase activity is 
suppressed, and NRF2 levels increase. NRF2 can be also regulated by its Neh6 region (right): DSGIS motif is phosphorylated 
by GSK3β and recruits ubiquitin ligase adapter β-TrCP for proteasome degradation by a Cullin1/Rbx1 (CUL1) complex (SCF). 
Another mechanism for NRF2 degradation is the E3 ubiquitin ligase HRD1. Activated NRF2 enters the nucleus and dimerizes 
with MAFs to promote transcription of ARE‐dependent genes.  
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5.2. Function of NRF2 in neurogenesis. 
 
NRF2 modulates a global cellular response to promote cell survival, cell growth, self-renewal, 
differentiation, and increased lifespan, all of which are relevant to the function of the NSCs (Zhu et al., 
2013; Ryoo et al., 2016; Murakami and Motohashi, 2015; Murakami et al., 2017; Gurusamy et al., 2010; 
Cai et al., 2012; Gambari et al., 2014). Particularly, Wakabayashi and colleagues described how NRF2 
regulates Notch1 expression through an ARE in its promoter region, thus impacting on cell proliferation 
(Wakabayashi et al., 2010). Furthermore, NRF2 has been linked to the activity of trophic factors, 
including VEGF, IGF-1 and TGF-β, which are also important for NSCs (Kweider et al., 2011; Lee et al., 
2005). Another mechanism by which NRF2 controls cell proliferation and differentiation is the regulation 
of redox signaling by the control of antioxidant molecules, such as superoxide dismutase (SOD), 
glutathione (GSH), glutamate-cysteine ligase (GCL) catalytic subunit (GCLC) and modifier subunit 
(GCLM) and the detoxification enzyme heme oxygenase 1 (HO1) (Wild et al., 1999; He et al., 2001; 
Venugopal and Jaiswal, 1998). The intracellular redox state is emerging as a critical aspect of NSC 
physiology (Noble et al., 2003; Smith et al., 2000). Thus, NRF2 emerges as a key factor for the proper 
functioning of NSCs. 
 
5.3. NRF2 in aging and AD. 
 
In this study, we will focus in the impact of NRF2 in neurogenesis during aging and AD. Given 
the impact of inflammation and oxidative stress in aging and neurodegenerative disease (Jo et al., 2010; 
Liu et al., 2017; Smith et al., 2012), and the role of NRF2 as a master regulator of anti-inflammatory and 
antioxidant response, it is important to elucidate the impact of NRF2 in age-related disorders. As it has 
been described for neurogenesis, during aging NRF2 activity also declines, parallel to increased activity 
of its negative regulators (KEAP1, GSK3 and HRD1) and an epigenetic silencing of its promoter (Zhang 
et al., 2015; Silva-Palacios et al., 2018; Suh et al., 2004). In the major age-related neurodegenerative 
disease, AD, NRF2 activity also decreased, probably due to the hyperactivation of its inhibitor GSK3β 
(Leroy et al., 2007; Blalock et al., 2004; Hooper et al., 2008). NRF2 has been shown to be a protective 
factor against AD pathology, and NRF2 expression is low in aged AD animal models and AD patient 
brains (Kanninen et al., 2008; Ramsey et al., 2007; Johnson and Johnson, 2015; Rojo et al., 2017). For 
example, NRF2 reduces the levels of phosphorylated TAU by inducting autophagy adaptor protein 
nuclear dot protein 52 kDa (NDP52) (Jo et al., 2014). Interestingly, one haplotype allele in the promoter 
of NRF2 encoding gene (NFE2L2) was associated with an earlier onset of AD, implying that common 
variants of the NFE2L2 gene might affect AD progression (von Otter et al., 2010).  
All these studies suggest the potential of NRF2 activation to optimally modulate NSCs function 
with age and to attenuate the progression of neurodegeneration and cognitive impairment (Bahn and Jo, 
2019; Cuadrado et al., 2019; Cuadrado et al., 2018).   
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6. NRF2 and Hippo pathway in stemness. 
 
It is generally accepted that the stemness promoting activity of NRF2 is due to its homeostatic 
functions. However, high NRF2 expression is observed in embryonic, pluripotent and cancer stem cells 
(Jia et al., 2015; Wu et al., 2015; Zhu et al., 2014), suggesting additional functions in stem cells 
maintenance. As described previously, NRF2 controls the expression of the stemness associated protein 
Notch1 (Wakabayashi et al., 2010), while NRF2 inactivation affects stem cell renewal (Zhu et al., 2013). 
However, a mechanistic connection between stemness and NRF2 has not been demonstrated yet. Here, 
we focused on the Hippo pathway effector Transcriptional co-activator with PDZ-binding motif (TAZ) 
that is described in the following section as a possible target of NRF2 in stem cells. 
 
7. Transcriptional cofactor TAZ. 
 
Transcriptional co-activator with PDZ-binding motif (TAZ) is a transcriptional cofactor also 
known as WWTR1 (WW-domain containing transcriptional regulator 1) that was initially described as a 
14-3-3 binding protein (Kanai et al., 2000). TAZ is, together with Yes-associated protein (YAP), one of 
the major effectors of the Hippo signaling pathway. The Hippo pathway involves a highly conserved 
cascade of serine/threonine protein kinases which comprises the mammalian Ste20-like kinases (MST1/2) 
and large tumour suppressor kinase 1/2 (LATS1/2) (Chan et al., 2005; Callus et al., 2006). The Hippo 
pathway regulates organ size during development, cell proliferation, apoptosis, cell-cell contact 
inhibition, stem cell self-renewal, and tissue regeneration (Yang and Xu, 2011; Varelas, 2014). 
 
7.1. Structure and regulation of TAZ. 
 
TAZ comprises 400 amino acids organized in several motifs and domains (Fig. 9). First, the 
protein-interaction domain WW, comprises two tryptophan (W) residues separated by 20-23 amino acids 
and recognizes a PPxY motif (proline/proline/any amino acid/tyrosine) related to control of TAZ 
subcellular localization (Salah et al., 2012).  
 
 
Figure 9.  TAZ structure. TAZ possesses several domains and motifs that regulate its function: a 14-3-3 binding motif and 
TEAD binding-domain in the N-terminal, a WW domain, a coiled-coiled (CC) motif and a transcriptional activation domain and 
a PDZ binding motif and in the C-terminal. Some key posttranslational modifications are also shown. Ser-51 indicates the main 
residue implicated in TEAD-binding. Residue numbers are shown for the human protein.  
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The N-terminal region of TAZ mediates binding to the Transcriptional enhancer factor TEF-1 
(TEAD) transcription factors, the main cofactors of TAZ (Chan et al., 2009). The TEAD-binding region 
of TAZ is in very close proximity (possibly overlapping) with that required for 14-3-3 binding (Varelas, 
2014). The main residue implicated in TAZ-TEAD interaction is the Ser-51, as replacement of this Ser-
51 by an alanine (TAZS51A) abolishes the interaction between TAZ and TEADs (Zhang et al., 2009). 
When the Hippo pathway is activated, for example in response to cell density, polarity signals, or 
mechanical cues (Bae and Luo, 2018), phosphorylated MST1/2, complexed with its regulatory subunit 
Salvador family WW domain containing protein 1 (SAV1), phosphorylates and activates LATS1/2, in 
complex with its regulatory subunit Mps One Binder 1 (MOB1). Activated LATS phosphorylates TAZ 
at Ser-89 to enhance cytoplasmic retention of TAZ by increasing the interaction between TAZ and 14-3-
3 (Lei et al., 2008). This events result in separation of TAZ from its transcription factor, therefore 
inhibiting transcription of TAZ-target genes (Basu et al., 2003; Kanai et al., 2000) (Fig. 10). 
The C-terminal region mediates interactions with PDZ domains by a PDZ-binding motif.  PDZ 
domains are found in transmembrane and cytoskeleton associated proteins (Ye and Zhang, 2013; Kanai 
et al., 2000). Near this C-terminal region, TAZ presents a transcriptional activation domain.  
 TAZ contains four consensuses serine-rich phosphodegron motifs (HxRxxS). Besides Ser-89, 
LATS kinase also phosphorylates TAZ at Ser-66, Ser-117 and Ser-311. The replacement of these four 
serines with alanines (TAZ4SA) conducts to TAZ resistance to the mobility shift caused by MST1/2 and 
LATS1/2 and leads to TAZ accumulation (Lei et al., 2008). LATS phosphorylation of TAZ in Ser-311 
confers a prime phosphorylation site for sequential phosphorylation Ser-314 by another kinase, Casein 
Kinase 1 (CK1). This cooperative phosphorylation recruits SCF/β-TrCP E3 ligase and leads to 
ubiquitination and proteasomal degradation of TAZ (Liu et al., 2010) (Fig. 10). Other regions are also 
important for TAZ regulation. Phosphorylation of TAZ by GSK3β on Ser-58 and Ser-62 in human TAZ 
also recruits β-TrCP, leading to TAZ degradation (Huang et al., 2012).  
Hippo pathway deactivation leads to the accumulation of non-phosphorylated TAZ and its 
translocation to the nucleus. There, TAZ interacts with a variety of transcription factors, not only TEAD, 
but also Runt-related transcription factor 2 (RUNX2) (Cui et al., 2003), T-box transcription factor 5 
(TBX5) (Murakami et al., 2005), paired box protein 3 (PAX3) (Murakami et al., 2006) and Mothers 
against decapentaplegic homolog 2, 3 and 4 (SMAD2/3/4) (Varelas et al., 2010; Varelas et al., 2008; Mo 
et al., 2014), among others (Liu et al., 2011). By binding to these factors, TAZ regulates the expression 
of genes involved in organ development, stem cell proliferation and development of human cancer (Cui 
et al., 2003; Murakami et al., 2005). 
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Figure 10. TAZ regulation by the Hippo pathway. When Hippo signaling is active the phosphorylated MST1/2 kinase, in 
complex with SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1. In turn, LATS1/2 
phosphorylates TAZ on highly conserved residues located within a consensus sequence (HxRxxS). The phosphorylation of 
TAZ promotes its cytoplasmic retention by 14-3-3, or its degradation. When the Hippo pathway is off, unphosphorylated 
TAZ goes to the nucleus, where it binds and activates the TEAD transcription factors and stimulates the expression of genes 
related to stemness, proliferation and survival. 
 
7.2. TAZ function in neurogenesis. 
 
The importance of Hippo signaling is illustrated in early animal development, as precise changes 
in TAZ/YAP localization are essential for determining some of the first cell fate events between 
trophectoderm or inner cell mass (Nishioka et al., 2009). Moreover, the Hippo pathway cross-talks with 
Wnt, BMPs, Notch, and Shh, as these signals also modulate the activities of YAP and TAZ (Hansen et 
al., 2015). In embryonic stem cells (ESCs), TAZ controls the localization of SMAD2/3-4 proteins in the 
nucleus which are required for maintenance of self-renewal markers. Furthermore, TAZ loss, but not 
YAP, results in neuroectoderm differentiation (Varelas et al., 2008). Regarding neurogenesis, most 
studies have focused in Hippo signaling and YAP, and little is known about the implication of TAZ. For 
example, reduced YAP levels result in a decreased number of neuroepithelial cells in the developing 
chick neural tube and Xenopus laevis embryo, whereas increased nuclear YAP-TEAD activity drives the 
expansion of these cells (Cao et al., 2008; Gee et al., 2011). The expression of dominant-negative MST2 
or knockdown of LATS1/2 activity was similarly found to drive proliferation of neuroepithelial cells. 
Additionally, neurofibromin 2 (NF2) has been shown to suppress mouse NPCs expansion by inhibiting 
YAP activity (Lavado et al., 2013). The same group has recently found that inhibition of Hippo pathway 
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by LATS1/2 ablation, accompanied by YAP activation, in apical NPCs results in their transient 
expansion, quickly followed by massive apoptosis (Lavado et al., 2018). All this data point YAP as a 
“stemness” factor, but the specific role of its paralog TAZ in NSC function and neuronal differentiation 
is yet to be identified.  
 
7.3. TAZ function in glioblastoma. 
 
The Hippo pathway controls organ size and prevents tumorigenesis by inhibiting cell proliferation 
and promoting apoptosis (Pan, 2010). Therefore, lack of Hippo signaling is associated with tumour 
progression, and elevated expression and activity of YAP and TAZ co-activators is found in various 
human cancers (Zender et al., 2006; Chan et al., 2008). The implication of TAZ in cancer has been further 
analyzed in tumorigenesis, metastasis, and drug resistance (Pan, 2010; Barron and Kagey, 2014; Gomez 
et al., 2014). One of the main TAZ/TEAD targets is connective tissue growth factor (CTGF), a cytokine 
important for cell growth and development, which is significant for TAZ function in promoting cell 
proliferation (Zhang et al., 2009; Zhao et al., 2008a). TAZ sustains proliferation and tumorigenicity of 
neuroblastomas by targeting CTGF and platelet-derived growth factor β (PDGF-β) (Wang et al., 2015a). 
Additionally, another direct target of TAZ/TEAD, cysteine-rich, angiogenic inducer 61 (CYR61), 
cooperatively acts with CTGF to render taxol resistance to TAZ overexpressing breast cancer cells (Lai 
et al., 2011). Higher expression of another TAZ target, baculoviral inhibitor of apoptosis repeat containing 
5 (BIRC5), was associated with worse overall survival in patients with glioma (Zhang et al., 2018). 
Regarding GBM, TAZ expression is upregulated in gliomas and correlates with tumour grade (Li 
et al., 2016b). Yang and colleagues showed that TAZ can promote proliferation and tumour formation in 
glioblastoma CSCs (Yang et al., 2016). Even more, overexpression of TAZ promoted resistance to the 
cytotoxic agent temozolomide in the human glioblastoma CSC cell line U87-MG, whereas knockdown 
of TAZ expression sensitized GBM U251-MG cells to temozolomide (Tian et al., 2015). Altogether, this 
data suggests that TAZ silencing serves as a potential target for the treatment of GBM. Determining the 
mechanisms used by TAZ to drive tumour growth and progression will clarify its value in cancer therapy. 
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Neurogenesis is a multiple step process that must be tightly orchestrated by multiple extrinsic and 
intrinsic factors. In this thesis we will explore the relevance of NRF2 and TAZ in the regulation of 
neurogenesis under physiological and pathological conditions. Our specific objectives are the following: 
 
1. Analysis of NRF2-mediated regulation of neurogenesis. 
 
1.1. Impact of NRF2 deficiency in hippocampus-related cognition. 
1.2. Role of NRF2 in the proliferative capacity of NSPCs. 
1.3. Implication of NRF2 in NSPCs differentiation. 
1.4. Relevance of NRF2 deficiency in neurogenesis in an AD mouse model. 
 
2. Analysis of the molecular connection between NRF2 and TAZ. 
 
2.1. In silico identification and further validation of putative Antioxidant Response Elements 
(AREs) in the WWTR1 gene. 
2.2. Validation of the NRF2/TAZ axis modulation in NSPCs. 
 
3. Analysis of the role of TAZ in neural stem cell fate. 
 
3.1. Characterization of TAZ expression in the neurogenic niche cell types. 
3.2. Impact of TAZ activity on neuronal differentiation. 
3.3. In silico identification and further validation of putative TAZ interaction regions in 
proneurogenic genes.  
3.4. Identification of TAZ as a transcriptional corepressor of proneurogenic genes. 
3.5. Pathophysiological significance of the TAZ/proneurogenic factors axis in glioblastoma. 
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1. Materials. 
 
1.1. Reagents. 
 
Cell culture: DMEM (Dulbecco’s Modified Eagle Medium) and PBS (Phosphate Buffered 
Saline) were prepared by the Culture Media Preparation Facility at the Instituto de Investigaciones 
Biomédicas “Alberto Sols” (UAM-CSIC); DMEM: F12 (1:1), DMEM/F-12 GlutaMAX™ Supplement, 
neurobasal medium, fetal bovine serum (FBS), B27 supplement, B27 supplement minus vitamin A, 
glutamine, sodium pyruvate, non-essential aminoacids (L-Ala 44 mM, L-Asn 45 mM, L-Asp 40 mM, L-
Glu 40 mM, L-Pro 30 mM),  trypsin, trypsin- ethylenediaminetetraacetic acid (EDTA) (0.05%) phenol 
red, epidermal growth factor (EGF), mouse protein native, basic fibroblast growth factor (bFGF) 
recombinant human protein, Opti-MEM, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
(HEPES), Penicillin-Streptomycin, Ca2+/Mg2+-free Hank’s balanced salt solution (HBSS) (Gibco, 
Thermo Fisher Scientific, Grand Island, NY, USA); accutase (StemCell Technologies); gentamicin 
(Laboratorios Normon, Madrid, Spain); amphotericin B (Lonza, Hopkinton, MA, USA); heparin, 
polybrene, puromycin, poly-D-lysine hydrobromide (Sigma-Aldrich, St. Louis, Missouri, USA); human 
fibroblast growth factor and epidermal growth factor (hFGF-2 and hEGF) (Peprotech, NJ, USA); Matrigel 
hESC-Qualified Matrix (Corning, Bedford, MA, USA); plastic material (Falcon, Thermo Fisher 
Scientific and BD Biosciences, San Jose, CA, USA); coverslips (VWR, Lutterworth, UK).  
Pharmacological activators, inhibitors and other compounds: R, S-sulforaphane (SFN) (LKT 
Laboratories, St Paul, USA). 
DNA manipulation and extraction: Antibiotics: ampicillin (Sigma-Aldrich). Plasmid DNA 
preparation: Genopure Plasmid Maxi Kit (Roche Applied Science, Penzberg, Germany), Speedtools 
Plasmid DNA Purification Kit (mini preps) (Biotools, Madrid, Spain). Plasmid digestions: restriction 
enzymes (Thermo Fisher Scientific and New England Biolabs). DNA cloning: alkaline phosphatase 
(Roche), T4 polynucleotide kinase and T4 DNA ligase (Promega). DNA electrophoresis: agarose 
(CONDA laboratories, Madrid, Spain) and low melting temperature agarose (Nusieve, agarose, Lonza). 
SYBR Safe DNA Gel Stain (Thermo Fisher Scientific). DNA molecular weight markers: DNAλ HindIII 
(Thermo Fisher Scientific). DNA purification from band in agarose gel: “Geneclean® Kit” (MP 
Biomedicals).  
Transfection reagents: TransFectin™ Lipid Reagent (BioRad,  Hercules, California, USA), 
Lipofectamine 2000 Reagent, Lipofectamine Transfection Reagent and PLUS Reagent (Invitrogen). 
Protein electrophoresis, transfer and immunoblotting: Protein quantification DC Protein 
Assay (BioRad). Molecular weight markers: “Bench protein ladder” (Invitrogen). Cuvettes, TEMED (N 
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N N′N′-Tetramethylethylenediamine), ammonium persulfate, acrylamide/bys-acrylamide (BioRad), 
Immobilon-P membranes (Millipore), enhanced chemiluminescence substrate (AmershamTM ECLTM 
Select Western Blotting Detection Reagent, GE Healthcare).  
RNA extraction and qRT-PCR: TRIzol® Plus RNA Purification Kit (Thermo Fisher 
Scientific). DNase I, amplification grade (Thermo Fisher Scientific). Retrotranscriptase (High Capacity 
RNA-to-cDNA Kit, Applied Biosystems). SYBR green, PCR plates (Applied Biosystems), chloroform, 
isopropanol, ethanol (Merck).  
RNA and DNA quantification: NanoDropTM spectrophotometer (Thermo Fisher Scientific). 
Luciferase activity: Dual-Luciferase® Reporter Assay System (Promega). 
Live assay: Calcein (#C3099, Molecular Probes/ Thermo Fisher Scientific). 
Proliferation assay: Click-iT™ 5-ethynyl-2'-deoxyuridine (EdU) Alexa Fluor™ 488 Imaging 
Kit (C10337, Thermo Fisher Scientific). 
Brain dissection and sectioning: scissors, scalpels, forceps (Fine Science Tools). 
Immunofluorescence and immunohistochemistry: paraformaldehyde, formic acid, Triton X-
100, 3´-3´-diaminobenzidine tetrahydrochloride (DAB), bovine serum albumin (BSA), xylol, cresyl 
violet acetate (Sigma-Aldrich); DEPEX mounting media, ProLong™ Gold antifade mountant, horse 
serum (Thermo Fisher Scientific).  
Chromatin Immunoprecipitation assay (ChIP): formaldehyde (Fluka, 47630), glycine (Bio-
Rad, 161–0718), protein G Sepharose (GE Healthcare, 17-0618-01), Glycogen (Invitrogen, 10814-010), 
proteinase K (Sigma-Aldrich, P2308), Triton X-100 (Sigma-Aldrich, T8787), phenylmethylsulfonyl 
fluoride (PMSF) (Sigma-Aldrich, P7626), leupeptin (Sigma-Aldrich, L8511), phenol: chloroform: 
isoamyl alcohol 25:24:1 (Sigma-Aldrich, P2069). 
1.2. Antibodies. 
 
1.2.1. Primary antibodies. 
Primary antibodies used in this study are indicated in Table 1. The specificity of TAZ antibody 
is showed in Fig. 11. 
 
 
 
 
MATERIAL AND METHODS 
 
67 
 
Antibody Reference Clonality Isotype Dilution and application 
Acetyl-Histone H3 Sigma Aldrich. 06-599. Polyclonal Rabbit 1.5 µg/106 cells (ChIP) 
ACTB 
Santa Cruz Biotechnology. Sc-
1616. 
Polyclonal Goat 1/5000 (WB) 
APP/Aβ (6E10) Covance. 803001. Monoclonal Mouse 
1/2000 (WB) 
1/500 (IHC-Fr/p) 
Caspase-3 Cell Signaling Technology. 9662. Polyclonal Rabbit 1/1000 (WB) 
CHD4 Abcam. Ab72418. Polyclonal Rabbit 3 µg/106 cells (ChIP) 
CTGF (L-20) 
Santa Cruz Biotechnology. 
Sc-14939. 
Polyclonal Goat 1/2000 (WB) 
Doublecortin 
(DCX) 
Santa Cruz Biotechnology. Sc-
8066. 
Polyclonal Goat 1/250 (IHC-Fr; ICC/IF) 
GAPDH Millipore. CB1001. Monoclonal Mouse 1/15000 (WB) 
GFAP Dako. Z0334. Polyclonal Rabbit 1/200 (IHC-Fr; ICC/IF) 
GFAP Sigma-Aldrich. G3893. Monoclonal Mouse 1/200 (IHC-Fr; ICC/IF) 
hNRF2 Abyntek. Abgent#AJ1555a. Polyclonal Rabbit 1/2000 (WB) 
IgG2a Abcam. Ab18413. Monoclonal Mouse 3 µg/106 cells (ChIP) 
Ki67 (SP6) Abcam. Ab16667. Monoclonal Rabbit 1/2000 (IHC-Fr; ICC/IF) 
Lamin B 
Santa Cruz Biotechnology. Sc-
6217. 
Polyclonal Goat 1/2000 (WB) 
MAP2 Sigma-Aldrich. M9942. Monoclonal Mouse 1/200 (ICC/IF) 
Nestin Abcam. Ab11306. Monoclonal Mouse 1/200 (IHC-Fr; ICC/IF) 
Nestin Novus Biologicals. NB100-1604. Polyclonal Chicken 1/500 (IHC-Fr; ICC/IF) 
Nestin (10c2) 
Santa Cruz Biotechnology. Sc-
23927. 
Monoclonal Mouse 1/200 (IHC-Fr; ICC/IF) 
NEUROD (A-10) 
Santa Cruz Biotechnology. Sc-
46684. 
Monoclonal Mouse 1/500 (WB) 
NQO1 Abcam. Ab34173. Polyclonal Rabbit 1/2000 (WB) 
NQO1 Abcam. Ab2346. Polyclonal Goat 1/2000 (WB) 
NRF2 Homemade (Cuadrado´s Lab). Polyclonal Rabbit 1/2000 (WB) 
RNA Pol II  (A-
10) 
Santa Cruz Biotechnology. Sc-
17798. 
Monoclonal Mouse 3 µg/106 cells (ChIP) 
p-Tau (Ser202, 
Thr205) (AT-8) 
Thermo Scientific. MN1020. Monoclonal Mouse 1/200 (IHC-Fr/p; ICC/IF) 
Rabbit IgG 
Control 
Abcam. Ab37415. Polyclonal Rabbit 1.5 µg/106 cells (ChIP) 
SOX2 R&D Systems. AF2018. Polyclonal Goat 
1/500 (IHC-Fr; ICC/IF) 
1/2000 (WB) 
Tau (H-150) Santa Cruz Biotech. Sc-5587. Polyclonal Rabbit 1/200 (IHC-Fr/p; ICC/IF) 
TAU (HT7) Thermo Scientific. MN1000B. Monoclonal Mouse 
1/2000 (WB) 
1/250 (IHC-Fr/p; ICC/IF;IHC-
P) 
TAZ Sigma Aldrich. HPA007415. Polyclonal Rabbit 
1/2000 (WB) 
1/200 (IHC-Fr; ICC/IF) 
1/100 (ChIP)  
Tubulin β class III 
(TUBB3) 
Sigma-Aldrich. T2200.  Polyclonal Rabbit 1/200 (ICC/IF) 
V5 Life Technologies. 37-7500. Monoclonal Mouse 1/2000 (WB) 
YAP/TAZ  
(D24E4) 
Cell Signaling Technology. 8418. Monoclonal Rabbit 
1/2000 (WB) 
1/250 (IHC-Fr; ICC/IF; IHC-P) 
Table 1. Primary antibodies used in immunoblots, immunofluorescence and ChIP, indicating their reference, clonality, isotype 
and application. ICC/IF: immunocytochemistry/immunofluorescence; IHC-Fr, immunohistochemistry on floating slices; IHC-p, 
immunohistochemistry on paraffin slices; WB, western blot; ChIP, chromatin immunoprecipitation.  
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Figure 11. Characterization of the TAZ 
antibody. (A) Representative confocal 
images of TAZ immunostaining in 
untransfected cells (CT), or cells expressing 
wild type (TAZ-WT), or mutant TAZS51A, 
TAZ4SA and TAZ4SA+S51A, after 5 days of 
retroviral transduction. (B) Representative 
confocal images of TAZ immunostaining in 
shCO and shTAZ in ReNcells after 5 days of 
lentiviral transduction. (C) Representative 
immunoblot analysis of TAZ in ReNcells 
CT, TAZ-WT, TAZ4SA and TAZ4SA+S51A, 
shCO and shTAZ after 5 days of viral 
transduction, showing a specific band around 
50 kDa. 
 
1.2.2. Secondary antibodies. 
The secondary antibodies conjugated to horseradish peroxidase (HRP) used in WB and the 
secondary antibodies conjugated to Alexa Fluor® for immunofluorescence are described in Table 2.  
Antibody Reference Clonality Isotype Dilution and application 
Alexa Fluor 647 
Donkey anti-Goat 
Abcam. Ab150131. Polyclonal Donkey 1/500 (IHC-Fr; ICC/IF) 
Alexa Fluor 647 
Donkey anti-
Mouse 
Thermo Fisher. A-31571. Polyclonal Donkey 1/500 (IHC-Fr; ICC/IF) 
Alexa Fluor 488 
Donkey anti-
Mouse 
Thermo Fisher. A-21202. Polyclonal Donkey 1/500 (IHC-Fr; ICC/IF) 
Alexa Fluor 555 
Donkey anti-
Rabbit 
Thermo Fisher. A-31572. Polyclonal Donkey 1/500 (IHC-Fr; ICC/IF) 
Alexa Fluor 647 
Donkey anti-
Rabbit 
Thermo Fisher. A-31573. Polyclonal Donkey 1/500 (IHC-Fr; ICC/IF) 
Alexa Fluor 555 
Donkey anti-Rat 
Abcam. Ab150154. Polyclonal Donkey 1/500 (IHC-Fr; ICC/IF) 
ECLTM Anti-
Rabbit IgG HRP 
GE Healthcare. NA934V. Polyclonal Donkey 1/1000 (WB) 
ECLTM Anti-
Mouse IgG HRP 
GE Healthcare. NA931V. Polyclonal Donkey 1/1000 (WB) 
Anti-Goat IgG 
HRP 
Novex Life Technologies. 
A15999. 
Polyclonal Donkey 1/1000 (WB) 
Table 2. Secondary antibodies used in immunoblots and immunofluorescence. ICC/IF: 
immunocytochemistry/immunofluorescence; IHC-Fr, immunohistochemistry on floating slices; WB, western blot. 
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1.3. Plasmids. 
 
pcDNA3.1-mNrf2-V5/HisB: plasmid encoding the wild type sequence of murine NRF2, with a 
V5 tag (GKPIPNPLLGLDST) in the C-terminus. This plasmid was originally provided by Dr. John D. 
Hayes (Division of Cancer Research, School of Medicine, Ninewells Hospital and Medical School, 
University of Dundee, Dundee). 
pcDNA3.1-mNrf2-ΔETGE-V5/HisB: plasmid encoding the KEAP1-insensitive version of 
murine NRF2, with a V5 tag in the C-terminus. This construct lacks residues 79- ETGE-82, responsible 
for the high affinity binding to KEAP1. This plasmid was originally provided by Dr. John D. Hayes. 
pTK-Renilla: plasmid used as an internal control in the luciferase assays. It contains the sea 
pansy (Renilla reniformis) luciferase gene under the control of the thymidine kinase promoter from 
Herpes Simplex Virus for its constitutive expression in mammalian cells. 
p29SOD1: luciferase reporter pGL3-basic with a modified version of firefly (Photinus pyralis) 
luciferase under the control of the 29 bp-long minimal promoter from the human SOD1 gene (Rojo et al., 
2004). This vector has been optimized for monitoring transcriptional activity in transfected eukaryotic 
cells. 
WWTR1-ARE2-LUC reporter and WWTR1-ARE-mutated-LUC reporter: oligonucleotides 
with three tandem repetitions of ARE2 or ARE2-mutated of the WWTR1 gene promoter (Sigma-Aldrich) 
were subcloned into the NheI and XhoI sites of a p29SOD1 vector described above. Artificial 
oligonucleotides are indicated below: ARE sequence is indicated in red, separated with a BamHI site 
(underlined) and a random separating-sequence (bold letters). Asterisk indicates mutated NheI site to 
facilitate re-ligated vectors exclusion with NheI digestion prior to transformation. Bold and red letters in 
WWTR1 ARE2-mutated indicate nucleotide site mutation. 
WWTR1 ARE2: 
5’- CTAGT*GTGACTCAGCTGGATCCGTGACTCAGCTACGTGAGTGACTCAGCTC    -3’ 
3’-     A*CACTGAGTCGACCTAGGCACTGAGTCGATGCACTCACTGAGTCGAGAGCT-5’  
WWTR1 ARE2-mutated: 
5’- CTAGT*GCGACTCAACTGGATCCGCGACTCAACTACGTGAGCGACTCAACTC    -3’ 
3’-     A*CGCTGAGTTGACCTAGGCGCTGAGTTGATGCACTCGCTGAGTTGAGAGCT-5’ 
 
SOX2-TEAD1(a)-LUC reporter: oligonucleotides with three tandem repetitions of TEAD1(a) 
sequence in the promoter of SOX2 (Sigma-Aldrich) were subcloned into the NheI and XhoI sites of a 
p29SOD1 vector described above. Artificial oligonucleotides are indicated below: TEAD-recognized 
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sequence is indicated in red, separated with a BamHI site (underlined) and a random separating-sequence 
(bold letters). Asterisk indicates mutated NheI site to facilitate re-ligated vectors exclusion with NheI 
digestion prior to transformation.  
5´- CTAGT*CCCCATTCCCATCGGATCCCCCCATTCCCATCACGTGACCCCATTCCCATCC-3´ 
3´-     A*GGGGTAAGGGTAGCCTAGGGGGGTAAGGGTAGTGCACTGGGGTAAGGGTAGGAGCT-5´ 
 
pMD2.G: plasmid that encodes the G protein from the envelope of the Vesicular Stomatitis Virus 
used for lentiviral production (Addgene, #12259). 
pSPAX2: packaging plasmid that encodes the Gag and Pol proteins from the Human 
Immunodeficiency Virus necessary for lentiviral production (Addgene, #12260). 
pLKO.1-TRC control: plasmid used for the generation of lentiviral particles with the sequence 
CCGCAGGTATGCACGCGT to be used as a non-hairpin control (Addgene, #10879). 
pLKO.1-puro shNRF2 (mouse): plasmid used for the generation of lentiviral particles with the 
sequence CCAAAGCTAGTATAGCAATAA transcribed into a short hairpin RNA (shRNA) sequence 
against murine Nfe2l2 gene (MISSION shRNA, Sigma- Aldrich). 
pLKO.1-puro shNRF2 (human): several plasmids have been used to knockdown human 
NFE2L2 gene, used for the generation of lentiviral particles (MISSION© shRNA, Sigma-Aldrich, 
SHCLNG-NM_006164) and are indicated below with their targeting sequence:   
- TRCN0000007555: AGTTTGGGAGGAGCTATTATC. 
- TRCN0000007556: GCACCTTATATCTCGAAGTTT. 
- TRCN0000007557: CCCTGTTGATTTAGACGGTAT. 
- TRCN0000007558: CCGGCATTTCACTAAACACAA. 
- TRCN0000273494: AGTTTGGGAGGAGCTATTATC. 
pLKO.1-puro shTAZ (human): plasmid used for the generation of lentiviral particles with the 
sequence GCGTTCTTGTGACAGATTATA transcribed into a shRNA sequence against human WWTR1 
gene (shRNA WWTR1 SHCLNG-NM_015472 TRCN0000370007) (MISSION© shRNA, Sigma-
Aldrich). 
pLKO.1-puro shTEAD2 (human): plasmid used for the generation of lentiviral particles with 
the sequence ATGACCTGTGAGATCACAAAG transcribed into a shRNA sequence against human 
TEAD2 gene (shRNA TEAD2 SHCLNG-NM_003598, TRCN0000426430) (MISSION© shRNA, 
Sigma-Aldrich). 
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pLKO.1-puro shTEAD1/3/4 (human): plasmid used for the generation of lentiviral particles 
with the sequence ATGATCAACTTCATCCACAAG transcribed a shRNA sequence targeting an 
identical region in TEAD1, TEAD3 and TEAD4. This plasmid was a generous gift from Prof. Zengqiang 
Yuan. 
pWPXL: plasmid generated from pWPXL-GFP, a plasmid for the generation of lentiviral 
particles expressing the green fluorescence protein (GFP) under the control of the Elongation Factor 1α 
promoter. This plasmid was originally provided by Dr. Didier Trono (School of Life Sciences, École 
Polytechnique Fédérale de Lausanne, Switzerland). In the pWPXL plasmid, the GFP encoding sequence 
has been removed. 
pWPXL-mNrf2-V5/HisB: plasmid for the generation of lentiviral particles expressing the 
murine NRF2 and with a V5 tag in the C-terminus. The mNrf2-V5/HisB insert from pcDNA3.1-mNrf2-
V5/HisB was subcloned into the BstEII and SmaI/PmeI restriction sites of the pWPXL vector. 
pWPXL-mNrf2-ΔETGE-V5/HisB: plasmid for the generation of lentiviral particles expressing 
the murine version of NRF2 lacking residues 79-ETGE-82 and with a V5 tag in the C-terminus. The 
mNrf2-ΔETGE-V5/HisB insert from pcDNA3.1-mNrf2-ΔETGE-V5/HisB was subcloned into the BsteII 
and SmaI/PmeI restriction sites of the pWPXL vector. 
pCMV-Gag-Pol: retroviral packaging vector which encodes for retroviral genes Gag and Pol 
(Cell Biolabs, RV-111). 
pCMV-VSV-G: plasmid encoding the envelope protein for producing retroviral particles 
(Addgene, #8454). 
pCL-Ampho: packaging vector designed to maximize recombinant-retrovirus titers (Novusbio, 
NBP2-29541). 
pBABE-puro: control retroviral vector for the overexpression of TAZ mutants. This plasmid 
presents puromycin selection (Addgene, #1764). 
pBABE-puro-TAZ-WT: retroviral vector encoding the wild type sequence of human TAZ 
protein. This plasmid was a generous gift from Dr. Kun-Liang Guan (Department of Pharmacology and 
Moores Cancer Center, University of California, San Diego, USA) (Fig. 12). 
pBABE-puro-TAZ-S51A: retroviral vector encoding the TEAD-binding-defective mutant form 
of human TAZ. Serine 51 has been replaced to alanine which selectively abolishes TAZ ability to activate 
TEAD (Zhang et al., 2009). This plasmid was a generous gift from Dr. Kun-Liang Guan (Fig. 12). 
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pBABE-puro-TAZ-4SA: retroviral vector encoding constitutively active mutant form of human 
TAZ, resistant to inhibition by LATS kinases. All putative phosphorylation sites, the four serine residues 
in the HxRxxS motifs, have been replaced to alanine residues (S66A, S89A, S117A, and S311A) (Lei et 
al., 2008). This plasmid was a generous gift from Dr. Kun-Liang Guan (Fig. 12). 
pBABE-puro-TAZ-4SA-S51A: retroviral vector encoding constitutively active and TEAD-
defective mutant of human TAZ. This plasmid was a generous gift from Dr. Kun-Liang Guan (Fig. 12).  
 
Figure 12. Graphical overview of the different TAZ mutants used in this study. (A) Wild type TAZ is phosphorylated by 
LATS kinases leading to sequestration in the cytosol with 14-3-3 proteins and its proteasomal degradation. (B) Mutant TAZ-
51A cannot bind TEAD and competes with endogenous TAZ for phosphorylation (dominant negative). (C) Mutant TAZ-4SA is 
not phosphorylated by LATS kinases and therefore is constitutively active. (D) Mutant TAZ-4SA-51A combines constitutive 
activation with lack of TEAD binding. 
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1.4. Buffers and solutions. 
 
General buffers: Luria-Bertani medium (LB) for the growth of bacteria, LB agar plates, 
phosphate saline buffer (PBS), 1 M Tris-HCl pH 7.5, 1 M Tris-HCl pH 8.8, 1 M Tris- HCl pH 6.6, 1 M 
HEPES pH 7.5, 10% sodium dodecyl sulfate (SDS), 0.5 M EDTA pH 8.0 and 0.5 M EGTA pH 7.5 were 
provided by the Culture Media Preparation Facility at the Instituto de Investigaciones Biomédicas 
“Alberto Sols” (UAM-CSIC). 
Cellular lysis buffer: 50 mM Tris pH 7.6, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% SDS. 
Protein loading buffer for SDS-PAGE (5X): 50 mM Tris-HCl pH 6.8, 2% SDS, 0.1% 
bromophenol blue, 10% glycerol, 150 mM β-mercaptoethanol. 
Electrophoresis running buffer: 0.37% EDTA, 191 mM glycine, 0.1% SDS and 25 mM Tris-
HCl pH 7.4. 
Transfer buffer: 25 mM Tris-HCL pH 7.4, 191 mM glycine and 20% methanol. 
Tris buffered saline with Tween 20 (TTBS): 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% 
Tween-20. 
DNA loading buffer: DNA Gel Loading Dye (6X) (Thermo Scientific), consisting on 10 mM 
Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% xylene cyanol, 60% glycerol and 60 mM EDTA. 
Tris buffered saline (TBS): 100 mM Tris-HCl pH 7.5 and 225 mM NaCl. 
Tris-EDTA buffer (TE): 10 mM Tris-HCl pH 7.5 and 1 mM EDTA. 
Tris base, acetic acid and EDTA buffer (TAE): 40 mM Tris-HCl pH 7.5, 20 mM acetic acid 
and 1mM EDTA. 
ChIP assay buffers: PBS, Elution Buffer (1% SDS, 0.1 M NaHCO3), SDS Lysis Buffer (1% 
SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0), Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 
mM EDTA, 16.7 mM Tris-HCl (pH 8.0), 167 mM NaCl), Low Salt Washing Buffer (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl), High Salt Washing Buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl), LiCl Washing Buffer 
(0.25 mM LiCl, 1% NP-40, 1% sodiumdesoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0) and TE 
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA). 
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1.5. Bacterial stocks. 
 
The high efficiency competent strain DH5-α of Escherichia coli was provided by the Culture 
Media Preparation Facility from the Instituto de Investigaciones Biomédicas “Alberto Sols” (UAM-
CSIC). 
1.6. Cell lines. 
 
HEK293T: cell line derived from human embryonic kidney cells, generated in 1987 in Dr. 
Michele P. Calos (Standford University, USA) by stable insertion of the simian virus 40 (SV40) large T 
antigen in the HEK293 cell line. This allows a very efficient replication of vectors carrying the SV40 
region of replication, achieving remarkable expression levels. 
HEK293T/17: specific clone (clone 17) from HEK293T cells that was selected for its high 
transfectability (Rockefeller University, USA), which makes them especially suitable for lentiviral and 
retroviral production. 
Murine Neural Stem/Progenitor Cells: primary neural stem/progenitor cell cultures were 
generated from the neurogenic niches of postnatal and adult Nrf2-WT, Nrf2-KO, APP-TAU-Nrf2-WT 
and APP-TAU-Nrf2-KO with the method described in section 2.2.1. 
Human Neural Progenitor Cell line ReNcell VM: The immortalized neural progenitor cell line 
derived from ventral mesencephalon of human fetal brain were purchased from EMD Millipore (Billerica, 
MA, USA, Ref. SCC008). ReNcell VM cell line was developed by the ReNeuron Group plc. Cells were 
immortalized using retroviral transduction with the v-myc oncogene and are able to generate neurons and 
glia cells under differentiation conditions. In this study ReNcell VM will be abbreviated to ReNcell. 
U87-MG (ATCC® HTB­14™): Human primary glioblastoma/astrocytoma cell line derived by 
explant technique from a male patient (Ponten and Macintyre, 1968; Westermark et al., 1973). 
1.7. Animals. 
 
Animals were housed under a 12 h light-dark cycle. Food and water were provided ad libitum 
and mice were cared according to protocols approved by the Ethics Committee for Research of the 
Universidad Autónoma de Madrid following institutional, Spanish and European guidelines (RD 
53/2013, and ECC 566/2015, 2010/63/UE European Council Directives).  
C57/BL6J-Nrf2-/- (Nrf2-/-) mice and their wild type counterparts were kindly provided by Dr. 
Masayuki Yamamoto (Tohoku University Graduate School of Medicine, Sendai, Japan) (Itoh et al., 
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1997). C57/BL6J-Nrf2-/- mice bear a lacZ-neo cassette replacing a 1.2 kb long segment from the fifth 
exon of Nrf2.  
APP-TAU-Nrf2+/+ (AT-Nrf2+/+) and APP-TAU-Nrf2-/- (AT-Nrf2-/-) mice were obtained by 
crossing the proper founder mice. APPV717I mice expressing in heterozygosis the human APP isoform 695 
carrying the V717I (London) mutation under the control of neuron specific mouse Thy1 promoter (Vidal 
et al., 1990; Moechars et al., 1999), were backcrossed with C57/BL6J-Nrf2+/+ or C57/BL6J-Nrf2-/- mice 
for over five generations. TAUP301L mice, expressing in homozygosis human TAU isoform of 441 
aminoacids containing four repeats, with 2 N-terminal inserts, and carrying P301L mutation (Tg(Thy1-
MAPT*P301L)2Vln) under control of the neuron-specific mouse Thy1 gene promoter (Terwel et al., 
2005), were backcrossed with C57/BL6J-Nrf2+/+ or C57/BL6J-Nrf2-/- mice for over five generations.  
APPV717I (Nrf2+/+ or Nrf2-/-) mice and TAUP301L (Nrf2+/+ or Nrf2-/-) mice were backcrossed for over five 
generations to obtain offspring APP-TAU-Nrf2+/+ (AT-Nrf2+/+) and APP-TAU-Nrf2-/- (AT-Nrf2-/-), 
respectively. 
Nude mice (Foxn1nu) are athymic and lack cell-mediated immunity (The Jackson Laboratory, 
stock #002019) (Kaushik et al., 1995). 
1.8. Human material. 
 
Human glioblastomas (GB) were derived from brain surgery biopsies in the Hospital Ramón y 
Cajal (Madrid, Spain). These cells were kindly supplied by Dr. Marta Izquierdo (Centro de Biología 
Molecular “Severo Ochoa” - UAM), with the approval of the Ethic Committees of UAM and Hospital 
Ramón y Cajal. 
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2. Methods.  
 
2.1.  In silico assays. 
 
2.1.1. In silico analysis of putative binding sequences of transcription factors. 
 
The putative elements recognized by the transcription factors of interest were identified based on 
the data available in the Encyclopedia of DNA Elements at UCSC (ENCODE) 
(https://genome.ucsc.edu/encode/) for human genome (Feb. 2009). This database contains chromatin 
immunoprecipitation (ChIP) information available for several transcription factors. Regarding NRF2, 
there is not data available, but there is for other ARE-binding factors such as MAFF, MAFK and Bric-a-
brac homodimerization domain and cap ‘n’ collar homolog 1 (BACH1). For transcription cofactor TAZ 
studies, data are available for several TAZ-binding partners as TEADs, SMADs and RUNX. These 
sequences were localized in DNase hypersensitive and H3K27Ac-enriched regions, often found near 
regulatory elements and, in particular, in promoters. The selected sequences from ENCODE where next 
compared with the consensus sequence recognized by each transcription factor based on the position 
frequency matrix from the JASPAR database (http://jaspar.genereg.net/) derived from published and 
experimentally defined transcription factor binding sites for eukaryotes, which is converted to a PSSM 
(Position Specific Scoring Matrix) (PSSM for each transcription factor analyzed are available in Tables 
3 to 9) using log2(odd-ratio) (Sandelin et al., 2004; Khan et al., 2018). The robustness of these PSSMs 
depends on the amount of data available for each transcription factor in the JASPAR database. For 
analysis, a script was generated with Python 3.4 (Appendix I). The relative score for each putative site 
was calculated with the following formula: 
 
𝑆𝑐𝑜𝑟𝑒 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 =
𝑆𝑐𝑜𝑟𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝑚𝑎𝑥 − 𝑆𝑐𝑜𝑟𝑒 min 𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒
𝑆𝑐𝑜𝑟𝑒 max 𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒 − 𝑆𝑐𝑜𝑟𝑒 min 𝑝𝑜𝑠𝑠𝑖𝑏𝑙𝑒
 
 
where score of the sequence max is the addition of the score of each pair base of the selected sequence 
based on the PSSM, the score min possible is the summation of all negative values of the PSSM, so the 
lowest possible score able to obtain for a sequence, and the score max possible is the addition of all the 
positive values from the PSSM, so the highest possible score able to obtain. The Python script for NRF2 
and its PSSM were a courtesy of Natalia Jiménez-Moreno (present address: University of Bristol, UK).  
The script was modified for TEADs, SMADs and RUNX2 to obtain their PSSM. The data of the relative 
scores for the putative binding sites are available in Results. 
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 1 2 3 4 5 6 7 8 9 10 11 
A 1.1375 -2.3219 -2.3219 2.0704 -2.3219 0.4854 0.2630 1.7655 -2.3219 -2.3219 1.6781 
C -1.3219 -2.3219 -2.3219 -2.3219 1.8480 -0.7370 1.1375 -2.3219 -2.3219 2.0704 -0.7370 
G 1.0000 -2.3219 2.0000 -2.3219 -1.3219 -1.3219 -1.3219 -0.7370 2.0704 -2.3219 -0.7370 
T -2.3219 2.0704 -1.3219 -2.3219 -0.7370 1.2630 0.0000 -0.7370 -2.3219 -2.3219 -1.3219 
 
Table 3. Position specific scoring matrix (PSSM) for NRF2 and its motif from JASPAR 
database. PSSM is derived from the frequency matrix available in JASPAR database.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A -0.58496 1.73697 -1.58496 2.11548 -1.58496 -1.58496 -1.58496 -1.58496 1.00000 -0.58496 0.00000 -1.58496 
C 1.22239 -1.58496 2.11548 -1.58496 -1.58496 -1.58496 2.11548 2.00000 -1.58496 1.41504 0.73697 0.00000 
G -0.58496 0.41504 -1.58496 -1.58496 -1.58496 -1.58496 -1.58496 -1.58496 -1.58496 0.73697 0.41504 1.58496 
T 0.73697 -1.58496 -1.58496 -1.58496 2.11548 2.11548 -1.58496 -0.58496 1.41504 -1.58496 0.41504 0.00000 
 
Table 4. Position specific scoring matrix (PSSM) for TEAD1 and its motif from 
JASPAR database. PSSM is derived from the frequency matrix available in JASPAR 
database.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
A 0.0264 -0.6064 1.7058 -1.7602 1.9347 -5.4972 -3.0821 -3.9122 -3.9122 0.9622 -0.2620 -0.2748 -0.3008 
C 0.1077 0.8187 -2.9122 1.8217 -4.4972 -3.6227 -3.9122 1.8865 1.9235 -1.1514 -0.2748 0.3525 0.7123 
G -0.2620 -0.7246 -0.9324 -3.1753 -3.4972 -4.2748 -3.7602 -3.6227 -5.0821 -1.2493 0.6183 0.1273 -0.1995 
T 0.1370 0.0053 -3.1753 -3.4972 -3.7602 1.9540 1.9150 -2.4383 -2.8342 0.2754 -0.2620 -0.2620 -0.4972 
 
Table 5. Position specific scoring matrix (PSSM) for TEAD2 and its motif from 
JASPAR database. PSSM is derived from the frequency matrix available in JASPAR 
database.  
 
 
 1 2 3 4 5 6 7 8 
A 1.14803 -1.16312 1.92317 -12.46518 -0.30815 -12.46518 -12.46518 1.92317 
C -6.39909 1.74252 -12.46518 -12.46518 -7.88022 1.92317 1.92317 -2.44282 
G 0.65667 -3.67728 -12.46518 -12.46518 -2.54334 -12.46518 -12.46518 0.61413 
T -2.34884 -12.46518 -12.46518 1.92317 1.57776 -12.46518 -10.14326 1.27291 
 
Table 6. Position specific scoring matrix (PSSM) for TEAD3 and its motif from 
JASPAR database. PSSM is derived from the frequency matrix available in JASPAR 
database. 
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 1 2 3 4 5 6 7 8 9 10 
A -0.18715 1.35382 0.78330 2.00143 -3.52214 -0.24010 -7.98157 -2.33771 1.18082 -0.20021 
C 0.51429 -3.45801 2.00143 -4.28113 -7.98157 -7.98157 2.00143 2.00143 -1.60653 0.19834 
G -0.22668 0.53807 -2.85228 -3.52214 -7.98157 -3.89410 -3.65964 -6.98157 -0.15502 -0.33771 
T -0.22668 -3.02737 -3.73364 -3.22668 2.00143 2.00143 -3.17421 0.46552 0.79979 0.27110 
 
Table 7. Position specific scoring matrix (PSSM) for TEAD4 and its motif from 
JASPAR database. PSSM is derived from the frequency matrix available in JASPAR 
database. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
A -0.4285 -0.1901 -3.9053 -2.7247 -7.8122 -7.8122 -1.0707 -0.0843 -7.8122 1.7690 -2.8580 -0.9295 -1.0178 
C 0.9460 -1.5642 -4.6423 -2.2886 2.0016 -7.8122 0.0458 -0.8349 1.9968 -3.4902 1.7133 1.3776 -0.0640 
G -0.4113 -2.6829 1.9659 -1.1117 -7.8122 -7.8122 1.2646 0.3222 -5.8122 -3.5642 -0.7461 -2.2272 -2.6423 
T -0.7461 1.4046 -7.8122 1.6777 -7.8122 2.0016 -3.2272 0.3376 -7.8122 -1.1975 -7.8122 -0.5548 1.2673 
 
Table 8. Position specific scoring matrix (PSSM) for SMAD2/3/4 and its motif from 
JASPAR database. PSSM is derived from the frequency matrix available in JASPAR 
database. 
 
 1 2 3 4 5 6 7 8 9 
A 0.9466 1.7204 1.7204 -10.9726 -10.9726 -0.0695 -10.9726 1.7204 1.0646 
C -0.8785 -1.8511 -2.6239 1.7204 1.7204 -5.7632 1.7204 -2.0748 -1.5675 
G -2.6195 -0.7247 -10.9726 -10.9726 -10.9726 1.2283 -10.9726 -2.1303 -0.8241 
T 0.4521 -1.7853 -10.9726 -10.9726 -10.9726 -4.0538 -10.9726 -3.3877 -1.7247 
 
Table 9. Position specific scoring matrix (PSSM) for RUNX2 and its motif from 
JASPAR database. PSSM is derived from the frequency matrix available in JASPAR 
database. 
 
 
2.1.2. Brain RNA-seq data. 
 
The Brain RNA-seq database from Stanford University, Stanford, CA, USA 
(http://www.brainrnaseq.org/) was analyzed for TAZ encoding-gene expression in astrocytes, neurons 
and endothelial cells both in human and murine tissue. This database contains transcriptome data from 
purified populations of the main cell types present in the brain, but not for neural stem cells. Murine data 
was obtained by RNA sequencing of cell types derived from the cerebral cortex (Zhang et al., 2014). 
Transcriptome profiles for humans were obtained from purified cell cultures derived from juvenile and 
adult temporal lobe cortex tissue and brain fetal tissue (Zhang et al., 2016). 
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2.1.3. UCSC Xena platform. 
 
UCSC Xena system is an analysis tool which hosts datasets from several landmark cancer 
genomics resources as TCGA (The Cancer Genome Atlas) (https://xenabrowser.net/). This platform was 
examined to obtain the survival rate and the correlation between different proteins based on the data 
available in TCGA for low-grade glioma and glioblastoma (Goyal, 2019).  
 
2.2.  In vitro assays. 
 
2.2.1. Cell lines. 
 
HEK293T and HEK237T/17 cells were grown in DMEM supplemented with 10% FBS, 4 mM 
L-glutamine and 80 μg/ml gentamicin. 
 
U87-MG and GB from human explant were grown in adhesion conditions in DMEM 
supplemented with 10% FBS, 4 mM L-glutamine, 5 mM HEPES, 80 μg/ml gentamicin and 1 µg/ml 
amphotericin B. When maintained in stem cell culture conditions, cells were plated on uncoated 10 cm 
dishes in DMEM: F12 (1:1) supplemented with 2 mM L-glutamine, 5 mg/ml albumax I, 6 mg/ml glucose, 
B27 supplement (without vitamin A), 15 ng/ml hFGF-2, 20 ng/ml hEGF, 2 μg/ml heparin, 80 μg/ml 
gentamicin and 1 µg/ml amphotericin B, and allowed to grow forming spheres in an incubator with 5% 
CO2 and 95% atmospheric air at 37°C. 
 
Human neural progenitor ReNcells were grown in neurobasal medium supplemented with 1X 
B27 supplement, 2 mM L-glutamine, 1X non-essential aminoacids, 1 mM sodium pyruvate, 20 ng/ml 
hEGF, 20 ng/ml hFGF-2, 100 U/ml penicillin/streptomycin and 1 µg/ml amphotericin B. ReNcells were 
plated onto Corning Matrigel hESC-Qualified Matrix-coated T75 cell culture flasks and maintained in an 
incubator with 5% CO2 and 95% atmospheric air at 37°C. 
 
Primary neural stem/progenitor cell (NSPCs) cultures were stablished from the neurogenic 
niches of the SGZ and SVZ of mice from postnatal day 0-4 and 3-month-old mice of Nrf2+/+, Nrf2-/-, AT-
Nrf2+/+ and AT-Nrf2-/- genotypes following the protocol described in (Bernardino et al., 2008). Briefly, 
after the mice were euthanized by decapitation, brains were removed and chopped in 450 µm sections. 
Under the magnifier, neurogenic niches were isolated in each section with ultrafine forceps and put in 
dissection media (Ca2+/Mg2+- free HBSS supplemented with 100 U/ml penicillin/streptomycin). Then, 
tissue pieces were digested in 0.025% trypsin and 0.265 mM EDTA during 10 min at 37°C.Cells were 
washed twice in dissection media and the pellet was dissociated in the proliferation medium 
(DMEM/F12/Glutamax supplemented with 1x B27 without vitamin A, 10 ng/ml EGF, 5 ng/ml bFGF, 2 
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µg/ml heparin and 100 U/ml penicillin/streptomycin) by gentle trituration with a P1000 pipette. For adult-
derived cultures, the medium was the same as for neonatal-derived cultures but using 20 ng/ml EGF, 20 
ng/ml bFGF and 4 µg/ml heparin. Single cells were then plated on uncoated 10-cm dishes at a 
concentration of 200,000 cell/ml and were allowed to grow in an incubator with 5% CO2 and 95% 
atmospheric air at 37°C. In culture, the progenitor cells proliferate and form neurospheres (Fig. 13). 
 
 
Figure 13. Primary neural stem/progenitor cells cultures establishment. Neural stem/progenitor cells were isolated from the 
neurogenic niches (subventricular zone (SVZ) and subgranular zone (SGZ)) of neonatal and adult mice. 
 
2.2.2. Proliferation assays of primary cultures of NSPCs. 
 
Neurosphere quantification: Primary neurospheres were dissociated with 1X accutase for 5 min 
at 37°C and cultured at low density (20,000 cells/ml) in proliferation media to obtain the secondary 
neurospheres. Secondary neurospheres were quantified by counting 16 distinct fields in each culture dish 
(three dishes per condition) under 4X magnification (AxioPhot, Carl Zeiss). Similar protocol was 
followed for the quantification of neurospheres from U87-MG and GB cultures, but using Trypsin-EDTA 
to dissociate the neurospheres. 
 
Cell number quantification: neurospheres were disaggregated with accutase to quantify cell 
number using a Neubauer chamber. This protocol was followed for the quantification of cell number in 
U87-MG and GB cultures. 
 
Serial dilution assay: secondary neurospheres were disaggregated with accutase and seeded into 
a 96-well plate in an amount of 5, 25, 125, 250, 500 and 1000 cells/well. Five wells per condition were 
plated. Cells were incubated in 5% CO2 and 95% atmospheric air at 37°C in proliferation media during 7 
days allowing the formation of tertiary neurospheres. Formed neurospheres were quantified under 4x 
magnification in each well (Corenblum et al., 2016). 
 
Cell pair assay: primary neurospheres were disaggregated with accutase and plated on poly- D-
lysine-coated coverslips at low density (10,000 cells/cm2) for 24 h with proliferation media containing 
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half concentration of EGF and bFGF and immunostained for SOX2 and Nestin following the protocol 
described in section 2.2.9. This assay allows for the quantification of the number of symmetric cell 
divisions (self-renewal potential, both cells in the pair are SOX2+/Nestin+) and asymmetric divisions 
(differentiation of neural stem/progenitor cells, SOX2+/Nestin+ and SOX2-/Nestin- cells present in the 
cell pair (Fig. 14). Divisions were quantified under 40X magnification (Leica TCS SP5 Confocal Laser 
Scanning Microscope) and using FiJi (ImageJ Software). 
 
 
Figure 14. Cell pair assay. Neural progenitor cells could undergo symmetric divisions (left) giving rise to two progenitors 
siblings, positive for SOX2 and Nestin. Neural progenitor cells could also give rise to a progenitor cell and a differentiated cell 
(asymmetric division, right). 
 
EdU assay: Neurospheres were plated on poly- D- lysine- coated glass coverslips in proliferation 
media and treated with 10 µM 5-ethynyl-2'-deoxyuridine (EdU) (Click-iT® EdU Imaging Kits, 
Invitrogen) during 8 h and allow to differentiate for 5 days in differentiation media 
(DMEM/F12/Glutamax, 1X B27 without vitamin A and 100 U/mL penicillin/streptomycin). Finally, cells 
were fixed with 4% paraformaldehyde (PFA) and immunostained for EdU following the manufacturer´s 
instructions. Immunolabeling with the primary antibodies detailed in the Table 1 was performed as 
described in section 2.2.9. Nuclei were counterstained with Hoestcht 33342. At least 20 neurospheres per 
condition were analyzed under 40X magnification (Leica TCS SP5 Confocal Laser Scanning 
Microscope). 
 
2.2.3. Calcein-AM Cell Viability Assay. 
 
Neurospheres were plated in poly- D- lysine covered glass coverslips and treated in proliferation 
media with 3 µM Calcein-AM (acetoxymethyl ester of calcein) (#C3099, Molecular Probes/Invitrogen) 
during 30 min at 37°C, and fixed with 4% PFA. Nuclei were counterstained with 4',6-diamidino-2-
fenilindol (DAPI). Calcein-AM is a non-fluorescent and membrane permeable compound. In live cells, 
Calcein-AM is converted by cytoplasmatic esterases to calcein, a green fluorescent (excitation at 488 nm 
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and emission at 520 nm), and non-permeable membrane compound which is retained in the cytoplasm of 
live cells, giving them a green fluorescent labelling. In death cells, the absence of active esterases impedes 
Calcein-AM conversion to calcein, not acquiring green fluorescence (Fig. 15). Live cells were quantified 
under 40X magnification (Leica TCS SP5 Confocal Laser Scanning Microscope) and using FiJi (ImageJ 
Software). 
 
Figure 15. Graphic overview of Calcein-AM cell viability assay. Calcein-AM is membrane-permeable and non-fluorescent. 
In healthy cells, cytoplasmatic esterases cleave it into calcein, a green fluorescent dye that is retained in the cell. In dead cells 
esterase activity is missing and Calcein-AM does to convert into the green fluorescent Calcein  
 
2.2.4. Differentiation assays of primary culture of NSPCs.  
 
Five-day-old secondary neurospheres were plated on poly- D- lysine- coated coverslips, at 
approximately 30 neurospheres per coverslips, and incubated for 7 days in differentiation medium 
(DMEM: F12-Glutamax, B27 without vitamin A and 100 U/ml penicillin/streptomycin). After fixation 
in 4% PFA, cells were immunolabelled as described below and quantified under 40x magnification (Leica 
TCS SP5 Confocal Laser Scanning Microscope) and using FiJi (ImageJ Software). 
 
2.2.5. Differentiation assays of ReNcells. 
 
ReNcells were plated on Corning Matrigel hESC-Qualified Matrix coated coverslips, at a density 
of 30,000 cells/cm2, and incubated for 30 days in differentiation medium: neurobasal medium 
supplemented with 1X B27 supplement, 2 mM L-glutamine, 1X non-essential aminoacids, 1 mM sodium 
pyruvate, 100 U/ml penicillin/streptomycin and 1 µg/ml amphotericin B solution. Media were changed 
twice a week. 
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2.2.6. Transient transfections. 
 
Transient transfections in HEK293T were performed with TransFectinTM Lipid Reagent 
according to the manufacturer’s instructions.  
 
2.2.7. Production of lentiviral stocks and transduction of cell lines. 
 
Recombinant lentiviral stocks were produced in HEK293T/17 cells at 80% cell density by co-
transfecting 10 μg of transfer vector, 6 μg of envelope plasmid pMD2.G and 6 μg of packaging plasmid 
pSPAX2, using 24 μl PLUS Reagent and 36 μl Lipofectamine Transfection Reagent for each 10-cm plate. 
Cells were incubated in transfection mix and Opti-MEM during 6 h at 37°C. Then, the medium was 
replaced with fresh DMEM supplemented with 10% FBS, 4 mM L-glutamine and 80 μg/ml gentamicin. 
Virus particles were harvested at 24 h and 48 h post-transfection after filtration with 45-µm filter.  
 
Lentiviral transduction of primary cultures of NSPCs: 3.6 ml of lentiviral suspension with 4 µg/ml 
polybrene were added to cells in adhesion condition in dishes coated with poly- D-lysine in DMEM 
supplemented with 10% FBS and 80 μg/ml gentamicin. After 16 h, the media was replaced by 
proliferation media and 12 h later, cells were plated in suspension in proliferation media and the different 
assays were performed as described above. 
 
Lentiviral transduction of glioblastoma cell lines: U87-MG and GB cells were incubated with 3.6 
ml of lentiviral suspension plus 4 µg/ml polybrene in adhesion conditions in DMEM supplemented with 
10% FBS, 4 mM L-glutamine, 5 mM HEPES, 80 μg/ml gentamicin and 1 µg/ml amphotericin B. After 
16 h, the following day, cells were seeded in stem cell conditions in uncoated 10 cm dishes in DMEM: 
F12 (1:1) supplemented with 2 mM glutamine, 5 mg/ml Albumax I, 6 mg/ml glucose, B27 supplement 
(without vitamin A), 15 ng/ml hFGF-2, 20 ng/ml hEGF, 2 μg/ml heparin, 80 μg/ml gentamicin and 1 
µg/ml amphotericin B. Infected cells were selected using 1 mg/ml puromycin when necessary. 
 
Lentiviral transduction of ReNcells: 3.6 ml lentiviral suspension with 4 µg/ml polybrene per T75 
flask were added to ReNcells incubated in neurobasal medium supplemented with 1X B27 supplement, 
2 mM L-glutamine, 1X non-essential aminoacids, 1 mM sodium pyruvate, 20 ng/ml hEGF, 20 ng/ml 
hFGF-2, 100 U/ml penicillin/streptomycin and 1 µg/ml amphotericin B solution. The following day, 
medium was replaced by fresh media and infected cells were selected using 0.5 mg/ml puromycin when 
necessary. 
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2.2.8. Production of retroviral stocks and transduction of cell lines. 
 
Retroviral stocks were produced in HEK293T/17 cells by co-transfecting 10 μg of transfer vector, 
6 μg of pCMV-Gag-Pol, 5 μg of pCMV-VSV-G and 6 μg of pCL-Ampho, using 24 μl PLUS Reagent 
and 36 μl Lipofectamine Transfection Reagent for each 10 cm plate. Cells were incubated in transfection 
mix and Opti-MEM during 6 h at 37°C. After 6 h at 37°C the medium was replaced with fresh specific 
medium for each cell line. For each p100, virus particles were harvested at 24 h and 48 h post-transfection 
after filtration with 45 µm filter. Retroviral particles cannot be frozen and retroviral transduction has to 
be performed immediately. 
Retroviral transduction of cell lines: cells were seeded at low density (for retroviral transduction 
cells have to be proliferating) and incubated with 6 ml of the specific retroviral suspensions with 4 µg/ml 
polybrene for each T75 during 16 h. Then, medium was changed by fresh medium. Infected cells were 
selected using 0.5 µg/ml (ReNcells) or 1 µg/ml (U87-MG and GB) puromycin. 
 
2.2.9. Immunofluorescence analysis of cell cultures. 
 
Cells were seeded on sterile coverslips in 24-well plates as specified for each cell type. For 
secondary neurospheres, plates were centrifuged 5 min at 112 g. Then, cells were washed twice with PBS 
to remove cell media and fixed with 4% PFA during 15 min at room temperature. Coverslips were washed 
three times during 5 min/each with PBS and blocked in PBS containing 0.5% Triton X-100 and 3% bovine 
serum albumin during one hour. Coverslips where then incubated during 2 h at room temperature and 
overnight at 4°C with relevant primary antibodies (Table 1). Next, coverslips were washed gently with 
PBS and incubated 2 h at room temperature with appropriate secondary antibodies coupled to 
fluorochromes Alexa Fluor 488, 594, or 647 (Table 2) and nuclei were counterstained with DAPI for 10 
min at room temperature. After washing with PBS and sterile water to remove salts, coverslips were 
mounted in slides using ProLong. Images were acquired using Leica TCS SP5 Confocal Laser Scanning 
Microscope and cells were quantified using FiJi (ImageJ Software). 
 
2.2.10. Analysis of neuron complexity.  
 
After differentiation of primary NSPCs and ReNcells, immunostaining with specific neuronal 
markers was performed as described in section 2.2.9. To quantify neuronal complexity, Sholl analysis 
was performed using the Simple neurite tracer plugin 
(http://homepages.inf.ed.ac.uk/s9808248/imagej/tracer/); total axonal, dendrite or neurite lengths were 
determined using NeuronJ (https://imagescience.org/meijering/software/neuronj/) and the image 
processing package Fiji (http://pacific.mpicbg.de/wiki/index.php/Main_Page). At least 60 neurons were 
analyzed per assay. 
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2.2.11. Cell lysis, electrophoresis and immunoblotting. 
 
Cells were homogenized in cellular lysis buffer (50 mM Tris pH 7.6, 400 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% SDS.), followed by an incubation 15 min at 95ºC, sonicated with the ultrasonic 
processor UP100H (100W, 30kHz) (Hielscher Ultrasonics GmbH, Teltow, Germany) 10 times at 60% of 
amplitude and 0.5 cycles, and centrifuged 10 min at 19,000 g. Samples were quantified with the Bradford 
method (Pierce TM BCA Protein Assay Kit) and 1X protein loading buffer (6.5 mM Tris-HCl pH 6.8, 
25% glycerol, 10% SDS, 0.5% bromophenol blue and 5% β-mercaptoethanol) was added per sample. 
Samples were incubated 5 min at 95ºC and centrifugated at 19,000 g for 5 min. Equal amounts of samples 
were resolved by SDS-PAGE together with molecular weight markers. After electrophoresis, proteins 
were transferred to 0.45 μm pore size Immobilon-P membranes at 100V for 2 h. 
For immunoblotting, membranes were hydrated in methanol and incubated 5 min in TTBS buffer. 
Membranes were blocked with 4% bovine serum albumin (BSA) or 5% non-fat dry milk in TTBS. After 
washing, membranes were incubated overnight with indicated primary antibodies diluted in 0.4% BSA 
in TTBS in the conditions indicated in Table 1. Membranes were washed with TTBS and incubated with 
the appropriate HRP-conjugated secondary antibodies (Table 2) at 1:10,000. After gentle washing, 
proteins were detected by enhanced chemiluminescence (GE Healthcare, RPN2232). 
2.2.12. Analysis of mRNA levels by quantitative real-time polymerase chain reaction.  
 
Total RNA extraction was performed with TRIzol® Plus RNA Purification Kit following the 
manufacturer´s instructions. DNase I, Amplification Grade, was applied to 1 µg of RNA after its 
quantification with NanoDropTM spectrophotometer (Thermo Fisher Scientific) following the 
manufacturer´s instructions to eliminate possible genomic DNA contaminations. cDNA was then 
obtained with Retrotranscriptase High Capacity RNA-to-cDNA Kit.  
Sybr Green Master Mix was used for the quantitative real time polymerase chain reaction (qRT-
PCR). For each reaction, 5 pmol of forward- and reverse-specific oligonucleotides for each transcript 
were utilized (Table 10 and 11). Reactions took place in a StepOne thermocycler. Reaction conditions 
were 10 min denaturation at 95°C followed by 40 cycles [15 s at 95°C (denaturation), 30 s at 60 °C 
(annealing) and 30 s at 60 °C (elongation)]. The amplification specificity of oligonucleotides was 
analyzed by their melting curve. Messenger RNA (mRNA) levels were estimated with the ΔΔCt method, 
using the geometric media of ACTB (Actb), GAPDH (Gapdh) and TBP (Tbp) house-keeping genes as 
reference. Samples were analyzed in quadruplicate. 
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GENE PRODUCT FORWARD PRIMER (5´- 3´) REVERSE PRIMER (5´- 3´) 
ACTB TCCTTCCTGGGCATGGAG AGGAGGAGCAATGATCTTGATCTT 
ASCL1 CATCTCCCCCAACTACTCCA GAAAGCCATGTCTCTCAGGC 
BIRC5 ACCCCGGAGCGGATGG GCAACCGGACGAATGCTTTT 
CD44 ACAAGCACAATCCAGGCAAC GCTGGTATGAGCTGAGGCTG 
CTGF CTTCTGTGACTTCGGCTCCC GATGCAGGGAGCACCATCTT 
CYR61 CCAAGAAATCCCCCGAACCA CGGAACCGCATCTTCACAGT 
GAPDH CTCTCTGCTCCTCCTGTTCGAC TGAGCGATGTGGCTCGGCT 
NEUROD1 GGTGCCTTGCTATTCTAAGACGC GCAAAGCGTCTGAACGAAGGAG 
NEUROG2 ATCCGAGCAGCACTAACACG GCTGAGGCACAGTTAGAGCC 
NFE2L2 AAACCAGTGGATCTGCCAAC GTGACTGAAACGTAGCCGAAGA 
NQO1 GTTCATAGGAGAGTTTGCTT CCTTGCAGAGAGTACATGGA 
SOX2 GAGCTTTGCAGGAAGTTTGC GCAAGAAGCCTCTCCTTGAA 
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
TEAD1 CTGAGTCGCAGTTACCACCA AGCCTGGAGCCTTTTCAAG 
TEAD2 ACATGATGAACAGCGTCCTG CAGCAGTTCCTGGGTGTCTC 
TEAD3 CATCGAGCAGAGCTTCCAG CGTGCAATCAACTCATTTCG 
TEAD4 GCCTTCCACAGTAGCATGG AAAGCTCCTTGCCAAAACC 
WWTR1 TTTCCTCAATGGAGGGCCA GGGTGTTTGTCCTGCGTTTT 
Table 10. Human primers used for quantitative real time polymerase chain reaction (qRT-PCR). 
 
GENE 
PRODUCT 
FORWARD PRIMER (5´- 3´) REVERSE PRIMER (5´- 3´) 
Actb TCCTTCCTGGGCATGGAG AGGAGGAGCAATGATCTTGATCTT 
Gapdh CGACTTCAACAGCAACTCCCACTCTTCC TGGGTGGTCCAGGGTTTCTTACTCCTT 
Ctgf CCTGCCATTACAACTGTCCT GTTCGTGTCCCTTACTTCCTG 
Nqo1 GGTAGCGGCTCCATGTACTC CATCCTTCCAGGATCTGCAT 
Nrf2 CCCGAAGCACGCTGAAGGCA CCAGGCGGTGGGTCTCCGTA 
Tbp TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
Wwtr1 GAGAGGATTAGGATGCGTCAAG GGATCTGAGCTACTGTTGGTG 
Table 11. Mouse primers used for quantitative real time polymerase chain reaction (qRT-PCR). 
 
2.2.13. Chromatin immunoprecipitation (ChIP) assays. 
 
ReNcells were transduced with pBABE-puro (control) and pBABE-puro-TAZ-4SA retroviral 
particles and grown on T75 flasks. After 5 days-post-transduction, cells were fixed with 1% PFA for 12 
min on ice and the reaction was neutralized with 125 mM glycine. Cells were then washed twice with 
cold PBS and lysed. Cells were sonicated twice for 4 min at highest power to obtain 200-800 bp DNA 
fragments. Supernatant was diluted 10-fold with ChIP dilution buffer and pre-cleared with Protein G 
Sepharose. Supernatant was incubated with primary antibodies overnight at 4ºC. Anti-IgG antibodies 
were used as a negative control. DNA was eluted and purified, analyzing the presence of previously 
identified putative binding sites by qRT-PCR with specific primers (Table 12 and Table 13). Samples 
from at least four independent ChIPs were analyzed. 
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GENE PRODUCT FORWARD PRIMER (5´- 3´) REVERSE PRIMER (5´- 3´) 
WWTR1 ARE1 GCACCAGAGGGCATACATCT AACCACACCATCAGGAAAGC 
WWTR1 ARE2 AATCCTGTGGGGTGGGTACT CAGGTACTGCCCGTAAGAGG 
WWTR1 ARE3 TTCCAGGAAAAACAGGATGG GAGGCTCCAGAACCTCAATG 
WWTR1 ARE4 AATGAAGGCTGGGTGTTCAG TCAAAAACACACCCTCAGCA 
WWTR1 ARE5 CCTGATTTGGCTCATCTGCT AGCAGCCATGTGAAAGGTCT 
WWTR1 ARE6 AGTGAAGCCAGGAAGGAGGT CACTTCCCAAACCCAGGATA 
WWTR1 ARE7 TTCCAGCTGTAGGTGCCTTT CATGAGTCCCTGTGAGCAAA 
WWTR1 ARE8 ATTCAGCCCTGCTTTTACCC CCCTCTTTTCTCGTCCCTGT 
WWTR1 ARE9 CGCGGAGAAATTATCTGCTT CTTTCTCCTTCCCCCTTCAG 
ACTB CACCCAGCACATTTAGCTAGCTGA TTCAGAGCAACTGCCCTGAAAGCA 
NQO1* TCTCAGTTTTTGCCCTTATTTAA TAAAAAGTAGAGTGGTTGGAGTGATGACG 
HMOX1 CCCTGCTGAGTAATCCTTTCCCGA ATGTCCCGACTCCAGACTCCA 
NQO1 TGCACCCAGGGAAGTGTGTTGTAT CCCTTTTAGCCTTGGCACGAAA 
Table 12. Oligonucleotides used for chromatin immunoprecipitation (ChIP) analysis. ARE: Antioxidant Response Element. 
 
GENE PRODUCT FORWARD PRIMER (5´- 3´) REVERSE PRIMER (5´- 3´) 
CTGF 3´UTR GGTTTGGCCTAGCACTCCA TCTGGTGACCTGCTCAATTT 
CTGF TCAGACGGAGGAATGCTGAG CGAGGCTTTTATACGCTCCG 
CMYC Enh. 4 GGGGAACTCTCACTCTCCTTTGA CCAGGGGGTCTTTACACAGC 
CMYC Enh. 6 AGGGTCCTGGGCTTTTTCAG GGGCCATTCGTCACCTTTTC 
CYR61 AGCAAACAGCTCACTGCCTT ATGGTAGTTGGAGGGTCGTG 
SOX2 TIR-a (1) CATTTGAAAGCCGCACGACC ATGCTTCTACTGTCTGCCCC 
SOX2 TIR-a (2) ACCGAAACCCTTCTTACGGG AACCGTAGCAAAGGGGATGC 
SOX2 TIR-a (3) GCACGACCGAAACCCTTCTT TCAACCGTAGCAAAGGGGAT 
SOX2 TIR-b (1) AGAGAAAACCTGGGGAGGGT GCAAAGCTCCTACCGTACCA 
SOX2 TIR-b (2) CTGGACTTCTTTTTGGGGGACT GCAAAGCTCCTACCGTACCA 
SOX2 TIR-c (1) ATTACCCTCTTGGGTCCTGG CAGCGCACACTGGGAGAA 
SOX2 TIR-c (2) AAATTACCCTCTTGGGTCCTGG CACACTGGGAGAAGGCGG 
ASCL1 TIR-a (1) TGGGTGCTCACCTCCTATACT GTGGGATTCACACCTCAGGC 
ASCL1 TIR-a (2) TTTGGGTGCTCACCTCCTAT GGATTCACACCTCAGGCCTTT 
ASCL1 TIR-b CGTCATTACTGCCCACCATC TAAAGGGCCAAGGGGATGAC 
ASCL1 TIR-c (1) AGGCCACCAGTTGTACTTCA TGCCACTTTGAGTTTGGACAG 
ASCL1 TIR-c (2) GCCACCAGTTGTACTTCAGCA GCCACTTTGAGTTTGGACAGTA 
NEUROG2 TIR-a (1) TGCAACTGGTTCCTGTGATCT GCCAGCCATTGCAAATCTGT 
NEUROG2 TIR-a (2) TGGTTCCTGTGATCTCTTCACC CAGCCATTGCAAATCTGTGGA 
NEUROG2 TIR-a (3) GGGGAATGCAACTGGTTCCT ACCAGCAAAATCATTCAGATGC 
NEUROG2 TIR-a (4) GCAACTGGTTCCTGTGATCT TTACCAGCAAAATCATTCAGATGC 
NEUROG2 TIR-b (1) AGAGGGGCAGGTTAGAAGTCA AGCCTAAATTTCCACGCTTGC 
NEUROG2 TIR-b (2) TGTTTTGTTAGAGGGGCAGGT GCCTAAATTTCCACGCTTGCAT 
NEUROD1 TIR-a (1) GTCCGCGGAGTCTCTAACTG ATGCGCCATATGGTCTTCCC 
NEUROD1 TIR-a (2) CTAACTGGCGACAGATGGGC CATTTGTATGCCGCGGAGC 
NEUROD1 TIR-a (3) CTGCGGGTAAAAACAGGTCC ACGTGACCTGCCCATTTGTAT 
NEUROD1 TIR-b (1) CCTTGAGTATTCACACCATGGAA GAGCGGTAACAGGTAGCAGG 
NEUROD1 TIR-b (2) TGGATACCTTGAGTATTCACACCA GGAGCGGTAACAGGTAGCAG 
NEUROD1 TIR-c AGCCAGGACAGAAATGGAAGT TGCCCGACAGGATAATGTGT 
Table 13. Oligonucleotides used for chromatin immunoprecipitation (ChIP) analysis. TIR: TAZ interacting region.  
MATERIAL AND METHODS 
 
88 
 
2.2.14. Measurement of luciferase activity. 
 
For ARE-LUC luciferase assay, HEK293T cells were seeded in 24-well (75,000 cells per well) 
plates and transiently transfected with Tranfectin according to the manufacturer’s instructions with the 
expression vectors WWTR1 ARE2-WT, WWTR1 ARE2-mutated or positive control HMOX1-ARE-Luc. 
pTK-Renilla was also transfected to be used as an internal control. After 24 h after transfection, cells 
were lysed in 100 μl lysis buffer (Promega) and 40 μl of this lysate was used for the luciferase assay, 
performed according to the manufacturer’s instructions.  
For SOX2-TEAD1(a)-LUC luciferase assay, HEK293T cells were seeded in 24-well (75,000 cells 
per well) plates and transiently transfected with Tranfectin according to the manufacturer’s instructions 
with SOX2-TEAD1(a)-luc vector, Renilla vector and increasing amounts of pBABE-puro-TAZ-4SA 
vector. For ReNcells luciferase assays, cells were previously infected with retrovirus encoding TAZ4SA 
and 24 h later they were plated on 24-multiwell (60,000 cells per well) and transfected with Lipofectamin 
2000 Reagent with SOX2-TEAD1(a)-luc plasmid and Renilla following manufacturer´s instructions. 
After 24 h, cells were lysed in 100 μl lysis buffer (Promega) and 40 μl of this lysate was employed for 
the luciferase assay, performed according to the manufacturer’s instructions. Luciferase expression was 
quantified as luminol oxidation with a GloMax 96 microplate luminometer with dual injectors (Promega). 
Each sample was measured in quadruplicate and normalized by the levels of Renilla. 
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2.3. In vivo assays. 
 
2.3.1. Morris water maze test (MWM).  
 
This test was conducted as double blind at the Animal Facility of Instituto Cajal. Animals 
performed 1 day of habituation trial in which animals with preferences between quadrants in the different 
experimental groups were discarded. After habituation, animals were trained to find the hidden platform 
for the following 5 days, doing 4 trials/day. Prior to the test, we confirmed that the mice to be analyzed 
exhibited similar motor competence, not detecting any inter-group differences in the average swim speed 
and travelled distance. Each animal spent 60 s in each trial, plus 20 s in the platform. On the 6th day, the 
animals were subjected to two trials, the first without the platform to assess possible differences in 
swimming speed between the animals and their preference for the platform quadrant. In the second trial, 
a visible platform was used to determine sensorimotor and motivational status of the animals.  
 
2.3.2. Electrophysiological recordings.  
 
These experiments were done double blind in collaboration with Prof. Ángel Nuñez (Department 
of Anatomy, Histology and Neuroscience, Medical College, UAM). Animals were anaesthetized by 
intraperitoneal injection of 1.6 g/ kg urethane and local 1% lidocaine. During the procedure, body 
temperature was maintained at 37°C with the help of a thermal blanket. Field potentials were recorded 
through tungsten microelectrodes (1 MΩ; World Precision Instruments) stereotaxically implanted in the 
DG (A: -2,3; L: 2; H: 1.5 mm from bregma) according to the Paxinos and Watson Atlas. Twisted bipolar 
electrodes for electrical stimulation were aimed at the medial perforant path (MPP) (A: -2.5; L: 0.5; H: 
1.5 mm from bregma) (Fig. 16). Baseline recordings were taken with test stimuli (10-50 mA, 0.3 ms, 0.5 
Hz) during 15 min before tetanic stimulation consisting of 3 pulse trains of 10-50 mA, lasting each pulse 
0.3 ms and at 50 Hz. Trains lasted 500 ms and the inter-train interval was 2 s. Recording was maintained 
for 30 min after tetanic stimulation. Field potentials were 0.1 Hz–1 kHz band-pass filtered, amplified 
(P15 Amplifier, Grass Co., USA), and digitized at 10 kHz (CED 1401; Cambridge Electronic Design). 
Signals were stored and off-line analysis was carried out with Spike 2 software (Cambridge Electronic 
Design, Cambridge, UK). Field potential segments of 5 min were analyzed to obtain the response average. 
The mean average response during the 15 min period before the tetanic stimulation was considered as 
100%. Recordings were accepted for analysis when baseline variability was less than 10%. 
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Figure 16. Graphic overview of electrophysiological recordings in 
the DG, indicating the positions of the stimulating electrode (Stim) on 
the medial perforant pathway (MPP) and recording electrode (Rec) in 
the dentate gyrus (DG). CA1 and CA3: Cornu Ammonis areas 1 and 3, 
respectively, EC: entorhinal cortex. 
 
 
2.3.3. Immunofluorescence on mouse tissues. 
 
Animals were anesthetized with 8 mg/kg ketamine and 1.2 mg/kg xylazine and perfused with 
phosphate-buffered saline, followed by fixation in 4% PFA and cryoprotected by soaking in 30% sucrose 
solution in phosphate buffer until they sank. The immunofluorescence was performed in 30 µm-thick 
sections. Briefly, free-floating sections were washed 3 times with PBS during 5 min each before blocking. 
Sections were blocked for 2 h at room temperature with PBS with 3% horse serum and 1% Triton X-100. 
Incubation with primary antibodies (Table 1) was performed for 2 h at room temperature and overnight 
at 4ºC in 10% blocking solution. Next day, sections were washed gently three times with PBS (5 
min/each) and incubated with the secondary antibodies (Table 2) in blocking solution. Nuclei were 
counterstained with a 15 min incubation in DAPI at room temperature. Sections were washed twice in 
PBS for 10 min/each and 0.03 M PB. Sections were mounted in gelatin coated glass slides with ProLong. 
Control sections were treated by following identical protocols but omitting the primary antibody.  
 
2.3.4. Immunohistochemistry. 
 
Immunohistochemistry was performed on 30 µm-thick coronal brain sections with a standard 
avidin- biotin immunohistochemical protocol. Briefly, free-floating sections were washed 3 times with 
1X PBS for 5 min/each and incubated with 0.5% H2O2 in PBS for 30 min at room temperature to block 
endogenous peroxidase activity. Antigen retrieval was performed with 10 mM citrate buffer pH 6 for 20 
min at 90ºC, or formic acid for 5 min at room temperature for APP/Aβ. Sections were incubated with 
blocking solution (3% BSA and 0.2% Triton X-100 in PBS) for 2 h. Incubation with the appropriate 
dilutions of the primary antibodies (Table 1) was done overnight at 4ºC. After washing several times with 
1X PBS, free floating sections were incubated with biotinylated secondary antibodies and the 
avidin/biotin system with the VectastainR ABC Kit (Vector Laboratories) according to manufacturer’s 
instructions. Labeling was developed with 0.009% H2O2, 0.025% 3-3’diaminobenzidine 
tetrahydrochloride (DAB) in PBS until the appearance of the desired intensity. Staining was stopped with 
washes with TBS. Sections were washed twice in 1X PBS for 10 min/each and 0.03 M PB. Sections were 
mounted on gelatin-coated glass slides, and de-hydrated by increasing concentrations of ethanol until 
absolute ethanol and finally, rinsed in xylol 6 times for 5 min/each. Slides were coversliped with DePeX 
(Serva). 
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2.3.5. Nissl staining. 
 
Nissl staining is based on cresyl violet (basic dye) which binds to negatively charged molecules 
like RNA and DNA. Brain sections were attached in gelatin- coated slides and washed quickly with H2O 
and incubated with 0.1% cresyl violet and 0.025% acetic acid in H2O for 20 min at room temperature. 
After washing with H2O, sections were de-hydrated by sequential immersion in 70%; 80% and 96% 
ethanol solutions. Sections were washed with 2% acetic acid in 96% ethanol for few seconds and de-
hydrated in absolute ethanol and xylol. Sections were coversliped with DePeX. 
 
2.3.6. Cell counting in immunofluorescence of brain sections. 
 
Cell counts were performed every 8 sections (30 µm-thick) through the DG and SVZ by using 
FiJi Software (ImageJ) under 40X magnification (Leica TCS SP5 Confocal Laser Scanning Microscope) 
for each cell type. Five adjacent sections per animal were quantified. 
 
2.3.7. Tumour induction in immunodeficient mice. 
 
Eight-week-old nude (Foxn1nu) male mice were used for xenograft. U87-MG cells (106 cells in 
0.1 ml PBS) were inoculated subcutaneously for tumour growth analysis. Tumour growth was examined 
every 5 days for up to 65 days. Tumour volume = π/6 × (mean diameter)3. For intracranial tumour assays, 
U87-MG cells (2x105 cells) were stereotaxically inoculated into the corpus striatum of the right brain 
hemisphere (1 mm anterior and 1.8 mm lateral to the bregma; 2.5 mm intraparenchymal) of mice under 
isoflurane gas anaesthesia. Mice were euthanized when they presented neurological symptoms or 
significant weight loss. Tumours were obtained surgically and fixed with 4% PFA. 
 
2.4. Statistical analysis. 
 
Unless otherwise indicated, all experiments were performed at least 3 times and all data are the 
mean of at least 3 independent samples ± standard error of the mean (SEM). A Student's t-test was used 
to assess differences between groups with Graph Pad Prism 5.0. and p<0.05 was considered significant. 
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I. NRF2 regulates 
hippocampal neural 
stem cell fate. 
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1. NRF2 deficiency impairs long-term potentiation. 
 
Adult wild type (Nrf2+/+) and Nrf2-deficient (Nrf2-/-) mice (6-month-old) were examined 
electrophysiologically for long-term potentiation (LTP) in the DG. The synaptic transmission in the DG 
was recorded in response to stimulation of the medial perforant path (MPP) (Fig. 16). High frequency 
stimulation increased the field excitatory post-synaptic potential (fEPSP) in control Nrf2+/+ mice, but these 
values were strongly diminished in Nrf2-/- mice (Fig. 17A and B), indicating that NRF2 is required for 
normal LTP. Under physiological conditions, LTP is inhibited in mature GCs by GABAergic 
interneurons. By contrast, newborn neurons are more plastic and less prone to GABAergic inhibition than 
the mature ones. Thus, the measurable LTP in the DG under physiological conditions is mainly derived 
from the newborn neurons (Wang et al., 2000; Schmidt-Hieber et al., 2004; Snyder et al., 2001; Saxe et 
al., 2006; Garthe et al., 2009). For this reason, in the following experiments, we analyzed if the LTP 
impairment found in Nrf2-/- mice could be related, at least in part, to abnormal hippocampal neurogenesis 
in adult mice.  
 
 
Figure 17. NRF2 deficiency impairs LTP. (A) LTP of field Excitatory Postsynaptic Potential (fEPSP) in 6-month-old animals 
before and after tetanic stimulation of the MPP. c5, c10, c15: control baseline recordings before tetanic stimulation. (B) 
Representative responses recorded from Nrf2+/+ and Nrf2-/- mice before (thin line) and after (thick line) high-frequency trains of 
tetanic stimulation. Calibration: 2 mV, 20 ms. Data are mean ± SEM (n = 6). Statistical analysis was performed with a Student's 
t-test. **p<0.01, and ***p<0.001 vs. the Nrf2+/+ group. 
 
2. The clonogenic and proliferative capacity of NSPCs from the SGZ is impaired in Nrf2-/- mice. 
 
First, we investigated the proliferative capacity of neural stem/progenitor cells (NSPCs) in the 
SGZ hippocampal neurogenic niche of Nrf2+/+ and Nrf2-/- mice at 3, 6 and 12 months of age. We performed 
immunostaining with the proliferative marker Ki67 in combination with the NSPC marker Nestin (Fig. 
18A and B). As expected, both Nrf2+/+ and Nrf2-/- mice exhibited a drastic reduction in proliferating cells 
with aging. However, the number of proliferating NSPCs was 50% lower in Nrf2-/- mice at all age points. 
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Figure 18. Reduction of 
proliferative NSPCs in the 
SGZ of Nrf2-/- mice. (A) 
Representative confocal 
microscope images of Ki67 
staining in the SGZ of 3-
month-old Nrf2+/+ and Nrf2-/- 
mice. The green channel for 
Nestin staining has been 
removed except in the inset to 
allow easier visualization of 
proliferating cells. Nuclei were 
counterstained with DAPI. White arrowheads point to Ki67+ cells. (B) Quantification of Ki67+ NSPCs in 3-, 6- and 12-month-
old mice of the indicated genotypes. Data represent mean ± SEM (n = 5). Statistical analysis was performed with a Student's t-
test. ***p ⩽ 0.001 vs. the Nrf2+/+ group. 
 
In order to compare proliferative and clonogenic capacities of NSPCs, we performed a 
neurosphere assay on NSPCs derived from the SGZ of newborn and 3-month-old Nrf2+/+ and Nrf2-/- mice. 
As expected, NSPCs derived from the SGZ of Nrf2+/+ mice expressed NRF2 protein and messenger RNA 
(mRNA), while NSPCs derived from the SGZ of Nrf2-/- did not (Fig. 19A, B and C). Moreover, Nrf2-/--
isolated NSPCs presented a reduced gene expression of the bona fide NRF2 target Nqo1, indicating an 
impairment in the NRF2-dependent transcriptional activity of these cells (Fig. 19C).  
 
Figure 19. Expression of NRF2 and 
NQO1 in NSPCs derived from the 
SGZ. (A) Representative immunoblot 
of NRF2 and NQO1 from Nrf2+/+ and 
Nrf2-/- neurospheres derived from the 
SGZ of 3-month-old mice, with Lamin 
B as a loading control. (B)  
Densitometric quantification of 
representative blots from A. Data are mean ± SEM (n = 4). (C) Relative expression of mRNA encoding NRF2 in Nrf2+/+ and 
Nrf2-/- neurospheres normalized by the geometric mean of Actb, Gapdh and Tbp levels. Data are mean ± S.D. (n = 4). In B and 
C, the statistical analysis was performed with a Student's t-test. ***p ⩽ 0.001 vs. the Nrf2+/+ group. 
 
To analyze their clonogenic capacity, first NSPCs were seeded them at low density (20,000 
cells/ml), so that only the self-renewing cells would be capable of forming new neurospheres. After 5 
days in culture under proliferation conditions, the cell number in the Nrf2-/--derived neurospheres was 
about 50% lower compared to Nrf2+/+, in neurospheres of both newborn and 3-month-old mice (Fig. 20A 
and G). Additionally, we found that NSPCs from Nrf2-/- mice had a lower clonogenic capacity as 
determined by the number of neurospheres formed after seeding equal amounts of Nrf2-/- and Nrf2+/+ 
NSPCs in a serial dilution assay (Fig. 20B, C and H, I). Ki67 immunostaining (Fig. 20D, E and J, K) and 
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Ki67 protein levels (Fig. 20F and L) also demonstrated a reduction in the number of proliferating cells in 
Nrf2-/--derived neurospheres.  
 
Figure 20. Impaired clonogenic 
and proliferative capacity of 
NSPCs from Nrf2-/- mice. (A) 
Determination of cell number 
after 5 days in culture from an 
initial seeding of 20,000 
NSPCs/ml derived from newborn 
Nrf2-/- vs. Nrf2+/+ mice. (B) 
Representative images of the 
neurospheres formed under these 
conditions. (C) Serial dilution 
assay of Nrf2+/+ and Nrf2-/- 
NSPCs from newborn mice 
showing the number of 
neurospheres formed after 7 days. 
Data are mean ± S.D. (n = 10). 
(D) Representative confocal 
images of the proliferative marker 
Ki67 in neurospheres derived 
from the SGZ of newborn mice of 
the indicated genotypes after 5 
days in vitro. Nuclei were 
counterstained with DAPI. (E) 
Quantification of Ki67+ cells in 
150-200 µm-diameter 
neurospheres from D. Data are 
mean ± SEM (n ≥ 10). (F) 
Representative immunoblots of 
NRF2 and Ki67 from Nrf2+/+ and 
Nrf2-/- neurospheres with 
GAPDH as a loading control. (G) 
Determination of cell number 
after 5 days in culture from an 
initial seeding of 20,000 NSPCs/ml derived from 3-month-old Nrf2-/- vs. Nrf2+/+ mice. (H) Representative images of neurospheres 
formed under these conditions. (I) Serial dilution assay of NSPCs derived from 3-month-old Nrf2+/+ and Nrf2-/-, showing the 
number of neurospheres formed after 7 days. Data are mean ± S.D. (n = 10). (J) Representative confocal image of the proliferative 
marker Ki67 in neurospheres derived from the SGZ of 3-month-old mice of the indicated genotypes after 5 days in vitro. Nuclei 
were counterstained with DAPI. (K) Quantification of Ki67+ cells in 150-200 µm-diameter neurospheres from J. Data are mean 
± SEM (n ≥ 10). (L) Representative immunoblots of NRF2 and Ki67 in Nrf2+/+ and Nrf2-/- neurospheres with GAPDH as a 
loading control. Statistical analysis were performed with a Student's t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. the Nrf2+/+ 
group. 
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In additional experiments, we tested caspase-3 cleavage as a measurement of cell death in the DG 
of 3-month-old Nrf2+/+ and Nrf2-/- mice (Fig. 21A) and in neurospheres from both genotypes (Fig. 21B 
and C). In vivo, we did not detect significant differences in cleaved caspase-3. In the established 
neurospheres from the DG of these mice, we detected very low levels of cleaved caspase-3 by 
immunoblot, suggesting that NSPCs are not undergoing apoptosis or they do it at undetectable levels. 
Furthermore, we determined the cell viability by Calcein staining. Calcein AM is a non-fluorescent, 
hydrophobic compound that easily permeates intact, live cells. The hydrolysis of Calcein AM by 
intracellular esterases produces Calcein, a hydrophilic, strongly fluorescent compound that is retained in 
the cell cytoplasm and emits green fluorescence. This assay did not show significant differences between 
Nrf2+/+ and Nrf2-/--derived neurospheres (Fig. 21D and E). Thus, the differences observed in clonogenic 
capacity between the both genotypes did not derive from changes in the viability of NSPCs. 
 
 
Figure 21. NRF2 deficiency does not increase apoptosis or affect cell viability. (A) Representative images of Nissl and 
cleaved- Caspase 3 immunohistochemistry in the DG of 3-month-old Nrf2+/+ and Nrf2-/- mice. (B) Representative immunoblot 
of Caspase 3 (35 kDa) and cleaved-Caspase 3 (17 kDa) in Nrf2+/+ and Nrf2-/- -derived neurospheres with GAPDH as loading 
control. (C) Densitometric quantification of cleaved Caspase 3 in representative blots from B. Data are mean ± SEM (n = 3). 
Statistical analysis with a Student's t-test indicated non-significant differences (ns). (D) Representative confocal images of 
Calcein staining in Nrf2+/+- and Nrf2-/--derived neurospheres. Nuclei were counterstained with DAPI. (E) Quantification of 
Calcein+ cells in C. Data are mean ± SEM (n = 20). Statistical analysis with Student's t-test indicated non-significant differences 
(ns). 
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Next, we conducted genetic modulation of NRF2 levels to further analyze its implication in 
NSPCs proliferation. On the one hand, we conducted rescue experiments by ectopic expression of NRF2 
in Nrf2-/- NSPCs with a lentiviral vector expressing a constitutively active mutant of NRF2. This mutant 
lacks residues 79-ETGE-82 (NRF2ΔETGE), being insensitive for KEAP1-mediated degradation, and 
resulting in NRF2 protein accumulation and increased transcriptional activity (Rada et al., 2011; Higgins 
and Hayes, 2011). We measured mRNA and protein levels after 5 days of transduction and found NRF2 
expression (Fig. 22A and B) accompanied by an increase in the protein and mRNA levels of its well-
known target NQO1 (Fig. 22A and C).  
When we quantified the number of cells in the secondary neurospheres after 5 days of lentiviral 
transduction, we found that ectopic expression of NRF2 led to an increase in the number of Nrf2-/--
NRF2ΔETGE NSPCs compared to the Nrf2-/--CT NSPCs (Fig.23A). In the serial dilution assay, the Nrf2-/--
NRF2ΔETGE NSPCs produced a significantly greater number of neurospheres at every dilution tested 
compared to Nrf2-/--Control NSPCs (Fig. 23B and C). Furthermore, ectopic expression of NRF2 led to an 
increase in the number of Ki67+ cells as determined by immunofluorescence (Fig. 23D and E) and 
immunoblot (Fig. 23F) Thus, ectopic expression of NRF2 partially rescued the clonogenic and 
proliferative capacity of Nrf2-/--derived NSPCs.  
 
On the other hand, we silenced NRF2 using shRNA against murine Nrf2 (shNRF2) in Nrf2+/+ 
NSPCs. A reduction at protein and mRNA levels of NRF2 and NQO1 was observed in NSPCs where 
NRF2 was knocked-down (Fig. 22D and E). To ensure that NRF2 was silenced, we used the NRF2 
activator sulforaphane (SFN) at a concentration of 15 µM during 6 h (Fig. 22F, G and H). SFN is an 
electrophilic NRF2-inducer which forms an adduct with KEAP1-Cys151 and disrupts the union between 
KEAP1 and CUL3, preventing NRF2 ubiquitination and subsequent proteasomal degradation and 
allowing NRF2 to accumulate, translocate to the nucleus and exert its transcriptional function (Takaya et 
al., 2012).  SFN induced an increase in NRF2 protein levels in the control NSPCs transduced with mock 
lentivirus (shCO), but not with shNRF2, indicating the efficient NRF2-knockdown (Fig. 22F and G). The 
NRF2-encoding gene promoter presents two ARE-like sequences, which allow NRF2 auto-regulation 
(Kwak et al., 2002). In this regard, when we determined by qRT-PCR the transcriptional level of NRF2, 
we found that this increment in NRF2 protein levels was accompanied by an increase in NRF2 transcript 
upon SFN treatment in Nrf2+/+-shCO NSPCs, but not in Nrf2+/+-shNRF2 NSPCs. This observation 
indicates that NRF2 accumulation leads to an increase in its transcriptional activity (Fig. 22H). 
Knockdown of NRF2 led to a reduction in the number of cells in the derived neurospheres (Fig. 
23G). In the serial dilution assay, Nrf2+/+-shNRF2 NSPCs produced a significantly lower number of 
neurospheres in each dilution compared to Nrf2+/+-shCO NSPCs (Fig. 23H and I). Additionally, the 
number of Ki67+ cells was significantly lower in neurospheres derived from Nrf2+/+-shNRF2 NSPCs 
(Fig.23J and K). This reduction in Ki67 was observed also at protein level (Fig. 23L). Thus, NRF2-
knockdown led to the impairment of clonogenic and proliferating capacity of NSPCs. Taken together, 
RESULTS 
102 
 
these results suggest a cell autonomous need of NRF2 to maintain the clonogenic and proliferative 
capacity of NSPC pool. 
 
 
Figure 22. Modulation of NRF2 protein levels by its ectopic expression or shRNA knockdown. (A) Representative 
immunoblots of NRF2, NQO1, and Lamin B as a loading control in Nrf2-/--derived NSPCs transduced with a lentivirus control 
(CT) or encoding active NRF2ΔETGE after 5 days of lentiviral transduction. (B) Densitometric quantification of NRF2 protein 
levels from A. Data are mean ± SEM (n = 3). (C) Relative expression of mRNA encoding Nqo1 in Nrf2-/--CT and Nrf2-/--
NRF2ΔETGE after 5 days from lentiviral transduction. Data are mean ± S.D. (n = 4). (D) Representative immunoblots of NRF2, 
NQO1 and Lamin B as a loading control in Nrf2+/+ NSPCs transduced with a lentivirus control (shCO) or mouse shNRF2 after 
5 days of lentiviral transduction.  (E) Relative expression of mRNA encoding Nrf2 and Nqo1 in Nrf2+/+-shCO and shNRF2 after 
5 days of lentiviral transduction determined by qRT-PCR. Data are mean ± S.D. (n = 4). (F) Representative immunoblots of 
NRF2, NQO1 and Lamin B as a loading control in Nrf2+/+ NSPCs transduced with lentivirus control (shCO) or mouse shNRF2 
after 5 days and treated with vehicle or sulforaphane (SFN, 15 µM, 6 h). (G) Densitometric quantification of representative blots 
from F. Data are mean ± SEM (n = 3). (H) Relative expression of mRNA encoding NRF2 in Nrf2+/+-shCO and shNRF2 after 6 
h of SFN treatment. In C, E, and H, mRNA levels are normalized by the geometric mean of Actb, Gapdh and Tbp levels. Data 
are mean ± S.D. (n = 4). Statistical analysis was performed with a Student's t-test. *p ⩽ 0.05; **p ⩽ 0.01; ***p ⩽ 0.001 vs. 
control group. 
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Figure 23. Impaired 
proliferative and 
clonogenic capacity of 
NSPCs from Nrf2-/- mice. 
(A) Cell number 
determination from an initial 
seeding of 20,000 cells/ml of 
Nrf2-/--NSPCs transduced 
with lentivirus encoding 
control (CT) or active 
NRF2ΔETGE after 5 days of 
lentiviral transduction. Data 
are mean ± S.D. (n = 10).  (B) 
Representative images of 
neurosphere formation under 
these conditions. (C) Serial 
dilution assay of Nrf2-/--CT 
and Nrf2-/--NRF2ΔETGE 
NSPCs showing the number 
of neurospheres formed after 
7 days. Data are mean ± S.D. 
(n = 10). (D) Representative 
confocal image of 
proliferative marker Ki67. 
Nuclei were counterstained 
with DAPI. (E) 
Quantification of Ki67+ cells 
in 150-200 µm-diameter 
neurospheres from D. Data 
are mean ± SEM (n ≥ 10). (F) 
Representative immunoblots 
of NRF2, Ki67 and Lamin B 
as loading control in Nrf2-/--
CT and Nrf2-/--NRF2ΔETGE 
neurospheres after 5 days of lentiviral transduction. (G) Cell number determination from an initial seeding of 20,000 cells/ml of 
NSPCs Nrf2+/+ transduced with lentivirus encoding shcontrol (shCO) or mouse shNRF2 and after 5 days of lentiviral 
transduction. Data are mean ± S.D. (n = 10). (H) Representative images of neurosphere formed under these conditions. (I) Serial 
dilution assay of Nrf2+/+-shCO and Nrf2+/+-shNRF2 NSPCs showing the number of neurospheres formed after 7 days. Data are 
mean ± S.D. (n = 10).  (J) Representative confocal image of proliferative marker Ki67 of neurospheres Nrf2+/+-shCO and Nrf2+/+-
shNRF2 after 5 days in vitro. Nuclei were counterstained with DAPI. (K) Quantification of Ki67+ cells in 150-200 µm-diameter 
neurospheres from J. Data are mean ± SEM (n ≥ 10). (L) Representative immunoblot analysis of NRF2, Ki67 and Lamin B as a 
loading control in Nrf2+/+-shCO and Nrf2+/+-shNRF2 neurospheres after 5 days of lentiviral transduction. Statistical analysis was 
performed with the Student's t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. control group. 
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3. Age-related decline of the NSPCs pool from the SGZ is exacerbated in NRF2-deficient mice. 
 
Next, we assessed the NSPCs pool in the SGZ. For this, we first performed immunostaining with 
Nestin, SOX2 and GFAP antibodies to determine the number of NSCs and NPCs, as these cell populations 
drive NSPCs towards mobilization and differentiation of neural lineages. NSCs were identified as 
Nestin+/SOX2+/GFAP+ cells and NPCs as Nestin+/SOX2+/GFAP- cells, and were distinguished 
morphologically: NSCs exhibit a non-branched long neurite across the GCL while NPCs are located at 
the basis of the granular layer and do not present long neurites (Fig. 24A) (Encinas et al., 2011). The 
number of NSCs and NPCs in Nrf2+/+ mice decreased with aging (Fig. 24B, C and D). Thus at 12 months 
of age the number of NSCs and NPCs had decreased to 50% compared to 3 months of age. Importantly, 
in 3-month-old Nrf2-/- mice the amount of these cells was already substantially decreased to ∼50%. This 
suggests that NRF2 deficiency accelerates aging-dependent decline of NSCs and NPCs in the 
hippocampal neurogenic niche.  
 
 
Figure 24. NRF2 deficiency provokes a drop in the pool of NSCs and NPCs. (A) Representative confocal image of the SGZ 
immunostained with GFAP, SOX2 and Nestin. White, black and yellow arrowheads point a typical NSC, NPC and astrocyte, 
respectively. Nuclei were counterstained with DAPI. (B) Representative confocal images of GFAP, SOX2 and Nestin in the 
SGZ of 3- (Upper panel), 6- (middle panel) and 12- (lower panel) month-old mice of the indicated genotypes. Dotted lines delimit 
the GCL and SGZ. (C) and (D) quantification of NSCs and NPCs, respectively, in 3-, 6- and 12-month-old mice of the indicated 
genotypes. Data represent mean ± SEM (n = 5). Statistical analysis was performed with a Student's t-test. *p ⩽ 0.05; **p ⩽ 0.01, 
***p ⩽ 0.001 vs. Nrf2+/+ mice. 
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Accordingly, the number of Nestin+ cells, evaluated by immunostaining, was decreased in Nrf2-/- 
neurospheres from newborn (Fig. 25A and B) and 3-month-old (Fig. 25D and E) mice, even at the protein 
level (Fig. 25C and F). 
 
 
Figure 25. NRF2 deficiency leads to a decreased of Nestin+ cells in neurospheres. (A) Representative confocal images of 
Nestin immunofluorescence on neurospheres derived from newborn mice of the indicated genotypes. (B) Quantification of 
Nestin+ cells in these neurospheres Data show mean ± SEM (n ≥ 10). (C) Representative immunoblots of NRF2, Nestin and 
Lamin B as a loading control in Nrf2+/+ and Nrf2-/- neurospheres derived from the SGZ of newborn mice. (D) Representative 
confocal images of Nestin immunofluorescence on neurospheres derived from 3-month-old mice of the indicated genotypes. (E) 
Quantification of Nestin+ cells in these neurospheres (n = 10). Data show mean ± SEM (n ≥ 10). (F) Representative immunoblot 
analysis of NRF2, Nestin and Lamin B as a loading control in Nrf2+/+ and Nrf2-/- neurospheres derived from the SGZ of 3-month-
old mice. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. Nrf2+/+ according to a Student's t-test. 
 
These results suggested an impaired self-renewal capacity of NSCs and NPCs. Therefore, we 
evaluated the number of symmetric and asymmetric divisions in cell culture based on SOX2 and Nestin 
immunostaining. Cells derived from symmetric divisions express SOX2 and Nestin in both siblings, while 
in asymmetric divisions only one sibling expresses SOX2 and Nestin (Fig. 26A). In Nrf2+/+ NSPCs 
cultures, 60% (in newborn isolated NSPCs) or 75% (in adult isolated NSPCs) of the cells underwent 
symmetric divisions (Fig. 26B and C). However, in the Nrf2-/- NSPCs symmetric divisions accounted for 
only 25%, thus inversely increasing the percentage of asymmetric divisions (Fig. 26B and C). These 
observations were further analyzed by rescuing Nrf2-/- NSPCs by lentivirus-mediated expression of 
NRF2ΔETGE. Ectopic expression of NRF2 led to an increase in symmetric divisions compared to the 
control (Fig. 26D). By contrast, lentiviral knockdown of NRF2 in Nrf2+/+ NSPCs resulted in a reduction 
of symmetric divisions (Fig. 26E). Taken together, these results suggest that NRF2 deficiency limits the 
self-renewal capacity of the NSPCs in the neurogenic niche of the SGZ. 
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Figure 26. NRF2 participates in self-renewal of NSPCs. (A) Representative confocal images of symmetric (upper panel) and 
asymmetric (lower panel) divisions by immunofluorescence of SOX2 and Nestin. Nuclei were counterstained with DAPI. (B) 
Quantification of symmetric and asymmetric divisions in cultures of NSPCs isolated from the SGZ of newborn mice. (C) 
Quantification of symmetric and asymmetric divisions in cultures of NSPCs isolated from the SGZ of 3-month-old mice. (D) 
Cell pair assay in cultures of Nrf2-/--CT and Nrf2-/-- NRF2ΔETGE NSPCs. (E) Quantification of symmetric and asymmetric 
divisions in cultures of Nrf2+/+ NSPCs transduced with control (shCO) or shRNA lentivirus to knockdown NRF2 (shNRF2). 
Data show mean ± S.D. (n = 60 pairs). ***p ⩽ 0.001 vs. experimental controls according to Student's t-test. 
 
4. Neuronal differentiation of NSPCs from the SGZ is impaired in Nrf2-/-  mice. 
 
We evaluated the capacity of the SGZ to produce new neurons using Doublecortin (DCX) 
staining that specifically labels neuroblasts and immature neurons (Fig. 27A and B). In both Nrf2+/+ and 
Nrf2-/- mice the amount of DCX+ cells decreased gradually to 10% at 12 months of age, but the SGZ of 
Nrf2-/- mice presented a lower capacity to generate these adult-born neurons already at 3 and 6 months of 
age. These data correlate with the impairment of LTP response in Nrf2-/- mice (Fig. 17). 
These results were also analyzed in neurospheres after removal of growth factors during 2 days 
in non-adherent conditions, allowing partial NSPCs differentiation. The amount of DCX+ cells in the 
neurospheres was substantially decreased to 20% in newborn (Fig. 28A and B) and 50% in 3-month-
old Nrf2-/- mice (Fig. 28C and D). 
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Figure 27. NRF2 deficiency leads to a reduction of adult-born neurons. (A) Representative images of DCX immunostaining 
in the SGZ of 3-, 6- and 12-month-old mice of the indicated genotypes. The white dotted line delimits the GCL. (B) 
Quantification of DCX+ cells of the indicated genotypes. Data represent mean ± SEM (n = 5). Statistical analysis was performed 
with a Student's t-test. *p ⩽ 0.05; ***p ⩽ 0.001 vs. Nrf2+/+ mice. 
  
Figure 28. NRF2 
deficiency leads to a 
decreased number of 
DCX+ cells in 
neurospheres. (A) 
Representative confocal 
images of DCX 
immunofluorescence on 
neurospheres derived from 
newborn mice of the 
indicated genotypes after two days without growth factors. (B) Quantification of DCX+ cells of in neurospheres of A (n ≥ 10). 
(C) Representative confocal images of DCX immunofluorescence on neurospheres derived from 3-month-old mice of the 
indicated genotypes after two days without growth factors. (D) Quantification of DCX+ cells in neurospheres of C (n ≥ 10). Data 
show mean ± SEM. **p ⩽ 0.01, ***p ⩽ 0.001 vs. Nrf2+/+ according to a Student's t-test. 
 
Next, we examined the differentiation potential of the NSPCs. When neurospheres are plated 
under adherent conditions on poly-D-lysine and grown in the absence of growth factors, NSPCs migrate 
away from the neurosphere core and spread around forming a carpet of cells differentiating to neurons, 
astrocytes and oligodendrocytes (Reynolds and Weiss, 1992; Reynolds and Weiss, 1996). First, following 
DCX and DAPI immunostaining, we observed a decrease in the migration distance of cells from newborn 
RESULTS 
108 
 
(Fig.29A and B) and, more notoriously, from 3-month-old (Fig. 29F and G) Nrf2-/- mice. DCX 
immunostaining in the differentiating cultures indicated impairment in the neuronal differentiation of 
Nrf2-/- neurospheres at birth (Fig. 29A and C) and at 3 months of age (Fig. 29F and H) measured as the 
percentage of DCX+ cells in the differentiation carpet. To analyze the maturation of these cells and their 
capacity to interact with other neurons, we performed Sholl analysis in DCX+ cells after 7 days of 
differentiation. This analysis measures the branching complexity in newborn (Fig. 29D and E) and 3-
month-old (Fig. 29I and J) derived cultures. DCX+ cells from Nrf2-/- mice showed a decrease in the 
number of neurite crossings suggesting a reduced maturation compared to those of Nrf2+/+ mice.  
 
 
Figure 29. Role of NRF2 in the differentiation of NSPCs in vitro. (A) Representative confocal images of DCX immunostaining 
of neurospheres from newborn mice grown after 7 days in differentiation conditions. Nuclei were counterstained with DAPI. (B) 
Measurement of the migration distance as determined by distance from the neurosphere edge (dotted line in A) to DAPI stained 
nuclei (n = 40). (C) Quantification of DCX+ cells from neurospheres shown in A (n = 12). (D) Sholl analysis of the neurons in 
the differentiated neurospheres derived from 3-month-old mice (n = 24). (E) Representative images of DCX+ cells in the Nrf2+/+ 
and Nrf2-/- cultures derived from newborn mice.  (F) Representative confocal images of DCX immunostaining of neurospheres 
from 3-month-old mice grown after 7 days in differentiation conditions. Nuclei were counterstained with DAPI. (G) 
Measurement of migration distance as determined by distance from the neurosphere edge (dotted line in F) to DAPI stained 
nuclei (n = 40). (H) Quantification of DCX+ cells from neurospheres shown in F (n = 12). (I) Sholl analysis of the neurons in 
the differentiated neurospheres derived from 3-month-old mice (n = 24). (J) Representative images of DCX+ cells in the Nrf2+/+ 
and Nrf2-/- cultures derived from 3-month-old mice. Data represent mean ± SEM. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. the 
Nrf2+/+ group according to a Student's t-test.  
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Genetic manipulation by lentiviral expression of NRF2 was also analyzed in differentiation 
assays. Neurospheres were seeded after 5 days of lentiviral transduction in differentiation conditions 
during 7 additional days (Fig. 30A). The migration distance was partially recovered by reintroduction of 
NRF2 expression in Nrf2-/- cultures (Fig. 30B and C), and reduced by knockdown of NRF2 in Nrf2+/+ 
cultures (Fig. 30E and F). Moreover, rescue of NRF2 expression in Nrf2-/- cultures led to enhanced 
neuronal differentiation quantified as DCX+ cells in the differentiation carpet (Fig. 30D). By contrast, 
silencing NRF2 in Nrf2+/+ neurospheres reduced significantly the percentage of DCX+ cells (Fig. 30G). 
All these data suggest that NRF2 is not only important for maintaining the NSPCs pool but also for 
supporting a proper neuronal differentiation.  
 
Figure 30. Impact of genetic modulation of 
NRF2 levels on neuronal differentiation of 
NSPCs. (A) Schematic overview of 
experimental procedure. (B) Representative 
confocal images of DCX immunostaining of 
control Nrf2-/- neurospheres (CT) or rescued by 
lentiviral expression of NRF2ΔETGE after 7 days 
in differentiation conditions. Nuclei were 
counterstained with DAPI. (C) Measurement of 
the cell migration distance from the neurosphere 
edge (dotted line in B) (n = 40). (D) 
Quantification of DCX+ cells in the 
differentiation carpet of Nrf2-/--CT and Nrf2-/--
NRF2ΔETGE cultures (n = 12). (E) Representative 
confocal images of DCX immunostaining of 
Nrf2+/+ neurospheres transduced with lentiviral 
control vector (shCO) or NRF2-knockdown 
(shNRF2) after 7 days in differentiation 
conditions. Nuclei were counterstained with 
DAPI. (F) Measurement of the cell migration 
distance from the neurosphere edge (dotted line 
in E) (n = 40). (G) Quantification of DCX+ cells 
in the differentiation carpet of Nrf2+/+-shCO and 
Nrf2+/+-shNRF2 cultures (n = 12). Data 
represent mean ± SEM. ***p ⩽ 0.001 vs. 
control- group according to a Student's t-test. 
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5. NRF2 deficiency impairs the balance in neuron/glia differentiation. 
 
Our previous data suggest that NRF2 participates in the fate of NSPCs. To determine the role of 
NRF2 in this process, we performed a differentiation assay after incubation of Nrf2+/+ and Nrf2-/- isolated 
neurospheres during 8 h with EdU, a nucleoside analogue of thymidine which is incorporated into DNA 
of proliferating cells during active DNA synthesis (Fig. 31A). Thus, we can mark NSPCs with EdU and 
monitor their differentiation dynamics. The rate of differentiation of EdU+ cells towards astrocytes 
(GFAP+ cells) and neurons (DCX+ cells) in Nrf2+/+ cultures was similar (Fig. 31B, C and D). By contrast, 
in Nrf2-/--derived-cultures, this ratio favoured astroglial differentiation, with an 80% of EdU+ cells being 
GFAP+, while only 20% were DCX+ (Fig. 31B, C and D). Thus, NRF2 deficiency affects the 
differentiation rate of NSPCs, favouring astroglial differentiation. 
 
 
Figure 31. NRF2 influences the fate of NSPCs. (A) Schematic overview of experimental procedures: Nrf2+/+ and Nrf2-/- formed 
neurospheres where incubated during 8 h with EdU and allowed to differentiate during 7 days. (B) Representative confocal 
images of EdU, DCX and GFAP immunostaining in Nrf2+/+ and Nrf2-/- cultures of NSPCs after 7 days in differentiation 
conditions. Yellow arrowhead: DCX+/EdU+ cells; Purple arrowhead: DCX+/EdU- cells; Green arrowhead: GFAP+/EdU+ cells. 
Nuclei were counterstained with Hoestcht 33342. (C) Quantification of DCX+/EdU+ cells. (D) Quantification of GFAP+/EdU+ 
cells. Data represent mean ± SEM (n = 20). **p ⩽ 0.01 vs. control group according to a Student's t-test. 
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Astrocyte differentiation of NSCs in vivo in the SGZ was analyzed in 3, 6 and 12-month-old 
Nrf2+/+ and Nrf2-/- mice by GFAP and SOX2 immunostaining, using co-labelling with Nestin (not showed 
in the figure to facilitate the view of astrocytes) to distinguish between astrocytes and NSPCs (Fig. 32A 
and B). The amount of astrocytes in the SGZ and GCL increased during aging, but more importantly, the 
Nrf2-/- mice exhibited higher abundance of astrocytes at all ages (Fig. 32A and B). Then, we evaluated 
the astroglial differentiation in vitro, using GFAP staining in neurospheres Nrf2+/+ and Nrf2-/- after 7 days 
in differentiation conditions. We detected an increase in the number of astrocytes in Nrf2-/- vs Nrf2+/+ 
cultures, being 20% higher in newborn (Fig. 33A and B) and 40% higher in 3-month-old derived 
neurospheres (Fig. 33C and D). Furthermore, rescuing NRF2 expression in Nrf2-/- cultures resulted in a 
reduction to 20% of GFAP+ cells (Fig. 33E and F). When we silenced NRF2 expression in Nrf2+/+ 
cultures, we observed an increase in astrocytes (Fig. 33G and H).  
All these experiments indicate that NRF2 is required not only for the proliferation of NSPCs, but 
also to keep the balance between neuronal and glial differentiation. 
 
 
Figure 32. NRF2 deficiency leads to an increase in astroglial differentiation. (A) Representative confocal images of 
astrocytes immunostained with GFAP and SOX2 in the SGZ of 3-, 6- and 12-month-old mice of the indicated genotypes. Dotted 
lines limit SGZ and GCL. (B) Quantification of astrocytes in the SGZ and GCL of the indicated mice. Data represent mean ± 
SEM (n = 5). Statistical analysis was performed with a Student’s t-test. *p ⩽ 0.05, ***p ⩽ 0.001 vs. Nrf2+/+ mice. 
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Figure 33. NRF2 deficiency favours astroglial differentiation of NSPCs. A) Representative confocal images of GFAP 
immunostaining of neurospheres from newborn mice grown after 7 days in differentiation conditions. Nuclei were counterstained 
with DAPI. (B) Quantification of GFAP+ cells from neurospheres shown in A (n = 12). (C) Representative confocal images of 
GFAP immunostaining of neurospheres from 3-month-old mice grown after 7 days in differentiation conditions. Nuclei were 
counterstained with DAPI. (D) Quantification of GFAP+ cells from neurospheres shown in C (n = 12). (E) Representative 
confocal images of GFAP immunostaining of control Nrf2-/- neurospheres (CT) or rescued by lentiviral expression of NRF2ΔETGE 
after 7 days in differentiation conditions. Nuclei were counterstained with DAPI. (F) Quantification of GFAP+ cells in the 
differentiation carpet of Nrf2-/--CT and Nrf2-/--NRF2ΔETGE cultures (n = 12). (G) Representative confocal images of GFAP 
immunostaining of Nrf2+/+ neurospheres transduced with lentiviral control vector (shCO) or NRF2-knockdown (shNRF2) after 
7 days in differentiation conditions. Nuclei were counterstained with DAPI. (H) Quantification of GFAP+ cells in the 
differentiation carpet of Nrf2+/+-shCO and Nrf2+/+-shNRF2 cultures (n = 12). Data represent mean ± SEM. ***p ⩽ 0.001 vs. 
control group according to a Student's t-test. 
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II. Relevance of NRF2 in 
neurogenesis in a mouse 
model of AD. 
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1. Characteristics of the AD mouse model. 
 
The role of NRF2 in maintenance of the SGZ neurogenic niche under the proteinopathy 
associated with AD has not been explored. We sought to determine if NRF2 deficiency, a typical hallmark 
of aging, might affect the neurogenic niche of the SGZ under conditions of amyloidopathy and tauopathy. 
To this purpose, we used a transgenic mouse expressing the human mutant proteins APPV717I and 
TAUP301L under the control of Thy1 promoter in a genetic background with (AT-Nrf2+/+) and without 
NRF2 (AT-Nrf2-/-) (Rojo et al., 2017) (extended description is provided in Material and Methods). These 
mice develop amyloidopathy and tauopathy over time (Rojo et al., 2017) that correlate with disrupted 
autophagic degradation of APP and TAU (Pajares et al., 2016), exacerbated microglial activation (Rojo 
et al., 2018) and a low-grade persistent oxidative stress as determined by a drop in reduced glutathione 
levels, and an increase in protein carbonyls and peroxidised lipids (Rojo et al., 2017).  
First, we characterized the expression of the human APPV717I or TAUP301L transgenes in the DG 
of 3, 6 and 12-month-old AT-Nrf2+/+ and AT-Nrf2-/- mice (Fig. 34A and B). NSPCs did not express human 
APPV717I or TAUP301L transgenes (data not shown), consistent with previous reports indicating that 
transgenes under the control of the Thy1 promoter co-localize with neuronal markers as MAP2 and 
Tubb3, but not with the NSPCs marker Nestin (Alic et al., 2016; Vidal et al., 1990; Hirrlinger et al., 2005; 
Lim et al., 2001). By immunohistochemistry, we determined the presence of neurons expressing human 
TAU and APP in the SGZ already at 3 months and also at 6 and 12 months of age. Furthermore, the 
expression of human TAU and APP in the SGZ was similar in both mouse types (Fig. 34A and B). 
   
Figure 34. Distribution of human TAU+ and APP+ neurons in the DG of the indicated genotypes. (A) Representative images 
of TAU+ neurons (HT7 clone) in the DG of 3, 6 and 12-month-old AT-Nrf2+/+ and AT-Nrf2-/- mice. White arrowheads indicate 
TAU+ neurons. Dotted lines delimit the DG. Insets are representative images of phosphorylated TAU+ neurons (AT-8 clone). 
(B) Representative images of APP/Aβ (6E10 clone) in 3, 6 and 12-month-old AT-Nrf2+/+ and AT-Nrf2-/- mice. White arrowheads 
indicate APP/Aβ+ neurons. Dotted lines delimit the DG. 
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2. NRF2 deficiency aggravates the cognitive impairment of AD mice. 
 
We tested the cognitive function related with the hippocampus. The Morris water maze (MWM) 
test is a widely used method to assess hippocampal spatial learning and memory in rodents (Morris, 1984; 
Morris et al., 1982). Thus, we evaluated the learning performance of 6-month-old AT-Nrf2+/+ and AT-
Nrf2-/- mice using this test (Fig. 35A and B) and measured the time necessary for the mice to find a 
submerged hidden platform (acquisition time) over 5 days (Fig. 35A). While the acquisition time of AT-
Nrf2+/+ mice decreased over training from 60 s to 20 s, indicating a normal learning performance, AT-
Nrf2-/- mice still needed almost 40 s on the fifth day. Additionally, on the sixth day the hidden platform 
was removed to estimate spatial-memory, indicated as the tropism of the animals to remain at the haunt 
quadrant (Fig. 35B). AT-Nrf2+/+ mice spent significantly more time in the target quadrant compared to 
AT-Nrf2-/-, indicating that NRF2-absence correlated with impaired spatial memory already at 6 months 
of age in these AD mice. 
In order to further analyze hippocampal function, we measured LTP in medial perforant path-to-
DG synapses in 6-month-old AT-Nrf2+/+ and AT-Nrf2-/- mice (Fig 35C and D). The recordings in the DG 
showed that the fEPSP was significantly lower after the administration of high-frequency stimuli in the 
AT-Nrf2-/- mice compared to AT-Nrf2+/+ mice. Considering that, under normal conditions, the only 
measurable LTP in the DG is derived from adult-newborn neurons (Wang et al., 2000; Schmidt-Hieber 
et al., 2004; Snyder et al., 2001; Saxe et al., 2006; Garthe et al., 2009), these results indicate that NRF2 
deficiency worsens the cognitive function related with adult hippocampal neurogenesis. 
 
 
Figure 35. NRF2 deficiency impairs spatial learning memory and LTP in AD mice. (A) MWM performance indicated as 
acquisition time in the 5 trials for 6-month-old mice of the indicated genotypes. Data represent mean ± SEM (n = 10). (B) Top 
circles, representative swimming tracks of mice when the hidden platform had been removed. Lower graph, quantification of 
time spent in the target quadrant. Data represent mean ± SEM (n = 10). (C) LTP recordings for 6-month-old mice of the indicated 
genotypes. Data represent mean ± SEM (n = 6). (D) Illustrative responses recorded from the indicated mice before (thin line) 
and after (thick line) high-frequency trains of stimulation. Statistical analysis was performed with a Student’s t-test *p ⩽ 0.05; 
**p ⩽ 0.01 vs. AT-Nrf2+/+. 
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3. NRF2 deficiency correlates with a decrease in NSPCs in the SGZ of AD mice. 
 
To analyze the dynamics of the NSPC pool under proteinopathic conditions, we immunostained 
dividing NSPCs with the NSPC marker Nestin and the proliferative marker Ki67 in the SGZ of 3, 6 and 
12-month-old AT-Nrf2+/+ and AT-Nrf2-/- mice and found that the proliferative rate declined with time, 
reaching almost undetectable levels at 12 months (Fig. 36A and B). Importantly, AT-Nrf2-/- mice 
exhibited a drastic reduction in the pool of proliferative NSPCs (Ki67+/Nestin+ cells) already at 3 months 
compared to AT-Nrf2+/+ mice (Fig. 36A and B). Since at this age we did not find significant differences 
in APP/TAU expression in neurons (Fig. 34A and B), these results suggest that the disruption of the 
neurogenic niche is a very early event in the proteinopathy-associated neuronal damage. 
 
 
Figure 36. NRF2 deficiency correlates with a decrease in proliferative NSPCs in the SGZ of AD mice. (A) Representative 
confocal images of the NSPCs marker Nestin and the proliferative marker Ki67 in the SGZ of 3-month-old mice of the indicated 
genotypes. White arrowheads point to Ki67+/Nestin+ cells. (B) Quantification of Ki67+ cells in 3-, 6- and 12-month-old mice of 
the indicated genotypes. Data represent mean ± SEM (n = 5). **p ⩽ 0.01; ***p ⩽ 0.001 vs. AT-Nrf2+/+ according to a Student’s 
t-test. 
 
We also monitored the pool of NSCs and NPCs by triple labelling with GFAP, SOX2 and Nestin. 
NSCs and NPCs were identified by their morphology: NSCs, in contrast to NPCs, present a long process 
crossing the GCL and are Nestin+/SOX2+/GFAP+ (Encinas et al., 2011). As shown in Fig. 37, although 
the NSC and NPC pools decline in both genotypes during aging, they were 3 folds lower in AT-Nrf2-/- 
compared to AT-Nrf2+/+ mice already at 3 months. Therefore, the proteinopathy in the hippocampus 
induces a dependence of NRF2 in order to maintain this pool.  
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Figure 37. NRF2 deficiency leads to a strong reduction in the number of NSCs and NPCs in the hippocampus. (A) 
Representative confocal image of GFAP, SOX2 and Nestin immunofluorescence in 3-, 6- and 12-month-old mice of the indicated 
genotypes. Dotted lines delimit the SGZ and the GCL. (B) Quantification of NSCs in 3-, 6- and 12-month-old mice of the 
indicated genotypes. (C) Quantification of NPCs in 3-, 6- and 12-month-old mice of the indicated genotypes based on the 
immunostaining showed in (A). Data show mean ± SEM (n = 4). **p ⩽ 0.01; ***p ⩽ 0.001 vs. AT-Nrf2+/+ according to a 
Student’s t-test. 
 
4. NRF2 deficiency in AD mice favours astroglial vs. neuronal differentiation. 
 
We performed immunostaining with the marker of neuroblasts and immature neurons, DCX in 
the SGZ of 3, 6 and 12-month-old AT-Nrf2+/+ and AT-Nrf2-/- mice (Fig 38A and B). As expected, during 
aging, the cell density of DCX+ cells was decreasing, but its cell number was lower in AT-Nrf2-/- even at 
3-months of age (Fig. 38A and B), suggesting an accelerated loss of neurogenic capacity under NRF2-
deficient conditions.  
Next, we determined the astrocyte differentiation of NSCs in the SGZ by immunostaining with 
GFAP, accompanied by Nestin (not seen in the figure to facilitate the view of GFAP staining) to 
distinguish astrocytes from NSCs. The population of astrocytes was enriched in AT-Nrf2-/- at all ages 
studied (Fig. 39A and B). These results suggest that loss of NRF2 favours NSPCs differentiation to 
astrocytes at the expense of neuronal differentiation and exhaustion of NSPCs pool. 
Our findings point NRF2 as a factor required for hippocampal NSPCs to undergo proper 
proliferation and differentiation under AD pathological conditions, and suggest that NRF2 up-regulation 
might provide a mechanism to preserve the neurogenic functionality of the hippocampus. 
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Figure 38. Lack of NRF2 impairs neuronal differentiation in AD mice. (A) Illustrative confocal images of the immature 
neuron marker DCX in the SGZ of 3-, 6- and 12-month-old mice of the indicated genotypes. Dotted lines delimit the SGZ and 
the GCL. (B) Quantification of DCX+ cells under the conditions detailed in (A). Data show mean ± SEM (n = 4). **p ⩽ 0.01; 
***p ⩽ 0.001 vs. AT-Nrf2+/+ according to a Student’s t-test. 
 
 
Figure 39. Lack of NRF2 favours astrogliogenesis in AD mice. (A) Representative confocal images of astrocyte marker GFAP 
and SOX2 immunostaining in the SGZ of 3-, 6- and 12-month-old mice of the indicated genotypes. Dotted lines delimit the SGZ 
and the GCL. (B) Quantification of astrocytes based on (A). Data show mean ± SEM (n = 4). **p ⩽ 0.01; ***p ⩽ 0.001 vs. AT-
Nrf2+/+ according to a Student’s t-test. 
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III. The transcription factor 
NRF2 is a regulator of 
WWTR1/TAZ gene 
expression. 
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1. The WWTR1 promoter has functional NRF2-binding sites. 
 
We looked for putative NRF2-regulated AREs (Antioxidant Response Elements) in the TAZ-
encoding gene (WWTR1) by using the ENCODE (https://genome.ucsc.edu/encode/) of the human genome 
(Feb. 2009). This database contains experimental data from chromatin immunoprecipitation (ChIP) 
studies of several transcription factors. Although NRF2 is not included, we examined three other ARE-
binding factors, MAFK, MAFF and BACH1, for which information is available, in DNase sensitive 
regions (Keene et al., 1981; McGhee et al., 1981) and enriched in acetylation in Lys27 of histone H3 
(H3K27Ac), regions which are related to active enhancers (Creyghton et al., 2010) (Fig. 40A). We 
compared this information with the position specific scoring matrix (PSSM) for the consensus sequence 
recognized by NRF2, depicted at the JASPAR database (http://jaspar.genereg.net/) using a Python 3.4- 
script (Appendix I).We obtained a relative score for each sequence and considered those with a threshold 
value over 80%. We retrieved 9 putative ARE candidates in regulatory regions of TAZ with this 
bioinformatics approach (Table 14). Sequences in the regulatory regions of the bona fide NRF2-targets 
HMOX1 and NQO1 were analyzed as positive controls (Table 14). 
 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
ARE PUTATIVE 
BINDING SEQUENCE 
HMOX1 chr22:35773158- 35773147 18.97 99.7 GTGACTCAGCA 
NQO1 chr16:69760919-69760908 18.97 99.7 GTGACTCAGCA 
WWTR1 ARE1 chr3: 149435325-149435336 11.34 81.4 GTGCCAGAGCA 
WWTR1 ARE2 chr3: 149378461-149378450 15.97 92.5 GTGACTCAGCT 
WWTR1 ARE3 chr3: 149365723-149365712 13.15 85.7 ATGATTATGCA 
WWTR1 ARE4 chr3: 149365892-149365903 13.84 87.4 ATGTCTAAGCA 
WWTR1 ARE5 chr3: 149299667-149299656 13.44 86.4 ATGAGTCTGCA 
WWTR1 ARE6 chr3: 149294176-149294165 15.16 90.5 ATGAGACAGCA 
WWTR1 ARE7 chr3: 149258004-149258015 13.94 87.6 ATGATGCAGCA 
WWTR1 ARE8 chr3: 149254494-149254483 13.36 86.2 CTGACTAAGCC 
WWTR1 ARE9 chr3: 149230221-149230232 15.04 90.2 CTGAGTGAGCG 
 
Table 14. Putative Antioxidant Response Elements (AREs) for MAFK/MAFF/BACH1 in the WWTR1 gene found in the 
ENCODE database by a bioinformatics analysis, taking a threshold of relative score higher than the 80%. The table also shows 
the max score and the chromosomic localization in the human genome. The most relevant bases for NRF2/MAF binding are 
shown in bold. 
 
2. Validation of putative AREs in the TAZ promoter by ChIP and luciferase assays.  
 
These putative AREs were further analyzed in ChIP assays (Fig. 40B) in HEK293T cells 
transfected with an expression vector for V5-tagged NRF2 (pcDNA3.1-mNRF2ΔETGE-V5). ChIPs were 
performed with anti-V5 antibody and with anti-IgG as negative control. Immunoprecipitated DNA was 
analyzed by qRT-PCR with specific primers surrounding the putative AREs (Table 11). At least 1 of the 
9 putative AREs analyzed, ARE2, exhibited significantly high enrichment although not as strong as the 
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positive controls HMOX1 and NQO1 (Fig. 40B). No enrichment was detected with specific primers for 
ACTB as a negative control, or for an upstream region of NQO1 that does not contain an ARE (NQO1*) 
(Pajares et al., 2016). In additional experiments, three tandem nucleotide sequences of ARE2 were cloned 
in the promoter region of a luciferase reporter in a non-modified form (ARE2-WT) or with the most 
conserved T and G residues mutated (ARE2-mutated) (Fig. 40C). HEK293T cells were transiently co-
transfected with these reporters and the positive control HMOX1-ARE plus increasing amounts of the 
activated NRF2ΔETGE-V5. We found that NRF2 induced luciferase expression in the ARE2-WT and the 
positive control HMOX1-ARE, but not in the ARE2-mutated reporter (Fig. 40D). Altogether, these results 
indicate that NRF2 binds and activates at least one specific ARE enhancer in the WWTR1 gene promoter. 
 
 
Figure 40. The WWTR1 promoter has at least one functional NRF2-binding site. (A) Representative scheme of the gene 
WWTR1 encoding TAZ. Regions enriched in acetylated histone H3 lysine 27 (H3K27ac) are shown in blue. Regions sensitive to 
DNase are represented as dark boxes. Experimental sequences reported to bind MAFK, MAFF and BACH1 were analyzed of 
the presence of AREs (ARE 1-9). (B) ChIP analysis of putative AREs found in (A) using the anti-V5 antibody vs. a control IgG 
in HEK293T cells overexpressing NRF2ΔETGE-V5. (C) Luciferase reporter constructs used for assessment of wild type or mutated 
ARE2 functionality in pGL3basic vector. (D) HEK293T cells were transfected with wild type or mutated ARE2 reporter plus 
increasing amounts of NRF2ΔETGE-V5. Luciferase activity was measured 24 h after transfection. The reporter construct carrying 
an ARE from HMOX1 was used as control. Luciferase activities were normalized to renilla activity. Results are shown relative 
to control and are mean ± S.D. (n = 3). **p ⩽ 0.01 according to a Student’s t-test. 
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3. Changes in NRF2 expression modify TAZ levels in NSPCs. 
 
Next, we further extended these observations to the NSPCs isolated from the SGZ of 3-month-
old Nrf2+/+ and Nrf2-/- mice. In agreement with the results obtained in the previous assays, NRF2 
deficiency in the neurospheres led to a reduction of protein levels of NQO1, as a positive control, as well 
as TAZ and its target CTGF (Fig. 41A). This reduction was also observed at transcriptional level by qRT-
PCR (Fig. 41B).  
 
Figure 41. NRF2 deficiency is accompanied 
with a reduction in TAZ levels and its targets 
in NSPCs. (A) Representative immunoblot of 
NRF2, NQO1, TAZ, CTGF and Lamin B as a 
loading control of NSPCs isolated from the DG 
of 3-month-old mice.  (B) mRNA levels of 
Nrf2, Nqo1, Wwtr1 and Ctgf were determined 
by qRT-PCR and normalized by the geometric 
mean of Actb, Gapdh and Tbp levels. Data are presented as mean ± S.D. (n = 6). ***p ⩽ 0.001 vs. Nrf2+/+ according to a Student’s 
t-test.  
 
To get further insight into these results, we down-regulated NRF2 in the human NSPCs 
immortalized cell line ReNcells. NRF2-knockdown reduced the protein levels of NQO1 and provoked a 
slight reduction in TAZ determined by immunoblot analysis (Fig. 42A). At transcriptional level, NRF2-
knockdown triggered a reduction in NQO1 and subtle reduction in WWTR1 transcripts (Fig. 42A and B).  
 
Figure 42. Genetic down-regulation of NRF2 
decreases TAZ levels in ReNcells. (A) 
Representative immunoblot analysis of NRF2, TAZ, 
NQO1 and GAPDH and Lamin B as a loading 
controls (n = 3) of ReNcells transduced with empty 
vector or lentiviral vector for NRF2 knockdown 
(shNRF2).  (B) mRNA levels of NRF2, NQO1, and 
WWTR1 were determined by qRT-PCR and 
normalized by the geometric mean of ACTB, 
GAPDH and TBP levels. Data are presented as mean 
± S.D. (n = 4). **p ⩽ 0.01, ***p ⩽ 0.001 vs. shCO 
according to a Student’s t-test.  
 
Then, we used genetic and chemical strategies to upregulate NRF2 in ReNcells. Ectopic 
overexpression of NRF2 led to increased levels of control NQO1 protein and mRNA but also TAZ and 
its target CTGF (Fig. 43A and B). In additional experiments, ReNcells were treated with the NRF2 
activator sulforaphane (SFN, 15 μM) for different times (Fig 43C-F). SFN led to the accumulation of 
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NRF2 protein within the first 3 h and then slowly decreased to basal levels at 48 h (Fig. 43C). The increase 
in NRF2 also correlated with a gradual increase in NQO1, TAZ and CTGF proteins and transcripts (Fig. 
43C-F). Although the effect at the transcript level for TAZ was more transient than for NQO1, both 
proteins remained elevated for at least 12- 48 h. By contrast, CTGF increased more slowly reaching 
maximal protein and transcript levels at 48 h. These results are consistent with a first wave of NRF2-
dependent transcriptional activation that includes NQO1 and TAZ, followed by a second wave when TAZ 
levels are high enough to induce expression of the CTGF gene. 
Altogether, these results indicate a link between NRF2 and TAZ expression in murine and human 
NSPCs. 
 
 
Figure 43. Genetic and pharmacological up-regulation of NRF2 increases TAZ levels in ReNcells. (A) Representative 
immunoblot analysis of NRF2, TAZ, NQO1, CTGF and GAPDH and Lamin B as a loading controls (n = 3) of ReNcells 
transduced with empty vector or lentiviral vector for overexpression of NRF2.  (B) mRNA levels of NQO1, WWTR1 and CTGF 
were determined by qRT-PCR and normalized by the geometric mean of ACTB, GAPDH and TBP levels. Data are presented as 
mean ± S.D. (n = 4). **p ⩽ 0.01, ***p ⩽ 0.001 vs. CT according to a Student’s t-test. (C) ReNcells were treated with sulforaphane 
(SFN) (15 μM) for the indicated times. (C) Representative immunoblot analysis of NRF2, TAZ, NQO1, CTGF and GAPDH as 
a loading control (n = 3). (D, E, F) mRNA levels of NQO1 (D), WWTR1 (E) and CTGF (F) were determined by qRT-PCR and 
normalized by the geometric mean of ACTB, GAPDH and TBP levels. Data are presented as mean ± S.D. (n = 4). *p ⩽ 0.05, **p 
⩽ 0.01 according to a Student’s t-test. The blue area represents the wave of NRF2 dependent transcription and the green area 
depicts a second wave that involves NRF2 and also TAZ-dependent transcription. The time for transition from one wave to the 
other was chosen arbitrarily. 
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IV. The transcription 
cofactor TAZ regulates 
proneurogenic genes 
expression. 
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1. TAZ expression is absent in mature neurons. 
 
To study the function of TAZ in neurogenesis, we first consulted the Brain RNA-seq database. 
This database provides the expression levels of numerous genes in the main cell types of human (Zhang 
et al., 2016) and murine brain (Zhang et al., 2014). We found that WWTR1 expression, encoding TAZ, is 
mostly limited to astroglia and endothelial cells but is low in neurons of either humans (Fig. 44A) or mice 
(Fig. 44B). 
 
Figure 44. WWTR1 expression in the human and murine brain. 
(A) Distribution of WWTR1 mRNA in cell types isolated from human 
grey matter from mature brain specimens after removal of meninges 
and blood clots. For details of human data see (Zhang et al., 2016).  
(B) Analysis of WWTR1 mRNA expression in glia, neurons and 
vascular cells isolated from mouse cerebral cortex. For details of 
mouse data see (Zhang et al., 2014). Data show mean ± SEM. Data 
were obtained from the Brain RNA-seq database. FPKM: fragments 
per kilobase million. 
 
These differences prompted us to analyze WWTR1 expression during differentiation of NSPCs in 
the two main murine neurogenic niches: the SGZ of the DG and the SVZ of the striatum, in newborn and 
3-, 6-, and 12-months-old mice. We combined TAZ immunostaining with Nestin to identify NSPCs, and 
with DCX to identify neuroblasts and immature neurons. The specificity of anti-TAZ antibody was 
validated in Figure 11. As expected, the pool of progenitors (Nestin+ cells) declined with aging, both in 
the SVZ (Fig. 45A and C) and the SGZ (Fig. 46A and C). The number of neuroblasts and immature 
neurons (DCX+ cells) also declined in the SVZ (Fig. 45B and C) and the SGZ (Fig. 46B and C). More 
importantly, we detected that TAZ-expressing cells also decayed parallel to the exhaustion of the pool of 
progenitors (Fig 45C and Fig 46C). Furthermore, in double immunofluorescence assays we found that 
TAZ is expressed in Nestin+ cells but not in DCX+ cells, both in the SVZ (Fig. 45D) and the SGZ (Fig. 
46D) and the pool of double Nestin+/TAZ+ cells (NSPCs expressing TAZ) dramatically declined after 3 
months of age in both locations. Furthermore, measuring the distribution of TAZ+ cells between the 
different populations, almost all TAZ+ cells were Nestin+, and no one DCX+, indicating that TAZ 
expression is limited to NSPCs in the murine neurogenic niches (Fig. 45E and 46E). Even more, a small 
proportion of TAZ+ cells were GFAP+, which is expressed in astrocytes and NSCs. These results indicate 
that TAZ expression in murine neurogenic niches is mostly limited to NSPCs and astrocytes, and is absent 
in neurons already from immature stages. 
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Figure 45. TAZ distribution in the subventricular zone (SVZ). (A) Representative confocal immunofluorescence of Nestin 
and TAZ. (B) Representative confocal immunofluorescence DCX and TAZ. Nuclei were counterstained with DAPI. White 
arrowheads indicate TAZ+ cells also delineated with white dotted lines. Blue dotted lines delimit DCX+/ TAZ ̶  cells. (C) 
Quantification of total Nestin+, DCX+ or TAZ+ cells in the SVZ of newborn, 3-, 6- and 12-month-old mice. Data represent mean 
± SEM (n = 5). (D) Quantification of the total number of Nestin+/TAZ+ or DCX+/TAZ+ in the SVZ of newborn, 3-, 6- and 12- 
month-old mice. Data represent mean ± SEM (n = 5). (E) Pie charts represent the distribution of TAZ+ cells as the percentage of 
TAZ cells that are Nestin+, DCX+ or GFAP+, ± SEM in the SVZ of newborn, 3-, 6- and 12-month-old mice (n = 5). 
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Figure 46. TAZ distribution in the murine SGZ. (A) Representative confocal immunofluorescence of Nestin and TAZ. (B) 
Representative confocal immunofluorescence of DCX and TAZ. Nuclei were counterstained with DAPI. White arrowheads 
indicate TAZ+ cells also delineated with white dotted lines. Blue dotted lines point DCX+/ TAZ ̶  cells. Yellow arrowheads in A 
indicate Nestin+ blood vessels, which have not been quantified in this study. (C) Quantification of total Nestin+, DCX+ or TAZ+ 
cells in the SGZ of newborn, 3-, 6- and 12-month-old mice. Data represents mean ± SEM (n = 5).  (D) Quantification of the total 
cell number co-expressing Nestin+/TAZ+ cells or DCX+/TAZ+ cells in the SGZ of newborn, 3-, 6- and 12-month-old mice. Data 
represent mean ± SEM (n = 5). (E) Pie charts represent the distribution of TAZ+ cells as the percentage of TAZ cells that are 
Nestin+, DCX+ or GFAP+, ± SEM in the SGZ of newborn, 3-, 6- and 12-month-old mice (n = 5). 
 
2. TAZ expression declines during neuronal differentiation. 
 
Then, we analyzed the expression of TAZ during differentiation of the human immortalized 
NSPC line ReNcell. As shown in Fig. 47A, under stem growth conditions (in the presence of growth 
factors) these cells exhibited the Nestin marker of NSPCs but also expressed TAZ both in the nucleus 
and cytoplasm (white arrowheads), consistent with our observations in the neurogenic niches. After 7 
days in differentiation medium (in the absence of growth factors), many NSPCs were differentiating to 
immature neurons (DCX+), while others retained the expression of GFAP, marker of both NSPCs and 
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astrocytes.  Importantly, DCX+ cells did not express TAZ (Fig. 47B, blue arrowheads) in agreement with 
our observations in the murine neurogenic niches (Fig. 45 and 46). We also determined a progressive loss 
of Nestin+ NSPCs to 50%, a progressive increase of DCX+ immature neurons to 40%, and, more 
relevant, a decrease in TAZ expression to 70% that paralleled the loss of NSPCs (Fig. 47C). 
Additionally, the loss of TAZ+ cells was further correlated with neuronal differentiation because the 
fraction of Nestin+/TAZ+ cells remained constant while that of DCX+/TAZ+ cells declined (Fig. 47D). 
This decay was parallel to neuronal maturation, analyzed as neurite length (Fig. 47E and F). Moreover, 
TAZ nuclear expression decreased as neural maturation proceeded (Fig. 47F).  These results demonstrate 
a negative correlation between TAZ expression and exit of stemness towards neuronal differentiation.  
 
 
Figure 47. TAZ expression declines during neuronal differentiation. (A) Representative confocal images of ReNcells 
immunostained with Nestin and TAZ under proliferative conditions. White arrows indicate TAZ+ cells. (B) Representative 
confocal images of specific neuronal marker DCX, astrocyte and NSPCs marker GFAP with TAZ immunostaining of ReNcells 
after 7 days of in vitro differentiation. Blue arrows indicate TAZ  ̶ cells. (C) Quantification of Nestin+, DCX+ and TAZ+ ReNcells 
during differentiation. (D)  Percentage of Nestin+/TAZ+ of total Nestin+ cells and DCX+/TAZ+ of total DCX+ ReNcells during 
differentiation. (E) Representative images of DCX+ cells after 3 and 7 days of differentiation. (F) Percentage of cells expressing 
nuclear TAZ (left Y axis) and neurite length (right Y axis) of DCX+ cells during neuronal differentiation, indicating neuronal 
maturation. Data are mean ± SEM (n ≥ 50). 
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3. TAZ depletion in neural progenitors favours neuronal differentiation. 
 
In order to determine if this negative correlation was evidencing a role of TAZ in the control of 
stemness vs. neuronal differentiation, ReNcells were infected with a control lentivirus (shCO) or with a 
lentivirus for human TAZ-knockdown (shTAZ), allowed to growth 5 days under proliferative conditions 
and them grown in differentiation medium for 30 days (Fig. 48A). Neuronal differentiation was analyzed 
with the specific markers DCX (neuroblasts and immature neurons), MAP2 (dendrite marker), TUBB3 
(neuronal marker) and TAU (axon marker) (Fig. 48B, C, D). We detected that TAZ silencing resulted in 
an increase in the number neurons as determined by the quantification of DCX+ (Fig. 48B and E), MAP2+ 
(Fig. 48B and F), TUBB3+ (Fig. 48C and G) and TAU+ (Fig. 48D and H) cells. We next evaluated 
neuronal complexity and maturation as determined by dendrite length, based on MAP2 staining, and 
axonal length, based on TAU staining. TAZ-knocked-down cells presented longer dendrites (Fig. 48I) 
and axons (Fig. 48J) than shCO-infected cells. These results indicate that loss of TAZ favours neuronal 
differentiation. 
 
Figure 48.  Loss of 
TAZ favours neuronal 
differentiation. (A) 
Schematic overview of 
the experimental 
procedure: ReNcells 
were transduced with 
lentivirus encoding 
shcontrol (shCO) or 
human shTAZ and after 
5 days were plated 
under differentiation 
conditions for 30 days. 
(B) Representative 
confocal images of 
neuronal markers DCX 
and MAP2 with TAZ. 
(C) Representative 
images of TUBB3 
immunofluorescence 
staining. (D) 
Representative image 
of TAU 
immunofluorescence. Nuclei were counterstained with DAPI. (E) Quantification of DCX+ cells described in B. (F) 
Quantification of MAP2+ cells described in B.  (G) Quantification of TUBB3+ cells described in C. (H) Quantification of TAU+ 
cells described in D. (I) Dendrite length based on MAP2 staining. (J) Axon length based on TAU staining. Data are mean ± 
SEM (n ≥ 20). Statistical analysis was performed with the Student’s t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. shCO. 
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4. TAZ inhibits neuronal commitment partially in a TEAD-dependent manner. 
 
As an additional approach, we overexpressed several mutant TAZ versions during 5 days in 
proliferation medium and analyzed ReNcells differentiation after 30 days in differentiation medium, 
without growth factors (Fig. 49A). Expression of wild type TAZ (TAZ-WT) reduced the neuronal 
differentiation as determined with the DCX (Fig. 49B and C), MAP2 (Fig. 49B and D) and TAU (Fig.49B 
and E) markers. Moreover, expression of the constitutively stable mutant of TAZ (TAZ4SA) abolished 
completely neuronal differentiation (Fig. 49B, C, D and E). Regarding neuronal maturation, we observed 
an impairment in dendrite (MAP2 staining) and axon (TAU) length in TAZ-overexpressing cells, 
indicating that TAZ not only diminishes neuronal differentiation, but also affects further stages of 
neuronal maturation (Fig. 49F and G). 
TEAD transcription factors are the main transcriptional co-partners of TAZ. To gain more insight 
into the implication of TEADs in neuronal commitment, we expressed mutant forms of TAZ defective in 
the binding to TEAD, were the Ser-51 has been mutated to alanine (TAZS51A) and the constitutively active 
TAZ (TAZ4SA+S51A) (Zhang et al., 2009) (Fig. 12).  Expression of TAZS51A partially restored neuronal 
differentiation as determined with DCX (Fig. 49B and C), MAP2 (Fig. 49B and D) and TAU (Fig.49B 
and E) immunostaining. Moreover, TAZ4SA+S51A, that is not degradable and does not bind TEAD, partially 
restored neuronal differentiation despite harbouring high TAZ levels (Fig. 49B to E). These findings 
indicate that TAZ repression of neuronal differentiation is partially TEAD-dependent. These observations 
were further extended to study the neuronal complexity as described previously. In line with the data on 
neuronal differentiation, we found that overexpression of TEAD-binding defective TAZ mutants partially 
restored the dendrite and axonal length (Fig. 49F and G). 
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Figure 49.  TAZ impairment of neuronal differentiation is partially TEAD-dependent. (A) Schematic overview of 
experimental design: ReNcells were transduced with empty vector (CT) or retroviral vector for overexpression of TAZ-WT and 
TAZ mutants TAZS51A, TAZ4SA and TAZ4SA+S51A and, after 5 days of retroviral transduction, plated under differentiation 
conditions during 30 days. (B) Immunostaining of neuronal markers DCX, MAP2 and TAU. Nuclei were counterstained with 
DAPI. (C, D, E) Quantification of DCX+ (C), MAP2+ (D) and TAU+ (E). (F) Measurement of dendrite length based on MAP2 
staining. (G) Measurement of axonal length based on TAU staining. Data are mean ± SEM (n ≥ 20). Statistical analysis was 
performed with the Student’s t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. CT. #p ⩽ 0.05; ##p ⩽ 0.01, ###p ⩽ 0.001 comparing 
TAZS51A vs. TAZ-WT. $p ⩽ 0.05; $$p ⩽ 0.01, $$$p ⩽ 0.001 comparing TAZ4SA+S51A vs. TAZ4SA. 
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5. Identification of putative TAZ interacting regions in proneurogenic genes. 
 
To assess why TAZ represses neurogenesis, we first analyzed the possible link between TAZ and 
transcription factors known to be positive regulators of neurogenesis, such as SOX2 (Panaliappan et al., 
2018; Lim et al., 2017; Steevens et al., 2017; Ng et al., 2013; Amador-Arjona et al., 2015) and proneural 
basic helix-loop-helix factors (bHLH) ASCL1 (Castro et al., 2011; Memic et al., 2016), NEUROG2 
(Lacomme et al., 2012; Hufnagel et al., 2010; Heng et al., 2008) and NEUROD1 (Pataskar et al., 2016; 
Kuwabara et al., 2009). First, we surveyed the ENCODE of the human genome (Feb. 2009) in search for 
TAZ-regulated elements. Although TAZ does not bind directly to gene regulatory elements, ENCODE 
includes information about TAZ co-partners TEAD4 (Zhang et al., 2009), SMAD2 (Varelas et al., 2008) 
and RUNX (Kim et al., 2018). Furthermore, this database also gathers information of DNase 
hypersensitive areas and H3K27Ac, which correlates with open chromatin that characterizes regulatory 
regions. In addition, we obtained the PSSM for the consensus sequence recognize by TAZ co-partners 
TEAD1, TEAD2 (Fig. 50B and C), TEAD3, TEAD4, SMAD2/3/4 and RUNX2 (Tables 4 to 9) based on 
the frequency matrix depicted at the JASPAR database. We then compared the regulatory regions 
retrieved from ENCODE for each gene with the PSSM of the consensus sequence for each transcription 
factors using a Python-based bioinformatics analysis (Appendix I). 
Using this script, we obtained a relative score for each sequence and considered those with a 
relative score higher than 80%. We identified several putative TEADs, SMADs and RUNX binding sites 
in the gene regulatory regions of SOX2 and bHLH factors ASCL1, NEUROG2 and NEUROD1 (Table 15 
to 20). Sequences in the regulatory regions of the bona fide TAZ-targets CTGF and CYR61 were analyzed 
as positive controls (Table 15 to 20). As it is shown in Table 15 to 20, the proneurogenic genes presented 
several putative binding sequences for TAZ co-transcriptional partners with relative scores similar or 
even higher to those found in bona fide TAZ targets. 
  
RESULTS 
137 
 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD1 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269288-132269276 13.77 82.8 AACATTTCTGAG 
chr6:132269659-132269671 15.62 85.8 TACATTCTACCT 
chr6:132270157-132270169 13.62 82.5 TACATTCTGGTG 
chr6:132270884-132270872 12.97 81.5 GACATTCCAAGA 
chr6:132270949-132270961 13.1 81.7 CTCATTCCAGCA 
chr6:132272609-132272621 17.78 89.3 CGCATTCCTCCC 
CYR61 
chr1:86046332-86046344 16.14 86.6 AGCATTCCTGAG 
chr1:86047219-86047207 16.2 86.7 TGCATTCCAGCC 
chr1:86047721-86047733 18.56 90.5 TGCATTCCTCTG 
chr1:86048360-86048348 14.99 84.8 CACATCCCACCC 
SOX2 
chr3:181431413-181431401 13.88 83 TCCATTCCCCCG (b) 
chr3:181428382-181428394 13.77 82.8 AAGATTCCTGAG (c) 
ASCL1 chr12:103349554-103349542 13.99 83.1 CACATCCCTGAC (b) 
NEUROG2 chr4:113435415-113435427 14.3 83.6 TGCATTCCCCCT (a) 
NEUROD1 
chr2:182543940-182543952 15.41 85.4 TACATTTCAGCG (c) 
chr2:182544023-182544035 15.78 86 CACATTCTACTT (c) 
Table 15. Putative TEAD1 binding sequences in the promoter regions of SOX2 and bHLH factors genes with a relative score 
higher than 80%. The table also shows the max score and the localization in the human genome. 
 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD2 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269289-132269276 8.66 91.1 AAACATTTCTGAG 
chr6:132269658-132269671 9.07 91.5 TTACATTCTACCT 
chr6:132270885-132270872 12.97 95.5 AGACATTCCAAGA 
chr6:132270948-132270961 10.85 93.3 TCTCATTCCAGCA 
chr6:132272599-132272612 12.99 95.6 GGACATTCCTCGC 
CYR61 
chr1:86046331-86046344 10.42 92.9 CAGCATTCCTGAG 
chr1:86047220-86047207 13.29 95.9 TTGCATTCCAGCC 
chr1:86047720-86047733 10.16 92.6 CTGCATTCCTCTG 
chr1:86048153-86048140 10.58 93.1 ATACATTTCTGGC 
chr1:86048573-86048560 8.39 90.8 TCACAGTCCTGGT 
chr1:86049144-86049157 11.28 93.8 GGGCATTCCATCC 
SOX2 
chr3:181431414-181431401 6.99 89.3 GTCCATTCCCCCG (b) 
chr3:181428381-181428394 8.06 90.5 CAAGATTCCTGAG (c) 
chr3:181428844-181428831 8.49 90.9 CCCCATTCCCATC (a) 
ASCL1 
chr12:103349820-103349833 9.6 92 CCACATACCAAGA (a) 
chr12:103349555-103349542 9.57 92 CCACATCCCTGAC (b) 
chr12:103354060-103354047 7.77 90.1 CAACATTTCTATA (c) 
NEUROG2 
chr4:113435031-113435044 5.56 87.9 TTGCATTCAATCA (b) 
chr4:113438807-113438794 7.65 90 TAACACTCCAACT 
chr4:113435345-113435358 9.31 91.8 ATACATTTCTTTC (a) 
NEUROD1 
chr2:182543939-182543952 10.29 92.8 GTACATTTCAGCG (c) 
chr2:182544022-182544035 9.16 91.6 ACACATTCTACTT (c) 
chr2:182544640-182544653 8.01 90.4 CCACTTTCCCCCC (b) 
chr2:182545564-182545577 9.07 91.5 CTCCATTCCGGCC (a) 
Table 16. Putative TEAD2 binding sequences in the promoter regions of SOX2 and bHLH factors genes with a relative 
score higher than 85%. The table also shows the max score and the localization in the human genome. 
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GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD3 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132270622-132270614 10.89 97.2 ACATACCG 
chr6:132269884-132269892 6.86 95.2 GGATTCCG 
chr6:132270883-132270875 14.08 98.7 ACATTCCA 
chr6:132270950-132270958 10.59 97 TCATTCCA 
chr6:132271352-132271344 8.64 96.1 AAATACCT 
chr6:132272601-132272609 13.43 98.4 ACATTCCT 
CYR61 
chr1:86046333-86046341 12.94 98.2 GCATTCCT 
chr1:86047218-86047210 13.59 98.5 GCATTCCA 
chr1:86047722-86047730 12.94 98.2 GCATTCCT 
chr1:86048065-86048057 10.4 96.9 GCATACCG 
chr1:86048501-86048509 7.98 95.7 AAATACCG 
chr1:86049146-86049154 13.59 98.5 GCATTCCA 
chr1:86048877-86048869 8.64 96.1 AAATACCT 
SOX2 
chr3:181430473-181430481 7.98 95.7 AAATACCG 
chr3:181431412-181431404 2.17 92.9 CCATTCCC (b) 
chr3:181430283-181430291 5.92 94.7 GAATGCCT 
chr3:181428383-181428391 8.01 95.8 AGATTCCT (c) 
chr3:181428711-181428703 4.13 93.8 GCATCCCA 
ASCL1 
chr12:103349822-103349830 12.2 97.8 ACATACCA (a) 
chr12:103350367-103350359 7.52 95.5 GGATTCCT 
NEUROG2 
chr4:113434627-113434619 4.54 94.1 AGATGCCA 
chr4:113439907-113439899 8.17 95.8 GGATTCCA 
chr4:113435416-113435424 9.23 96.4 GCATTCCC (a) 
NEUROD1 
chr2:182542983-182542975 5.6 94.6 ACATGCCC 
chr2:182543732-182543740 5.92 94.7 GAATGCCT 
chr2:182544713-182544705 5.64 94.6 GGATACCT (b) 
chr2:182545492-182545484 8.16 95.8 GCATGCCG (a) 
chr2:182545234-182545242 10.04 96.8 GAATTCCT 
Table 17. Putative TEAD3 binding sequences in the promoter regions of SOX2 and bHLH factors genes with a relative score 
higher than 90%. The table also shows the max score and the localization in the human genome. 
 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD4 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269659-132269669 12.98 94.9 TACATTCTAC 
chr6:132270202-132270212 12.64 94.6 AACATTCTTC 
chr6:132270884-132270874 14.12 96 GACATTCCAA 
chr6:132272600-132272610 14.13 96.1 GACATTCCTC 
chr6:132272772-132272762 11.87 93.8 AAAATTCTAT 
CYR61 
chr1:86046332-86046342 12.82 94.8 AGCATTCCTG 
chr1:86047293-86047303 9.02 91 AAAATACTAG 
chr1:86047219-86047209 13.16 95.1 TGCATTCCAG 
chr1:86048500-86048510 9.18 91.1 GAAATACCGG 
chr1:86049145-86049155 13.77 95.7 GGCATTCCAT 
chr1:86048878-86048868 10.75 92.7 GAAATACCTT 
SOX2 
chr3:181430472-181430482 9.18 91.1 TAAATACCGG 
chr3:181431587-181431577 8.26 0.90.2 TAAATACTGT 
chr3:181430289-181430279 8.44 90.4 GGCATTCATG 
chr3:181428382-181428392 8.78 90.8 AAGATTCCTG (c) 
ASCL1 
chr12:103349821-103349831 12.62 94.6 CACATACCAA (a) 
chr12:103353739-103353729 12.28 94.2 AGCATTCTAT 
NEUROG2 
chr4:113434601-113434591 11.38 93.3 GAAATTCTTC 
chr4:113439588-113439578 11.24 93.2 CAAATTCTGT 
chr4:113435415-113435425 10.91 92.9 TGCATTCCCC (a) 
NEUROD1 
chr2:182543738-182543728 9.05 91 GGCATTCATT 
chr2:182543940-182543950 8.8 90.8 TACATTTCAG (c) 
chr2:182544023-182544033 13.72 95.6 CACATTCTAC (c) 
chr2:182545233-182545243 12.84 94.8 CGAATTCCTC 
Table 18. Putative TEAD4 binding sequences in the promoter regions of SOX2 and bHLH factors genes with a relative score 
higher than 90%. The table also shows the max score and the localization in the human genome. 
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GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
SMAD2/3/4 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269508-132269521 8.17 92 GAGGCTACCACAT 
chr6:132270238-132270225 8.2 92 TAGTCTATCAACC 
chr6:132270384-132270397 13.87 95.8 ATGTCTCTCACTC 
chr6:132270796-132270809 5.12 90 TTGTCTGACTTCT 
chr6:132272476-132272489 13.97 95.9 CTGGCTGTCTCCT 
CYR61 
chr1:86046219-86046206 14.07 96 GTGTCTGTCTCCC 
chr1:86047067-86047080 8.74 92.4 CTGCCTGCCACTG 
chr1:86048336-86048349 7.99 91.9 TTGCCTGGCAGGT 
chr1:86049198-86049185 8.32 92.1 CTGCCTCTCACA 
SOX2 
chr3:181431086-181431099 6.2 90.7 CCCTCTCACACAT 
chr3:181429502-181429515 8.17 92 GTGGCTGGCAGGC 
chr3:181428859-181428846 11.01 93.9 CTGTCTGCCCCCA (a) 
ASCL1 
chr12:103351454-103351467 8.37 92.1 CACTCTCTCACTT 
chr12:103350931-103350918 7.24 91.4 TTCTCTCTCTCCT 
NEUROG2 
chr4:113435134-113435121 5.98 90.5 CCATCTGTCTCTT 
chr4:113436841-113436828 10.56 93.6 CTGACTGGCAGCA 
chr4:113437328-113437341 14.71 96.4 GTGTCTGGCACAC 
NEUROD1 
chr2:182542551-182542564 7.44 91.5 ATGACTCGCTCAT 
chr2:182542875-182542862 9.08 92.6 ATGTCTTCCACGT 
chr2:182543475-182543488 10.29 93.4 TTGTCTGCCTCGT 
chr2:182544227-182544240 7.28 91.4 GGGTCTTCCACCC 
chr2:182544628-182544615 5.27 90.1 GGGACTCACTCCT (b) 
chr2:182545412-182545425 6.01 90.6 TCGTCTCCCGCCC 
Table 19. Putative SMAD2/3/4 binding sequences in the promoter regions of SOX2 and bHLH factors genes with a relative 
score higher than 90%. The table also shows the max score and the localization in the human genome. 
 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
RUNX2 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6: 132269512-132269521 4.14 94.1 CTACCACAT 
chr6: 132270934-132270925 6.64 95.6 CAACCACCA 
chr6: 132271935-132271926 11.74 98.6 CAACCGCAA 
CYR61 
chr1: 86046444-86046453 7.27 96 AGACCGCGA 
chr1: 86047194-86047203 5.36 94.8 CGACCACAC 
chr1: 86047279-86047270 12.26 99 AAACCACAA 
chr1: 86048526-86048517 8.11 96.5 GAACCGCAG 
SOX2 
chr3: 181430686-181430695 6.83 95.7 TACCCGCAG 
chr3: 181430914-181430905 9.88 97.5 TAACCACAG 
chr3: 181431302-181431311 9.71 97.4 AAACCGCGA 
chr3: 181431473-181431464 0.08 91.6 GTACCACTA 
chr3: 181430222-181430231 2.43 93.1 CCACCGCGG 
chr3: 181430304-181430295 3.62 93.8 GGACCACAC 
chr3: 181428582-181428591 6.87 95.7 CCACCACAA 
chr3: 181429469-181429460 6.06 95.2 ACACCACAC 
ASCL1 
chr12: 103349919-103349928 8.2 96.5 TCACCACAA 
chr12:103350513-103350504 4.44 94.3 CTACCGCCA 
chr12: 103353685-103353694 3.78 93.9 AAACCCCAT 
chr12: 103353976-103353967 9.48 97.3 AAACCACAT 
NEUROG2 
chr4: 113436266-113436257 10.77 98.1 AAACCGCAT 
chr4: 113439955-113439964 6.08 95.2 TAACCCCAA 
NEUROD1 
chr2: 182542264-182542255 4.84 94.5 ACACCACGA 
chr2: 182542484-182542475 0.92 92.2 AACCCACTG 
chr2: 182543055-182543046 4.12 94.1 AACCCACCA 
chr2: 182543029-182543038 6.77 95.7 AGCCCGCAA 
chr2: 182543908-182543899 6.64 95.6 CAACCACCA 
 chr2: 182543847-182543856 0.95 92.2 ACACCACTC 
 chr2: 182544607-182544598 1.82 92.7 TTACCGCTC 
 chr2: 182545639-182545648 6.83 95.7 TACCCGCAG 
Table 20. Putative RUNX2 binding sequences in the promoter regions of SOX2 and bHLH factors genes with a relative 
score higher than 90%. The table also shows the max score and the localization in the human genome. 
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6. Validation of putative TAZ interacting regions in proneurogenic genes. 
 
In order to validate the TAZ-interacting regions with highest scores, we first determined which 
TEADs are expressed in ReNcells by qRT-PCR analysis. We determined that TEAD2 and TEAD1 were 
the most highly expressed TEADs (Fig. 50A). Therefore, we evaluated the putative binding sequence for 
TEAD1 and TEAD2, although some of these regions also included other TEADs and SMADs-binding 
sequences. For this reason, we called these regions TAZ-interacting regions (TIR) (Table 15 to 20, 
indicated as (a), (b) and (c)). In Fig. 51, TIR regions are showed in the proneurogenic genes accompanied 
by the data from ENCODE database for DNase sensitive regions, H3K27Ac areas and RNA Pol II 
enriched regions.  
 
Figure 50. Expression of 
TEADs transcripts in 
ReNcells. (A) mRNA levels of 
the TEADs 1 to 4 were 
determined by qRT-PCR and 
normalized to the levels of 
TEAD1. Data represent mean ± 
S.D. (n ≥ 8). (B) TEAD2 motif 
from JASPAR database 
indicating its consensus 
binding profile. (C) Position 
specific scoring matrix 
(PSSM) for TEAD2 PSSM 
derived from the frequency 
matrix available in JASPAR 
database. 
 
To validate the TIRs with the highest score in each proneurogenic gene, TAZ interaction to these 
sequences was determined by ChIP analysis. ReNcells were transduced with a retroviral vector expressing 
the constitutively stable mutant TAZ4SA (Lei et al., 2008). TAZ was immunoprecipitated with an anti-
TAZ antibody and an anti-IgG antibody was used as a negative control. TAZ binding was analyzed by 
qRT-PCR employing as template the immunoprecipitated DNA and primers designed to specifically 
amplify TIRs (Table 13). We detected TAZ enrichment to the well-known positive control TIRs in CTGF, 
MYC and CYR61, whereas TAZ did not bind to a region of CTGF that does not contain any TIR (CTGF 
3´UTR) (Fig. 52). Immunoprecipitation with TAZ showed enrichment of several TIRs in SOX2, ASCL1, 
NEUROG2 and NEUROD1 genes (Fig. 52). Therefore, TAZ binds regulatory regions of proneurogenic 
genes. 
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Figure 51. Schemes of the genes encoding SOX2 and bHLH factors ASCL1, NEUROG2 and NEUROD1. (A) SOX2, (B) 
ASCL1, (C) NEUROG2, and (D) NEUROD1 genes from the ENCODE for the human genome. Putative TAZ interacting regions 
(TIR) in the genes were identified taking as reference the regions localized in DNAse-sensitive and H3K27Ac-rich regions, i.e. 
most likely regulatory promoter regions. Regions sensitive to DNase are represented as dark boxes. RNA Pol II enrichment 
regions determined by ChIP-seq for RNA polymerase II (Pol II) in CD4 cells (Barski et al., 2007) are indicated in blue.  
 
Figure 52. TAZ recognizes specific 
regions in SOX2 and bHLH genes. ChIP 
analysis of putative TIRs described in 
Figure 51 using the anti-TAZ antibody vs. a 
control IgG in ReNcells overexpressing 
TAZ4SA after 5 days of retroviral 
transduction. Regions of CTGF, MYC and 
CYR61 were analyzed as positive controls, 
and a region of CTGF (CTGF 3´UTR) that 
does not contain TIR was amplified as 
negative control.  
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To evaluate the functionality of the putative TEAD1(a)-binding sequence found in the SOX2 
gene, we next generated a luciferase reporter. Three tandem nucleotide sequences of TEAD1(a)-binding 
sequence in the SOX2 gene (5´-CCCCATTCCCATC-3´) were cloned in the promoter region of a 
luciferase reporter (p29S0D1) as shown in Fig. 53A. Note that only the TEAD1(a)-binding sequence were 
cloned in the vector, not including other regulatory regions of SOX2 gene. HEK293T cells were 
transiently co-transfected with this construct or an empty vector plus a Renilla expression vector (pTK-
Renilla) used for normalization and increasing amounts of TAZ4SA. Luciferase activity was measured 
following 24 h after transfection. We found that TAZ overexpression induced luciferase activity in a 
concentration dependent manner in the reporter carrying TEAD1(a), but not in the negative control (Fig. 
53B). To further determine the response of SOX2-TEAD1(a) sequence to TAZ in NSPCs, CT or TAZ4SA-
overexpressing ReNcells were transiently transfected with the empty vector or the TEAD1(a)-luciferase 
construct. Luciferase activity was measured 24 h after the transient transfection of luciferase constructs. 
We found a slight non-significant increase in CT ReNcells compared to the control conditions, probably 
due to the endogenous TAZ in these cells, and a significant increase in luciferase activity in TAZ4SA 
ReNcells (Fig. 53C). Altogether, these results confirm that TEAD1(a) binding sequence responses to 
TAZ, indicating that it is probably a proper TEAD1-binding sequence. 
 
 
Figure 53. TEAD1-binding element in the SOX2 gene responds to TAZ overexpression. (A) Luciferase reporter construct 
carrying 3 tandem putative TEAD1(a)-binding sequences from the SOX2 gene or an empty vector as negative control controlling 
the expression of luciferase. (B) HEK293T cells were co-transfected with the reporters represented in A and increasing amounts 
of TAZ4SA construct. Values were normalized to pTK-Renilla activity and presented as fold of change. Data are mean ± S.D. (n 
= 6). Statistical analysis was performed using Student’s t test. ** p ⩽ 0.01 and *** p ⩽ 0.001 vs. basal levels. (C) ReNcells 
transducted with retroviral control vector (CT) or retroviral vector encoding constitutive active TAZ4SA were co-transfected with 
the empty vector or SOX2-TEAD1(a) luciferase reporter contruct. Values were normalized to pTK-Renilla activity and presented 
as fold of change. Data are mean ± S.D. (n = 6). Statistical analysis was performed using Student’s t-test. ** p ⩽ 0.01 vs. CT 
empty vector.  
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7. TAZ expression inversely correlates with the levels of SOX2 and several proneuronal bHLH 
factors. 
 
Since we found that TAZ co-partners recognize sequences in the regulatory regions of 
proneurogenic genes, we analyzed the relevance of TAZ in the regulation of their expression. First, we 
knocked-down TAZ in ReNcells using a lentiviral vector for shTAZ. After 5 days of lentiviral 
transduction, we found a decrease in TAZ protein levels and its well-known target CTGF (Fig. 54A). 
TAZ knockdown was accompanied by an increase in the protein levels of SOX2 and NEUROD1 (Fig. 
54A). Furthermore, we found a decrease to 50% in TAZ transcript, WWTR1, and 30% in the bona fide 
targets CTFG and CYR61 (Fig. 54B). Under the same conditions, a significant increase in the transcripts 
of the proneurogenic factors SOX2, ASCL1, NEUROG2 and NEUROD1 was observed (Fig. 54C).  
 
 
Figure 54. TAZ depletion favours the expression of SOX2 and several bHLH factors. (A) Representative immunoblot 
analysis of TAZ, CTGF, SOX2, NEUROD1 and GAPDH as a loading control in shCO and shTAZ cells after 5 days of lentiviral 
transduction. (B) mRNA levels of WWTR1 and its targets CTGF and CYR61. (C) mRNA levels of SOX2, ASCL1, NEUROG2 
and NEUROD1. For B and C, ReNcells were transduced with lentiviral vectors shCO and shTAZ and after 5 days the levels of 
the indicated transcripts were determined by qRT-PCR and normalized by the geometric mean of ACTB, GAPDH and TBP 
levels. Data are mean ± S.D. (n = 4). Statistical analysis was performed using a Student’s t-test. **p ⩽ 0.01, ***p ⩽ 0.001 vs. 
shCO. 
 
Next, we analyzed the protein and transcript levels of the proneurogenic factors in ReNcells 
transduced with a retroviral vector for expression of active mutant TAZ4SA for 0, 1, 2 and 5 days after 
transduction under proliferation conditions (Fig. 55A). As expected, we saw a gradual increase of the 
bona fide TAZ target CTGF in parallel to TAZ overexpression (Fig. 55B).  At the same time, SOX2 and 
NEUROD1 levels declined (Fig. 55B). At the transcriptional level, the increase in the TAZ transcript 
(WWTR1) was accompanied by an increase in its positive controls CTFG and CYR61 (Fig. 55C), but also 
a high decrease in the proneurogenic factors SOX2, ASCL1, NEUROG2 and NEUROD1 (Fig. 55D).  
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Figure 55. Upregulation of TAZ decreases the levels of SOX2 and several bHLH factors. (A) Schematic overview of 
experimental procedure: ReNcells were transduced with retroviral particles encoding TAZ4SA and the protein and mRNA levels 
were determined after 0, 1, 2 and 5 days post-transduction. (B) Representative immunoblot of TAZ, CTGF, SOX2, NEUROD1 
and GAPDH as a loading control in ReNcells transduced with TAZ4SA-expressing retrovirus after 0, 1, 2 and 5 days post-
transduction. (C) mRNA levels of WWTR1 and its targets CTGF and CYR61. (D) mRNA levels of SOX2, ASCL1, NEUROG2 
and NEUROD1. For C and D, mRNA levels were determined by qRT-PCR and normalized by the geometric mean of ACTB, 
GAPDH and TBP levels. Data represent mean ± S.D. (n = 4). 
 
To uncover the effect of TAZ in proneurogenic genes during differentiation, we overexpressed 
wild type TAZ (TAZ-WT) and constitutively active TAZ (TAZ4SA) by retroviral transduction in ReNcells 
and allow them to grow 5 days under proliferation conditions. Next, we removed the growth factors and 
analyzed the protein and transcript levels of several proneurogenic factors at 0, 2 and 4 days under 
differentiation conditions (Fig. 56A). In TAZ overexpressing cells, we found accumulation of TAZ and 
its target CTGF by immunoblot (Fig. 56B), and CTGF and CYR61 transcripts (Fig. 56C).  At the same 
time points, SOX2 and NEUROD1 protein levels declined (Fig. 56B). On the other hand, the expression 
of proneurogenic factors increased during differentiation in the control (CT) transduced cells, while 
SOX2, ASCL1, NEUROG2 and NEUROD1 remained low in TAZ-WT cells and were almost supressed in 
TAZ4SA cells (Fig. 56D). Together these results strongly suggest that TAZ is a negative regulator of these 
proneurogenic factors.  
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Figure 56. Overexpression of TAZ decreases the levels of SOX2 and bHLH factors during differentiation. (A) 
Representative scheme of experimental procedure: ReNcells were transduced with retroviral vector control (CT), TAZ-WT or 
TAZ4SA and grown for 5 days in proliferative conditions and samples were analyzed at 0, 2 and 4 days in differentiation 
conditions. (B) Representative immunoblot analysis of TAZ, CTGF, SOX2, NEUROD1 and GAPDH as a loading ReNcells CT, 
TAZ-WT and TAZ4SA at 0, 2 and 4 days of differentiation. (C) mRNA levels of CTGF and CYR61. (D) mRNA levels of SOX2, 
ASCL1, NEUROG2 and NEUROD1. For C and D, mRNA levels were determined by qRT-PCR and normalized by the geometric 
mean of ACTB, GAPDH and TBP levels. Data represent mean ± S.D. (n = 4). Statistical analysis was performed using Student’s 
t-test. ***p ⩽ 0.001 vs. CT. 
 
8. TAZ repression of proneurogenic genes is partially TEAD-dependent. 
 
To gain more insight into the implication of TEAD transcription factors in the regulation of 
proneurogenic factors, we expressed the defective TEAD-binding TAZ mutants. As expected, retroviral 
overexpression of TAZ-WT and active TAZ4SA led to an increase in the TAZ target CTGF after 5 days 
(Fig. 57A). At the same time, this CTGF accumulation was partially reverted by the TAZS51A mutant 
defective in TEAD-binding (Fig. 57A). Furthermore, SOX2 protein levels decrease in TAZ-WT and even 
more in TAZ4SA conditions. The mutant TAZ4SA+S51A, which disrupted TEAD binding, largely abolished 
the ability of TAZ to repress SOX2 (Fig. 57A and B). Similar results were observed with NEUROD1 
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(Fig. 57A and C). Parallel to the increase in TAZ targets (CTGF and CYR61) in TAZ-WT and TAZ4SA 
transduced ReNcells (Fig. 57D), we found a decrease at the transcriptional level of SOX2 and proneural 
ASCL1, NEUROG2 and NEUROD1 factors, being this repression almost complete in cells expressing 
TAZ4SA (Fig. 57E). By contrast, this repression by TAZS51A and TAZ4SA+S51A was almost absent for SOX2 
and partially reverted for ASCL1, NEUROG2 and NEUROD1 (Fig. 57E). TAZ can induce itself, making 
possible that ectopically expressed TAZ might induce endogenous TAZ expression, which is will not be 
defective in TEAD-binding. 
 
 
Figure 57. Downregulation of SOX2 and bHLH factors by TAZ is partially TEAD-dependent. (A) Representative 
immunoblots of TAZ, CTGF, SOX2, NEUROD1 and GAPDH as a loading control in ReNcells CT, TAZ-WT, TAZS51A, TAZ4SA 
and TAZ4SA+S51A after 5 days of retroviral transduction. (B) Densitometric quantification of SOX2 protein levels in (A) relative 
to GAPDH. (C) Densitometric quantification of NEUROD1 protein levels in (A) relative to GAPDH. Data are mean ± SEM (n 
= 4). (D) mRNA levels of TAZ targets CTGF and CYR61 (E) mRNA levels of SOX2, ASCL1, NEUROG2 and NEUROD1 after 
5 days of retroviral transduction. For D and E, mRNA levels were determined by qRT-PCR and normalized by the geometric 
mean of ACTB, GAPDH and TBP levels. Data are presented as mean ± S.D. (n = 4). Statistical analysis was performed using 
Student’s t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. control conditions. #p ⩽ 0.05; ##p ⩽ 0.01, ###p ⩽ 0.001 comparing 
TAZS51A vs. TAZ-WT. $p ⩽ 0.05; $$p ⩽ 0.01, $$$p ⩽ 0.001 comparing TAZ4SA+S51A vs. TAZ4SA. 
 
To further investigate the role of TEADs in TAZ repression of proneurogenic genes we used 
ReNcells retrovirally transduced with TAZ4SA. In these cells, we performed knockdown of the TEAD 
isoforms using lentiviral vectors directed to TEAD1/3/4 and TEAD2 (altogether named shTEAD) (Fig. 
58A). Depletion of TEADs (Fig. 58B) conducted to lower levels on CTGF and CYR61 transcripts as 
expected (Fig. 58C), but also to up-regulation of proneurogenic transcripts (Fig. 58D). Altogether, these 
results suggest that TEADs are involved in the repressive function of TAZ on proneurogenic factors.  
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Figure 58. TEAD knockdown partially recovers the mRNA levels of SOX2 and bHLH factors. (A) Schematic overview of 
experimental design: ReNcells were transduced with retroviral vector for overexpression of TAZ4SA and, after 1 days of retroviral 
transduction, transduced with lentiviral control (shCO) or shTEAD1/3/4 + shTEAD2 (shTEAD) and allowed to grow 5 days 
under proliferative conditions. (B) mRNA levels of TEAD1, TEAD2, TEAD3 and TEAD4. (C) mRNA levels of CTGF and 
CYR61. (D) mRNA levels of SOX2, ASCL1, NEUROG2 and NEUROD1. For B, C and D, mRNA levels were determined by 
qRT-PCR and normalized by the geometric mean of ACTB, GAPDH and TBP levels. Data represent mean ± S.D. (n = 4). 
Statistical analysis was performed using Student’s t-test. ***p ⩽ 0.001 vs. shCO. 
 
9. TAZ induces epigenetic changes at the regulatory regions of proneurogenic genes. 
 
We next explored epigenetic mechanisms underlying repression of the proneurogenic genes by 
TAZ. When CT and TAZ4SA-ReNcells were maintained for 5 days in proliferation and 4 additional days 
in differentiation (Fig. 59A) they presented an increase in the canonical TAZ target CTGF, while SOX2 
and NEUROD1 levels were decreased (Fig. 59B). At transcriptional level, TAZ targets CTGF and CYR61 
also increased (Fig. 59C) and while proneurogenic transcripts decreased (Fig. 59C). By ChIP-qPCR 
analysis, we found TAZ enrichment in positive controls and also in the TIRs of proneurogenic genes 
described in Figure 51, but not in the negative control (CTGF 3´UTR) in TAZ4SA cells compared to the 
control (Fig. 59D). We investigated the recruitment of RNA polymerase II (RNA Pol II) which is engaged 
together with the transcription machinery to the promoter in the eukaryotic genes (Roeder, 2005; 
Sandoval et al., 2004). RNA Pol II occupancy was significantly reduced at regulatory regions of 
proneurogenic genes in TAZ4SA-expressing cells compared to control cells, while RNA Pol II levels were 
higher in CTGF and CYR61 regulatory regions (Fig. 59E). 
We then surveyed major histone modifications. Histone 3 (H3) acetylation in the N-terminal 
Lysine 9, is generally associated with gene activation (Kuo et al., 1996; Strahl and Allis, 2000). ChIP-
qPCR assays using anti-acetylated Lys9-H3 antibody (AcH3) indicated that H3 acetylation was increased 
in TAZ bona fide targets CTGF and CYR61, while it was reduced by TAZ4SA overexpression in 
proneurogenic genes in the same TIRs, with no changes in the negative control (Fig. 59F). The regulation 
of histone acetylation suggested the implication of nucleosome remodelling and deacetylase complex 
(NuRD) (Lai and Wade, 2011). Using ChIP-qPCR assay, we confirmed the enrichment of NuRD subunit 
chromodomain-helicase-DNA-binding protein 4 (CHD4) in some TIRs of SOX2 and bHLH factors (Fig. 
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59G). On the basis of these results, we propose that TAZ represses proneurogenic gene expression by 
changes in histone acetylation and RNA Pol II occupancy at their regulatory regions. 
Altogether, our results characterize for the first time TAZ as a master repressor of neuronal 
differentiation by the transcriptional repression of proneurogenic genes, and this repression is partially 
TEAD-dependent. 
 
Figure 59. TAZ recognizes specific regions in SOX2 and bHLH factors and represses their transcription. (A) 
Representative scheme of experimental procedure: ReNcells were transduced with retroviral vector control (CT) or TAZ4SA and 
grown for 5 days in proliferative conditions and 4 days in differentiation conditions. (B) Representative immunoblot analysis of 
TAZ, CTGF, SOX2, NEUROD1 carrying GAPDH and Lamin B as a loading controls in ReNcells CT or expressing TAZ4SA. 
(C) mRNA levels of TAZ targets CTGF and CYR61 and SOX2, ASCL1, NEUROG2 and NEUROD1. mRNA levels were 
determined by qRT-PCR and normalized by the geometric mean of ACTB, GAPDH and TBP levels. Data are mean ± S.D. (n = 
4). Statistical analysis was performed using Student’s t-test. ***p ⩽ 0.001 vs. CT. (D-G) ChIP analysis of putative TIRs described 
in Figure 51 using anti-TAZ (D), anti-RNA Pol II (E), anti-AcH3 (F) and anti-CHD4 (G) antibodies vs. a control IgG in ReNcells 
CT or overexpressing TAZ4SA and normalized relative CT. Regions of CTGF and CYR61 were analyzed as positive controls, 
and a region of CTGF (CTGF 3´UTR) that does not contain TIR was used as negative control. 
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V. Pathophysiological 
significance of the axis 
TAZ/proneurogenic factors 
in glioblastoma. 
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1. TAZ negatively correlates with the levels of proneurogenic factors in low-grade gliomas and 
glioblastomas. 
 
To assess the relevance of the TAZ-proneurogenic genes in glioblastomas, we consulted the 
UCSC Xena platform (http://xena.ucsc.edu/). This platform is a cancer genomics browser for viewing, 
analysing and visualizing the public data hubs of cancer genomics and clinical data from several projects 
as The Cancer Genome Atlas (TCGA) or Pan-Cancer Atlas, among others (Goyal, 2019). We analyzed 
the correlations between expression of TAZ and several proneurogenic genes in 1152 patient samples of 
lower grade glioma and glioblastoma (GBMLGG). First, we confirmed the positive correlation between 
TAZ gene expression (WWTR1) and its bona fide targets CTGF, baculoviral IAP repeat containing 5 
(BIRC5) and CD44 (Fig. 60A to C). In the same samples, we found that TAZ expression correlates 
inversely with that of proneurogenic factors SOX2 (Fig. 61A), ASCL1 (Fig. 61B), NEUROG2 (Fig. 61C) 
and NEUROD1 (Fig. 61E). Moreover, this negative correlation was also present with several neurogenins 
(NEUROG3) (Fig. 61D) and NEUROD factors (Fig. 61F to H).  
Moreover, when we examined the Kaplan-Meier curves of each factor, we found that the higher 
expression of WWTR1 and its targets CTGF, BIRC5 and CD44 was accompanied with poor prognosis 
(Fig. 62A to D). In accordance with the negative reciprocity with TAZ, high expression levels of 
proneurogenic genes correlated with a greater life expectancy of the patients (Fig. 63A to H). All in all, 
this bioinformatics analysis shows for the first time the negative correlation between TAZ and 
proneurogenic factors in human GBMLGG. 
 
 
Figure 60. The expression of WWTR1 and its targets CTGF, BIRC5 and CD44 positively correlate in human lower grade 
gliomas and glioblastomas. Graph showing positive correlation between expression of WWTR1 and CTGF (A), BIRC5 (B) and 
CD44 (C) in the TCGA datasets from 1152 patient samples of GBMLGG. Expression levels in A, B and C, expressed as 
log2(x+1) transformed RSEM normalized counts, were directly obtained from the UCSC Xena platform. Pearson’s correlation 
coefficient (R) and p-value were calculated as a function of the t distribution.  
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Figure 61. WWTR1 expression negatively correlates with proneurogenic genes in human lower grade gliomas and 
glioblastomas. Graph showing positive correlation between transcript levels of WWTR1 and SOX2 (A), ASCL1 (B), NEUROG2 
(C), NEUROG3 (D), NEUROD1 (E), NEUROD2 (F), NEUROD4 (G) and NEUROD6 (H) in the TCGA datasets from 1152 
patient samples of GBMLGG. Transcript levels, expressed as log2(x+1) transformed RSEM normalized counts, were directly 
obtained from the UCSC Xena platform. Pearson’s correlation coefficient (R) and p-value were calculated as a function of the t 
distribution.  
 
 
Figure 62. WWTR1 and high expression of its targets reduces the life-expectancy in patients with lower grade gliomas 
and glioblastoma patients. Kaplan-Meier survival curves of 1152 patients with GBMLGG obtained from the UCSC Xena 
platform for WWTR1 (A), CTGF (B), BIRC5 (C) and CD44 (D). Patients were stratified in two groups using Z-score values. 
Statistically significant differences in survival between groups were calculated using the log-rank test. 
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Figure 63. High expression levels of proneurogenic factors correlate with better life-expectancy in patients with lower 
grade gliomas and glioblastomas. Kaplan-Meier survival curves of 1152 patients with GBMLGG obtained from the UCSC 
Xena platform for SOX2 (A), ASCL1 (B), NEUROG2 (C), NEUROG3 (D), NEUROD1 (E), NEUROD2 (F), NEUROD4 (G) and 
NEUROD6 (H). Patients were stratified in two groups using Z-score values. Statistically significant differences in survival 
between groups were calculated using the log-rank test. 
 
2. TAZ overexpression favours tumorigenicity of cancer stem cells and represses the 
expression of proneurogenic factors. 
 
Cancer stem cells (CSCs) are responsible drug resistance and tumour relapse. To gain a more 
precise insight in the role between TAZ and several proneurogenic genes in cancer, we used the 
glioblastoma cell line U87-MG which can be grown as glioma stem cells in the appropriate medium as 
floating neurospheres (Gargini et al., 2015; Gargini et al., 2016; Hardee et al., 2012). This cell line 
presented high levels of TAZ compared to the human NSPCs cell line ReNcells as determined by 
immunoblot analysis (Fig. 64A). We next tested the effect of TAZ overexpression by retroviral 
transduction of U87-MG cells under neurosphere growth conditions. Overexpression of TAZ by retroviral 
transduction in U87-MG cells (Fig. 64B) led to an increase at the protein level of TAZ-regulated gene 
CTGF and the transcripts of CTGF, BIRC5 and CD44 (Fig. 64C). In parallel, a significant down-
regulation of SOX2, ASCL1, NEUROG2 and NEUROD1 mRNA levels was observed (Fig. 64D), 
suggesting that the repressor function TAZ on proneurogenic genes is conserved in this glioma stem cell 
line. 
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Figure 64. TAZ overexpression correlates negatively with the levels of proneurogenic transcripts in the glioblastoma cell 
line U87-MG. (A) Representative immunoblot of TAZ and GAPDH as a loading control in U87- MG in cancer stem cell (CSC) 
conditions and ReNcells under proliferative conditions. (B) Representative immunoblot analysis of TAZ and Lamin B as a 
loading control in U87- MG CT and TAZ-WT CSC conditions. (C) mRNA levels of WWTR1 and its targets CTGF, BIRC5 and 
CD44 in U87-MG cells CT and TAZ-WT (D) mRNA levels of SOX2 and bHLH factors ASCL1, NEUROG2 and NEUROD1 in 
U87-MG cells CT and TAZ-WT. In C and D, mRNA levels were determined by qRT-PCR and normalized by the geometric 
mean of ACTB, GAPDH and TBP levels. Data are presented as mean ± S.D. (n = 4). Statistical analysis was performed using 
Student’s t-test. *p ⩽ 0.05, ***p ⩽ 0.001 vs. CT. 
 
We found a slight increase to almost 150% compared to the control in the number of secondary 
neurospheres formed in TAZ-WT-derived cultures (Fig. 65A and B) and a significant increase in the 
number of cells (Fig. 65C). Even more, when U87-MG cells were injected subcutaneously for xenograft 
analysis in athymic mice, TAZ overexpression led to a subtle increase in tumour volume compared to the 
control (Fig. 65D and E). Next, we tested the tumourigenicity of TAZ-overexpressing glioma stem cells 
by intracranial xenotransplants in athymic mice.  The survival rate of mice inoculated with control cells 
was roughly 40 days and was decreased to  30 days in the TAZ overexpressing cells (Fig. 65F). We 
speculate that the low effect of TAZ overexpression might be due to the fact that glioma stem cells exhibit 
basally high TAZ levels (Li et al., 2016b) (Fig. 64A). 
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Figure 65. TAZ overexpression favours cancer stem cell proliferation and tumorigenesis. (A) Representative images of U-
87 MG-derived neurospheres transduced with retroviral control (CT) or encoding human TAZ-WT. (B) Quantification of the 
number of secondary neurospheres as a percentage relative to control. Data are presented as mean ± S.D. (n = 3) *p ⩽ 0.05 vs. 
CT according to a Student’s t-test. (C) Quantification of the number of cells represented as percentage of control. Data are 
presented as mean ± S.D. (n = 3) ***p ⩽ 0.001 vs. CT according to a Student’s t-test. (D) Growth curves of subcutaneously 
xenografted athymic mice with U87-MG cells transduced with empty retrovirus (CT) or a retrovirus expressing wild-type TAZ 
(TAZ-WT) and implanted. Data are presented as mean ± SEM. (n = 4). (E) Upper panel, representative tumours of each 
experimental condition at the end point (scale bar, 1 cm); lower graph, quantification of the final tumour volume. Data are 
presented as mean ± SEM. (n = 4). (F) Kaplan-Meier survival curves for mice bearing intracranial U87-MG xenografts CT and 
TAZ-WT (n = 6). 
 
3. TAZ-knockdown reduces the tumorigenicity of glioma stem cells and leads to an increase 
in proneurogenic transcripts. 
 
We next tested the effect of depleting TAZ in U87-MG lentivirally-transduced with shRNA 
against TAZ for 5 days under neurosphere growth conditions. As shown in Fig, 66, we found that TAZ-
knockdown led to a decrease of its target CTGF (Fig. 66A). This decrease was also observed at the 
transcriptional level with a drastic reduction in WWTR1 and its targets CTGF, BIRC5 and CD44 (Fig. 
66B). At the same time, TAZ-knockdown correlated with a discrete increase in SOX2 and ASCL1 
transcripts and a more than 4 folds induction of NEUROG2 and NEUROD1 (Fig. 66C). These significant 
results encouraged us to further confirm them using glioblastoma stem cells obtained from patient explant 
(GB). TAZ-knockdown in these glioblastoma explant (Fig. 66D and E) led to a decrease in its targets 
(Fig. 66E) and a significant increase of SOX2 and bHLH factors transcripts (Fig. 66F). 
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Figure 66. TAZ depletion favours the expression of SOX2 and several bHLH factors in the glioblastoma cell line U87-
MG and GB. (A) Representative immunoblot analysis of TAZ and GAPDH as a loading control in U87-MG shCO and shTAZ 
after 5 days of lentiviral transduction in CSC growth medium. (B) mRNA levels of WWTR1 and its targets CTGF, BIRC5 and 
CD44 in U87-MG cells shCO and shTAZ after 5 days of lentiviral transduction. (C) mRNA levels of SOX2 and bHLH factors 
ASCL1, NEUROG2 and NEUROD1 in U87-MG cells shCO and shTAZ after 5 days of lentiviral transduction. (D) Representative 
immunoblot analysis of TAZ and Lamin B as a loading control in GB shCO and shTAZ after 5 days of lentiviral transduction in 
CSC growth medium. (E) mRNA levels of WWTR1 and its targets CTGF, BIRC5 and CD44 in GB cells shCO and shTAZ after 
5 days of lentiviral transduction. (F) mRNA levels of SOX2 and bHLH factors ASCL1, NEUROG2 and NEUROD1 in GB cells 
shCO and shTAZ after 5 days of lentiviral transduction. In B, C, E and F, mRNA levels were determined by qRT-PCR and 
normalized by the geometric mean of ACTB, GAPDH and TBP levels.  Data are presented as mean ± S.D. (n = 4). Statistical 
analysis was performed using Student’s t-test. *p ⩽ 0.05, **p ⩽ 0.01, ***p ⩽ 0.001 vs. shCO. 
We found that U87-MG TAZ-deficient cells showed 10 folds fewer secondary neurospheres (Fig. 
67A and B) and lower cell number (Fig. 67C), indicating a deficient proliferative rate compared to control 
TAZ-expressing cells.  
Next, we assessed the tumorigenicity of TAZ-knocked-down glioma stem cells in 
xenotransplanted athymic mice. The growth of subcutaneous xenografts was substantially reduced by 
silencing the expression of TAZ in U87-MG cells as determined by the tumour volume (Fig. 67D and E). 
Very importantly, TAZ-depletion reduced the malignancy of the intracranial tumours and increased the 
life expectancy of these mice from 40 days in the control cells to more than 70 days in the TAZ-deficient 
cells (Fig. 67F).  
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Altogether, our results support a role of this novel TAZ/proneurogenic axis in lower grade 
gliomas and glioblastomas, unveiling a new pathway to be further explored for therapeutic applications 
in cancer. 
 
Figure 67. TAZ-deficiency impairs the tumorigenicity of glioblastoma cancer stem cells. (A) Representative images of U87-
MG- derived neurospheres after 5 days of lentiviral transduction with shCO or human shTAZ. (B) Quantification of the number 
of secondary neurospheres as percentage relative to shCO. Data are presented as mean ± S.D. (n = 3) **p ⩽ 0.01 vs. shCO 
according to a Student’s t-test. (C) Quantification of the number of cells represented as percentage relative to shCO. Data are 
presented as mean ± S.D. (n = 3) **p ⩽ 0.01 vs. shCO according to a Student’s t-test. (D) Growth curves of xenograft tumours 
of U87-MG glioblastoma cells transduced with a lentivirus encoding shCO or human shTAZ and implanted subcutaneously in 
athymic mice. Data are presented as mean ± SEM (n = 4). *p ⩽ 0.05 according to a Student’s t-test. (E) Upper panel, 
representative tumours of each experimental condition at the end point (scale bar, 1 cm); lower graph, quantification of the final 
tumour volume. Data are presented as mean ± SEM (n = 4). *p ⩽ 0.05 vs. shCO according to a Student’s t-test. (F) Kaplan-
Meier survival curves for mice bearing intracranial U87-MG xenografts shCO and shTAZ. Log-rank test between shCO and 
shTAZ is indicated (n = 6). 
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1. NRF2 controls neural stem cell fate at the hippocampus. 
 
Many studies have analyzed the implication of hippocampal adult neurogenesis in synaptic 
plasticity of the hippocampus and cognitive function (Toda and Gage, 2018), but our study reports a 
crucial role of transcription factor NRF2 in the mobilization and differentiation of the NSPCs in the 
hippocampal neurogenic niche of the SGZ (Fig. 68). In the adult, NSPCs give rise to new neurons that 
integrate in the pre-existing hippocampal neural circuitry at the level of the granular layer (Zhao et al., 
2008b) and participate in LTP, which plays a major role in hipocamppal functions related to learning and 
memory (Garthe et al., 2009; Moser et al., 1998; Whitlock et al., 2006; Nabavi et al., 2014). In fact, 
depletion of hippocampal neurogenesis results in LTP loss and cognitive impairment (Snyder et al., 2001; 
Iscru et al., 2013; Saxe et al., 2006). In this study, we measured LTP in the DG, which under physiologic 
conditions is mainly derived from the born neurons of the adult brain (Wang et al., 2000; Schmidt-Hieber 
et al., 2004; Snyder et al., 2001; Saxe et al., 2006; Garthe et al., 2009). We describe, for the first time, an 
impairment in normal LTP linked to NRF2 deficiency. In line with this, Hooper et al described LTP 
impairment in transgenic mice conditionally overexpressing GSK3β (Hooper et al., 2007) which is a 
negative regulator of NRF2 (Cuadrado, 2015; Rada et al., 2011; Rada et al., 2012). In other behavioural 
test aimed at analysis of depression, the forced swimming test, NRF2-deficient mice presented increased 
immobility without affecting locomotive activity (Martin-de-Saavedra et al., 2013), which is interpreted 
as the onset and persistence of a depressive-like state (Stone and Lin, 2011; Sun et al., 2011; Serchov et 
al., 2015). Thus, NRF2 deficiency leads to behavioural and cognitive changes in mice. 
Adult hippocampal neurogenesis is highly regulated by extrinsic and intrinsic factors (Cameron 
and McKay, 1999; Gould et al., 1999; Kempermann and Gage, 1998; Kempermann et al., 1997; 
Kempermann and Gage, 2002; Mirescu et al., 2004; Gould and Tanapat, 1999; van Praag et al., 1999). A 
common theme that is nowadays emerging suggests that changes in the intracellular redox status are 
crucial for the biology of NSPCs (Madhavan, 2015). Recent studies showed an increase in the number of 
mitochondria and overall production of ROS during mobilization of NSPCs in the SGZ of adult rodents 
(Walton et al., 2012). Furthermore, Le Belle and colleagues described that NSPCs maintain high ROS 
levels and are highly responsive to ROS stimulation (Le Belle et al., 2011). Although the authors did not 
analyze NRF2 directly, a bioinformatics analysis based on previous transcriptomics data sets (Wang et 
al., 2009; Anantharam et al., 2007) did show changes in the levels of several antioxidant enzymes whose 
expression is regulated by NRF2.  Unfortunately, we could not analyze NRF2 protein levels by 
immunohistochemistry in the SGZ, because of the low specificity for IHC of available antibodies. Despite 
of this, we found by immunoblot the absence of NRF2 and the reduction of its transcriptional signature 
in NSPCs isolated from the SGZ of NRF2 deficiency mice as expected, and, interestingly, NSPCs from 
either newborn or 3 month-old Nrf2-/- mice exhibited a substantially compromised proliferation rate. Our 
results are in line with a previous study showing that a highly reduced intracellular redox state promotes 
proliferation and survival (Smith et al., 2000). Neuronal differentiation was also compromised by NRF2 
DISCUSSION 
 
162 
 
deficiency, while ectopic expression of NRF2 rescued normal neuronal differentiation. Even more, based 
on EdU assay, NRF2 deficiency altered the physiologic balance between glial and neuronal differentiation 
of NSPCs, favouring formation of astrocytes. Consistent with this, NRF2 potentiates retinoic acid-
induced neuronal differentiation of the SH-SY5Y neuroblastoma cell line (Zhao et al., 2009). By contrast, 
NRF2 overexpression in differentiating neurons leads to inhibition of neurite outgrowth and arborisation, 
and electrophysiological maturation (Bell et al., 2015). Thus, NRF2 repression is necessary for neuronal 
maturation, but NRF2 presence creates the intracellular environment that supports the neural niche. 
To further analyze the impact of NRF2 in self-renewal of NSPCs, we used a genetic approach 
based on lentiviral expression of NRF2 in otherwise deficient NSPCs. Ectopic expression of NRF2 
rescued NRF2-deficient NSPCs to cloning and proliferative values similar to those of wild type NSPCs. 
Additionally, decreasing or increasing NRF2 expression by genetic means was sufficient to significantly 
suppress or rejuvenate NSPCs properties, respectively. These findings are in line with the data from 
Coremblum and colleagues, who determined that early postnatal NSPCs express high levels of NRF2, 
while the NSPCs from aged animals, with lower regenerative capacity, have reduced NRF2. The studies 
also ascertain that decreasing or increasing NRF2 levels in the young and aged cells respectively, is 
sufficient to negatively or positively alter the regenerative capacity of NSPCs (Corenblum et al., 2016). 
Pharmacological induction of NRF2 with resveratrol demonstrated that this compound reverses the 
decline NSPCs proliferation and neurogenesis induced by ionizing radiation of brain tumours (Prager et 
al., 2016). Resveratrol also protected hippocampal NSPCs in ethanol-treated rodents (Xu et al., 2015) and 
in prenatally stressed in rats (Madhyastha et al., 2013).  
In order to understand how NRF2 controls the fate of NSPCs, we used the cell pair assay that 
indicates whether NSC divisions lead to identical siblings with self-renewal capacity or to two different 
cells, one remaining proliferative and the other entering a differentiation program (Xapelli et al., 2013). 
The current model of mobilization of the NSPCs establishes that a NSC progenitor will divide 
symmetrically for several generations to perpetuate the progenitor pool. At the same time, a certain 
number of asymmetric divisions will lead to a supply of neurons and astrocytes to accommodate specific 
demands. The last division leads to differentiation of both siblings into astrocytes (Encinas et al., 2011). 
The fact that the NSPCs pool was exhausted more rapidly in the Nrf2-/- mice suggests that either cell-
autonomous alterations or the micro-environmental influence leads to the mobilization and terminal 
differentiation of these neural progenitors. Consistent with this hypothesis, we found an inverse 
correlation between Ki67-stained progenitors and GFAP-stained astrocytes. Although we cannot discard 
a micro-environmental influence, our results with the cell pair assay in cell culture, in the absence of other 
cell types, indicate that NRF2 deficiency leads to cell-autonomous alterations. Indeed, we found that 
NRF2 deficiency resulted in an increase of asymmetric divisions, leading to the reduction in the number 
of progenitors. These findings suggest that the exacerbated exhaustion of the NSPCs pool in the Nrf2-/- 
mice is due to an increase in asymmetric divisions, together with imbalance in the cell fate to increase the 
number of astrocytes and reduce neurons. This hypothesis is consistent with the well reported observation 
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that NRF2 is required to counterbalance the high levels of intracellular ROS of highly proliferating cells 
(Schumacker, 2006; Toyokuni et al., 1995; Noble et al., 2003; Rafalski and Brunet, 2011). 
The role of NRF2 in neurogenesis has been related to signaling pathways that regulate cell 
proliferation and differentiation. For example, a functional ARE recognized by NRF2 has been identified 
in the promoter region of Notch1 (Wakabayashi et al., 2010; Wakabayashi et al., 2015), the main player 
of Notch signaling (Engler et al., 2018). In the same way, several studies described the crosstalk between 
NRF2 and Wnt signaling (Rada et al., 2015; L'Episcopo et al., 2013). In a bidirectional feedback loop, 
NRF2 deficiency could deregulate Wnt signaling (L'Episcopo et al., 2013) and, on the other hand, 
activation of Wnt signaling can prevent NRF2 phosphorylation through GSK3β/β-TrCP and its posterior 
proteasomal degradation, driving to NRF2 accumulation (Rada et al., 2015). Furthermore, NRF2 is linked 
to the activity of a number of trophic factors including VEGF, PDGF, IGF-1 and TGF-β which are also 
important for NSPCs (Li et al., 2016a; Ashino et al., 2013; Wiesner et al., 2013; Hsieh, 2012). All these 
studies point NRF2 as a major regulator of NSPCs fate and function. 
 
 
Figure 68. NRF2 controls the neural stem cell fate in a cell autonomous way. Absence of NRF2 conducts to an impaired the 
self-renewal capacity of neural stem/progenitor cells (NSPCs) and an imbalance in astroglial/ neuronal differentiation, impacting 
the normal hippocampal cognitive function. 
  
DISCUSSION 
 
164 
 
2. Relevance of NRF2 in neurogenesis in a mouse model of Alzheimer´s disease. 
 
NRF2 orchestrates a symphony of homeostatic responses to multiple stressors that characterize 
neurodegenerative disease (Deshmukh et al., 2017; Johnson and Johnson, 2015; Ramsey et al., 2007; 
Sandberg et al., 2014; Pajares et al., 2015). Although it is known that NRF2 and the neurogenic niche of 
the SGZ losses activity under pathologic conditions such as AD, the molecular mechanisms behind this 
correlation are largely unknown. For this reason, we recapitulated the main hallmarks of AD pathology, 
by expressing human APPV717I and TAUP301L in wild type (AT-Nrf2+/+) or NRF2-knockout (AT-Nrf2-/-) 
mice. In fact, we confirmed the presence of the neuropathological hallmarks of AD, TAU-aggregates and 
amyloid plaques (Goedert et al., 1991; Braak and Braak, 1996) in the hippocampus of these mice. 
The absence of NRF2 exacerbated cognitive deficits and impaired LTP in the AT-Nrf2-/-mice. 
The fact that memory and learning were severely impaired in these mice as early as 6 months of age 
suggests that the lack of NRF2 might replicate a prodromal condition of human AD (Wilson et al., 2011). 
These observations also fit with a previous report showing that NRF2 deficiency exacerbated the deficits 
in spatial learning and memory, as well as in working and associative memory in the APP/PS1 mouse 
model of amyloidopathy (Branca et al., 2017). Even more, Kanninen et al., described a memory 
improvement in these mice after NRF2 lentiviral transduction into the hippocampus and this improvement 
was associated with a reduction in soluble forms of Aβ1–40 and Aβ1–42 (Kanninen et al., 2009). Moreover, 
our AT-Nrf2-/-mice presented high levels of the soluble Aβ*56 oligomer (Rojo et al., 2017) which has 
been reported to induce memory impairment in very early in the pathogenesis of AD (Lesne et al., 2013; 
Lesne et al., 2006). 
The fact that at 3 months of age the proteinopathy is similar between AT-Nrf2+/+ and AT-Nrf2-/-  
mice but the neurogenic niche is highly damaged in AT-Nrf2-/-  mice suggests that already at this early 
age there is an attempt of the diseased hippocampus to compensate the ongoing neuronal damage. In fact, 
the hippocampus of AT-Nrf2-/-  mice exhibits increased levels of oxidative and pro-inflammatory markers 
compared to AT-Nrf2+/+ mice, suggesting that the proteotoxic insult renders these animals more sensitive 
to oxidative and inflammatory stress (Rojo et al., 2017). These data correlate with previous studies 
highlighting the implication of persistent oxidative and inflammatory stress in mild cognitive impairment 
and in AD onset and progression (Gabbita et al., 1998; Nunomura et al., 1999; Pratico, 2008). Another 
study also supports the impairments in both the proliferative capacity of NSPCs and in the neuronal 
differentiation early in the AD progression in the APP/PS1 mice (Demars et al., 2010) and in the 3xTg 
mouse model harbouring human mutant PS1M146V, APPKM670/671NL and TAUP301L (Rodriguez et al., 2008a; 
Hamilton et al., 2010), even preceding cognitive deficits (Lazarov and Marr, 2010; Lazarov and Marr, 
2013; Hollands et al., 2016). 
Others studies provide evidence of the involvement of NRF2 in neuroprotection both in cell 
culture of primary postmitotic neurons and in animal models of CNS diseases (Lazarov et al., 2010; 
Kanninen et al., 2009; Shih et al., 2003; Zhao et al., 2015). Regarding neurogenesis, our results are in 
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agreement with a previous study showing that up-regulation of NRF2 ameliorated amyloid β-mediated 
neural stem cell death (Karkkainen et al., 2014). Related to other neurodegenerative disorders, mice 
submitted to the Parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) exhibited 
reduced neurogenesis in the SVZ via impaired NRF2‐mediated adaptation to inflammation (L'Episcopo 
et al., 2013).  
The fact that NRF2 possesses both a neuroprotective and a neurogenic function raises the 
tempting hypothesis that NRF2 up-regulation may be a good possibility to increase the capacity of 
transplanted NCPCs to preserve the neurogenic functionality of the hippocampus against proteinopathy. 
 
3. NRF2 and the Hippo pathway interact through the transcriptional control of the TAZ 
coding gene WWTR1. 
 
The Hippo pathway is a potent regulator of cell proliferation, differentiation, and tissue 
homeostasis (Misra and Irvine, 2018) and appears to be influenced by the redox status. Thus, Gandhirajan 
et al., described TAZ as the redox sensor and H2O2 exposure leads to increased stability and activation of 
TAZ due to reversible S-glutathionylation at conserved cysteine residues. This suggests that ROS could 
enhance TAZ protein stability and facilitate tissue repair (Gandhirajan et al., 2016). Because NRF2 is 
also a potent regulator of cell proliferation and differentiation, and elicits an antioxidant defence, we 
studied the possible connection between both pathways. We have found that NRF2 regulates the 
expression of the TAZ coding gene WWTR1 (Fig. 69). 
NRF2 deficiency in NSPCs cultures correlated with low protein and transcript levels of TAZ. As 
described before, NRF2-deficient NSPCs also present low proliferate rate (Robledinos-Anton et al., 
2017). Furthermore, genetic (shRNA and NRF2 overexpression) and chemical (sulforaphane) 
manipulation of NRF2 in human immortalized NSPCs indicate that the transcript and protein levels of 
TAZ and TAZ-dependent genes are, at least in part, governed by the levels of NRF2 in neural stem cells 
(Fig. 69). 
We have identified several putative AREs by informatics analysis in the WWTR1 gene promoter. 
This analysis was based on the study of other basic region leucine zipper (bZIP)-type transcription factors 
that also bind AREs, specifically MAFF, MAFK and BACH1 (Katsuoka and Yamamoto, 2016; 
Jyrkkanen et al., 2011), for which ChIP sequencing data are available in the ENCODE database. The lack 
of data available for NRF2 binding in ENCODE could be related with the lack of specificity for ChIP 
analysis of NRF2 antibodies (Lau et al., 2013). Due to the variations within the sequences recognized by 
bZIP factors (Yamamoto et al., 2006), we compared this information with the human consensus sequence 
recognized by NRF2 described in the JASPAR database using a Python script. Of note, this script 
identified with a high relative score the already known AREs in the HMOX1 and NQO1 promoters. The 
most potent ARE in WWTR1 was located in a DNase-sensitive and H3K27-acetylated region, suggesting 
that it is accessible to the transcriptional machinery, but was not as potent as the canonical ARE of 
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HMOX1 which is rapidly induced upon NRF2 activation. Several studies have analyzed the NRF2 
transcriptional signature by microarray or RNA-sequencing approaches (Chorley et al., 2012; Namani et 
al., 2017). From these studies it is possible to distinguish grades of gene response to NRF2, from the most 
sensitive genes, related to the classical redox control, to others that require more time and persistent 
presence of NRF2 for induction. For instance, genes involved in metabolic reprograming or autophagy 
appear to require persistent exposure to NRF2 (Mitsuishi et al., 2012; Pajares et al., 2016).  
The NRF2 and TAZ crosstalk in neurogenesis should be further analyzed. Both proteins have 
been implicated in neurogenesis in connection with Wnt, Notch and Shh signaling pathways and the 
mechanistic connection might be at the level of phosphorylation by GSK-3 and subsequent proteasomal 
degradation (Rada et al., 2011; Huang et al., 2012). GSK3β associates with Axin and APC to make up a 
complex that targets the transcriptional regulator β-catenin for degradation (Stamos and Weis, 2013). 
Recent work shows that this complex destabilizes TAZ/β-catenin complexes (Azzolin et al., 2012). 
Stimulation of cells with Wnt ligands, which inhibits GSK3β activity, increases TAZ and β-catenin levels 
and nuclear activity. NRF2 also associates with Axin and this complex is destabilized by WNT-3A 
preventing its GSK3/β-TrCP-dependent proteasomal degradation, leading to increased levels of NRF2 
and its transcriptional signature (Rada et al., 2011). Thus, Wnt signaling leads to TAZ and NRF2 
accumulation. As described previously, NRF2 is implicated in Notch signaling, regulating Notch1 gene 
expression (Wakabayashi et al., 2015; Wakabayashi et al., 2010). Interestingly, Totaro et al. showed that 
mechano-activation of YAP/TAZ promotes epidermal stemness by inhibiting Notch signaling, a key 
factor for epidermal differentiation (Totaro et al., 2018; Totaro et al., 2017).  Several studies described 
the functional interplay between Hippo and Hedgehog signaling underlying temporal and spatial control 
of tissue growth and specification (Cotton et al., 2017; Levasseur et al., 2017). Recent data describe the 
transcriptional regulation of several Hedgehog signaling components by NRF2 (Martín-Hurtado et al., 
2019, under review). Thus, in the present study we tested the relationship between two factors implicated 
in the regulation of signaling pathways related to stem cells properties and function. 
The crosstalk between NRF2 and Hippo-pathway has been described with the other major Hippo 
effector, YAP. Ciamporcero et al found that silencing YAP protein expression reduced NRF2 protein and 
mRNA expression in bladder cancer cells. On the other hand, NRF2 silencing inhibited YAP expression. 
Both were involved in cytotoxic drug sensitivity and synergistically reduced the migration of 
chemoresistant bladder cancer cells (Ciamporcero et al., 2018). While in this study only a correlation 
between NRF2 and YAP levels was reported, here we have demonstrated the presence of NRF2-binding 
sequences in the regulatory region of TAZ-encoding gene. 
Taken together, our findings provide novel insights into the genomic targets of NRF2. Future 
work should aim to unravel how the relationship between NRF2 and TAZ contribute to cell proliferation 
under physiological and pathological conditions such as cancer. 
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Figure 69. NRF2 modulates TAZ levels in NSPCs. NRF2 binds ARE in the promoter regions of its target genes as NQO1 and 
in WWTR1 gene, encoding TAZ. In addition, we show here that NRF2 regulates the expression of WWTR1 in primary and 
immortalized NSPCs, that activates a battery of genes, such as CTGF, that participate in proliferative responses.  
 
4. TAZ is a transcriptional corepressor of neuronal differentiation. 
 
Our study addressed for the first time how the Hippo co-activator TAZ represses the expression 
of proneurogenic genes (Fig. 70). The transcriptional program underlying neural stem cell differentiation 
is regulated by largely unknown spatiotemporal patterns of gene expression (Guillemot, 2007; Spitz and 
Furlong, 2012). The Hippo pathway has been related with the maintenance of the NSPCs pool (Lavado 
et al., 2018), but the specific role of TAZ in neurogenesis has not been previously addressed. Interestingly, 
TAZ is implicated in epithelial–mesenchymal transition (EMT) in cancer (Wang et al., 2015b; Li et al., 
2015), a process that is critical for neuronal development and the migration of newborn neurons (Kwan 
et al., 2012). 
Based on the data available in the Brain RNA-seq database and our immunofluorescence analysis 
in vitro and in vivo, we found that TAZ expression is mostly limited to astrocytes and NSPCs, and 
decreases along neuronal maturation. Although no previous analysis were focused in TAZ expression in 
neurogenic niches, our findings are in line with the downregulation of the other Hippo effector, YAP, 
during neuronal differentiation (Zhang et al., 2012). YAP is also expressed in astrocytes and progenitors, 
but not in neurons (Huang et al., 2016). However, while we find that TAZ knockdown leads to neuronal 
differentiation, it is not clear that YAP will do the same. This could be related to different roles of TAZ 
and YAP or to misleading identification neurons. In fact, Zhang et al. used TUBB3 as a neuronal marker, 
which it is not specific as it is also expressed in astrocytes and progenitors (Draberova et al., 2008). On 
the contrary, we used several neuronal markers and astrocytic markers to ensure the proper identification 
of neurons.  
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Prompted for our findings, we assessed the presence of TAZ transcriptional co-partners binding 
sequences in proneurogenic genes. Bioinformatics approaches revealed that the promoters of the 
proneurogenic genes SOX2, ASCL1, NEUROG2 and NEUROD1 present putative sites for binding to 
TAZ-transcriptional co-partners. We then uncovered the relationship between TAZ expression and 
proneurogenic genes by showing TAZ enrichment in their regulatory regions. Furthermore, we ensured 
the accuracy of these sequences cloning an identified TEAD-binding sequence of SOX2 in the luciferase 
reporter and showing a TAZ-dependent response.  
The information available about the interaction between TAZ co-partners and proneurogenic 
genes is very scarce. However, the short half-life of proneurogenic factors indicates the relevance of their 
transcriptional regulation (Sriuranpong et al., 2002; Ali et al., 2011). It has been described that TAZ co-
partner SMAD (Varelas et al., 2008) shares many gene targets with cell-type specific transcription factors 
that participate in cellular identity (Mullen et al., 2011; Trompouki et al., 2011). Genome-wide 
experiments demonstrate that the proneural factor ASCL1 assists SMAD3 in binding to a subset of 
enhancers (Fueyo et al., 2018). Furthermore, Castro et al., described that ASCL1 targets the transcription 
factors TEAD1, TEAD2 and TAZ using genome-wide analysis of the developing ventral mesencephalon 
(Castro et al., 2011). Our bioinformatics analysis demonstrated that RUNX1/2- recognizes a sequence in 
the regulatory regions of proneurogenic genes. Fukui et al., showed that RUNX1 is down-regulated during 
neuronal differentiation, while NEUROG2 is upregulated, but the authors did not establish any further 
analysis to this correlation (Fukui et al., 2018). Thus, our study establishes for the first time the existence 
of TAZ-interacting regulatory regions in proneurogenic genes. Furthermore, the upregulation of TAZ 
repressed the expression of these genes, which was partially recovered by ablation of TAZ-TEAD 
interaction or TEAD-knockdown. The uncompleted recovery could be: a) because TAZ functional 
repression is partially TEAD-independent, b) ectopic TAZ upregulates endogenous TAZ, which is not 
TEAD-binding defective, hiding the TEAD-independent effect. As described in the ENCODE database, 
the TAZ enhancer regions comprise several TEAD-putative binding sequences. Furthermore, TEAD4 is 
a target of TAZ (Kim et al., 2015). TEADs are essential for the transcriptional co-activator function of 
TAZ (Zhang et al., 2009); hence, it would be unexpected that TEAD was also involved in their 
corepressor function.  
Our study shows that the interaction of TAZ with regulatory regions of proneurogenic genes 
conducts to decreased acetylation of the chromatin and reduced recruitment of RNA polymerase II (RNA 
Pol II). Of note, the same TAZ-TEAD complex activates genes such as CTGF and CYR61 but suppresses 
the transcription of others. Enhancer-bound TAZ–TEAD complexes regulate gene transcription by 
inducing p300-dependent acetylation at lysine 27 of histone H3 (H3K27ac) (Stein et al., 2015), through 
recruitment of the Mediator complex and induction of transcriptional elongation through the release of 
RNA polymerase II (Galli et al., 2015). Several recent studies have identified the interaction of TAZ or 
its Drosophila homolog Yki with other regulators of chromatin status as components of the chromatin-
remodelling complexes and histone methyltransferase complexes (Basu et al., 2013; Qing et al., 2014; 
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Skibinski et al., 2014; Oh et al., 2013). In our study, we described that nucleosome remodelling and 
histone deacetylase (NuRD) complex subunit CHD4 was enriched in the same regulatory regions of 
proneurogenic factors that were bound by TAZ (Lai and Wade, 2011). Recently, Kim et al., described the 
interaction between TAZ-paralog YAP with NuRD complex. In this study, the authors showed how the 
YAP/TEAD recruits the NuRD complex to deacetylate histones and supresses the expression of Trail and 
DNA Damage Inducible Transcript 4 (DDIT4)-encoding genes to promote cell growth and survival (Kim 
et al., 2015). The implication of NuRD in transcriptional repression of TAZ/TEAD has also been 
established by Beyer et al., who described a regulatory complex composed of TAZ/YAP/TEAD, 
SMAD2/3, and the pluripotency regulator OCT4, that collaborates with NuRD to suppress 
mesoendoderm genes (Beyer et al., 2013; Totaro et al., 2018). Indeed, TAZ can directly interact with 
histone deacetylation complex for TAZ/TEAD-induced suppression of ΔNp63 transcription (Valencia-
Sama et al., 2015). Together with these studies, our data suggests that TAZ supresses gene expression by 
directly interacting with the histone deacetylation complex and further affects RNA Pol II recruitment 
and gene transcription. 
It is important to point out the inter-relationship between proneurogenic factors. Although the 
repressor effect of TAZ on ASCL1 and NEUROG2 expression is as strong as on SOX2 and NEUROD1, 
the enrichment of TAZ in their regulatory regions and the effect in histone acetylation and RNA Pol II 
recruitment is not as strong. This could be related to the capacity of proneurogenic factors to regulate 
their own expression. For example, SOX2 can enhance the expression of ASCL1 and NEUROG2 by 
cooperating with RMST (Ng et al., 2013) and POU factors (Lodato et al., 2013) in ESCs and NPCs. 
NEUROG2 is a pioneer factor that upregulates SOX4, which co-activates NEUROD1 and NEUROD4 
(Smith et al., 2016). Thus, we speculate that TAZ-dependent repression of a proneurogenic factor 
presumably would impact the expression of others.  
The transcriptional corepressor activity of TAZ opens a new path for understanding the role of 
TAZ in neural stem cell fate and neuronal reprogramming (Bago et al., 2016; Tang et al., 2017; Dennis 
et al., 2019). Much work is still needed if we are to obtain a clear and comprehensive understanding of 
the operational logic focused on the TAZ repressor function in neurogenesis and its possible implication 
in neural stem cell therapy in neurodegeneration and cancer. 
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Figure 70. TAZ represses the program of neuronal differentiation. In the NSPCs, TAZ represses the expression of 
proneurogenic factors as SOX2 and bHLH factors ASCL1, NEUROG2 and NEUROD1 by epigenetic changes in the regulatory 
regions of their encoding genes. During NSPC-neuronal commitment, TAZ levels decrease, allowing the expression of 
proneurogenic genes and final neuronal differentiation. 
 
5. Implications of the novel TAZ/proneurogenic axis in cancer. 
 
There has been disappointingly slow progress in identifying effective therapies for GBM. This is 
due in part to a lack of understanding of the genes involved in the development of cancer stem cells 
(CSCs) that participate in the onset and growth of GBM (Chen et al., 2012; Lan et al., 2017).  
We investigated the correlation between TAZ and proneurogenic genes in lower grade glioma 
and glioblastoma patients using the UCSC Xena platform (Goyal, 2019). The correlation between TAZ 
and its bona fide targets was positive, while a tendency to negative correlation was found between TAZ 
and proneurogenic factors, in line with our previous findings in NSPCs. Furthermore, TAZ and its targets 
were associated with poor prognosis while high expression of proneurogenic factors was associated with 
longer patient survival. These findings are in line with the observation that TAZ is generally 
overexpressed in CSCs and in GBM patients with poor prognosis (Bhat et al., 2011; Yang et al., 2016; Li 
et al., 2016b). Furthermore, high WWTR1 levels are predictors of chemoresistance. Indeed, it has been 
reported that overexpression of TAZ correlated with resistance to the alkylating agent temozolomide, 
which is the gold standard treatment for gliomas (Tian et al., 2015). Strikingly, ASCL1 is expressed in 
many gliomas, at low and high levels depending on tumour type (Phillips et al., 2006; Rheinbay et al., 
2013; Rousseau et al., 2006; Somasundaram et al., 2005). High ASCL1 expression makes GBM more 
responsive to Notch inhibition leading to cell cycle exit and neuronal differentiation, and leads to better 
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overall survival, suggesting that the ASCL1 status should be used to monitor drug responsiveness (Park 
et al., 2017). Upregulation of another neurogenin, NEUROG1, has been linked to a higher probability of 
long-term survival of GBM patients (Lu et al., 2016).  
To interrogate functional properties of glioblastoma CSCs, we used patient-derived CSC cultures. 
These cells reflect the properties of primary GBM tumours (Lan et al., 2017; Lee et al., 2006; Meyer et 
al., 2015; Pollard et al., 2009) following orthotopic xenograftment (Ben-David et al., 2017; Lan et al., 
2017). We found that TAZ levels were higher in these cells compared to the non-tumorigenic ReNcell 
neural stem cell line, further demonstrating an abnormal up-regulation of TAZ in CSCs. Furthermore, 
CSCs were strictly dependent of TAZ expression to develop spheroids in vitro. TAZ silencing in the same 
cells reduced their tumorigenesis, both in subcutaneous and intracranial xenografts, further demonstrating 
that TAZ is necessary to maintain CSCs stemness. Consistent with these findings, other studies also 
showed that TAZ depletion inhibits the proliferation and self-renewal of GBM CSCs (Zhang et al., 2019; 
Yang et al., 2016). 
In this study, we show for the first time that TAZ levels inversely correlate with proneurogenic 
gene expression in CSCs. It is important to highlight that proneurogenic factors can inhibit tumorigenesis 
in GBM (Swartling et al., 2014; Swartling et al., 2015; Su et al., 2014). For example, increasing the 
expression of ASCL1 in GBM CSCs results in suppression of self-renewal, promotion of differentiation 
and, most significantly, decrease in tumorigenesis (Narayanan et al., 2018; Park et al., 2017; Tang et al., 
2017). Introduction of NEUROG2 or NEUROD1 in GBMs resulted in cell cycle arrest and massive cell 
death, and the few surviving cells differentiate into neuron-like cells (Guichet et al., 2013). Recently, Gao 
et al., supressed CSCs growth by a drug cocktail that upregulates ASCL1, NEUROG2 and NEUROD1 and 
reprograms tumour cells into neuronal like cells, suppressing tumour growth and promoting the survival 
in GBM patient derived xenograft (Gao et al., 2019). Retinoic acid, a neuronal differentiation agent, was 
assessed for the pro-differentiation and anti-proliferation effects on glioma cells. It induced differentiation 
and therapy-sensitizing effects, impaired the secretion of angiogenic cytokines, and disrupted CSCs 
motility (Campos et al., 2010). All these studies highlight the potential of pro-differentiation treatment to 
target the CSCs in glioblastoma. Thus, we speculate that the tumorigenic function of TAZ could be 
related, at least partially, to its ability to repress proneurogenic genes and TAZ knockdown could be used 
as a pro-differentiation cancer cell therapy (Hide et al., 2013). 
At this time, no selective TAZ inhibitor is available, but at least as a proof-of concept, we found 
that genetic knockdown of TAZ drastically increased the expression of proneurogenic genes in gliomas. 
Although some of caveats exist, TAZ-knockdown or exogenous over-expression of proneurogenic factors 
may warrant further consideration as a therapeutic approach in glioblastomas.   
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6. Concluding remarks and future perspectives. 
 
Many studies have described that the transcriptional signature of NRF2 is necessary to maintain 
general homeostasis. In this work, we identified a role of NRF2 in a cell-autonomous regulation of 
neurogenesis. Recently, the Hippo pathway effectors are receiving attention in the study of cell 
proliferation and fate under physiologic and pathologic conditions. Here, we described the link between 
NRF2 and TAZ, opening a new window to understand their implication in stem cell properties. We also 
identified TAZ as a transcriptional corepressor of the neuronal differentiation program, highlighting the 
importance of TAZ-knockdown for neural stem cell-based therapy and glioblastoma treatment. 
Therefore, therapeutic possibilities may arise based on the exploitation of NRF2 and TAZ as crucial 
regulators of neurogenesis in chronic diseases. 
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1. NRF2 controls the proliferation and differentiation of hippocampal neural stem/progenitor cells. 
2. NRF2 deficiency impairs hippocampal neurogenesis in a murine model of Alzheimer´s disease. 
3. NRF2 recognizes ARE sequences in the promoter region of the TAZ-encoding gene and 
modulates its expression in neural stem/progenitor cells. 
4. TAZ is a transcriptional corepressor of the proneurogenic genes SOX2, ASCL1, NEUROG2 and 
NEUROD1, participating in inhibition of neuronal differentiation. 
5. The tumorigenic function of TAZ inversely correlates with expression of proneurogenic genes in 
glioblastoma. 
 
 
 
1. NRF2 controla la proliferación y diferenciación de las células troncales/progenitores neurales 
hipocampales. 
2. La falta de NRF2 altera la neurogénesis hipocampal en un modelo murino de la enfermedad de 
Alzhéimer. 
3. NRF2 reconoce secuencias ARE en la región promotora del gen que codifica a TAZ y modula su 
expresión en células troncales/progenitores neurales. 
4. TAZ actúa como un corepresor transcripcional de los genes proneurogénicos SOX2, ASCL1, 
NEUROG2 y NEUROD1, participando en la inhibición de la diferenciación neuronal. 
5. La función tumorigénica de TAZ correlaciona inversamente con la expresión de genes 
proneurogénicos en glioblastoma. 
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Appendix I. Script created with Python to compare in human genes the putative AREs, TEAD, SMADs 
and RUNX- binding sequences with the PSSM and calculate their relative score. In green are the values 
which have to been changed for each transcription factor. |Max| and |Min| correspond to absolute value 
of maximum and minimum calculated from PSSM matrix and N correspond to the number of positions 
of PSSM matrix. PSSM is obtained from the frequency matrix of each transcription factor from JASPAR 
database.   
import sys 
import re 
 
def Get_PSSM(FileName): 
tmp=(Ihrie and Alvarez-Buylla, 2011) 
MyFile=open(FileName,’r’) 
for Nt in [“A”,“C”,“G”,“T”]: 
pos=MyFile.readline() 
tmp[Nt]=pos.strip().split(“\t”) 
MyFile.close() 
return(tmp)  
 
def Get_Coordin(Coord): 
MyRE=r’(\w*)(chr[0-9XY]{1,2}):(\d+)-(\d+)’ 
MyReg=re.compile(MyRE) 
Res=MyReg.search(Coord) 
return(Res.groups()) 
 
def Get_MaxScore(Seq,PSSM): 
MaxSc=-100000 
book={} 
for idx in range(len(Seq)-len(PSSM[“A”])+1): 
tmpSc=0 
sseq=”” 
sequence=[] 
sequence2=[] 
for pos in range(len(PSSM[“A”])): 
tmpSc=tmpSc+float(PSSM[Seq[idx+pos]][pos]) 
sseq=sseq + Seq[idx+pos] 
if MaxSc<tmpSc: 
MaxSc=tmpSc 
sequence.append(str(tmpSc)) 
sequence2.append(sseq) 
book=dict(list(book.items()) + list((dict(zip(sequence,sequence2))).items())) 
return(MaxSc) 
 
def Get_Seq(Seq,PSSM): 
MaxSc=-100000 
book={} 
for idx in range(len(Seq)-len(PSSM[“A”])+1): 
tmpSc=0 
sseq=”” 
sequence=[] 
sequence2=[] 
for pos in range(len(PSSM[“A”])): 
tmpSc=tmpSc+float(PSSM[Seq[idx+pos]][pos]) 
sseq=sseq + Seq[idx+pos] 
if MaxSc<tmpSc: 
MaxSc=tmpSc 
sequence.append(str(tmpSc)) 
sequence2.append(sseq) 
book=dict(list(book.items()) + list((dict(zip(sequence,sequence2))).items())) 
return(book[str(MaxSc)])) 
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def Main(Args): 
PSSM={} 
PSSM=Get_PSSM(Args[1]) 
MyFile=open(Args[2],’r’) 
for Line in MyFile: 
Fields=Line.strip().split(“\t”) 
(Name,Chr,Str,End)=Get_Coordin(Fields[0]) 
directseq=Fields[1] 
basecomplement={“A”:”T”:”C”:”G”,”T”:”A”:”G”:”C”} 
rDNAsense=directseq[::-1] 
antisenseDNA=”” 
for base in rDNAsense: 
antisenseDNA = antisenseDNA+basecomplement[base] 
MaxScore=Get_MaxScore(Fields[1].upper(),PSSM) 
MaxScore2=Get_MaxScore(antisenseDNA.upper(),PSSM) 
Sequence=Get_Seq(Fields[1].upper(),PSSM) 
Sequence2=Get_Seq(antisenseDNA.upper(),PSSM) 
finded= Fields[1].find(Sequence) 
finded2= antisenseDNA.find(Sequence2) 
if int(Str)>int(End): 
print(Name,”\t”,Chr,”\t”,str(int(Str)-finded),”\t”,str(int(Str)-finded-
N),”\t”,  
round(MaxScore,2),”\t”,round(MaxScore+|Min|)/(|Max|+|Min|),3),”\t”, 
Sequence,”\t”, str(finded2+int(End)),”\t”, str(finded2+int(End)+N),”\t”,
  
round(MaxScore2,2),”\t”,round(MaxScore2+|Min|)/(|Max|+|Min|),3),”\t”,Seque
nce2) 
else: 
print(Name,”\t”,Chr,”\t”,str(finded+int(Str)),”\t”,str(finded+int(Str)+N),”\t
”, 
round(MaxScore,2),”\t”,round(MaxScore+|Min|)/(|Max|+|Min|),3),”\t”, 
Sequence,”\t”,str(int(End)-finded2),”\t”,str(int(End)-finded2-N),”\t”, 
round(MaxScore2,2),”\t”,round(MaxScore2+|Min|)/(|Max|+|Min|),3),”\t”,Seque
nce2) 
MyFile.close() 
 
if__name__==’__main__’: 
if len(sys.argv)<2: 
print(“You must provide the name of the files containing the sequences and 
PSSM”) 
else: 
Main(sys.argv) 
sys.exit()  
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A B S T R A C T
Neural stem/progenitor cells (NSPCs) located at the subgranular zone (SGZ) of the hippocampus participate in
the maintenance of synaptic networks that ensure cognitive functions during life. Although it is known that this
neurogenic niche losses activity with oxidative stress and ageing, the molecular events involved in its regulation
are largely unknown. Here, we studied the role of transcription factor Nuclear Factor-Erythroid 2-Related Factor
2 (NRF2) in the control of NSPCs destinies in the SGZ. We ﬁrst describe that NRF2-knockout (Nrf2-/-) mice
exhibit impaired long term potentiation, a function that requires integrity of the SGZ, therefore suggesting a
cognitive deﬁcit that might be linked to hippocampal neurogenesis. Then, we found a reduction in NSCs from
birth to adulthood that was exacerbated in Nrf2-/- vs. Nrf2+/+ mice. The clonogenic and proliferative capacity of
SGZ-derived NSPCs from newborn and 3-month-old Nrf2-/- mice was severely reduced as determined in neu-
rosphere cultures. Nrf2-deﬁciency also impaired neuronal diﬀerentiation both the SGZ, and in neurosphere
diﬀerentiation assays, leading to an abnormal production of astrocytes and oligodendrocytes vs. neurons. Rescue
of Nrf2-/- NSPCs by ectopic expression of NRF2 attenuated the alterations in clonogenic, proliferative and dif-
ferentiating capacity of hippocampal NSPCs. In turn, knockdown of the NRF2 gene in wild type NSPCs re-
produced the data obtained with Nrf2-/- NSPCs. Our ﬁndings demonstrate the importance of NRF2 in the
maintenance of proper proliferation and diﬀerentiation rates of hippocampal NSPCs and suggest that inter-
ventions to up-regulate NRF2 might provide a mechanism to preserve the neurogenic functionality of the hip-
pocampus.
1. Introduction
Nuclear Factor-Erythroid 2-Related Factor 2 (NRF2) is a transcrip-
tion factor that regulates homeostatic responses to multiple stressors.
Initially connected with biotransformation reactions, it is known to
participate in the regulation of hundreds of human genes involved in
antioxidant defense, anti-inﬂammatory response, autophagy, metabolic
reprograming of tumor cells, etc. [1–4]. Modulation of the expression of
these genes provides a global cellular response to promote cell survival,
cell growth, self-renewal, diﬀerentiation, proliferation, and increased
lifespan, which may be relevant to the function of stem cells [5–7].
NRF2 is expressed in virtually every tissue and promotes survival of
stem cells from several origins [8–10]. In the brain, the direct im-
plication of NRF2 in regulation of neural stem cells (NSCs) has been
reported only in connection with the normal decline of its activity
during aging and the reduction of the NSCs pool at the subventricular
zone (SVZ) of the striatum [11].
The adult brain harbors another region of persistent lifelong neu-
rogenesis: the subgranular zone (SGZ) of the dentate gyrus (DG) that has
been much less explored [12]. This region contains quiescent neural
stem cells (NSCs) that on speciﬁc demands are mobilized towards
generation of rapidly-dividing neural progenitor cells (NPCs), neurons
and astrocytes. Newly generated granular neurons are required for the
electrophysiological functioning of the perforant path (PP), involved in
spatial learning and memory consolidation [13–15]. Progressive loss of
neurogenesis at the SGZ has been associated with aging, which also
correlates with decline of NRF2 activity [16,17] and with alterations in
redox homeostasis. In fact, a relevance of reactive oxygen species (ROS)
http://dx.doi.org/10.1016/j.redox.2017.06.010
Received 20 April 2017; Received in revised form 30 May 2017; Accepted 25 June 2017
⁎ Correspondence to: Instituto de Investigaciones Biomédicas “Alberto Sols", C/ Arturo Duperier 4, 28029 Madrid, Spain.
E-mail address: antonio.cuadrado@uam.es (A. Cuadrado).
Redox Biology 13 (2017) 393–401
Available online 27 June 2017
2213-2317/ © 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
MARK
in neural stem/progenitor cell (NSPCs) physiology is suggested by high
expression levels of antioxidant genes encoding SOD1, SOD2, GPX, etc.
[18]. However, the role of NRF2 in the homeostasis of the neurogenic
niche of the SGZ has not been explored.
In this study, we have analyzed the mobilization of the NSPCs pool
of the SGZ in Nrf2-/- mice at early age and adulthood. We report that
exhaustion of NSCs and NPCs of the SGZ pool occurs more rapidly in
Nrf2-knockout (Nrf2-/-) mice, when compared to wild type (Nrf2+/+)
mice, which is correlated with the loss of electrophysiological activity
of the perforant path.
2. Material and methods
2.1. Animals
C57BL/6 mouse colonies of the Nrf2-/- and Nrf2+/+ genotypes were
established from funders kindly provided by Prof. Masayuki Yamamoto
(Tohoku University Graduate School of Medicine, Sendai, Japan) [19].
All the animal procedures were performed according to the protocols
approved by the Ethical Committee for Research of the Universidad
Autónoma de Madrid, following institutional, Spanish and European
guidelines (Boletín Oﬁcial del Estado of 18 March 1988; and 86/609/
EEC, 2010/63/EU European Council Directives).
2.2. Electrophysiological recordings
Data were obtained from six urethane-anaesthetized (1.6 g/kg i.p.)
mice of 6 months of age per group as described in [20]. Brieﬂy, ﬁeld
potentials were recorded through tungsten macroelectrodes (1 MΩ;
World Precision Instruments) stereotaxically implanted in the DG (A:
-2,3; L: 2; H: 1.5 mm from bregma, according to the Paxinos and
Watson Atlas [21]). Twisted bipolar electrodes for electrical stimulation
were aimed at the perforant path (A: -2.5; L: 0.5; H: 1.5 mm from
bregma) [22]. Baseline recordings were taken with test stimuli
(10–50 mA, 0.3 ms, 0.5 Hz) during 15 min before tetanic stimulation
consisting of three pulse trains of 10–50 mA, each pulse lasting 0.3 ms
and at 50 Hz. Trains lasted 500 ms and the inter-train interval was 2 s.
Recording was maintained for 30 min after tetanic stimulation. Field
potentials were 0.1 Hz to 1 kHz band-pass ﬁltered, ampliﬁed (P15
Ampliﬁer, Grass Co., USA), and digitized at 10 kHz (CED 1401; Cam-
bridge Electronic Design). Signals analysis was carried out with Spike 2
software (Cambridge Electronic Design, Cambridge, UK). Field poten-
tial segments of 5 min were analyzed to obtain the response average.
The mean average response during the 15 min period before the tetanic
stimulation was considered as 100%. Recordings were accepted for
analysis when baseline variability was less than 10%.
2.3. Immunoﬂuorescence on mouse tissues and stereological analysis
Brain tissue immunoﬂuorescence was performed in 30 µm-thick
sections as previously described [2]. Antibodies are described in Suppl.
Table S1. Control sections were treated with identical protocol but with
the omission of the primary antibody. Cell counts were performed using
Fiji Software (http://ﬁji.sc/Fiji) [23] in 5 sections of the DG separated
by 240 µm.
2.4. Cell culture and reagents
Human embryonic kidney HEK293T cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with
10% fetal bovine serum (HyClone), 4 mM L-Glutamine (Gibco) and
80 mg/ml gentamicin (Laboratorios Normon). R,S-sulforaphane (SFN;
LKT Laboratories, Inc.). Culture of SGZ-derived NSPCs from new-born
0–4 days old pups was described in [24]. For culture of NSPCs from 3-
months-old mice, the same protocol was used with the following
medium: DMEM/F12/Glutamax, B27 without vitamin A, 20 ng/ml
epidermal growth factor (EGF), 20 ng/ml basic ﬁbroblast growth factor
(bFGF), 4 µg/ml heparin, and 100 U/ml penicillin/streptomycin.
2.5. Immunoﬂuorescence of neurospheres
Neurospheres were adhered to poly-D-lysine-coated coverslips by
centrifugation (634g, 5 min), and ﬁxed with 4% paraformaldehyde.
Then, neurospheres were washed, blocked in PBS containing 0.5%
Triton X-100% and 3% bovine serum albumin and incubated overnight
(at 4 °C) with the relevant primary antibodies and for 2 h at RT with the
appropriate secondary antibodies coupled to Alexa Fluor 488, 594, or
647 (1:500) (Life Technologies-Molecular Probes, Grand Island, NY,
USA). Nuclei were stained with DAPI. Images were quantiﬁed using Fiji
Software (http://ﬁji.sc/Fiji).
2.6. Serial dilution assay
This assay was performed as described in [11]. Brieﬂy, secondary
neurospheres were disaggregated with accutase (StemCell Technolo-
gies) and seeded into a 96-well plate at 5, 25, 125, 250, 500 and 1000
cells/well dilution. Cells were kept in 5% CO2 and 95% atmospheric air,
at 37 °C, in proliferation media, during 7 days, which allowed the for-
mation of tertiary neurospheres. Neurosphere number was determined
as de average from 5 wells.
2.7. Cell pair assay
As described in [25], a single cell suspension of NSPCs was plated on
poly-D-lysine-coated coverslips at a low density (10,000 cells/cm2).
Cells were cultured for 24 h in DMEM/F12/Glutamax, B27 (without
vitamin A) supplemented with 5 ng/ml or 10 ng/ml EGF and 2.5 or
10 ng/ml bFGF, for pup- or adult-derived neurospheres, respectively.
After ﬁxation with 4% PFA, cells were immunostained for SOX2. This
assay allowed the quantiﬁcation of symmetric cell divisions (self-re-
newal with both SOX2+ siblings) and asymmetric divisions (diﬀer-
entiation with one SOX2+ and one SOX2- sibling).
2.8. Diﬀerentiation assays and Sholl analysis
Five-day-old secondary neurospheres were plated on poly-D-lysine-
coated coverslips and incubated for 7 days in diﬀerentiation media
(DMEM/F12-Glutamax, B27 without vitamin A, and 100 U/ml peni-
cillin/streptomycin). Immunostaining and quantiﬁcation were per-
formed as described above. To quantify neuronal diﬀerentiation, Sholl
analysis was performed using the Simple neurite tracer plugin (http://
homepages.inf.ed.ac.uk/s9808248/imagej/tracer/) and the image pro-
cessing package Fiji (http://paciﬁc.mpicbg.de/wiki/index.php/Main_
Page) in images of diﬀerentiated neurospheres immunolabeled for DCX
(Santa Cruz).
2.9. Production of lentiviral stocks and infection of NSPCs
Recombinant lentiviral stocks were produced in HEK 293 T/17 cells
by cotransfecting 10 μg of transfer vector (control plasmid,
NFE2L2ΔETGE [26], shCO or shNRF2 (shCLN_NM_010902, MISSION
shRNA, Sigma)), 6 μg of envelope plasmid pMD2.G (Addgene; de-
posited by Dr. Didier Trono) and 6 μg of packaging plasmid pSPAX2
(Addgene; deposited by Dr. Didier Trono), using Lipofectamine 2000
Reagent (Invitrogen Life Technologies). After 12 h at 37 °C the medium
was replaced with fresh DMEM containing 10% fetal bovine serum.
Virus particles were harvested at 24 h and 48 h post-transfection. Ad-
hered NSPCs were incubated with the lentivirus stock for 24 h in DMEM
supplemented with 10% FBS and 12 additional hours in proliferation
medium. Then, cells were cultured in suspension to allow neurosphere
formation.
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2.10. Immunoblotting
This protocol was performed as described in [1]. Brieﬂy, cells were
homogenized in lysis buﬀer (TRIS pH 7.6 1 M, 400 mM NaCl, 1 mM
EDTA, 1 mM EGTA and 1% SDS) and samples heated at 95 °C for
15 min, sonicated and precleared by centrifugation. Primary antibodies
used are detailed in Suppl. Table S1.
2.11. Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA extraction and q-RT-PCR were done as detailed else-
where [27]. Primer sequences are shown in Suppl. Table S2. All PCRs
were performed in triplicate.
2.12. Statistical analysis
Data are presented as mean± SEM. Statistical assessments of dif-
ferences between groups were analyzed using GraphPad Prism 5 soft-
ware by one or two-way ANOVA or unpaired Student's t-tests, assuming
a normal distribution and equal variances as indicated in the legends.
3. Results
3.1. NRF2 deﬁciency impairs long term potentiation
Adult Nrf2+/+ and Nrf2-/- mice (6-months old) were examined
electrophysiologically for hippocampal long term potentiation (LTP).
The synaptic transmission of granule cells of the DG was recorded in
response to perforant path (PP) stimulation (Fig. 1A). High frequency
stimulation increased the ﬁeld excitatory post-synaptic potential
(fEPSP) in control Nrf2+/+ mice, but these values were strongly di-
minished in Nrf2-/- mice (Fig. 1B-C), indicating for the ﬁrst time that
NRF2 is required for normal LTP. As the PP is dependent on the activity
of excitatory granule neurons of the DG, and these cells are replaced by
NSPCs from SGZ [28], we hypothesized that this might be due, at least
in part, to impaired hippocampal neurogenesis in Nrf2-/- mice.
3.2. The clonogenic and proliferative capacity of NSPCs from the SGZ is
impaired in NRF2-deﬁcient mice
We ﬁrst conﬁrmed by qRT-PCR and immunoblotting that NSPCs of
the SGZ express NRF2 (Suppl. Fig. 1A-C) and performed im-
munostaining of the proliferative marker Ki67 in combination with the
NSPC marker Nestin to evaluate the number of proliferative NSPCs in
the SGZ (Fig. 2A-B). As expected both Nrf2+/+ and Nrf2-/- mice ex-
hibited a drastic reduction of proliferating cells with aging. However
the number of proliferating NSPCs was ∼50% lower in Nrf2-/- mice
NSPCs. In order to compare proliferative and clonogenic capacities of
NSPCs, we performed neurosphere assays from 3-months old mice.
After 5 days in culture the number of cells in the Nrf2-/- neurospheres
was about ∼50% lower compared to Nrf2+/+ (Fig. 2C). Then, we
found that NSPCs from Nrf2-/- mice had a lower clonogenic capacity as
determined by the number of neurospheres formed after seeding equal
amounts of Nrf2-/- and Nrf2+/+ NSPCs (Fig. 2D). In addition, Ki67
immunostaining also demonstrated a reduction in the number of pro-
liferating cells in Nrf2-/--derived neurospheres (Fig. 2E-F). In agreement
with these results, immunoblot analyses indicated that two proliferative
markers, Ki67 and PCNA, were reduced in Nrf2-/--derived neurospheres
(Suppl. Fig. 2A). Similar results were found in neurosphere cultures
established from postnatal (P0-P4) mice (Suppl. Fig. 2B-E). In addi-
tional experiments, we analyzed caspase-3 cleavage as a measurement
of cell death in the SGZ (data not shown) and neurospheres from both
genotypes (Suppl. Fig. 3). We detected very low levels of cleaved cas-
pase-3 by immunohistochemistry or immunoblot, suggesting that
NSPCs are not undergoing apoptosis or they do it at undetectable level.
In order to further analyze the involvement of NRF2 in these
processes, we rescued NRF2 expression in Nrf2-/- NSPCs with a lenti-
viral vector expressing a constitutively active mutant of NRF2
(NRF2ΔETGE) [26] (Suppl. Fig. 4A-B). Expression of NRF2 partially im-
proved the clonogenic and proliferative capacity of Nrf2-/- NSPCs,
leading to increased number of neurospheres as well as of Ki67+ cells
(Fig. 2G-J). Additionally, we silenced NRF2 with a lentiviral shRNA
vector in Nrf2+/+ NSPCs. Evidence of NRF2-knockdown was provided
after induction with the NRF2 activator sulforaphane (SFN) (Suppl.
Fig. 4C-D). Knock-down of NRF2 led to a reduction in clonogenic and
proliferating capacity of NSPCs (Fig. 2K-N). Taken together these re-
sults suggest a cell autonomous need of NRF2 to maintain the clono-
genic and proliferative capacity of NSPC pool.
3.3. Age-related exhaustion of the NSPCs pool from the SGZ is exacerbated
in NRF2-deﬁcient mice
We analyzed by immunostaining with Nestin, SOX2 and GFAP
Fig. 1. NRF2 deﬁciency impairs long term potentiation. A, upper draw points the positions of
the stimulating electrode on the perforant pathway and recording electrode on the
granule cell layer: DG, dentate gyrus; CA1 and CA3, Cornu Ammonis areas 1 and 3, re-
spectively. B, representative responses recorded from Nrf2+/+ and Nrf2-/- mice before
(thin line) and after (thick line) high-frequency trains of tetanic stimulation. Calibration:
2 mV, 20 ms. C, LTP of ﬁeld excitatory postsynaptic potential (fEPSP) in 6-month-old
animals before and after tetanic stimulation of the perforant pathway. c5, c10, c15:
baseline recordings before tetanic stimulation. Data are mean± SEM (n = 6). Statistical
analysis was performed with two-way ANOVA followed by Bonferroni post-hoc test.
**p<0.01, and ***p< 0.001 comparing Nrf2-/- versus Nrf2+/+ group.
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antibodies the number of quiescent neural progenitors (QNPs) and
amplifying neural progenitors (ANPs), as these cell populations drive
NSPCs towards mobilization and diﬀerentiation of neural lineages.
QNPs were identiﬁed as Nestin+/SOX2+/GFAP+ cells and ANPs as
Nestin+/SOX2+/GFAP-cells, and were distinguished morphologically:
QNPs exhibit a non-branched long neurite across the granular cell layer
while ANPs are located at the basis of the granular layer and do not
present long neurites (Fig. 3A) [29]. The number of QNPs and ANPs in
Nrf2+/+ mice decreased with aging (Fig. 3B-D). Thus at 15 months of
age the number of QNPs and ANPs had decreased to ∼50% compared
Fig. 2. Impaired proliferative and clonogenic capacity of NSPCs from Nrf2-/- mice. A, confocal microscope images of Ki67 staining in the SGZ of 3-month-old mice. The green channel for
Nestin staining has been removed except in the inset to allow easier visualization of proliferating cells. Nuclei were counterstained with DAPI. B, quantiﬁcation of Ki67+ cells in 3-, 6- and
12-month-old mice. Data represent mean values± SEM (n = 4). C, number of cells after 5 days in culture from an initial seeding of 20,000 NSPCs/ml derived from Nrf2-/- vs. Nrf2+/+ 3-
month-old mice. D, serial dilution assay of Nrf2+/+ and Nrf2-/- cultures showing the number of neurospheres formed after 7 days (n = 5). E-F, immunoﬂuorescence and quantiﬁcation of
Ki67+ cells, counterstained with DAPI, in neurospheres with similar size (n = 10). G-N, parallel analysis in Nrf2-/--derived NSPCs infected with a control vector (CT) or a lentivirus
expressing active NRF2ΔETGE (G-J), and Nrf2+/+-derived NSPCs infected with control (shCO) and shNRF2 lentivirus (K-N). Data show mean values± SEM. **p< 0.01, ***p< 0.001
according to a Student's t-test vs. either Nrf2-/- (B, C, D, F) or the experimental groups (G,H, J, K, L and N).
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to 3 months of age. Importantly, in 3-month-old Nrf2-/- mice the
amount of these cells was already substantially decreased to ∼50%.
Accordingly, the number of Nestin+ cells was decreased in Nrf2-/-
neurospheres from newborn (Suppl. Fig. 2F-G) and 3-month-old
(Fig. 3E-F) mice.
As these results suggested impaired capacity of QNPs and ANPs to
proliferate and diﬀerentiate, we further analyzed the number of sym-
metric and asymmetric divisions in cell culture following staining with
SOX2 (Fig. 3G-J). Cells derived from symmetric divisions express SOX2
in both siblings, while in asymmetric divisions only one of the siblings
expresses SOX2. As expected ∼75% of the Nrf2+/+ NSPCs derived
from symmetric division. However in the Nrf2-/- NSPCs symmetric di-
visions accounted for only∼25% (Fig. 3H). In line with this, the Nrf2-/-
NSPCs from newborn mice exhibited an increment in asymmetric di-
visions as compared to control NSPCs (Suppl. Fig. 2H). These data were
further conﬁrmed by rescuing Nrf2-/- NSPCs with the lentivirus-
mediated expression of NRF2ΔETGE (Fig. 3I). Moreover, knocking-down
NRF2 in Nrf2+/+ NSPCs resulted in a reduction in symmetric divisions
(Fig. 3J). Taken together, these results suggest that NRF2 deﬁciency
limits the self-renewal capacity of the neurogenic niche of the SGZ.
3.4. Neuronal diﬀerentiation from NSPCs of the SGZ is impaired in NRF2-
deﬁcient mice
We analyzed the capacity of the SGZ to produce new neurons using
doublecortin (DCX) staining that speciﬁcally labels neuroblasts and
immature neurons (Fig. 4A-B). In both Nrf2+/+ and Nrf2-/- mice the
amount of DCX+ cells decreased gradually to ∼10% at 12 months of
age but the SGZ of Nrf2-/- mice presented a lower capacity to generate
these neuronal progenitors already at 3 and 6 months of age. These
results were also analyzed in neurospheres and again the amount of
DCX+ cells was substantially decreased to ∼20% in newborn (Suppl.
Fig. 3. NRF2-deﬁciency provokes a drop in the pool of QNPs and ANPs and an increase of asymmetric divisions of NSPCs. A, confocal image of a SGZ immunostained GFAP/SOX2/Nestin.
Arrows point a typical ANP, QNP and astrocyte (see text). B, same staining for 3- (Upper panel), 6- (middle panel) and 15- (low panel) month-old mice. C-D, quantiﬁcation of QNPs (C)
and ANPs (D) in 3-, 6- and 15-month-old mice (n = 3). E-F, nestin immunoﬂuorescence on neurospheres derived from 3-month-old mice (n = 10). G-J, cell pair assay of NSPCs by SOX2
immunoﬂuorescence. G, example of symmetric and asymmetric divisions. Quantiﬁcation of symmetric and asymmetric divisions in cultures from 3-month-old (H) mice, Nrf2-/- NSPCs
infected with control or NRF2ΔETGE expression lentivirus (I) and Nrf2+/+ NSPCs infected with control or shRNA lentivirus to knock-down NRF2 (J) (n = 60 pairs). Data show mean
values± SEM.*p< 0.05, **p<0.01, ***p< 0.001 according to a student's t-test vs. either Nrf2-/- (C, D, F and H) or the experimental groups (I and J).
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Fig. 2H-I) and ∼50% in 3-month-old Nrf2-/- mice (Fig. 4C-D).
Next, we analyzed the diﬀerentiation potential of the NSPCs. When
plated on poly-D-lysine and grown in the absence of growth factors
NSPCs migrate away from the neurosphere core and spread around
forming a carpet of cells diﬀerentiated to neurons, astrocytes and oli-
godendrocytes [30]. First, following DCX and DAPI staining, we noted a
decrease in the migration distance of cells from newborn (Suppl.
Fig. 5A-B) and, more notoriously, from 3-month-old (Fig. 5A-B) Nrf2-/-
mice. The migration distance was improved by reintroduction of NRF2
expression in Nrf2-/- cultures (Fig. 5E-F), and worsened by knock-down
of NRF2 in Nrf2+/+ cultures (Fig. 5H-I). DCX staining in the diﬀer-
entiating cultures indicated impairment in the neuronal diﬀerentiation
of Nrf2-/- neurospheres at birth (Suppl. Fig. 5C) and at 3 months of age
(Fig. 5C). Moreover, rescue of NRF2 expression in Nrf2-/- cultures led to
enhanced neuronal diﬀerentiation (Fig. 5G). On the other hand, silen-
cing NRF2 in Nrf2+/+ neurospheres reduced signiﬁcantly the percen-
tage of DCX+ cells (Fig. 5J). To analyze the maturation of these cells
and their capacity to interact with other neurons, we performed a Sholl
analysis, that measures the branching complexity, in newborn (Suppl.
Fig. 5D) and 3-month-old (Fig. 5D) mice. DCX+ cells from Nrf2-/- mice
showed a decrease in the number of neurite crossings suggesting a re-
duced maturation compared to those of Nrf2+/+ mice. All these data
suggest that NRF2 is not only important to maintain the NSPCs pool but
also to support a proper neuronal diﬀerentiation.
3.5. NRF2-deﬁciency impairs the neuron/glia diﬀerentiation balance
Astrocyte diﬀerentiation in the SGZ was analyzed by GFAP and
SOX2 staining (Fig. 6A-B). The Nrf2-/- mice exhibited a growing in-
crease in astrocyte abundance at the SGZ for 3, 6 and 15 months of age.
When we analyzed the astroglial diﬀerentiation in vitro, using GFAP
staining, we noted an increase in the number of astrocytes in Nrf2-/- vs
Nrf2+/+ cultures, being 20% higher in newborn (Suppl. Fig. 5E-F) and
40% higher in 3-month-old-derived neurospheres (Fig. 6C-D). The in-
crease in astrocytes was also observed Nrf2+/+ cultures when we si-
lenced NRF2 expression (Fig. 6G-H). Furthermore, recovering NRF2
expression in Nrf2-/- cultures resulted in a reduction to 20% of GFAP+
cells (Fig. 6E-F). Oligodendrocyte diﬀerentiation was analyzed with
OLIG2 staining. Nrf2-/- neurospheres from newborn (Suppl. Fig. 5G-H)
and 3-month-old mice (Fig. 6I-J) exhibited ∼2-folds increase in the
number of oligodendrocytes. In line with these results, reintroduction of
NRF2 in Nrf2-/- NSPCs reduced signiﬁcantly the number of OLIG2-po-
sitive cells (Fig. 6K-L) while NRF2 silencing in Nrf2+/+ cultures re-
sulted in an enrichment in oligodendrocytes under diﬀerentiating
conditions (Fig. 6M-N). These results could not be replicated in mice
(data not shown), in agreement with reports suggesting that NSPCs
from the SGZ might not generate oligodendrocytes in vivo [31,32]. All
these measurements indicate that NRF2 is a key regulator of the balance
between neuronal and glial diﬀerentiation.
4. Discussion
Here we report for the ﬁrst time the role of NRF2 in mobilization
and diﬀerentiation of NSPCs in the SGZ, a neurogenic niche that par-
ticipates in neurogenesis of the adult hippocampus and therefore has
crucial implications in preservation of cognitive functions. SGZ NSPCs
appear to have a crucial role in the replacement of new neurons in
granule cell layer [33]. These adult-born neurons synaptically integrate
in the pre-existing hippocampal neural circuitry and participate in LTP,
which plays a role in learning and memory [13,34,35]. In turn, de-
pletion of hippocampal neurogenesis results in LTP loss [36,37].
It has been reported that local induction of oxidative stress during
mobilization of neural precursors can occur given the evidence that
oxidized DNA and lipids are present in the SGZ of adult rodents [38].
Although the authors did not analyze NRF2 directly, a bioinformatics
analysis based on previous transcriptomics data sets [39,40] did show
changes in the levels of several antioxidant enzymes whose expression
is regulated by NRF2. We could not analyze NRF2 protein levels by
immunohistochemistry in the SGZ (data not shown) and, in fact, NRF2
levels were almost undetectable by immunoblotting in NSPCs isolated
from the SGZ (Suppl. Fig. 1) and SVZ (data not shown). However, these
cells responded to the NRF2 activator SFN indicating that although low,
NRF2 is expressed under basal conditions and responds to environ-
mental inducers. To avoid oﬀ-target eﬀects of NRF2 activating drugs,
we used a genetic approach based on lentiviral reintroduction of NRF2
in NSCs. Ectopic expression of NRF2 rescued otherwise NRF2-deﬁcient
NSPCs to cloning and proliferative values, similar to those of wild type
NSPCs. Our results are in agreement with a previous study showing that
up-regulation of NRF2 ameliorated amyloid β-mediated neural stem
cell death [41]. This study also demonstrated that neuronal diﬀer-
entiation of NSPCs is enhanced by NRF2 overexpression [41]. Ad-
ditionally, we found that decreasing or increasing NRF2 expression by
Fig. 4. NRF2-deﬁciency leads to a reduction of DCX+ cells. A and B, DCX immunostaining in the SGZ of 3-, 6- and 12-month-old mice (n = 3). C-D, DCX immunoﬂuorescence in
neurospheres derived from 3-month-old mice (n = 10). Data represent mean values± SEM. *p<0.05, **p< 0.01 and ***p<0.001 according to a Student's t-test vs. the Nrf2-/- group.
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genetic means was suﬃcient to signiﬁcantly suppress or rejuvenate the
neurogenic niche of the SGZ. Furthermore, SGZ NSPCs from either new
born or 3 month-old Nrf2-/- mice exhibited substantially compromised
proliferation and neuronal diﬀerentiation. Our results are in line with a
previous study showing that a highly reduced intracellular redox state
promotes proliferation and survival, whereas a highly oxidized state
results in greater diﬀerentiation and cell death [42].
In order to understand how NRF2 controls the fate of NSPCs, we used
the cell pair assay that indicates whether NCS divisions lead to identical
siblings with proliferating capacity (symmetric division) or to two dif-
ferent cells, one retaining proliferation capacity and the other entering a
diﬀerentiation program (asymmetric division) [25]. The current model of
mobilization of the NSPC pool establishes that a NSC progenitor will di-
vide symmetrically for several generations to maintain the progenitor
pool. At the same time, a certain number of asymmetric divisions will lead
to a supply of neurons as well as astrocytes to accommodate speciﬁc de-
mands. The last division leads to diﬀerentiation of both siblings into as-
trocytes [29]. The fact that the NSPC pool was exhausted more quickly in
the Nrf2-/- mice suggested that either cell-autonomous alterations or
micro-environmental inﬂuence leads to the mobilization and terminal
diﬀerentiation of these neural progenitors. Consistent with this hypothesis,
we found an inverse correlation between Ki67-stained progenitors (Fig. 2)
and GFAP-stained astrocytes (Fig. 6). Moreover, in the cell pair assay, we
found that NRF2 deﬁciency resulted in an increase of asymmetric divi-
sions, leading to the reduction in the number of progenitors. These
ﬁndings suggest that the exhaustion of the NSPC pool in the Nrf2-/- mice is
due to an increase in asymmetric divisions, together with imbalance in the
cell fate to increase the number of astrocytes and reduce neurons. This
hypothesis is consistent with the well reported observation that NRF2 is
required to counterbalance the high levels of intracellular ROS of highly
proliferating cells [43,44]. Furthermore, our study also connects the ob-
served pattern of decline in NSPC function with cognitive impairment.
These results identify for the ﬁrst time NRF2 as an important factor
to prevent the decline in the NSPC pool of the SGZ, during aging, and
have important implications towards understanding fundamental as-
pects of NSPC biology and promising therapeutic interventions in dis-
orders involving hippocampal function.
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ABSTRACT 
Transcription factor NRF2 orchestrates a cellular defense against oxidative stress and so 
far, has been involved in tumor progression by providing a metabolic adaptation to 
tumorigenic demands and resistance to chemotherapeutics. In this study, we discover that 
NRF2 also propels tumorigenesis in gliomas and glioblastomas by inducing the expression 
of the transcriptional co-activator TAZ, a protein of the Hippo signaling pathway that 
promotes tumor growth. The expression of the genes encoding NRF2 (NFE2L2) and TAZ 
(WWTR1) showed a positive correlation in 721 gliomas from The Cancer Genome Atlas 
database. Moreover, NRF2 and TAZ protein levels also correlated in immunohistochemical 
tissue arrays of glioblastomas. Genetic knock-down of NRF2 decreased, while NRF2 
overexpression or chemical activation with sulforaphane, increased TAZ transcript and 
protein levels. Mechanistically, we identified several NRF2-regulated functional enhancers 
in the regulatory region of WWTR1. The relevance of the new NRF2/TAZ axis in 
tumorigenesis was demonstrated in subcutaneous and intracranial grafts. Thus, intracranial 
inoculation of NRF2-depleted glioma stem cells did not develop tumors as determined by 
magnetic resonance imaging. Forced TAZ overexpression partly rescued both stem cell 
growth in neurospheres and tumorigenicity. Hence, NRF2 not only enables tumor cells to 
be competent to proliferate but it also propels tumorigenesis by activating the TAZ- 
mediated Hippo transcriptional program.  
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INTRODUCTION 
Glioblastomas (GBs) are the most common primary malignant brain tumor and remain 
incurable, with a poor survival rate after diagnosis. They present somatic mutations in receptor 
tyrosine kinase pathways, p53 and retinoblastoma, that correlate with their anatomopathological 
classification (Hanif et al., 2017). However, the participation of other effectors in their molecular 
pathology is less known. 
NRF2 (Nuclear factor (erythroid-derived 2)-like 2) is a basic region-leucine zipper 
transcription factor that forms heterodimers with small musculoaponeurotic fibrosarcoma proteins 
(MAFs) in the nucleus (Cuadrado et al., 2018). The heterodimer recognizes an enhancer sequence 
termed antioxidant response element (ARE) that is present in the regulatory regions of more than 
200 genes (ARE genes). ARE genes encode a broad network of enzymes involved in phase I, II, and 
III biotransformation reactions, antioxidant mechanisms encompassing NADPH-, glutathione- and 
thioredoxin-mediated reactions, lipid and iron catabolism, autophagy gene expression, etc. Through 
this complex transcriptional network, NRF2 coordinates multifaceted responses to diverse forms of 
stress for the maintenance of a stable internal environment (Hayes and Dinkova-Kostova, 2014; Lee 
et al., 2018). It is now accepted that these homeostatic functions provide a growth advantage to 
cancer cells in the hostile tumor microenvironment and promote cancer progression (DeNicola et 
al., 2011), metastasis (Wang et al., 2008), and resistance to chemo- and radiotherapy (Namani et al., 
2017; Padmanabhan et al., 2006; Sporn and Liby, 2012). Its activity is generally increased in 
glioblastoma cell lines (Cong et al., 2013) and tumors (Kanamori et al., 2015), and elimination of 
NRF2 expression inhibits the proliferation and self-renewal of glioma stem cells (Kanamori et al., 
2015). 
The tumor promoting activity of NRF2 is due to its homeostatic functions. However, high 
NRF2 expression is observed in embryonic, pluripotent and cancer stem cells (Jia et al., 2015; Wu 
et al., 2015; Zhu et al., 2014a) in in vitro culture, suggesting additional pro-tumorigenic functions. 
NRF2 controls the expression of the stemness associated protein NOTCH1 (Wakabayashi et al., 
2010), while NRF2 inactivation affects stem cell renewal (Jia et al., 2015; Zhu et al., 2014a; Zhu et 
al., 2013). However, a mechanistic connection between stemness and NRF2 has not been 
demonstrated yet. Here, we focused on the Hippo pathway effector TAZ (Transcriptional co-
activator with PDZ-binding motif). The Hippo pathway is a Ser/Thr phosphorylation-dependent 
cascade that, through the YAP and TAZ co-activators of TEADs1-4, participates in regulation of 
organ development, cell proliferation, migration, invasion, and stemness in multiple human cancers 
(Moroishi et al., 2015). TAZ, encoded by WWTR1 (WW domain-containing transcription regulator 
protein 1), is a crucial element of the Hippo signaling pathway. Its expression is elevated in several 
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tumor types including gliomas (Zhou and Lei, 2016) and correlates with the grade of malignancy, 
being maximal in glioblastomas (Bhat et al., 2011). Patients with TAZ over-expressing tumors 
exhibit a poor prognosis, and, in cell models, TAZ promotes tumor progression, while its 
knockdown prevents proliferation, tumorigenicity and invasion of glioma cells (Bhat et al., 2011). 
TAZ is exquisitely regulated at the level of protein stability by a wide range of stress signals such as 
mechanical stress, low energy status, hypoxia and osmotic stress (Dupont et al., 2011; Zhou et al., 
2015). These signals activate the Hippo pathway, leading to TAZ phosphorylation and subsequent 
cytoplasmic retention and degradation (Liu et al., 2010; Yu and Guan, 2013). However, little is 
known about the regulation of its encoding gene, WWTR1, despite it must be crucial in order to 
sustain high long-term levels of TAZ activity. 
In this study, we analyzed if NRF2 might activate the Hippo pathway at the level of TAZ, 
taking GBs as a model. We report that NRF2 induces the expression of WWTR1, which is partly 
required for its oncogenic activity. Thus, NRF2 delivers a growth, proliferative and survival signal 
through TAZ in glioblastomas, which is not directly related to redox metabolism or cytoprotection. 
These results provide a new strategy for targeted glioblastoma therapy at the level of NRF2 by 
reducing not only its cytoprotective function but also the TAZ-dependent growth and proliferative 
signature. 
 
 
RESULTS 
Analysis of NFE2L2 and WWTR1 expression in GBs 
We first analyzed the frequency of mutations in the genes KEAP1, and NFE2L2, encoding the main 
NRF2 repressor KEAP1 and NRF2, respectively, as well as several other growth-related pathways 
in 721 brain tumors from The Cancer Genome Atlas (TCGA) database. Only 11 tumors exhibited 
mutations in KEAP1 or NFE2L2 and only 32 in genes of the Hippo pathway (Fig. 1A). LGGs 
exhibited frequent mutations in IDH1, encoding Isocitrate Dehidrogenase-1 and ATRX, encoding 
ATP-dependent helicase. By contrast, GBs were prone to mutations in EGFR, encoding Epidermal 
Growth Factor Receptor, and PTEN, encoding Phosphatase and Tensin Homolog (Fig. 1B). It has 
been previously reported that LGGs exhibit low NRF2 levels, but the role of this factor in GB is 
poorly defined. In search for a mechanistic role of NRF2 in GBs, we focused in the Hippo pathway 
because the lack of frequent mutations might allow unmasking its physiological mechanism of 
regulation and its pathological subversion. We found a positive correlation in the abundance of 
NFE2L2 and WWTR1 transcripts in both LGGs and GBs (Fig. 1C and D). Furthermore, we 
observed a striking similarity in the prognosis of NFE2L2 and WWTR1 overexpressing gliomas. 
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Besides, high expression of either of them had a bad prognosis with an average of 1.7 years survival 
in both cases (Fig. 1E).  
We further investigated NRF2 and TAZ protein levels in a tissue array of 26 histologically-
defined GBs, all of which were negative for IDH1 and ATFX mutations (Supplementary Fig. 
S1A). As an additional control of NRF2 activity, we analyzed the downstream regulated gene 
product NADP(H) quinone oxidoreductase (NQO1). Fig. 1F shows three representative GBs with 
correlatively low, medium and high levels of NRF2, TAZ and NQO1 proteins. Densitometric 
quantification further demonstrated a statistically significant correlation in the expression of NRF2, 
TAZ and NQO1 proteins (Fig. 1G and 1H). Moreover, there is a positive correlation in the 
expression of NRF2 and TAZ with the proliferation marker ki67 (Supplementary Fig. S1A and 
S1B). Considering the strong correlation observed in prognosis, transcript and protein levels, in the 
following experiments we studied a potential mechanistic connection between NRF2 and TAZ. 
Changes in NRF2 expression modify TAZ levels in tumor explants and cell lines 
Four explants originated from independent GBs were lentivirally-transduced for 7 days with short 
hairpin RNAs, control (shco) or specific for NRF2 knock-down (shNRF2) (Fig. 2A and 2B). 
Efficient knock-down of NRF2 was confirmed at both the mRNA and protein levels to just 10-20% 
of its original expression levels. As expected, NRF2 knock-down led to the down-regulation of the 
bonafide NRF2 target NQO1 but, importantly, also led to a decrease of TAZ transcript and protein 
levels.  
We further extended these observations to the GB cell lines U-373 MG and U-87 MG. In 
agreement with the results obtained in tumor explants, lentiviral knock-down of NRF2 for 7 days in 
U-373 MG cells led to a reduction of NQO1, as a control, as well as WWTR1 and two of its targets 
BIRC5 and CTGF (with subtle changes in CD44) (Fig. 2C and 2D). By contrast, TAZ knock-down 
reduced the expression of WWTR1 and its targets but did not have a significant effect on the mRNA 
levels of NFE2L2 or NQO1. Similar results were found in U-87 MG cells (Fig. 2E and 2F). 
Moreover, a time-course of lentiviral knock-down of NRF2 further demonstrated a progressive 
reduction in transcript and protein levels of NQO1 as expected but also of TAZ (Supplementary 
Fig. S2A and S2B). As additional controls, another shNRF2 lentivirus yielded comparable results 
(Supplementary Fig. S2C and S2D) and ectopic expression of NRF2 in the shNRF2-knocked-
down cells rescued TAZ levels (Supplementary Fig. S2E). These results indicate that NRF2 is 
required for expression of TAZ. 
Then, we used genetic and chemical strategies to upregulate NRF2. Lentiviral over- 
expression of NRF2 for 4 days led to a modest increase in TAZ and NQO1 mRNA and protein 
levels in two primary glioblastomas (GB1 and GB3) (Fig. 3A and 3B) and U-373 MG and U-87 
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MG cells (Supplementary Fig. S3A and S3B). The low effect of NRF2 overexpression might be due 
to the fact that glioma stem cells exhibit basally high NRF2 levels (Zhu et al., 2014b). Therefore, 
we analyzed the effect of NRF2 overexpression in the non-tumorigenic ReNcell stem cell line, 
which exhibits low NRF2 expression (Fig. 3C and Supplementary Fig. S3C). Ectopic expression of 
NRF2 in these cells led to increased levels of control NQO1 protein and mRNA but also TAZ and 
its target CTGF (Fig. 3D and 3E).  
In order to analyze the temporal changes in the NRF2 and TAZ transcriptional signatures, 
we treated these cells with the NRF2 activator sulforaphane (SFN, 15 μM). NRF2 was stabilized 
within the first 3 h of treatment and then slowly decreased to basal levels at 48 h (Fig. 3F). This 
change correlated with a gradual accumulation of NQO1 and TAZ, first at the transcriptional level 
and then at the protein level (Fig. 3F, 3G and 3H). Although WWTR1 gene induction was more 
modest than that for NQO1, at the protein level TAZ also remained significantly elevated for at 
least 48 h (Fig. 3G). Thereafter, CTGF transcript levels augmented slowly in a fashion consistent 
with the TAZ increase, further leading to the accumulation of CTGF protein by 48 h (Fig. 3F and 
3H). These results suggest a mechanistic connection between NRF2 and the TAZ transcriptional 
programme. Thus, a first wave of NRF2-dependent transcriptional activation that included NQO1 
and TAZ (blue area in Fig. 3H) was followed by a second more modest wave where TAZ levels 
were high enough to expression of the CTGF gene (green area in Fig 3H).  
The regulation of WWTR1 by NRF2 is not dependent of the redox state 
NRF2 reinforces the antioxidant defense to tolerate the redox alterations of tumor cells. Therefore, 
we determined if the reduction of WWTR1 expression in NRF2-depleted cells could be attributed to 
a modification of the redox environment. NRF2 was silenced in the four GB explants and the two 
GB cell lines, and the levels of reactive oxygen species (ROS) were measured with the fluorescent 
probe hydroethidine (HE) by flow cytometry. As shown in Fig. 4A, NRF2-depletion did not 
increase ROS levels in any of the cell lines analyzed except U-87 MG, and yet there was a drastic 
reduction of TAZ protein levels, suggesting that the regulation of WWTR1 by NRF2 is redox-
independent. We further analyzed NRF2 knocked-down U-87 MG cells after incubation with the 
membrane permeable glutathione analog monoethylglutathione (GSH-MEE). The combination of 
NRF2 silencing and GSH-MEE exposure led to graded levels of HE fluorescence (Fig. 4B and 4C), 
and again TAZ levels were only dependent on NRF2 expression (Fig. 4D). These results indicate 
that NRF2 regulates TAZ by a redox-independent mechanism. 
The WWTR1 promoter has functional NRF2-binding sites 
We then looked for putative NRF2-regulated AREs in the WWTR1 gene by using the Encyclopedia 
of DNA Elements at UCSC (ENCODE) 
Escoll et al, 2019  7 
 
(http://www.webcitation.org/query?url=https%3A%2F%2Fgenome.ucsc.edu%2F&date=2015-07-
29) of the human genome (Feb. 2009). This database contains experimental data from chromatin 
immunoprecipitation (ChIP) studies of several transcription factors. Although NRF2 is not 
included, we analyzed three other ARE-binding factors, MAFK, MAFF and BACH1, for which 
information is available, and retrieved 9 putative ARE candidates according to the consensus 
sequence for NRF2 binding depicted at the JASPAR database (http://jaspar.genereg.net/) 
(Supplementary Table S1A). As shown in Fig. 5A, some of these AREs are located at 
transcriptionally active chromatin sites, as determined by the presence of DNAse and acetylation 
sensitive regions. Additionally, a similar analysis of the YAP coding gene (YAP1) evidenced three 
putative AREs with high score (Supplementary Table S1A and Supplementary Fig. S4A) and in 
fact, YAP was also down-regulated in NRF2-silenced GBMs (Supplementary Fig. S3B and S4C). 
Focusing our study on TAZ, the nine putative AREs of the WWTR1 gene were further analyzed by 
ChIP assays for endogenous NRF2 in two glioblastoma explants (Fig. 5B and Supplemental Table 
1B). To avoid potential unspecific binding, we further confirmed these results with the 
immunoprecipitation of a V5 tagged-NRF2 construct in HEK293T transfected cells (Supplemental 
Fig. 5A) (McMahon et al., 2003). Immunoprecipitated DNA was analyzed by qRT-PCR with 
specific primers surrounding the putative AREs (Supplementary Table S2). At least 3 of the 9 
putative AREs analyzed, termed ARE2, ARE5 and ARE6, exhibited high enrichment although not 
as strong as the positive controls HMOX1 and NQO1 (Fig. 5B, 5C and Supplementary Table 
S1B). No enrichment was detected with specific primers for ACTB or for an upstream region of 
NQO1 that does not contain an ARE (NQO1*) (Pajares et al., 2016), carried as negative controls. 
We chose ARE2, which is located in the 5'-regulatory region, and shows the lowest enrichment of 
the three AREs in the primary GBs for additional characterization in reporter luciferase assays. 
Three tandem nucleotide sequences of ARE2-WT or ARE2-mutated in the most conserved T and G 
residues were cloned in the promoter region of a luciferase reporter (Fig. 5D). Because GBs were 
difficult to transfect, we used U-87 MG and U-373 MG cells. We found that NRF2 interference 
reduced the luciferase expression of ARE2-WT reporter while the ARE2-mutated reporter did not 
respond at all (Fig. 5E). Additionally, HEK293T cells transiently co-transfected with these 
reporters plus increasing amounts of NRF2-ΔETGE-V5 exhibited increased luciferase activity of 
ARE2-WT but not ARE2-mutated (Supplementary Fig. S5B). Altogether, these results indicate 
that NRF2 binds and activates specific ARE sequences in the WWTR1 gene promoter. 
TAZ rescues neurosphere growth of NRF2 knocked-down glioma stem cells 
Cancer stem cells are responsible for anticancer drug resistance and tumor relapse. Two different 
glioblastoma explants, GB1 and GB3, and both U-373 MG and U-87 MG cell lines can be grown as 
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glioma stem cells in the appropriate medium as floating spherical colonies, termed neurospheres 
(Gargini et al., 2015; Gargini et al., 2016; Hardee et al., 2012). Therefore, we next tested the effect 
of depleting either NRF2 or TAZ under neurosphere growth conditions. Lentiviral knock-down of 
NRF2 or TAZ yielded GB1 (Fig. 6A- 6C), GB3 (Fig. 6D- 6F), U-87 MG cells (Supplementary 
Fig. S6A and S6B) and U-373 MG cells (Supplementary Fig. S6C and S6D) unable to grow as 
neurospheres. Moreover, glioma stem cell frequency was decreased as determined in limiting 
dilution assays (Supplementary Table S3A), demonstrating the importance of both proteins for 
cancer stem cell growth. In rescue experiments, NRF2 knock-down was combined with ectopic 
retroviral expression of TAZ in glioblastomas explants GB1 (Fig. 6G- 6I), GB3, (Fig. S6J- 6L), U-
87 MG (Supplementary Fig. 6E- 6H) and U-373 MG (Supplementary Fig. 6I and 6H). As 
shown in Supplementary Fig. 6F, overexpression of TAZ led to the induction of the TAZ-
regulated genes BIRC5 and CD44 despite NRF2-knockdown. Regarding neurosphere growth (Fig. 
6H, 6I, 6K, 6L, Supplementary Fig. 6G- 6J), TAZ also partially rescued both the number of 
neurospheres and the number of cells and also, glioma stem cell frequency in limiting dilution 
assays (Supplementary Table S3B). Altogether, these results point to TAZ as an instrumental 
effector of NRF2-driven cancer stem cell growth. 
The NRF2/TAZ axis is essential for tumorigenesis of GBs  
We assessed the tumorigenicity of NRF2- or TAZ-knocked down glioma stem cells in 
xenotransplanted athymic mice. The growth of subcutaneous xenografts was substantially reduced 
by silencing the expression of either transcription factor in U-87 MG cells (Fig. 7A, and 7B) or U-
373 MG cells (Supplementary Fig. S7A and S7B). In mice intracranially inoculated with U-87 MG 
cells, the survival rate was roughly 30 days and increased up to 40 and 60 days by selective 
silencing of NRF2 or TAZ, respectively (Fig. 7C).  
In order to better reproduce the human pathology, we orthotopically implanted GB3 primary tumor 
cells and monitored tumor formation in the brain by magnetic resonance imaging (Fig. 7D and 7E). 
These cells developed tumors that, like in humans, exhibited heterogeneous and diffused borders 
with peritumoral and systemic brain edema (Supplemental Fig. 7C). Primary GB3 cells developed 
tumors before 10 days. However, when the same cells were knocked-down for expression of NRF2 
or TAZ, they did not generate tumors at least after 30 days (Fig. 7D and 7E).  
In additional rescue experiments we tested the relevance of TAZ as an effector of NRF2-mediated 
tumorigenicity. TAZ over-expression in control cells expressing basal levels of NRF2 did not lead 
to a statistically significant increase in tumor volume. However, TAZ over-expression restored by 
20% the growth of tumors derived from NRF2- knocked-down U-87 MG (Fig. 7F and 7G) and U-
373 MG cells (Supplementary Fig. S7D and S7E). In intracranial tumors, mouse life expectancy 
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decreased from 45 days in the control NRF2-silenced cells to 35 days in the TAZ rescued cells (Fig. 
7H). These results indicate that TAZ is one effector of NRF2-induced tumorigenicity in GBs.  
DISCUSSION 
An effective therapy for GB would be possible if its molecular pathology was better known. In the 
TCGA database we found that somatic mutations in the NRF2 and Hippo pathways are rare (Fig. 
1A) whereas EGFR and PTEN mutations are very frequent. However, NRF2 levels were high in 
these glioma stem cells compared to the non- tumorigenic neural stem cell line ReNcell, therefore 
demonstrating an abnormal up- regulation of NRF2 in GBs. These results suggest that NRF2 
activation might be connected with subversion of signaling pathways that impinge on EGFR or 
PTEN. We have previously reported that chemical or genetic inhibition of PTEN in prostate and 
endometrial cancers leads to the activation of NRF2. This is due to the constitutive inhibition of 
glycogen synthase kinase-3 (GSK-3), thus relieving NRF2 from the GSK3/beta-TrCP ubiquitin-
proteasome pathway (Cuadrado, 2015; Rada et al., 2011; Rada et al., 2012).  
We also found that the transcript levels of WWTR1 exhibit the same trend as NRF2 to be increased 
in GBs, suggesting that they might be mechanistically connected. Genetic (shRNA and NRF2 
overexpression) and chemical (sulforaphane) manipulation of NRF2 indicated that the transcript 
and protein levels of TAZ and TAZ-dependent genes are, at least in part, governed by the levels of 
NRF2. Because TAZ responds to stress signals, we analyzed if the changes in TAZ levels could be 
attributed to an indirect effect that might result from variations in oxidative stress when NRF2 is 
silenced. However, under cancer stem cell growth conditions, the depletion of NRF2 did not lead to 
measurable redox changes except in U-87 MG cells. Although at first glance this finding may seem 
surprising, it should be noted that up-regulation of NRF2 not only provides redox tolerance, but also 
a metabolic switch towards the pentose phosphate pathway that leads to NADPH and ribose 
production as precursors for cell growth and division. This metabolic reprograming may be 
particularly important in tumors with low growth rate where redox alterations are not so relevant 
and yet need growth precursors. In any case, the fact that U- 87 MG submitted to GSH-MEE did not 
alter TAZ levels further suggests that NRF2 can regulate TAZ in a redox-independent manner.  
We identified several putative AREs in the WWTR1 gene promoter. The most potent ARE located 
at a highly DNAse-sensitive and H3K27-acetylated region, suggesting that it is accessible to the 
transcriptional machinery, but was not as potent as the canonical ARE of HMOX1, which is rapidly 
induced upon NRF2 activation. Several studies have analyzed the NRF2 transcriptional signature by 
microarray or RNA-sequencing approaches (Chorley et al., 2012; Namani et al., 2017). From these 
studies it is possible to distinguish grades of gene response to NRF2, from the most sensitive ones, 
related to the classical redox control, to others that need more time and persistent presence of 
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NRF2. For instance, genes involved in metabolic reprograming or autophagy appear to require 
persistent exposure to NRF2 (Mitsuishi et al., 2012; Pajares et al., 2016). Therefore, we suggest that 
a low but persistent level of TAZ expression elicited by NRF2 may contribute to promotion of 
tumorigenesis in GBs. Considering that cell specific epigenetic changes may hinder regulatory 
sequences, the relevance of this NRF2/TAZ axis needs to be evaluated under the particular 
conditions of each cellular model.  
Glioma stem cells were strictly dependent of NRF2 expression to develop spheroids and tumors, in 
agreement with a previous study (Ji et al., 2013), as NRF2 knocked-down xenografts exhibited a 
dramatic reduction in tumor formation following subcutaneous and intracranial inoculation. 
Interestingly, TAZ overexpression partially restored stem cell growth and tumorigenicity, further 
demonstrating that TAZ is an effector of NRF2 to support stemness. However, this effect was 
modest, suggesting the NRF2 uses additional pathways to elicit tumorigenicity. In fact, besides it 
role in redox regulation, recent studies further suggest that NRF2 regulates pathways involved in 
tumorigenesis and self-renewal such as Shh ((Jang et al., 2016), Wnt (Rada et al., 2015) and Notch 
(Wakabayashi et al., 2014).  
It would be expected that the Hippo pathway is silent in cancer cells for TAZ to remain 
transcriptionally active. However, among the 721 gliomas analyzed, only 4.4% exhibited mutations 
that might potentially inactivate the Hippo pathway (Fig. 1A and (Sanchez-Vega et al., 2018)). 
Moreover, TAZ expression was increased in these tumors, therefore indicating additional 
mechanisms for TAZ up-regulation. Our study identifies NRF2 as one such mechanism, hence 
probably counteracting repressor signals and providing a tumor growth advantage.  
An efficient therapy for GBs must consider that high NFE2L2 and WWTR1 levels are predictors of 
chemoresistance (Rocha et al., 2016; Tian et al., 2015). Indeed, overexpression of NRF2 and TAZ 
correlated with resistance to the alkylating agent temozolomide, which is the gold standard 
treatment for gliomas. At this time, no selective NRF2 inhibitor is available, but at least as a proof-
of-concept, we found that genetic knock- down of NRF2 drastically reduced TAZ transcriptional 
signature and stemness in gliomas. Contrary to EGFR and PTEN, the observation that NFE2L2 is 
not frequently mutated in GBs and that yet NRF2 is strictly necessary to sustain tumorigenesis of 
glioblastoma stem cells provides a rationale to use drugs that could modulate NRF2 activity as a 
downstream effector of these mutated genes.  
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EXPERIMENTAL PROCEDURES 
Glioma database analyses 
LGG and GB datasets were retrieved from The Cancer Genome Atlas 
(https://www.ncbi.nlm.nih.gov/pubmed/27157931) and analysed for NFL2L2 and WWTR1 
expression (https://xenabrowser.net/; https://www.ncbi.nlm.nih.gov/pubmed/24120142). Mutations 
in the Hippo pathway or other signaling genes were also analysed from the TCGA datasets, which 
were downloaded respectively from cBioPortal (http://www.cbioportal.org/) and TCGA databases 
(http://tcga-data.nci.nhi.gov/docs/publications/lgggbm_2015), using the UCSC cancer browser. 
Cell culture and reagents 
The validated cell lines HEK293T, U-373 MG and U-87 MG were maintained in Dulbecco's 
Modified Eagle Medium supplemented with 10% fetal bovine serum. Human GBs explants were 
kindly supplied by Dr Marta Izquierdo (Centro de Biología Molecular “Severo Ochoa” - 
Autonomous University of Madrid). Most experiments with these explants were performed with 
GB1 and GB3 because they exhibit the highest proliferative rates. All experiments were conducted 
under neurosphere culture conditions as described previously (Gargini et al., 2015). Inmortalized 
human neural stem cells derived from ventral mesencephalon of fetal brain (ReNcell) were plated 
onto Corning® Matrigel® hESC-Qualified Matrix (CORNING) and maintained in Neurobasal 
medium (Gibco) containing 2% B27 Supplement (Gibco) (v/v), 20 ng/ml recombinant human EGF 
(Peprotech), 20 ng/ml recombinant human basic FGF (Peprotech), 100 U/ml 
Penicillin/Streptomycin (Life Technologies) and 1% Amphotericin b solution (Lonza) in 5% CO2 at 
37°C conditions. Sulforaphane (SFN) and GSH-MEE were purchased from Sigma-Aldrich. 
Limiting dilution assays were performed essentially as described in (Hu and Smyth, 2009). The 
final data and the statistical significances were calculated using the Extreme Limiting Dilution 
Analysis (ELDA) software (http://bioinf.wehi.edu.au/software/limdil/ index.html) (Hu and Smyth, 
2009). 
Immunoblotting 
This protocol was performed as described in (Pajares et al., 2016). Briefly, cells were homogenized 
in lysis buffer (TRIS pH 7.6 50 mM, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA and 1% SDS) and 
samples were heated at 95°C for 15 min, sonicated and pre-cleared by centrifugation. Proteins were 
resolved in SDS-PAGE, transferred to Immobilon-P (Millipore) membranes and proteins of interest 
were detected with the following primary antibodies: NRF2 (homemade and validated in (Rada et 
al., 2011)), NQO1 (ab2346, Abcam), GAPDH (CB1001, Merck Millipore), YAP/TAZ (8418, Cell 
Signaling Techonology); LaminB (sc-6217, Santa Cruz Biotechnology). Proper peroxidase-
conjugated secondary antibodies were used for detection by enhanced chemiluminescence (GE 
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Healthcare). 
Lentiviral and retroviral vector production and infection 
Pseudotyped lentiviral vectors were produced in HEK293T cells transiently co-transfected with 10 
µg of the corresponding lentiviral vector pWXL, 6 µg of the packaging plasmid pSPAX2 (12260, 
Addgene) and 6 µg of the VSV-G envelope protein plasmid pMD2G (12259, Addgene) using 
Lipofectamine Plus reagent according to the manufacturer’s instructions (Invitrogen). Retrovirus 
supernatant was prepared by transfection of phoenix-Ampho cells (Garry Nolan, Baxter Laboratory 
in Genetic Pharmacology, Department of Microbiology and Immunology, Stanford University, 450 
Serra Mall) with 5 g of each plasmid using Lipofectamine Plus. Lentiviral vector shRNA control 
(shco), several shNRF2 and shTAZ were purchased from Sigma-Aldrich (MISSION shRNA). The 
lentiviral vector pWPXL-NRF2-WT (NRF2) was homemade using as expression vector pWPXL 
(control) (12257, Addgene). The retroviral vectors used were: pBabePuro (1764, Addgene) and 
pBabePuroTAZ-WT (TAZ) (generous gift from Kun-Liang Guan). Cells were infected in the 
presence of 4 g/ml polybrene (Sigma-Aldrich) and selected with 1 g/ml puromycin (Sigma-
Aldrich). 
Chromatin immunoprecipitation (ChIP) assay 
This protocol was performed as described in (Pajares et al., 2016). Briefly, cells derived from two 
different glioblastoma explants were grown under stemness conditions and allowed to form 
neurospheres. Neurospheres were trypsinized and fixed with 1% formaldehyde. For HEK293T, 
cells were transfected with plasmid pcDNA3-NRF2-ΔETGE-V5 encoding a NRF2 cDNA that lacks 
the high-affinity binding site for KEAP1 and contains a V5 tag. DNA complexes were 
immunoprecipitated with either anti-NRF2 (homemade) and rabbit anti-IgG (ab37415, Abcam) for 
glioblastoma explants or anti-V5 (37-7500, Invitrogen) and mouse anti-IgG (ab18413, Abcam) 
antibodies for transfected HEK293T cells. qRT-PCR was performed with the primers shown in 
Supplementary Table S2. Samples from at least 3 independent ChIPs were analyzed. 
Analysis of mRNA levels 
Total RNA extraction and qRT-PCR were done as detailed in (Rojo et al., 2010). Primer sequences 
are shown in Supplementary Table S4. Data analysis was based on the CT method, with 
normalization of the raw data to the housekeeping gene GAPDH (Applied Biosystems). All PCRs 
were performed from triplicate samples. 
Xenograft and intracranial tumorigenicity assays 
Balb/c athymic Nude-Foxn1nu mice (Harlan) were used for the xenograft (eight-week-old males) 
and intracranial (six-week-old females) tumor assays. U-373 MG or U-87 MG cells (106 cells in 0.1 
ml PBS) were inoculated subcutaneously. For xenografts, tumor growth was examined every 5 days 
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for up to 65 days. Tumor volume = π/6 × (mean diameter)3 (Escoll et al., 2017). U-87 MG (105 cells 
in 2 µl PBS) or GB3 explant glioblastoma cells (2x105 cells in 2µl PBS with 5 ng/µl recombinant 
human basic FGF and 5 ng/µl recombinant human EGF, both from Peprotech) were inoculated 
intracranially at the right hemisphere (1 mm anterior, 1.8 mm lateral to bregma and 3 mm intra-
parenchymal). The Intracranial tumor assay protocol was performed as described previously 
(Gargini et al., 2016). 
Magnetic resonance imaging (MRI) 
MRI experiments were performed on a Bruker AVANCE III system (Bruker Medical GmbH®) 
using a 7.0-T horizontal superconducting magnet, equipped with a gradient insert (60 mm inner 
diameter) with a maximum intensity of 360 mT/m and a 1H selective surface coil (23 mm 
diameter). For assessing the tumor growth, contrast enhanced T1-weighted (CE-T1W) imaging was 
acquired after the intraperitoneal administration of 0.3M-Gd- diethylenetriaminepentaacetic acid 
(Magnevist®) at a dose of 0.2 mmol/kg. Images were obtained with a spin-echo sequence and the 
following parameters: repetition time = 250 ms, echo time = 10 ms, averages = 6, acquisition matrix 
= 256 × 256, in-plane resolution of 78 × 78 μm2, slice thickness = 1.0 mm and 10 slices in axial 
orientation (total acquisition time of 4.8 min). For assessing the edema, T2-weighted (T2W) spin-
echo images were acquired with a rapid acquisition with relaxation enhancement sequence and the 
following parameters: repetition time = 2500 ms, echo time = 45 ms, averages = 5, RARE factor = 
8, acquisition matrix = 256 × 256, in-plane resolution of 78 × 78 μm2, slice thickness = 1.0 mm and 
10 slices in axial orientation (total acquisition time of 5 min). During the procedure, the mice are 
anesthetized and their vital signs are controlled. Tumor volumes were measured from anatomical 
CE-T1W images with ImageJ software.  
Immunohistochemistry 
Four m-thick sections of paraffin-embedded samples of glioblastoma tissue from patients treated 
at the Instituto de Investigación Sanitaria La Paz (IdiPaz, Madrid, Spain) were arrayed in a 
collection of three tissue microarray slides. Taken together, these slides encompassed 26 good 
tumor cores. Sections were deparaffinized and rehydrated in water, and antigen retrieval was carried 
out by incubation in 1 mM EDTA, 0.05% Tween 20, pH 8.0 at 50°C for 45 min. Endogenous 
peroxidase and nonspecific antibody reactivity was blocked with peroxidase blocking reagent 
(Dako) at room temperature for 15 min. The sections were then incubated for 60-90 min at 4°C with 
the corresponding peroxidase conjugated primary antibodies for NRF2 (PA1-38312, Thermo Fisher 
Scientific), TAZ (HPA007415, Sigma-Aldrich), NQO1 (ab34173, Abcam), ATRX (DIA-AX1, 
Dianova), IDH1 (DIA-H09, Dianova), ki67 (M7240, Dako) and developed with 3,3′-
diaminobenzidine (DAB). Negative controls with goat serum replacing the primary antibody were 
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used. The slides were mounted with DPX (VWR International). Detection was performed with the 
Envision Plus Detection System (Dako). All tumors were negative for IDH1 and ATRX mutations, 
therefore confirming that according to histological classification they were GBs. Densitometric 
quantification was done using macros of the ImageJ software. 
Luciferase reporter generation and luciferase assay 
Oligonucleotides with 3 tandem repetitions of the putative ARE2-WT and ARE2-mutaded were 
cloned as detailed in Supplementary Table S5 and previously described (Pajares et al., 2018). 
Cells were transiently transfected with the expression vectors ARE2-WT, ARE2-mutated or 
positive control ARE-Luc. pTK-Renilla was also transfected as an internal control. Luciferase 
assays were performed with the Dual- Luciferase Reporter Assay System (Promega, E1910) as 
previously described (Rada et al., 2012). 
Flow cytometry determination of reactive oxygen species. 
Intracellular reactive oxygen species (ROS) were detected in a FACScan flow cytometer (Becton-
Dickinson) with hydroethidine (HE) (ThermoFisher Scientific), which upon oxidation emits orange 
fluorescence (BP 575/24 nm).  Cells were incubated for 1 h at 37°C with 2 M HE and then 
detached from the plate, washed once with cold PBS, and analyzed immediately. 
Statistical analyses 
Data are presented as mean ± S.D. (standard deviation) or S.E.M. (standard error of the 
mean) as indicated in each case. Statistical assessments of differences between groups were 
analyzed using GraphPad Prism 5 software by the unpaired Student’s t-test. For the scatter plots, the 
Pearson correlation coefficient (R) and the p-value associated with this coefficient were analyzed. 
Statistically significant differences in Kaplan-Meier survival curves were calculated with the log-
rank test. 
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LEGENDS TO FIGURES 
Figure 1. Analysis of NFE2L2 and WWTR1 expression in GBs. (A- E) Analysis of NFE2L2 and 
WWTR1 expression in 721 gliomas from the TCGA database. (A) Analysis of somatic mutations in 
genes of the Hippo pathway, KEAP1 and NFE2L2. (B) Analysis of the most frequent somatic 
mutations in gliomas. (C) NFE2L2 and WWTR1 mRNAs are increased in GBs compared to LGGs. 
p-values for differences between groups are indicated in each graph and calculated using Student’s 
t-test. (D) Scatter plot showing positive correlation between NFE2L2 and WWTR1 expression. The 
Pearson correlation coefficient (R) and the p-value associated with this coefficient are indicated. (E) 
Kaplan-Meier survival curves of patients with gliomas. Patients were stratified in two groups using 
NFE2L2 or WWTR1 Z-score values. Statistically significant differences in survival between groups 
were calculated using the log-rank test. (F- H) NRF2 and TAZ protein levels are positively 
correlated in GBs. A tissue array of 26 glioblastomas was analyzed. (F) Sections of three 
representative tumors with antibodies against NRF2, TAZ and NQO1 (scale bar, 50 μm). (G, H) 
Scatter plot showing positive correlation between densitometric quantification of DAB-staining (as 
percentage of area) of NRF2 and TAZ (G) or NRF2 and NQO1 (H). The Pearson correlation 
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coefficient (R) and the p-value associated with this coefficient are indicated. See also 
Supplementary Figure S1. 
Figure 2. NRF2 knocked-down cells exhibit decreased TAZ levels. (A, B) Four human 
glioblastoma explants (GB1, GB2, GB3 and GB4) were transduced with a lentivirus encoding 
control shRNA (shco) or human shNRF2. (A) mRNA levels of NFE2L2 and WWTR1 were 
determined by qRT-PCR and normalized by GAPDH. Data are mean ± S.D. (n = 3). Statistical 
analysis was performed with the Student’s t-test. **p ⩽ 0.01. (B) Representative immunoblot 
analysis of NRF2, TAZ, NQO1 and GAPDH and LaminB as loading controls (n = 3). (C, D), U-373 
MG and (E, F) U-87 MG glioblastomas cell lines were transduced with lentiviral vectors containing 
shcontrol (shco), human shNRF2 or human shTAZ. (C, E) mRNA levels of NFE2L2, NQO1, 
WWTR1, BIRC5, CTGF and CD44 were determined by qRT-PCR and normalized by GAPDH. Data 
are mean ± S.D. (n = 3). Statistical analysis was performed with the Student’s t-test. **p ⩽ 0.01; 
(NS, indicated not statistically significant). (D, F) Representative immunoblot analysis of NRF2, 
TAZ, NQO1 and GAPDH and LaminB as loading controls (n = 4). Similar results were obtained 
with a different shNRF2 (Supplementary Fig. S2). 
Figure 3. Genetic and pharmacological up-regulation of NRF2 increases TAZ levels. (A, B) GB1 
and GB3 glioblastoma cells were transduced with empty vector or lentiviral vector for 
overexpression of NRF2. (A) Representative immunoblot analysis of NRF2, TAZ, NQO1 and 
GAPDH as a loading control (n = 3). (B) Messenger RNA (mRNA) levels of WWTR1 were 
determined by qRT-PCR and normalized by GAPDH. Data are presented as mean ± S.D. (n = 3) 
**p ⩽ 0.01 according to a Student’s t-test. (C) Representative immunoblot analysis of NRF2, TAZ, 
GAPDH and LaminB as loading controls in ReNcell, GB1 and GB3. (D, E) ReNcell were 
transduced with empty vector or lentiviral vector for overexpression of NRF2. (D) Representative 
immunoblot analysis of NRF2, TAZ, NQO1, CTGF and GAPDH as a loading control (n = 3). (E) 
Messenger RNA (mRNA) levels of NQO1, WWTR1 and CTGF were determined by qRT-PCR and 
normalized by GAPDH. Data are presented as mean ± S.D. (n = 3) **p ⩽ 0.01 according to a 
Student’s t-test. (F- H) ReNcell cells were treated with sulforaphane (SFN) (15 μM) for the 
indicated times. (F) Representative immunoblot analysis of NRF2, TAZ, NQO1, CTGF, GAPDH 
and LaminB as loading controls (n = 3). (G) Densitometric quantification of TAZ levels 
representative blots from (F) relative to GAPDH and LaminB levels. Data are mean ± S.D. (n = 3) 
*p ⩽ 0.05 according to a Student’s t-test. (H) Messenger RNA (mRNA) levels of NQO1, WWTR1 
and CTGF were determined by qRT-PCR and normalized by GAPDH. Data are presented as mean 
± S.D. (n = 3) **p ⩽ 0.01 according to a Student’s t-test. The blue area represents the wave of 
NRF2 dependent transcription and the green area depicts a second wave that involves NRF2 and 
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also TAZ-dependent transcription. The time for transition from one wave to the other was chosen 
arbitrarily. See also Supplementary Figure S3. 
Figure 4. The regulation of WWTR1 by NRF2 is not dependent of the redox state. (A) U-87 MG 
and U-373 MG glioblastoma cells and four human glioblastoma explants (GB1, GB2, GB3 and 
GB4) were transduced with lentiviral vectors containing shcontrol (shco) or human shNRF2 and 
changes in intracellular ROS were determined by HE staining (n = 3). (B- D) U-87 MG 
glioblastoma cells were transduced with lentiviral vectors containing shco or human shNRF2 and 
treated with GSH-MEE (10 mM, 16 h). (B, C) Flow cytometry analysis of shNRF2-induced 
intracellular ROS production in HE stained cells. A representative sample of 10,000 cells is shown 
for each condition. (D) Representative immunoblot analysis of NRF2, TAZ and GAPDH as a 
loading control (n = 3). 
Figure 5. The WWTR1 promoter has functional NRF2-binding sites. (A) Representative scheme of 
the gene WWTR1 encoding TAZ. Regions enriched in acetylated histone H3 lysine 27 (H3K27ac) 
are shown in blue and regions sensitive to DNase are represented as dark boxes. Experimental 
sequences reported to bind MAFK, MAFF and BACH1 factors were analyzed for the presence of 
AREs (ARE 1-9). (B, C) ChIP analysis of putative AREs found in (A) using the anti-NRF2 
antibody vs. a control IgG in glioblastoma explant cells GB1 (B) and GB3 (C). (D) Luciferase 
reporter constructs used for assessment of wild type (WT) or mutated ARE2 functionality in 
pGL3basic vector. (E) U-87 MG (left) and U-373 MG (right) glioblastomas cell lines were 
transduced with lentiviral vectors containing shco and human shNRF2 and transfected with wild 
type or mutated ARE2. Luciferase activity was measured 24 h after transfection. Luciferase 
activities were normalized to renilla activity. Results are shown relative to control and are mean ± 
S.D. (n = 3). **p ⩽ 0.01 according to a Student’s t-test. See also Supplementary Table S1, Table 
S2, Table S5, Supplementary Figure S4 and Figure S5. 
Figure 6. Ectopic expression of TAZ rescues neurosphere growth of NRF2-knocked-down glioma 
stem cells GB1 (A- C) and GB3 (D- F) cells were transduced with lentivirus encoding shco, human 
shNRF2 or human shTAZ. (A, D) Representative immunoblot analysis of NRF2, TAZ and GAPDH 
as a loading control (n = 3). (B, E) Representative images of tumor neurosphere formation. Scale 
bar, 100 μm. (C, F) Quantification of the number of secondary neurospheres or the number of cells 
represented as percentage relative to shco. Data presented mean ± S.D. (n = 3) **p ⩽ 0.01 
according to a Student’s t-test. GB1 (G- I) and GB3 (J, L) cells were transduced with empty 
retrovirus as control or a retrovirus expressing TAZ, and then with a lentivirus expressing shco or 
shNRF2. (G, J) Representative immunoblot analysis of NRF2, TAZ and GAPDH as a loading 
control (n = 3). (H, K) Representative images of tumor neurosphere formation. Scale bar, 100 μm. 
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(I, L) Quantification of the number of secondary neurospheres and the number of cells represented 
as a percentage relative to control-shco. Data are presented as mean ± S.D. (n = 3) **p ⩽ 0.01 
according to a Student’s t-test. See also Supplementary Figure S6 and Supplementary Table S3. 
Figure 7. Ectopic expression of TAZ rescues tumorigenesis of NRF2-knocked-down glioma stem 
cells. (A, B) U-87 MG glioblastoma cells were transduced with a lentivirus encoding shco, human 
shNRF2 or human shTAZ and implanted subcutaneously in athymic mice. (A) Growth curves of 
xenograft tumors. Data are presented as mean ± S.E.M. (n = 4). *p ⩽ 0.05 according to a Student’s 
t-test. (B) Upper panel, representative tumors of each experimental condition at the end point (scale 
bar, 1 cm); lower graph, quantification of the final tumor volume. Data are presented as mean ± 
S.E.M. (n = 4). *p ⩽ 0.05 according to a Student’s t-test. (C) Kaplan-Meier survival curves of mice 
orthotopically implanted in the brain. Log-rank test between shco and shNRF2 is indicated (n = 6). 
(D, E) GB3 glioblastoma explant cells were transduced with a lentivirus encoding shco, human 
shNRF2 or human shTAZ and orthotopically implanted in the brain in athymic mice. (D) 
Representative image of T1 MRI of each experimental condition after 10, 20 and 30 days post-
surgery. Green arrows indicate the tumor in shco or the injection scar in shNRF2 or shTAZ. (E) 
Growth curves of brain tumors. Data are presented as mean ± S.E.M. (n = 6) **p ⩽ 0.01 according 
to a Student’s t-test. (F, G) U-87 MG cells were transduced with empty retrovirus or a retrovirus 
expressing TAZ and then with lentivirus encoding shco or shNRF2 and implanted subcutaneously 
in athymic mice. (F) Growth curves of xenograft tumors. Data are presented as mean ± S.E.M. (n = 
4). *p ⩽ 0.05 according to a Student’s t-test. (G) Upper panel, representative tumors of each 
experimental condition at the end point (scale bar, 1 cm); lower graph, quantification of the final 
tumor volume. Data are presented as mean ± S.E.M. (n = 4). *p ⩽ 0.05 according to a Student’s t-
test. (H) Kaplan-Meier survival curves of mice orthotopically implanted in the brain. Log-rank test 
between control/shNRF2 and TAZ/shNRF2: p = 0.056 (n = 5). See also Supplementary Fig. S7.  
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SUPPLEMENTAL MATERIAL 
Supplemental Table S1. (A) Putative Antioxidant Response Elements (AREs) in the 
WWTR1 and YAP1 genes found the ENCODE data base of ChIP data for 
MAFK/MAFF/BACH1. A bioinformatics analysis was used to identify putative sites with a 
relative score higher than the 80% (24). The table also shows the max score, the 
localization in the human genome and ARE sequences with the most relevant bases for 
binding of the NRF2/MAF heterodimer in bold. The table also shows the negative control 
ARE (ACTB and NQO1*) and positive control ARE (HMOX-1 and NQO1). (B) 
Independent ChIP assays in GB1, GB3 and HEK293T cells, similar to those shown in Fig. 
5 and Supplemental Fig. S5. 
A     
Gene 
Localization of ARE site 
in the human genomic 
Max score Relative score Sequence 
WWTR1 ARE1 chr3: 149435325-149435336 11.34 0.814 GTGCCAGAGCA 
WWTR1 ARE2 chr3: 149378461-149378450 15.97 0.925 GTGACTCAGCT 
WWTR1 ARE3 chr3: 149365723-149365712 13.15 0.857 ATGATTATGCA 
WWTR1 ARE4 chr3: 149365892-149365903 13.84 0.874 ATGTCTAAGCA 
WWTR1 ARE5 chr3: 149299667-149299656 13.44 0.864 ATGAGTCTGCA 
WWTR1 ARE6 chr3: 149294176-149294165 15.16 0.905 ATGAGACAGCA 
WWTR1 ARE7 chr3: 149258004-149258015 13.94 0.876 ATGATGCAGCA 
WWTR1 ARE8 chr3: 149254494-149254483 13.36 0.862 CTGACTAAGCC 
WWTR1 ARE9 chr3: 149230221-149230232 15.04 0.902 CTGAGTGAGCG 
ACTB chr7:5570750-5570824 – – None 
NQO1* chr16:69763868-69764006 – – None 
HMOX-1 chr22:35773158- 35773147 18.97 0.997 GTGACTCAGCA 
NQO1 chr16:69760919-69760908 18.97 0.997 GTGACTCAGCA 
YAP1 ARE1 chr11:102009509-102009498 11.72 0.823 ATGACTCAGAT 
YAP1 ARE2 chr11:102062347-102062358 11.58 0.819 GTGACTCATCT 
YAP1 ARE3 chr11:102097615-102097626 11.58 0.819 GTGACTCACCT 
 
 
 
B 
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 GB1 GB3 HEK293T 
Gene 
ChIP 2 ChIP 2 ChIP 2 ChIP 3 
IgG NRF2 IgG NRF2 IgG V5 IgG V5 
WWTR1 ARE1 1.0 1.6 1.0 1.1 1.0 2.0 1.0 1.5 
WWTR1 ARE2 1.0 6.1 1.0 1.9 1.0 5.7 1.0 5.4 
WWTR1 ARE3 1.0 2.2 1.0 1.2 1.0 1.3 1.0 1.3 
WWTR1 ARE4 1.0 1.5 1.0 0.9 1.0 1.2 1.0 1.2 
WWTR1 ARE5 1.0 3.5 1.0 5.1 1.0 5.5 1.0 6.1 
WWTR1 ARE6 1.0 4.4 1.0 4.0 1.0 3.3 1.0 1.8 
WWTR1 ARE7 1.0 2.6 1.0 1.3 1.0 2.3 1.0 2.2 
WWTR1 ARE8 1.0 1.5 1.0 4.1 1.0 1.6 1.0 1.3 
WWTR1 ARE9 1.0 10.3 1.0 1.2 1.0 1.9 1.0 1.8 
ACTB 1.0 1.6 1.0 1.1 1.0 1.1 1.0 1.3 
NQO1* 1.0 2.2 1.0 1.1 1.0 2.0 1.0 1.0 
HMOX-1 1.0 7.6 1.0 19.3 1.0 130.4 1.0 266.2 
NQO1 1.0 32.9 1.0 79.3 1.0 39.9 1.0 58.4 
Supplemental Table S2. Oligonucleotides used for ChIP. 
Gene Forward Sequence 5´-3´ Reverse Sequence 5´-3´ 
WWTR1 ARE1 GCACCAGAGGGCATACATCT AACCACACCATCAGGAAAGC 
WWTR1 ARE2 AATCCTGTGGGGTGGGTACT CAGGTACTGCCCGTAAGAGG 
WWTR1 ARE3 TTCCAGGAAAAACAGGATGG GAGGCTCCAGAACCTCAATG 
WWTR1 ARE4 AATGAAGGCTGGGTGTTCAG TCAAAAACACACCCTCAGCA 
WWTR1 ARE5 CCTGATTTGGCTCATCTGCT AGCAGCCATGTGAAAGGTCT 
WWTR1 ARE6 AGTGAAGCCAGGAAGGAGGT CACTTCCCAAACCCAGGATA 
WWTR1 ARE7 TTCCAGCTGTAGGTGCCTTT CATGAGTCCCTGTGAGCAAA 
WWTR1 ARE8 ATTCAGCCCTGCTTTTACCC CCCTCTTTTCTCGTCCCTGT 
WWTR1 ARE9 CGCGGAGAAATTATCTGCTT CTTTCTCCTTCCCCCTTCAG 
ACTB CACCCAGCACATTTAGCTAGCTGA TTCAGAGCAACTGCCCTGAAAGCA 
NQO1* TCTCAGTTTTTGCCCTTATTTAA TAAAAAGTAGAGTGGTTGGAGTGATGACG 
HMOX-1 CCCTGCTGAGTAATCCTTTCCCGA ATGTCCCGACTCCAGACTCCA 
NQO1 TGCACCCAGGGAAGTGTGTTGTAT CCCTTTTAGCCTTGGCACGAAA 
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Supplemental Table S3. (A, B) Glioma stem cell frequency of GB1 and GB3 cells as 
determined by limiting dilution analysis. A serial dilution of 16,000 to 60 cells per well 
were analyzed for neurosphere formation after 5 days. The glioma stem cell frequency was 
determined by ELDA (n = 8). (A) Cells were transduced with lentiviruses encoding shco, 
human shNRF2 or human shTAZ. (B) Cells were transduced with empty retrovirus as 
control or a retrovirus expressing TAZ, and then with a lentivirus expressing shco or 
shNRF2. See also Fig. S6. 
A   
Glioma stem cell frecuency 
    p-value  
 Lower Estimate Upper shco-shNRF2 shco-shTAZ  
shco 2413 1538 980   
G
B
1
 shNRF2 19123 11333 6716 1.23x10
-8  
shTAZ 23811 13705 7889  1.08 x 10-9 
shco 3052 1937 1229   
G
B
3
 shNRF2 120052 39058 12708 3.48x10
-10  
shTAZ 867335 123437 17568  1.54 x 10-12 
 
B   
Glioma stem cell frecuency 
  p-value  
 
Lower Estimate Upper 
control/shco 
control/shNRF2 
control/shNRF2 
TAZ/shNRF2 
control/shco 
TAZ/shco 
 
control/shco 3401 2168 1382    
G
B
1
 control/shNRF2 14101 8631 5283 4.51 x 10-5   
TAZ/shco 2490 1542 955   NS 
TAZ/shNRF2 6694 4255 2705  0.04  
control/shco 2244 1425 905    
G
B
3
 control/shNRF2 124985 40102 12867 4.87 x 10-13   
TAZ/shco 2691 1663 1027   NS 
TAZ/shNRF2 15673 8630 4752  0.0106  
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Supplemental Table S4. Oligonucleotides used for qRT-PCR. 
Gene Forward Sequence 5´-3´ Reverse Sequence 5´-3´ 
BIRC5 ACCCCGGAGCGGATGG GCAACCGGACGAATGCTTTT 
CD44 ACAAGCACAATCCAGGCAAC  GCTGGTATGAGCTGAGGCTG  
CTGF CTTCTGTGACTTCGGCTCCC GATGCAGGGAGCACCATCTT 
GAPDH CTCTCTGCTCCTCCTGTTCGAC TGAGCGATGTGGCTCGGCT 
NFE2L2 AAACCAGTGGATCTGCCAAC GTGACTGAAACGTAGCCGAAGA 
NQO1 GTTCATAGGAGAGTTTGCTT CCTTGCAGAGAGTACATGGA 
WWTR1 TTTCCTCAATGGAGGGCCA GGGTGTTTGTCCTGCGTTTT 
YAP1 GAACTGCTTCGGCAGGTGA GGGCTAACTCCTGACATTTTGG 
 
Supplemental Table S5. Oligonucleotides used for construction of luciferase reporters. 
Underlined sequences correspond to three putative AREs. Bold letters correspond to 
mutated nucleotides. 
WWTR1 ARE2-WT: 
5’- CTAGTGTGACTCAGCTGGATCCGTGACTCAGCTACGTGAGTGACTCAGCTC    -3’ 
3’-     ACACTGAGTCGACCTAGGCACTGAGTCGATGCACTCACTGAGTCGAGAGCT-5’ 
WWTR1 ARE2-mutated: 
5’- CTAGTGCGACTCAACTGGATCCGCGACTCAACTACGTGAGCGACTCAACTC    -3’ 
3’-     ACGCTGAGTTGACCTAGGCGCTGAGTTGATGCACTCGCTGAGTTGAGAGCT-5’ 
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Supplemental Figure S1. (A) Sections of three representative tumors with antibodies 
against IDH1, ATRX and ki67 (scale bar, 50 μm). (B, C) Scatter plot showing positive 
correlation between percentage of positive cell for ki67 and densitometric quantification of 
DAB-staining (as percentage of area) of NRF2 (B) or TAZ (C). The Pearson correlation 
coefficient (R) and the p-value associated with this coefficient are indicated. See also Fig. 
1. 
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Supplemental Figure S2. (A, B) U-87 MG cell lines were transduced for 1, 3 or 5 days 
with lentivirus encoding shco or shNRF2. (A) Messenger RNA (mRNA) levels of NFE2L2, 
NQO1 and WWTR1 were determined by qRT-PCR and normalized by GAPDH. Data are 
presented as mean ± S.D. (n = 3) **p ⩽ 0.01 according to a Student’s t-test. (B) 
Representative immunoblot analysis of NRF2, TAZ, NQO1 and GAPDH as a loading 
control (n = 3). (C, D) U-87 MG cell lines transduced with lentivirus encoding control 
shRNA (shco) or against NRF2 using two different shNRF2 (shNRF2-1 and shNRF2-2). 
(C) Messenger RNA (mRNA) levels of NFE2L2 and WWTR1 were determined by qRT-
PCR and normalized by GAPDH. Data are presented as mean ± S.D. (n = 3) **p ⩽ 0.01 
according to a Student’s t-test. (D) Representative immunoblot analysis of NRF2, TAZ and 
GAPDH as a loading control (n = 3). (E) U-87 MG cells were transduced with lentiviral 
empty vector (control) or lentiviral vector for expression of NRF2 (NRF2), and then with 
lentivirus encoding shco or shNRF2. Representative immunoblot analysis of NRF2, TAZ 
and GAPDH as a loading control (n = 3). See also Fig. 2. 
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Supplemental Figure S3: (A, B) U-373 MG and U-87 MG glioblastoma cells were 
transduced with empty vector or lentiviral vector for overexpression of NRF2. (A) 
Representative immunoblot analysis of NRF2, TAZ, NQO1 and GAPDH as a loading 
control (n = 3). (B) Messenger RNA (mRNA) levels of WWTR1 were determined by qRT-
PCR and normalized by GAPDH. Data are presented as mean ± S.D. (n = 3) **p ⩽ 0.01 
according to a Student’s t-test. (C) Representative immunoblot analysis of NRF2, TAZ and 
GAPDH as a loading control in ReNcell, U-87 MG and U-373 MG. See also Fig. 3. 
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Supplemental Figure S4: (A) Representative scheme of the gene YAP1 encoding YAP. 
Regions enriched in acetylated histone H3 lysine 27 (H3K27ac) are shown in blue and 
regions sensitive to DNase are represented as dark boxes. Experimental sequences reported 
to bind MAFK, MAFF and BACH1 factors were analyzed for the presence of AREs (ARE 
1-3). (B, C) GB1 and GB3 were transduced with a lentivirus encoding shco or shNRF2. (B) 
mRNA levels of WWTR1 and YAP1 were determined by qRT-PCR and normalized by 
GAPDH. Data are mean ± S.D. (n = 3). Statistical analysis was performed with the 
Student’s t-test. **p ⩽ 0.01. (C) Representative immunoblot analysis of NRF2, YAP, TAZ 
and GAPDH and LaminB as loading controls (n = 3). See also Fig. 5 and Supplemental 
Table S1. 
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Supplemental Figure S5. (A) ChIP analysis of putative AREs found in WWTR1 using the 
anti-V5 antibody vs. a control IgG in HEK293T cells overexpressing NRF2-ΔETGE-V5. (B) 
HEK293T cells were transfected with wild type or mutated ARE2 reporter plus increasing 
amounts of NRF2-ΔETGE-V5. Luciferase activity was measured 24 h after transfection. The 
reporter construct carrying an ARE from HMOX1 was used as control. Luciferase activities 
were normalized to renilla activity. Results are shown relative to control and are mean ± 
S.D. (n = 3). **p ⩽ 0.01 according to a Student’s t-test. See also Fig. 5 and Supplemental 
Table S1. 
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Supplemental Figure S6. Ectopic expression of TAZ rescues neurosphere growth of 
NRF2-knocked-down glioma stem cells U-87 MG (A, B) and U-373 MG (C, D). Cells 
were transduced with lentiviruses encoding shco, human shNRF2 or human shTAZ. (A, C) 
Representative images of tumor neurosphere formation. Scale bar, 100 μm. (B, D) 
Quantification of the number of secondary neurospheres or the number of cells represented 
as percentage relative to shco. Data are presented as mean ± S.D. (n = 3) **p ⩽ 0.01 
according to a Student’s t-test. U-87 MG (E- H) and U-373 MG (I, J) cells were transduced 
with empty retrovirus as control or a retrovirus expressing TAZ, and then with a lentivirus 
expressing shco or shNRF2. (E) Representative immunoblot analysis of NRF2, TAZ and 
GAPDH as a loading control (n = 3). (F) mRNA levels of BIRC5 and CD44 were 
determined by qRT-PCR and normalized by GAPDH. Data are presented as mean ± S.D. (n 
= 3) **p ⩽ 0.01 according to a Student’s t-test. (G, I) Representative images of tumor 
neurosphere formation. Scale bar, 100 μm. (H, J) Quantification of the number of 
secondary neurospheres and the number of cells represented as a percentage relative to 
control-shco. Data are presented as mean ± S.D. (n = 3) **p ⩽ 0.01 according to a 
Student’s t-test. See also Fig. 6. 
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Supplemental Figure S7. (A, B) U-373 MG glioblastoma cells were transduced with 
lentivirus shRNA control (shco), human shNRF2 or human shTAZ, and were implanted in 
nude mice. (A) Growth curves of xenograft tumors. The tumor volume was followed-up at 
the indicated times. Data are presented as mean ± S.E.M. (n = 4). **p ⩽ 0.01 according to a 
Student’s t-test. (B) Upper panel, representative tumors of each experimental condition at 
the end point (scale bar, 1 cm); lower graph, quantification of the final tumor volume. Data 
are presented as mean ± S.E.M. (n = 4). **p ⩽ 0.01 according to a Student’s t-test. Edema 
associated with the intracranial tumor formed by GB3. Slices -1, 0 and +1 correspond to 
three serial sections of the same tumor developed by the shco condition. Slice 0 is also 
shown in Fig. 7D. Representative image of T2 MRI after 10, 20 and 30 days post- surgery. 
Red arrows indicate edema.  (D, E) U-373 MG cells were transduced with retrovirus 
encoding pBabe-puro alone (control) or pBabe-puro-TAZ (TAZ) and then with lentivirus 
expressing shco or shNRF2 and implanted in athymic mice. (D) Growth curves of 
xenograft tumors. Data are presented as mean ± S.E.M. (n = 4). p = 0.08 according to a 
Student’s t-test. (E) Upper panel, representative tumors of each experimental condition at 
the end point (scale bar, 1 cm); lower graph, quantification of the final tumor volume. Data 
are presented as mean ± S.E.M. (n = 4). p = 0.08 according to a Student’s t-test. See also 
Fig. 7. 
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GRAPHICAL ABSTRACT 
Scheme showing the main findings of this study: NRF2 induces target genes such as 
GCLC, NQO1, HMOX1, etc. that in cancer cells may provide a cytoprotective response to 
stressful signals including radiotherapy and chemotherapy. In addition, we show here that 
NRF2 also induces the expression of WWTR1, encoding the transcription factor TAZ, that 
provides direct input into cancer progression by activating a battery of genes that 
participate in proliferative responses and cancer stem cell renewal. The combined 
expression of NRF2 and its target TAZ are characteristic of poor prognosis in 
glioblastomas.  
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ABSTRACT 
In this study, we investigated the role of the Hippo pathway effector TAZ in the neuronal 
specification of NSPCs. We described that TAZ expression in murine neurogenic niches is mainly 
restricted to NSPCs and absolutely absent in neurons since immature states. We found that TAZ 
expression declines during neuronal specification of human NSPCs, being neuronal maturation improve 
by the loss of TAZ in initial NSPCs. Furthermore, TAZ overexpression in hNSPCs impairs their neuronal 
commitment in, at least in part, TEAD-dependent manner. Indeed, TAZ deletion is accompanied by an 
increment in the transcripts of SOX2 and proneural bHLH factors ASCL1, NEUROG2 and NEUROD1, 
meanwhile TAZ overexpression downregulates these transcripts. Basing our studies in bioinformatics 
analysis, we found that the regulatory regions of the genes encoding SOX2 and proneural bHLH factors 
ASCL1, NEUROG2 and NEUROD1 present putative sites recognized by TAZ-DNA-binding partners 
TEAD1/2/3/4 and SMAD 2/3/4. By chromatin immunoprecipitation analysis, we confirmed the 
enrichment on TAZ in the regulatory regions of these genes. Furthermore, TAZ enrichment in these 
regions conducts to a reduction in histone acetylation and less recruitment of RNA Pol II. Altogether, our 
results point TAZ as a transcriptional corepressor of SOX2 and proneural bHLH, thus leading to ablation 
of neuronal cell fate specification and differentiation. 
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INTRODUCTION 
 
The Hippo pathway is a conserved cascade of kinases related to development, differentiation, 
organ size and regeneration (Mo et al. 2014). In mammals, Hippo pathway comprises the serine/threonine 
kinases MST1/2 and LATS1/2 and one of its major targets is TAZ (transcriptional coactivator with PDZ 
binding motif). Activation of Hippo pathway results in TAZ phosphorylation and triggers its inactivation 
via sequestration by 14-3-3 in cytoplasm or its degradation via ubiquitin-proteasome-dependent manner. 
When Hippo pathway is inactivated, unphosphorylated TAZ migrates to the nucleus, where it acts as the 
binding partner of several transcription factors (TFs), mainly TEADs (Chan et al. 2009), but also others 
as SMADs (Varelas et al. 2008) and RUNX (Cui et al. 2003). Upon its binding to these TFs, hippo 
transducer TAZ regulates the expression of genes related to cell growth, self-renewal and oncogenic 
transformation (Chan et al. 2009; H. Zhang et al. 2009). Although TAZ implication in cell proliferation 
and migration is widely known in cancer (Bhat et al. 2011; M. Wang et al. 2015a), little is known about 
its role in the neuronal commitment of neural stem/progenitor cells (NSPCs).  
These NSPCs are multipotent stem cells which undergo asymmetric division generating neural 
progenitors and neurons (Taverna et al. 2014). This process involves a number of key factors, including 
Sex-determining region Y (SRY)-related HMG box 2 (SOX2) and proneural basic helix-loop-helix 
(bHLH) factors (Ma et al. 1996; Sommer et al. 1996). 
SOX2, a member of the SOXB1 family of transcription factors, is expressed in all NSPCs in 
CNS, playing roles in maintaining NSPCs stemness during development (Cavallaro et al. 2008). SOX2, 
itself, can induce the conversion of NG2 glia into induced neurons in the adult mouse cerebral cortex 
(Heinrich et al. 2014). Furthermore, SOX2 marks epigenetically the regulatory regions of proneural 
bHLH genes, thereby enabling appropriate activation of the differentiation program upon exposure to a 
neurogenic stimulus (Amador-Arjona et al. 2015; Ng et al. 2013). In vertebrates, bHLH proneural factors 
comprise among others ASCL1 (Achaete-Scute complex-like 1), Neurogenin-2 (NEUROG2) and 
NEUROD1. Transient expression of these proneural factors drives neuronal generation from NSPCs 
(Bertrand et al. 2002). For example, ASCL1 is necessary to induce cell cycle exist and neuronal 
specification, not only in NSPCs (Wilkinson et al. 2013), but also in somatic non-neural cells (Berninger 
et al. 2007) (Chanda et al. 2014). Together with Neurogenin-2, ASCL1 regulates the progression of retinal 
neurogenesis (Hufnagel et al. 2010) and promotes deep-layer neurogenesis in the murine neocortex 
(Dennis et al. 2017). Neurogenin-2 also regulates cell cycle exit on neuronal progenitors (Lacomme et al. 
2012) and initiates a cascade of other critical proneural transcription factors, one of which is NEUROD1. 
NEUROD1 has been related with terminal differentiation, neuronal maturation and survival (Gao et al. 
2009) (Hevner et al. 2006; Pataskar et al. 2016) (Aprea et al. 2014). 
Although the function of SOX2 and proneural bHLH factors has been hardly studied in the 
context of neurogenesis and several of these genes are included in strategies for the conversion of somatic 
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non-neural cells into neuronal lineage, they are still some questions about their transcriptional activation 
or inactivation during neuronal commitment. 
In this study, we investigated the role of TAZ in the neuronal specification of NSPCs. TAZ 
deletion is accompanied by an increment in the transcripts of SOX2 and proneural bHLH factors ASCL1, 
NEUROG2 and NEUROD1, meanwhile TAZ overexpression downregulates these transcripts. By 
chromatin immunoprecipitation analysis, we confirmed the enrichment on TAZ in the regulatory regions 
of these genes, conducting to a lower levels of histone acetylation and RNA-polymerase II (RNA Pol II) 
recruitment. Altogether, our results point TAZ as a transcriptional co-repressor of SOX2 and proneural 
bHLH, thus leading to ablation of neuronal cell fate specification and differentiation. 
 
RESULTS 
 
TAZ expression is absent in mature neurons. 
 
To study the function of TAZ in neurogenesis, we first consulted the Brain RNA-seq database. 
This database provides the expression levels of numerous genes in the main cell types of human (Y. 
Zhang et al. 2016) and murine brain (Y. Zhang et al. 2014). We found that WWTR1 expression, encoding 
TAZ, is mostly limited to astroglia and endothelial cells and, surprisingly, is low in neurons of either 
humans (Fig.1A) or mice (Fig. 1B). 
These differences prompted us to analyse WWTR1 expression in the two main murine neurogenic 
niches: the subventricular zone (SVZ) of the striatum and the subgranular zone (SGZ) of the dentate gyrus 
(DG), in newborn and 3-, 6-, and 12-months-old mice. We combined TAZ immunostaining with Nestin 
to identify NSPCs, and DCX to identify neuroblasts and immature neurons. The specificity of anti-TAZ 
antibody was validated in Fig. S1A-C. As widely reported, the pool of progenitors (Nestin+ cells) greatly 
declined with aging, both in the SVZ (Fig. 1E and Fig. S1D) and the SGZ (Fig. 1G and Fig. S1E). The 
number of neuroblasts and immature neurons (DCX+ cells) also decayed with aging in SVZ (Fig. 1F and 
Fig. S1D) and the SGZ (Fig. 1H and Fig. S1E). More importantly, we found that TAZ-expressing cells 
also declined parallel to the exhaustion of the pool of progenitors (Fig. S1D and Fig. S1E). Furthermore, 
in double immunofluorescence assays we found that TAZ is expressed in Nestin+ cells but not in DCX+ 
cells, both in the SVZ (Fig. 1C) and the SGZ (Fig. 1D) and the pool of double Nestin+/TAZ+ cells 
(NSPCs expressing TAZ) dramatically declined after 3 months of age in both locations. These results 
indicate that TAZ expression in murine neurogenic niches is mostly limited to NSPCs and is absent in 
neurons already from immature stages. 
Then, we analyzed the expression of TAZ during differentiation of the human immortalized 
NSPC line ReNcell. As shown in Fig. 2A, under stem growth conditions (in the presence of growth 
factors) these cells exhibited the Nestin marker of NSPCs but also expressed TAZ both in the nucleus 
and cytoplasm (white arrowheads), consistent with our observations in the neurogenic niches. After 7 
Robledinos-Antón et al, 2019  5 
 
days in differentiation medium (in the absence of growth factors), many NSPCs were differentiating to 
immature neurons (DCX+), while others retained the expression of GFAP, marker of both NSPCs and 
astrocytes.  Importantly, DCX+ cells did not express TAZ (Fig. 2B) in agreement with our observations 
in the murine neurogenic niches (Fig. 1). We also found a progressive loss of Nestin+ NSPCs to ⁓50%, 
a progressive increase of DCX+ immature neurons to ⁓40%, and, more relevant, a decrease in TAZ 
expression to ⁓70% that paralleled the loss of NSPCs (Fig. 2C). Additionally, the loss of TAZ+ cells was 
further correlated with neuronal differentiation because the fraction of Nestin+/TAZ+ cells remained 
constant while that of DCX+/TAZ+ cells declined (Fig. 2D). This decay was parallel to neuronal 
maturation, analyzed as neurite length (Fig. 2E and 2F). Moreover, TAZ nuclear expression decreased as 
neural maturation proceeded (Fig. 2F).  These results demonstrate a negative correlation between TAZ 
expression and exit of stemness towards neuronal differentiation. 
 
TAZ depletion in neural progenitors favours neuronal differentiation. 
 
In order to determine if this negative correlation was evidencing a role of TAZ in the control of 
stemness vs. neuronal differentiation, ReNcells were infected with a control lentivirus (shCO) or with a 
lentivirus for human TAZ-knockdown (shTAZ) (Fig. S2A), allowed to growth 5 days under proliferative 
conditions and them grown in differentiation medium for 30 days (Fig. 3A and B). Neuronal 
differentiation was analyzed with the specific markers DCX (neuroblasts and immature neurons), MAP2 
(dendrite marker), TUBB3 (neuronal marker) and TAU (axon marker) (Fig. 3B, C, D). We found that 
TAZ silencing resulted in an increase in the number neurons as determined by the quantification of DCX+ 
(Fig. 3B and E), MAP2+ (Fig. 3B and F), TUBB3+ (Fig. 3C and G) and TAU+ (Fig. 3D and H) cells. 
We next evaluated neuronal complexity and maturation as determined by dendrite length, based on MAP2 
staining, and axonal length, based on TAU staining. TAZ-knocked-down cells presented longer dendrites 
(Fig. 3I) and axons (Fig. 3J) than shCO-infected cells. These results indicate that loss of TAZ favours 
neuronal differentiation. 
 
TAZ inhibits neuronal commitment partially in a TEAD-dependent manner. 
 
As an additional approach, we overexpressed several mutant TAZ versions during 5 days in 
proliferation medium (Fig. S2B) and analyzed ReNcells differentiation after 30 days in differentiation 
medium, without growth factors (Fig. 4A and B). Expression of wild type TAZ (TAZ-WT) reduced the 
neuronal differentiation as determined with the DCX (Fig. 4B and C), MAP2 (Fig. 4B and D) and TAU 
(Fig. 4B and E) markers. Moreover, expression of the constitutively stable mutant of TAZ (TAZ4SA) 
abolished completely neuronal differentiation (Fig. 4B, C, D and E). Regarding neuronal maturation, we 
found an impairment in dendrite (MAP2 staining) and axon (TAU) length in TAZ-overexpressing cells, 
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indicating that TAZ not only diminishes neuronal differentiation, but also affects further stages of 
neuronal maturation (Fig. 4F and G). 
TEAD transcription factors are the main transcriptional co-partners of TAZ. To gain more insight 
into the implication of TEADs in neuronal commitment, we expressed mutant forms of TAZ defective in 
the binding to TEAD, were the Ser-51 has been mutated to alanine (TAZS51A) and the constitutively active 
TAZ4SA+S51A which does not bind 14-3-3 proteins and is not targeted for degradation (H. Zhang et al. 
2009).  Expression of TAZS51A partially restored neuronal differentiation as determined with DCX (Fig. 
4B and C), MAP2 (Fig. 4B and D) and TAU (Fig.4B and E) immunostaining. Moreover, TAZ4SA+S51A, 
that is not degradable and does not bind TEAD, partially restored neuronal differentiation despite 
harbouring high TAZ levels (Fig. 4B to E). These findings indicate that TAZ repression of neuronal 
differentiation is partially TEAD-dependent. These observations were further extended to study the 
neuronal complexity as described previously. In line with the data on neuronal differentiation, we found 
that overexpression of TEAD-binding defective TAZ mutants partially restored the dendrite and axonal 
length (Fig. 4F and G). 
 
Identification of putative TAZ interacting regions in proneurogenic genes. 
 
To address why TAZ represses neurogenesis, we first analyzed the possible link between TAZ 
and transcription factors known to be positive regulators of neurogenesis, such as SOX2 and 
proneurogenic basic helix-loop-helix factors (bHLH) ASCL1, NEUROG2 and NEUROD1. First, we 
surveyed the Encyclopedia of DNA Elements at UCSC (ENCODE) of the human genome (Feb. 2009) in 
search for TAZ-regulated elements. Although TAZ does not bind directly to gene regulatory elements, 
ENCODE includes information about TAZ co-partners TEAD4, SMAD2 and RUNX. Furthermore, this 
database also gathers information of DNase hypersensitive areas and acetylation in Lys27 of histone H3 
(H3K27Ac), which correlates with open chromatin that characterizes regulatory regions. In addition, we 
obtained the position specific scoring matrix (PSSM) for the consensus sequence recognize by TAZ co-
partners TEAD1, TEAD2 (Fig. S4B and S4C), TEAD3, TEAD4, SMAD2/3/4 and RUNX2 based on the 
frequency matrix depicted at the JASPAR database. We then compared the regulatory regions retrieved 
from ENCODE for each gene with the PSSM of the consensus sequence for each transcription factors 
using a Python-based bioinformatics analysis (Table S10). 
Using this script, we obtained a relative score for each sequence and considered those with a 
relative score higher than 80%. We identified several putative TEADs, SMADs and RUNX binding sites 
in the gene regulatory regions of SOX2 and bHLH factors ASCL1, NEUROG2 and NEUROD1 (Table S1 
to S6). Sequences in the regulatory regions of the bona fide TAZ-targets CTGF and CYR61 were analyzed 
as positive controls (Table S1 to S6).  
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TAZ expression inversely correlates with the levels of SOX2 and several proneuronal bHLH 
factors. 
 
Since we found that TAZ co-partners recognize sequences in the regulatory regions of 
proneurogenic genes, we analyzed the relevance of TAZ in the regulation of their expression. First, we 
knocked-down TAZ in ReNcells using a lentiviral vector for shTAZ. After 5 days of lentiviral 
transduction, we found a decrease in TAZ protein levels and its well-known target CTGF (Fig. 5A). TAZ 
knockdown was accompanied by an increase in the protein levels of SOX2 and NEUROD1 (Fig. 5A). 
Furthermore, we found a decrease to ⁓50% in TAZ transcript, WWTR1, and ⁓30% in the bona fide targets 
CTFG and CYR61 (Fig. 5B). Under the same conditions, we found a significant increase in the transcripts 
of the proneurogenic factors SOX2, ASCL1, NEUROG2 and NEUROD1 (Fig. 5C). 
Next, we analyzed the protein and transcript levels of the proneurogenic factors in ReNcells 
transduced with a retroviral vector for expression of active mutant TAZ4SA for 1, 2 and 5 days (Fig. S3). 
As expected, we saw a gradual increase of the bona fide TAZ target CTGF in parallel to TAZ 
overexpression (Fig. S3A).  At the same time, SOX2 and NEUROD1 levels declined (Fig. S3A). At the 
transcriptional level, the increase in the TAZ transcript (WWTR1) was accompanied by an increase in its 
positive controls CTFG and CYR61 (Fig. S3B), but also a decrease in the proneurogenic factors SOX2, 
ASCL1 NEUROG2 and NEUROD1 (Fig. S3C). 
To uncover the effect of TAZ in proneurogenic genes during differentiation, we overexpressed 
wild type TAZ (TAZ-WT) and constitutively active TAZ (TAZ4SA) by retroviral transduction in ReNcells 
and allow them to grow 5 days under proliferation conditions. Next, we removed the growth factors and 
analyzed the protein and transcript levels of several proneurogenic factors at 0, 2 and 4 days under 
differentiation conditions (Fig. S3). In TAZ overexpressing cells, we found accumulation of TAZ and its 
target CTGF by immunoblot (Fig. S3D), and CTGF and CYR61 transcripts (Fig. S3E).  At the same time 
points, SOX2 and NEUROD1 protein levels declined (Fig. S3D). On the other hand, the expression of 
proneurogenic factors increased during differentiation in the control (CT) transduced cells, while SOX2, 
ASCL1, NEUROG2 and NEUROD1 remained low in TAZ-WT cells and were almost supressed in TAZ4SA 
cells (Fig. S3F). Together these results strongly suggest that TAZ is a negative regulator of these 
proneurogenic factors. 
 
TAZ repression of proneurogenic genes is partially TEAD-dependent. 
 
To gain more insight into the implication of TEAD transcription factors in the regulation of 
proneurogenic factors, we expressed the defective TEAD-binding TAZ mutants. As expected, retroviral 
overexpression of TAZ-WT and active TAZ4SA led to an increase in the TAZ target CTGF after 5 days 
(Fig. 5D). At the same time, this CTGF accumulation was partially reverted by the TAZS51A mutant 
defective in TEAD-binding (Fig. 57A). Furthermore, SOX2 protein levels decrease in TAZ-WT and even 
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more in TAZ4SA conditions. The mutant TAZ4SA+S51A, which disrupted TEAD binding, largely abolished 
the ability of TAZ to repress SOX2 (Fig. 5D and E). Similar results were observed with NEUROD1 (Fig. 
5D and F). Parallel to the increase in TAZ targets (CTGF and CYR61) in TAZ-WT and TAZ4SA transduced 
ReNcells (Fig. 5G), we found a decrease at the transcriptional level of SOX2 and proneural ASCL1, 
NEUROG2 and NEUROD1 factors, being this repression almost complete in cells expressing TAZ4SA 
(Fig. 5H). By contrast, this repression by TAZS51A and TAZ4SA+S51A was almost absent for SOX2 and 
partially reverted for ASCL1, NEUROG2 and NEUROD1 (Fig. 5H). As it will be discussed, TAZ can 
induce itself, making possible that ectopically expressed TAZ might induce endogenous TAZ expression, 
which is will not be defective in TEAD-binding. 
To further investigate the role of TEADs in TAZ repression of proneurogenic genes we used 
ReNcells retrovirally transduced with TAZ4SA. In these cells, we performed knockdown of the TEAD 
isoforms using lentiviral vectors directed to TEAD1/3/4 and TEAD2 (altogether named shTEAD) (Fig. 
S4). Depletion of TEADs (Fig. S4D) conducted to lower levels on CTGF and CYR61 transcripts as 
expected (Fig. S4E), but also to up-regulation of proneurogenic transcripts (Fig. S4F). Altogether, these 
results suggest that TEADs are involved in the repressive function of TAZ on proneurogenic factors. 
 
TAZ induces epigenetic changes at the regulatory regions of proneurogenic genes. 
 
We next explored epigenetic mechanisms underlying repression of the neurogenic genes by TAZ. 
When CT-ReNcells (CT) and TAZ4SA-ReNcells were maintained for 5 days in proliferation and 4 
additional days in differentiation (Fig. 6A) they presented and increase in the canonical TAZ target CTGF, 
while SOX2 and NEUROD1 levels were decreased (Fig. 6B). At transcriptional level, TAZ targets CTGF 
and CYR61 also increased (Fig. 6C) and while proneurogenic transcripts decreased (Fig. 6D). By ChIP-
qPCR analysis, we found TAZ enrichment in positive controls and also in the TAZ-interacting regions 
(TIRs) of proneurogenic genes described in Figure S5 and Tables S1 to S6, but not in the negative control 
(CTGF 3´UTR) in TAZ4SA cells compared to the control (Fig. 6E). We investigated the recruitment of 
RNA polymerase II (RNA Pol II) which is engaged together with the transcription machinery to the 
promoter in the eukaryotic genes (Roeder 2005) (Sandoval et al. 2004). RNA Pol II occupancy was 
significantly reduced at regulatory regions of proneurogenic genes in TAZ4SA-expressing cells compared 
to control cells, while RNA Pol II levels were higher in CTGF and CYR61 regulatory regions (Fig. 6F). 
We then surveyed major histone modifications. Histone 3 (H3) acetylation in the N-terminal 
Lysine 9, is generally associated with gene activation (Kuo et al. 1996) (Strahl and Allis 2000). ChIP-
qPCR assays using anti-acetylated Lys9-H3 antibody (AcH3) indicated that H3 acetylation was increased 
in TAZ bona fide targets CTGF and CYR61, while it was reduced by TAZ4SA overexpression in 
proneurogenic genes in the same TIRs, with no changes in the negative control (Fig. 6G). On the basis of 
these results, we propose that TAZ represses proneurogenic gene expression by changes in histone 
acetylation and RNA Pol II occupancy at their regulatory regions. 
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Altogether, our results characterize for the first time TAZ as a master repressor of neuronal 
differentiation program, and this repression is partially TEAD-dependent. 
 
DISCUSSION 
 
Our study addressed for the first time how the Hippo co-activator TAZ represses the expression 
of proneurogenic genes. The transcriptional program underlying neural stem cell differentiation is 
regulated by largely unknown spatiotemporal patterns of gene expression (Guillemot 2007) (Spitz and 
Furlong 2012). The Hippo pathway has been related with the maintenance of the NSPCs pool (Lavado et 
al. 2018), but the specific role of TAZ in neurogenesis has not been previously addressed. Interestingly, 
TAZ is implicated in epithelial–mesenchymal transition (EMT) in cancer (Q. Wang et al. 2015b) (Li et 
al. 2015), a process that is critical for neuronal development and the migration of newborn neurons (Kwan 
et al. 2012). 
Based on the data available in the Brain RNA-seq database and our immunofluorescence analysis 
in vitro and in vivo, we found that TAZ expression is mostly limited to astrocytes and NSPCs, and 
decreases along neuronal maturation. Although no previous analysis were focused in TAZ expression in 
neurogenic niches, our findings are in line with the downregulation of the other Hippo effector, YAP, 
during neuronal differentiation (H. Zhang et al. 2012). YAP is also expressed in astrocytes and 
progenitors, but not in neurons (Huang et al. 2016). However, while we find that TAZ knockdown leads 
to neuronal differentiation, it is not clear that YAP will do the same. This could be related to different 
roles of TAZ and YAP or to misleading identification neurons. In fact, Zhang et al. used TUBB3 as a 
neuronal marker, which it is not specific as it is also expressed in astrocytes and progenitors (Draberova 
et al. 2008). On the contrary, we used several neuronal markers and astrocytic markers to ensure the 
proper identification of neurons.  
Prompted for our findings, we analyzed the presence of TAZ transcriptional co-partners binding 
sequences in proneurogenic genes. Bioinformatics approaches revealed that the promoters of the 
proneurogenic genes SOX2, ASCL1, NEUROG2 and NEUROD1 present putative sites for binding to 
TAZ-transcriptional co-partners. We then uncovered the relationship between TAZ expression and 
proneurogenic genes by showing TAZ enrichment in their regulatory regions. Furthermore, we ensured 
the accuracy of these sequences cloning an identified TEAD-binding sequence of SOX2 in the luciferase 
reporter and showing a TAZ-dependent response.   
The information available about the interaction between TAZ co-partners and proneurogenic 
genes is very scarce. However, the short half-life of proneurogenic factors indicates the relevance of their 
transcriptional regulation (Sriuranpong et al. 2002) Ali (Ali et al. 2011). It has been described that TAZ 
co-partner SMAD (Varelas et al. 2008) shares many gene targets with cell-type specific transcription 
factors that participate in cellular identity (Mullen et al. 2011) (Trompouki et al. 2011). Genome-wide 
experiments demonstrate that the proneural factor ASCL1 assists SMAD3 in binding to a subset of 
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enhancers (Fueyo et al. 2018). Furthermore, Castro et al., described that ASCL1 targets the transcription 
factors TEAD1, TEAD2 and TAZ using genome-wide analysis of the developing ventral mesencephalon 
(Castro et al. 2011). Our bioinformatics analysis demonstrated that RUNX1/2- recognizes a sequence in 
the regulatory regions of proneurogenic genes. Fukui et al., showed that RUNX1 is down-regulated 
during neuronal differentiation, while NEUROG2 is upregulated, but the authors did not establish any 
further analysis to this correlation (Fukui et al. 2018). Thus, our study establishes for the first time the 
existence of TAZ-interacting regulatory regions in proneurogenic genes. Furthermore, the upregulation 
of TAZ repressed the expression of these genes, which was partially recovered by ablation of TAZ-TEAD 
interaction or TEAD-knockdown. The uncompleted recovery could be: a) because TAZ functional 
repression is partially TEAD-independent, b) ectopic TAZ upregulates endogenous TAZ, which is not 
TEAD-binding defective, hiding the TEAD-independent effect. As described in the ENCODE database, 
the TAZ enhancer regions comprise several TEAD-putative binding sequences. Furthermore, TEAD4 is 
a target of TAZ (Kim et al. 2015). TEADs are essential for the transcriptional co-activator function of 
TAZ (H. Zhang et al. 2009); hence, it would be unexpected that TEAD was also involved in their 
corepressor function.  
Our study shows that the interaction of TAZ with regulatory regions of proneurogenic genes 
conducts to decreased acetylation of the chromatin and reduced recruitment of RNA Pol II. Of note, the 
same TAZ-TEAD complex activates genes such as CTGF and CYR61 but suppresses the transcription of 
others. Enhancer-bound TAZ–TEAD complexes regulate gene transcription by inducing p300-dependent 
acetylation at lysine 27 of histone H3 (H3K27ac) (Stein et al. 2015), through recruitment of the Mediator 
complex and induction of transcriptional elongation through the release of RNA polymerase II (Galli et 
al. 2015). Several recent studies have identified the interaction of TAZ or its Drosophila homolog Yki 
with other regulators of chromatin status as components of the chromatin-remodelling complexes and 
histone methyltransferase complexes (Basu et al. 2013) (Qing et al. 2014) (Skibinski et al. 2014) (Oh et 
al. 2013). Recently, Kim et al., described the interaction between TAZ-paralog YAP with the nucleosome 
remodelling and histone deacetylase (NuRD) complex (Lai and Wade 2011). In this study, the authors 
showed how the YAP/TEAD recruits the NuRD complex to deacetylate histones and supresses the 
expression of Trail and DNA Damage Inducible Transcript 4 (DDIT4)-encoding genes to promote cell 
growth and survival (Kim et al. 2015). The implication of NuRD in transcriptional repression of 
TAZ/TEAD has also been established by Beyer et al., who described a regulatory complex composed of 
TAZ/YAP/TEAD, SMAD2/3, and the pluripotency regulator OCT4, that collaborates with NuRD to 
suppress mesoendoderm genes (Beyer et al. 2013) (Totaro et al. 2018). Indeed, TAZ can directly interact 
with histone deacetylation complex for TAZ/TEAD-induced suppression of ΔNp63 transcription 
(Valencia-Sama et al. 2015). Together with these studies, our data suggests that TAZ supresses gene 
expression by directly interacting with the histone deacetylation complex and further affects RNA Pol II 
recruitment and gene transcription. 
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It is important to point out the inter-relationship between proneurogenic factors. Although the 
repressor effect of TAZ on ASCL1 and NEUROG2 expression is as strong as on SOX2 and NEUROD1, 
the enrichment of TAZ in their regulatory regions and the effect in histone acetylation and RNA Pol II 
recruitment is not as strong. This could be related to the capacity of proneurogenic factors to regulate 
their own expression. For example, SOX2 can enhance the expression of ASCL1 and NEUROG2 by 
cooperating with RMST (Ng et al. 2013) and POU factors (Lodato et al. 2013) in ESCs and NPCs. 
NEUROG2 is a pioneer factor that upregulates SOX4, which co-activates NEUROD1 and NEUROD4 
(Smith et al. 2016). Thus, we speculate that TAZ-dependent repression of a proneurogenic factor 
presumably would impact the expression of others.  
The transcriptional corepressor activity of TAZ opens a new path for understanding the role of 
TAZ in neural stem cell fate and neuronal reprogramming (Bago et al. 2016) (Tang et al. 2017) (Dennis 
et al. 2019). Much work is still needed if we are to obtain a clear and comprehensive understanding of 
the operational logic focused on the TAZ repressor function in neurogenesis and its possible implication 
in neural stem cell therapy in neurodegeneration and cancer. 
 
MATERIALS METHODS 
 
Brain RNA-seq. 
The Brain RNA-seq database of the Stanford University (http://www.brainrnaseq.org/) was 
analysed for expression of WWTR1. Human and mouse data were obtained as described in (Y. Zhang et 
al. 2014) and (Y. Zhang et al. 2016).  
 
Animals. 
Animals were housed under a 12 h light-dark cycle. Food and water were provided ad libitum 
and mice were cared according to protocols approved by the Ethics Committee for Research of the 
Universidad Autónoma de Madrid following institutional, Spanish and European guidelines (RD 
53/2013, and ECC 566/2015, 2010/63/UE European Council Directives).  
 
Cell culture and reagents.  
HEK293T were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% fetal 
bovine serum (Sigma-Aldrich, St. Louis, Missouri, USA), 4 mM L-Glutamine (Gibco) and 80 mg/ml 
gentamicin (Laboratorios Normon, Madrid, Spain), 100 U/ml penicillin/streptomycin (Life Technologies, 
Grand Island, NY, USA) and 1% amphotericin B solution (Lonza, Hopkinton, MA, USA) in 5% CO2 at 
37 °C conditions. The immortalized human neural stem cell line derived from ventral mesencephalon of 
fetal brain (ReNcell VM, named in this study ReNcells) was purchased from EMD Millipore (Billerica, 
MA, USA). ReNcells were plated onto Corning Matrigel hESC-Qualified Matrix (CORNING, Bedford, 
MA, USA)-coated T75 cell culture flasks (BD Biosciences, San Jose, CA, USA) and maintained in 
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neurobasal medium (Gibco, Thermo Fisher Scientific, Grand Island, NY, USA) supplemented with 2% 
(v/v) B27 supplement (Gibco), 20 ng/ml recombinant human epidermal growth factor (Peprotech, NJ, 
USA), 20 ng/ml recombinant human basic fibroblast growth factor (Peprotech, NJ, USA), 100 U/ml 
penicillin/streptomycin (Life Technologies, Grand Island, NY, USA) and 1% amphotericin B solution 
(Lonza, Hopkinton) in 5% CO2 at 37 °C conditions.  
 
Lentiviral and retroviral vector production and infection. 
Pseudotyped lentiviral vectors were produced in HEK293T cells transiently co-transfected with 
10 µg of the corresponding lentiviral vector plasmid, 6 µg of the packaging plasmid pSPAX2 (Addgene 
Watertown, MA, USA) and 6 µg of the VSV-G envelope protein plasmid pMD2G (Addgene) using 
Lipofectamine Plus reagent according to the manufacturer’s instructions (Invitrogen país). Retrovirus 
supernatant was prepared by transfection of HEK293T cells with 5 g of each plasmid using 
Lipofectamine Plus. Lentiviral vector shRNA control (shco), shTAZ, and several shTEAD2 were 
purchased from Sigma-Aldrich. Lentiviral vector shTEAD1/3/4 was a generous gift from Prof. Zengqiang 
Yuan (Chinese Academy of Sciences, Beijing, China). The retroviral vectors used were: pBabePuro 
(Addgene), pBabePuroTAZ-WT, pBabePuroTAZS51A (TEAD-binding-defective mutant), 
pBabePuroTAZ4SA (constitutive active TAZ with all four serine residues in the HxRxxS motif replaced 
with alanine: S66A, S89A, S117A, and S311A), and pBabePuroTAZ4SA+S51A (generous gifts of Prof. Kun-
Liang Guan). Cells were infected in the presence of 4 g/ml polybrene (Sigma-Aldrich) and selected with 
0.5 g/ml puromycin (Sigma-Aldrich). 
 
Immunofluorescence. 
Thirty µm-thick coronal murine brain sections were processed for immunofluorescence microscopy as 
previously described (Robledinos-Anton et al. 2017). Antibodies are shown in Supplementary Table S9. 
Images were obtained using Leica TCS SP5 confocal microscope and cell counts were performed using 
FiJi Software (ImageJ). ReNcells VM were adhered on Corning Matrigel hESC-Qualified Matrix coated 
coverslips, and fixed with 4% paraformaldehyde. Immunofluorescence was performed as described in 
(Robledinos-Anton et al. 2017). Briefly, cells were washed, blocked in PBS containing 0.5% Triton X-
100% and 3% bovine serum albumin and incubated for 16 h at 4 °C with the relevant primary antibodies 
and for 2 h at room temperature with the appropriate secondary antibodies coupled to Alexa Fluor 488, 
555/546, or 647 (1:500) (Life Technologies-Molecular Probes, Grand Island, NY, USA). Nuclei were 
stained with DAPI. Images were quantified using the Fiji Software (http://fiji.sc/Fiji). 
 
Differentiation and neuron complexity.  
ReNcell VM were plated after five days of lentiviral/retroviral infection on Corning Matrigel 
hESC-Qualified Matrix coated coverslips and incubated for 30 days in differentiation medium 
(Neurobasal medium supplemented with 2% (v/v) B27 supplement and antibiotics). Immunostaining and 
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quantification were performed as described in (Robledinos-Anton et al. 2017). Primary antibodies are 
described in Supplementary Table S9. To quantify neuronal complexity, Sholl analysis was performed 
using the Simple neurite tracer plugin (http://homepages.inf.ed.ac.uk/s9808248/imagej/tracer/); total 
axonal, dendrite or neurite length were determined using NeuronJ 
(https://imagescience.org/meijering/software/neuronj/) and the image processing package Fiji 
(http://pacific.mpicbg.de/wiki/index.php/Main_Page). 
 
Immunoblotting. 
Immunoblotting was performed as described in (Pajares et al. 2016). Briefly, cells were 
homogenized in lysis buffer (TRIS pH 7.6 50 mM, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA and 1% 
SDS) and samples were heated at 95°C for 15 min, sonicated and pre-cleared by centrifugation 10 min at 
13,000 rpm. Proteins were resolved in SDS-PAGE, transferred to Immobilon-P (Millipore) membranes 
and detected with primary antibodies (Supplementary Table S9). Proper peroxidase-conjugated 
secondary antibodies were used for detection by enhanced chemiluminescence (GE Healthcare, Chicago, 
Illinois, USA). 
 
Bioinformatics analysis of response elements for TAZ co-transcription factors. 
Putative TEADs, STATs and SMADs binding domains in SOX2, bHLH factor-encoding genes 
and TAZ-target genes were identified in ENCODE (genome-euro.ucsc.edu) for the human genome taking 
as a reference the available chromatin immunoprecipitation data for TAZ transcriptional cofactors 
TEADs and SMADs in DNase-sensitive and H3K27Ac-rich regions. A frequency matrix of the consensus 
binding sequence of each transcription factor based on the JASPAR database (http://jaspar.genereg.net/) 
was converted to a position-specific scoring matrix and a script was generated with the Python 3.4 
program to scan the promoter sequences with candidate response elements as previously described 
(Pajares et al. 2016).  
 
Chromatin immunoprecipitation (ChIP). 
This protocol was performed as described in (Pajares et al. 2016). Briefly, ReNcells were 
transfected with plasmid CT or pBabePuroTAZ4SA encoding a constitutive activated TAZ (Bhat et al. 
2011). The qRT-PCR from immunoprecipitated DNA with antibodies described in Supplementary Table 
S9. PCR reactions were done with the primers shown in Supplementary Table S7. Samples from 4 
independent immunoprecipitations were analyzed. 
 
Analysis of mRNA levels. 
Total RNA extraction, reverse transcription and quantitative polymerase chain reaction (qRT-
PCR) were done as detailed in (Rojo et al. 2010). Primer sequences are shown in Supplementary Table 
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S8. Data analysis was based on the CT method, with normalization of the raw data to the housekeeping 
gene GAPDH (Applied Biosystems). All PCRs were performed from triplicate samples. 
Statistical analysis. 
Data are presented as mean ± S.D. or S.E.M. Statistical assessments of differences between groups 
were analyzed using GraphPad Prism 5 software by the unpaired Student’s t-test. For the scatter plots, 
the Pearson correlation coefficient (R) and the p-value associated with this coefficient were analyzed. 
Statistically significant differences in Kaplan-Meier survival curves were calculated with the log-rank 
test. 
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LEGENDS TO FIGURES 
 
Figure 1. TAZ distribution in human and murine brain. (A) Distribution of WWTR1 mRNA in cell 
types isolated from human grey matter from mature brain specimens after removal of meninges and blood 
clots. For details of human data see (Y. Zhang et al. 2016).  (B) Analysis of WWTR1 mRNA expression 
in glia, neurons and vascular cells isolated from mouse cerebral cortex.  WWTR1 transcript is lower in 
neurons compared to glia and vascular cells both in human and mice brain. For details of mouse data see 
(Y. Zhang et al. 2014). In panels A and B, data were obtained from the Brain-RNAseq database. (C) TAZ 
distribution in the subventricular zone (SVZ) neurogenic niche: quantification of the total cell number 
coexpressing Nestin and TAZ or DCX and TAZ in the SVZ of newborn, 3-, 6- and 12- months old mice. 
(D) TAZ distribution in murine hippocampal neurogenic niche: quantification of the total cell number 
coexpressing Nestin and TAZ or DCX and TAZ in the subgranular zone (SGZ) neurogenic niche of 
newborn, 3-, 6- and 12- months old mice. (E) Representative immunofluorescence pictures of Nestin and 
TAZ staining from the neurogenic niche SVZ from the indicated mice, showing TAZ accumulation in 
Nestin positive cells. (F) Representative immunofluorescence pictures from the SVZ neurogenic niche of 
indicated mice showing immunostaining of neuronal marker Doublecortin (DCX) and TAZ. (G) 
Representative immunofluorescence pictures of Nestin and TAZ staining from the neurogenic niche SGZ 
from the indicated mice. (H) Representative immunofluorescence pictures from the SGZ neurogenic 
niche of indicated mice showing immunostaining of DCX and TAZ. Nuclei are counterstained with 
DAPI. White arrowheads indicate TAZ positive cells also delineated with white dotted lines. Yellow 
arrowheads in G indicate Nestin+ blood vessels, which have not been quantified in this study. Blue dotted 
lines indicate DCX positive and TAZ negative cells. 
  
Figure 2. TAZ expression declines during neuronal differentiation. (A) Representative confocal 
images of ReNcells immunostained with Nestin and TAZ under proliferative conditions. White arrows 
indicate TAZ+ cells. (B) Representative confocal images of specific neuronal marker DCX, astrocyte and 
NSPCs marker GFAP with TAZ immunostaining of ReNcells after 7 days of in vitro differentiation. Blue 
arrows indicate TAZ- cells. (C) Quantification of Nestin+, DCX+ and TAZ+ ReNcells during 
differentiation. (D)  Percentage of Nestin+/TAZ+ of total Nestin+ cells and DCX+/TAZ+ of total DCX+ 
ReNcells during differentiation. (E) Representative images of DCX+ cells after 3 and 7 days of 
differentiation. (F) Percentage of cells expressing nuclear TAZ (left Y axis) and neurite length (right Y 
axis) of DCX+ cells during neuronal differentiation, indicating neuronal maturation. Data are mean ± 
SEM (n ≥ 50). 
 
Figure 3.  Loss of TAZ favours neuronal differentiation. (A) Schematic overview of experimental 
procedure: ReNcells were transduced with lentivirus encoding shcontrol (shCO) or human shTAZ and 
after 5 days of lentiviral transduction plated under differentiation conditions during 30 days. (B) 
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Representative immunofluorescence confocal images of neuronal markers DCX and MAP2 with TAZ. 
(C) Representative images of TUBB3 immunofluorescence staining. (D) Representative image of TAU 
immunofluorescence staining. Nuclei are counterstained with DAPI. (E) Quantification positive DCX 
cells of cultures described in B. (F) Quantification positive MAP2 cells of cultures described in B.  (G) 
TUBB3-positive cells quantification of cultures described in C. (H) TAU-positive cells quantification 
from the cultures described in D. (I) Neurite length measurements based on MAP2 staining. (J) Axonal 
length measurements of TAU-positive cells. Data are mean ± S.D. (n ≥ 10). Statistical analysis was 
performed with the Student’s t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.005. 
 
Figure 4.  TAZ impairment of neuronal differentiation is partially TEAD-dependent. (A) Schematic 
overview of experimental design: ReNcells were transduced with empty vector (CT) or retroviral vector 
for overexpression of TAZ-WT and TAZ mutants TAZS51A, TAZ4SA and TAZ4SA+S51A and, after 5 days of 
retroviral transduction, plated under differentiation conditions during 30 days. (C) Immunostaining of 
neuronal markers DCX, MAP2 and TAU. (D, E, F) Quantification of DCX+ (D), MAP2+ (E) and TAU+ 
(F) ReNcells transduced with CT, TAZ-WT, TAZS51A, TAZ4SA and TAZ4SA+S51A after 30 days of 
differentiation. (G) Measurement of dendrite length based on MAP2 staining (H) Measurement of axonal 
length based on TAU staining. Data are mean ± SEM (n ≥ 10). Statistical analysis was performed with 
the Student’s t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. CT. #p ⩽ 0.05; ##p ⩽ 0.01, ###p ⩽ 0.001 
comparing TAZS51A vs. TAZ-WT. $p ⩽ 0.05; $$p ⩽ 0.01, $$$p ⩽ 0.001 comparing TAZ4SA+S51A 
vs. TAZ4SA. 
 
Figure 5. TAZ as a transcriptional repressor of SOX2 and bHLH factors. (A) Representative 
immunoblot analysis of TAZ, CTGF, SOX2, NEUROD1 and GAPDH as a loading control in shCO and 
shTAZ cells after 5 days of lentiviral transduction. (B) mRNA levels of WWTR1 and its targets CTGF 
and CYR61. (C) mRNA levels of SOX2, ASCL1, NEUROG2 and NEUROD1. (D) Representative 
immunoblots of TAZ, CTGF, SOX2, NEUROD1 and GAPDH as a loading control in ReNcells CT, TAZ-
WT, TAZS51A, TAZ4SA and TAZ4SA+S51A after 5 days of retroviral transduction. (E) Densitometric 
quantification of SOX2 protein levels in (A) relative to GAPDH. (F) Densitometric quantification of 
NEUROD1 protein levels in (A) relative to GAPDH. Data are mean ± SEM (n = 4). (G) mRNA levels of 
TAZ targets CTGF and CYR61. (H) mRNA levels of SOX2, ASCL1, NEUROG2 and NEUROD1 after 5 
days of retroviral transduction. mRNA levels were determined by qRT-PCR and normalized by the 
geometric mean of ACTB, GAPDH and TBP levels. Data are presented as mean ± S.D. (n = 4). Statistical 
analysis was performed using Student’s t-test. *p ⩽ 0.05; **p ⩽ 0.01, ***p ⩽ 0.001 vs. control conditions. 
#p ⩽ 0.05; ##p ⩽ 0.01, ###p ⩽ 0.001 comparing TAZS51A vs. TAZ-WT. $p ⩽ 0.05; $$p ⩽ 0.01, $$$p ⩽ 0.001 
comparing TAZ4SA+S51A vs. TAZ4SA. 
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Figure 6. TAZ recognizes specific regions in SOX2 and bHLH factors and repress their 
transcription. (A) Representative scheme of experimental procedure: ReNcells were transduced with 
retroviral vector control (CT) or TAZ4SA and grown for 5 days in proliferative conditions and 4 days in 
differentiation conditions. (B) Representative immunoblot analysis of TAZ, CTGF, SOX2, NEUROD1 
carrying GAPDH and Lamin B as a loading controls in ReNcells CT or expressing TAZ4SA. (C) mRNA 
levels of TAZ targets CTGF and CYR61. (D) mRNA levels of SOX2, ASCL1, NEUROG2 and NEUROD1. 
For C and D, mRNA levels were determined by qRT-PCR and normalized by the geometric mean of 
ACTB, GAPDH and TBP levels. Data are mean ± S.D. (n = 4). Statistical analysis was performed using 
Student’s t-test. ***p ⩽ 0.001 vs. CT. (E) ChIP analysis of putative TIRs described in Figure S5 using 
the anti-TAZ antibody vs. a control IgG in ReNcells CT or overexpressing TAZ4SA and normalized 
relative CT. (F) ChIP analysis of putative TIRs described in Figure S5 using the anti-RNA Pol II antibody 
vs. a control IgG in ReNcells CT or expressing TAZ4SA and normalized relative to CT cells. (G) ChIP 
analysis of putative TIRs described in Figure S5 using the anti-AcH3 antibody vs. a control IgG in 
ReNcells CT or expressing TAZ4SA and normalized relative to CT. Regions of CTGF and CYR61 were 
analyzed as positive controls, and a region of CTGF (CTGF 3´UTR) that does not contain TIR was used 
as negative control. 
 
Supplementary Figure 1. Specificity of TAZ antibody. (A) Representative confocal images of TAZ 
immunostaining in CT, TAZ-WT, TAZS51A, TAZ4SA and TAZ4SA+S51A, after 5 days of retroviral 
transduction. (B) Representative confocal images of TAZ immunostaining in shCO and shTAZ ReNcells 
after 5 days of lentiviral transduction.  (C) Representative immunoblot analysis of TAZ in ReNcells CT, 
TAZ-WT, TAZ4SA and TAZ4SA+S51A, shCO and shTAZ after 5 days of viral transduction, showing a 
specific band around 50 kDa. (D) Quantification of total Nestin, DCX or TAZ positive cells in the 
neurogenic niche of SVZ of newborn, 3-, 6- and 12-months old mice (n = 5). (E) Quantification of total 
Nestin, DCX or TAZ positive cells in the neurogenic niche of the SGZ of newborn, 3-, 6- and 12-months 
old mice (n = 5). 
 
Supplementary Figure 2. (A) Representative immunoblot analysis of TAZ and GAPDH as a loading 
control in ReNcells shCO and shTAZ after 5 days of lentiviral transduction used for the differentiation 
assays in Figure 3. (B) Representative immunoblot analysis of TAZ and GAPDH as a loading control in 
ReNcells CT, TAZ-WT, TAZS51A, TAZ4SA and TAZ4SA+S51A after 5 days of retroviral transduction used in 
the differentiation assays in Figure 4. 
 
Supplementary Figure 3. Gradually genetic upregulation of TAZ directly decreases SOX2 and 
bHLH factors levels. (A) Representative immunoblot of TAZ, CTGF, SOX2, NEUROD1 and GAPDH 
as a loading control in ReNcells transduced with TAZ4SA-expressing retrovirus after 1, 2 and 5 days post 
infection. (B) mRNA levels of WWTR1 and its targets CTGF and CYR61. (C) mRNA levels of SOX2, 
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ASCL1, NEUROG2 and NEUROD1. (D) Representative immunoblot analysis of TAZ, CTGF, SOX2, 
NEUROD1 and GAPDH as a loading ReNcells CT, TAZ-WT and TAZ4SA at 0, 2 and 4 days of 
differentiation. (E) mRNA levels of CTGF and CYR61. (F) mRNA levels of SOX2, ASCL1, NEUROG2 
and NEUROD1. mRNA levels were determined by qRT-PCR and normalized by the geometric mean of 
ACTB, GAPDH and TBP levels. Data represent mean ± S.D. (n ≥ 4). Statistical analysis was performed 
using Student’s t-test. ***p ⩽ 0.001 vs. CT. 
 
Supplementary Figure 4. TEADs transcripts expression in ReNcells. (A) mRNA levels of the 
different TEADs (1-4) transcripts in ReNcells were determined by qRT-PCR and normalized by TEAD1. 
Data represent mean ± S.D. (n ≥ 8). (B) TEAD2 motif from JASPAR database indicating its binding 
profile. (C) Position specific scoring matrix (PSSM) for TEAD2 PSSM is derived from the frequency 
matrix available in JASPAR database. (D) mRNA levels of TEAD1, TEAD2, TEAD3 and TEAD4. (E) 
mRNA levels of CTGF and CYR61. (F) mRNA levels of SOX2, ASCL1, NEUROG2 and NEUROD1. 
mRNA levels were determined by qRT-PCR and normalized by the geometric mean of ACTB, GAPDH 
and TBP levels. Data represent mean ± S.D. (n ≥ 4). Statistical analysis was performed using Student’s t-
test. ***p ⩽ 0.001 vs. shCO. 
 
Supplementary Figure 5. Schemes of the genes encoding SOX2 and bHLH factors ASCL1, 
NEUROG2 and NEUROD1. (A) SOX2, (B) ASCL1, (C) NEUROG2, and (D) NEUROD1 genes from the 
ENCODE for the human genome. Putative TAZ interacting regions (TIR) in the genes were identified 
taking as reference the regions localized in DNAse-sensitive and H3K27Ac-rich regions, i.e. most likely 
regulatory promoter regions. Regions sensitive to DNase are represented as dark boxes. RNA Pol II 
enrichment regions determined by ChIP-seq for RNA polymerase II (Pol II) in CD4 cells (Barski et al. 
2007) are indicated in blue.   
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Figure S3. 
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Figure S4. 
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SUPPLEMENTAL MATERIAL 
Supplemental Table S1. Putative TEAD1 binding sequences in the promoter regions of SRY-
box 2 (SOX2) and bHLH factors genes with a relative score higher than 80%. The table also 
shows the max score and the localization in the human genome. 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD1 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269288-132269276 13.77 82.8 AACATTTCTGAG 
chr6:132269659-132269671 15.62 85.8 TACATTCTACCT 
chr6:132270157-132270169 13.62 82.5 TACATTCTGGTG 
chr6:132270884-132270872 12.97 81.5 GACATTCCAAGA 
chr6:132270949-132270961 13.1 81.7 CTCATTCCAGCA 
chr6:132272609-132272621 17.78 89.3 CGCATTCCTCCC 
CYR61 
chr1:86046332-86046344 16.14 86.6 AGCATTCCTGAG 
chr1:86047219-86047207 16.2 86.7 TGCATTCCAGCC 
chr1:86047721-86047733 18.56 90.5 TGCATTCCTCTG 
chr1:86048360-86048348 14.99 84.8 CACATCCCACCC 
SOX2 
chr3:181431413-181431401 13.88 83 TCCATTCCCCCG (b) 
chr3:181428382-181428394 13.77 82.8 AAGATTCCTGAG (c) 
ASCL1 chr12:103349554-103349542 13.99 83.1 CACATCCCTGAC (b) 
NEUROG2 chr4:113435415-113435427 14.3 83.6 TGCATTCCCCCT (a) 
NEUROD1 
chr2:182543940-182543952 15.41 85.4 TACATTTCAGCG (c) 
chr2:182544023-182544035 15.78 86 CACATTCTACTT (c) 
 
Supplemental Table S2. Putative TEAD2 binding sequences in the promoter regions of SRY-
box 2 (SOX2) and bHLH factors genes with a relative score higher than 85%. The table also 
shows the max score and the localization in the human genome. 
 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD2 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269289-132269276 8.66 91.1 AAACATTTCTGAG 
chr6:132269658-132269671 9.07 91.5 TTACATTCTACCT 
chr6:132270885-132270872 12.97 95.5 AGACATTCCAAGA 
chr6:132270948-132270961 10.85 93.3 TCTCATTCCAGCA 
chr6:132272599-132272612 12.99 95.6 GGACATTCCTCGC 
CYR61 
chr1:86046331-86046344 10.42 92.9 CAGCATTCCTGAG 
chr1:86047220-86047207 13.29 95.9 TTGCATTCCAGCC 
chr1:86047720-86047733 10.16 92.6 CTGCATTCCTCTG 
chr1:86048153-86048140 10.58 93.1 ATACATTTCTGGC 
chr1:86048573-86048560 8.39 90.8 TCACAGTCCTGGT 
chr1:86049144-86049157 11.28 93.8 GGGCATTCCATCC 
SOX2 
chr3:181431414-181431401 6.99 89.3 GTCCATTCCCCCG (b) 
chr3:181428381-181428394 8.06 90.5 CAAGATTCCTGAG (c) 
chr3:181428844-181428831 8.49 90.9 CCCCATTCCCATC (a) 
ASCL1 
chr12:103349820-103349833 9.6 92 CCACATACCAAGA (a) 
chr12:103349555-103349542 9.57 92 CCACATCCCTGAC (b) 
chr12:103354060-103354047 7.77 90.1 CAACATTTCTATA (c) 
NEUROG2 
chr4:113435031-113435044 5.56 87.9 TTGCATTCAATCA (b) 
chr4:113438807-113438794 7.65 90 TAACACTCCAACT 
chr4:113435345-113435358 9.31 91.8 ATACATTTCTTTC (a) 
NEUROD1 
chr2:182543939-182543952 10.29 92.8 GTACATTTCAGCG (c) 
chr2:182544022-182544035 9.16 91.6 ACACATTCTACTT (c) 
chr2:182544640-182544653 8.01 90.4 CCACTTTCCCCCC (b) 
chr2:182545564-182545577 9.07 91.5 CTCCATTCCGGCC (a) 
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Supplemental Table S3. Putative TEAD3 binding sequences in the promoter regions of SRY-
box 2 (SOX2) and bHLH factors genes with a relative score higher than 90%. The table also 
shows the max score and the localization in the human genome. 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD3 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132270622-132270614 10.89 97.2 ACATACCG 
chr6:132269884-132269892 6.86 95.2 GGATTCCG 
chr6:132270883-132270875 14.08 98.7 ACATTCCA 
chr6:132270950-132270958 10.59 97 TCATTCCA 
chr6:132271352-132271344 8.64 96.1 AAATACCT 
chr6:132272601-132272609 13.43 98.4 ACATTCCT 
CYR61 
chr1:86046333-86046341 12.94 98.2 GCATTCCT 
chr1:86047218-86047210 13.59 98.5 GCATTCCA 
chr1:86047722-86047730 12.94 98.2 GCATTCCT 
chr1:86048065-86048057 10.4 96.9 GCATACCG 
chr1:86048501-86048509 7.98 95.7 AAATACCG 
chr1:86049146-86049154 13.59 98.5 GCATTCCA 
chr1:86048877-86048869 8.64 96.1 AAATACCT 
SOX2 
chr3:181430473-181430481 7.98 95.7 AAATACCG 
chr3:181431412-181431404 2.17 92.9 CCATTCCC (b) 
chr3:181430283-181430291 5.92 94.7 GAATGCCT 
chr3:181428383-181428391 8.01 95.8 AGATTCCT (c) 
chr3:181428711-181428703 4.13 93.8 GCATCCCA 
ASCL1 
chr12:103349822-103349830 12.2 97.8 ACATACCA (a) 
chr12:103350367-103350359 7.52 95.5 GGATTCCT 
NEUROG2 
chr4:113434627-113434619 4.54 94.1 AGATGCCA 
chr4:113439907-113439899 8.17 95.8 GGATTCCA 
chr4:113435416-113435424 9.23 96.4 GCATTCCC (a) 
NEUROD1 
chr2:182542983-182542975 5.6 94.6 ACATGCCC 
chr2:182543732-182543740 5.92 94.7 GAATGCCT 
chr2:182544713-182544705 5.64 94.6 GGATACCT (b) 
chr2:182545492-182545484 8.16 95.8 GCATGCCG (a) 
chr2:182545234-182545242 10.04 96.8 GAATTCCT 
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Supplemental Table S4. Putative TEAD4 binding sequences in the promoter regions of SRY-
box 2 (SOX2) and bHLH factors genes with a relative score higher than 90%. The table also 
shows the max score and the localization in the human genome. 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
TEAD4 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269659-132269669 12.98 94.9 TACATTCTAC 
chr6:132270202-132270212 12.64 94.6 AACATTCTTC 
chr6:132270884-132270874 14.12 96 GACATTCCAA 
chr6:132272600-132272610 14.13 96.1 GACATTCCTC 
chr6:132272772-132272762 11.87 93.8 AAAATTCTAT 
CYR61 
chr1:86046332-86046342 12.82 94.8 AGCATTCCTG 
chr1:86047293-86047303 9.02 91 AAAATACTAG 
chr1:86047219-86047209 13.16 95.1 TGCATTCCAG 
chr1:86048500-86048510 9.18 91.1 GAAATACCGG 
chr1:86049145-86049155 13.77 95.7 GGCATTCCAT 
chr1:86048878-86048868 10.75 92.7 GAAATACCTT 
SOX2 
chr3:181430472-181430482 9.18 91.1 TAAATACCGG 
chr3:181431587-181431577 8.26 0.90.2 TAAATACTGT 
chr3:181430289-181430279 8.44 90.4 GGCATTCATG 
chr3:181428382-181428392 8.78 90.8 AAGATTCCTG (c) 
ASCL1 
chr12:103349821-103349831 12.62 94.6 CACATACCAA (a) 
chr12:103353739-103353729 12.28 94.2 AGCATTCTAT 
NEUROG2 
chr4:113434601-113434591 11.38 93.3 GAAATTCTTC 
chr4:113439588-113439578 11.24 93.2 CAAATTCTGT 
chr4:113435415-113435425 10.91 92.9 TGCATTCCCC (a) 
NEUROD1 
chr2:182543738-182543728 9.05 91 GGCATTCATT 
chr2:182543940-182543950 8.8 90.8 TACATTTCAG (c) 
chr2:182544023-182544033 13.72 95.6 CACATTCTAC (c) 
chr2:182545233-182545243 12.84 94.8 CGAATTCCTC 
 
Supplemental Table S5. Putative SMAD2/3/4 binding sequences in the promoter regions of 
SRY-box 2 (SOX2) and bHLH factors genes with a relative score higher than 90%. The table 
also shows the max score and the localization in the human genome. 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
SMAD2/3/4 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6:132269508-132269521 8.17 92 GAGGCTACCACAT 
chr6:132270238-132270225 8.2 92 TAGTCTATCAACC 
chr6:132270384-132270397 13.87 95.8 ATGTCTCTCACTC 
chr6:132270796-132270809 5.12 90 TTGTCTGACTTCT 
chr6:132272476-132272489 13.97 95.9 CTGGCTGTCTCCT 
CYR61 
chr1:86046219-86046206 14.07 96 GTGTCTGTCTCCC 
chr1:86047067-86047080 8.74 92.4 CTGCCTGCCACTG 
chr1:86048336-86048349 7.99 91.9 TTGCCTGGCAGGT 
chr1:86049198-86049185 8.32 92.1 CTGCCTCTCACA 
SOX2 
chr3:181431086-181431099 6.2 90.7 CCCTCTCACACAT 
chr3:181429502-181429515 8.17 92 GTGGCTGGCAGGC 
chr3:181428859-181428846 11.01 93.9 CTGTCTGCCCCCA (a) 
ASCL1 
chr12:103351454-103351467 8.37 92.1 CACTCTCTCACTT 
chr12:103350931-103350918 7.24 91.4 TTCTCTCTCTCCT 
NEUROG2 
chr4:113435134-113435121 5.98 90.5 CCATCTGTCTCTT 
chr4:113436841-113436828 10.56 93.6 CTGACTGGCAGCA 
chr4:113437328-113437341 14.71 96.4 GTGTCTGGCACAC 
NEUROD1 
chr2:182542551-182542564 7.44 91.5 ATGACTCGCTCAT 
chr2:182542875-182542862 9.08 92.6 ATGTCTTCCACGT 
chr2:182543475-182543488 10.29 93.4 TTGTCTGCCTCGT 
chr2:182544227-182544240 7.28 91.4 GGGTCTTCCACCC 
chr2:182544628-182544615 5.27 90.1 GGGACTCACTCCT (b) 
chr2:182545412-182545425 6.01 90.6 TCGTCTCCCGCCC 
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Supplemental Table S6. Putative RUNX2 binding sequences in the promoter regions of SRY-
box 2 (SOX2) and bHLH factors genes with a relative score higher than 90%. The table also 
shows the max score and the localization in the human genome. 
 
GENE 
(HUMAN) 
LOCALIZATION IN THE 
HUMAN GENOME 
MAX 
SCORE 
RELATIVE 
SCORE (%) 
RUNX2 PUTATIVE 
BINDING SEQUENCE 
CTGF 
chr6: 132269512-132269521 4.14 94.1 CTACCACAT 
chr6: 132270934-132270925 6.64 95.6 CAACCACCA 
chr6: 132271935-132271926 11.74 98.6 CAACCGCAA 
CYR61 
chr1: 86046444-86046453 7.27 96 AGACCGCGA 
chr1: 86047194-86047203 5.36 94.8 CGACCACAC 
chr1: 86047279-86047270 12.26 99 AAACCACAA 
chr1: 86048526-86048517 8.11 96.5 GAACCGCAG 
SOX2 
chr3: 181430686-181430695 6.83 95.7 TACCCGCAG 
chr3: 181430914-181430905 9.88 97.5 TAACCACAG 
chr3: 181431302-181431311 9.71 97.4 AAACCGCGA 
chr3: 181431473-181431464 0.08 91.6 GTACCACTA 
chr3: 181430222-181430231 2.43 93.1 CCACCGCGG 
chr3: 181430304-181430295 3.62 93.8 GGACCACAC 
chr3: 181428582-181428591 6.87 95.7 CCACCACAA 
chr3: 181429469-181429460 6.06 95.2 ACACCACAC 
ASCL1 
chr12: 103349919-103349928 8.2 96.5 TCACCACAA 
chr12:103350513-103350504 4.44 94.3 CTACCGCCA 
chr12: 103353685-103353694 3.78 93.9 AAACCCCAT 
chr12: 103353976-103353967 9.48 97.3 AAACCACAT 
NEUROG2 
chr4: 113436266-113436257 10.77 98.1 AAACCGCAT 
chr4: 113439955-113439964 6.08 95.2 TAACCCCAA 
NEUROD1 
chr2: 182542264-182542255 4.84 94.5 ACACCACGA 
chr2: 182542484-182542475 0.92 92.2 AACCCACTG 
chr2: 182543055-182543046 4.12 94.1 AACCCACCA 
chr2: 182543029-182543038 6.77 95.7 AGCCCGCAA 
chr2: 182543908-182543899 6.64 95.6 CAACCACCA 
 chr2: 182543847-182543856 0.95 92.2 ACACCACTC 
 chr2: 182544607-182544598 1.82 92.7 TTACCGCTC 
 chr2: 182545639-182545648 6.83 95.7 TACCCGCAG 
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Supplemental Table S7. Oligonucleotides used for ChIP. 
GENE PRODUCT FORWARD PRIMER (5´- 3´) REVERSE PRIMER (5´- 3´) 
CTGF 3´UTR GGTTTGGCCTAGCACTCCA TCTGGTGACCTGCTCAATTT 
CTGF TCAGACGGAGGAATGCTGAG CGAGGCTTTTATACGCTCCG 
CYR61 AGCAAACAGCTCACTGCCTT ATGGTAGTTGGAGGGTCGTG 
SOX2 TIR-a (1) CATTTGAAAGCCGCACGACC ATGCTTCTACTGTCTGCCCC 
SOX2 TIR-a (2) ACCGAAACCCTTCTTACGGG AACCGTAGCAAAGGGGATGC 
SOX2 TIR-a (3) GCACGACCGAAACCCTTCTT TCAACCGTAGCAAAGGGGAT 
SOX2 TIR-b (1) AGAGAAAACCTGGGGAGGGT GCAAAGCTCCTACCGTACCA 
SOX2 TIR-b (2) CTGGACTTCTTTTTGGGGGACT GCAAAGCTCCTACCGTACCA 
SOX2 TIR-c (1) ATTACCCTCTTGGGTCCTGG CAGCGCACACTGGGAGAA 
SOX2 TIR-c (2) AAATTACCCTCTTGGGTCCTGG CACACTGGGAGAAGGCGG 
ASCL1 TIR-a (1) TGGGTGCTCACCTCCTATACT GTGGGATTCACACCTCAGGC 
ASCL1 TIR-a (2) TTTGGGTGCTCACCTCCTAT GGATTCACACCTCAGGCCTTT 
ASCL1 TIR-b CGTCATTACTGCCCACCATC TAAAGGGCCAAGGGGATGAC 
ASCL1 TIR-c (1) AGGCCACCAGTTGTACTTCA TGCCACTTTGAGTTTGGACAG 
ASCL1 TIR-c (2) GCCACCAGTTGTACTTCAGCA GCCACTTTGAGTTTGGACAGTA 
NEUROG2 TIR-a (1) TGCAACTGGTTCCTGTGATCT GCCAGCCATTGCAAATCTGT 
NEUROG2 TIR-a (2) TGGTTCCTGTGATCTCTTCACC CAGCCATTGCAAATCTGTGGA 
NEUROG2 TIR-a (3) GGGGAATGCAACTGGTTCCT ACCAGCAAAATCATTCAGATGC 
NEUROG2 TIR-a (4) GCAACTGGTTCCTGTGATCT TTACCAGCAAAATCATTCAGATGC 
NEUROG2 TIR-b (1) AGAGGGGCAGGTTAGAAGTCA AGCCTAAATTTCCACGCTTGC 
NEUROG2 TIR-b (2) TGTTTTGTTAGAGGGGCAGGT GCCTAAATTTCCACGCTTGCAT 
NEUROD1 TIR-a (1) GTCCGCGGAGTCTCTAACTG ATGCGCCATATGGTCTTCCC 
NEUROD1 TIR-a (2) CTAACTGGCGACAGATGGGC CATTTGTATGCCGCGGAGC 
NEUROD1 TIR-a (3) CTGCGGGTAAAAACAGGTCC ACGTGACCTGCCCATTTGTAT 
NEUROD1 TIR-b (1) CCTTGAGTATTCACACCATGGAA GAGCGGTAACAGGTAGCAGG 
NEUROD1 TIR-b (2) TGGATACCTTGAGTATTCACACCA GGAGCGGTAACAGGTAGCAG 
NEUROD1 TIR-c AGCCAGGACAGAAATGGAAGT TGCCCGACAGGATAATGTGT 
 
Supplemental Table S8. Oligonucleotides used for qRT-PCR. 
GENE PRODUCT FORWARD PRIMER (5´- 3´) REVERSE PRIMER (5´- 3´) 
ACTB TCCTTCCTGGGCATGGAG AGGAGGAGCAATGATCTTGATCTT 
ASCL1 CATCTCCCCCAACTACTCCA GAAAGCCATGTCTCTCAGGC 
CTGF CTTCTGTGACTTCGGCTCCC GATGCAGGGAGCACCATCTT 
CYR61 CCAAGAAATCCCCCGAACCA CGGAACCGCATCTTCACAGT 
GAPDH CTCTCTGCTCCTCCTGTTCGAC TGAGCGATGTGGCTCGGCT 
NEUROD1 GGTGCCTTGCTATTCTAAGACGC GCAAAGCGTCTGAACGAAGGAG 
NEUROG2 ATCCGAGCAGCACTAACACG GCTGAGGCACAGTTAGAGCC 
SOX2 GAGCTTTGCAGGAAGTTTGC GCAAGAAGCCTCTCCTTGAA 
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
TEAD1 CTGAGTCGCAGTTACCACCA AGCCTGGAGCCTTTTCAAG 
TEAD2 ACATGATGAACAGCGTCCTG CAGCAGTTCCTGGGTGTCTC 
TEAD3 CATCGAGCAGAGCTTCCAG CGTGCAATCAACTCATTTCG 
TEAD4 GCCTTCCACAGTAGCATGG AAAGCTCCTTGCCAAAACC 
WWTR1 TTTCCTCAATGGAGGGCCA GGGTGTTTGTCCTGCGTTTT 
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Supplemental Table S9. Primary antibodies. 
Antibody Reference Clonality Isotype Dilution and application 
Acetyl-Histone 
H3 
Sigma Aldrich. 06-599. Polyclonal Rabbit 1.5 µg (ChIP) 
CTGF (L-20) 
Santa Cruz Biotechnology. 
Sc-14939. 
Polyclonal Goat 1/2000 (WB) 
Doublecortin 
Santa Cruz Biotechnology. Sc-
8066. 
Polyclonal Goat 1/250 (IHC-Fr; ICC/IF) 
GAPDH Millipore. CB1001. Monoclonal Mouse 1/15000 (WB) 
GFAP Dako. Z0334. Polyclonal Rabbit 1/200 (IHC-Fr; ICC/IF) 
GFAP Sigma-Aldrich. G3893. Monoclonal Mouse 1/200 (IHC-Fr; ICC/IF) 
IgG2a Abcam. Ab18413. Monoclonal Mouse 1/250 (ChIP) 
Lamin B 
Santa Cruz Biotechnology. Sc-
6217. 
Polyclonal Goat 1/2000 (WB) 
MAP2 Sigma-Aldrich. M9942. Monoclonal Mouse 1/200 (ICC/IF) 
Nestin Abcam. Ab11306. Monoclonal Mouse 1/200 (IHC-Fr; ICC/IF) 
Nestin Novus Biologicals. NB100-1604. Polyclonal Chicken 1/500 (IHC-Fr; ICC/IF) 
Nestin (10c2) 
Santa Cruz Biotechnology. Sc-
23927. 
Monoclonal Mouse 1/200 (IHC-Fr; ICC/IF) 
NEUROD (A-10) 
Santa Cruz Biotechnology. Sc-
46684. 
Monoclonal Mouse 1/500 (WB) 
RNA Pol II  (A-
10) 
Santa Cruz Biotechnology. Sc-
17798. 
Monoclonal Mouse 3 µg (ChIP) 
Rabbit IgG 
Control 
Abcam. Ab37415. Polyclonal Rabbit 1/100 (ChIP) 
SOX2 R&D Systems. AF2018. Polyclonal Goat 
1/500 (IHC-Fr; ICC/IF) 
1/2000 (WB) 
TAZ Sigma Aldrich. HPA007415. Polyclonal Rabbit 
1/2000 (WB) 
1/200 (IHC-Fr; ICC/IF) 
1/100 (ChIP)  
Tubulin β class 
III (TUBB3) 
Sigma-Aldrich. T2200.  Polyclonal Rabbit 1/200 (ICC/IF) 
V5 Life Technologies. 37-7500. Monoclonal Mouse 1/2000 (WB) 
YAP/TAZ  
(D24E4) 
Cell Signaling Technology. 8418. Monoclonal Rabbit 
1/2000 (WB) 
1/250 (IHC-Fr; ICC/IF; IHC-P) 
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Abstract
Signiﬁcance: Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting
human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical
scavenging of pro-oxidant molecules, has been unsuccessful. Recent Advances: An alternative emerging approach is
to target the enzymatic sources of disease-relevant oxidative stress. Several such enzymes and isoforms have been
identiﬁed and linked to different pathologies. For some targets, the respective pharmacology is quite advanced, that is,
up to late-stage clinical development or even on the market; for others, drugs are already in clinical use, although not
for indications based on oxidative stress, and repurposing seems to be a viable option. Critical Issues: For all other
targets, reliable preclinical validation and drug ability are key factors for any translation into the clinic. In this study,
speciﬁc pharmacological agents with optimal pharmacokinetic proﬁles are still lacking. Moreover, these enzymes also
serve largely unknown physiological functions and their inhibition may lead to unwanted side effects. Future
Directions: The current promising data based on new targets, drugs, and drug repurposing are mainly a result of
academic efforts. With the availability of optimized compounds and coordinated efforts from academia and industry
scientists, unambiguous validation and translation into proof-of-principle studies seem achievable in the very near
future, possibly leading towards a new era of redox medicine. Antioxid. Redox Signal. 23, 1113–1129.
Introduction
Oxidative stress is the production of reactive oxygenspecies (ROS) to high nonphysiological concentrations
or at nonphysiological locations.Mechanistically, this can lead
to DNA damage, lipid peroxidation (72), protein modiﬁcation,
and other pathological effects observed in various chronic
disorders, including neurodegenerative, cardiovascular and
diabetes-associated renal diseases, and cancer.Many therapeutic
attempts to improve patient-relevant outcomes using exoge-
nous small-molecule antioxidants, such as vitamins C and E,
have failed (38) or even increased mortality (101) such as in
the settings of diabetes mellitus (168, 169).
Possible explanations for this paradox may reside in the
lack of speciﬁcity of antioxidants towards a certain cellular
compartment or tissue, and/or the possibility of generating
reductive stress, by increasing levels of reducing agents and
therefore disturbing redox homeostasis in the opposite
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direction. Exogenous antioxidants are also likely to interfere
with both disease-triggering and physiological ROS levels.
The latter regulate extracellular matrix, control vasomotor
activity, are involved in the innate immune response, and
promote cell differentiation, proliferation, and migration
(4, 10, 161, 163).
Another somewhat indirect type of antioxidant therapeutic
strategy that could have fewer side effects relies on the ac-
tivation of endogenous antioxidant responses. In this context,
pharmacological activation of the transcription factor NRF2
is promising therapeutic option currently studied clinically.
The conceptual difference between these two antioxidant
approaches is broad unspeciﬁc scavenging versus a localized
response at physiological (sub)cellular sites. Only the latter
has promise in leaving physiological ROS formation and
signaling intact.
Of far broader relevance is a third approach that involves the
speciﬁc inhibition of the disease-relevant sources of ROS. In
this case, the key question is which enzyme to target. Besides
NADPH oxidases (NOXs) (10), xanthine oxidase (XO) (96),
uncoupled nitric oxide synthase (uc-NOS) (155), and mono-
amine oxidases (MAOs) (39), other sources such as cyto-
chrome P450 oxidases (44), lipoxygenases (170), and the
mitochondrial electron transport chain (134) are all able to
generate ROS. Among these, NOXs stand out as their primary
function is to produce ROS. All other enzymes do not form
ROS as their primary function, but only as a collateral or side
product. Examples include uc-NOS, uncoupled mitochondria,
and XO. Additional approaches include the inhibition of
ROS-toxifying peroxidases, such as myeloperoxidase (MPO),
or the functional repair of oxidatively damaged proteins, such
as the redox-sensitive soluble guanylate cyclase (sGC), a
principle that has already entered the clinic.
We here review the current status and outlook of the most
advanced areas in the ﬁeld of translational redox medicine by
focusing on drugs in four categories:
 Activators of endogenous antioxidant defense systems
(indirect antioxidants)
 Inhibitors of ROS formation
 Inhibitors of ROS toxiﬁcation
 Compounds that allow functional repair of ROS-induced
damage
Activators of Antioxidant Defense Systems
The main, if not only, representativemembers of this group
of drugs are nuclear factor (erythroid-derived 2)-like 2 (NRF2)
activators. NRF2 is a basic region-leucine zipper (bZIP) tran-
scription factor (Fig. 1A) that forms heterodimers with other
bZIP partners, of which the small musculoaponeurotic ﬁbro-
sarcoma proteins are the best characterized. Together, they
recognize an enhancer sequence termed Antioxidant Response
Element (ARE) that is present in the regulatory regions of over
250 genes (ARE genes), including antioxidant genes such as
HMOX1 (coding heme oxygenase-1) (58). These genes encode
enzymes involved in antioxidant reactions, including those
driven by glutathione and thioredoxin, generation of nicotin-
amide adenine dinucleotide phosphate (NADPH), biotrans-
formation, proteostasis, and even DNA repair (58, 90, 135).
The main mechanism of regulation of NRF2 transcrip-
tional activity is through control of protein stabilization by
the E3 ligase adapter Kelch-like ECH-associated protein 1
FIG. 1. Domain structures of NRF2 and KEAP1. (A) Domain structure of NRF2. NRF2 possesses six highly conserved
domains called NRF2-ECH homology (Neh) domains (105). The functional role of each Neh domain is speciﬁed. Within
the Neh2 domain, the low-afﬁnity (DLG) and high-afﬁnity (ETGE) binding domains to KEAP1 are zoomed in. (B) Domain
structure of a KEAP1 monomer showing the position of cysteine residues. The N-terminal BTB (bric-a-brac, tramtrack,
broad-complex) domain participates in homodimerization and binding to Cul1/Rbx. The C-terminal region, Kelch repeat,
DGR domain, contains a WD40 propeller that binds NRF2 at its Neh2 domain. The intervening region connects BTB
and DGR domains and is particularly rich in redox-sensitive cysteine residues. C151 is targeted by some electrophiles
(tert-butylhydroquinone, diethylmaleate, sulforaphane, and dimethylfumarate; see Fig. 2) disrupting the KEAP1-Cul3 in-
teraction. Other important cysteines are C272 and C288 that react with other compounds (15-deoxy-D12,14-prostaglandin J2,
2-cyano-3,12 dioxooleana-1,9 diene-28-imidazolide, ebselen, and cadmium chloride; see Fig. 2) leading to a conforma-
tional distortion of the DC domain and altering the KEAP1-NRF2 interaction (147). BTB, (bric-a-brac, tramtrack, broad-
complex); DGR, double glycine repeat; DLG, aspartate leucine glycine; ETGE, glutamate, threonine, glycine, glutamate;
KEAP1, kelch-like ECH-associated protein 1; Rbx, ring box protein.
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(KEAP1). This is a homodimeric zinc (Zn) ﬁnger protein that
bridges NRF2 with the E3 ligase complex formed by Cullin3
and Rbx proteins (Cul3/Rbx). Under homeostatic conditions,
the N-terminal domain of the KEAP1 homodimer binds
one molecule of NRF2 at two amino acid sequences of low
(aspartate leucine glycine) and high glutamate, threonine,
glycine, and glutamate (ETGE) afﬁnity, thus presenting
NRF2 to ubiquitination by Cul3/Rbx (152). However, in the
presence of ectopic or endogenous electrophiles, KEAP1 is
inactivated.
Mechanistically, electrophiles modify sulfhydryl groups of
speciﬁc redox-sensitive cysteines of KEAP1, including C151,
C273, and C288 (Fig. 1B). These modiﬁcations of KEAP1
lead to changes in NRF2 recognition, alterations in dimer
conformation, or interaction with Cul3/Rbx. As a result, NRF2
escapes KEAP1-dependent degradation, accumulates in the
nucleus, and activates ARE genes.
KEAP1 is one of the best-suited proteins to act as an
electrophilic/redox sensor as it contains a large number of
cysteine residues (27 in the human protein) and can function as
an electrophile trap. However, other proteins such as phos-
phatase and tensin homolog (PTEN), which is mutated in a
large number of human tumors, are also redox sensitive (55, 79,
84) and affect NRF2 activity. The catalytic C124 residue of
PTEN can be modiﬁed through adduct formation with strong
electrophiles such as synthetic triterpenoids (2-cyano-3,12-
dioxooleana-1,9-dien-28-oic acid-imidazolide; CDDO-Im)
(114) and tert-butylhydroquinone (121). This modiﬁcation
results in loss of the PTEN lipid phosphatase activity and yields
a more sustained activation of signaling events downstream of
phosphoinositide 3-kinase, leading to NRF2 activation by a
KEAP1-independent mechanism (117, 118). Thus, electro-
philic targeting ofNRF2may involve not onlyKEAP1 but also
other redox-sensitive enzymes. Moreover, KEAP1 interacts
with other proteins that also contain the high-afﬁnity binding
motif, ETGE (57), such as inhibitor of nuclear factor kappa-B
kinase subunit beta and Bcl-2 (78, 109). Hence, some results
obtained from KEAP1 mutant or -deﬁcient cells may not be
necessarily related to the control of NRF2.
Several groups of electrophilic compounds induce NRF2
in cell culture and less frequently in animals or humans (120)
[Fig. 2; for a detailed list of KEAP1 ligands, see refs. (37, 59,
91)]. Many of these compounds are used as nutraceuticals,
and for some of them, there is evidence of clinical efﬁcacy.
The most successful drug of this type is the ester derivative of
fumaric acid, dimethyl fumarate (DMF) (87). DMF crosses
the gastrointestinal barrier where it is converted into mono-
methyl fumarate. The ﬁrst clinical use of DMF was for the
topical treatment of psoriasis in 1994 (5). More recently, an
oral formulation of DMF, known as BG12, was commer-
cialized for the treatment of relapsing–remitting multiple
sclerosis (14, 76). Other autoimmune diseases such as lupus
erythematosus, asthma, and arthritis are under investigation
with other formulations of fumarate esters (128, 153).
Other lines of research have focused on targeting NRF2 in
degenerative diseases where low-grade chronic inﬂammation
is present. One very potent synthetic triterpenoid, CDDO-
methyl ester, bardoxolone methyl, has been studied in great
detail for treatment of diabetic nephropathy (157). The initial
excitement about this compound was set back by a small yet
signiﬁcant increase in the risk of heart failure. Importantly
though, this effect appears not to be related to NRF2 targeting,
but rather to alteration of endothelin signaling, leading to
reduction in urine volume and sodium excretion in some
patients with advanced chronic kidney disease (26). Bar-
doxolone methyl is now being studied in new indications
for pulmonary arterial hypertension, melanoma, and Frie-
dreich’s ataxia.
A third NRF2 inducer that has reached the level of clinical
studies is the isothiocyanate sulforaphane (SFN) isolated
from broccoli sprout extracts. Contrary to DMF and bar-
doxolone methyl, a drawback of this compound is the ab-
sence of a pure formulation that could be used clinically and
the lack of commercial value. Nevertheless, SFN provided
proof of concept that NRF2 targeting has a therapeutic
potential (40, 129, 132). Furthermore, NRF 2 agonists in
clinical development are summarized in Table 1.
Inhibitors of ROS-Forming Enzymes
NADPH oxidase inhibitors
NOXs are transmembrane proteins comprising seven
members (NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1,
and DUOX2). Each NOX isoform has speciﬁc tissue ex-
pression and regulation (10, 85). The catalytic core of all
NOXs contains four conserved C-terminal NADPH-binding
subregions and two ﬂavin adenine dinucleotide (FAD)-
binding subregions, as well as four conserved histidine resi-
dues, which coordinate two nonidentical iron heme prosthetic
groups located between transmembrane domains 3 and 5.
They are commonly referred to as the inner and outer heme,
depending on their proximity to the cytosol and extracellular
space, respectively. NOX activity was ﬁrst described in
neutrophils (7) where it forms superoxide anion radical (O2
-)
as part of the phagocytic oxidative burst of the innate immune
response (65). All NOX enzymes catalyze the reduction of
extracytosolic oxygen (i.e., in phagosomes, endosomes, or
the extracellular space) with cytosolic NADPH serving as an
electron donor. The activity of most NOX isoforms is tightly
regulated: NOX1, NOX2, and NOX3 require the presence of
cytosolic proteins, while NOX4 generates ROS in a consti-
tutive manner; NOX5 and DUOX isoforms require increased
cellular Ca2+ concentrations and binding to N-terminal EF-
hand domains for full activity. NOX5 is also a notable ex-
ception with respect to preclinical target validation; it is
present in several mammals, including humans, but not in
mice and rats. Increasing evidence shows that inhibition of
NOX activity can be beneﬁcial in multiple models of human
diseases [for details, see Casas et al. in the same Forum (24)].
In addition, NOX2-derived ROS can have anti-inﬂammatory
effects under certain conditions such as rheumatoid ar-
thritis and multiple sclerosis (67). This provides a rationale
for the development of NOX activators. Many advantages
and pitfalls of currently available NOX inhibitors have
been recently comprehensively reviewed in (4) and (69).
In this study, we focus on three chemical compound fam-
ilies, with one compound currently in clinical development
(Table 2).
GKT136901 and GKT137831 were developed by Gen-
KyoTex to explore structure–activity relationship along
pyrazolopyridine dione compounds (82). These compounds
were selected based on oral bioavailability and beneﬁcial
pharmacokinetic parameters (4, 70). They block NOX1,
NOX4, NOX5, and DUOX (142) activity in the micromolar
DRUGS IN REDOX MEDICINE 1115
range. In terms of off-targets effects, GKT136901 also scav-
enges peroxynitrite (125), but no interference was identiﬁed
with other redox-sensitive enzymes, G-protein-coupled recep-
tors, kinases, ion channels, or other enzyme activity (4).
However,GKT136901 interactswithAmplexRedﬂuorescence
and dose dependently decreases the signal, thereby complicating
the interpretation of in vitro results (4). Preclinical results show
that GKT137831 reduces glomerular injury and structural
changes, aswell asmacrophage inﬁltration andproinﬂammatory
transcription factor expression, in models of diabetic nephrop-
athy (54, 70). GKT137831 has entered a clinical study phase II
clinical trial, testing its efﬁcacy in diabetic type 2 patients with
diabetic nephropathy (50a) (study completed 2015).
Vasopharm developed the triazolo pyrimidine, VAS2870,
following a screening approach for NOX2 inhibitors (139,
148). Its derivative, VAS3947, was later generated to slightly
improve VAS solubility while keeping a similar NOX in-
hibitory proﬁle.
Both compounds are able to inhibit different NOX iso-
forms, such as NOX2 (4), NOX 4, and NOX5 (3, 81), in the
micromolar range. Intrathecal injection of VAS2890 signif-
icantly reduced cerebral infarct volume and ROS production
in a mouse stroke model, suggesting a crucial contribution of
one or more NOX enzymes in stroke (Table 2).
However, VAS2870 presents a number of limitations: (i) it
blocks NOX2-derived ROS in neutrophils; (ii) its mode of
action is independent of NOX2 (50); (iii) it is cytotoxic at low
concentrations (171); and (iv) it exerts thioalkylation of cysteine
residues in vitro, with so far unknown functional relevance
(4, 144). In terms of drug development, a proof of principle of
VAS compounds in humans is currently unfeasible due to their
low solubility and unknown oral pharmacokinetic proﬁle.
FIG. 2. Molecular formu-
las of some common redox-
active compounds. These
compounds are capable of
modifying protein cysteine
thiols by oxidation, reduction,
alkylation, and metal chela-
tion and presumably disrupt
the KEAP1/NRF2 interaction.
The classiﬁcation has been
simpliﬁed fromMa et al. (91).
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Recently, GSK2795039, a novel NOX2 inhibitor, abolished
NOX2-inducedROSproduction inamodelofpaw inﬂammation
and is protective in an animalmodel of acute pancreatitis (62). A
pharmacokinetic/pharmacodynamic evaluation indicates that
GSK2795039 is suitable for in vivo use. Further assessment of
this compoundwill provide insights regarding its possible utility
for validation of NOX2 as a pharmacological target.
XO inhibitors
Xanthine oxidoreductase (XOR), a 300-kDa homodimer,
can exist as an NAD-dependent dehydrogenase (XD) or as an
O2-dependent oxidase (XO), depending on the oxidation state
of its cysteine thiols (95). XD can be converted into the ROS-
generating XO either by formation of intramolecular dis-
ulﬁde bonds (reversible) or by proteolytic cleavage of a loop
region connecting the FAD-binding domain and the
molybdenum-binding domain (irreversible) (107). While XD
depends on NAD+ (31, 140), XO uses O2 as electron acceptor
and generates O2
- and H2O2 as products (110). As a conse-
quence, XO conversion from XD could be a direct conse-
quence of increased oxidative stress and results in further
production of ROS by XO.
XO may contribute to the pathogenesis of various diseases,
such as coronary artery disease, type 2 diabetes, and idiopathic
dilated cardiomyopathy (21, 22). The XO inhibitor, allopuri-
nol, an analog of hypoxanthine, and its active metabolite,
oxypurinol, have been in clinical use formore than 40 years for
the treatment of hyperuricemia and gout (41). A recent meta-
analysis of 38 clinical trials with allopurinol or oxypurinol in
patients with chronic heart failure and coronary artery disease
has concluded that XO inhibition improves endothelial func-
tion and circulating markers of oxidative stress in patients
with, or at risk of, cardiovascular disease (61). Because het-
erogeneity in those studies made it impossible to come to a
conclusion on the effect of XO inhibitors on cardiac outcome,
larger prospective multicenter trials are needed (61). Most
recently, a study involving 253 high-risk heart failure patients
with elevated uric acid levels failed to show improvement with
allopurinol in clinical and functional parameters (53).
In 2009, the XOR inhibitor, febuxostat (TEI-6720, TMX-
67), was approved by the Food and Drug Administration and
marketed for gout (9) as more selective and potent than
allopurinol and oxypurinol (110). In contrast to allopurinol,
febuxostat has no structural similarity to a purine. Therefore, it
has no effects on the activities of other enzymes involved in
purine and pyrimidinemetabolism, such as guanine deaminase,
hypoxanthine-guanine phosphoribosyltransferase, purine nu-
cleoside phosphorylase, orotate phosphoribosyltransferase, and
orotidine-5V-monophosphate decarboxylase, compared with
allopurinol (166). Contrary to allopurinol and oxypurinol,
febuxostat, a potent inhibitor of both XO and XD (146), forms
stable long-lasting complexes with the oxidized XOR (111). Its
therapeutic application may be useful in cases of allopurinol
incompatibility (8). From an experimental point of view,
febuxostat may be a superior tool over allopurinol, which may
have intrinsic radical scavenging properties that could make it
difﬁcult to distinguish between its antioxidant effects and XO
inhibition. For example, it was proposed that the protective
effects of allopurinol after hypoxia cannot be entirely explained
by XO inhibition alone (104).
Another compound used in preclinical studies is BOF-4272
[sodium-8-(3-methoxy-4-phenylsulﬁnyl-phenyl) pyrazolo[1,
5-a]-1,3,5-triazine-4-olate monohydrate] (112), which specif-
ically inhibits XO-based O2
- generation (94, 100, 123, 145).
However, it could not be tested clinically because of unfa-
vorable pharmacokinetics due to both hepatic metabolism and
poor intestinal absorption (108).
Other newly introduced XO inhibitors, such as naphto-
ﬂavons, 1,3,5-triazine-based purine analogs, and topiroxostat
(FYX-051, 4-[5-pyridin-4-yl-1H-[1, 2, 4] triazol-3-yl]pyridine-
2-carbonitrile), are currently being tested in preclinical studies
(86, 93, 108, 131). A selection of substances in clinical devel-
opment is shown in Table 3.
MAO inhibitors
The attention on MAO as a drug target has been driven by
the serendipitous discovery of the antidepressant effect of the
Table 3. Monoamine Oxidase and Xanthine Oxidase Inhibitors:
Mechanism of Action and Treatment Indications
Target Compound Basic mechanism of action Pathology
MAO Hydrazines (Phenelzine,
isocarboxazid,
tranylcypromine)
Nonselective and irreversible MAO
inhibitors
Major depressive disorder (130)
Moclobemide,
toloxatone, pirlindole
Selective and reversible MAO-A inhibitors Depression, anxiety (130)
Rasagiline, selegiline Selective and irreversible MAO-B inhibitors PD, depression, neurodegenerative
diseases (30)
Saﬁnamide Selective and reversible MAO-B inhibitor PD (15, 16)
XO Allopurinol and
oxypurinol
XOR inhibitor oxypurinol is the active
metabolite of allopurinol.
Hyperuricemia and gout (46)
cardiovascular disease
Febuxostat Nonpurine XOR inhibitor. More selective
and potent than allopurinol. Do not
interfere with other metabolic enzymes.
Hyperuricemia and gout (8) more
effective, safe, and well tolerated
than allopurinol (8, 27).
BOF-4272 Inhibits XOR-based superoxide generation. Impossible for clinical use due to low
blood concentrations (112)
Topiroxostat XOR inhibitor Hyperuricemia and gout (86, 93, 107)
PD, Parkinson’s Disease; MAO, monoamine oxidase; BOF-4272 sodium,7-[4-(benzenesulﬁnyl)-3-methoxyphenyl]-1,3,9-triaza-5-
azanidabicyclo[4.3.0]nona-3,6,8-trien-2-one; XO, xanthine oxidase; XOR, xanthine oxidoreductase.
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antitubercular agent, iproniazid, which was found to act as an
MAO inhibitor (35). This observation paved the way to the
clinical use of MAO inhibition in depressive disorders (130).
Recently, MAO has become also a drug target for ROS-related
pathologies. Due to its localization on the outer mitochondrial
membrane, H2O2 and other MAO products [aldehydes and
ammonia; for details, see Casas et al. in the same Forum (24)]
can accumulate in the mitochondria to a signiﬁcant extent and
affect mitochondrial function (73). This can further lead to
ampliﬁcation of oxidative stress and cell damage so that the
inhibition of MAO is beneﬁcial in a number of disease models
[for details, see Casas et al. in the same Forum (24); (11, 17,
18, 36, 73, 74, 98, 136, 156, 165)].With the possible exception
of NOX4 [for details, see Hirschha¨user et al. in the same
Forum (63)]), MAO is the only known mitochondrial ROS
source that can be inhibited pharmacologically without inter-
fering with energy metabolism.
MAO exists in two isoforms, A and B, which generate H2O2
as a by-product during the oxidative deamination of biogenic
monoamines. A wide range of MAO inhibitors are in clinical
use, targeting one or both isoforms. Clorgyline is the proto-
typic MAO-A-speciﬁc inhibitor, while deprenyl inhibits
MAO-B, and pargyline is nonselective. Recently, other more
selective MAO inhibitors have been developed for the treat-
ment of depressive disorders (130). Of those, phenelzine,
isocarboxazid, and tranylcypromine are nonselective and ir-
reversible MAO inhibitors, while moclobemide, toloxatone,
and pirlindole are MAO-A selective and reversible. Selective
and irreversible MAO-B inhibitors, such as selegiline and ra-
sagiline, are widely prescribed for the treatment of affective
and neurodegenerative disorders (Table 3), for example, mild
symptoms of Parkinson’s disease (PD) and associated motor
ﬂuctuations (30). Recently, speciﬁc and reversible MAO-B
inhibitor, saﬁnamide, has been launched in Germany for the
treatment of mid- to late-stage PD in combination with levo-
dopa or other PD therapies (15, 16). The therapeutic potential
of MAO-B inhibitors is currently being evaluated also for the
treatment of Alzheimer’s disease. GABA formation from re-
active astrocytes is mediated by MAO-B and affects synaptic
plasticity, learning, and memory (71). Since astrocytic GABA
and MAO-B are upregulated also in postmortem brains of
individuals affected by Alzheimer’s disease, MAO-B inhibi-
tion has been proposed as a potentially effective therapeutic
strategy for treating memory impairment in this disease. In-
deed, ladostigil, a dual acetylcholine butyrylcholine esterase
and brain-selective MAO-A and -B inhibitor, was shown to
antagonize scopolamine-induced impairment in spatial mem-
ory (66). More recently, a new small-molecule MAO-B
inhibitor, EVT 302, is currently in phase IIb clinical trial for
the treatment of Alzheimer’s disease.
MAO inhibition can also be the result of an off-target
effect. For example, the PPAR-gamma agonist, pioglitazone,
used for the treatment of type 2 diabetes, speciﬁcally inhibits
MAO-B in a reversible manner (12), a property that is not
shared by other members of the glitazone family, such as
troglitazone and rosiglitazone. Importantly, this off-target
effect may contribute to the beneﬁcial effects of pioglitazone
in diabetic cardiomyopathy.
To date, MAO inhibitors have been used in patients to
preserve or increase monoamine levels. It remains to be
investigated clinically whether MAO inhibitors modulate
oxidative stress-based pathologies and whether their use can
be extended to other indications. The most relevant hurdle in
the clinical development of MAO inhibitors is represented by
a hypertensive reaction occurring when selective MAO-A
inhibition is combined with intake of tyramine-rich food,
such as aged cheese and alcoholic beverages (43). Tyramine
is mostly oxidized by intestinal MAO-A; MAO-A inhibition
causes an increase in circulating tyramine, which is taken
up by postganglionic sympathetic neurons and induces
noradrenaline release. However, MAO-B and reversible
MAO-A inhibitors are devoid of this potential risk (167).
Other minor contraindications and concerns related to MAO
inhibitors are listed in (162).
NOS inhibitors
Nitric oxide (NO) is another ROS, although mostly with
beneﬁcial effects. However, under certain conditions, over-
production may cause cell death, for example, in neurotrauma
and stroke. Most NOS inhibitors are based on displacing the
substrate, arginine, off its binding site. However, none of these
has been approved as a drug for any indication. The most
dramatic failure was NG-mono-methyl-l-arginine (L-NMMA)
in septic shock (89), where L-NMMA resulted in a 10%
increase in overall mortality due to a higher proportion of
cardiovascular deaths. Another analog, the amidino amino acid
N6-(1-iminoethyl)-l-lysine (L-NIL), applied as its 5-tetrazole-
amide prodrug (L-NIL-TA, SC-51) was tested to treat asthma.
Oral administration of L-NIL-TA reduced exhaled NO levels
in both healthy volunteers and asthmatics for at least 72h
without affecting blood pressure and pulse rate, but did not
improve respiratory function (56). Finally, GW273629 (3-[[2-
[(1-iminoethyl)amino]ethyl] sulfonyl]-l-alanine) was ineffec-
tive in the treatment of acute migraine (154).
The most advanced and currently most successful thera-
peutic approach is to target another and more unique binding
site in NOS, the redox-sensitive cofactor, tetrahydrobiopterin
(13, 48). Vasopharm’s VAS203 has been successfully devel-
oped up to phase II for traumatic brain injury (141) (Table 4).
Inhibitors of ROS Toxiﬁcation
These inhibitors target enzymes that do not produce ROS
but metabolize ROS to other more toxic species. The most
prominent example is myeloperoxidase (MPO).
MPO inhibitors
MPO is a heme protein that can use H2O2 to oxidize Cl
- to
the highly reactive hypochlorous acid (HOCl), a potent oxi-
dizing agent, but can also generate free radicals through its
catalytic peroxidase cycle (77). Besides the major halide Cl-,
MPO can also utilize bromide (Br-) to form brominating
species, including hypobromous acid (HOBr) (60).
MPO is abundant in neutrophils and certain macrophages
where it plays a role in the innate immune response. MPO-
derived oxidants also have the potential to cause host tissue
injury via initiation of post-translational protein modiﬁcations
(i.e., chlorination) of proteins (115, 164) and lipid peroxidation
(124). As a result, MPO-mediated oxidative damage is thought
to contribute to a wide range of chronic inﬂammatory diseases,
including cardiovascular and neuroinﬂammatory diseases
(33, 106). The extracellular Br- concentration is much lower
than that of Cl- (149). Thus, the physiological relevance of
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brominating oxidants such as HOBr, although they elicit an-
timicrobial effects in vitro (80, 159), has yet to be determined.
However, complete deﬁciency of MPO can be detrimental.
For example, mice deﬁcient in MPO and the low-density
lipoprotein receptor (Ldlr), that is, Mpo-/-Ldlr-/-mice, de-
velop larger atherosclerotic lesions comparedwith Ldlr-/-mice
(20), and engraftment of bone marrow from Mpo-/-mice into
Ldlr-/-mice increases rather than decreases the size of ath-
erosclerotic lesions (20). Moreover, mice lacking MPO are
more susceptible to experimental autoimmune encephalomy-
elitis, a mouse model of multiple sclerosis (19), and are pro-
tected from some features of PD (28). As a result of the implied
overall beneﬁt of phagocyte MPO, pharmacological strategies
to attenuateMPO-mediated inadvertent oxidant damage aim at
partial rather than complete inhibition of the enzyme.
Until recently, no speciﬁc MPO inhibitors were described
that could be considered drug candidates. Although a number
of commercially available compounds, including hydro-
xamic acids, hydrazines, and hydrazides, were used previ-
ously to inhibit the catalytic activity of MPO (92), they are
not speciﬁc and also inhibit other heme peroxidases.
More recently, AstraZeneca found that 2-thioxanthines are
potent and selective suicide inhibitors of MPO. Upon oxi-
dation by MPO compound I, the thioxanthine radical forms
an adduct with the heme prosthetic group of the enzyme,
resulting in inactivation of MPO (150). These new com-
pounds inhibit MPO activity in plasma, decrease protein
chlorination in a mouse model of peritonitis, and elicit a
range of beneﬁcial effects in various disease models, without
interfering with the killing of bacteria by neutrophils or other
peroxidases, for example, thyroid peroxidase or lactoperox-
idase activity (150). A number of thioxanthines have yielded
positive results in preclinical and clinical studies. For
example, the thioxanthine, AZD5904, stopped progression of
emphysema and small airway remodeling and partially pro-
tected against pulmonary hypertension in a guinea pig model
of chronic obstructive pulmonary disease (COPD) induced
by exposure to cigarette smoke (29). In addition to AZD5904
entering phase I clinical trials for COPD and multiple scle-
rosis, AstraZeneca has completed a phase IIA clinical trial
with another thioxanthine, AZD3241, in patients with PD
(116) (Table 5).
Another small-molecule inhibitor ofMPO is INV-315with a
submicromolar IC50 [0.9lM; (88)]. INV-315 decreases plaque
burden and improves endothelial function in apolipoprotein E-
deﬁcient mice fed a high-fat diet for 16 weeks, a commonly
used mouse model of atherosclerosis (88). However, no direct
evidence for MPO inhibition or improved endothelial function
was provided in that study. Pﬁzer, Inc., has also implemented a
discovery program targeting MPO in inﬂammation and has
ﬁled patents for 2-thiopyrimidones (Fig. 3), which have a
structure that is similar to 2-thioxanthines, suggesting that they
may also act as suicide inhibitors by forming adducts with the
heme moiety of MPO (23).
Functional Repair of ROS-Induced Protein Damage
This category of ROS-related drugs does not modulate
ROS formation, but corrects some of its functional conse-
quences. In the present review, we focus on NO-cGMP sig-
naling, which appears to be one of the major mechanisms of
deregulation initiated by oxidative stress (97). ROS can in-
terfere with NO-cGMP signaling in three manners:
 by uncoupling NOS,
 by chemically scavenging NO, or
 by oxidatively damaging the NO receptor, sGC.
Table 5. Myeloperoxidase Inhibitors: Mechanism of Action and Treatment Indications
Compound Chemical characteristics Basic mechanism of action Pathology
AZD3241 2-thioxanthine derivate MPO inhibitor by forming an adduct with
the heme prosthetic group of the enzyme.
Peritonitis (preclinical data)
PD (116)
AZD5904 2-thioxanthine derivate MPO inhibitor, Similar mechanism
of action as AZD3241.
Chronic obstructive pulmonary
disease (29)
MPO, myeloperoxidase.
Table 4. Nitric Oxide Synthase NOS Inhibitors: Mechanism of Action and Treatment Indications
Compound Chemical characteristics Basic mechanism of action Pathology
L-NMMA Arginine derivate Nonselective NO synthase inhibitor Septic shock dramatic failure
in clinical trials (89)
VAS203 Tetrahydrobiopterin
derivate
Nonselective NO synthase inhibitor Traumatic brain injury (141)
Tilarginine
acetate
Arginine derivate Nonselective NO synthase inhibitor Cardiogenic shock
complicating—acute
myocardial infarction (2)
L-NIL Arginine derivate L-NIL-TA
and SC-51 prodrug oral
administration
Inducible NO synthase inhibitor Asthma (56)
GW273629 Alanine derivate Inducible NO synthase inhibitor Acute migraine (154)
GW273629, (3-[[2-[(1-iminoethyl)amino]ethyl]sulfonyl]-l-alanine); L-NIL-TA, L-N6-(1-iminoethyl)lysine-5-tetrazole-amide; L-NMMA,
1-(4-aminopentyl)-2-methylguanidine; SC-51, L-N6-(1-iminoethyl)lysine 5-tetrazole amide.
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This essentially leads to four therapeutic options:
 to recouple uc-NOS [e.g., in peripheral arterial disease
(Clinical Trials Registry ACTRN12609000882224)]
 to replenish scavenged NO via NO donor compounds
 to sensitize sGC for lower NO levels [e.g., in pulmonary
arterial hypertension (52) and chronic thromboembolic
pulmonary hypertension (51)]
 to (re-)activate oxidatively damaged and heme-free
sGC (apo-sGC) (e.g., in calciﬁc aortic valve stenosis
[NCT02481258] and neuropathic pain [NCT00799656])
NO donors
For over 100 years, NO-releasing drugs have been in clin-
ical use. However, they have several serious side effects that
will most likely lead to their eventual replacement. First, many
NO donors are subject to tolerance, leading to loss of efﬁcacy
and requiring treatment interruptions. Moreover, they can lead
to systemic hypotension and reﬂex tachycardia. Another
concern is the fact that under oxidative stress, additional NO
from NO donors leads to a spillover and sGC activation, but
may also be metabolized to peroxynitrite. Thus, with NO do-
nors, NO-cGMP signaling is partially and acutely recovered,
but this happens at the expense of a chronic buildup of un-
wanted post-translational modiﬁcations such as protein tyro-
sine nitration (133). In addition, NO-drug hybrid molecules
comprising an established drug and an NO-releasing moiety
have been developed with the aim to preserve the pharmaco-
logical activity of the lead structure and add possibly beneﬁcial
effects ofNO. Of themany compounds tested and developed, a
series of NO-NSAIDs (nonsteroidal anti-inﬂammatory drugs),
nitrosylated adrenoreceptor antagonist moxisylate (S-NO-
moxisylate), and latanoprostene bunod (VESNEO), an NO-
donating prostaglandin F2-alpha analog, are currently most
advanced. The latter is currently in phase III clinical devel-
opment for the reduction of intraocular pressure in patients
with glaucoma and ocular hypertension. Results from the
phase 2b study conﬁrmed that the drug is safe (158). Whether
these combinations will not have similar limitations as other
NO donors remains to be seen.
HNO donors
Besides classical NO donors andNO-drug hybridmolecules,
recent preclinical studies and a phase IIa study reveal the
therapeutic potential of an NO-related species, nitroxyl (HNO),
which is developed as an HNO-donating drug (CXL-1020) by
Cardioxyl, for acute decompensated heart failure therapy (122).
However, serious inﬂammatory irritation at the injection site
led to development of a second-generation HNO donor, CXL-
1427, which is currently in clinical phase II testing. In contrast
to NO donors, HNO donors such as Angeli’s Salt/HNO appear
to not induce tolerance, at least preclinically (6, 68, 103). In-
terestingly, HNO seems resistant towards scavenging by su-
peroxide and retains efﬁcacy after repeated infusions (45, 103,
113, 122, 151). However, further proof-of-concept studies need
to be performed with safe HNO donors.
Recoupling uc-NOS
Oxidative damage of NOS is seen predominately not only
forNOS3/eNOS but also for NOS1/nNOS (102). For this, two
reversible processes are important, the oxidation of the
redox-sensitive NOS cofactor, tetrahydrobiopetrin (BH4)
(119), and the accumulation of an endogenous antagonist at
the arginine substrate binding site, asymmetric-dimethyl-l-
arginine (ADMA). ADMA is an independent risk marker, if
not a risk factor, for cardiovascular disease states [for details,
see Frijhoff et al. in the same Forum (47)], which may be
mechanistically related to uc-NOS.
To replenish the BH4 binding site, BH4 substitution is an
option (143). However, BH4 therapy under oxidative stress
may also carry the risk of leading to BH2 accumulation, a BH4
antagonist at the NOS BH4 binding site (13). The so-called
salvage pathway recycles oxidized BH2 back to BH4 via di-
hydrofolate reductase (25). Moreover, angiotensin II type 1
receptor blockers and statins may, among other actions, in-
crease the expression of the BH4-forming GTP cyclohydrolase
1 and therefore normalize low BH4 levels (160). High doses of
l-arginine may compete off ADMA on eNOS or normalize
intracellular ADMA levels. However, a direct antioxidant ef-
fect of the guanidine group is also possible (83). Moreover,
important differences exist in the bioavailability of arginine in
humans versus rodents. Hence, l-citrulline, which is absorbed
with near 100% bioavailability, may be a better alternative in
humans and is subject to ongoing trials (Australian New
Zealand Clinical Trials Registry ACTRN12609000882224).
sGC stimulators and activators
Although stimulation and activation of sGC may sound
similar, both innovative drug classes display entirely differ-
ent modes of action and target different redox and disease
states of the NO receptor, sGC. sGC stimulators (sGCs) such
as riociguat (BAY 63-2521), vericiguat (BAY 1021189),
BAY 41-8543, and BAY 60-4552, and YC-1 (49) bind to an
allosteric binding site of Fe(II)heme-containing sGC and
allosterically sensitize the enzyme for diminished biophase
levels of endogenous NO. In a disease condition where bio-
phase levels of NO are diminished, for example, by oxidative
stress, higher or physiological increases in cGMP tissue
levels can be achieved. Clinical indications may be similar to
NO donors, but without the risk of tolerance and protein
nitration as an accumulating by-product.
FIG. 3. Selective myeloperoxidase inhibitors. (A) Struc-
ture of the 2-thioxanthine, TX1 (150). (B) Basic structure of 2-
thiopyrimidone compounds in development by Pﬁzer, Inc. R1
is a ﬁve- to six-membered aromatic ring with one to three
heteroatoms,while R2 is a fully saturated, partially unsaturated
of fully unsaturated 1- to 14-membered straight carbon chain.
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In contrast, sGC activators (sGCa), such as cinaciguat
(BAY 58-2667), ataciguat (HMR 1766), and S3448 (126),
activate only Fe(III)heme-oxidized or heme-free (apo-)sGC.
They do this by either replacing the weakly bound oxidized
heme in (apo-)sGC or by directly occupying the orphaned
heme pocket in apo-sGC (138).
Otherwise, apo-sGC would be ubiquitinated at the empty
heme binding site and degraded (64, 99). Therefore, sGC
activators also stabilize apo-sGC. The ratio of oxidized or apo-
sGC to Fe(II)-sGC is increased under oxidative stress condi-
tions (42). In a condition where just NO levels are diminished,
but Fe(II)sGC is intact, sGCa would be ineffective. Most re-
cently two other sGCa, GlaxoSmithKline’s GSK218123A and
Boehringher-Ingelheims’s Bl 703704, have been tested pre-
clinically in different animal models of hypertension (32) and
kidney diseases (137). The possible beneﬁt of this new com-
pound class and precise mechanism of action, as well as safety,
need to be further validated.
Conclusion
In recent years, considerable data have accrued, indicating
that disturbances in redox homeostasis are a common mech-
anism in different cardiovascular, neurological, and metabolic
diseases. However, oxidative stress was hitherto not pharma-
cologically targetable, and the only strategy tested so far, using
antioxidants, has been ineffective or even harmful. A possible
reason for this is the lack of speciﬁcity for disease triggering
versus physiological ROS that have a signaling, rather than
pathological, role. Furthermore, ROS scavenging by antioxi-
dants takes place in all (sub)cellular locations, not just those
relevant for the disease. Innovative drugs need to target
disease-relevant ROS-producing enzymes, ROS toxifying
enzymes, or proteins damaged by ROS. For all of these, small
molecules have become available that are able to perturb
speciﬁc targets and allow for therapeutic proof-of-concept
studies.
These include not only new compounds but also some well-
characterized drugs, such as allopurinol and MAO isoform-
selective inhibitors, which have been clinically used for
decades, although not with the purpose to inhibit ROS for-
mation. In addition, sGC stimulators (in the clinic), NOX in-
hibitor (entering phase III), NOS inhibitors (phase II-III), sGC
activators (phase I-II), and superoxide dismutase mimetics
such as GC4410 (phase I) [for details, see Schmidt et al. in the
same Forum (127)] are rapidly gaining relevance. Other pos-
sible clinical candidates are, for example, mitochondria tar-
geted antioxidants such as mitoquinone and mito TEMPO [for
details, see Schmidt et al. in the same Forum (127)].
However, in several cases (e.g., NOX inhibitors), there is an
unmet need for isoform-selective drugs. Finally, promising
results have been obtained with activators of the transcription
factor NRF2, even though in this case the mechanisms are
more complex. In particular, one NRF2-activating compound,
FIG. 4. Compounds targetingROS sources, ROS toxiﬁers, and enzymes damaged byROS. The physiologic interaction of
NRF2 and KEAP1 underlies a negative feedback mechanism. Disruption of this interaction can be caused by electrophilic
compounds, which react with speciﬁc cysteines of Keap1. Keap 1 is a sensor for environmental and endogenous reactive oxygen
and nitrogen species. In conditions of ROS overload, NRF2 escapes Keap1-dependent degradation, accumulates in the nucleus,
and activates ARE genes, leading to activation of glutathione and thioredoxin metabolism, including GPx and TPx. Sources that
produceO2
- areNOX,XO, andMAO. Superoxide anionwill be detoxiﬁed by SOD toH2O2 and further by catalase toH2O orwill
react with NOS-derived NO to form peroxynitrite (ONOO-). On the other side, NO activates the sGC, which results in cGMP
generation and stimulates protein kinase G signaling. The NO production can be reduced by inhibition of NOS with the
endogenous l-arginine analog ADMA. In oxidative stress conditions, the sGC heme can be oxidized or removed (apo-sGC),
leading to NO unresponsive sGC. Selected inhibitors and activators are indicated with inhibiting or activating arrows and blocks,
respectively. ADMA, asymmetric-dimethyl-l-arginine; ARE, antioxidant responsive element; apo-sGC, heme-free soluble
guanylate cyclase; cGMP, cyclic guanosine monophosphate; GPx, glutathione peroxidase; MAO, monoamine oxidases; NO,
nitric oxide; NOS, nitric oxide synthase; NOX, nicotinamide adenine dinucleotide phosphate oxidase; ROS, reactive oxygen
species; sGC, soluble guanylate cylcase; SOD, superoxide dismutase; TPx, thioredoxin peroxidase; XO, xanthine oxidase.
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BG12, is effective and approved for the treatment of multiple
sclerosis and, following its success, other NRF2 activators are
currently being tested in proof-of-principle studies for various
inﬂammatory diseases (Fig. 4).
Outlook
New, more speciﬁc pharmacological agents and future drugs
are likely to transform the ﬁeld of oxidative stress, with its many
potential medical implications. Indirectly acting compounds
(e.g., sGCs) have already provided proof of concept. The ﬁnal
breakthrough will be achieved when inhibitors of ROS-forming
enzymes will enter evidence-based medicine.
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A B S T R A C T
The European Cooperation in Science and Technology (COST) provides an ideal framework to establish multi-
disciplinary research networks. COST Action BM1203 (EU-ROS) represents a consortium of researchers from
diﬀerent disciplines who are dedicated to providing new insights and tools for better understanding redox
biology and medicine and, in the long run, to ﬁnding new therapeutic strategies to target dysregulated redox
processes in various diseases. This report highlights the major achievements of EU-ROS as well as research
updates and new perspectives arising from its members. The EU-ROS consortium comprised more than 140
active members who worked together for four years on the topics brieﬂy described below. The formation of
reactive oxygen and nitrogen species (RONS) is an established hallmark of our aerobic environment and
metabolism but RONS also act as messengers via redox regulation of essential cellular processes. The fact that
many diseases have been found to be associated with oxidative stress established the theory of oxidative stress as
a trigger of diseases that can be corrected by antioxidant therapy. However, while experimental studies support
this thesis, clinical studies still generate controversial results, due to complex pathophysiology of oxidative stress
in humans. For future improvement of antioxidant therapy and better understanding of redox-associated disease
progression detailed knowledge on the sources and targets of RONS formation and discrimination of their
detrimental or beneﬁcial roles is required. In order to advance this important area of biology and medicine,
highly synergistic approaches combining a variety of diverse and contrasting disciplines are needed.
1. Introduction
Andreas Daiber and Fabio Di Lisa.
1.1. Mission, structure and major achievements of EU-ROS consortium
The COST Action BM1203 (EU-ROS) is a research consortium of
networking supported by the European Cooperation in Science and
Technology (COST), which is embedded within the Biomedicine and
Molecular Biosciences Domain. It covers areas of basic, preclinical and
clinical research in biology, chemistry, physics and medicine, not only
on mammalian cells but also plants, bacteria and other organisms. The
mission of EU-ROS is to advance the ﬁeld of redox biology and
oxidative stress research by bringing together multi-disciplinary experts
by organizing scientiﬁc meetings and providing funds for the exchange
of researchers between laboratories (for more details see www.eu-ros.
eu or www.cost.eu/COST_Actions/bmbs/Actions/BM1203). During the
active funding period of EU-ROS (2013–2016) we organized ten major
scientiﬁc meetings, supported 29 short-term scientiﬁc missions for
research visits of postdoctoral fellows and Ph.D students, and co-
organized three scientiﬁc symposia at European conferences of the
Society for Free Radical Research Europe (SFRRe). In order to foster the
next generation of redox biology scientists we also supported numerous
early-stage researchers and invited them either to the six training
schools that we (co)organized or to the young investigator sessions at
our meetings. Among the major achievements of EU-ROS are three
major successful grant applications within the European H2020 funding
scheme as well as three major coordinated collections of position
papers, reviews and original articles published by our members
[1–4]. The “small to medium sized enterprises” (SME) participating in
EU-ROS ﬁled three patents with the help of research collaborations
established within our consortium. In order to disseminate the collected
knowledge to a broader audience of non-expert scientists and the public
we also opened a EU-ROS YouTube channel (https://www.youtube.
com/channel/UCXFnyGD4uVFUTcLshvDtxcQ). The present collection
of research updates and perspectives represents the ﬁnal dissemination
of COST Action BM1203 (EU-ROS).
In order to achieve the scientiﬁc objectives, as laid down in the
memorandum of understanding of COST Action BM1203, we deﬁned 6
working groups (WG) with elected leaders, each representing a
taskforce for a speciﬁc area of research or organization/management:
WG1 Sources of ROS (Ulla Knaus), WG2 Molecular Mechanisms (Agnes
Görlach), WG3 Drugs & Tools (Tamara Seredenina), WG4 Biomarkers
(Pietro Ghezzi/Paul Winyard), WG5 Imaging (Yves Frappart) and WG6
Technology Transfer & Funding (Vincent Jaquet).
1.2. Redox biology and oxidative stress: the EU-ROS approach
The fact that life requires oxygen, which per se represents a
1 These authors contributed equally and should be considered joint ﬁrst or senior
authors.
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chemically aggressive molecule [5], bears the risk that biomolecules in
all aerobic living species on earth are targets of oxidative modiﬁcations
resulting from uncontrolled formation of reactive oxygen species
(ROS2) and reactive nitrogen species (RNS3). In order to prevent
oxidative damage, all aerobic organisms have developed highly eﬃ-
cient antioxidant strategies during evolution. However, these highly
reactive species may be generated accidentally as a result of altered
metabolism (e.g. during mitochondrial respiration) or can be formed
deliberately (e.g. by professional ROS-producing enzymes at sites of
inﬂammation). Hence, it is not surprising that most metabolic diseases,
as well as those pathologies associated with low-grade inﬂammation,
display increased patterns of biomarkers of oxidative stress [6]. It is
well established that cardiovascular [7–9], neurodegenerative [10,11],
metabolic [12,13] and inﬂammatory diseases [14–16] are associated
with increased oxidative stress (some rare immune diseases are linked
to insuﬃcient ROS formation [17]). Despite the large body of evidence
linking oxidative stress with many common diseases, which is sup-
ported by the signiﬁcant correlation of redox biomarkers with cardio-
vascular and all-cause mortality [18–20], direct clinical proof is still
lacking that oral therapy with antioxidants, such as vitamin C and E,
helps to prevent the development or progression of these diseases. Most
large-scale antioxidant clinical trials yielded disappointing results
regarding all-cause mortality and in some cases oral antioxidants had
detrimental eﬀects [21–23] and to this date no “antioxidant” is
admitted as a drug for clinical use [24]. More recent reports in
publication channels dedicated to the non-expert or public readership
highlighted the potential risks associated with excessive oral consump-
tion of antioxidants (see online publications by Mustain [25] and Riley
[26]). Antioxidant therapy was also mentioned among “the science
myths that will not die” [27]. In contrast, a large number of small to
intermediate size cohort studies with short-term and parenteral vitamin
C therapy showed highly beneﬁcial eﬀects in various cardiovascular
disease settings, and, for vitamin D, positive reports on oral therapy
exist [9,19,28]. The most likely explanation for the antioxidant
/oxidative stress paradox may be that reactive oxygen and nitrogen
species (RONS) are not only injurious (oxidative stress) but also
modulate important biological functions (redox signaling). Accord-
ingly, chronic, systemic oral therapy with antioxidants will likely
interfere with important ROS-mediated cellular processes, such as
stress adaptation by ischemic preconditioning [19,21,28]. Additional
reasons for the failure of large trials on oral antioxidant therapy might
comprise the pro-oxidant eﬀects of vitamin C and E radicals, reaction
kinetics that are too slow, or lack of eﬀective concentrations at sites of
RONS formation. It is also possible that the patients included in these
trials had already been exposed to drugs with pleiotropic antioxidant
eﬀects (e.g. ACE inhibitors or statins) (all reviewed in [19,21,28]). In
addition, as shown by the EPIC Norfolk study, large antioxidant clinical
trials suﬀer from suboptimal control of their potential eﬃcacy, such as
not measuring the patients’ plasma levels of antioxidants to verify
compliance [29]. This study also showed that vitamin C concentrations
in the blood inversely correlate with all-cause mortality in healthy
volunteers. The inherent problems of vitamin C and E, that were mostly
used in clinical trials, were also highlighted by Darley-Usmar and
colleagues by a previous review [30]. Moreover, Forman, Davies and
Ursini postulated that the nucleophilic tone and para-hormesis (para-
doxic oxidative activation of intrinsic defence mechanisms such as the
NRF2 pathway) is more important than free radical scavenging proper-
ties of antioxidants for their beneﬁcial eﬀects in vivo [31].
This obvious paradox in antioxidant therapy eﬃcacy warrants
better understanding of the role of RONS in physiology and pathophy-
siology. Our consortium put forward the concept that the failure of the
traditional antioxidants such as vitamin C and E was predictable
considering the above-mentioned limitations, but that excessive forma-
tion of RONS (mostly termed “oxidative stress”) plays a role in disease
development and progression or, at least, leads to stable biomarkers
(e.g. oxidatively modiﬁed biomolecules) that can be used for diagnostic
aspects in various diseases (reviewed in full detail in the Forum issue by
EU-ROS members [2]). In brief, we believe that activation of intrinsic
antioxidant processes (e.g. NRF2-dependent pathways), inhibition of
disease-relevant sources of RONS (e.g. isoform-speciﬁc NOX inhibitors),
scavenging of disease-triggering RONS by site- and time-speciﬁc
antioxidants or even repair of oxidatively inactivated enzymes (the
most prominent examples being sGC activators) represent recently
clinically established or promising future antioxidant strategies. The
main concept of our biomedical approach and working scheme is shown
in Fig. 1.1.
The present overview is an interdisciplinary forum of opinions from
various experts in the ﬁeld of redox biology and oxidative stress
research participating in EU-ROS. We have separated the present work
into 11 sections since the contributions cover a wide range of scientiﬁc
topics (mammals, worms, bacteria, plants) and even the terminology of
RONS varies substantially depending on whether they belong to rather
theoretical and basic science oriented disciplines or biomedical and
clinical research areas. RONS regulate not only hydrogen sulﬁde (H2S)
but also nitric oxide (•NO) and carbon monoxide (CO), thereby aﬀecting
all major gasotransmitter systems [33,34]. Also the concept of ROS-
induced ROS formation (the crosstalk of diﬀerent ROS-producing
systems) is highlighted in the subsequent sections [35,36]. These direct
and indirect mechanisms based upon redox modiﬁcations or direct
reactions with other messengers (e.g. •NO and H2S) underlie RONS
involvement in receptor-dependent signaling pathways, also due to the
modulation of expression and activity of transcription factors. The
contributions below also highlight how RONS contribute to established
signaling pathways by their redox modulation. The interactions of
RONS with microparticles [37–39], protein aggregates [40,41] and the
gasotransmitter H2S [33,42] represent important examples that illus-
trate how RONS as messengers indirectly inﬂuence other signaling
systems. Therefore, far from being merely biological waste products,
RONS represent highly active and tightly regulated signaling molecules.
2. Conceptual and mechanistic aspects of ROS and oxidative stress
Ulla G. Knaus (ulla.knaus@ucd.ie).
2.1. Background and terminology
“ROS is over”, a statement at the ESF-EMBO meeting (Spain 2015)
by Fulvio Ursini, should probably be extended to “Oxidative Stress is
over” (Ulla G. Knaus). There is no doubt that ROS exist and that the
concept of oxidative stress summarizes certain conditions connected to
a variety of diseases. However, the unspeciﬁc usage of these blanket
terms, especially during recent years, does not adequately reﬂect the
diversity of reactive oxygen metabolites being produced, the intricate
regulation of redox signaling and the oxidant-antioxidant balance, or
2 Throughout this report, the term ROS refers almost exclusively to hydrogen peroxide
and superoxide anion radical since both species are involved in redox signaling and are
formed by a number of enzymatic sources. Other ROS include the hydroxyl radical or
singlet oxygen, which however have most likely no speciﬁc roles in redox signaling but
rather contribute to unspeciﬁc oxidative damage and oxidative stress. A large number of
organic peroxides (e.g. lipid peroxides) are also covered by the term ROS but these species
are only marginally discussed in the present overview. Other ROS such as hypochlorite
are also not in the focus of the present work.
3 Throughout this report, the term RNS refers almost exclusively to peroxynitrite,
peroxynitrous acid and derived free radicals (e.g. hydroxyl radicals and nitrogen dioxide
radicals). Peroxynitrite anion has a high speciﬁcity for activated thiols and readily reacts
with carbon dioxide (the latter supports radical reactions). Peroxynitrous acid also has a
high speciﬁcity for activated thiols but also reacts with transition metal complexes. RNS
also comprises nitric oxide, which upon reaction with oxygen can form nitrogen dioxide
radicals or nitrosating species such as N2O3 and has a high aﬃnity for transition metal
complexes such as iron(II), all of which contributes to the potent redox signaling
properties of nitric oxide. However, in the context of “oxidation of biomolecules” the
term RNS does not refer to nitric oxide due to its weak reactivity towards biomolecules in
general.
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the causality of oxidative modiﬁcations versus detrimental outcome in
biological systems. “ROS” is discussed below in detail, while oxidative
stress is usually deﬁned as an imbalance between production of ROS
and antioxidants and the ensuing pathophysiological consequences of
increased, unspeciﬁed ROS. If the term oxidative stress is used retro-
spectively via determination of oxidative modiﬁcations of proteins,
lipids or DNA, it might instead be oxidative damage. Direct measure-
ments of oxidative stress often use oxidized glutathione as readout, but
Morgan et al. identiﬁed immediate glutathione disulﬁde removal
pathways and antioxidant backup systems that ensured redox home-
ostasis [43]. In some circumstances oxidative stress is correlated with
the presence or upregulation of an enzyme that can (but might not)
generate superoxide or hydrogen peroxide, or the presence of cell types
that produce these species when activated. However, the outcome in
redox biology will always be dependent on the type of oxygen species
generated over a certain time period at a certain location. One example
is wound healing which requires ROS [44], but may progress to ﬁbrosis
when deregulation of the process occurs [45]. Another example is
hypoxic tissue reconstitution facilitated by the neutrophil oxidative
burst [46] versus neutrophil-mediated tissue injury in other circum-
stances [47]. What happens when the predominant superoxide source is
missing is evident in chronic granulomatous disease (CGD), an inher-
ited immunodeﬁciency caused by inactivating variants of the NOX2
NADPH oxidase complex. CGD patients present not only with life-
threatening infections, but also with hyperinﬂammation, and Cybb-/-
(Nox2) knockout mice show an increase in proinﬂammatory mediators
and tissue damage in disease models [48–50].
As Carsten Berndt and Marcus Conrad note, ROS, a widely used
umbrella term, urgently needs speciﬁcation. Its use is misleading, as
just some of the molecules encompassed under this term are indeed
reactive species. This is especially true for the non-radical species, and
it is another common misunderstanding that all ROS are radicals.
Unlike the hydroxyl radical (HO•) or the superoxide anion radical (O2•-)
singlet oxygen (1O2) or hydrogen peroxide (H2O2) are not radicals,
which is underlined by the diﬀerent reactivities (second order rate
constant M−1 s−1) of ROS with a given substrate (methionine) that
range from 2×10−2 (H2O2) to 7x109 (HO•) [51]. Another often
neglected fact is the continuous formation of certain reactive species
by enzymes under physiological conditions. Ero1α, for instance, gen-
erates one H2O2 molecule following each disulﬁde bridge formed in the
endoplasmic reticulum. Therefore, reactive species cannot be consid-
ered solely a phenomenon of damage and disease. These species formed
under physiological conditions can contribute to diverse cellular
functions. For instance, reversible oxidative posttranscriptional thiol
modiﬁcations are important during several processes in cells or even
whole organisms including embryonic development [52,53]. Moreover,
the formation of reactive species at diﬀerent subcellular sites distin-
guishes between cellular functions, such as stem cell maintenance or
diﬀerentiation [54]. Not only posttranslational oxidative modiﬁcations,
but also damage by certain types of reactive species can be a trigger for
speciﬁc cellular functions: Ferroptosis after lipid peroxidation was
recently shown to speciﬁcally impede reprogramming into neurons
[55]. For these reasons, it is impossible to measure “ROS”, to induce
“ROS”, to inhibit “ROS”, or to accumulate “ROS”. Besides scientiﬁc
recognition, limited experimental tools are a problem to move research
forward (or back) to the speciﬁc investigation of speciﬁc species.
Promising in vivo tools are highly sensitive genetically encoded
ﬂuorescence probes [56] and genetic cell and animal models with
targeted deﬁciencies in professional redox enzymes dealing with a
select subset of distinct reactive species, such as the ferroptosis
regulator glutathione peroxidase 4 [57]. Several research communities
focus or have focused on ROS molecules, e.g. the Oxygen Club of
California, the Society for Free Radical Research (SFRR), and EU-ROS.
Hence, researchers working in the ﬁeld of redox biology must,
whenever possible, discriminate among the diﬀerent partially reduced
forms of oxygen being studied as this will allow us to acknowledge their
diﬀerent chemical features and/or biological functions as well as
ultimately help to provide strong and solid mechanistic data on
important biological processes.
2.2. ROS sources and their activation
There are circumstances where the term “ROS” is unavoidable,
mainly due to our inability to exactly measure the species generated in
a spatiotemporal manner or to correctly identify or discriminate
between species responsible for a certain biological event. Sometimes
a mixture of oxygen metabolites is produced as several sources are
stimulated or interact with each other. Thus, ROS sources should not be
considered isolated enzymatic systems, and biological processes may
involve ROS-induced ROS (Andreas Daiber and Matthias Oelze). There
is increasing evidence that they can crosstalk with each other via
reactive oxygen and nitrogen species signaling [35,58]. The theory of
so-called “kindling radicals” or also the “bonﬁre” hypothesis is based on
the formation of a few primary ROS that “inﬂame” a cascade of ROS
RONS 
sources
Beneﬁcial redox signaling Detrimental in speciﬁc disease
Should be preserved by redox
drugs
Should be speciﬁcally inhibited in 
speciﬁc disease
Possible strategies: Repair of proteins, source speciﬁc inhibitors, acvators of
endogenous anoxidant systems, inhibion of toxiﬁers, cell- ,organelle-, or species-
speciﬁc direct RONS scavengers
Requires advanced imaging and biomarkers to verify successful therapy
RONS 
targets
Fig. 1.1. The main concept of our biomedical approach and working scheme within the EU-ROS consortium as explained in detail previously [32].
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ampliﬁcation by stimulating the sources of secondary ROS (Fig. 2.1A).
This was ﬁrst described for mitochondria [59] and involves several
mitochondrial pores that are required for the release of mitochondrial
ROS such as the mitochondrial permeability transition pore, aquaporins
or the inner membrane anion channel as well as sources of oxidants
(e.g. respiratory complexes, p66shc, monoamine oxidases) [18]. This
crosstalk concept can be extended to almost all kinds of sources of
oxidants. We have described “redox switches” that lead to uncoupling
of endothelial nitric oxide synthase (eNOS), redirecting this enzyme
from nitric oxide to superoxide production and thereby changing the
entire vascular phenotype from a dilated, anti-thrombotic, anti-inﬂam-
matory state to a constricted, thrombotic and inﬂammatory state
(Fig. 2.1B) [18,20,60]. Likewise, initially formed “kindling” ROS easily
activate xanthine oxidase by a thiol oxidation-dependent and proteo-
lytic conversion of xanthine dehydrogenase to the oxidase form [60] or
activate NADPH oxidases (NOX), either by redox-sensitive activation of
protein kinase C and translocation of cytosolic subunits (for NOX1 and
NOX2) or by upregulation of all NOX isoforms by redox-sensitive
transcription factors or changes in mRNA stability [60]. The most
important crosstalk between diﬀerent sources of oxidants was described
for mitochondria and NOX, which was reviewed in full detail by us and
others [18,58]. We have observed this kind of crosstalk in nitroglycerin-
induced endothelial dysfunction and oxidative stress [61], in models of
aging-induced vascular dysfunction and oxidative stress [62], as well as
Fig. 2.1. (A) Crosstalk between diﬀerent sources of ROS and RNS (mitochondria, NADPH oxidases, xanthine oxidase and NO synthase). Xanthine oxidase (XO) originates from oxidative
stress-mediated conversion of the xanthine dehydrogenase via oxidation of critical thiols in cysteine535/992. NO synthases (mainly eNOS) are uncoupled upon oxidative depletion of
tetrahydrobiopterin (BH4), S-glutathionylation (-SSG) and other redox switches. Mitochondrial superoxide/hydrogen peroxide formation may be triggered by oxidative stress from all
ROS sources (including other damaged/activated mitochondria) via redox-activation of PKC, MAPK, other kinase pathways and potential involvement of redox-sensitive mitochondrial
ATP-sensitive potassium channels (mtKATP) with subsequent p66Shc, monoamine oxidase (MAO), respiratory complex activation or impairment of mitochondrial antioxidant defence.
Mitochondrial superoxide/ hydrogen peroxide is released to the cytosol via mitochondrial pores and channels (e.g. redox-sensitive mitochondrial permeability transition pore (mPTP),
inner membrane anion channel (IMAC) or aquaporins) or by diﬀusion due to increased mitochondrial permeability under pro-inﬂammatory conditions. In the cytosol these species (along
with released calcium) cause activation of redox-sensitive protein kinases (PKC) and tyrosine kinases (cSrc) with subsequent activation of NADPH oxidases and ampliﬁcation of the
cellular oxidative stress. Modiﬁed from [35, 64]. With permission of Elsevier. Copyright 2010 & 2015. (B) Redox switches in endothelial nitric oxide synthase (eNOS). X-ray structure of
human eNOS with the ironporphyrin (blue), the substrate L-arginine (green), the P450-forming axial iron-thiolate ligand from a cysteine residue (yellow), the cofactor
tetrahydrobiopterin (BH4) (purple), the zinc-thiolate complex forming cysteines (red, two from each subunit), and the zinc ion (brown). The boxes represent the ‘‘redox switches’’ in
eNOS, such as S-glutathionylation, PKC- and protein tyrosine kinase-2 (PYK-2)–dependent phosphorylation, oxidative BH4 depletion, disruption of the zinc-sulfur cluster, as well as
asymmetric dimethylarginine (ADMA) synthesis/degradation, all of which contribute to the regulation of its enzymatic activity. GSH, glutathione; GSSG, glutathione disulﬁde. The crystal
structure was rendered from the protein database entry 3NOS (DOI:10.2210/pdb3nos/pdb) using the PyMOL Molecular Graphics System Version 1.2r1 (DeLano Scientiﬁc LLC). Adapted
from [60]. With permission of Mary Ann Liebert, Inc. Copyright 2014 .
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in angiotensin-II induced hypertension and immune cell activation
[63]. In conclusion, the redox crosstalk between diﬀerent sources of
oxidants may explain why multiple publications describe diﬀerent ROS
sources as the major pathological trigger in a certain disease (e.g. for
the hypertension mitochondrial respiratory chain, NOX1, NOX2, NOX4
and xanthine oxidase) and that pharmacological or genetic blockade of
one of these sources was enough to prevent the adverse phenotype [18].
If this concept can be translated to patients, it may be enough to target
one speciﬁc source of ROS to prevent or retard the progression of a
certain disease.
Determination of the ROS source(s) and their interactions is still
challenging. The multitude of potential inputs range from NADPH
oxidases (NOX1-5, DUOX1-2) and the mitochondrial electron chain, to
xanthine oxidase, monoamino oxidase(s), cyclooxygenase(s), lipoxy-
genase(s), lysyl oxidase(s), cytochrome P450, or MICAL family mem-
bers, to name a few. In all of the cases, the oxygen metabolite
superoxide (O2•-) or H2O2 is primarily generated as a by-product of
key enzymatic reactions of a particular enzyme. NADPH oxidases are
the only enzymes solely dedicated to regulate O2- (NOX1-3, 5) and
H2O2 (NOX4, DUOX1-2) production [65]. How certain NADPH oxidases
can internally convert O2•- to H2O2 when using NADPH as the electron
donor for the one-electron reduction of molecular oxygen is still
unresolved. This feature discriminates the signaling input of NOX4
and DUOX1-2 from other family members due to the diﬀusibility and
longer half-life of H2O2 versus O2•- or secondary reactive metabolites.
2.3. ROS sources in microbiota
O2•-/ H2O2 generation by enzymes and their consequences are
mainly considered in the context of plant or animal hosts. However,
hosts are colonized by an ecological community of commensal,
symbiotic and pathogenic microorganisms, collectively termed micro-
biota. The presence and composition of the microbiota, which includes
bacteria, fungi and viruses and resides in bioﬂuids or on epithelial
surfaces, is critical for health and disease. Bacteria represent the
majority of the human microbiota (1014 bacterial cells) with estimates
of 1000 or more bacterial species. Bacteria-host interactions in redox
biology have been mostly deﬁned by infections, where host defense
relies on NOX2-mediated oxidative destruction of pathogens.
Yet an immediate and close relationship exists between commen-
sals, pathogens and host epithelial surfaces, which is best characterized
in the intestine. In the gut, feedback communication ensues with
bacteria as inducers, targets and producers of ROS (Ulla G. Knaus and
Gratiela G. Pircalabioru). The association of germ-free mice with
microbiota induced the expression of epithelial DUOX2 [66]. Intestinal
pathogens such as C. jejuni, K. pneumoniae, or L. monocytogenes
triggered by a yet unknown mechanism the activation of NOX1 and
DUOX2, resulting in O2•- generation and H2O2 release into the gut
lumen [67,68]. Enteropathogenic E. coli stimulated a NOX1-mediated
pathway that included ASK1, p38 and AFT-2 and culminated in an over
20-fold upregulation of the DUOX2 complex [69]. Others reported that
Lactobacillaceae activate NOX1, thereby promoting intestinal stem cell
proliferation and wound healing responses [70]. While pathogens and
segmented ﬁlamentous bacteria can gain access to the epithelium,
lactobacilli usually colonize the further removed, loose mucus layer.
However, any disruption of the barrier including changes in perme-
ability or mucus composition/density will permit the interaction of
commensals with host cells and may result in ROS signaling via NOX
and/or mitochondria. For example, mitochondrial ROS is required for
NLRP3 inﬂammasome activation by bacteria or bacterial products, and
subsequent IL-1β and IL-18 production [71]. The bacteria-host inter-
action will also initiate release of H2O2 from the mucosal surface.
Uptake of H2O2 by extracellular bacteria alters their transcriptional
program and intrabacterial signaling. Although antioxidant defense
genes will be upregulated, Fenton reaction-associated oxidations will
decrease phosphotyrosine signaling and alter pathogenicity gene reg-
ulation [68,69]. These oxidative modiﬁcations reduce the virulence of
extracellular bacteria, which can then be eliminated more eﬃciently by
the host.
Certain commensals, in particular Lactobacillus and Lactococcus
strains, use endogenous H2O2 production as their own means of
communication. The bacterial enzymes capable of generating H2O2
are largely unknown except for L. acidophilus [72], although the
consequences to host physiology and niche protection have been
reported. The antiinﬂammatory eﬀects of lactobacilli are multifaceted,
but lactobacilli-mediated killing of pathogens (e.g. S. enterica, E. coli)
has been ﬁrmly associated with their H2O2 production [73]. Even some
catalase-negative pathogens use endogenous H2O2 production for intra-
and inter-bacterial signaling. Aerobic growth of Streptococcus pneumo-
niae leads to pyruvate oxidase (SpxB)-mediated H2O2 generation, which
was required for fatty acid metabolism and inhibited replication of
other microorganisms competing for the same environmental niche
[74,75]. In conclusion, bacteria need to be considered as endogenous
sources and exogenous inducers of H2O2, thereby propagating intra-and
interkingdom signaling.
This connection between bacteria and the host has been studied
extensively in the nematode worm Caenorhabditis elegans [76–79], but
as Elizabeth A. Veal and Antonio Miranda-Vizuete comment, C. elegans
can serve as a general model for redox biology and has already provided
signiﬁcant new insight into the interplay between ROS, ROS signaling
and aging. Notably, genetic studies have failed to show that the ROS-
detoxifying activities of any of C. elegans’ array of ROS-metabolizing
enzymes protects against aging. However, these studies have revealed
speciﬁc roles for several of these proteins in redox signaling, protein
homeostasis or regulation of normal physiology. For example, glu-
tathione reductase is essential for cell division during embryonic
development [80], thioredoxin reductase or glutathione reductase
activity for larval development to reduce disulﬁde bonds of cuticle
components prior to molting [81] and the peroxiredoxin PRDX-2 for
regulation of feeding behavior [82] and normal levels of insulin
secretion [83]. The causative role of ROS-induced damage in animal
aging has also been challenged by the unexpected discovery that
increases in ROS can actually promote C. elegans longevity (for review
see [84]). Nevertheless, stress-activated transcription factors DAF-16
and SKN-1 (orthologous to the mammalian FOXO and NRF2 transcrip-
tion factors), which promote the expression of a range of defenses,
including ROS-detoxifying and phase 2 metabolism enzymes, are vital
for survival under stress conditions, during infection and the extended
lifespan associated with inhibition of a variety of pathways. As the
primary tissue encountering xenobiotics and pathogens that trigger
increases in ROS, intestinal levels of these proteins seem particularly
important for survival under stress conditions. However, studies with
tissue-speciﬁc transgenes and RNAi have indicated that cell non-
autonomous signals from neurons and germline cells play an important
part in regulating these stress defenses (for reviews see [85,86]).
Moreover, there is increasing evidence that maintaining C. elegans on
diﬀerent strains of E. coli can profoundly inﬂuence ROS production,
redox signaling, metabolism and longevity [87]. C. elegans transparency
throughout its entire life cycle has enabled the development of a variety
of ﬂuorescent redox-sensitive probes that can be employed to monitor
in vivo changes in redox status. For example, analysis of animals
expressing a genetically encoded peroxide sensor has suggested that
peroxide levels are higher during larval development than in adults but
rise again following the reproductive period [88]. Recent advances in
genome editing tools, NGS approaches to identify mutations obtained
by traditional mutagenesis screens, redox proteomics, including OxIC-
AT, metabolomics, and high throughput techniques for genome-wide
and tissue-speciﬁc RNAi-screening and lifespan analyses have all added
to the C. elegans toolbox that enhance the power of C. elegans as a model
to advance the redox biology ﬁeld. The simplicity, ease of manipula-
tion, microscopic examination, short lifespan and vast range of genetic
and post-genomic tools have established C. elegans as a powerful model
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for providing mechanistic insight into the role of redox changes in
normal physiology and disease.
2.4. Redox regulation via redox modiﬁcations of biomolecules and altered
phosphorylation
ROS, in particular H2O2, participate in redox regulation and
signaling responses by modifying proteins, lipids and DNA. An emer-
ging concept is redox control of protein-protein interactions (Andrew R.
Pitt and Corinne M. Spickett). Signal transduction via proteins contain-
ing redox-sensitive cysteine residues is now a well-established concept,
and the list of such proteins is growing rapidly [89]. The cysteine
residues involved are most commonly ones with unusually low pKas,
which therefore exist as thiolates under physiological conditions [90].
The oxidation of these residues to form a disulﬁde by reaction with a
second, resolving cysteine alters the structure and activity of the
protein. A fundamental requirement of redox regulation in signaling
is that it must be reversible, and thioredoxin is a central enzyme that
mediates the reduction of protein disulﬁdes via formation of an
intermolecular disulﬁde with the target protein. Covalent and non-
covalent protein-protein interactions are known to be critical in
signaling pathways and are thought to contribute to the commonly
observed pleiotrophic eﬀects of ligands and crosstalk between signaling
pathways [91]. Advances in proteomic technologies have facilitated
studies of the interactomes of an expanding number of proteins. Not
surprisingly, these approaches have also been applied to redox proteins,
and much attention has focused on members of the thioredoxin family.
The covalent interactomes of thioredoxin from Plasmodium falciparum
and tryparedoxin from Trypanosoma cruzi have been reported, driven by
the need to identify novel drug targets for protozoan parasites, and in
Escherichia coli, 268 substrates for Trx were reported from experiments
involving strains engineered to optimize trapping of the covalent
interaction [92]. The human glutathione-S-transferase P interactome
has also been reviewed recently, and includes known key players in
redox sensing such as STAT3 and NRF2 [93]. There are many reports of
interactions of other redox proteins, and in an attempt to bring together
all the available information, an “oxidative status interactome map” has
been created of known interactions of human cellular-level oxidative
status proteins [94]. Although all of these articles report the general
interactions of redox-active proteins, the eﬀect of the redox status of the
individual proteins on their interactome, especially the non-covalent
interactome, has largely been ignored. One study that has addressed
this issue investigated the diﬀerential interactome of the tumor
suppressor PTEN in native (reduced) and reversibly oxidized forms,
and reported a number of proteins whose levels changed signiﬁcantly
depending on the redox state, including Anxa2, Trx and Prdx1 [95].
More studies of this kind would help to understand cell redox
regulation, and would provide an additional dimension to oxidative
status protein mapping.
Oxidative regulation of protein phosphorylation is not only an
important part of eﬃcient and essential signal propagation, but can also
promote a deregulated state when the reversibility of the oxidation is
compromised. This can happen by irreversible overoxidation of cy-
steines or by irreversible oxidative modiﬁcation of other amino acids
such as methionine or tyrosine. In balanced conditions H2O2 is required
in the endoplasmic reticulum (ER) for oxidative protein folding, while
overproduction of ROS results in ER stress. This two edged sword is
discussed by Andreas Petry and Agnes Görlach using ER-localized
NADPH oxidases as example [96,97]. ER stress activates the unfolded
protein response (UPR) in three main steps (or phases). Activation of
the Protein Kinase RNA-like Endoplasmic Reticulum Kinase (PERK),
which phosphorylates eIF2alpha, results in general inactivation of CAP-
dependent translation, despite some speciﬁc exceptions such as the
transcription factor ATF4. Then, ER stress activates the inositol requir-
ing element 1 (IRE1) – which splices the mRNA of XBP1 – and the
transcription factor ATF6. ATF4, ATF6 and XBP1 induce the expression
of genes involved in protein folding and degradation in order to
reestablish proper protein folding and to remove protein debris. In
the later ER stress response, pro-apoptotic proteins are upregulated
such as CHOP in order to activate programmed cell death if the cell
cannot resume physiological function.
ROS act especially on the phosphorylation status of eIF2alpha since
protein phosphatase 1 (PP1), which controls together with GADD34 the
dephosphorylation of eIF2alpha, is redox sensitive. H2O2 is able to
oxidize a cysteine close to the catalytic core in a reversible manner
resulting in the inactivation of PP1. Sources for ROS in ER stress are
Ero1 in the ER or mitochondria, but also NADPH oxidases play a role.
NOX1, NOX4 and p22phox were shown to interact with ER proteins such
as PDI [98], and NADPH oxidase derived ROS were involved in the ER
stress response [99–102]. In response to ER stress due to inhibition of
N-glycosylation, NOX4 associated with GADD34 thereby oxidizing PP1,
extending eIF2alpha phosphorylation and promoting survival of cardi-
omyocytes [101]. However, other reports showed that 7-keto-choles-
terol-induced ER stress in human arterial smooth muscle cells induced
NOX4, resulting either directly in cell death [100] or in increased
autophagy [99], which demonstrated a pro-apoptotic role for NOX4. In
addition, NOX1 and NOX2 can play a pro-apoptotic role in cardiomyo-
cytes [102] and renal cells [103] in response to ER stress. In summary,
ROS derived from NADPH oxidases participate in the ER stress
response. However, the subsequent outcome seems to be dependent
on the cellular context, the stimuli used, the spatial distribution and the
type of ROS. It is important to take these parameters into account when
analyzing the role of ROS in ER stress and other pathophysiological
conditions.
Another enzyme connected to ER stress is neutral sphingomyelinase
(N-SMase). Sphingomyelinases (SMases) are categorized into neutral,
acid and alkaline subtypes and hydrolyze sphingomyelin to ceramide
[104]. Mutay Aslan discusses the accumulating evidence that ceramide
induces oxygen species production via the mitochondrial respiratory
chain [105,106] and stimulates inducible nitric oxide synthase (NOS2)
expression [107]. Indeed, activation of neutral sphingomyelinase (N-
SMase) is reported to be involved in various disease pathologies
connected to “oxidative stress”. Studies have shown that ischemia
reperfusion (IR) injury leads to activation of N-SMase in rat cardiac
myocytes [108] and rat liver [109]. Repletion of glutathione (GSH) via
N-acetylcysteine (NAC) treatment in post-myocardial infarction rat
hearts resulted in inhibition of N-SMase and decreased oxidative stress
resulting in improved left ventricular function [110]. Similarly, inhibi-
tion of N-SMase reduced elevated levels of nitrative and oxidative stress
markers in liver IR injury [111].
Neutral SMase is localized in sphingolipid-rich membrane fractions
[111], establishing the structural basis for its functional interaction
with NOS [112]. Cellular stress responses, which increase N-SMase
activity, also aﬀect NOS2 expression and nitric oxide bioavailability. It
has been reported that ceramide production by N-SMase is a key
mediator in the induction of NOS2. Other studies showed that
exogenous ceramide induces NOS2 expression in rat primary astrocytes
[113] and reported positive modulation of NOS2 gene expression by
SMase and/or ceramide in vascular smooth muscle cells and microglia
[114,115]. Neutral SMase inhibition decreased both NOS2 and nitro-
tyrosine levels in an experimental model of glaucoma [116] and liver IR
injury [109]. In summary, studies reveal that cellular stress responses
signiﬁcantly increase N-SMase activity and sphingomyelin/ceramide
levels, leading to increased nitrative and oxidative modiﬁcations.
Inhibition of N-SMase signiﬁcantly reduced oxidant and nitrative stress
markers, which emphasizes the need for future studies evaluating
agents blocking N-SMase activity that can facilitate the development
of treatment strategies to alleviate inﬂammation and oxidative injury.
The close relationship between bacteria and host is evident in
bacterial toxin production that alters redox regulation in the host and in
the response of bacteria to host-derived secondary oxygen metabolites
generated as an innate immune response by post-translationally
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modifying bacterial proteins for protection and survival. Amanda J.
Edson and Kari E. Fladmark discuss how cyanotoxins induce oxidative
modiﬁcations in the host. The overabundance of cyanobacteria in
aquatic ecosystems may result in a large increase in the manufacture
and release of cyanotoxins into the aquatic environment, which cause
human health implications through biomagniﬁcation [117]. A variety
of cyanotoxins are produced by a wide range of cyanobacteria includ-
ing: microcystins [118,119] (MC), nodularin [120] (NOD), and β-N-
methylamino-L-alanine [121,122] (BMAA). Microcystins and nodularin
are potent inhibitors of Ser/Thr protein phosphatases (PP), speciﬁcally
PP1 and PP2A [118,120] through direct interaction at the catalytic site
[123]. Both toxins are cyclic peptides containing several non-proteino-
genic amino acids [118,120]. BMAA has been shown to indirectly target
PP2A by inhibitory phosphorylation mediated through BMAA activa-
tion of the glutamate receptor mGluR5 [124]. However, unlike MC and
NOD, BMAA is a non-proteinogenic amino acid with a high degree of
structural similarity to simple amino acids allowing it to be misincor-
porated into proteins leading to an additional toxic eﬀect [121]. MC,
NOD, and BMAA exposure of cells has been found to promote protein
hyperphosphorylation, increase ROS production, and induce apoptosis
[118,120,121,124].
Phosphorylation of proteins including ROS scavenging enzymes
may be one of the major mechanisms of ROS induction by cyanotoxins.
PP inhibitory action of cyanotoxins will result in broad protein
hyperphosphorylation. In addition to ROS induction through PP
inhibition, BMAA may also increase ROS through a non-glutamatergic
mechanism [122]. H2O2 accumulation occurs within minutes in MC and
NOD-exposed hepatocytes followed by cytoskeletal rearrangement and
apoptosis [119,120]. Ca2+/calmodulin-dependent protein kinase II
(CaMKII) has been shown to be essential in MC- and NOD-induced
apoptosis and acts up-stream of H2O2 accumulation. Inhibition of PP by
toxin exposure prevents the dephosphorylation of CaMKII autopho-
sphorylated on Thr287/286 [123] leading to kinase hyper-activation.
Rather surprisingly, CaMKII seems to be responsible for all observed MC
and NOD-induced phosphorylation supporting its role as a key actor in
cytotoxicity. Toxin-induced H2O2 generation may also amplify CaMKII
activity and thereby also H2O2 generation through speciﬁc methionine
oxidation of CaMKII [123]. The role of CaMKII in BMAA-induced
toxicity remains to be elucidated, however CaMKII is shown to bind to
and regulate the directly BMAA targeted mGluR5 receptor [125]. The
converging signaling pathways of BMAA, MC and NOD suggest that co-
existence of these toxins may increase the environmental risk factor to
human health.
2.5. Oxidative stress and adaptation processes
Hypochlorous acid (HOCl) is a strong oxidant produced by activated
neutrophils that kills pathogenic bacteria. Thus, bacteria have to defend
against hypochlorite to maintain the reduced state of their cytoplasm.
Gram-negative bacteria utilize glutathione (GSH) as their major thiol-
redox buﬀer, but most Gram-positive bacteria do not produce GSH.
Melanie Hillion and Haike Antelmann study redox modiﬁcations in
Gram-positive bacteria under oxidative stress. Actinomycetes utilize
mycothiol (MSH; AcCys-GlcN-myoinositol), which functions in protec-
tion against reactive oxygen, nitrogen and electrophilic species, anti-
biotics and heavy metals [126,127]. Firmicutes bacteria, including
Bacillus and Staphylococcus species produce the redox buﬀer bacillithiol
(BSH; Cys-GlcN-malate). BSH-deﬁcient Staphylococcus aureus isolates
were more sensitive to antibiotics (fosfomycin and rifampicin) and
showed reduced survival in macrophage infection assays [127]. Thus,
BSH biosynthesis genes could be drug targets for the development of
novel antibiotics to treat S. aureus infections. Under conditions of
NaOCl stress, BSH plays an important role in the protection and redox
regulation of proteins by formation of BSH mixed protein disulﬁdes,
termed S-bacillithiolation [127]. In Bacillus subtilis, S-bacillithiolation
controls the activity of the organic hydroperoxide repressor OhrR and
the methionine synthase MetE [127,128]. S-bacillithiolation of the
OhrR repressor leads to derepression of the OhrA peroxiredoxin that
confers NaOCl resistance. S-bacillithiolation of MetE in its Zn-binding
active site leads to methionine auxotrophy under oxidative stress. Two
bacilliredoxins (BrxA and BrxB) with unusual CGC active site motifs
were characterized that function in the reduction of S-bacillithiolated
OhrR and MetE [129]. De-bacillithiolation results in the formation of
bacillithiolated Brx (Brx-SSB) that requires BSH and an uncharacterized
BSSB reductase for recycling. However, the bacilliredoxin pathway is
redundant with the thioredoxin pathway in vivo for reduction of BSH
mixed protein disulﬁdes.
In Corynebacterium glutamicum, about 25 S-mycothiolated proteins
were identiﬁed under hypochlorite stress conditions [130]. These
include many metabolic enzymes, such as the methionine synthase
MetE, the glycogen phosphorylase MalP, the myoinositol-1-phosphate
synthase Ino1 and antioxidant enzymes (Tpx, Gpx, MsrA). S-mycothio-
lation of MalP is required for the oxidative stress resistance of C.
glutamicum and could prevent glycogen degradation under NaOCl stress
to save the energy and carbon source. Redox regulation of the thiol
peroxidase Tpx, the MSH peroxidase Mpx and the methionine sulfoxide
reductase MsrA was recently studied. The mycoredoxin (Mrx1) and
thioredoxin (Trx) pathways are both involved in reduction and
regeneration of S-mycothiolated Mpx and MsrA to restore their enzyme
activities for detoxiﬁcation of peroxides and reduction of methionine
sulfoxides [131,132]. In conclusion, S-bacillithiolation and S-mycothio-
lation are widespread redox modiﬁcations in Gram-positive bacteria
that function in redox regulation and thiol-protection under oxidative
stress conditions.
Acclimatization of an organism to stress or so-called precondition-
ing is a modulating response that prevents pathophysiological damage.
In plants, waves of calcium and ROS are generated as response to
abiotic stress, pathogen infection and mechanical injury. These waves
mediate long-distance signaling and systemic cell-to-cell communica-
tion [133]. Khrystyna Semen and Olha Yelisyeyeva propose mitochon-
drial ROS oscillations as a balancing factor in mammalian metabolism.
The development of a hormetic reaction (preconditioning or mild
stress) represents one approach to increase resistance to oxidative
damage and eliminate signs of oxidative stress (OS), which is involved
in multiple pathological processes and aging [134,135]. A hormetic
reaction is triggered by a mild energy deﬁcit, which precludes some
increase in ADP/ATP and NAD+/NADH ratios leading to activation of
redox processes and energy function of mitochondria. As a result,
mobilization of various metabolic pathways, especially PUFA oxidation,
takes place which promotes the ﬂow of succinate into the Krebs cycle,
activation of succinate oxidation and monopolization of the respiratory
chain by succinate dehydrogenase. Such a metabolic state promotes
more diverse shunting of the Krebs cycle with activation of glutamine/
glutamate metabolism, the glyoxalate cycle, peroxisomal oxidation and
accumulation of succinate. At the same time, activation of transaminase
and alcohol dehydrogenase (ALDH2) reactions causes an increased ﬂow
of alpha-ketoglutarate and its more eﬃcient oxidation [30,136,137].
Simultaneous activation of pathways related to these two reciprocal
mitochondrial substrates serves as an important mechanism involved in
the hormetic response. At the cell level that is reﬂected by the improved
interactions between catabolism and anabolism, while excessive ﬂow of
electrons in the respiratory chain can be controlled by several
mechanisms of “mild uncoupling” including reverse electron transport
from Complex II to Complex I, activation of sirtuins (especially SIRT1)
and uncoupling proteins. The ﬁne-tuned leak of electrons that occurs
with an increase in membrane and ATP potentials is further involved in
production of a certain amount of superoxide, hydrogen peroxide and
nitric oxide [30,60]. Subsequently these reactive oxygen/nitrogen
species function as signaling molecules for multiple pathways, mainly
HIF/NRF2/NF-κB and their crosstalk, rather than promote excessive
oxidative damage to macromolecules.
Mild prooxidant activity accompanying the formation of a hormetic
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response gives rise to the production of metabolic “endogenous”
oxygen, which can be readily used either for oxygenase or oxidase
reactions, maintenance of pO2 and elimination of hypoxia. Under such
circumstances the activity of oxygen dependent enzymes, including
those involved in H2S/NO/CO synthesis, is optimized, which promotes
activation of K+ATP, BK and TRP channels. In fact, more frequent
oscillation of ROS and metabolism dependent O2 promote sustained
eﬃcient function of mitochondria, which in turn leads to prolongation
of free radical reactions (FRR) and membrane lipid peroxidation in the
cell. The oscillatory nature of ROS/O2 and related regulatory substances
is the least studied aspect in free radical biology. In our opinion, the
most important outstanding questions include the mechanisms of
ﬂuctuations of ROS/O2, transcriptional factors and other regulatory
substances derived from oxidative modiﬁcations of lipid and proteins,
their pattern and localization in cell compartments. A better under-
standing of these mechanisms will promote therapeutic manipulation of
ROS generation and thus, the dynamic association of respiratory
complexes (supercomplex formation) to maintain optimal energy
function of the mitochondria. Energy produced during FRR may play
a crucial regulatory role to achieve better self-organization of the
metabolism, improved stress resistance and sustained hormetic reac-
tions.
For some diseases, including cardiovascular disease, cancer, or
metabolic and neurological pathologies, the involvement of redox
deregulation is unquestionable. Fernando Antunes and Paula M. Brito
discuss how systems quantitative redox biology may bring us closer to
an in depth understanding of “ROS”, their eﬀects and therapeutic
intervention in disease. Deregulation of reactive oxygen, nitrogen, and
sulfur species (RONSS) aﬀects cellular and organismal well being.
RONSS target selected proteins either by binding to, or oxidizing metal
centers or cysteine residues at the level of speciﬁc organs, tissues, cell
types, and cellular organelles. These selected proteins constitute redox
switches. Most of them are controlled by reversible oxidation and are
key players in many signal transduction pathways [138]. The identiﬁ-
cation of hundreds of redox switches by large scale proteomic analysis
[138] has provided new potential therapeutic targets and biomarkers
that are yet to be explored. Thus, a critical mass has been reached to
implement an ambitious translational redox biomedicine program.
Perhaps the most important barrier to the development of such a
program is the complexity of RONSS eﬀects, including biphasic curves
with narrow concentration ranges that often lead to contradictory
conclusions. Such complex behavior is caused by the highly interactive
molecular network formed by redox switches. A promising approach to
deal with this issue is systems quantitative redox biology [139,140] that
integrates the network of redox-regulated pathways and has the
potential to predict the behavior of redox networks when interrogated
with a pharmaceutical drug. This will help identify redox circuits that
are amenable to redox therapeutic interventions without triggering
undesired responses by pathways that share the same redox mediators.
RONSS generation is tightly controlled with respect to kinetics,
concentration and subcellular location [141]; the implications of these
observations are that highly targeted redox therapies, as opposed to
systemic antioxidant interventions, are key for a viable pharmacologi-
cal strategy. Recent advances in nanotechnology have provided new
tools to deliver drugs to speciﬁc therapeutic target locations and have
the potential to generate new classes of drugs that contain redox-active
molecules or molecules that modulate the levels of RONSS as active
pharmaceutical ingredients.
2.6. Microparticles and reactive oxygen species
According to Rhian M. Touyz, microparticles, also termed micro-
vesicles, are cell membrane-derived fractions, which are generated
from activated cells that undergo stress or injury [37]. Theoretically all
cell types are able to generate microparticles, which are detectable in
biological ﬂuids. In the circulation the major microparticle subtypes are
derived from platelets, neutrophils, erythrocytes and endothelial cells
and are measured and phenotyped by speciﬁc markers and ﬂow
cytometry [37,142]. Microparticles have distinct characteristics: they
are 100–1000 nm in diameter, contain features of their parent cells and
do not contain nuclear material. Microparticles were ﬁrst considered as
‘plasma dust’ representing cell debris; however, it is now clear that
these elements are biologically functional and that they are signatures
of the cells from which they are derived. Accordingly, microparticles
have been considered as biomarkers of various pathologies
[37,142,143]. Many pathological states including cardiovascular dis-
eases, kidney disease, cancer, diabetes, thrombosis among others are
associated with increased levels of circulating microparticles. In addi-
tion, increasing evidence indicates that microparticles themselves can
contribute to pathophysiological processes, because they contain
proteins, enzymes, nucleic acids, cytoskeletal machinery, specialized
lipids and microRNAs, that can be transferred to other cells, thereby
initiating signaling events and changes in target cell function
[144–146]. Through this mechanism, microparticles also play an
important role in cell-cell communication and cross-talk. As such
microparticles are now considered not only biomarkers of diseases,
but also biovectors. In addition, because microparticles transfer their
‘cargo’, they have been considered as novel delivery systems for
therapeutics [147]. Increased circulating levels of microparticles are
found in conditions associated with oxidative stress, including hyper-
tension, diabetes, kidney disease and cancer. Moreover, many of the
mechanisms underlying the generation of microparticles involve ROS
and many of the eﬀects of microparticles are redox sensitive [148,149].
Formation of microparticles involves lipid oxidation, mitochondrial
activation, caspases, calcium signaling and Rho kinase activation,
processes linked to increased intracellular ROS bioavailability. Micro-
particles can possess the enzymatic machinery responsible for ROS
formation, including NOX subunits and/or nitric oxide synthase (NOS)
and there is growing evidence that microparticles can generate ROS and
nitric oxide (•NO) [148,149]. Microparticles are supposed to transfer
O2•-, H2O2 and •NO to neighboring cells, and they can stimulate
production of ROS in target cells by stimulating cellular oxidases
[150]. These processes can be inhibited by ROS scavengers, NOX
inhibitors, NOS inhibitors and antioxidants. Hence microparticles are
inﬂuenced by redox processes and can themselves modulate redox-
sensitive signaling pathways [37,148,149]. While it is clear that
oxidative stress and microparticle formation are closely linked and that
microparticles can act as biovectors inﬂuencing cellular redox pro-
cesses, many of the studies were performed under in vitro conditions in
cell-based systems. The pathophysiological signiﬁcance of these pro-
cesses in vivo awaits further clariﬁcation.
2.7. Conclusions
To tackle these questions a multipronged approach is necessary. In
depth understanding of the spatiotemporal role of a particular ROS
source in vivo can only be achieved by scientiﬁc endeavors that
combine basic discovery with appropriate animal models. But these
studies depend on the development of improved tools for visualization
and quantiﬁcation of the oxygen metabolite generated. In addition, a
combination of the expertise of redox biologists, systems biologists,
nanotechnologists and clinical scientists will be required to support the
successful translation of redox biology knowledge into viable pharma-
cological treatments and novel diagnostic biomarkers of diseases, which
will have a major scientiﬁc and socio-economic impact.
3. ROS as signaling molecules
Agnes Görlach (goerlach@dhm.mhn.de) and Andreas Petry (petry@
dhm.mhn.de).
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3.1. Introduction
Reactive oxygen species (ROS) in high concentrations have dama-
ging actions, but in lower concentrations they can act as signaling
molecules (Fig. 3.1). ROS generated by the activation of enzymes such
as NOX, xanthine oxidases, uncoupled NO synthases and other sources
such as arachidonic acid metabolizing enzymes, lipoxygenases and
cycloxygenases, the cytochrome P450s, peroxidases and other hemo-
proteins, as well as ROS generated by mitochondria seem to play
various roles in the cellular signaling network under diﬀerent physio-
logical and pathophysiological conditions. Various cellular antioxidant
systems oppose ROS load thereby limiting not only cellular damage, but
also contributing to ROS-dependent signaling.
3.2. Role of ROS in VEGF and TGF signaling
The dual role of ROS as either damaging or signaling molecules is
well illustrated in the vascular system. For example, as discussed by
María Monsalve and Ignacio Prieto, ROS have been demonstrated to be
central in the control of angiogenesis and are required for the induction
of endothelial cell migration and proliferation. VEGF-A is the most
potent and primary endothelial cell speciﬁc angiogenic growth factor
and stimulates vascular permeability, endothelial cell proliferation,
migration and tube formation, primarily through the VEGF-A receptor 2
(VEGFR-2). ROS work both upstream and downstream of VEGF-A.
Exogenous ROS administration induces VEGF-A levels and promotes
endothelial migration and proliferation, which can lead to diabetic
retinopathy, development of vasa vasorum in atherosclerosis and tumor
angiogenesis [151]. ROS-sensitive transcription factors and coactiva-
tors have been identiﬁed that can directly regulate VEGF-A mRNA
levels, such as the hypoxia-inducible factors 1α and 2α (HIF-1α, HIF-
2α) [152–154], the transcriptional coactivator peroxisome proliferator
γ coactivator 1α (PGC-1α) [155], but also Ref-1, p53, NF-κB and Ets-1
[156].
ROS have also been shown to regulate VEGFR-2 activity and
signaling [157]. The antioxidant protein peroxiredoxin II (PrxII) has
been found associated with VEGFR-2 and is necessary to prevent its
oxidation. VEGFR-2 oxidation renders the receptor insensitive to VEGF-
A stimulation [158]. Following VEGFR-2 stimulation and tyrosine
phosphorylation, the receptor can be dephosphorylated by several
phosphatases such as protein tyrosine phosphatases (PTPs) and den-
sity-enhanced phosphatase-1(DEP-1)/CD148 which can be inactivated
by ROS [159,160]. Downstream of VEGFR-2, several signaling nodes
have also been shown to be ROS sensitive such as PI3K/AKT [161].
Importantly, VEGFR-2 activation can induce ROS production by
endothelial cells (EC), and abrogation of VEGFR-2-dependent induction
of ROS levels abolishes VEGF-A eﬀects on EC migration and prolifera-
tion. It has been amply demonstrated that VEGF-A stimulates ROS
production through the activation of NOX enzymes in EC [156]. VEGF-
A/VEGFR2-dependent activation of NOX1 has been related to increased
angiogenic tube formation of EC [162]. NOX2 knockout mice display
impaired neovascularization in hind limb ischemia and their ECs have
much reduced VEGF-A induced proliferation and migration [163,164].
In addition, NOX4 siRNA inhibited VEGF-induced EC migration and
proliferation [165]. Upon VEGF-A-stimulated receptor phosphoryla-
tion, TSAd-dependent Src activation recruits the scaﬀold protein IQG-
AP1 that promotes the recruitment of Rac1 and NOX2 to initiate ROS
production [166,167]. Furthermore, inhibition of mitochondrial ROS
production was suﬃcient to abrogate VEGF-A and EC migration
independent of NOX enzymes [168]. One possible mechanism could
be inactivation and transcriptional downregulation of PGC-1α follow-
ing PI3K/AKT activation in response to growth factor stimulation that
results in the enhanced production of mitochondrial ROS required to
promote endothelial cell migration [169]. Furthermore, several lines of
evidence suggest that NOX enzymes can function downstream of
mitochondria. Hence, depletion of mtDNA reduces NOX activity, while
induction of mitochondrial dysfunction increases mitochondrial ROS
production resulting in the activation of NOX enzymes [58]. Enhanced
mitochondrial ROS production was suﬃcient to recapitulate most if not
all the features of diabetic retinopathy, and the underlying mechanism
involved was associated with ROS-dependent constitutive activation of
VEGFR-2, and reduced sensitivity to VEGF-A stimulation. Importantly,
both a mitochondrial targeted antioxidant and a general NOX inhibitor
eﬀectively normalized VEGF-A signaling and endothelial tube forma-
tion, indicating that both NOX and mitochondrial ROS are functionally
co-regulated in this context [170,171].
Other factors that have been identiﬁed as potent inducers of ROS
belong to the TGF-β family. These cytokines play essential roles in the
maintenance of tissue homeostasis, regulation of cell growth, migration
and invasion, extracellular matrix remodeling and immune suppression
[172]. As Isabel Fabregat points out, deregulation of TGF-β signaling is
frequently observed in disease states, such as ﬁbrosis, inﬂammation and
cancer, being considered responsible for part of the sequence of events
leading to the end-stage of these diseases [173]. Initial studies in the
middle of the 1990s indicated that TGF-β mediates ROS production
[174,175] and a NOX activity was suggested to be responsible for the
release of H2O2 [174,176]. Nowadays, NOXs are considered as relevant
mediators of TGF-β actions in diﬀerent cells, contributing to the
regulation of growth, death and activation of myoﬁbroblasts, key
executers of the ﬁbrotic process. Although diﬀerent NOXs have been
proposed to be modulated by TGF-β, NOX1 and NOX4 appear to be the
NOXs most frequently involved in its actions. Under physiological
circumstances, NOX4 is transcriptionally upregulated by TGF-β in a
Smad-3-dependent manner and is considered a mediator of TGF-β-
mediated suppressor eﬀects. In particular, NOX4 is required for TGF-β-
induced apoptosis in epithelial cells [177,178]. In contrast, NOX1,
activated by TGF-β in a caveolin-1-dependent manner, plays opposite
roles, stimulating anti-apoptotic signals and preventing cell death
[179]. Deciphering the speciﬁc roles of NOX1 and NOX4 in TGF-β
actions during tumorigenesis will require further investigations, but
current data indicate that overactivation of growth factor signals favor
activation of NOX1 and inhibit NOX4 up-regulation, which would
prevent cell death [180]. Once cells overcome apoptosis, NOX4 might
Fig. 3.1. Summary scheme of ROS acting as signaling molecules in diﬀerent disease
settings but also in physiological processes.
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promote pro-tumorigenic actions of TGF-β, such as epithelial-mesench-
ymal transitions (EMT), that induce cell migration and invasion [181].
Strong evidence supports a role of NOX4 in mediating TGF-β-induced
myoﬁbroblast activation in diﬀerent models of ﬁbrosis [182,183], as
well as in the maintenance of the phenotype of myoﬁbroblasts [184].
NOX4 also mediates TGF-β-induced apoptosis in epithelial cells
[178,184], which contributes to the inﬂammatory process that concurs
with increased activation of myoﬁbroblasts and extracellular matrix
deposits. These studies provide proof of concept for therapeutic
targeting of NOX4 to inhibit TGF-β-induced ﬁbrogenesis. However,
further research is required to validate the safety of these inhibitors, at
least in those tissues where TGF-β acts as a tumor suppressor factor. In
this sense, recent results indicate that knockdown of NOX4 increases
proliferation and tumorigenic properties of liver tumor cells [185].
3.3. Redox regulation of fundamental cellular processes such as cell death
In a more general way, the dual role of ROS has been associated
with diﬀerent cancer types. As Guia Carrara and Geoﬀrey L. Smith
explain, elevated levels of ROS have been a well established property of
most cancers where they contribute to many aspects of tumor devel-
opment and progression, including cell proliferation, genomic instabil-
ity, resistance to apoptosis, cell adhesion and motility, and a metabolic
shift to glycolysis [186,187]. On the other hand, excess ROS is
deleterious to the survival and proliferation of cancer cells. Hence,
endogenous antioxidants are also upregulated to detoxify the cell and
maintain a delicate balance of elevated intracellular ROS that is
beneﬁcial to malignant cells [186,187]. Recently, the Transmembrane
Bax Inhibitor-1 Motif-containing (TMBIM) protein family has received
increasing attention in relation to its role in cancer, which is supported,
for instance, by dysregulation of expression being associated with many
cancer types and by the characterization of its multiple functions that
constitute important hallmarks of malignancy [188]. The Golgi anti-
apoptotic protein (GAAP) is a member of the TMBIM family and is
projected by phylogenetic analyses to have originated before the
divergence of plants and protozoa about 2000 million years ago
[189]. Orthologues of the human GAAP are remarkably conserved at
the protein level (e.g. amino acid sequence, length and hydrophobicity
proﬁle) throughout eukaryotes, prokaryotes and some poxviruses, in
agreement with a highly conserved ancestral structure and function
[190–192]. Since the ﬁrst discovery of this gene in 2002 in camelpox
virus [193], several cellular functions and structural properties of
GAAPs from various origins have been described. Within eukaryotes,
GAAPs regulate Ca2+ levels and ﬂuxes from the principal intracellular
stores (Golgi and ER), confer resistance to a broad range of apoptotic
stimuli and promote cell adhesion and migration via the activation of
store-operated Ca2+ entry (SOCE) [193-195]. Importantly, these multi-
transmembrane proteins were shown recently to form cation-selective
ion channels, potentially forming the basis for the modulation of the
diverse functions of GAAPs [191]. In view of these functions as
important hallmarks of cancer, the eﬀects of human GAAP on ROS
homeostasis in the context of cancerous cells were investigated.
Signiﬁcantly greater overall basal ROS levels, and more speciﬁcally
basal H2O2, were detected intracellularly in cells over-expressing
GAAP. In addition, cells over-expressing GAAP displayed greater
invasive capabilities in tissue culture, which was conﬁrmed by the
opposite eﬀect upon GAAP knock down by siRNA. Furthermore, the
activity of secreted matrix metalloproteinases 2 and 9, which are
sensitive to regulation by ROS and play a key role in migration and
invasion, was dysregulated in these cells. Although both the mechan-
istic links between these observations and the contribution of Ca2+
remain to be established, ROS appear to be a common factor of
importance and relevance in understanding the contribution of GAAP
in cancer development. Furthermore, the diverse multifunctional
properties of GAAP provide a useful common starting point from which
the complex interplay between ROS homeostasis with other important
hallmarks of cancer such as cell invasion, migration, and resistance to
apoptosis can be studied.
Other cellular structures with a putative relation to ROS are
centrosomes. Centrosomes are the microtubule organizing centers
(MTOCs) that nucleate and organize microtubules. They have critical
roles in various processes, including cell division and polarity. Over 100
years ago, it was claimed that centrosome aberrations may lead to
genomic instability and consequently to cancer [196]. As Lokman
Varisli and Serap Ilikay summarize, it was reported that genetic
manipulations that lead to centrosome ampliﬁcation can cause tumor
development [197]. Consistently, centrosome abnormalities have been
observed in many human cancers and in premalignant lesions [198].
Increased centrosome numbers can arise from various mechanisms,
such as centrosome overduplication, cell fusions or failures during
cytokinesis [199]. However, the causes and mechanisms leading to
these eﬀects are not fully understood. In recent years, it was suggested
that ROS may be involved in the regulation of centrosome organization.
Indeed, various researchers reported that oxidative stress may lead to
increases in the number of centrosomes. However, there are contra-
dicting reports in this area. While some researchers reported that
oxidative stress can trigger hyperampliﬁcation of centrosomes and
consequently may promote progression of cancer [200], others sug-
gested that centrosomal abnormalities may contribute to the entry of
the cells into senescence, thus preventing proliferation of damaged
cells. Consequently, centrosome abnormalities are a part of the defense
mechanism that inhibits carcinogenesis [201,202]. On the other hand,
it is known that centrosomes are shielded from oxidative stress through
their association with peroxiredoxin I (PRX1) during interphase, while
this enzyme is inhibited by cyclin-dependent kinase 1 (Cdk1) in mitosis
[203]. Moreover, it was reported that the local concentration of H2O2
around centrosomes is involved in the regulation of centrosomal levels
of some cell/centrosome cycle related proteins and also in the regula-
tion of mitotic entry [203]. In concordance, it was shown that reduction
of peri-centrosomal H2O2 by centrosome-targeted catalase inhibits entry
of cells into mitosis [203]. Consistently, treatment of mitotic cells with
H2O2 causes mitotic slippage and consequently formation of hyperte-
traploid cells [204]. Although the mechanisms of H2O2 induced mitotic
slippage have not been entirely elucidated, this eﬀect is probably
related to exposure of naked centrosomes to H2O2 without a Prx1 (and
probably other antioxidants) shield during mitosis.
3.4. Redox regulation involving mitochondria
In mitochondria, the thiol redox conditions are essentially con-
trolled by glutathione and thioredoxin systems. In the latter, a reducing
sequence starting with NADPH allows the transfer of electrons to
thioredoxin in a process mediated by the mitochondrial selenoenzymes
thioredoxin reductases (TrxR2). NADPH is maintained in a reduced
form by speciﬁc dehydrogenases and by the membrane-bound transhy-
drogenase. Alberto Bindoli and Maria Pia Rigobello discuss, that TrxR2
is able to reduce, in addition to its speciﬁc substrate thioredoxin (Trx2),
a large number of diﬀerent molecules. Thioredoxin is a key component
of the thioredoxin system acting as a wide-ranging protein-disulﬁde
reductase and therefore controlling the redox state of diﬀerent factors
[205]. In particular, Trx2 reduces Prx3, which therefore controls the
levels of H2O2. The mitochondrial isoform of cyclophilin (CypD) plays a
relevant role in regulating the mitochondrial permeability transition
pore [206] and is endowed with redox properties due to the presence of
speciﬁc cysteine residues [207]. In isolated rat heart mitochondria, the
inhibition of TrxR2 with the gold compound auranoﬁn leads to a
concomitant oxidation of Trx2, Prx3 and CypD as demonstrated by the
redox Western blot technique [208]. Similarly, CEM-R cancer cells
incubated with auranoﬁn or other inhibitors of thioredoxin reductase
such as ATO (arsenic trioxide) and CNDB (1-chloro-2,4-dinitrobenzene)
show also a concurrent oxidation of Trx2, Prx3 and CypD. Both in
mitochondria and cancer cells, the addition of H2O2 leads to an
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oxidation pattern similar to that observed after treatment with inhibi-
tors of TrxR2 [208]. In addition, CypD co-immunoprecipitates with
both Trx2 and Prx3 [208] indicating a potential cooperation involving
these proteins. These results indicate that CypD can act as a redox
protein able to modulate the mitochondrial functions such as mem-
brane permeability and that the redox conditions of CypD may be
controlled by the thioredoxin system. Of note, Prx3 can act as a sensor
of hydrogen peroxide and transduce this oxidation to CypD. This view is
further supported by a molecular modeling approach showing a
potential interaction of CypD both with Trx2 and Prx3 [208].
As Carlos M. Palmeira and Anabela P. Rolo point out, mitochondria
play also an essential role in energy production and cellular home-
ostasis. Their highly dynamic nature, based on alterations in biogenesis,
mitophagy, fusion and ﬁssion, allows adjustment of the sequential
oxidoreductive reactions in the electron transport chain (ETC) and
dissipation of the membrane potential by ATP synthase in response to
diﬀerent environmental cues [209]. Such adaptive processes may
involve signaling by ROS and explain how mild levels of mitochon-
drial-derived ROS trigger a hormetic response resulting in extended
lifespan. As ROS are an inevitable by-product of oxidative phosphor-
ylation, alterations in the mitochondrial oxidative rate with a conse-
quent excessive load of ROS, have been traditionally associated with
pathological processes such as cancer, diabetes and neurodegeneration.
Although in mammals the exact signal released by mitochondria that
triggers a hormetic response is still uncertain, more and more studies
are addressing ROS as promoters of mitohormesis, as opposed to their
pro-aging action due to persistently induced oxidative damage. The
concept of mitohormesis proposes that a mild increase in mitochondrial
ROS may act as a sublethal trigger of cytoprotective long-lasting
metabolic and biochemical changes against larger subsequent stresses
[210]. Caloric restriction (CR) has been repeatedly shown to decrease
risk- actors for major age-related diseases and to increase lifespan in
various organisms. Early on, work in C. elegans [211] has shown that
reduced glucose availability was linked to an increase in both ROS and
catalase activity, ultimately culminating in increased survival rates.
Several other studies have further demonstrated that many strategies
promoting longevity share a common downstream aspect, that is:
increased mitochondrial ROS. Inhibition of the mitochondrial ETC by
certain mutations or inactivation of mitochondrial superoxide dismu-
tase increases C. elegans lifespan, as reviewed by Dancy et al. [212].
Low doses of rotenone, an inhibitor of complex I, have also been shown
to extend the lifespan of C. elegans [212] as well as to induce hormesis
in primary human ﬁbroblasts, an eﬀect not possible in older cells or
with higher concentrations of rotenone [213]. Inhibition of mTORC
signaling and the consequent induction of autophagy by caloric
restriction or by pharmacological agents has also been found to
promote longevity in yeast, worms, ﬂies and mice, as recently reviewed
[214]. Further, it has been shown that hearts with impaired mitophagy
and consequent accumulation of damaged ROS-forming mitochondria
develop cardiomyopathy, which can be surprisingly improved by the
ROS-dependent activation of compensatory autophagic pathways of
mitochondrial quality control, preventing a vicious cycle of ROS
formation and mitochondrial dysfunction [215].
3.5. Role of ROS in hypoxia
When oxygen availability is reduced (hypoxia), eukaryotic cells
sense this reduction and trigger a series of cellular and systemic
responses that facilitate adaptation to hypoxia, including the optimiza-
tion of oxygen consumption. As Pablo Hernansanz-Agustín and Antonio
Martínez-Ruiz explain, some of these responses are mediated through
transcriptional regulation by the stabilization of hypoxia-inducible
factors (HIFs); however, this mechanism requires at least several hours
for activation, and there is crosstalk with ROS signaling (for a recent
review, see [216]). Several acute responses operate in minutes in
specialized organs in which local temporal changes in the redox state
have been implied. One example is the carotid body, which senses
variations in blood oxygen to activate the respiratory center. The search
for the molecular mechanisms of oxygen sensing in carotid body cells
has recently led Fernández-Agüera et al. to propose a fundamental role
for mitochondrial complex I in the production of a ROS signal in
response to hypoxia [217]. For a long time there has been a debate on
whether hypoxia increases or decreases ROS production, with appar-
ently contradictory reports in the literature. This controversy might
arise from the ROS source studied, from the cell type, tissue or organism
examined, from the techniques used to measure diﬀerent ROS, and/or
from the duration of hypoxia applied in each study. It has recently been
shown that several cell types respond to acute hypoxia with a transient
increase in superoxide production at the beginning of hypoxia, which
has been called a superoxide burst in acute hypoxia [218]. This may
explain in part the apparently divergent results found by diﬀerent
groups that have not taken into account the time frame of acute hypoxic
ROS production. Molecular mechanisms in acute hypoxia might involve
mitochondrial complex I and the mitochondrial sodium/calcium ex-
changer (NCLX) (Hernansanz-Agustín et al., manuscript under evalua-
tion). Superoxide production in acute hypoxia seems to be a common
mechanism for diﬀerent cell types, but it would elicit diﬀerent
responses in specialized cells and tissues where the adequate compo-
nents for signal transduction may be present such as cysteine residues
sensitive to reversible oxidation. Examples of this are the carotid body
cells where localized ROS production inhibits K+ channels [217,219];
or the pulmonary arteries where mitochondrial ROS production may
elicit a signal cascade including ceramide production, further ROS
production by NADPH oxidases and alterations in ion channel activity
[220]. In endothelial cells, by using specialized thiol redox proteomics
methods, the reversible oxidation of a range of protein cysteine residues
has been observed that could mediate acute responses to hypoxia in
these cells [221]. Another molecular example of a hypoxia signal
transducer is the Na+,K+ ATPase, with cysteine residues that are
sensitive to variations in the oxygen concentration, and that alter the
function of the protein (recently reviewed in [222]). In conclusion, ROS
production is being increasingly considered as a key signaling event in
acute hypoxia, and the molecular mechanisms and functional conse-
quences of this event are currently an active ﬁeld of research, with
implications for molecular physiology and pathology.
An enzyme family that requires oxygen for function, and is thus
related to oxygen availability, are •NO synthases. As Damir Kračun and
Agnes Görlach discuss, all three family members, endothelial NOS
(eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS), catalyze the
reaction of •NO production by binding a number of cofactors such as
ﬂavin adenine dinucleotide (FAD), ﬂavin mononucleotide (FMN),
heme, 5,6,7,8-tetrahydrobiopterin (BH4) and calmodulin to convert L-
arginine and O2 to L-citrulline and •NO.
The ﬂow of electrons within NOS is tightly regulated. If disturbed,
the chemical reduction of oxygen and the generation of •NO are
uncoupled and O2•- is generated from the oxygenase domain. In
particular, failure of adequate provision of the cofactor BH4 shifts
electrons to molecular oxygen rather than to L-arginine, thus transform-
ing NOS into a pro-oxidant superoxide anion-generating enzyme [223].
Conditions of low oxygen availability have diﬀerential eﬀects on
•NO levels: decreased, increased and unchanged levels were reported. In
some cases, the diﬀerences might have been due to diﬀerent detection
methods. Moreover, in several cases, NOS expression levels did not
match the •NO levels measured. While several reports showed that NOS
expression increased under hypoxia, there was no concomitant increase
in •NO levels [224]; recent data indicate that hypoxia leads to
uncoupling of NOS, which might explain this observation [225].
Mechanistically, a decrease in BH4 levels observed under hypoxia in
vitro and in vivo has been related to this eﬀect. BH4 levels in the
endothelium are controlled through de novo BH4 synthesis by GTP
cyclohydrolase I (GTPCH-1), loss of BH4 by oxidation to 7,8-dihydro-
biopterin (BH2), and regeneration of BH4 from BH2 by dihydrofolate
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reductase (DHFR) [226]. While GTPCH-1 downregulation under hy-
poxia was not clearly demonstrated, recent data show that hypoxia can
decrease the levels of DHFR, thus diminishing the capacity to recycle
BH2 to BH4 [225]. In support of this ﬁnding, treatment with folic acid
(FA), which has been shown to upregulate DHFR levels under normoxic
conditions [227], restored DHFR, BH4, and •NO levels in hypoxic cells
[225]. Decreased levels of BH4 and DHFR together with diminished •NO
bioavailability were also observed in vivo in mice suﬀering from
chronic hypoxia-induced pulmonary hypertension. While treatment
with the biopterin precursor sepiapterin, which needs to be converted
to BH4 by DHFR, only marginally aﬀected this disease [228], treatment
with FA not only enhanced •NO and BH4 bioavailability but also
diminished pulmonary hypertension [225]. Since a decline in DHFR
has also been reported to promote angiotensin-II induced hypertension
[227], preservation of DHFR levels appears to be an important
mechanism to combat uncoupling of NOS and its associated patholo-
gies.
3.6. Redox regulation of gene expression via modulation of transcription
factors and epigenetic pathways
Conditions of low oxygen are also favorable for stem cell main-
tenance. As Holger Steinbrenner and Lars-Oliver Klotz point out, adult
mammals harbor multipotent somatic stem cells that are capable of
replenishing terminally diﬀerentiated functional cells for maintenance
and regeneration of tissues as well as for adaptation to metabolic
demands. Examples include hematopoietic stem cells (HSCs) located in
bone marrow, epithelial stem cells in intestinal crypts, and mesench-
ymal stem cells in adipose tissue and bone marrow. Somatic stem cells
in adults are often quiescent but they may temporarily re-enter the cell
cycle and proliferate rapidly in response to the appropriate signals. In
recent years, it has become increasingly evident that even slight
variations in intra- and extracellular levels of ROS may exert a profound
impact on the fate and function of stem cells [229,230]. ROS serve as
signaling molecules that aﬀect the balance between self-renewal and
diﬀerentiation of stem cells, their commitment, diﬀerentiation and
maturation to specialized cell types, and their survival and aging. ROS
involved in these processes, such as superoxide and hydrogen peroxide
(H2O2), derive for the most part from the mitochondrial respiratory
chain and from membrane-bound NADPH oxidases [229,230]. Tran-
scription factors of the forkhead box, class O (FoxO) family participate
in regulating and ﬁne-tuning ROS-modulated cellular diﬀerentiation
processes, as illustrated by the following examples. FoxOs stimulate the
biosynthesis of ROS-reducing proteins located in mitochondria [super-
oxide dismutase 2 (SOD2), peroxiredoxins 3 and 5], in peroxisomes
(catalase), and extracellularly [selenoprotein P (SelP)] [231]. Elevated
Fig. 3.2. (A) Reactive oxygen species can display their regulatory eﬀect on the classical gene regulatory machinery and on epigenetic processes. One of the prominent pathways attributed
to oxidative stress is thiol oxidation, which is involved in OxyR, NF-κB and KEAP1 signaling. Oxygen sensing prolyl hydroxylases represent another class of redox-dependent enzymes. For
example, epigenetic involvement of ROS has been attributed to oxidative conversion of 5-mC to 5-hmC. (B) ROS impact on mRNA stability at the cytosolic level. Reactive oxygen species
are involved in GAPDH signaling by directly altering its structure with the help of GSH or S-nitrosoglutathione (GSNO), and thus activate translation of endothelin-1 (ET-1) mRNA (i). AP-
1 thiol redox regulation directly aﬀects the gene regulating factor HuR by stability of its target mRNAs (ii). ROS have been implicated in the regulation of miRNA pathways, altering
mRNA stability and their transport inside the cytosol. HRE means hormone response element. With permission of Elsevier and the authors. Copyright 2015.
Adapted from [238].
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circulating levels of SelP may then result, by means of its function as a
plasma selenium transporter, in increased biosynthesis and cellular
activity of antioxidant and redox state-modulating selenoenzymes such
as glutathione peroxidases and thioredoxin reductases [231]. Thus,
FoxOs are crucial for cellular stress resistance and longevity. Tightly
controlled increases in FoxO expression and activity may balance ROS
generation in diﬀerentiating cells through an adaptive up-regulation of
antioxidant enzymes, which has been well documented for adipogen-
esis; committed mesenchymal stem cells (preadipocytes) of the sub-
cutaneous adipose tissue may undergo clonal expansion in response to
high nutrient intake. This is followed by growth arrest and terminal
diﬀerentiation into mature lipid-accumulating adipocytes. Adipogenic
diﬀerentiation of human adipose tissue-derived stem cells has been
shown to be associated with elevated ROS generation, and it was
stimulated both by exogenous application of H2O2 and by overexpres-
sion of Nox4. During adipogenesis, expression of FoxO1 and FoxO3
genes as well as the FOXO target genes coding for catalase and SOD2
were upregulated; silencing of FoxO1 suppressed adipogenesis [232].
The continuous renewal of the intestinal epithelium represents another
example that illustrates the importance of ROS for diﬀerentiation
processes: stem cells located at the bottom of intestinal crypts are
capable of proliferating and diﬀerentiating into absorptive and secre-
tory cell types. The switch between cell proliferation and diﬀerentia-
tion/growth arrest is typically associated with changes in the intracel-
lular glutathione (GSH/GSSG) and in the extracellular cysteine/cystine
redox potentials in the gut: proliferation is fostered in a reducing redox
environment, whereas a modest shift towards the oxidation side of the
two redox couples favors diﬀerentiation. A highly oxidized glutathione
redox status, however, associates with cell death [233]. Human
intestinal epithelial Caco-2 cells, a commonly used in vitro model for
intestinal diﬀerentiation, stop proliferation and undergo diﬀerentiation
into enterocytes/colonocytes following conﬂuency. Diﬀerentiation of
Caco-2 cells is associated with induction of FoxO1 and SelP [234], an
antioxidant protein that was identiﬁed as a FoxO1 target gene [235].
Thus, FoxO1-mediated up-regulation of antioxidant enzymes might
limit the severity and duration of the redox shift during enterocyte
diﬀerentiation.
Stem cell diﬀerentiation has been also associated with epigenetic
alterations. As Alina Hanf and Andreas Daiber summarize, there is a
growing body of evidence that ROS/RNS contribute to the regulation of
gene expression and genome stability not only by modulation of
transcription factors, mRNA stability and DNA damage/repair, but also
inﬂuence epigenetic pathways by aﬀecting the function or expression of
histone and DNA modifying enzymes (Fig. 3.2) [236–238]. For
instance, it was shown that oxidative stress alters global histone
methylation by attenuating Fe(II)- and α-ketoglutarate-dependent
histone demethylase activity of Jumonji C (JmjC) domain-containing
enzymes and TET DNA hydroxylases [237,238]. Furthermore, it is well
established that levels of HDAC2 are decreased due to inﬂammation-
induced ROS/RNS production in chronic obstructive pulmonary disease
(COPD) [239]. Another example is the generation of reactive halogen
compounds, such as 5-chlorocytosine, by ROS/RNS, leading to inaccu-
rate methylation by DNA methyltransferase (DNMT) [240]. Adverse
redox regulation of epigenetic processes may ultimately result in
pathological consequences such as dysfunctional energy metabolism
or increased oxidative stress that are associated with cardiovascular
pathologies. For instance, hydrogen peroxide (H2O2) alters the binding
of DNA methyl-transferases (DNMTs) to chromatin leading to hypo-
methylation in atherosclerosis [241,242]. Furthermore, epigenetic
silencing of superoxide dismutase 2 (SOD2) by selective hypermethyla-
tion of CpG islands in the SOD2 gene is associated with pulmonary
arterial hypertension [242,243], and oxidation of HDAC4 by NOX4-
mediated ROS production was observed in cardiac hypertrophy [244].
There is experimental evidence that cardiomyocytes of failing hearts
undergo signiﬁcant changes in epigenetic proﬁles of H3K4 and H3K9
methylation marks that go hand in hand with ROS-induced changes in
histone demethylase activity [242,245,246]. This has also been ob-
served in humans with heart failure [247]. Not only histone modifying
enzymes but also histone proteins themselves can be directly aﬀected
by oxidizing and nitrating agents since exposure to peroxynitrite
induces dityrosine formation in histone H2A and H2B leading to
structural changes by intra-molecular cross-linking [248,249]. Dityr-
osine bridge formation represents an irreversible oxidative modiﬁcation
and it may be speculated that histones carrying this modiﬁcation
account for the persistent changes in gene expression observed in
various disease states. In conclusion, epigenetic regulation by ROS/RNS
in the setting of various oxidative stress-associated disorders may
become an attractive target for redox medicine in the near future.
In addition to histone- and DNA-modifying enzymes, microRNAs
(miRNAs) have an important impact on the epigenetic landscape. They
comprise a large family of conserved, small (19–25 nucleotides (nt)
long), non-coding RNAs that regulate gene expression at the post-
transcriptional level. miRNAs bind to the 3′-untranslated region (3′-
UTR), coding sequences or 5′-untranslated region (5′-UTR) of target
messenger RNAs, thus leading to the inhibition of translation or mRNA
degradation [250,251]. As Verónica Miguel and Santiago Lamas
explain, it has recently been found that miRNAs are able to “ﬁne-tune”
the regulation of redox signaling. This may occur by direct interaction
with NRF2, the major transcriptional regulator in the defense against
ROS [252,253], or its co-regulators Kelch-like ECH-associated protein 1
(KEAP1) and CNC homolog 1 (Bach1), or by controlling the generation
of ROS [254]. This new subset of miRNAs, that either regulate redox
pathways or are themselves regulated by the cellular redox state, has
been termed “redoximiRs” [255]. As pointed out above, ﬁbrosis is an
aberrant repair process that results from chronic inﬂammation and
leads to excessive extracellular matrix (ECM) deposition that ultimately
impairs organ function [256]. Myoﬁbroblasts are considered the
quintessential cell type responsible for ECM accumulation [257].
Fibrosis of major organs including liver, lung, heart, skin and kidney
share common molecular mechanisms regarding the genesis of the
ﬁbrotic process such as the essential role of the TGF-β pathway [258].
However, major diﬀerences exist regarding the cellular origin of
myoﬁbroblasts and the role of epithelial-mesenchymal transitions
(EMT) in each particular organ [259]. The lack of eﬀective and speciﬁc
therapeutic alternatives for ﬁbrosis prevention or cure remains a
fundamental clinical challenge in all organs. In the last decade, miRNAs
have been shown to be modulators of pro- and anti-ﬁbrotic processes in
human diseases and this subset of miRNAs are called “ﬁbromiRs”
[260,261]. Aberrant expression of ﬁbromiRs drives the initiation and
progression of the ﬁbrotic process in response to persistent tissue injury.
Moreover, TGF-β signaling through Smad proteins can regulate the
transcription of miRNAs by DNA binding or miRNA maturation by
associating with the Drosha/DGCR8 complex [262], suggesting a
possible link between miRNAs and ﬁbrogenesis. The overlap between
the sets of ﬁbromiRs and redoximiRs is now becoming evident and is of
potential importance for both mechanistic and translational purposes
[263]. Currently several miRNAs pertaining to this intersection have
been described and are the objects of intense research, including miR-
21 [264–266], miR-29 [267,268], miR-9 [269,270], miR-199 [271] and
miR-433 [272]. Of interest, some of these miRNAs, such as miR-21, may
regulate metabolic pathways related to fatty acid oxidation, a process
that has been proven crucial for the pathogenesis and perpetuation of
ﬁbrosis in the kidney [273–275]. Overall, the crosstalk regulation
between redox balance and miRNA function appears to be an exciting
avenue of research, which may lead to a more profound comprehension
of ﬁbrosis and eventually to provide eﬀective therapeutic alternatives.
3.7. Redox signaling via RONS-derived electrophiles such as oxidized lipids
Fibrosis and inﬂammatory diseases have been also associated with
lipid oxidation. As Catarina B. Afonso and Corinne M. Spickett discuss,
oxidized phospholipids (OxPLs) have a known role in several inﬂam-
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matory diseases such as atherosclerosis and diabetes, but also in
neurodegenerative diseases including Alzheimer's and Parkinson's dis-
ease. Although they mostly have a pro-inﬂammatory role, as reviewed
recently [276,277], their capacity as anti-inﬂammatory agents has also
been described. The anti-inﬂammatory activity of OxPLs has been
shown to involve several pathways (reviewed in [278]). The mechan-
isms by which they act include the inhibition of nitric oxide synthesis in
macrophages; activation of peroxisome proliferator activated receptors
(PPARs), leading to inhibition of major inﬂammatory pathways (such as
the NF-κB and AP-1 signaling pathways); attenuation of dendritic cell
activation and maturation, and inhibition of T-cell proliferation and
cytotoxicity, which are important in the adaptive immune system. One
of the most studied anti-inﬂammatory mechanisms by which OxPLs act,
however, involves the regulation of Toll-like Receptors (TLRs). These
receptors are responsible for innate immune responses by recognizing
pathogen-associated molecular patterns (PAMPs). The presence of
oxidized phospholipids appears to selectively inhibit some proteins of
this family (such as TLR2 and TLR4), possibly through binding to
assessory proteins important for their activity [278]. However, much
research has been performed using speciﬁc oxidized phospholipids, and
the diﬀerent phospholipid species could alter the response observed
[279]. Also, their anti-inﬂammatory activity is known to depend on
several factors. For example, low concentrations (< 25 µM) of the oxPL
are thought to be anti-inﬂammatory, whereas higher concentrations
(> 50 µM) tend to be pro-inﬂammatory and cytotoxic [276]. The
eﬀects of cell type [280] and the presence of endotoxin [281] have
also been reported. The potential of OxPLs for the diagnosis and
treatment of inﬂammatory diseases is evident, but further research is
necessary to characterize the relationships fully.
ROS, RNS and lipid peroxidation (LPO) products are not only crucial
in regulating cellular signaling processes under physiological and
pathophysiological conditions, they are also crucial in the cellular
response to materials, acting in turn as chemo-attractants, signaling
molecules and agents of degradation [282]. As Pierre-Alexis Mouthuy
and Neven Žarković point out, such interactions between cells, materi-
als (or ‘scaﬀolds’), and bioactive molecules can be observed in tissue
engineering in order to improve or replace biological tissues in
regenerative medicine. In this context, modulation of ROS may have
the potential to improve the quality of the engineered constructs. So far,
approaches in tissue engineering that target ROS in order to improve
cell-material interactions have focused on antioxidant therapies to
minimize oxidative stress in cells. However, it is challenging to provide
antioxidant concentrations that are physiologically relevant and re-
spond to variations of oxidative stress levels, which may occur during
new tissue formation. Thus, recent strategies aim to develop polymeric
scaﬀolds that undergo oxidative degradation and/or release bioactive
molecules such as antioxidants in response to the oxidant concentra-
tions [283–285]. On the other hand, considering the multiple roles that
oxidants play during the response to biomaterials, pro-oxidant thera-
pies are also becoming attractive for tissue engineering applications.
The LPO products, like 4-hydroxynonenal (HNE) known as a "second
messenger of free radicals", are particularly interesting candidates to be
supplemented as bioactive molecules. Namely, despite being biomar-
kers of pathological oxidative stress, LPO products have been shown to
stimulate cell proliferation and matrix synthesis [286,287]. Compared
to ROS and RNS, the LPO products have the advantage of forming
rather stable protein adducts. Moreover, their hydrophobicity suggests
that their incorporation into a hydrophobic polymer matrix (such as
biodegradable polyesters) could lead to a slow and prolonged release,
which is desirable for tissue engineering applications. Overall, the
existing evidence supports the idea of providing LPO products during
tissue engineering in order to stimulate cell inﬁltration and new tissue
formation. Such a novel approach has been proposed as a supplement
for a bone regeneration strategy, which is currently being tested using
HNE.
Moreover, proteins can be modiﬁed by covalent reactions on the
nucleophilic residues cysteine, histidine, arginine and lysine, leading to
the formation of a wide variety of adducts with oxidized products of
lipids. As Bebiana C. Sousa and Corinne M. Spickett explain, even
though protein lipoxidation can occur under basal conditions, it is
increased and thought to be relevant in pathophysiological conditions
[288]. In order to understand their impact on a complex matrix like
cells, tissues or body ﬂuids, potentially important protein-lipid adducts
are often generated in vitro under controlled conditions [289]. This
approach has the advantage of potentially decoding the reactivity of
each speciﬁc electrophilic lipid species and speciﬁc fragmentation
patterns of lipoxidation adducts, allowing a targeted analysis in
complex biological samples. On the other hand, this strategy also
presents some disadvantages, as previously reported by other authors
[290,291]. Mass spectrometry (MS)-based analytical approaches are
one of the most popular methodologies to study biological systems and
are used extensively in the study of protein-lipid adducts. The adducts
are detected by MS analysis, often involving liquid-chromatography
followed by top-down or bottom-up proteomic strategies. Because the
top-down approach requires expensive mass analyzers with high mass
accuracy and resolution, the bottom-up approach is the most commonly
used. However, it also involves disadvantages; for example, when the
aldehydes react with lysine and arginine, this leads to additional
diﬃculties since these modiﬁcations may interfere with trypsin diges-
tion, which is typically used in proteomics. Furthermore, stabilization
of adducts is required prior to the enzymatic digestion and MS analysis
due to their labile nature. Certain MS/MS conditions can cleave labile
post-translational modiﬁcations during peptide fragmentation, result-
ing in the neutral loss of the modiﬁcation. For these reasons, it is
advantageous to use enrichment procedures and chemical labeling in
order to improve sensitivity and selectivity. Western blot immunoassay
using speciﬁc or non-speciﬁc antibodies can also be performed,
followed by in-gel digestion and MS analysis for protein identiﬁcation.
However, the cross-reactivity of some antibodies with diﬀerent lipids is
a major disadvantage. The development of new MS approaches could
provide tools to identify and quantify lipid-protein adducts and under-
stand their eﬀects upon oxidative stress and related pathophysiological
conditions [292].
3.8. Interaction of the gasotransmitter H2S with ROS and RNS
In recent years, H2S biology has attracted a lot of attention by
unraveling multiple physiological roles for this gasotransmitter, linking
it to disease conditions and oﬀering novel translational opportunities,
as summarized by Andreas Papapetropoulos (Chair of the COST Action
BM1005 (ENOG)). Hydrogen sulﬁde is generated in mammalian cells by
three distinct enzymes: cystathionine-β synthase (CBS), cystathionine-γ
lyase (CSE) and 3-mercaptopyruvate sulfotransferase (3MST)
[293,294]. Although the exact levels of H2S in cells remain unknown,
they are most likely in the nM range. In addition to free H2S, acid-labile
and protein-bound sulfane sulfur pools exist [295]. H2S is a weak acid
and readily ionizes at physiological pH, with 70% of H2S existing in the
anionic sulﬁde (HS-) form [293]. H2S is a weaker reductant than
cysteine and glutathione. This, in addition to its much lower concen-
tration compared to glutathione and protein thiols, argues against a role
for H2S as a “professional” direct reducing agent in a cellular context.
H2S most likely acts as a signaling molecule boosting endogenous
antioxidant mechanisms.
Low levels of H2S are neuroprotective, cardioprotective, anti-
apoptotic and anti-inﬂammatory [293]. Many of its biological actions
have been attributed to its antioxidant properties [293,296]. H2S
impacts on the cellular redox state as it reacts with ROS, inhibits ROS
production, activates antioxidant enzymes and upregulates the expres-
sion of antioxidant genes. H2S reacts with ROS/RNS including HOCl,
O2•─, H2O2 and ONOO─ [297]. With the exception of HOCl, the reaction
rate constants of H2S with the above-mentioned oxidants are low,
suggesting that they are most likely of little biological signiﬁcance
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[295]. The reaction of H2S with free radicals can give rise to a number
of novel species. Of particular interest is the reaction between H2S and
•NO, which generates S/N hybrid species and HNO• [298].
NRF2 is a transcription factor that acts as a major regulator of the
cellular defense response to oxidative stress since it is the master
transcription factor regulating antioxidant genes [299,300]. NRF2 is
found in a complex with Kelch-like ECH-associated protein 1 (KEAP1)
in the cytosol that facilitates its degradation through the proteasome
pathway. Following exposure to oxidative stress, KEAP1 dissociates
from NRF2 allowing it to escape from ubiquitination and enabling
translocation to the nucleus where it binds to antioxidant response
elements in the promoter region of several genes. Treatment of cells or
animals with H2S donors causes persulﬁdation of KEAP-1 on cysteine-
151, which in turn causes a conformational change in KEAP1 allowing
it to dissociate from NRF2 [301]. In addition to NRF2 activation, H2S
donor administration up regulates NRF2 expression [294].
Treatment with H2S has been shown to be protective against a
variety of oxidative stress-related injuries and ROS-induced toxicity
[296]. From a mechanistic point of view the protective eﬀects of H2S, in
addition to NRF2, have been linked to increased activity of antioxidant
enzymes such as superoxide dismutase, catalase and glutathione
peroxidase, inhibition of superoxide generation and lipid peroxidation
and reduction of NOX expression [296,301]. Moreover, treatment with
H2S donors increases the cellular concentration of reduced glutathione
by promoting cysteine and cystine uptake and by upregulating the level
of the GSH biosynthetic enzyme γ-glutamylcysteine synthase and GSH
reductase; H2S also increases thioredoxin-1 gene expression [296].
4. Redox biomarkers
Paul Winyard (E-mail: p.g.winyard@exeter.ac.uk) and Pietro Ghezzi
(E-Mail: P.Ghezzi@bsms.ac.uk).
4.1. Introduction
This section will deal with selected redox biomarkers. As the
causative molecules of oxidative damage are ROS, one might expect
most studies would be performed by measuring ROS, such as the
superoxide radical or the hydroxyl radical, (among others) in patients’
ﬂuids, just as inﬂammation researchers measure the level of inﬂamma-
tory cytokines in disease. However, most ROS are extremely unstable,
with half-lives of 10−6 −10−9 s. Also “more long-lived” ROS, such as
hydrogen peroxide, have a half-life of less than a millisecond [302].
Therefore, it is diﬃcult to measure them in biological ﬂuids. ROS can be
measured during their production in vitro using chemicals (e.g. “spin
traps” and “ﬂuorescent probes”) to detect them while they are
produced, but they cannot be measured in stored plasma or stored
culture supernatants. Therefore, we do what is done in high energy
physics. Not being able to detect subatomic particles, we can only have
a clue of their presence by the traces they leave. The main feature of
ROS is their high reactivity, hence the name, and measurement of
oxidized macromolecules that can arise by interaction with endogenous
ROS can give us an estimate of the production of ROS (Fig. 4.1) [6].
Likewise, upregulation of ROS enzymatic sources or so-called toxiﬁers
(e.g. myeloperoxidase) can also work as biomarkers of oxidative stress.
Measurement of these oxidized molecules can provide three types of
biomarkers. Some can be indicators of the production of ROS. An
example is S-thiolated hemoglobin (whose oxidation, to our knowledge,
has no pathogenic role). This is similar to the situation with glycated
hemoglobin (HbA1c) in diabetes, a good and stable indicator of how
much the organism has been exposed to high blood glucose, but which,
unlike blood glucose, has limited functional consequences in vivo.
Others are, in eﬀect, biomarkers of oxidative stress, that is, they reﬂect
oxidative damage that may have biological consequences. An example
of this type is oxidized DNA metabolites, as they may potentially be
responsible for oxidative stress-induced mutagenesis and cancer. A
third group of biomarkers consists of oxidized products that have an
Fig. 4.1. Redox pathways associated with putative biomarkers of oxidative stress. The processes that lead to oxidative modiﬁcations of proteins, lipids, and nucleotides are highly
complex. Enzymes, such as XO, NOX, and NOS, can produce ROS and RNS. These ROS can furthermore serve as substrates for other enzymes to generate additional types of ROS, such as
the generation of HOCl from H2O2 by MPO. Cellular systems and enzymes, including the GSH and thioredoxin system, together with peroxiredoxins (T/Prx), counterbalance the
production of ROS. In addition, increased levels of ROS activate NRF2 to transcribe genes that are involved in counteracting these ROS. Oxidative stress aﬀects cGMP signaling through its
eﬀects on nitric oxide (•NO) production, scavenging, and on the •NO receptor sGC. cGMP, cyclic guanosine monophosphate; GSH, glutathione; H2O2, hydrogen peroxide; HOCl,
hypochlorous acid; MPO, myeloperoxidase; NOS, nitric oxide synthase; NOX, NADPH oxidase; RNS, reactive nitrogen species; ROS, reactive oxygen species; sGC, soluble guanylate
cyclase; XO, xanthine oxidase. Adpated from [6]. With permission of Mary Ann Liebert, Inc. Copyright 2015.
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intrinsic biological activity, which may propagate some of the con-
sequences of oxidative stress – such as hydroxynonenal, an aldehyde
generated by lipid oxidation [303].
This review will deal with diﬀerent types of stable redox biomarkers
that can be used in biological samples from clinical or population-based
studies. The biomarkers have been grouped in the subsections below
according to their identity as oxidation products of proteins, lipids, or
DNA.
4.2. Protein oxidation products as redox biomarkers
The following section was composed by Serge P. Bottari, Stuart P.
Meredith and Corinne M. Spickett. Biological systems are exposed to
various endogenous and exogenous oxidants capable of modifying
proteins, which, among other processes, may aﬀect cell signaling
pathways [304] and contribute to inﬂammatory diseases [302]. A
number of acute and chronic diseases have been reported to cause, be
accompanied by, or be due to, "oxidative stress". This stress can be
considered as a deregulation of redox signaling resulting in an excess of
ROS, which may be responsible for further complications.
Since the major substrate of the primary ROS, O2•-, in terms of
kinetics is •NO (the reaction with O2•- has a rate constant which is 3–4
times greater than the rate constant for the dismutation of O2•-
catalyzed by SOD), oxidative stress is generally preceded – and
accompanied by – an increased generation of RNS, essentially perox-
ynitrite (ONOO-), which, in the case of excessive concentrations, can
cause nitro-oxidative stress [305]. Since RNS can, like ROS, alter
proteins, lipids and nucleic acids, RNS may also be involved in
pathological mechanisms [306,307]. Interestingly, however, most
posttranslational protein modiﬁcations due to RNS appear to often be
reversible in vivo. Therefore, nitro-oxidation should be considered as a
potential therapeutic target, as the modiﬁcations involved are modu-
lated primarily by the redox status, •NO and O2•- ﬂuxes [308], the
former being easily manipulable.
The major pathophysiological nitro-oxidative protein modiﬁcations
elicited by ONOO- are glutathiolation and S-nitrosation of Cys and
nitration of Tyr residues. Other modiﬁcations are zinc ﬁnger oxidation
and methionine sulfoxidation. •NO by itself is a major neurotransmitter
and an activator of soluble guanylate cyclase. Its reaction with O2•-
therefore has dual consequences: primarily the generation of novel
messengers (RNS) and a decreased bioavailability of •NO with direct
consequences on its targets [305,307].
Antibody-based methods are among the most common techniques
for identifying and quantifying these oxidative post-translational
modiﬁcations to amino acid residues. The most common techniques
(Table 4.1) include ELISA, Western blotting (WB) and immunostaining
techniques, such as immunohistochemistry (IHC) and immunocyto-
chemistry (ICC). The accuracy of these techniques relies on the
speciﬁcity of the available antibodies, but not all antibodies are
validated for all procedures [309]. The majority of antibodies against
oxidative posttranslational modiﬁcations are primarily validated for
Western blotting (~75%), with smaller numbers suitable for the other
techniques (IHC ~40% and ELISA ~35%), and they are not necessarily
interchangeable. Searching on databases such as CiteAb and Biocom-
pare suggests there are more than 500 commercially available anti-
bodies to modiﬁed residues (Table 4.1), but on average less than 15% of
these have been speciﬁcally cited in scientiﬁc publications. Some
antibodies are more extensively cited and used in diﬀerent techniques,
so selecting the appropriate one is important.
An important issue is the speciﬁcity of the antibodies, which may
vary according to the immunogen used to generate them, including the
carrier. The most commonly used approach is conjugation of the
modiﬁed residue to either keyhole limpet hemocyanin (KLH) or bovine
serum albumin (BSA), but others were produced by immunizing
directly with proteins treated with oxidizing, chlorinating or nitrating
agents. A limitation of using modiﬁed BSA or other proteins is that it
generates antibodies to a variety of epitopes on the antigen that may
lead to cross reactivity upon translation, especially as most nitrating
and chlorinating agents are also oxidizing, so a wide range of oxidative
posttranslational modiﬁcations result. Even using synthetic modiﬁed
residues conjugated to a carrier protein, there are likely to be several
antibodies to epitopes that do not include the modiﬁcation site, so
puriﬁcation is required. Thus the resulting polyclonal sera are semi-
speciﬁc at best; while monoclonal products are better, some cross-
reactivity is still possible. For example, limitations of antibodies and
antibody-dependent assays for methionine sulfoxide have been re-
ported [310,311]. This indicates the importance of understanding the
nature of the antibody being used in order to interpret results correctly,
but unfortunately, often little information is available from the
supplier. It also suggests the beneﬁt of producing better characterized
antibodies, possibly with known sequence speciﬁcity in addition to
modiﬁcation speciﬁcity.
Among the applications of the above antibodies to immunochemical
assays, it is of primary interest to be able to detect and quantify nitro-
oxidative "stress" in pathophysiological situations before irreversible
oxidative cell damage occurs. Among the nitro-oxidative protein
modiﬁcations, the most stable and therefore easiest one to investigate
is Tyr nitration. Indeed, glutathiolation and S-nitrosation, being heavily
dependent upon the redox state, can easily be artifactually generated or
reduced in biological samples.
In order to achieve monitoring of nitro-oxidative "stress" in patho-
physiological situations, Rocha et al. developed an ELISA assay for the
quantitative determination of nitrated albumin in plasma. Indeed,
assaying free or peptide-bound nitroTyr does not reﬂect nitro-oxidative
stress as most of it is of dietary origin [312].
This test allowed Bottari's group to monitor the occurrence of
systemic nitro-oxidative "stress" under two conditions which can lead
to severe long-term psychomotor retardation: perinatal asphyxia and
Table 4.1
Summary of the types of antibodies currently available against oxidatively modiﬁed residues.
Modiﬁcation Number of
Antibodies
Antibodies Cited Clonality (mAb:
pAb)
Most Common Antigen Range of Validated
Techniques
3-Chlorotyrosine 1 1 0:1 3-Chlorotyrosine (no details) IA, IHC
3-Nitrotyrosine 439 15 129:310 3-Nitrotyrosine conjugated to KLH WB, ELISA, ICC, IF, IHC, IP
S-nitrosocysteine 1 0 0:1 Recombinant protein ELISA, WB
Cysteine sulfenic Acid 3 3 0:3 Sulfenic acid-cysteine (2-thiodimedone-speciﬁc Ig) WB
Cysteine sulﬁnic acid 1 0 0:1 Cysteine sulﬁnic acid adducts ELISA, IHC
Cysteine sulfonate 3 3 0:3 Dimedone-modiﬁed cysteine conjugated to KLH WB
5-Hydroxytryptophan 17 1 8:9 Conjugated to bovine serum albumin via a
glutaraldehyde linkage
WB, ELISA, ICC, IHC, IF
Methionine sulfoxide 3 2 0:2 Protein with methionine sulfoxide modiﬁcations WB
Hydroxyproline 19 3 0:19 Conjugated to bovine serum albumin ELISA, IHC, ICC, WB
Carbonyl 43 41 27:16 Conjugated to bovine serum albumin ELISA, IHC, ICC, WB
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neonatal hypoglycemia [313,314]. Whereas the clinical signiﬁcance
and importance of perinatal asphyxia on neurodevelopmental outcome
of severely and even moderately aﬀected newborns is now generally
accepted, this has not been the case for neonatal hypoglycemia whose
clinical signiﬁcance is still a matter of intense debate [315–319].
Interestingly, animal models of these two conditions invariably show
cerebral insult associated with increased tyrosine nitration both in vitro
and in vivo. These observations have been conﬁrmed in postmortem
cerebral and medullar tissues of asphyxiated neonates [320,321].
Since high peroxynitrite ﬂux generation has been reported to cause
neuronal apoptosis, Wayenberg et al. investigated potential correlations
between plasma nitroalbumin levels and other biological and clinical
parameters in asphyxiated and hypoglycemic neonates [313]. In
perinatal asphyxia, it was found that plasma nitroalbumin concentra-
tions at day 1 to be strongly correlated with the severity of neonatal
encephalopathy (χ2 =7.23; p<0.05) indicating the occurrence of
systemic nitro-oxidative stress in these infants. Nitroalbumin levels
were also inversely correlated (p< 0.05) with Apgar score (a marker
for the health of newborns) and arterial blood pH and directly with
creatinemia, arterial base deﬁcit and lactacidemia. The latter correla-
tion indicates a correlation between the degree of hypoxia and albumin
nitration, whereas the increase in creatinemia is indicative of a
decreased glomerular ﬁltration rate, which may reﬂect aﬀerent arter-
iolar vasoconstriction. Nitroalbumin levels were back to control levels
at day 4 suggesting that this stress was transient [313].
It has been well documented that moderate and severe neonatal
encephalopathy are often associated with subsequent periventricular
leucomalacia and cerebral palsy, often leading to impaired neurodeve-
lopmental outcome. The data of Wayenberg et al. therefore suggest that
increased RNS generation may play a role in hypoxic-ischemic brain
injury. Further studies are required to verify whether plasma nitroal-
bumin may serve as a marker of nitro-oxidative stress in neuroprotec-
tive trials.
In neonatal hypoglycemia [314], Wayenberg et al. found an inverse
correlation between glycemia and plasma nitroalbumin as early as the
ﬁrst hour of life (r=−0.35; p<0.02) and through day 1. Lactacidemia
was inversely correlated with nitroalbumin suggesting that lactate may
serve as an alternate fuel. Another interesting ﬁnding is the strong
correlation between nitroalbumin levels and the severity and duration
of the hypoglycemic events determined as area-under-the-curve. Simi-
larly, in neonates who had more than 2 hypoglycemic episodes during
the ﬁrst 24 h of life, nitroalbumin levels were still signiﬁcantly elevated
at day 4.
Whereas, as mentioned earlier, the impact of neonatal hypoglyce-
mia on neurodevelopmental outcome is still a matter of debate, our
data clearly indicate that severe and repeated hypoglycemic events
during the ﬁrst 24 h of life induce an important and long-lasting
systemic nitro-oxidative stress both in preterm and term infants, which
may be involved in the cerebral insult responsible for the psychomotor
retardation reported by several authors. These observations therefore
provide grounds for timely and appropriate management of neonatal
hypoglycemia and call for further studies on careful metabolic mon-
itoring and long-term follow-up of the neurodevelopmental outcome of
these infants.
In conclusion, plasma nitroalbumin determination provides a highly
sensitive and robust marker, which may prove useful for monitoring
nitro-oxidative stress and for understanding the involvement and role of
redox deregulations and RNS in various pathophysiological conditions.
4.3. Lipid oxidation products as redox biomarkers
The following section was composed by Opeyemi S. Ademowo,
Irundika Dias and Helen Griﬃths. Malondialdehyde (MDA) is the best
known and most abundant (10–20 µM in plasma) end-product of the
autocatalytic lipid peroxidation chain reaction. In addition to alde-
hydes, other common cholesterol, phospholipid and polyunsaturated
fatty acid peroxidation biomarkers that are formed include ketones
such as 4-hydroxynonenal, alcohols such as isoprostanes, hydroper-
oxides such as 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phospho-
choline (POVPC) and cyclic endoperoxides. Polyunsaturated fatty acids
(free or in phospholipids) with methylene interrupted unconjugated
oleﬁnic bonds are highly susceptible to free radical oxidation and yield
hydroperoxide species in situ, which in the case of membranes, are
released by phospholipases. Commonly reported examples of oxidized
cholesterols (oxysterols) include 6-cholesten-5α-hydroperoxide, 7-ke-
tocholesterol, 7-dehydrocholesterol and 25-hydroxycholesterol [322].
The suitability of these molecules as biomarkers is dependent on their
stability, ease of enrichment or separation and accurate detection
methods in the presence of several orders of magnitude higher
concentrations of the parent lipid. The commonly used thiobarbituric
acid-reactive substances (TBARs) assay lacks speciﬁcity for MDA
measurement in biological materials and is not a method of choice
for MDA quantitation [323].
Lipid peroxidation analysis by absorption spectrometry has been
superseded by the accurate determination of unmodiﬁed or derivatized
lipids using chromatographic separation followed by mass spectrometry
(MS) methods. Gas and liquid chromatography have been used
successfully according to equipment availability, but LC is easier as it
does not require the samples to be volatilized. The precision of such
methods is achieved by: 1) stability of the analyte; 2) enrichment of the
analyte; 3) speciﬁc detection by multiple reaction monitoring transi-
tions; 4) the sensitivity of the MS method including variation in dwell
time; and 5) the availability of stable isotope standards for the species
of interest.
For MDA, the commercial deuterated standard is available to
support stable isotope dilution methods; successful derivatization and
stabilization in acetone has been achieved using pentaﬂuorobenzylbro-
mide followed by extraction using toluene to remove matrix followed
by GC separation to enrich for species of interest [324], and using 3-
nitrophenylhydrazine to derivatize followed by LC separation using
stable isotope dilution methods to compensate for matrix eﬀects during
electrospray ionization [325].
Quantiﬁcation is typically achieved by selected ion monitoring
(SIM) after MS (e.g. of m/z 251 for MDA and m/z 253 for its stable
isotope after neutral loss of PFB) and selected reaction monitoring
(SRM) by MS/MS of the mass transition (e.g. m/z 251→ m/z 175 for d0-
MDA and m/z 253→ m/z 177 for d2-MDA) [324]. By derivatizing MDA,
these methods capture the reactive carbonyl prior to sample processing.
Similar to MDA, 4-HNE is highly reactive and MS methods of
analysis typically rely on derivatization using PFB to stabilize the
reactive carbonyl. After GC separation and analysis by the SIM method,
the deuterated analog, HNE-d11, has been successfully used for
quantitation [326]. Plasma concentrations of 4HNE are ~100 nM.
Isoprostanes (IsoPs) are stable products of polyunsaturated fatty
acid peroxidation. F2-isoP, the most common, is derived from arachi-
donic acid with a concentration< 0.5 nM in the plasma of healthy
human subjects. One LC-MS method using deuterated standardization
has been described, despite this method having the potential to be the
most sensitive and speciﬁc for many diﬀerent isomeric forms. Solid
phase extraction was adopted to remove contaminants and following
LC-MS, two MRM transitions were acquired per analyte for quantiﬁca-
tion and conﬁrmation of IsoPs [327]. The recovery of the spiked
standard was 70–120%.
Oxidized cholesterols have biological activity [328] although they
are found at very low concentrations in plasma (7-ketocholesterol: <
75 nM). They are often esteriﬁed. Some methods describe saponiﬁca-
tion to release the free oxidized cholesterol as an index of oxidative
stress whereas other authors prefer to analyze the biologically active
free oxidized forms. Solid phase or liquid-liquid extraction and protein
precipitation during sample preparation has proved to be important for
sample enrichment. The incorporation of deuterated standards using
stable isotope dilution enables absolute recovery to be reported. Using a
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monolithic column, eﬃcient chromatographic separation of isomeric
oxysterols was achieved; MRM transitions of m/z 369/287 enabled
speciﬁc detection for 7-ketocholesterol with 81–108% recovery [329].
In order to highlight the innovations in the ﬁeld of lipid peroxida-
tion product analysis by LC, a recent approach for detection of the
oxidized phospholipid POVPC has been described that relies on a
nanoparticle-based strategy for successful trapping and enrichment of
aldehyde-containing oxidized phospholipids [330]. After derivatization
of carbonyl containing phospholipids with a bifunctional reagent
containing a thiol moiety to bind onto nanoparticles, the derivative
and enriched moieties can be released by a reducing agent for analysis
by LC-MS/MS. The authors highlight a two-fold improvement in the
sensitivity of POVPC detection using nanoparticles.
As LC-MS/MS with SRM methods and deuterated standards become
more widely available, a new era of reliable lipid peroxidation analysis
will dawn enabling researchers to understand the concentration and
species produced in diﬀerent biological contexts. Improved enrichment
techniques that minimize the risk of artefactual oxidation and novel
chromatographic materials that can oﬀer improved separation of
amphipathic molecules are key to further development in this ﬁeld.
4.4. Nucleic acid oxidation products as redox biomarkers
The following section was composed by Marcus S. Cooke, Mahsa
Karbaschi and Henrik E. Poulsen. Nucleic acid oxidation has attracted
attention since it was shown that it was one of the most abundant DNA
modiﬁcations [331]. It also is a pre-mutagenic lesion that induces CG:
TA transversion mutations. The guanine moiety is particularly prone to
oxidation and is studied as a prototype for both DNA and RNA
oxidation. In DNA it can be measured as the nucleoside upon digestion
and hydrolysis. The gold standard for measurement is now ultra-high-
performance liquid chromatography with tandem mass spectrometry
for quantiﬁcation. The optimum method includes extensive chromato-
graphy, isotope dilution with the use of both quantiﬁer and qualiﬁed
ions [332]. The oxidized nucleosides from both DNA and RNA are
excreted into urine and are used as non-invasive biomarkers [6].
Biomonitoring such damage, both in vitro and in vivo, is therefore
critical to understanding the mechanisms linking damage with disease,
but achieving this can present technical challenges. Blood is a poten-
tially problematic matrix to measure oxidatively generated DNA
damage, as it is necessarily invasive (typically ~5 mL is needed);
peripheral blood mononuclear cells need to be isolated before analysis
or storage, which is a time-consuming process; and artefactual damage
occurs when whole blood is frozen without a cryopreservative. To
address this, a novel approach has been described that signiﬁcantly
simpliﬁes biomonitoring in vivo: small volumes of whole blood are
suﬃcient (250 µl from a ﬁnger prick), which facilitates simple collec-
tion and storage without artefacts, together with use in the comet assay
without prior isolation of peripheral blood mononuclear cells [333].
Recently, a novel comet assay tank and rack design was described,
which exploits holding the slides in a vertical orientation, rather than
horizontal [334]. This innovation results in signiﬁcant improvements in
sample throughput (~90% decrease in slide handling time), together
with a much smaller footprint, and enhanced cooling. In contrast to
blood, urine is non-invasive, although it is also possible to measure
biomarkers of oxidative stress in other extracellular matrices [335].
Mass spectrometric approaches remain the gold standard for urinary 8-
oxodG analysis, but modiﬁcations to a commercially available ELISA
for 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) have improved its
accuracy [336,337]. Most recently, the Cooke laboratory has estab-
lished an approach that allows genome-wide assessments of DNA.
There are many reports of increased excretion of the guanine
nucleoside into urine or elevated tissue levels in many diseases, and
this has led many researchers to conclude that nucleic acid oxidation is
important in many diseases. Oxidative stress-induced damage to nucleic
acids (including DNA, RNA and the corresponding nucleotide pools) has
been implicated in the pathogenesis of numerous diseases, including
cancer, cardiovascular disease and neurodegenerative disease [338].
However, there is a diﬀerence between occurrence and importance, and
also there is the problem of whether the lesion causes the disease or is a
consequence of the disease. The classic criteria for causation are given
by the nine Bradford-Hill criteria [339]: strength, consistency, speciﬁ-
city, temporality, biological gradient, plausibility, coherence, experi-
ment, and analogy. For DNA oxidation there are few publications on the
strength (urinary excretion of the oxidized deoxyguaninosine nucleo-
side (8oxodG)). Consistency is limited and there are only a few existing
cohort studies, yet they have shown an association with lung cancer in
non-smokers [340] and with breast cancer [341]. These eﬀects are
small and probably not important on an individual basis, although they
might be important from a public health point of view. There are no
important data to evaluate criteria 2,3,4,5. Criterion 6 (plausibility) is
provided by the demonstration of GC: TA transversion mutations, even
though the quantitative eﬀect is not established. Criterion 7 is partly
fulﬁlled by epidemiological and experimental evidence, and for criter-
ion 8 (experiment) there are data from DNA repair knock-out animals
that support the idea that the oxidative modiﬁcations are linked to
cancer development, or to premature aging [342].
RNA oxidation has only recently attracted attention. The evidence is
limited to hemochromatosis [343] and diabetes [344,345]. The data
support criterion 1 in that the eﬀects are considerable, but the rest of
the criteria are only supported by hypotheses [346].
Beside the Bradford Hill criteria, there are some additional aspects
that need to be considered in the context of clinical utility. If a high
level of a biomarker is associated with a disease, are there means to
reduce the levels and will this either prevent the disease or improve
survival of patients with the disease? There are no data on this.
Presently, the quest is to identify non-pharmacological or pharmacolo-
gical means that are non-toxic and that can reduce markers of DNA or
RNA oxidation. Hitherto, the only example is blood-letting for the
treatment of hemochromatosis that reduces the biomarker for RNA
oxidation and also is well established to reduce the morbidity from high
body iron [343]. Still, particularly regarding type 2 diabetes, the clear
association between morbidity/mortality and the levels of RNA oxida-
tion is very promising with a potential to identify or develop novel
treatments for type 2 diabetes.
4.5. Conclusion
This comprehensive review has provided a summary of some of the
protein-, lipid-, and nucleic acid-based biomarkers of oxidative stress,
some of the latest developments in the assay methods by which they
may be measured, and some of the applications of these methods in
clinical studies. As described above, in general, gas/liquid chromato-
graphy-mass spectrometry often provides the platform of choice for the
determination of all these types of biomolecules, due to the speciﬁcity
and sensitivity of this platform. However, this type of platform does not
necessarily provide a method that is suitable for large-scale clinical
studies because of the relatively high cost of mass spectrometry
equipment and, frequently, the relatively high time demands for sample
preparation. Even mass spectrometry approaches are not without the
dangers of artefacts. It should also be borne in mind that good
analytical sensitivity and speciﬁcity for a particular biomarker does
not necessarily translate into good clinical diagnostic sensitivity and
speciﬁcity when testing the utility of the biomarker in the diagnosis of a
speciﬁc human disease.
Immunochemical methods such as ELISAs might provide alterna-
tive, high-throughput approaches for the analysis of oxidative stress
biomarkers (as described above for a range of protein oxidation
products, including 3-nitrotyrosine within the albumin polypeptide
backbone). However, great caution should be exercised in relation to
the speciﬁcity of the antibodies used in ELISAs, and it is evident from
Table 4.1 that many commercially available antibodies directed against
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protein oxidation products have received limited validation.
One of the challenges in this area is for the “redox biology
community” to work together to validate a group of harmonized assays,
which will constitute reference standards for oxidative stress biomar-
kers in clinical studies. An important series of investigations (the
National Institute of Environmental Health Biomarkers of Oxidative
Stress Study), addressed the question of which assays provide valid
read-outs of oxidative stress induced in animal models. The mass
spectrometry-based measurement of F2-isoprostanes was identiﬁed as
a “gold standard” biomarker of free radical damage caused by carbon
tetrachloride in rats [347]. A viewpoint regarding the current status of
oxidative stress biomarkers as clinically useful tools was provided by a
recent review [6]. Visualization of biomarkers measured in various
diseases by cluster analysis (Fig. 4.2) shows that the majority of studies
have used ROS-induced modiﬁcations as markers of oxidative stress
[6]. There is also ongoing discussion on whether traditional assays for
ROS and RNS detection are still useful in certain setups or should be
replaced by more advanced techniques [348–350].
The current review has included some indications as to how
oxidative stress biomarkers assays may be applied to medical research
studies, but the demonstrated clinical value of oxidative stress measures
in diagnosis or monitoring in patients has so far been disappointing. In
this respect, the challenge is to validate oxidative stress assays in terms
of clinical utility – i.e. clinical diagnostic sensitivity and clinical
diagnostic speciﬁcity. The development of oxidative stress biomarkers
needs the substantial further attention of researchers, particularly in
relation to the identiﬁcation of validated biomarkers for the study of: (i)
the pharmacodynamics of novel redox-based therapeutics in animal
models of disease, (ii) the clinical diagnosis and/or monitoring of
human diseases in which oxidative stress is involved, and (iii) clinical
trials of novel redox-based therapeutics. As long as the above three
areas remain inadequately addressed, we will continue to struggle to
translate our increasing understanding of redox biology into advances
in human disease therapies based on redox medicine. The studies
described above, in relation to nitrated albumin as a biomarker in
perinatal asphyxia and neonatal hypoglycemia, begin to take us in the
right direction. But the important challenge of identifying reference
methods for oxidative stress assays still has some way to go.
5. Optimizing ROS detection using EPR or ﬂuorescence: in vivo
applications to mammalian cells, tissues and plant biology
Yves M. Frappart (E-mail: yves.frapart@parisdescartes.fr).
5.1. Introduction
When oxygen ﬁrst appeared on Earth, living systems had to adapt to
this particular oxidant molecule. This resulted in various reactive
oxygen species (ROS: mainly superoxide anion, hydrogen peroxide,
but also 1O2, hydroxyl radical) that must be regulated by all aerobic
organisms. Due to the regulatory role of ROS and crosstalk between
these molecules, their level and localization are therefore critical
parameters for biology and medicine. In order for the measurements
to be most useful, it often is essential to measure the amount of ROS at
particular sites and under appropriate conditions. Speciﬁc, sensitive
and localized measurements of ROS require special methodologies. As
ROS are correlated to oxygen levels, in vivo conditions should be
applied to study their biological eﬀects, which is not always possible.
Oxygen concentration is therefore a key element in every experiment.
There is no gold standard modality to determine, quantify or localize
the various ROS species. Scientists who evaluate ROS have to use
diﬀerent modalities, with diﬀerent qualities and limitations depending
on the experimental conditions. Over the last decade, approximately
75% of all reports on ROS have been determined with ﬂuorescence
imaging, especially in vitro [355]; almost all the other references have
used electron paramagnetic resonance (EPR or electron spin resonance
[ESR]) with or without spin trapping for their detection or imaging
[356]. Nevertheless other modalities are emerging such as nuclear
magnetic resonance imaging (MRI) [357], echography [358] or posi-
tron emission tomography [359]. New methodologies such as immuno-
spin trapping [360] are also emerging all the time so that it is not
possible to give an exhaustive list. Fig. 5.1 shows enzymatic sources of
RONS, the reactive species being formed, the potential footprints they
leave and imaging techniques that may be applied to measure them
Fig. 4.2. Cluster analysis of ROS biomarkers in disease. Diﬀerent diseases were clustered according to described ROS biomarkers in Refs. [351–353] and studies described in this review.
Some disease conditions cluster as might be expected, such as ischemia/reperfusion and heart failure, and amyotrophic lateral sclerosis and multiple sclerosis. A comprehensive analysis
of ROS markers and pattern analysis in diseases might uncover common disease mechanisms or new measures of disease progression or treatment outcome. Cluster analysis was
performed using Genesis software (https://genome.tugraz.at/genesisclient/genesisclient_description.shtml) as described in Mengozzi et al. [354]. Adpated from [6]. With permission of
Mary Ann Liebert, Inc. Copyright 2015.
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[361].
Despite its limitation, EPR is still the most suitable technique to
detect ROS. EPR can be used in diﬀerent methodologies such as EPR
coupled to spin-trapping. It is the most speciﬁc method, as stated by K.
Abbas and F. Peyrot.
5.2. Spin trapping coupled to EPR is an under used speciﬁc method to
measure oxidative stress in biological systems
Electron paramagnetic resonance (EPR) is the gold standard to
detect paramagnetic species. However, when the aim is the detection of
short-lived radicals involved in oxidative stress, such as O2•- in living
systems, direct detection is not possible due to the low sensitivity of the
technique. To overcome this limitation, the spin trapping method was
introduced in the 1970s. It relies on the speciﬁc single-step addition
reaction of the radical of interest on an EPR-silent molecule, named the
spin trap, which yields a persistent radical, called the spin adduct, the
EPR spectrum of which is characteristic of the trapped radical. The most
commonly used spin traps for O2•- in aqueous medium are derivatives of
the cyclic nitrone 5,5-dimethyl-1-pyrrolidine N-oxide (DMPO, e.g.
DEPMPO) (Fig. 5.2). Since its ﬁrst application to biological systems in
1979, important contributions have been made to improve spin trap
structures based on mechanistic analysis of the spin trapping reaction
and of the spin adduct decomposition pathways [362,363], but also to
improve the methodology by characterizing its limitations, artefacts,
and sources of misinterpretations [364–368]. Intracellular detection
and quantiﬁcation are not straightforward, and in vivo detection of O2•-
is impossible with spin traps coupled to EPR. However extracellular
detection of O2•- produced by cells can now be achieved with excellent
speciﬁcity and satisfactory sensitivity with CD-DIPPMPO, an extracel-
lular spin trap [369]. Spin trapping of NO is based on its high aﬃnity
towards ferrous iron and trapping as stable nitrosyl-iron complexes is
achieved by either adding iron-diethyldithiocarbamate (Fe(II)(DETC)2)
to tissues or isolated cells [63,370], or by measurement of endogen-
ously formed nitrosyl-iron complexes such as Hb-NO [371,372].
Nitrosyl-iron complexes produce typical triplet EPR signals (Fig. 5.2).
Though a few spin traps are commercially available, their cost is
prohibitive considering that their purity is usually not suﬃcient for
biological studies. Since the quality of the supplies has not improved
over the years, there is a need for a greater collaboration between
biologists, synthetic chemists, experts in EPR spectroscopy and spin
trapping from platforms dedicated to EPR studies of biological systems
at national and European levels so that recent advances can be made
accessible to all, in order to address questions relative to oxidative
stress in biological systems. A few years ago, as Ron Mason was trying
to ﬁnd new accurate ways to use spin trapping in order to determine
superoxide levels in living systems, he introduced immuno spin-
trapping, which he presented in a recent review [360]. Immuno spin-
trapping uses spin-trap antibodies to ensure the detection of the long
lived biological species with various methodologies (UV, mass spectro-
metry, MRI). Spectroscopists can now speciﬁcally detect superoxide in
vitro; they have therefore moved on to try to overcome the problem in
vivo by studying the redox status. Redox status is related to the balance
of many biological species (oxidants and reductants or antioxidants).
Despite its hazy deﬁnition, the redox status can be used as a tool by
biologists in many cases. This kind of measurement is based on the
aminoxyl (nitroxide), hydroxyamine redox equilibrium. It is suitable for
in vivo imaging [374] and often uses soluble molecular probes. When
aminoxyl linked to proteins is used, the redox status and conforma-
tional changes can be addressed, as presented by A. Pavićević and M.
Zatloukalová: the “Assessment of redox status and conformational
changes of proteins using EPR spin labeling”, which gives biologists
two important sets of information for their studies. Under diﬀerent
physiological and patho-physiological conditions, proteins undergo
various conformational changes, which can be studied with a variety
of experimental techniques. One of these techniques is EPR, also known
as electron spin resonance spectroscopy (ESR), coupled with the use of
paramagnetic compounds called spin labels (SLs). SLs, which are
commonly employed for such measurements, are derivatives of cyclic
aminoxyl (often addressed as nitroxide) radicals, a class of compounds
containing an>N-O∙ moiety sterically shielded by methyl groups (or
other types of groups) attached to the neighboring carbon atoms. In
solutions, these molecules are allowed to rotate freely (short rotational
correlation time, τc), and thus the resulting EPR spectrum is composed
of three sharp isotropic lines (for 14N nitroxides). However, when
molecular motions are restricted (long τc) the overall spectral shapes
change, i.e. a broadening of the lines occurs due to the anisotropy of
hyperﬁne splitting constants and g-values. If an appropriate SL is
attached to a protein, the anisotropic spectra of the immobilized>N-
O∙ moiety provide valuable information about: 1) the hydrophobic/
hydrophilic nature of the binding site in the protein; 2) the inﬂuence of
the local environment induced by various reagents, temperature and pH
change, etc.; 3) the binding capacity of the protein; 4) the distances
between the active sites of the protein; 5) the folding and unfolding of
the protein, which is an especially interesting topic when membrane
proteins are studied; 6) the secondary structure of the protein; 7) the
dynamics of the protein backbone; and 8) protein-protein and lipid-
protein interactions [375,376]. Numerous SLs have been synthesized
for this purpose, a few of which are commercially available. Some of the
SLs bind non-covalently to the proteins, while others are intended to
covalently bind to speciﬁc amino acid residues, such as sulfhydryl
groups (-SH). The technique involving the application of the latter is
known as site-directed spin labeling (SDSL), and is frequently used in
synergy with site-directed mutagenesis. Even though the application of
SDSL can be beneﬁcial, the use of conventional site-speciﬁc spin labels
(SSLs) suﬀers from a number of drawbacks, so the label has to be chosen
prudently, and experiments must be planned thoroughly. For instance,
the methanethiosulfonate spin label (MTSSL) binds solely to the
sulfhydryl group of free cysteine residues. However, it also tends to
form dimers, resulting in dipole-dipole interactions, and consequently
in the formation of extra spectral features [377]. On the other hand,
Fig. 5.1. Spectrum of diﬀerent ROS imaging techniques. In the upper part, diﬀerent
sources of ROS are shown: Mitochondria (mito), lipoxygenases (LPO), monoamine
oxidase (MAO), nicotinamide adenine dinucleotide phosphate oxidase (NOX4 and NOX
1/2/5), xanthine oxidase (XO), functional nitric oxide synthases (NOS) and dysfunctional
/ uncoupled eNOS (u-eNOS). These result in diﬀerent types of ROS [including superoxide
radical (O2•─), hydrogen peroxide (H2O2), hypochlorous acid (HOCl, not shown in the
scheme), peroxynitrite anion (ONOO─), nitric oxide (•NO)] and ROS-induced modiﬁca-
tions of GSH, NADPH, proteins, or glucose uptake, which, in turn, are detected by
diﬀerent imaging technologies. Adpated from [361]. With permission of Mary Ann
Liebert, Inc. Copyright 2016.
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maleimido- (MSLs) and 2-iodoacetamido- spin labels (IASLs) need to be
incubated with the protein at certain pH values, otherwise they bind
not only to –SH, but also to the amino groups.
The protein spin labeling EPR technique has not been used
exclusively to study protein conformations and interactions, but has
also been applied as a diagnostic tool for various malignancies and
benign tumors [378], sepsis [378], diabetes [379], atherosclerosis
[379], and cirrhosis [380]. The commonly used methods to detect the
aforementioned pathologies include the labeling of blood plasma/
serum with 16-doxyl stearic acid (16-DS). 16-DS was chosen due to
its high aﬃnity for human serum albumin (HSA). Peptides and
metabolites synthesized in the aﬀected organ become attached to
HSA, thereby changing its binding capacity and conformation. Such
modiﬁcation is expressed as varied contributions of the unbound,
strongly and weakly bound 16-DS to the albumin from the sera of
patients, as opposed to healthy individuals. These contributions are
calculated using simulation software to decompose EPR spectra, and
data are further processed, mainly by neural network software or
discriminant analyses. On the other hand, in vitro studies demonstrate
that ROS may damage HSA and aﬀect its transport function [381].
Though this methodology oﬀers satisfying accuracy, sensitivity and
speciﬁcity, and though the procedure seems relatively simple, there are
several technical issues that make this diagnostic tool anything but
easy. In a recent work by A. Pavićević et al., the analysis of the binding
of two spin-labeled fatty acids (SLFAs) to commercial HSA was reported
[382]. The obtained data indicate that ethanol, which is extensively
used in diagnostic spin labeling protocols, aﬀects the binding of SLFAs
to HSA. In order to avoid using ethanol, test tubes should initially be
labeled with a small volume of SLFAs dissolved in an organic solvent
and left to evaporate. Afterwards, a certain amount of serum should be
added and incubated under constant vortexing. The weakness of such
an experimental setup is that SLFAs bind to a lower extent to HSA, due
to their low water solubility. There are also other diﬃculties with using
16-DS. One of them is its binding to seven possible sites of HSA;
consequently, information about conformational changes cannot be
obtained from the speciﬁc site. The other issue is that the doxyl group is
positioned nearly at the end of the hydrocarbon chain, opposite the
carboxylic group. Therefore, anchoring the 16-DS molecule to HSA
causes the doxyl moiety to protrude through the albumin's surface
[382,383]. Accordingly, 16-DS appears to be an unreliable reporter to
Fig. 5.2. (A) Determination of mtROS triggered NADPH oxidase activation in isolated human neutrophils by electron paramagnetic resonance measurement. Freshly isolated human
neutrophils (22x106 PMN/mL) were incubated in PBS with 300 µM Ca2+/Mg2+ and 10 mM DEPMPO for 15 min at 37 °C. Activators and inhibitors of phagocytic NOX were added as
shown in the ﬁgure. The spectrum for phorbol ester (PDBu)-stimulated PMN is displayed at decreased intensity (1/10). All reactions below the red spectrum contained 20 µM
myxothiazol. Incubations were with NOX inhibitor (VAS2870), intracellular calcium chelator (BAPTA-AM), cSrc kinase inhibitor (PP2) and PKC inhibitor (chelerythrine). All spectra were
recorded at room temperature in 50 µl glass capillaries (Hirschmann Laborgeräte GmbH, Eberstadt, Germany). EPR conditions: B0 =3300 G, sweep =150 G, sweep time =60 s,
modulation =3000 mG, MW power =10 mW, gain =9x102 using a Miniscope MS200 from Magnettech (Berlin, Germany). Representative spectra of mixed DEPMPO-OOH• and
DEPMPO-OH• adduct for 2 independent experiments. Spectra were recorded as described previously [373]. With permission of Mary Ann Liebert, Inc. Copyright 2014. (B) Whole blood
Hb-NO levels were determined by electron paramagnetic resonance spectroscopy as a read-out of iNOS activity in endotoxemic (lipopolysaccharide-treated) rats. The EPR measurements
were carried out at 77 K using an X-band table-top spectrometer MS400 (Magnettech, Berlin, Germany). The instrument settings were as follows: 10 mW microwave power, 7000 mG
amplitude modulation, 100 kHz modulation frequency, 3300 G center ﬁeld, 300 G sweep width, 60 s sweep time and 3 scans. With permission of Springer-Verlag Berlin Heidelberg.
Copyright 2015. (C) Aortic •NO formation was measured in untreated control and angiotensin-II infused hypertensive mice by EPR spin trapping using Fe(DETC)2. Each spectrum was
measured from one murine aorta. The representative spectra below the bar graph are the mean of all measurements. EPR conditions: B0 =3276 G, sweep =115 G, sweep time =60 s,
modulation =7000 mG, MW power =10 mW, gain =9x102 using a Miniscope MS400 from Magnettech (Berlin, Germany). The A23187-stimulated •NO signal was absent when the aorta
were denuded, L-NAME (200 µM) was added, or when aorta from eNOS-/- mice were used (not shown). With permission of Mary Ann Liebert, Inc. Copyright 2014.
(a) Adapted from [63]. (b) Adapted from [371]. (c) Adapted from [63].
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detect local changes in albumin hydrophobic pockets.
Considering all the indicated diﬃculties, the course of our research
was oriented towards estimating the diagnostic potential of other SLs,
initially through in vitro studies on puriﬁed HSA, and eventually on
blood serum samples. The emphasis was on SSLs and SLFAs with a
doxyl group attached to the hydrocarbon chain closer to the carboxylic
moiety. The preliminary data indicated that the 3-maleimido proxyl (3-
MSL) is able to report changes in the cysteine-34 (Cys-34) environment,
induced by the binding of fatty acids, warfarin, ibuprofen and
benzodiazepines, whose interactions with HSA have been studied
exhaustively.
The use of SSLs can also reﬂect the antioxidant capacity and redox
state of HSA (from its free –SH group), since this probe does not bind to
the oxidized forms of –SH. The joint electrochemical and EPR study of
cytochrome c derivatives indicates that the use of SLs speciﬁc for
cysteine residues has great potential to estimate the redox state of other
proteins bearing free –SH groups as well.
It is very diﬃcult in such innovative methods to reach satisfying
accuracy. One way can be to combine multiple methodologies such as
“electrochemistry and EPR”. EPR can be completed by electrochemistry
to get accurate oxygen concentration information by EPR [384]. Better
than adding these methods, one can couple them; this is the proposition
of J. Vacek and M. Mojovic that encourages eﬀorts to “couple
Electrochemistry and EPR”.
5.3. Electrochemistry and EPR to investigate antioxidant and prooxidant
systems
Redox-active and reactive chemical forms directly contribute to
homeostasis, the maintenance of a stable internal environment. There is
therefore an emphasis on the direct detection and imaging of these
chemical entities, among which we classify free radicals, or substances
collectively known as RONS as well as an extensive group of anti-
oxidants. Therefore, combining electrochemical methods and EPR
spectroscopy represents a highly eﬃcient solution, and both methods
can be complementary (thus oﬀ-line) or may be applied in situ (i.e. on-
line). Electrochemical methods may be used to monitor redox pro-
cesses; cyclic voltammetry is preferred, or advanced pulse voltammetric
techniques, which have a higher sensitivity due to the elimination of
capacitive currents [385].
Usually carbon electrodes and anodic voltammetry are used to
predict the electron-donor capacity and general reactivity of the
examined molecules. The oxidation products can then be identiﬁed,
which can be further investigated electrochemically, or even isolated
and characterized after electrolysis. When interpreting the electroche-
mical data (voltammograms), we assume that an eﬀective antiradical or
antioxidant agent is oxidized at potentials approaching zero, where the
electron-donor capacity, and hence its eﬀectiveness, decreases with the
increase of anodic potential. Given that many antioxidants are subject
to multicomponent (pH-dependent) redox transformations, we always
evaluate the potential of the ﬁrst oxidation peak. Analyses are
conveniently performed in an aqueous medium at pH 7.4 in the
presence or absence of molecular oxygen, to eliminate artiﬁcial eﬀects
associated with the spontaneous oxidation of the examined samples. If
the redox process is associated with the formation of a radical
intermediate, it is practically impossible to detect by electrochemical
approaches. For this purpose, EPR spectroscopy, also known as electron
spin resonance (ESR) spectroscopy is used [386]. With EPR, we can
monitor the absorption of microwave radiation by chemical forms with
one or more free electrons, e.g. free radicals, in a strong magnetic ﬁeld.
They can be analyzed using the EPR directly in solution or cell
homogenates, in a tissue or even during the anodic reaction on the
electrode surface. If the lifetime of the radical forms is too short, the
spin-trapping technique is used.
Mojovic et al. present their research on the oxidation of phenolic
antioxidants as an example of an eﬀective combination of electroche-
mical and EPR methods. Although this type of exogenous antioxidant is
often perceived sceptically in terms of its biological eﬀect in vivo, a
number of these substances are highly eﬀective experimental antiox-
idants, and in some cases, even chemoprotective agents are fully usable
in prophylactic treatments and complementary medicine [387]. One of
the most important examples is that of ﬂavonolignans, which are used
as hepatoprotectants and antidotes for selected mushroom poisoning.
The main example is silybin and its 2,3-dehydroderivative, whose
mechanisms of redox transformations and antioxidant eﬀects have
been studied [388]. Both of these substances, and also their structural
congeners, are characterized by a pleiotropic mode of action, which is
partly based on their ability to modulate signaling pathways, or
receptor systems in cells (see Section 10.4.2), and also by a combination
of their antioxidant vs. prooxidant eﬀects. The antioxidant eﬀect is
associated with a relatively high electron-donor capacity, especially for
ﬂavonolignan 2,3-dehydroderivatives, and also their metal-chelating
capacity. Conversely, pro-oxidant eﬀects are associated with the
transition of ﬂavonolignans to reactive aryloxy radical forms or with
the formation of highly reactive ﬂavonolignan-metal complexes, which
may secondarily generate free radicals through a Fenton-like reaction
[389]. Square-wave voltammetry on carbon electrodes [388] was used
to investigate the mechanism of redox behavior and analyze the
electron-donor capabilities of these substances. EPR spectroscopy was
further applied for the direct analysis of aryloxy radicals of ﬂavono-
lignans that were generated in a strongly alkaline environment accord-
ing to the methodology developed initially for the purpose of research-
ing ﬂavonol and ﬂavone derivatives [390]. However, aryloxy radicals
can also be generated during the electrochemical oxidation of ﬂavono-
lignans. Their short lifetime, however, makes their identiﬁcation or
further analysis impossible. For this purpose, an in situ spectroelec-
trochemical technique was developed, where the oxidation of the
ﬂavonolignan occurs in the presence of the spin-trap probe 5-tert-
butoxycarbonyl-5-methyl-1-pyrroline-N-oxide (BMPO). The radicals
produced during the electrooxidation therefore associate with BMPO
and give rise to a stable radical adduct, which can be subsequently
quantiﬁed by EPR [391]. In addition to the above, we see EPR as an
eﬀective tool to analyze metal ﬂavonoid complexes. EPR techniques
were applied to the characterization of the highly reactive oxovana-
dium(IV)/silybin complex, which induces the formation of RONS in the
cellular environment [392].
The main prerequisite to combining electrochemical methods and
EPR spectroscopy in the study of antioxidant and prooxidant molecules
(or molecules which combine both eﬀects) is based on the fact that EPR
enables the visualization of free radicals in situ, which are not
detectable by electroanalytical approaches. By contrast, EPR exhibits
zero interference with the parent forms of the studied species, nor with
the ﬁnal products formed during their redox transformations. Oﬀ-line
applications of EPR and electroanalysis have recently started to ﬁnd
applications in research of more complex cellular systems and in vivo
monitoring and imaging [393]. In the above, in situ approaches (e.g.
[391]) were previously only applied in molecular studies with isolated
chemical species, whereas future applications clearly point towards the
on-line connection of EPR spectroscopy with electroanalysis under
more complex (preferably in vivo) conditions. There is clearly potential
in the application of implantable microelectrode systems, in the
optimization of new technical solutions for spectroelectrochemical
instrumentation and in the development of new hybrid techniques
based on electrochemical microscopy in combination with EPR imaging
approaches.
Applications of electroanalysis in conjunction with EPR spectro-
scopy are demonstrated here with low-molecular redox-active sub-
stances, monomeric ﬂavonolignans, exhibiting an antioxidant eﬀect
while under other speciﬁc conditions, exhibiting a prooxidant eﬀect.
The applicability of the above techniques in research on biopolymers,
speciﬁcally proteins, is demonstrated in Section 5.2.
As discussed before, ﬂuorescence is the most used methodology,
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especially for microscopy. As an example, one can use genetically
encoded probes, as proposed by Vsevolod Belousov to detect hydrogen
peroxide.
5.4. H2O2 detection using genetically encoded probes and nanoparticles
Out of the many techniques to study redox reactions, imaging using
ﬂuorescent genetically encoded biosensors oﬀers the widest set of
advantages. First, most importantly, it allows the monitoring of redox
events in real time in situ and in vivo. Second, the protein nature of the
sensors allows subcellular targeting similar to conventional ﬂuorescent
proteins. Recently several technological improvements in the area of
redox imaging were achieved.
Since the development of the ﬁrst genetically encoded redox
biosensors, they have all been based on ﬂuorescent proteins with green
emission [394]. The development of the ﬁrst red ﬂuorescent probes for
H2O2, HyPerRed, made multiparameter imaging possible by using co-
expression of this sensor with green-emitting probes for H2O2, GSH/
GSSG and pH. Using HyPerRed, ER stress- induced H2O2 transients in
the mitochondrial matrix were detected for the ﬁrst time within living
cells [395]. Interestingly, the increase in H2O2 was not associated with
any detectable increase in the mitochondrial matrix GSSG content.
Moreover, no H2O2 increase was observed in the inter-membrane space
or the cytoplasm of the same cells.
Another important direction in the improvement of genetically
encoded redox sensors is the expansion of the concentration limits of
detection. For example, for H2O2 signaling studies, it would be
important to have a sensor that reﬂects changes in near-basal concen-
trations of H2O2. Although it is not yet clear what the basal concentra-
tions of H2O2 are, the ﬁrst successful attempt to make the H2O2 probes
more sensitive has been made recently [396]. The sensor consists of the
redox-sensitive ﬂuorescent protein roGFP2 fused to yeast peroxiredoxin
Tsa2. This peroxidase has a 100 fold higher reaction rate than OxyR and
Orp1 - the domains used in previous H2O2 sensors, HyPer [397] and
Orp1-roGFP2 [398]. The Tsa2 part of the sensor is, however, made non-
sensitive to H2O2. Instead, it brings roGFP2 in close proximity to
endogenous Tsa1 incorporating into Tsa1 decamers. Therefore roGFP2
within the probes form redox relays with endogenous Tsa1 rather than
with fused Tsa2 inactivated by point mutagenesis. The resulting probe
is half-oxidized under basal conditions and sensitive to both increases
and decreases in H2O2. Still some eﬀort has to be made to make
roGFP2-Tsp2 functional in cells other than yeast and to improve the
reduction speed of the sensor.
One of the basic properties of redox signaling is a high spatio-
temporal control over location, and the amounts of the oxidants
produced [399]. However, the exact sizes of H2O2 microdomains are
not easy to estimate because of the optical limits of ﬂuorescent
microscopy. Super-resolution microscopy becomes a more and more
popular instrument to study ﬁne structures in cells, however it has
never been used before to study dynamic processes, such as second
messenger dynamics and enzymatic activities. Recently, the H2O2
sensor HyPer2 was successfully used in sub-diﬀraction microscopy.
The exceptional photo stability of the sensor made its use in Stimulated
Emission Depletion (STED) microscopy possible. Fused to cytoskeleton
structures, HyPer2 was able to resolve the structures with superior
resolution and report H2O2 dynamics in growth factor- stimulated cells.
Uneven dynamics of the sensor oxidation between two ﬁlaments
separated by a distance of 100–200 nm suggests a less than ~100 nm
diﬀusion radius of H2O2 in the cytoplasm of ﬁbroblasts.
On the other hand, developments have been made in the chemical
probes used for detection [400], such as near-infrared sensitive probes
[401], biphoton probes or nanoparticles (NPs). According to A. Suha
Yalçın, NPs are becoming widely used tools in the ﬁeld of sensing and
imaging. Success in developing diﬀerent luminescence probes has
enabled the monitoring of ROS production both in cells and whole
animals [402–404]. Among these are peroxalate-based NPs formulated
from peroxalate esters and ﬂuorescent dyes that are used to image H2O2
in vivo with high speciﬁcity and sensitivity. Peroxalate NPs were
capable of imaging H2O2 in the peritoneal cavity of mice during a
lipopolysaccharide-induced inﬂammatory response [402]. The method
was further improved by reducing the size of the NPs and modifying
their content to detect H2O2 at physiological concentrations. Chemilu-
minescent NPs have also been exploited for the in vivo targeting and
imaging of tumors and were successfully used to image H2O2 as a tumor
signal molecule [405]. Probes that improve the stability of peroxalates
in aqueous systems are sensitive to low concentrations of H2O2 within
the physiological range. Chen et al. [406] have recently developed a
novel upconversion luminescence nanoprobe to detect ROS in aqueous
solutions, as well as diagnose rheumatoid arthritis and to bioimage ROS
in living cells.
5.5. High throughput assays for superoxide and hydrogen peroxide for
rigorous and speciﬁc activity of NADPH oxidases
J. Zielonka and B. Kalyanaraman propose that the combination of
ﬂuorescence and EPR spin trapping may yield better results. RONS
encompass a range of species displaying oxidizing, nitrating, nitrosating
and/or halogenating properties. To better understand the pathophysio-
logical mechanisms of ROS/RNS it is crucial to detect and identify the
speciﬁc species responsible for a given biological eﬀect and to
selectively inhibit the source of its formation. NADPH oxidases are a
family of enzymes, the only known function of which is transferring
electrons from NADPH to molecular oxygen, and the concomitant
generation of O2•– and H2O2. NADPH oxidases have been identiﬁed as
a promising therapeutic target for diseases bearing an oxidative stress
component. Despite the wide eﬀort to develop inhibitors of the NOX
isoforms, only a limited number of such inhibitors are available. This is
due to serious limitations of the assays used to develop NOX inhibitors.
Typically, sensitive, but non-selective and artefact-prone assays have
been applied for the detection of NOX-derived oxidants, leading to a
high rate of false positive hits in high throughput screenings. For
example, it has been demonstrated that the L-012 probe to detect
superoxide requires one-electron oxidation and may generate super-
oxide by itself [407]. Also, in many assays horseradish peroxidase
(HRP) is used as a catalyst of the oxidation of the probe by NOX-derived
H2O2. The lack of probe selectivity for a speciﬁc oxidant and the
susceptibility of the HTS assays to peroxidase substrates and inhibitors
led to the controversy over the NOX-inhibitory potency of the positive
hits selected, including apocynin, VAS2870 and 2-acetylphenothiazine
[408].
Recently, Zielonka et al. have developed new assays to monitor the
activity of the NADPH oxidases [409] and used them to screen a small
library of bioactive compounds for potential NOX2 inhibitors [410].
These assays take advantage of the probes, which react directly with
O2•– or H2O2 and form easily detectable, ﬂuorescent products. The
authors designed and synthesized a cell-impermeable analog of hydro-
ethidine, called hydropropidine (HPr+) to detect NOX2-derived O2•–
[411]. Upon its reaction with superoxide, HPr+ undergoes oxidation to
red ﬂuorescent 2-hydroxypropidium whose ﬂuorescence quantum yield
can be increased further in the presence of DNA. In order to detect H2O2
the authors applied coumarin boronic acid (CBA), which upon oxida-
tion forms the blue ﬂuorescent 7-hydroxycoumarin (umbelliferone).
Both assays can be carried out in a 384-well plate format, with rapid
measurements using a ﬂuorescence plate reader. For the secondary
assays, they applied two probes: hydroethidine (HE) for O2•– and
Amplex Red with HRP for H2O2. HE-based assay was coupled to rapid
UHPLC-based detection of 2-hydroxyethidium as a speciﬁc product of
the reaction of HE with O2•–. The Amplex Red-based assay was used in
combination with the ﬂuorescence plate reader. Both secondary
(orthogonal) assays can be carried out in a 384-well plate format. All
four assays can be used for high throughput monitoring of NOX activity,
with the HE assay requiring rapid, microwell plate-compatible UHPLC
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instruments. Rapid UHPLC analyses also enable simultaneous monitor-
ing of O2•– and H2O2 formation, using a mixture of HE and CBA probes
[409,410]. The positive hits identiﬁed with these assays can be tested in
conﬁrmatory assays, including the measurement of the rates of oxygen
consumption by NADPH oxidase in a medium throughput manner using
a Seahorse XF96 extracellular ﬂux analyzer and in lower throughput
EPR spin trapping of superoxide using DEPPMPO or DIPPMPO cyclic
nitrone spin traps.
The newly developed assays provide a framework for reliable
measurement of the activity of NADPH oxidases and other cellular
sources of O2•– and H2O2. Rapid and rigorous detection and quantita-
tion of O2•– and H2O2 will lead to better understanding of the chemical
biology of O2•–/H2O2-producing enzymes (e.g. NOX isoforms) and will
also help discover speciﬁc inhibitors of NOX isoforms.
Most of the time, ROS detection is applied to biomedical science,
but very important results can be obtained in plant science, which helps
to understand posttranslational modiﬁcations, as proposed by B. De
Smet, F. Van Breusegem and J. Huang. The oxidation of crucial
cysteines to sulfenic acid (SOH), has emerged as a biologically relevant
post-translational modiﬁcation (PTM) with particular importance in
redox-mediated signal transduction [412]. Thus, identifying the sulfe-
nome under oxidative stress would allow us to identify key redox-
sensors and –transducers [413,414].
5.6. Chemical and genetic tools for plant sulfenomics
The oxidation of crucial cysteines to sulfenic acid (SOH), has
emerged as a biologically relevant post-translational modiﬁcation
(PTM) with particular importance in redox-mediated signal transduc-
tion [412]. Thus, identifying the sulfenome under oxidative stress
would allow us to identify key redox-sensors and -transducers
[413,414].
Sulfenomic studies have only recently been applied to plants
[414–416]. As sulfenic acid is often unstable, its identiﬁcation was
mainly examined on a protein-by-protein-basis. At present, both
chemical and genetic approaches are used in plants. The majority of
the chemical probes are dimedone derivatives (5,5-dimethyl-1,3-cyclo-
hexanedione), that selectively react with sulfenic acid [417]. The bio-
DCP1 probe, which was used in Medicago truncatula, is a dimedone
analog carrying a biotin aﬃnity tag used for puriﬁcation [416]. As
biotin has many drawbacks, new azido- and alkyne-functionalized
dimedone-analogs were developed that allow the addition of biotin
post-extraction on the dimedone-tag using click chemistry [415,418].
Their small size and membrane permeability allow the in vivo tagging
of sulfenylated proteins. In Arabidopsis cells, the DYn-2 probe was used
to identify the sulfenome under oxidative stress [415].
The yeast AP-1 (YAP1)-based probe oﬀers a genetic way for the in
vivo identiﬁcation of plant sulfenomes [54,55]. This was ﬁrst applied in
Medicago truncatula to identify the sulfenome upon Medicago truncatu-
la–Sinorhizobium meliloti symbiosis [416]. Recently, a YAP1C-GS probe
has been developed and expressed in Arabidopsis cells to reveal the
sulfenome under oxidative stress [414].
Using a genetic approach has the advantage that, once the material
is transformed, experiments are cost-eﬃcient, allowing multiple repeats
and treatments. Additionally, the probe can be targeted to speciﬁc
tissues or even organelles. On the other hand, chemical probes generate
a larger coverage of the sulfenome in a single experiment, as they
penetrate whole cells; they do not require transformation and generate
stable covalent bonds between the sulfenylated protein and the probes.
Another attractive diﬀerence is the mode of trapping the sulfenic acid.
Whereas the YAP1C genetic probe traps sulfenic acid in its protein
context, deﬁned by protein-protein interaction, the chemical probes
trap sulfenic acid independently of the protein environment. Another
characteristic to consider is that the incubation of the chemical probe
can inﬂuence the oxidation within a cell, which should not be a
problem for the permanently expressed genetic probe, although its
expression can act as a scavenger of the oxidized proteins and hence,
alter the cell/plant redox state.
As both genetic and chemical probes have speciﬁc advantages, the
combination of their data obtained with both probes covers the largest
part of the plant sulfenome. Current tools are based on protein-
identiﬁcation, rather than on site-identiﬁcation. Therefore, future
research should focus on mapping speciﬁc sulfenylation sites.
Quantifying the protein sulfenylation, or even the speciﬁc cysteine-
sulfenylation in response to several elicitors would further improve the
sulfenomic approaches and assess the role of cysteine-oxidation upon
redox signaling.
5.7. Conclusions
As outlined above, imaging ROS is still very challenging, and the
choice of the method will largely depend on the experimental condi-
tions. For the selective in vitro speciﬁc detection of superoxide on cells,
for example, EPR coupled to spin-trapping is the gold standard method.
Abbas et al. have recently developed the detection on living cells under
conditions close to in vivo conditions. Less selective, but allowing in
vivo EPR imaging and protein folding and mobility, EPR can be coupled
to spin labeling to allow redox status determination. Coupling to
electrochemistry allows the accurate determination of either the oxygen
levels, or the anti-oxidant's ability. Genetically encoded biosensors
make it possible to determine hydrogen peroxide and open the way to
in vivo luminescence bio imaging. Strong eﬀorts are made in chemistry
to allow the selective and easy detection of ROS with ﬂuorescent
probes, such as nanoparticles. NPs are versatile, and can be used to
detect superoxide anion and hydrogen peroxide. EPR and ﬂuorescence
can be coupled, as recently proposed by Zielonka et al.; this yields very
accurate detection of NADPH oxidase activity, a key enzyme in
oxidative stress. Combining diﬀerent methods can help understand
oxidative stress in a post-transcriptional pathway, as proposed by De
Smet, Van Breusegem and Huang in plant biology.
There is still no gold standard for ROS detection and imaging. Many
methods are under development, and more collaboration between
biologists, methodologists of the modality (e.g. ﬂuorescence, EPR)
and chemists is needed to make progress and avoid misinterpretations
of experiments leading to false conclusions.
6. Reactive oxygen and nitrogen species in cardiovascular
pathologies
Rainer Schulz (E-mail: rainer.schulz@physiologie.med.uni-gies-
sen.de), Andreas Daiber (E-Mail: daiber@uni-mainz.de) and Fabio Di
Lisa (E-mail: fabio.dilisa@gmail.com).
6.1. Introduction
In the cardiovascular system, reactive oxygen and nitrogen species
(RONS) play an ambivalent role in that small amounts of RONS mediate
protective eﬀects (anti-atherosclerotic [Schröder], pro-angiogenesis
[Matsui, Bachschmid], endogenous cardioprotection [Andreadou]),
while large quantities of RONS cause cell injury eventually leading to
loss of viability. RONS-induced cell derangements occur at the level of
any organ, including heart [Görbe, Giricz, Ferdinandy] and brain
[Casas, Schmidt], especially in the presence of co-morbidities (e.g.
diabetes [Schröder; Görbe, Giricz, Ferdinandy]). Furthermore, recent
work highlights the contribution of alterations of the intracellular Zn2+
pool [Tuncay, Turan] in RONS-induced cell injury. Importantly, the
source of RONS due to its cellular (parenchyma [Casas, Schmidt] vs.
vasculature [Schröder]) and subcellular localization might contribute
to the beneﬁcial [Schröder] or deleterious [Casas, Schmidt] action of
RONS. Among the many sources of RONS, a relevant role is played by
NADPH oxidases (NOX), uncoupled nitric oxide synthases (NOS) [Li,
Förstermann], and various processes in mitochondria. For instance, the
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ischemic heart accumulates succinate that upon reperfusion is oxidized
causing a burst in ROS formation due to reverse electron transport
[Mulvey, Krieg]. Strategies to reduce excessive RONS include admin-
istration of antioxidant enzymes (more recently incorporated in endo-
somes and targeted by antibodies to speciﬁc cell types [Muzykantov])
or pharmacological up-regulation of the endogenous antioxidant de-
fense [Lazou]. In addition, an antioxidative eﬀect has been reported for
compounds already used in daily practice. This is the case with
glucagon-like peptide-1 or DPP4-inhibitors [Steven, Daiber] that abro-
gate stress-induced blood cell derived RONS. However, antioxidant
strategies must be used with caution since they might interfere with
endogenous organ protection [Andreadou]. The chapter
“Cardiovascular Pathologies” discusses many of the above aspects and
is structured according to the importance of RONS in the blood vessels,
the heart and the brain (Fig. 6.1).
6.2. Oxidative stress and redox processes in atherogenesis and angiogenesis
As pointed out by Katrin Schröder, atherosclerosis is a vascular
disease characterized by plaque and neo-intima formation, as well as
local inﬂammation of the vessel wall. The latter is, in part, a
consequence of endothelial dysfunction. Monocytes are attracted and
adhere at sites of endothelial activation, invade the vessel wall and
support a vicious cycle of inﬂammation and cellular recruitment by
processes involving the formation of reactive oxygen and nitrogen
species (RONS). Especially the superoxide anion (O2•¯) is potentially
detrimental for vascular function and promotes atherosclerosis [419].
O2•¯ not only limits •NO-bioavailability, but also gives rise to ONOO¯,
which mainly acts as a potent toxic agent. The main source of RONS in
the vascular system is the family of NADPH oxidases, whose only
known function is the formation of O2•¯ and H2O2. The ﬁrst NADPH
oxidase identiﬁed was NOX2, which is the primary NADPH oxidase in
macrophages and leukocytes. Its native function is host defense by the
massive formation of O2•¯, H2O2 and resulting RONS, in a process
termed oxidative burst. Beside the detrimental consequence of massive
RONS formation, these species also play an essential role in signal
transduction. Recently additional NADPH oxidases have been identiﬁed
and it is now clear that the number of RONS produced, the site of their
formation as well as the type of RONS inﬂuences the subsequent
signaling. Within the NOX family, NOX4 is an exception as it mainly
produces intracellular H2O2 in a constitutive manner at very low
concentrations. NOX4-derived H2O2 does not inﬂuence •NO bioavail-
ability, rather it can directly react with proteins in signaling pathways.
In fact, NOX4 appears to exert a protective role in the vascular system
and prevents vascular inﬂammation [420]. This protection is, among
other mechanisms, mediated by the maintenance of NRF2 expression,
which eventually leads to the expression of heme oxygenase-1 (HO-1).
Through this pathway, NOX4 favors CO production, which contributes
to endothelial quiescence and prevents leukocyte adhesion. The pro-
tective role of NOX4 is supported by genetic approaches. Nox4 deletion
has been reported to promote atherosclerosis in both ApoE-/- mice and
in a model of locally deﬁned atherosclerosis through ﬂow restriction
(partial carotid artery ligation with high fat diet) [421]. Similar
evidence has been obtained in an LDL receptor knockout mouse
[422]. On the other hand, endothelial speciﬁc overexpression of Nox4
protected ApoE-/- mice against high fat diet induced atherosclerosis
[423]. Notably, Nox4 expression is reduced in diabetic patients who
develop atherosclerotic plaques when compared to diabetic individuals
without atherosclerosis [424]. In conclusion, various forms of stress
induce an increased expression of Nox4 that elicits protective mechan-
isms at least in the vascular system. Importantly, there is evidence that
the beneﬁcial role of NOX4 in vascular injury occurs not only in mice,
but it may also apply to clinical settings.
Matsui and Bachschmid propose that angiogenesis is redox regu-
lated by the formation of protein glutathione adducts. Oxidative post-
translational modiﬁcation may alter protein functions and mediate
cellular signaling. Protein thiols form reversible oxidative modiﬁcations
including S-sulfenylation (-SOH) and S-nitrosylation (-SNO) [425],
which may react with glutathione (GSH), an abundant intracellular
thiol, to form more stable GSH-protein adducts (S-glutathionylation)
[426]. Protein GSH-adducts can regulate enzyme activity, localization,
protein interactions and stability. Various proteins are known to be
modiﬁed by GSH adducts [427]. GSH adducts can be removed by
glutaredoxin-1 (Glrx), a cytosolic thioltransferase that in this way
completes the redox signaling cycle. The in vivo role of Glrx and its
protein targets in pathophysiology has been explored recently
[428–430]. Oxidants are increasingly recognized as factors that pro-
mote angiogenesis, and mouse studies revealed that decreasing oxi-
dants may impair ischemic revascularization after hind limb ischemia
[164]. Conversely, increasing oxidants by NOX4 or decreasing the
antioxidant response by means of Nrf2 deletion may improve ischemic
limb revascularization. These data put forward the concept that
oxidants play a protective role in ischemic revascularization, in
accordance with multiple reports on ROS conferring beneﬁcial redox
Fig. 6.1. Processes contributing to the increase in ROS levels in various tissues. Mitochondrial pathways are highlighted as prominent sources of ROS, especially in the heart. Besides their
involvement in tissue injury, ROS have been described also as mediators of cardiac protection against ischemia/reperfusion damage.
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signaling in other settings. Glrx is not merely an antioxidant, but
obviously also exhibits anti-angiogenic properties. Increased Glrx
expression inhibits the angiogenic activity of cultured endothelial cells
[431]. Consistent with this ﬁnding, Glrx overexpression in vivo also
attenuates revascularization after hind limb ischemia [430]. Glrx is
known to activate the NF-κB pathway [432]. NF-κB hyper-activation in
endothelial cells likely stimulates non-canonical Wnt5a signaling,
which induces expression and release of the soluble vascular endothe-
lial growth factor (VEGF) receptor 1 (sFlt-1) into plasma [430]. sFlt-1 is
a VEGF decoy receptor, blocking VEGF binding to the proangiogenic
VEGF receptor 2. Impaired ischemic revascularization in diabetic mice
is associated with elevated levels of sFlt-1 in the ischemic muscle.
Because Glrx expression is also NF-κB dependent, proinﬂammatory
conditions such as atherosclerosis [433] and diabetes [432] may
increase Glrx leading to impaired or dysregulated angiogenesis. Ablat-
ing endogenous Glrx further accelerates ischemic limb revasculariza-
tion. Hypoxia-inducible factor (HIF-1α), a major angiogenic transcrip-
tion factor, is stabilized by GSH adducts [428]. In normoxia HIF-1α is
hydroxylated and binds to ubiquitin ligase pVHL, which targets HIF-1α
to proteasomal degradation. GSH adducts, induced by oxidants or Glrx
inhibition, stabilize and activate HIF-1α. As previously reported, nitric
oxide-induced S-nitrosylation of HIF-1α [434] may also be converted
into more stable GSH adducts in the presence of GSH. Watanabe et al.
conﬁrmed a HIF-1α GSH adduct of Cys520 (mouse Cys533) by mass
spectrometry and demonstrated increased expression of HIF-1α and
VEGF-A in ischemic muscle of Glrx KO mice [428]. Increased GSH
protein adducts in ischemic limbs are not a hallmark of oxidative stress,
but rather contribute to beneﬁcial responses to ischemia through HIF-
1α activation. This may be a mechanism by which oxidants promote
ischemic revascularization. In summary, Glrx deletion may facilitate
revascularization of ischemic muscles not only by means of HIF-1α
stabilization, but also by an increase in GSH adducts of other proteins
involved in angiogenesis. Therefore, inhibiting Glrx can be a therapeu-
tic strategy to restore circulation in ischemic limbs.
6.3. RONS formation in ischemic preconditioning, cardiac cycle, ischemia/
reperfusion and cardiomyopathy
According to Andreadou, low levels of RONS may be associated
with beneﬁcial cardioprotection by interventions known as ischemic
pre- and post-conditioning (PC, PostC). Cardiac injury associated with
post-ischemic reperfusion is contributed mostly by an increased level of
reactive oxygen and nitrogen species (RONS), but also by the reduced
availability of “beneﬁcial” reactive species such as nitric oxide and
intracellular Ca2+ overload. These deleterious factors synergize in
favoring a prolonged opening of the mitochondrial permeability
transition pore (mPTP) that is generally considered as a determining
factor in ensuing cell death. However, despite the well-established
association between RONS elevation and reperfusion injury of the
heart, so far antioxidant treatments have hardly provided any ther-
apeutic beneﬁt in clinical studies of cardiac disease [435,436]. On the
other hand, reperfusion injury is greatly reduced by PC and PostC
[435,437]. Although the cardioprotective mechanisms triggered by
conditioning protocols are still a matter of debate [438], a general
consensus exists that RONS play a crucial role. Indeed, while an
excessive formation of RONS contributes to irreversible injury, small
amounts of RONS contribute to protection, possibly through a redox-
dependent activation of protective cytosolic kinases [439]. In this
respect RONS share the same paradox with the conditioning phenom-
ena per se, in that a short ischemia/reperfusion episode protects the
same as a mild RONS elevation, whereas a prolonged duration of
ischemia followed by reperfusion induces injury that largely depends
on lethal levels of intracellular RONS [439]. The role of antioxidant
compounds in cardioprotection induced by conditioning strategies is an
emerging issue, which needs elucidation in order to provide useful
information for the translation of the conditioning phenomena in
clinical practice [438]. We should mention that PC is mediated in part
by a mild formation of RONS, possibly in response to the opening of
mitochondrial KATP channels, and also PostC may lead directly or
indirectly to a decrease in RONS [440]. Since the role of antioxidant
Fig. 6.2. The data show marked increases of [Zn2+]i under either ROS (A) or RNS (B) increases. Bars represent means (± ) and *P<0.05 w.r.t. initial value. Inset: Representative
electron micrograph images under ZnPT (1-μM) exposure. Magniﬁcation: x12,930; bar: 1000 nm; N: nucleus, M: mitochondria, z: Z-line, L: lysosome, arrow: T-tubule, arrow head: sarco/
endoplasmic reticulum (SER).
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compounds in these conditioning phenomena might diﬀer to some
extent, it is important to distinguish their role in pre-and/or postcondi-
tioning separately. Several in vivo studies have thus far shown
divergent results concerning the role of widely used antioxidants in
the prevention and/or abrogation of the beneﬁcial eﬀects of PC in
reducing myocardial infarct size. Skyschally et al. [441] demonstrated
that the administration of ascorbic acid in pigs abolished the beneﬁcial
eﬀect of PC on infarct size possibly due to ROS scavenging [442].
Accordingly, we also showed that in rabbits the antioxidant action of
the acute administration of vitamin C, reﬂected by a decrease in blood
and tissue levels of lipid peroxidation products, abolished PC-induced
protection [441]. It is worth pointing out that the use of antioxidants is
increasing. This is related especially to the commercialization of
numerous nutritional supplements or plant extracts containing antiox-
idant compounds, such as polyphenols and ﬂavonoids that are mar-
keted for the prevention of cardiovascular diseases [443]. Based upon
the dependence of endogenous protective mechanisms on ROS genera-
tion, it is essential to know the role of all the antioxidant compounds in
diﬀerent physiological and pathological conditions of the cardiovascu-
lar system. The complete understanding of redox mechanisms control-
ling RONS levels in cardiovascular pathophysiology is likely to allow
the design of new clinical trials for the use of antioxidants in cardiac
diseases.
According to Tuncay and Turan, Zn2+ release during the cardiac
cycle results in increased intracellular free Zn2+([Zn2+]i) levels, and
this release is increased in the setting of oxidative stress [444,445].
However, it is not known whether or not there is a direct relationship
between the increased production of RONS and [Zn2+]i changes in
cardiomyocytes. Thus, by using confocal microscopy and the speciﬁc
ﬂuorescence dye FluoZin-3 AM (3 µM), [Zn2+]i changes were mon-
itored in a H9c2 cardiomyoblast cell-line exposed to RONS. Acute
increases in hydrogen peroxide (H2O2, 100 μM) induced marked
increases in [Zn2+]i, which could be reversed by a thiol reducing agent
like dithiothreitol (DTT, 500 μM) (Fig. 6.2A). The NO donor NaNO2
(100 µM) induced similar marked increases in [Zn2+]i, which was not
observed in the presence of a selective/potent soluble guanylyl cyclase
inhibitor like ODQ and was normalized with a heavy-metal Zn2+
chelator like TPEN (Fig. 6.2B).
Electron microscopic analysis also demonstrated that increased
[Zn2+]i can induce marked alterations in the ultrastructure of rat
cardiomyocytes such as clustering of mitochondria, disruption and
damage of myoﬁbrils, enlargement in T-tubules and distortion in the T-
tubules (TT) and sarcoplasmic reticulum (SR) intersection (Fig. 6.2,
inset). Acute increases in RONS can induce marked elevation of [Zn2+]i
in cardiomyocytes, which may underlie cardiac dysfunction under
oxidative stress. In conclusion, in cardiomyocytes, elevated [Zn2+]i
correlates with increased RONS levels.
Mulvey and Krieg highlight the important role of mitochondrial
metabolism and RONS formation in myocardial ischemia. RONS have
long been known to be key mediators of ischemia/reperfusion (IR)
injury, driving not only acute damage but also initiating the patholo-
gical cascade that develops over the subsequent weeks and months.
This RONS production has generally been assumed to be a non-speciﬁc
eﬀect of oxygen interacting with a dysfunctional mitochondrial respira-
tory chain upon its reintroduction to ischemic tissue at reperfusion, a
process, which is complex and imprecise. However, recent work from
our laboratory shows that contrary to this hypothesis there is in fact a
distinct metabolic mechanism responsible [136]. Using an untargeted
metabolomic approach, a metabolic hallmark of ischemia was identi-
ﬁed from a range of ischemic tissues, which notably included the
selective accumulation of succinate. Despite previous descriptions of
this in the literature [446], neither the mechanism behind this nor its
implications had been characterized. The succinate accumulated during
ischemia was found not to originate from normal cardiac metabolism,
but rather through aspartate-mediated pathways and reverse action of
succinate dehydrogenase (SDH), driven by accumulated ischemic
NADH passing electrons through complex I and onto the coenzyme Q
(CoQ) pool, which favors the reduction of fumarate by SDH to drive
succinate accumulation. Following reperfusion there was then a rapid
metabolism of is chemically accumulated succinate, with baseline levels
re-established within 5 min [136,447]. RONS generation from electrons
stored in the succinate pool is then thought to occur primarily through
the reverse action of complex I in a phenomenon known as reverse
electron transport (RET) that has been well characterized in vitro but
whose importance in vivo has only been recently understood [448].
Importantly, this model provided several testable predictions with
regard to the eﬀect of manipulating succinate levels in ischemic tissues
and therefore the downstream extent of RONS production and also
infarct size as a clinically relevant indicator of IR injury. Decreasing
mitochondrial succinate levels during ischemia using either an infusion
of the competitive SDH inhibitor dimethyl malonate [136] or sodium
malonate [449] resulted in a decrease in RONS production and reduced
infarct size in an in vivo mouse model of myocardial IR injury. These
could both be brought back to control levels by an infusion of dimethyl
succinate. In addition to modulation of mitochondrial metabolism,
recent evidence suggests it is also possible to modulate the quantity of
RONS produced at reperfusion from the electrons stored in the ischemic
succinate pool through inhibition of the active/deactive transition of
Complex I. During ischemia, Complex I enters the deactive state but is
rapidly reactivated at reperfusion, enabling it to support RONS
production by RET [450]. A growing body of evidence suggests a
central role for the Cys39 residue found within the ND3 subunit of
Complex I, and indeed it has recently been demonstrated using the
mitochondria-targeted S-nitrosothiol MitoSNO that S-nitrosation of this
residue can inhibit the active/deactive transition and so allow dissipa-
tion of the mitochondrial ischemic succinate pool via alternative
pathways to minimize the production of RONS by Complex I [451].
Based on considerations by Görbe, Giricz and Ferdinandy, mito-
chondrial RONS play an important role in metabolic cardiomyopathies.
A growing body of evidence indicates that mitochondrial oxidative
stress has a major role in the development of cardiomyopathies in
metabolic diseases [452–454]. Cardiac function relies heavily on intact
mitochondrial function including mitochondrial biogenesis, fusion,
ﬁssion, and autophagy-mitophagy. Disturbances in these processes
have been linked to increased mitochondrial oxidative stress and the
development of metabolic cardiomyopathies. Several oxidative and
nitrative stress-related cellular processes have been shown to be
deranged in metabolic disorders. In a rat model of hypercholesterole-
mia enhanced cellular peroxynitrite formation due to an upregulation
of NOX4 has been described and discussed as a potential mechanism of
cardiovascular complications [455,456] – of note, this ﬁnding high-
lights that NOX4 can play diﬀerent roles in diﬀerent organs or disease
settings depending on whether it confers beneﬁcial redox signaling or
contributes to excessive RONS formation. In the same model, mito-
chondrial expression of connexin43, which may reduce mitochondrial
reactive oxygen species production, was decreased [457]. Evidence
obtained in models of metabolic syndrome suggests that mitochondrial
oxidative stress is linked to cardiac dysfunction. Indeed, in high-fat diet
(HFD)-induced mouse models of metabolic syndrome the elevation in
myocardial mitochondrial RONS production was associated with re-
duced diastolic circumferential strain rate assessed by tagged cardiac
magnetic resonance imaging [458]. In addition, in mice, diastolic
dysfunction induced by a high-fat high-sucrose (HFHS) diet was
accompanied by a 3-fold greater rate of mitochondrial H2O2 production
along with a decrease in both oxygen consumption and ATP synthesis.
In this latter model transgenic expression of mitochondria-targeted
catalase alleviated oxidative stress and improved diastolic function
[459] indicating that mitochondrial ROS formation is causally linked to
contractile impairment. This relationship is further supported by
pharmacological approaches suggesting that decreasing mitochondrial
RONS levels might have a great therapeutic potential – keeping in mind
that RONS can also have beneﬁcial eﬀects as discussed for precondi-
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tioning phenomena above [438], and therefore the use of antioxidants
is always a two-edged sword that needs to be used with great caution.
Diabetic mice treated with a mitochondria-targeted antioxidant, Mito-
TEMPO, showed preserved heart rates and improved survival after
myocardial infarction [460] along with a decrease in mitochondrial
RONS generation, apoptosis and myocardial hypertrophy [461]. The
latter observations were also obtained ex vivo in hyperglycemic cultured
cardiomyocytes [461]. Drug candidates other than direct antioxidants
have also shown eﬃcacy in the treatment of metabolic cardiomyopa-
thies. Mitochondrial RONS cause opening of the mPTP channels in
which cyclophilin D has a major role. A novel inhibitor of cyclophilin D,
NIM811, reduced infarct size in diabetic rats [462]. Mitochondrial
aldehyde dehydrogenase-2 (ALDH-2), an enzyme responsible for the
removal of cardiotoxic aldehydes, is activated by physiological levels of
mitochondrial RONS. ALDH-2 overexpression is reported to reduce
diabetic cardiomyocyte hypertrophy and contractile dysfunction, while
activation of ALDH-2 by Alda-1 has been shown to alleviate high
glucose-induced apoptosis and the reduction in mitochondrial mem-
brane potential in H9C2 cells [463]. Although the above reports
connect increased mitochondrial RONS production to metabolic cardi-
omyopathies, a few studies showed a lack of correlation between
mitochondrial RONS formation and diabetic cardiomyopathy
[464,465]. These ﬁndings suggest that mitochondrial oxidative stress
might not be present in all models and at all stages of metabolic diseases
and that it might not be the common underlying mechanism of
metabolic cardiomyopathies, again, warranting caution with the use
of antioxidants although the targeted modulation of mitochondrial
RONS production and its downstream targets might represent applic-
able future therapeutic strategies.
6.4. RONS formation in cerebral ischemia and stroke
As pointed out by Casas and Schmidt, NADPH oxidase and nitric
oxide synthase derived RONS represent potential targets for stroke
therapy. Stroke is the leading cause of neurological impairment in
industrialized countries, making it the second leading cause of death
worldwide and the primary cause of disability. Despite this high
medical and social need, no neuroprotective agent is available for
clinical therapy and only a single drug reached the market, the anti-
thrombolytic drug rt-PA for ischemic stroke. However, due to its
multiple contraindications almost 85% of all stroke patients are
excluded from receiving this treatment. RONS have been considered
as key players in post-stroke neurodegeneration [466]. Targeting
pathologically relevant sources of RONS, such as NOX and NOS, may
thus provide promising innovative therapeutic approaches. NADPH
oxidases, which include the already mentioned NOX4, constitute the
only known enzyme family with the sole function to produce O2•¯ and
H2O2. The NOX family consists of seven isoforms: NOX1-5 and the dual
oxidases (DUOX 1–2). Due to accessory proteins, each isoform has a
distinct quaternary structure, activity regulation, tissue expression and
product. Therefore, not all isoforms may contribute equally to ischemic
injury [32]. Based on a systematic review and meta-analysis, NOX1
seems to play no role in stroke, neither in infarct size reduction nor in
neurological outcome. Similarly, the evidence for NOX2 is extremely
contradictory and more or less disproven by a pre-clinical randomized
controlled trial with the aim to validate NOX2 as a stroke target. This
study turned out negative highlighting a persistent publication bias
towards positive ﬁndings and the lack of statistical power in many
studies [467]. Conversely, brain ischemia is one of the best-validated
disease indications for NOX4. Under hypoxic conditions, NOX4 is
upregulated leading to oxidative damage, cytotoxicity and neuronal
death. Therefore, NOX4 inhibition has been recently considered as a
promising target for this pathology. Preclinical results show that NOX
inhibition by VAS2870 signiﬁcantly reduces infarct size and post-stroke
RONS formation, suggesting indeed a major contribution of this NOX.
Further pre-clinical experiments are being currently conducted using
speciﬁc NOX4 inhibitors and diﬀerent animal models of stroke [468].
Similarly, nitric oxide is also considered a member of the RONS family,
generated by diﬀerent NOS isoforms. Studies in mice showed that
deletion of neuronal NOS (isoform 1) leads to a signiﬁcant reduction of
post-stroke brain damage, suggesting therapeutic targeting of NOS-1. In
fact, it has been recently reported that NOS inhibition (L-NAME)
signiﬁcantly reduces tissue damage and infarct size post-stroke using
both in vitro and in vivo ischemia models [469]. However, this was not
the case for NOS1-PSD-95 interaction inhibitors, possibly by also
interfering with other, protective pathways. Pharmacological targeting
of NOX and NOS dependent oxidative stress clearly has neuroprotective
eﬀects and reduces infarct volume and RONS production after stroke
leading to improved neuronal function and survival. Current and future
experiments are aimed at validating these ﬁndings in phase II and III
clinical trials in other rodent and large animal species for further
clinical development as ﬁrst-in-class neuroprotective treatment of
stroke.
6.5. Therapeutic targeting of eNOS uncoupling and cardiovascular
oxidative stress and inﬂammation
Based on considerations by Li and Förstermann, pharmacological
prevention of eNOS uncoupling is another antioxidant therapeutic
strategy that may not interfere with the protective role of redox
signaling in the cardiovascular system [9]. Oxidative stress plays a
crucial role in the pathogenesis of cardiovascular disease. Among the
major producers of RONS, the uncoupled endothelial nitric oxide
synthase (eNOS) makes a signiﬁcant contribution to RONS generation
in cardiovascular tissues [470,471]. Under physiological conditions,
eNOS produces •NO. Endothelium-derived •NO has anti-hypertensive,
anti-thrombotic and anti-atherosclerotic properties by relaxing blood
vessels, inhibiting platelet aggregation/adhesion, preventing leukocyte
adhesion/migration, and inhibiting smooth muscle cell proliferation
[472]. Under pathological conditions associated with oxidative stress
and inﬂammation, eNOS can be converted from a •NO-producing
enzyme to a superoxide-generating molecule, a process termed eNOS
uncoupling. All cardiovascular risk factors, such as diabetes, hyperten-
sion, hypercholesterolemia and smoking, may induce eNOS uncoupling
[472]. A number of mechanisms may contribute to eNOS uncoupling
[9,473], with deﬁciency of the eNOS cofactor tetrahydrobiopterin
(BH4), deﬁciency of the eNOS substrate L-arginine, and eNOS S-
glutathionylation being the most important ones. Peroxynitrite and
superoxide can oxidize BH4 to dihydrobiopterin (BH2), leading to BH4
deﬁciency. A lack of BH4 can also be caused by a reduction of BH4 de
novo synthesis (e.g. due to down-regulation of the BH4-synthesizing
enzyme GTP cyclohydrolase I) or by a decrease of BH4 regeneration
from BH2 (e.g. down-regulation of the recycling enzyme dihydrofolate
reductase). A recent study demonstrates that BH4-dependent and S-
glutathionylation-induced eNOS uncoupling are mechanistically inde-
pendent but functionally linked [474]. L-Arginine deﬁciency can be
caused by inﬂammation-induced up-regulation of arginases, enzymes
that compete with eNOS for the same substrate. By producing super-
oxide, uncoupled eNOS augments the pre-existing oxidative stress and
further enhances eNOS uncoupling, creating a vicious circle. Interest-
ingly, some established cardiovascular drugs (and some other com-
pounds) show the potential to prevent eNOS uncoupling. The recou-
pling of eNOS may represent pleiotropic eﬀects of these drugs and
contribute to their therapeutic beneﬁt. Angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II type-1 (AT1) receptor antagonists,
statins, the organic nitrate pentaerythritol tetranitrate (PETN), eNOS
transcription enhancers and the red wine polyphenol resveratrol have
been shown to reverse eNOS uncoupling in disease models by elevating
tissue BH4 levels [475,476]. PETN [477] and the AT1 receptor blocker
telmisartan [478] additionally prevent eNOS S-glutathionylation.
Furthermore, arginase inhibition also represents a promising strategy
to recouple eNOS [479,480].
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As suggested by Muzykantov, the previously described detrimental
but also beneﬁcial eﬀects of RONS warrant careful targeting without
interfering with the beneﬁcial signaling pathways by using site- and
species-speciﬁc approaches [9]. Liposomes and other nanocarriers
improve the pharmacokinetics of antioxidants including N-acetyl
cysteine (NAC) and antioxidant enzymes (AOE, i.e. catalase and SOD)
and thus help alleviate vascular oxidative stress predominantly via
detoxiﬁcation of extracellular RONS [481]. In order to achieve targeted
endothelial interventions, these agents can be conjugated with anti-
bodies to endothelial determinants including cell adhesion molecules
ICAM [482] and PECAM [483]. In preclinical studies, diverse formula-
tions of such AOE conjugates (Ab/AOE) show binding to endothelium
after i.v. injection [482]. Targeting of these formulations qualitatively
improves protection of endothelial cells from extracellular RONS [484]
and RONS produced inside these cells [485]. As a result, Ab/AOE
injected into animals attenuated ischemia-reperfusion injury in lungs of
diverse species [486,487], normalized vasoreactivity in angiotensin II-
challenged mice [487], inhibited endothelial pro-inﬂammatory activa-
tion caused by cytokines and potentiated the anti-inﬂammatory eﬀect
of NO donors [485]. Further, an indirect inhibitor of NADPH-oxidase
loaded in Ab/liposomes accumulated in endothelial cells, inhibited
RONS production and provided more potent protection vs. non-targeted
counterparts against oxidative stress in mice [488]. Ab/liposomes
loaded with EUK-134, a superoxide dismutase/catalase mimetic, bound
to endothelial cells and alleviated endotoxin-induced lung inﬂamma-
tion in mice [489]. Likewise, PECAM-targeted nanocarriers loaded with
tocopherol and EUK-134 alleviated endothelial inﬂammatory activa-
tion. Encapsulation in polymeric nanocarriers protects AOE from
proteases [490]. Modulation of geometry and aﬃnity features of
targeted AOE formulations enables their delivery into endothelial
endosomes, quenching RONS produced in these vesicles and intercepts
pro-inﬂammatory endothelial signaling and abnormal activation [485].
Endothelial targeting of antioxidants enables anti-inﬂammatory me-
chanisms based on interception of endothelial RONS [9]. This drug
delivery strategy may ﬁnd utility in the management of acute vascular
oxidative stress and inﬂammation (Fig. 6.3).
As explained by Lazou, accumulating evidence supports a key role
for peroxisome proliferator activated receptors (PPARs) in regulating
the redox state in the cardiovascular system through transcriptional or
post-translational eﬀects and thereby controls the redox balance in
cardiac diseases [491]. PPARs are ligand activated transcription factors
that belong to the superfamily of nuclear hormone receptors, with well-
documented roles in the transcriptional regulation of cardiac lipid
metabolism and energy homeostasis. Their non-metabolic, anti-oxidant,
anti-ischemic and anti-inﬂammatory properties have emerged over the
past years and are being actively investigated in relation to cardiac
dysfunction. All three PPAR isoforms (α, β/δ, γ) have been implicated
in the modulation of oxidative stress, although diﬀerent mechanisms
may be employed by each of them. PPARα and PPARγ function in a
similar way towards the modulation of oxidative stress, mostly through
the transcriptional regulation of target antioxidant enzymes. PPARα
activation via cloﬁbrate diminishes RONS production and lipid perox-
idation in rat hearts subjected to acute myocardial ischemia through the
upregulation of transcription and activity of antioxidant enzymes such
as Cu/Zn-SOD (SOD1), Mn-SOD (SOD2), and catalase in the heart tissue
as well as the suppression of AT-1 induced NADPH activity [492]. The
PPARα agonist, WY14643, ameliorated oxidative stress in a rat model
of IR [493], which is reﬂected by HO-1 down-regulation post IR in
WY14643-treated myocardium. PPARγ agonists like troglitazone, rosi-
glitazone and pioglitazone induce glutathione peroxidase (GPx 3) in
human skeletal muscle cells and thioredoxin in neonatal rat cardiac
myocytes [491]. RONS generation was also suppressed in cultured
cardiac myocytes treated with a PPARβ/δ agonist due to upregulation
of catalase [494]. PPARβ/δ also inhibits RONS generation in vascular
muscle cells through inhibition of NADPH oxidases [495]. The eﬀect of
PPARβ/δ activation on antioxidant defense may also be attributed to
improved mitochondrial biogenesis through regulation of target genes
such as PGC-1 and mitofusin 2 [496]. Upregulation and activation of
PPARs have been also implicated in the endogenous mechanisms of
cardioprotection implying that PPAR activation prior to IR could confer
Fig. 6.3. Overview on therapeutic options for the improvement of vascular dysfunction. Targeted antioxidant interventions to alleviate pro-inﬂammatory activation and oxidative stress
in endothelial cells. Endothelial ROS from activated NOX2 enzyme in endosomes are formed in response to cytokine binding to the receptors and ignite signaling cascade of transcription
factor NFκB. Targeted delivery of antioxidants, antioxidant enzymes (AOE) and inhibitors of ROS production can be achieved using antibodies and other ligands of endothelial surface
determinants including cell adhesion molecules PECAM and ICAM. Surface-bound targeted AOE intercept extracellular ROS, whereas targeted formulations using the same ligands
conﬁgured in a way permitting internalization into the ROS-signaling endosomes allows interception of pro-inﬂammatory activation manifested among other characteristics by exposure
of inducible cell adhesion molecules – E-selectin, VCAM-1, and ICAM-1 - that can be detected using imaging probes conjugated to the ligands of these molecules. With permission of the
publisher. Copyright © 1999–2017 John Wiley & Sons, Inc. All Rights Reserved.
Adapted from [9].
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preconditioning-like protection to the myocardium. Activation of the
PPARα isoform results in signiﬁcant anti-infarct protection, comparable
with the eﬀect of classical ischemic preconditioning that appears to
involve survival cascades (ERK1/2 and PI3K/Akt), upregulation of
eNOS and the opening of mitochondrial KATP channels [497,498].
There are several remaining issues that need to be addressed regarding
the biological role of PPARs as regulators of the cardiac redox state,
especially regarding the translation of in vitro ﬁndings in the in vivo
setting. However, the pleiotropic activity of these receptors makes them
interesting therapeutic targets for the development of antioxidant
strategies that aim to control the intracellular redox balance in various
cardiac pathologies, especially linked to dyslipidemia, atherosclerosis,
and diabetes, that are frequently associated with cardiovascular
disorders.
Steven and Daiber emphasize the importance of the pleiotropic
antioxidant, anti-aggregatory and anti-inﬂammatory potential of estab-
lished drugs as exempliﬁed by DPP-4 inhibitors and GLP-1 analogs
[19]. Glucagon-like peptide-1 (GLP-1) is an incretin hormone and
released from L-cells in the intestine after food uptake [499,500]. Its
receptor belongs to the family of G-protein-coupled receptors and
binding of GLP-1 induces insulin release from beta cells of the pancreas.
GLP-1 is involved in glycemic control and due to rapid degradation by
the exopeptidase dipeptidyl peptidase-4 (DPP-4) its half-life is below
two minutes [501,502]. Accordingly, inhibition of DPP-4 and supple-
mentation of GLP-1 represent new therapeutic targets for the manage-
ment of diabetes. Besides this ﬁrst line indication, there are several
reports on beneﬁcial eﬀects of DPP-4 inhibition on cardiovascular
disease associated with atherosclerosis [503,504], but also with psor-
iasis [505], hepatic steatosis [506] and stroke [507]. All of these
diseases have in common, that inﬂammation and oxidative stress
contribute to their pathophysiology. It was previously shown that
DPP-4 inhibition suppresses the proinﬂammatory phenotype of isolated
myelomonocytic cells and proinﬂammatory cascades in endotoxemic
rats [508]. Investigation of the eﬀects of DPP-4 inhibition and GLP-1
supplementation on endotoxemia and septic shock revealed improved
survival of septic mice (lipopolysaccharide i.p. injection), even when
the therapy with the DPP-4 inhibitor linagliptin or the GLP-1 analog
liraglutide was started six hours after induction of endotoxemia [371].
The improvement of mortality is based on the control of the initial
inﬂammatory response, which characterizes LPS-induced endotoxemia.
The oxidative burst of inﬂammatory, myelomonocytic cells, oxidative
stress measured by dihydroethidium ﬂuorescence, expression of typical
inﬂammatory genes, as well as vascular inﬁltration of CD11b+ cells
was decreased in endotoxemic animals treated with linagliptin and
liraglutide. As a consequence, hemodynamic control was recovered by
linagliptin and liraglutide treatment preventing the development of
lethal hypotension in the endotoxemic animals, all of which was based
on activation of the AMP-dependent protein kinase (AMPK) [371]. Our
data suggest that DPP-4 inhibitors and GLP-1 analogs have inhibitory
eﬀects on myelomonocytic cells, which in the case of DPP-4 inhibition
do not entirely rely on the GLP-1 receptor [372]. Inﬂammation and
hemostasis are subject to a complex interplay in the setting of sepsis.
Thrombocytopenia and disseminated intravascular coagulation (DIC),
characteristic features leading to end organ damage and death in septic
shock, were signiﬁcantly improved by both drugs [372]. Similar results
were obtained in an animal model of experimental thrombosis [509].
Further support of this concept was based on the observation that GLP-1
analogs inhibit platelet activation and aggregation directly via the GLP-
1 receptor, which is expressed on murine and human thrombocytes, and
by cAMP/adenylyl cyclase signaling [372,509]. In conclusion, sepsis is
still a main cause of death all over the world. DPP-4 inhibition and GLP-
1 supplementation reduced the mortality in endotoxemic animals by
antioxidant, anti-inﬂammatory and antiaggregatory eﬀects (Fig. 6.4).
The potential use of these drugs in patients with sepsis or other
inﬂammatory diseases needs further exploration.
6.6. Conclusion
Evidence derived by experimental approaches exploiting powerful
tools of molecular and cell biology is rapidly advancing our under-
standing of redox reactions involved in RONS formation. These
molecules, which were once investigated only for their possible
involvement in numerous diseases, are now attracting wide interest
for their role as intracellular signals, especially those in response to
metabolic or mechanical changes. Therefore, besides the well-estab-
lished notions that high intracellular levels of RONS impair function
and viability of practically any cell type, a large body of evidence
indicates that ROS are involved in countless physiological processes and
trigger powerful mechanisms of protection against cell injury.
In this review section we summarized established concepts and
recent advances supporting the dual role of RONS in cardiovascular
pathophysiology. These novel ﬁndings might support the therapeutic
potential of antioxidant interventions and explain the failure of clinical
trials using this approach. Indeed, the issues that remain to be
elucidated outnumber those that have been clariﬁed.
7. ROS and the aging process
Jose Vina (E-mail: Jose. Vina@uv.es) and Gloria Olaso-Gonzalez (E-
mail: gloria.olaso@uv.es).
7.1. Introduction
The free radical theory of aging postulated by Harman in 1956 has
provided a theoretical framework for research oriented toward under-
standing the mechanisms of aging. This theory states that “aging and
Fig. 6.4. Proposed mechanisms of lipopolysaccharide (LPS)-induced vascular dysfunction
and improvement by linagliptin therapy. LPS treatment activates white blood cells (WBC,
envisaged by increased oxidative burst), increases serum levels of xanthine oxidase (XO),
increases DPP-4 serum activity and activates vascular cells (detected by expression of
endothelial adhesion molecules and inducible cyclooxygenase [COX-2]). This leads to the
inﬁltration of WBC to the vascular wall (detected by aortic FACS analysis for
myelomonocytic cells, inducible nitric oxide synthase [NOS2], NOX2 and myeloperox-
idase [MPO] expression) and oxidative damage of the vasculature (NOX1 expression, ROS
formation, 3-nitrotyrosine levels and lipidperoxidation by malondialdehyde [MDA]).
Finally, the tissue damage results in smooth muscle constriction and endothelial
dysfunction. With permission by Oxford University Press. Copyright © 2012.
Adopted from [508].
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the degenerative diseases associated with it are attributed basically to
the deleterious side attacks of free radicals (ROS) on cell constituents
and on the connective tissue” [510]. Mitochondria have a major role in
ROS production [511]. On the other hand, NADPH oxidases (NOXs) are
important enzyme systems involved in inducible ROS formation, since
they catalyze the partial reduction of O2 to form ROS. It has been shown
that the enhanced expression and/or activity of NOX family members,
in particular NOX4, plays an important role in age-associated diseases
such as cardiovascular disease, ﬁbrosis, cancer and neurodegenerative
diseases like Alzheimer's disease [512,513]. In this situation of mis-
balance, proteasome-mediated degradation of oxidized proteins is a
critical player for protein homeostasis maintenance. Proteasome dys-
function takes place during aging [514]. Proteasome up-regulation in
terms of assembly, quantity and function has been achieved through
genetic manipulation in animal models. This activation was shown to
be successful to decelerate aging progression by enhancing resistance to
oxidative stress. However, genetic manipulation is not applicable in
humans, so new studies should focus on the identiﬁcation of nutritional,
pharmacological or physiological interventions with proteasome acti-
vating properties.
Oxidative stress has been linked with age-associated diseases, but
also with a geriatric syndrome characterized by diminished functional
reserve and increased vulnerability to low power stressors, i.e. frailty
(Fig. 7.1). An association between systemic oxidative stress biomarkers
(malondialdehyde, isoprostanes, protein carbonylation and lipoprotein
phospholipase A2) and frailty has been reported in the geriatric
population [515,516]. Nevertheless, recent data have shown that lower
expression of genes related to antioxidant responses to oxidative stress
in older people is associated with a higher risk of being frail
independently of age and sex (see El Assar et al. contribution, Section
7.6).
In recent years, epidemiological as well as laboratory data have
shown that antioxidant supplementation is at least useless if not
detrimental in aging [517]. Indeed, antioxidant supplementation did
not lower the incidence of many age-associated diseases but, in some
cases, increased the risk of death [518].
This has cast doubts on the classical “free radical theory of aging”.
We thus proposed “the cell signaling disruption theory of aging”. This
theory postulates that “ROS” cause aging inasmuch as they alter—-
sometimes irreversibly—the signaling network of the cell. If the cell can
cope with the stress caused by relatively mild action of ROS, then
adaptation takes place and damage does not occur. If, however, the cell
is overwhelmed by the action of radicals, subcellular damage and aging
will take place”. Indeed, radicals serve as signals and interaction
between them is tightly balanced. In this sense, we cannot support
the idea of proposing antioxidant supplementation for the general
population. It is much better to increase endogenous defenses by
nutritional or physiological manipulation than administering antiox-
idant compounds, such as vitamin C or E. In any case, these considera-
tions do not detract from the free radical theory of aging, which has
been extremely useful and has fostered research by providing a general
theoretical framework on which many of us have based decades-long
experimental research.
7.2. NADPH oxidases in aging and age-associated diseases
Pidder Jansen-Dürr and Rafal Koziel summarize that superoxide
anions and other ROS can exert beneﬁcial eﬀects under normal
conditions through adaptive cellular signaling responses. On the other
hand, ROS are able to induce direct damage to biologically sensitive
targets like lipids, proteins and nucleic acids, and their overproduction
is involved in both chronic diseases and age-related diseases. To date, a
variety of diﬀerent theories of biological aging have been discussed
[519,520]; however, many of them describe ‘oxidative stress’ as the
Fig. 7.1. Scheme summarizing the main concepts of the free radical theory in aging and development of aging associated diseases and syndromes.
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common cause of aging.
The ‘free radical theory of aging’ predicts the major role of
mitochondria-derived ROS in aging [510], however, recent data
indicate a key role of other ROS sources in this process. A signiﬁcant
number of enzymatic or chemical processes are capable of producing
ROS in vivo; however, the NOXs are the primary enzyme systems
involved in inducible ROS formation [65,521,522]. The NOX family of
membrane-associated enzymes consists of seven isoforms, Nox1-5 and
Duox1-2, and catalyzes the reduction of O2 to form ROS [512,521]. The
role and mechanism of the activation of NOXs is isoform type,
intracellular localization as well as tissue type speciﬁc, and NOX
mediated oxidative stress is strongly associated with a variety of human
age-related diseases [523](see also below). A growing number of
studies indicate that NOX4 is localized to mitochondria in many cell
types and promotes aging. We have previously suggested a new
pathway by which sustained NOX4 activity decreases mitochondrial
function and induces premature senescence in human umbilical vein
endothelial cells (HUVEC). NOX4 induced premature senescence by
decreasing the concentration and activity of mitochondrial respiratory
chain complex I [524,525]. Accordingly, NOX4 knockdown reduced
mitochondrial H2O2 production and markers of oxidative DNA damage,
increased the cellular proliferation rate and prolonged the replicative
lifespan by more than 2-fold [524,525]. It remains to be shown if
increased NOX4 activity contributes to aging of the vasculature in
mammals.
The eﬀector role of NOX4, a constitutively active NOX isoform, to
drive cellular senescence is conserved for oncogene-induced senes-
cence, a tumor suppressor pathway that restricts the growth of pre-
neoplastic cells in mice and humans. Weyemi et al. found that NOX4 is
a critical mediator in the oncogenic H-RasV12-induced DNA-damage
response and subsequent senescence [526]. H-RasV12 overexpression
correlated with increased NOX4 expression, higher ROS levels, DNA
damage, histone H2A.X phosphorylation and p21Cip1 accumulation.
Similar conclusions were reached by Kodama et al. who showed that
NOX1- and NOX4-generated ROS play an important role in Ras-induced
premature senescence, which may involve the DNA damage response
and p38MAPK signaling pathways in primary human lung TIG-3 cells.
Both NOXs were upregulated by the Ras oncogene. Ablation of Nox1
and Nox4 by small interfering RNAs (siRNAs) blocked the RasV12
senescent phenotype including β-galactosidase activity, growth arrest
and accumulation of tumor suppressor proteins such as p53 and
p16Ink4a. The involvement of Nox1 in Ras-induced senescence was
also conﬁrmed with embryonic ﬁbroblasts derived from Nox1 knockout
mice [527]. Another study suggested an important role of NOX4 in
oncogene-independent senescence of hepatocellular carcinoma cells
[528].
Of interest is compelling evidence that enhanced expression and/or
activity of NOX family members, in particular NOX4, plays an
important role in age-associated diseases, including cardiovascular
disease, ﬁbrosis and cancer. In the vasculature, NOXs are a major
source of ROS and are key players in mediating redox signaling under
both physiological and pathological conditions. Cardiovascular disease
(CVD) is the leading cause of death, and aging is a major risk factor for
CVD development. A substantial number of studies describe the role of
NOX4 in the age-related pathology of the cardiovascular system. It was
shown that NOX4 has an impact on vasoconstriction, atherosclerosis
development, vascular cells hypertrophy, apoptosis and diﬀerentiation.
One of the major age-related arterial phenotypes thought to be
responsible for the development of CVD in older adults is endothelial
dysfunction. It was speculated that mitochondrial oxidative stress rises
when antioxidants are unable to counteract the ROS produced by
NOX4, triggering the aging process of the heart [529]. Wang et al.
[530] examined the involvement of NOX in age-associated cardiac
remodeling in a rodent model of aging and found that age-dependent
increases in blood pressure, cardiomyocyte hypertrophy, coronary
artery remodeling and cardiac ﬁbrosis were associated with increased
myocardial NOX2 activity. Another study indicates that NOX4 and
mitochondrial oxidative stress, but not NOX1 or NOX2, are mediators of
CVD in aging mice under hyperlipidemic conditions [531]. Whereas
initial results obtained with Nox4 KO mice did not reveal striking
phenotypical diﬀerences relative to wild type mice, there is now solid
evidence that the absence of NOX4 alters a number of physiological
heart parameters (see also above), and increases susceptibility to tissue
damage in a mouse model for stroke [532].
A crucial role of NOX4-derived ROS in age-related diseases was also
implicated in the initiation, establishment, and development of tissue
ﬁbrosis (reviewed in [533]). In particular, strong experimental evi-
dence suggests that pulmonary ﬁbrosis (also referred to as idiopathic
pulmonary ﬁbrosis, IPF, for the lack of a well-deﬁned etiology) is
caused by excessive NOX4 activity and can be at least partially reverted
by targeting the NOX4-NRF2 redox imbalance [534]. On the other
hand, work by the Armanios group has established that genetic
deﬁciencies in telomere maintenance systems cause IPF late in life
[535], which therefore has been referred to as a “short telomere
disease” [536], and the percentage of genetic lesions aﬀecting telomere
maintenance in IPF patients is steadily increasing. From these data, it
appears conceivable that telomere shortening and activation of NOX
enzymes, in particular NOX4, are mechanistically linked; however such
links have so far remained elusive. A potential role of NOX2 has been
found in age-related neurodegenerative diseases like Alzheimer's dis-
ease [513] and Parkinson's disease [537].
The incidence of most cancers increases dramatically with age,
indicating that, with a few exceptions, cancer is primarily an age-
associated disease. Concerning the role of NOX family members, a dual
role in carcinogenesis has been postulated. On the one hand, the
function of NOX to mediate oncogene-induced senescence, leading to
tumor suppression (see above), indicates that NOX activity restricts
tumor growth in some instances. On the other hand, production of ROS
by NOX enzymes is essential for signaling pathways driving cell
proliferation and survival, indicating that enhanced NOX activity in
epithelial cells favors tumorigenesis. This dual role of NOX-derived ROS
is best illustrated in prostate cancer, clearly one of the most relevant
age-associated malignancies. Analysis of radical prostatectomy tissue
samples and benign and malignant prostate epithelial cell lines
identiﬁed NOX5 as an abundantly expressed NOX isoform and sug-
gested that NOX5-derived ROS and subsequent depletion of PKCζ and
JNK inactivation play a critical role in modulating intracellular signal-
ing cascades driving the proliferation and survival of PCa cells [538].
On the other hand, increased expression of Nox4 in prostate stromal
cells (ﬁbroblasts) during their age-associated trans-diﬀerentiation to
myoﬁbroblasts leads to benign prostate hyperproliferation [539], a
condition referred to as “reactive stroma” [540] that is known to favor
the emergence of (epithelial) tumor cells in the prostate.
In conclusion, the existing evidence suggests that NOX family
members are important drivers of age-associated pathology, and
regulating NOX activity/expression and using mitochondrial antioxi-
dants are potential approaches to reducing aging-associated diseases.
7.3. Protein aggregates as redox signaling mediators in aging
The aging process and a number of age-associated diseases are
accompanied by the accumulation of high-molecular protein aggre-
gates, as reported by Tilman Grune. In the aging process these protein
aggregates are often referred to as lipofuscin, ceroid or age associated
ﬂuorophores. This material is largely composed of proteins, often
amounting to 60–80%. Some of these proteins are oxidized or modiﬁed
by various reactive metabolites, e.g. carbohydrates forming advanced
glycation end products. Various lipids form another major part of such
aggregated material. Interestingly, several authors report also the
inclusion of various metals in such protein aggregates.
This raised the question, whether included metals are able to trigger
metal-catalyzed redox reactions. It could be demonstrated that iron in
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protein aggregates is able to catalyze the Fenton-reaction and is only
partially chelatable by iron-chelators [541]. Moreover, in the same
study it could be demonstrated that in senescent cells protein aggre-
gates contribute to an age-associated shift in the redox-state [541].
Further studies revealed that such protein aggregates do have an
active surface. It is likely that due to the reactive surface of the
aggregate, e.g. due to reactive hydroperoxides or aldehydes, and due to
the hydrophobic patches – a result of the unfolding of the included
proteins - protein aggregates can bind cellular proteins. This inter-
actome might either be random or at least partially speciﬁc due to the
binding of protein-protein-interacting structures. The latter includes
certainly the binding of chaperones [542] or proteases designed to
degrade unfolded proteins, as in the proteasome [543].
The 20S proteasome is known to be the major intracellular protease
responsible for the degradation of damaged and oxidized proteins
[543]. On the other hand, it is also the central catalytic part of the
ubiquitin-proteasomal-system and, therefore, involved in the degrada-
tion of most cytosolic proteins [543]. The proteasome recognizes
unfolded protein structures. In the case of protein aggregates this leads
to an inhibition of the proteasome upon binding. This was shown in in
vitro senescence models [544] or in neurons of Alzheimer's disease
patients [545]. Proteasomal inhibition, in turn, leads to a proteasomal
mal-performance, leading to disturbances of the regulated turnover of
transcription factors, as shown in the case of AP-1 [546], HSF1 and
NRF2 [547]. Furthermore, it should be noted that proteasomal inhibi-
tion leads also to a vicious cycle in which a reduced level of degradation
of newly formed oxidized proteins leads to enhanced protein aggregate
formation.
In conclusion, it should be noted that accumulating protein
aggregates have multiple pathophysiological eﬀects and cannot be seen
as inert waste materials. However, more studies are needed to acquire a
more complete scheme of the action of protein aggregates and their
contribution to cellular senescence.
7.4. Proteasome activation as an anti-aging and anti-aggregation strategy
From the least to the most complex organisms, aging is a natural
inevitable process accompanied by several molecular and biochemical
failures. As explained by Niki Chondrogianni and Nikoletta
Papaevgeniou, damaged and/or wrongly produced macromolecules
tend to accumulate and aggregate, resulting in proteostasis impairment
that then triggers a cataract of system deﬁcits. Proteasome-mediated
degradation is a critical player for protein homeostasis maintenance;
proteasomes are large enzymatic complexes that regulate the cellular
protein load equilibrium by degrading the unnecessary peptides and
proteins. Proteasomal dysfunction is associated with the progression of
aging and protein aggregation further aggravates the problem [514].
Consequently, proteasome activation appears to be a promising anti-
aging and anti-aggregation approach.
Proteasome up-regulation in terms of assembly, quantity and
function has been achieved through genetic manipulation of various
catalytic or regulatory subunits or through treatment with speciﬁc
activating compounds. This activation has been shown to lead to
decelerated aging progression and to enhanced longevity. More speci-
ﬁcally, overexpression of β1 and β5 catalytic subunits endowed WI38
human ﬁbroblasts with increased resistance to oxidative stress and
elongated cellular lifespan [514]. Overexpression of the pbs-5 subunit
(nematode ortholog of β5) in C. elegans resulted in increased protea-
some content and function that led to enhanced resistance to oxidative
stress and extended lifespan in a daf-16-, skn-1- and hsf-1-dependent
manner [548]. In accordance, rpn-6.1 overexpression in C. elegans
triggered elevated proteasome activities leading to enhanced longevity
under conditions of mild heat stress [549]. The positive eﬀect of
proteasome activation on longevity was also shown in the fruit ﬂy
where overexpression of the RPN11 19S subunit resulted in enhanced
proteasome activities and extended lifespan [550]. With regard to
compounds, treatment with a pentacyclic triterpenoid, namely 18α-
glycyrrhetinic acid, resulted in increased proteasome content and
activity both in cellular (human ﬁbroblasts) and organismal (C. elegans)
models [551,552]. This compound was shown to promote proteasome
activation in an NRF2-dependent manner in ﬁbroblasts [551] and a
SKN-1-dependent manner in nematodes [552], with elongated lifespan
and increased stress resistance as the end result. Finally, rejuvenating
and anti-aging properties were attributed to quercetin-mediated pro-
teasome activation in human ﬁbroblasts [553].
Proteasome activation has also been shown to confer protection
against the devastating consequences of protein aggregation.
Enhancement of proteasome function through pbs-5 overexpression in
nematodes endowed animals with increased survival against expanded
polyglutamine and Aβ peptide proteotoxicity [548]. Similarly, rpn6.1
overexpression conferred proteotoxic stress resistance in a nematode
polyglutamine disease model [549], while RPN11 overexpression
suppressed the expanded polyglutamine- induced progressive neurode-
generation in fruit ﬂies [550]. Proteasome activation through 18α-
glycyrrhetinic acid treatment led to reduced Aβ peptide deposits both in
murine neuronal cells and in an Alzheimer's disease nematode model
thus resulting in decelerated progression of the disease's phenotype
[552]. Likewise, the polyphenol quercetin was found to induce protea-
some activity resulting in inhibition of paralysis in a transgenic C.
elegans strain serving as an animal model for Alzheimer's disease [554].
In conclusion, proteasome activation emerges as a promising
strategy in the battle against aging and proteotoxicity. Given that
genetic manipulation is not applicable in humans, future studies should
focus on the identiﬁcation of compounds with proteasome activating
properties as well as in the elucidation of the involved signals and
biochemical pathways.
7.5. Free radical theory of aging – dead or alive?
The “free radical theory of aging” was introduced in the early 1950s
through the work of Harman [510] and comprises investigations of the
role of reactive oxygen species (ROS) formation and mitochondrial
function in the aging process and, more recently, the implications of
ROS-triggered epigenetic processes and DNA damage for the etiology of
aging [555]. Lately, as discussed by Andreas Daiber and Yuliya Mikhed,
the ﬁeld of epigenetics has received considerable attention in the
context of aging theories. It has been shown that cellular senescence
leads to massive DNA demethylation, causing a state of DNA hypo-
methylation, particularly in the CpG islands [556] and multiple
epigenetic processes are regulated in a redox-dependent manner
[238]. Although the lessons learned from animal models of genetic
deletion or overexpression of important antioxidant enzymes such as
superoxide dismutases, glutathione peroxidases and catalase were
rather disappointing, since no clear correlation between life span and
the abundance of these antioxidant defense enzymes could be observed,
at least some of them (e.g. Sod1-/-) or double gene ablation combina-
tions showed reduced life expectancy, which would be in line with the
“free radical theory of aging” [557,558]. Moreover, the importance of
mitochondrial superoxide formation for survival (longevity) is high-
lighted by the fact that homozygous SOD2 deletion leads to perinatal or
neonatal lethality [559] and by the observation that mice deﬁcient in
the p66Shc-/- gene, a source of mitochondrial ROS formation, display a
30% longer life span [560]. According to more recent data, oxidative
stress in general and mitochondrial ROS formation in particular may
play an even more important role for the quality of life, healthy aging,
or the so-called “healthspan” than for the lifespan per se [561,562].
Healthy aging may be an even more important need and challenge in
our aging Western societies, also from an economical point of view
considering the tremendous costs associated with our public health
systems. The cardiovascular system seems to be an excellent example of
this concept. From a mechanistic basis the increasing superoxide
formation (coming from gradually increased mitochondrial leakage of
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electrons and NADPH oxidase-derived production due to low grade
inﬂammation) with progressing age will lead to antagonization of nitric
oxide, a major vasodilator and antiatherothrombotic signaling molecule
of the cardiovascular system [555]. Oxidative depletion of nitric oxide
bioavailability by superoxide and the reaction product peroxynitrite
will lead to impaired cGMP formation, inhibition of prostacyclin
synthase by tyrosine nitration and activation of the renin-angiotensin-
aldosterone system as well as endothelin-1 signaling, which will lead to
a complete switch from a vasculoprotective to a proatherothrombotic
phenotype [9]. In support of this concept, genetic deletion of mitochon-
drial antioxidant enzymes (Aldh2-/- and Sod2+/-) led to an increase in
mitochondrial ROS formation, 8-oxoguanine-dependent mitochondrial
DNA strand breaks and, most importantly, an impairment of endothe-
lium-dependent and –independent relaxation (vascular function)
(Fig. 7.2A-B) [563]. Likewise, genetic deletion of GPx-1 led to an age-
dependent impairment of endothelium-dependent and –independent
relaxation, increase in oxidative stress markers and eNOS uncoupling as
well as aggravation of inﬂammatory phenotype of the vasculature
(summarized in Fig. 7.2C) [62]. Although these animals showed no
obvious decrease in lifespan, it may be assumed that the proathero-
thrombotic and inﬂammatory phenotype will ultimately lead to in-
creased prevalence of cardiovascular complications as a consequence of
the higher burden of oxidative stress, thereby decreasing the health-
span.
Fig. 7.2. Correlations between mitochondrial oxidative stress (mtROS), mitochondrial DNA (mtDNA) damage and vascular (endothelial) function (ACh-induced maximal relaxation). (A)
mtROS formation was plotted for all age-groups and mouse strains versus the corresponding maximal eﬃcacy in response to acetylcholine (ACh). (B) mtROS was plotted for all age-groups
and mouse strains versus the corresponding mtDNA damage. ROS were measured using L-012 (100 µM) enhanced chemiluminescence in isolated cardiac mitochondria upon stimulation
with succinate (5 mM). r is the correlation coeﬃcient. (C) Hypothetic scheme of aging-induced vascular dysfunction and the role of mitochondria in this process. Aging-induced
mitochondrial dysfunction triggers mitochondrial reactive oxygen species (mtROS) formation from respiratory complexes I, II, and III (Q = ubiquinone). Break-down of mtROS is
catalyzed by glutathione peroxidase (GPx, for H2O2) or manganese superoxide dismutase (MnSOD), the latter is in turn inhibited by mitochondrial peroxynitrite (ONOO-) formation.
mtROS increase the levels of toxic aldehydes and inhibit the mitochondrial aldehyde dehydrogenase (ALDH-2), the detoxifying enzyme of those aldehydes. Increase in mtROS and toxic
aldehydes also leads to mtDNA strand breaks which leads to augmented dysfunction in respiratory chain complexes and further increase in mtROS since mtDNA encodes mainly for those
respiratory complexes. mtROS also activates mitochondrial permeability transition pore (mPTP), which upon opening releases mtROS to the cytosol leading to protein kinase C (PKC)-
dependent NADPH oxidase activation, eNOS uncoupling and ﬁnally to endothelial dysfunction [61]. Cytosolic reactive oxygen and nitrogen species (ROS/RNS) in turn were demonstrated
to activate KATP channels, which causes alterations in mitochondrial membrane potential (C) and further augments mtROS levels [564]. Eﬀects of rotenone (Rot), cyclosporine A (CsA),
diazoxide (Diaz) and glibenclamide (Glib) have been recently demonstrated in related models of vascular dysfunction and oxidative stress, nitroglycerin-induced nitrate tolerance and
angiotensin-II triggered hypertension [61,564]. With permission of the European Society of Cardiology. All rights reserved. © The Author and Oxford University Press 2008.
Adopted from [563].
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In conclusion, there is solid evidence for the “free radical theory of
aging” in experimental studies but translation to the clinical situation
requires large scale clinical trials, as currently undertaken by the
CHANCES consortium (10,622 individuals) reporting on a clear asso-
ciation between oxidative stress markers and all-cause mortality [565]
and the MARK-AGE consortium (3337 individuals) the data of which
are currently being prepared for ﬁnal dissemination [566].
7.6. ROS and frailty. Understanding the mechanisms of disability in older
people
According to Mariam El Assar and Leocadio Rodríguez-Mañas,
frailty is a geriatric syndrome characterized by diminished functional
reserve and increased vulnerability to low power stressors. Frailty
precedes disability, and, in addition, epidemiological cohorts have
demonstrated that the frailty phenotype predicts several outcomes such
as falls, hospitalization and mortality [567]. Although the biological
determinants of frailty are not well deﬁned, oxidative stress and
inﬂammation have been closely related to aging and seem to be
potential drivers of frailty pathogenesis. Inﬂammation and oxidative
stress are closely related processes with crosslinks between their
respective signaling pathways. In line with this, observational studies
have shown that frailty is associated with diﬀerent systemic inﬂamma-
tory biomarkers, including C-reactive protein, and interleukin-6 [568].
Elevated levels of pro-inﬂammatory cytokines have been shown to be
associated with increased risk of morbidity and mortality in frail older
subjects. Furthermore, an association between systemic oxidative stress
biomarkers (malondialdehyde, isoprostanes, protein carbonylation and
lipoprotein phospholipase A2) and frailty has been reported in a
geriatric population [515].
The prevalence of chronic diseases such as diabetes, cardiovascular
diseases and pulmonary diseases increases with aging. These chronic
conditions compromise muscle function, cardiovascular performance
and pulmonary function leading to increased vulnerability of the
organism when exposed to low intensity stressors. This scenario
represents the phenotypic manifestation of frailty. Consistently, all
these chronic diseases are associated with a higher risk of frailty in aged
populations. The contribution of oxidative stress and reactive oxygen
species (ROS) to the decline of diﬀerent functional systems associated
to aging and to age-related chronic diseases has been established [569].
For example, the defective nitric oxide signaling in aged muscle
vasculature has been attributed to increased inactivation of this
molecule by ROS leading to decreased muscle perfusion. On the other
hand, the lung is continuously exposed to oxidative stress while the
activity of antioxidant enzymes such as superoxide dismutase and
glutathione peroxidase decreases with aging. In addition, the induction
of heme oxygenase, which is involved in cellular protection against
oxidative stress, is defective in lungs of aged mice, further supporting
the involvement of oxidative stress in age-related pulmonary dysfunc-
tion.
Since frail older adults have minimal injury resilience and a notably
decreased response to stress, the diﬀerent pathways regulating cellular
response to stress (oxidative stress, hypoxia and inﬂammation among
others) stand out as possible players in the development of a frailty
phenotype. In this sense, aging, sedentary lifestyle and chronic diseases
could cause down-regulation of signaling pathways responsible for the
cellular response to oxidative stress, such as NRF2. This results in
impaired response to stress and increased oxidative stress leading to a
situation of vulnerability to stressors such as frailty. In fact, very recent
data obtained by our group have demonstrated that lower expression of
genes related to response to oxidative stress in older people is
associated with a higher risk of being frail independently of age and
sex (El Assar and Rodríguez-Mañas group).
Further investigations are deﬁnitely needed to ﬁll the gap of
knowledge of this evolving ﬁeld and provide possible targets for
intervention to promote health and independence in the elderly.
8. ROS and inﬂammation in health and disease
Manuela Garcia Lopez (E-mail: manuela.garcia@uam.es) and Javier
Egea (E-mail: javier.egea@inv.uam.es).
8.1. Introduction
Over the past decade, the study of the biological activity and
signiﬁcance of ROS have gained particular interest from both a
physiological and pathological perspective. Since ROS are highly
unstable and reactive molecules, they interfere with many cellular
processes. ROS react with lipids, nucleic acids and proteins, disrupting
their cellular functions. Oxidative stress occurs when the damaging
eﬀects of ROS exceed the ability of biological systems to neutralize the
oxidizing agents and to repair cellular damage. Physiologically, anti-
oxidant defenses are eﬃcient enough to neutralize the damaging eﬀect
of oxidizing molecules. In these conditions, the presence of ROS is
important for many physiological cellular processes and they partici-
pate as signaling molecules in a wide range of cellular functions. Hence,
ROS modulate intracellular transduction pathways and transcriptional
factors involved in cell proliferation, diﬀerentiation, and maturation
[570–572].
Chronic Granulomatous Disease (CGD) is a rare inherited innate
immunodeﬁciency caused by defective NADPH oxidase activity in
phagocytes and is recognized as a disease model to understand the
pathophysiological consequences of ROS deﬁciency [22]. CGD patients
suﬀer from life-threatening infections, but an apparent paradox be-
tween the absence of ROS production and hyperinﬂammation is often
observed in this disease [32,33]. The key producers of ROS in many
cells are the NOX enzymes, of which there are seven members with
diﬀerent tissue distributions and regulatory mechanisms. ROS produced
by the isoform NOX2 is essential to organize the response in host
defense against pathogens [573].
In the brain, ROS production regulates neuronal development from
neuronal precursors [574]. Redox signaling is also required to trigger
neuronal diﬀerentiation and axon formation [575]. Nitric oxide (•NO),
a diﬀusible intercellular messenger produced by neuronal nitric oxide
synthase (nNOS) exerts a dual regulatory role in neurovascular coupling
and neuroenergetics by regulating mitochondrial oxygen consumption
[576]. Therefore, ROS act as messengers in the transduction pathways
important for synaptic plasticity in the CNS.
The brain is particularly vulnerable to oxidative stress because it
consumes a large amount of oxygen, has abundant lipid content, and
has little antioxidant activity compared to other organs. The major
antioxidants in the brain are ascorbate, glutathione (GSH), and vitamin
E in the plasma membrane. GSH production is increased in response to
oxidative stress in astrocytes, cells that act as the main supplier of GSH
to neurons for antioxidant protection [577]. ROS accumulation in the
brain has been associated with the onset of neurodegenerative and
psychiatric diseases, whose main consequence is to reduce several
neuronal cellular functions. ROS accumulation in neurons and the
resulting oxidative stress are responsible for the loss of cognitive and
motor functions in several brain diseases.
Oxidative stress and chronic low grade inﬂammation are interde-
pendent processes that have been implicated in aging and many
pathological conditions like cardiovascular disease, neurodegenerative
diseases or cancer. Inﬂammatory cells can release ROS at the site of
inﬂammation increasing oxidative stress, while ROS can initiate
intracellular signaling cascades that increase proinﬂammatory gene
expression [47,578].
Chronic inﬂammation as a consequence of immune failure is often
associated with cancer (known as inﬂammation-induced tumorigen-
esis). Hence, in diﬀerent types of cancers, multiple pathways contribute
to chronic cytokine release. Hyperinﬂammation combined with loss of
adhesion and the release of angiogenic factors leads to cellular
proliferation.
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Here we will put forward some examples of how ROS and
inﬂammation can regulate physiological or pathological conditions in
diﬀerent systems.
8.2. Dual actions of NOX2-derived ROS
As pointed out by Jamel El-Benna and Pham My-Chan Dang, the
production of ROS by NOX2 is essential to mount a rapid response to
bacterial and fungal invasion; however, excessive or inappropriate ROS
production can induce severe tissue injury that participates in the
pathophysiology of acute and chronic inﬂammatory diseases
[579,580]. For several years, NOX2-derived ROS have been considered
as pro-inﬂammatory agents, but recent reports challenged this dogma
and suggested that they can also be anti-inﬂammatory [581].
Under physiological conditions, the objective of ROS production by
phagocytes is to kill and eliminate pathogens trapped inside the
phagosome [579]. When this goal is successfully achieved, ROS
production is terminated and the inﬂammation is resolved. Thus, the
physiological role of transient ROS production is anti-inﬂammatory as it
helps to eliminate inﬂammation resulting from the infection. In
addition to the “direct-ROS-killing eﬀect” during phagocytosis, NOX2-
derived ROS can have “paracrine-redox signaling eﬀects” that can
modulate the immune response. Indeed, NOX2-derived ROS can
dampen T-cell-dependent inﬂammation through alteration of T-cell
membrane oxidation status [582] and of Th17/Treg cell development
[583]. The anti-inﬂammatory role of NOX2-derived ROS is well
illustrated in chronic granulomatous disease (CGD) patients who have
a genetic defect in one of the NOX2 genes (see Section 8.3). Thus,
chronic NOX2 deﬁciency may cause “ROS-independent” inﬂammation
where ROS are not the causative factor. This “ROS-independent”
inﬂammation is also observed in autoimmune diseases as shown in
animal models [581,582,584]. In the presence of high levels of pro-
inﬂammatory mediators (cytokines, TLR agonists, lipid mediators…),
NOX2 can be hyper-activated, leading to excessive and prolonged ROS
production [583]. This high ROS production is undoubtedly deleter-
ious, as evidenced by the multiple antioxidant strategies that have been
developed by the organism to protect against ROS [585]. ROS,
particularly the diﬀusible hydrogen peroxide, can oxidize cellular
macromolecules (proteins, lipids, DNA), which leads to tissue injury
or to the alteration of cellular functions such as imbalance of
intracellular signaling pathways, cytokine production, protease activa-
tion and release [585], all of which participate in the “ROS-dependent
inﬂammation.” Indeed, inhibition of NOX2 and the use of certain anti-
oxidants protect from inﬂammation in animal models [586].
8.3. Chronic Granulomatous Disease (CGD): implication of NOX2
According to Marie José Stasia, Joe Dan Dunn and Thierry Soldati,
CGD is a rare inherited disorder in which phagocytic cells are unable to
kill pathogens during an infection. The molecular basis of this disease is
the absence of ROS production by the NADPH oxidase complex of
phagocytes which is composed of NOX2 and p22phox, also named the
membrane ﬂavocytochrome b558, and the cytosolic factors p47phox,
p67phox and p40phox. It is a genetically heterogeneous disease with all
ethnic groups equally aﬀected. The molecular basis of CGD is char-
acterized by two types of transmission and four main genetic forms. As
mentioned earlier, the major genetic form is X-linked CGD caused by
mutations in the CYBB gene encoding NOX2. X-CGD accounts for about
70% of the total cases reported to date [587]. The other types of CGD
are autosomal recessive forms (AR), characterized by mutations in
CYBA, NCF1 and NCF2 encoding p22phox, p47phox and p67phox
respectively [588]. Clear information on the severity of CGD according
to the genetic forms is diﬃcult to establish. However Kuhns et al.
demonstrated a relationship between the presence of residual ROS
production and the survival of CGD patients [589]. In addition,
mutations aﬀecting the membrane ﬂavocytochrome b558 composed
of p22phox and NOX2 seem to be associated with the most severe
clinical features of CGD [590]. Indeed, cytochrome b558 is the redox
core of the enzyme in which the electron transfer occurs to reduce the
molecular oxygen into superoxide.
The soil-dwelling, social amoeba, Dictyostelium discoideum (there-
after Dictyostelium) is an ideal model organism to determine immunity
functions of ROS and the consequences of ROS deﬁciency, i.e., CGD.
Dictyostelium amoebae prey on bacteria using phagocytic machinery
and intracellular killing mechanisms that are conserved in the immune
phagocytes of metazoa, e.g., mammalian macrophages and neutrophils,
and are utilized as a model phagocyte to study cell-autonomous
immunity [591,592]. Among the conserved machinery are three
NOX2 homologs of the NADPH oxidase catalytic subunit (NOX A, B
and C), a p22phox homolog, a single, putative NOX-activating protein
(NcfA, a homolog of p67phox), a secreted myeloperoxidase-like enzyme
(PoxA), and enzymes for metabolizing ROS such as superoxide dis-
mutases and catalases [593,594]. Dictyostelium also has homologs of
STATs, TRAFs, and guanylate-binding proteins, which are regulated by
ROS in macrophages [594], and employs autophagy as a defense
mechanism against cytosolic bacteria [595], which is activated down-
stream of ROS in macrophages.
Dictyostelium undergoes a developmental cycle during which
100,000 amoebae aggregate to form a multicellular slug that ultimately
diﬀerentiates into a spore-containing fruiting body. ROS scavengers
inhibit the initial aggregation of amoebae, and both NOX-deﬁcient
mutants and catalase deﬁcient mutants exhibit defects in fruiting body
formation [593,596,597]. The multicellular slug contains specialized
sentinel cells (s-cells) that serve as its patrolling innate immune system
[598]. Like neutrophils, S-cells extrude DNA-based extracellular traps
(ETs) via a NOX-dependent mechanism: S-cells from NOX-deﬁcient
mutants lose the ability to secrete ETs and to clear bacteria from the
slug and subsequent fruiting body [599]. Consequently Dictyostelium,
on the cusp of multi-cellularity, can be used to model CGD and the
inﬂuence of NOXs and ETs on the evolution of specialized immune cells
and to study the role of ROS in a host-pathogen interaction [600].
CGD patients suﬀer from recurrent and life threatening infections
during early childhood. Phagocytic cells from CGD patients adhere to
blood vessels, reach infectious sites by chemotaxis and phagocytose the
involved pathogens, but are unable to kill them because of the absence
of ROS production by the defective NOX complex. Thus, accumulation
of live pathogens in phagocytes, combined with the continuous release
of proinﬂammatory cytokines by these cells, leads to the formation of
granulomas in infected tissues. In addition, granuloma formation in
hollow organs like the kidneys or the gastrointestinal tract is respon-
sible for obstruction syndromes. Infections can be localized in tissues in
direct contact with the environment like the skin, the otorhinolaryngol-
ogy sphere or, more severely, the lungs. The disease has a more
dramatic eﬀect when infections and granulomas are in deep organs
such as the brain or the liver. Aspergillosis in the lungs is the ﬁrst cause
of death of CGD patients. One seemingly paradoxical observation that
needs to be addressed is: how does the absence of ROS lead to
hyperinﬂammation in CGD? Several hypotheses have been proposed.
The oldest one is that eﬀerocytosis by macrophages is reduced in CGD
[601]. The overall consequence will be unbalanced neutrophil necrosis,
an increase of proteases and toxic oxygen-derived components and
release of proinﬂammatory cytokines, which all contribute to local
inﬂammation. In addition, the absence of ROS production can be
responsible for defective activation of genes that regulate NFκB
signaling, which is involved in the restriction of the development of
inﬂammatory disorders [602]. Recently, it was shown that ROS
deﬁciency in CGD causes autophagy dysfunction in phagocytes, which
contributes to increased production of proinﬂammatory IL-1β. Indeed,
two CGD patients treated with an IL-1 receptor blocker showed rapid
and sustained improvement in colitis [603]. Furthermore, defective
ATM activation due to the absence of ROS production in a CGD patient
was linked to an exacerbation of proinﬂammatory cytokine release and
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apoptosis, which might explain the hyperinﬂammation in this disease
[604].
As components of the phagocytic NOX complex are expressed in
cells and tissues other than phagocytes, inactivating mutations in these
proteins can have pathophysiological consequences unrelated to im-
munodeﬁciency syndromes. ROS production by NOX enzymes controls
vascular function via modulation of NO bioactivity. Indeed NOX2
deﬁciency in CGD patients was related to enhanced arterial dilatation
[605]. Violi et al. demonstrated that in vivo platelet activation might be
directly associated with NOX2 activity. Thus decreased platelet marker
activation correlated with the absence of NOX2 expression found in
CGD patients. As NOX2-deﬁcient mice demonstrated impaired memory
and synaptic deﬁcit, a role of NOX2 in these processes was proposed
[606]. However, clinical studies in children with CGD were rather
ambiguous [607,608].
8.4. Neuromodulatory actions of nitric oxide
As summarized by J. Laranjinha and R.M. Barbosa, the brain is
bioenergetically exigent and, to optimize neuronal function and
survival it is equipped with ﬁne mechanisms for a precise spatial and
temporal control of cerebral blood ﬂow (CBF) that provides energy
substrates according to cellular activity. This process is achieved
through neurovascular coupling, an orchestrated intercellular commu-
nication among all components of the neurovascular unit (neurons,
astrocytes, perycites and microvessels) that results in a rapid and
restricted increase in CBF [609]. Yet neuronal energetics is non-linearly
coupled to an activity-dependent increase of CBF, i.e. neuronal activity-
induced increases in CBF are not accompanied by proportionate
increases in oxygen consumption by neuronal mitochondria [610].
Therefore, an activity-dependent CBF increase and oxygen utilization
by active neural cells are inextricably linked and establish a functional
metabolic axis in the brain termed the “neurovascular-neuroenergetic
coupling axis.” This axis incorporates interdependent processes that
need to be coordinated in the normal brain. An impaired functionality
of the neurovascular-neuroenergetic coupling axis poses a threat to the
healthy brain and can prove particularly detrimental for Alzheimer´s
disease and the aged brain.
•NO, a diﬀusible intercellular messenger synthesized by the neuron-
associated synthase isoform (nNOS), coordinates an integrated regula-
tion of this axis by mediating the neurovascular coupling process and by
regulating oxygen utilization by mitochondria. Two lines of reasoning
support this hypothesis. The ﬁrst is based on the in vivo dynamic and
simultaneous recordings [611] of •NO, oxygen and CBF. It has been
shown that upon glutamatergic stimulation of rodent hippocampus, •NO
synthesized by nNOS associated with the glutamate NMDA receptor
diﬀuses into neighboring vessels and induces an increase of CBF, which
couples to neuronal activity by activating soluble guanylate cyclase in
smooth muscle cells [612]. The transitory increases of •NO and CBF
from a basal level are temporarily and spatially coupled with oxygen
delivered from the vessels, encompassing a sequence of events consist-
ing of glutamatergic neuronal stimulation, •NO transients, CBF in-
creases and oxygen transients. According to the second line of reason-
ing, the best characterized interaction of •NO with the mitochondria is
the inhibition of cytochrome c oxidase by nanomolar concentrations of
•NO in competition with oxygen [613]. At physiological oxygen
concentrations, NMDA-evoked •NO production inhibits hippocampal
oxygen consumption at submicromolar concentrations and induces a
small diﬀerence in the concentration dynamics of •NO, reﬂecting that
diﬀerent states of neuronal activation may lead to diﬀerent outcomes in
terms of metabolic rate [614,615].
8.5. Thiol redox homeostasis in astrocytes
According to Gethin J. McBean, several decades of research have led
to the conclusion that astrocytes, the so-called ‘metabolic support’ cells
of the brain, act as the central supplier of glutathione (γ-glutamyl-
cysteinyl-glycine, GSH) for antioxidant protection of neurons. De novo
synthesis of GSH in astrocytes fulﬁlls the antioxidant capacity of those
cells and also provides precursors for GSH synthesis in neurons [616].
Cysteine is the rate-limiting substrate for GSH synthesis and is supplied
either by transport from the extracellular medium in the form of cystine
into astrocytes using the xc- exchanger, or directly into neurons as
cysteine via the EAAT3 subtype of the high-aﬃnity glutamate trans-
Fig. 8.1. Cysteine supply pathways in astrocytes. Cysteine is either taken up in its oxidized form, cystine, from the extracellular medium via the xc- cystine-glutamate exchanger, or
generated from methionine via the transsulfuration pathway. Cysteine is the immediate precursor for GSH, which is synthesized by the ﬁrst two enzymes of the γ-glutamyl cycle, as well as
taurine and hydrogen sulpﬁde. CBS, cystathionine-β-synthase; CDO, cysteine dioxygenase; CSA, cysteine sulﬁnic acid; CSE, cystathionine-γ-lyase; GCS, glutamate cysteine ligase; GS,
glutathione synthase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.
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porter. As the extracellular redox potential dictates a 5:1 ratio of cystine
to cysteine, the bulk of uptake takes place into astrocytes. In addition to
the xc- cystine-glutamate exchanger, cysteine can also be supplied by
transsulfuration (TS) from methionine via homocysteine, as shown in
Fig. 8.1. In normal astrocytes, the TS pathway supplies up to one third
of the cysteine required for GSH, with the majority coming from the
extracellular space [577,617].
It is well documented that GSH production in astrocytes is increased
in response to oxidative stress. Similarly, upregulation of both the xc-
exchanger and the TS pathway (via increased expression of the rate-
limiting enzyme, cystathionine-γ-lyase (also known as cystathionase;
CSE)) occurs following oxidative stress [617,618]. Interestingly, ex-
perimentally-induced oxidative stress in primary rat cortical astrocytes
shows that the relative contribution of the TS pathway to cysteine for
GSH increases to 60%, meaning that, under these conditions, the
majority of cysteine for GSH comes from this pathway, rather than
the xc- exchanger [577]. Pharmacological blockade of the xc- cystine-
glutamate exchanger in vitro also acts as a signal to upregulate CSE,
leading to enhanced synthesis of GSH [577]. It is not clear at present
whether the signal to increase ﬂux through the TS pathway occurs in
response to a fall in GSH within astrocytes, or to increased oxidative
stress, or both. It has been proposed that upregulation of cystine intake
under oxidative stress conditions is decoupled from GSH synthesis and,
instead, regulates an intracellular-extracellular cysteine-cystine redox
cycle [619]. This proposal ﬁts with our results showing that GSH
synthesis under oxidative stress conditions increases reliance on the TS
pathway. However, further work is required to fully evaluate the
interrelationship between these sources of cysteine for GSH, and other
important neuroprotective products, for example, taurine and hydrogen
sulﬁde.
Understanding the origin of cysteine for GSH is important for
evaluation of the antioxidant capacity of cells in neurodegenerative
disease. There are several examples in the literature of up-regulation of
the xc-cystine-glutamate exchanger during neurodegenerative disease
[620,621]. Indeed, at ﬁrst glance, it would appear that the capacity to
increase GSH synthesis during neurodegenerative disease-related oxi-
dative stress would be beneﬁcial. However, the downside is that
increased capacity of the xc-cystine-glutamate exchanger is inevitably
coupled to the release of glutamate. If this cannot be matched by high-
aﬃnity uptake, then the likelihood of glutamate-mediated neurotoxi-
city threatens neuronal well-being. This situation is well illustrated in
the case of glioma/astrocytoma. Here, tumor cells up-regulate the
xc-cystine-glutamate exchanger, but down-regulate the high-aﬃnity
glutamate transporters [622]. This imbalance generates the capacity
for destruction of neurons and increases the likelihood of epileptiform
activity. However, strategies to block the xc- exchanger in glioma
therapy have been unsuccessful. It is now recognized that drugs that
target both the xc- exchanger and the TS pathway have greater potential
as eﬀective therapeutics [623]. Research is ongoing to fully understand
the beneﬁcial potential of the TS pathway in astrocytes, particularly in
the context of astrocyte activation and the immune response.
8.6. Regulation of the oxidative and inﬂammatory response by microglial
α7 cholinergic receptors
As reported by Manuela G Lopez and Javier Egea, dysfunction of the
cholinergic system and mitochondria together with increased oxidative
stress and neuroinﬂammation has been reported during aging and
diseases related to age like Alzheimer´s and Parkinson´s disease
[624,625]. The α7 acetylcholine nicotinic receptor subtype (α7nAChR)
is expressed in neuronal and non-neuronal cells. Wang et al. [626]
identiﬁed that α7 nAChRs in blood monocytes control inﬂammation
under vagal stimulation and proposed the “cholinergic anti-inﬂamma-
tory pathway,” which regulates inﬂammation in the periphery. In the
central nervous system, microglia regulate the innate immune response
and also express α7 nAChRs; therefore, the role of these receptors in
microglial function is being studied.
Primary glial cultures exposed to the α7 nicotinic agonist
PNU282987 increased their mitochondrial mass and mitochondrial
oxygen consumption without generating oxidative stress. These
changes were not seen when the transcriptional factor NRF2 was
absent, when the HO-1 enzyme was inhibited and when PGC-1α was
silenced. In isolated microglia of adult animals treated with the
α7nAChR agonist, a signiﬁcant increase in mitochondrial mass was
also detected. Interestingly, LysMcre-Hmox1Δ/Δ animals, which lack
HO-1 in microglial cells, and PGC-1α-/- animals, which do not express
PGC-1α protein, showed lower microglial mitochondrial levels, and
treatment with PNU282987 did not change the mitochondrial levels.
These results indicate the important function of the α7nAChR/NRF2/
HO1 and PGC-1α axis to increase mitochondrial biogenesis and thereby
improve the bioenergetic status in microglia [627].
The α7 microglial nicotinic receptor also plays a strategic role in
controlling neuroinﬂammation to aﬀord neuroprotection under brain
ischemia conditions as shown in in vitro and in vivo models.
Organotypic hippocampal cultures (OHC) exposed to oxygen and
glucose deprivation (OGD) elicited cell death. However, the selective
α7nAChR agonist PNU282987 incubated post-OGD, reduced cell death,
ROS production and TNF-α release. The protective eﬀect of PNU282987
was lost in microglia-depleted OHCs as well as in OHCs from Nrf2
deﬁcient mice. Administration of the α7nAChR agonist 1 h after
induction of photothrombotic stroke in vivo reduced infarct size and
improved motor skills in Hmox1lox/lox mice that express normal levels of
HO-1, but not in LysMCreHmox1Δ/Δ in which HO-1 expression is
inhibited in myeloid cells, including the microglia [628]. These results
show that α7 microglial nicotinic receptors play a key role in control-
ling neuroinﬂammation and aﬀording neuroprotection under brain
ischemia.
Therefore, microglial activation of the α7 nAChR/NRF2/HO-1 axis
seems to play an important role in improving microglial bioenergetics
and reducing oxidative stress and neuroinﬂammation [629].
8.7. Regulatory mechanisms of ROS in the motor neuron
According to Anastasia Shakirzyanova and Rashid Giniatullin ROS
can also regulate neurotransmission at the neuromuscular junction.
Curiously, the actions of ROS are remarkably diﬀerent in the synapses
of newborns, adults and old rats [630]. Thus, it has been reported that
the inhibitory eﬀect of the diﬀusible mild oxidant H2O2 is much
stronger in old rats. In newborns tested during the whole ﬁrst postnatal
week, H2O2 did not aﬀect spontaneous transmitter release from nerve
endings and even potentiated the end-plate potentials. The resistance of
neonates to H2O2 inhibition was associated with higher catalase and
glutathione peroxidase activities in skeletal muscle. In contrast, the
activities of these enzymes were downregulated in old rats. These
results indicate that the vulnerability of transmitter release to oxidative
damage strongly correlates with aging and might be used as an early
indicator of senescence [630]. Consistent with this, it was shown that
the concentration of the redox active amino acid homocysteine
increases with aging and in many neurodegenerative diseases signiﬁ-
cantly aggravates ROS-induced depression of transmitter release from
motor nerve terminals. This provides a potential mechanism of
peripheral impairment in motor neuron diseases associated with
hyperhomocysteinemia [631]. Related to this, is has been reported
that the co-transmitter ATP, which operates via a ROS-dependent
mechanism, activates presynaptic P2Y12 receptors coupled to NOX to
generate endogenous ROS and that this signaling complex likely resides
in lipid rafts [632].
The association between ROS and motor neuron disease is exem-
pliﬁed in the case of amyotrophic lateral sclerosis (ALS), a neurode-
generative disease characterized by a progressive loss of motor neurons
and degradation of the neuromuscular junctions. In ALS, the decline in
synaptic function initiates from the presynaptic terminals. Experimental
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data have shown that in the neuromuscular junction, a classical model
of synaptic transmission, ROS have an inhibitory action on the
presynaptic releasing machinery, and it was proposed that the pre-
synaptic sensor of ROS was the SNARE protein Snap25 [633].
8.8. Inﬂammation and ROS in cancer
As explained by Kemal Sami Korkmaz and Bilge Debelec–Butuner,
chronic inﬂammation subsequent to immune failure or insults such as
microbial infections is often associated with cancer. The well-known
examples come from Helicobacter pylori and human papillomavirus
infections in stomach and cervix cancers respectively, where multiple
pathways synergistically contribute to the activation of cytokine
release, that combined with the loss of adhesion and the release of
angiogenic factors, may eventually contribute to cellular proliferation,
diﬀerentiation and tumor progression [634]. Thus, the immune defense
mechanisms that play important roles in guarding the organism against
environmental insults, might induce malignant growth in these tissues.
This event is termed inﬂammation-induced tumorigenesis.
Toll like receptor (TLR) function is critical for regulation of innate
and adaptive immune responses in normal cells and usually necessitates
distinguishing the defective functionality of the malignant cells that
might inﬂuence the sensory ability of the immune defense. Since
activation of the pro-survival factors such as NF-κB, ERK and JNK
kinases as well as increased levels of IL-6 and IL-12 correlate with
highly expressed TLR4 levels in malignant cells [635], these ﬁndings
indicate the important role of TLRs in chronic inﬂammation and cancer
development.
Interestingly, TLR4 has been associated with metastasis in various
types of cancer including the prostate. Highly metastatic human
prostate cancer cell lines, PC-3 and DU145, express higher levels of
TLR4 [636] compared to RWPE and LNCaP prostate cell lines
[634,637,638]. When these cells are treated in vitro with LPS, TNFα
is induced, reaching nM concentrations, and proliferation and migra-
tion of prostate cancer cells is observed [637,638]. Consistently, the
depletion of TLR4 expression inhibits the invasion of these cells and
also improves the survival of tumor-bearing animals [636,639], which
suggests that the higher TLR4 level or its activation signiﬁcantly
augments tumor cell proliferation upon cytokine exposure. Thus,
TLR4 expressed in normal and low-grade tumors could be a contribut-
ing factor to chronic inﬂammation that promotes carcinogenesis.
Nevertheless, the well-known prostate speciﬁc and androgen recep-
tor (AR) regulated tumor suppressor NKX3.1 encodes a homeobox
protein and facilitates the antioxidant response through transcription-
ally upregulating the glutathione peroxidases and peroxiredoxins
[640], which leads to subsequent deregulation of the intracellular
ROS levels and activation of the DNA damage response.
In addition, the growth rate is metabolically regulated via stress-
sensing Sirtuin 1 (SIRT1), an NAD-dependent deacetylase. Under
oxidative conditions, such as inﬂammation, SIRT1 deacetylates a
number of transcription factors, including p53, NBS1 and AR, which
contribute to the control of the cell cycle, DNA damage response and
steroid hormone action in prostate cells respectively. Therefore, SIRT1
has also been linked to tumor cell survival, particularly in prostate
cancer, by the deacetylation of AR. Thus, the inﬂammation induced via
TLR4-related cellular mechanisms contributes to the deregulation of the
antioxidant response and DNA damage recognition in prostate, where
the increased genetic heterogeneity is suppressed via AR, and its
deacetylation by activated SIRT1 counteracts the deregulation of cell
growth leading to stress tolerance in tumor progression.
8.9. Summary and conclusions
In this section we have seen some examples of how ROS formation
has regulatory mechanisms that can be implicated in health and
disease. ROS formed from NOX, mitochondria, or NO-producing
enzymes are not necessarily toxic, but rather compose a network
signaling system, known as redox regulation.
In the case of NOX2, we have seen that under physiological
conditions ROS production derived from NOX2 may have an anti-
inﬂammatory role when produced in a limited time and space, while a
defect in NOX2 can lead to “ROS-independent inﬂammation.” However,
when they are overproduced, they become pro-inﬂammatory as they
induce oxidative stress and changes in cell homeostasis during a “ROS-
dependent inﬂammation.” While the use of NOX2-deﬁcient mice has
advanced our knowledge on the role of NOX2, it is probably not the best
approach to determine whether the absence of NOX2 is protective
against inﬂammation, as the deletion of NOX2 inherently leads to a
dysregulation of the immune response. A clear example of a human
disease related to defects in NOX2 or associated subunits is chronic
granulomatous disease [641]; as a consequence of NOX2 deﬁciency,
neutrophil killing is defective due to the extremely low respiratory
burst in these cells during phagocytosis [642,643].
ROS generated by NOX enzymes can control vascular function via
modulation of NO bioactivity [644]. In the brain, NO can exert a
modulatory role both in the neurovascular coupling and in the
functionality of energy formation by the mitochondrial respiratory
chain. Therefore, neuronal-derived NO can be considered a master
regulator of the neurovascular-neuroenergetic coupling axis. Further-
more, dysfunction of the NO-dependent neurovascular and neuroener-
getic coupling has been related to the cognitive decline associated with
brain aging and Alzheimer´s disease [576].
Besides the regulatory mechanism of neuronal NO, glial cells also
play an active role in maintaining the redox balance in the brain. In line
with this, astrocytes act as the central supplier of GSH for antioxidant
protection of neurons. Cysteine is required to produce GSH in order to
control the antioxidant capacity of cells in neurodegenerative disease;
therefore, it is now recognized that drugs that target both the xc-
exchanger and the TS pathway have greater potential as eﬀective
therapeutics [623]. On the other hand, in microglial cells, cholinergic
stimulation of the α7 nicotinic receptor subtype is being recognized as a
target to control neuroinﬂammation and oxidative stress by inducing
hemoxygenase-1 to provide neuroprotection [628].
Homocysteine (HCY) is a pro-inﬂammatory sulfur-containing redox
active endogenous amino acid, whose concentration increases in
neurodegenerative disorders including ALS. At the neuromuscular
junction, the eﬀect of HCY on oxidative stress-induced impairment of
transmitter release was shown to be age-dependent [631]; older rats
were more sensitive to the inhibitory eﬀect of H2O2 than newborns,
most probably because the latter have higher levels of antioxidant
enzymes. Furthermore, activation of P2Y12 receptors by ATP, which is
co-released with ACh at the neuromuscular junction, can induce ROS
production by activating NADPH oxidase [632] and thereby control
neurotransmission.
Finally, inﬂammation and oxidative stress can participate in cancer.
Activation of pro-inﬂammatory cascades via TLR4 has been related to
highly metastatic tumors [636]. On the other hand, ROS production via
NOX2 can regulate inﬂammation [645]. In line with these observations,
it has been reported that NOX activity and expression is associated with
tumorigenesis of lung cancer, and that inhibition of NOX function or
mRNA expression can signiﬁcantly block lung cancer formation and
invasion [646].
In conclusion, ROS play a Janus-faced role: they can provide
physiological actions or contribute to pathogenesis. We have seen in
this review that the regulatory actions of ROS are complex and can
diﬀer from one cell system to another. Therefore, understanding the
ﬁne regulatory mechanisms of ROS in speciﬁc cells and tissues will
contribute to the identiﬁcation of precise targets and thus to the
development of more eﬃcient therapeutic strategies.
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9. The emerging roles of redox networks in tumor cell
proliferation, hearing loss, neuropsychiatric disorders and
cardiovascular pharmacology
Isabel Fabregat (E-mail: ifabregat@idibell.cat) and Santiago Lamas
(E-mail: slamas@cbm.csic.es).
9.1. Introduction
Our COST Action has invested a signiﬁcant amount of work and
interaction on major biomedical and clinical problems in which ROS
have an established role or where signiﬁcant evidence has been
mounted for their participation in the initiation, perpetuation or
resolution of the most pressing health challenges in the developed
world in the next decade. The focus of this section are the ideas,
expertise and studies of the members of the EU-ROS COST Action.
We have grouped the contributions in this sub-section into four
major categories: cancer, metabolic diseases, neuropathology and
cardiovascular diseases. A summary of these is depicted in Fig. 9.1.
A fundamental problem in cancer biology has to do with the
migration of tumor cells to extraneous tissue environments where they
may constitute the core of metastatic niches. The role of oxidative stress
germane to this phenomenon is far from clear and remains controver-
sial. For example, it has been found that melanoma metastasis may
progress by suppressing redox-related eﬀector molecules such as APE1/
REF-1 [647] and making melanoma cells less responsive to oxidative-
induced DNA damage. In contrast, it has been also reported that
oxidative stress may inhibit distant melanoma metastasis in vivo
[648]. In a similar vein, the targeting of fundamental endogenous
antioxidant systems, such as GSH and thioredoxins, has been proposed
as a potential advantageous therapy for cancer and HIV [649]. A more
detailed analysis on the molecular mechanisms related to redox
responses in the context of cancer cell migration is provided below.
Of interest, the cellular and molecular sources responsible for ROS
generation have been the object of intense study in pathophysiological
settings such as liver ﬁbrosis and carcinogenesis. Here too, the jury is
still out regarding the beneﬁcial or detrimental role of NOXs, especially
in reference to the apparently opposite eﬀects of NOX1 and NOX4 in
liver tumorigenesis, as discussed in the following paragraphs.
The Action has beneﬁted from the work of groups interested in the
redox regulation of neurological and psychiatric diseases with a speciﬁc
emphasis on two relatively unexplored areas: the inner ear and
schizophrenia. Of all the NOX isoforms, NOX3 is clearly the most
elusive, less studied and even less well understood, primarily due to its
restricted topological expression in the inner ear. One of the labora-
tories involved in this COST action has shed light on the function of
NOX3 in balance regulation and hearing function by developing
sophisticated mouse models that lend themselves to investigation of
this issue. The problem of hearing loss, either genetically based or
acquired after environmental exposure to noise or aging, has experi-
enced a recent twist where redox regulation has taken center stage.
Indeed, a very captivating report has described that pejvakin, a protein
related to peroxisomal function and proliferation, lies at the basis of an
inherited sensorineural form of deafness and its lack or malfunction
induced by oxidative stress makes the inner ear extremely vulnerable to
noise-induced damage [650]. NOX3 is expressed in the cochlea even
though mice devoid of it do not show an apparent hearing loss-related
phenotype. Whether peroxisomal generation of ROS is connected to
NOX3 function is a possibility that remains to be investigated. Another
set of diseases where the role of redox regulation is intriguing is in the
realm of neuropsychiatry. While a signiﬁcant amount of evidence
regarding the role of oxidative stress has accumulated in neurodegen-
erative diseases (please see the corresponding section), much less is
known in the context of psychoses. In the particular case of schizo-
phrenia, aside from profound alterations in the levels of several
neurotransmitters, a disturbed redox homeostasis has been evidenced
with a major focus on glutathione regulation. These intriguing ﬁndings
are discussed below highlighting the major advances and pitfalls in the
knowledge of this exciting research avenue.
There is currently little doubt about the relevant role played by
oxidative stress in the metabolic syndrome and in particular in type 2
diabetes. Both insulin production, as well as insulin signaling, are redox
sensitive processes, highly determined by the levels of O2•- and •NO, and
their interplay. Thus, impairment of physiological signaling by ROS/
RNS is implicated in the etiopathology of diabetes [651]. Some groups
in our COST Action are interested in exploring how the ﬁne tuning of
the O2•-/•NO ratio is regulated and how it aﬀects insulin synthesis and
degradation. Furthermore, oxidative stress contributes to pancreatic β
Fig. 9.1. Summarizing scheme on the contribution of ROS signaling to diﬀerent physiological and pathophysiological conditions. This section covers an ample spectrum of disorders with
the theme of redox signaling and nitroxidative stress as the common modulator of disturbances related to tumor cell migration, ﬁbrogenesis, hearing loss, neuropsychiatric disorders,
metabolic syndrome, drug metabolism, renal hemodynamics and lung hypoxia. In the slide the participation of relevant enzymatic pathways (NOXs, SODs, ALDH-2) are indicated. BMI:
body mass index. The rest of the abbreviations are deﬁned in the text.
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cell loss, which impairs insulin secretion [652]. Therefore, therapeutic
strategies to prevent β cell dysfunction require better knowledge about
how to protect them against direct or indirect eﬀects of free radicals
and lipid peroxidation. Also relevant is the fact that both insulin
sensitivity and metabolic homeostasis depend on the capacity of
adipose tissue to take up and utilize excess glucose and fatty acids.
This buﬀering capacity depends on physiological levels of •NO, whose
function may be altered by excessive formation of O2•- [653]. Interest-
ingly, recent evidences indicate that redox signaling and oxidative
stress may contribute to adipose tissue remodeling and this is a relevant
area of research. These new aspects about the relevance of ROS and
RNS in the context of metabolic syndromes and diabetes are expanded
below highlighting the major challenges addressed by research mem-
bers within the EU-ROS COST Action.
Cardiovascular physiology and pathophysiology have also been a
major object of this COST Action and this is reﬂected in the present
section of this overview. In this section we also include contributions of
the COST members related to vascular aspects with a speciﬁc focus. One
of these is the still unresolved and important problem of toxicity and
tolerance derived from the clinical use of organic nitrates. In the last
few years new light has been shed upon the molecular mechanisms
related to the side eﬀects of nitroglycerin and other nitrates evidencing
a major role for mitochondrial dysfunction and disruption of redox
homeostasis. A detailed update of the problem is provided in the section
that follows. A disturbed vascular redox balance underlies the patho-
physiology of important morbid conditions in other organs such as the
lung and kidney. In the lung, chronic hypoxic pulmonary hypertension
leads to vasoconstriction and vascular remodeling, two phenomena that
self-perpetuate the vicious cycle. In the kidney, studies in animals using
superoxide dismutase (SOD) mimetics point to an important role of
redox dysfunction in the increased vascular resistance associated with
chronic kidney disease and open the possibility of therapeutic inter-
vention. Both sets of concepts and data are appropriately discussed
below.
9.2. Cancer
The following subsections were composed by Esther Bertrán, Isabel
Fabregat, Ana Fernandes, and Nuno Saraiva.
9.2.1. Redox regulation of tumor cell migration
Several cellular and extracellular events are involved in ROS
production and can directly or indirectly impact on mechanisms
involved in diﬀerent types of cell migration thus contributing to the
invasiveness and poor prognosis of several cancers. These mechanisms
include invadopodia formation, MMP activation/expression, focal
adhesion dynamics, cell-cell contact, cytoskeleton remodeling, and
gene expression regulation (Fig. 9.2) [654–656]. In turn, many
mechanisms involved in cell migration, such as integrin signaling or
Ca2+ homeostasis aﬀect ROS production, creating intricate and still
poorly understood regulatory mechanisms [656,657]. ROS can act as
second-messengers by oxidizing cysteine residues that impose func-
tional changes on cell migration-relevant kinases, phosphatases and
transcription factors [658]. The uneven physical and temporal distribu-
tion/activity of the elements involved in ROS production (Fig. 9.2) can
lead to heterogeneous ROS accumulation within a migrating cell and
during the migration process. Several sources may contribute to the
generation of ROS (see ﬁgure). Their topological distribution inﬂuences
the localization and oxidative status of many regulatory elements, thus
allowing a redox-dependent spatial and temporal regulation of cell
migration/adhesion mechanisms. Mitochondrial ROS are associated
with the initial ECM contact while a cytosolic ROS increase is involved
Fig. 9.2. ROS and cell migration. (A) There are several sources of reactive species (RS) whose subcellular distribution dictates the fate and direction of cell migration. In this cartoon they
are indicated by Arabic numbers. (B) Key mechanisms involved in the redox-regulation of cell migration. The main eﬀectors participating in cell-cell contact adhesion, gene expression
activation, matrix degradation, cytoskeletal remodeling and focal adhesion are indicated.
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in cytoskeleton remodeling and NOX-derived ROS are involved in
invadopodia formation [186]. Additionally, the existence of an elevated
reductive potential as well as strong redox buﬀers is essential to limit
ROS diﬀusion and maintain a polarized distribution of oxidant inter-
mediates [657]. The ﬁnal outcome in cell proliferation, migration and
adhesion depends on the activation of a series of eﬀectors regulating
gene expression, matrix degradation, cytoskeletal remodeling and cell-
cell contact adhesion (see ﬁgure).
The complexity of mechanisms by which ROS mediate cancer cell
migration is still far from being understood. A general pattern of the
impact of ROS and antioxidants on tumor metastatic potential is
diﬃcult to depict given the inherent diﬀerences among cancer types.
For example, MnSOD expression may be highly dependent on the
primary tissue [659]. Even considering tumors from the same organ of
origin, the stage and grade of disease progression may inﬂuence
intracellular ROS and antioxidant enzyme levels. Most of the previous
studies on the inﬂuence of ROS in cell migration were performed in cell
culture models. However, the activity of antioxidant enzymes varies
with the culture conditions and declines after a high number of cell
passages. Another aspect that limits the usefulness of cell culture
models is their inability to recreate the tumor microenvironment,
which includes cancer cells, cancer stem cells and stromal components,
such as extracellular matrix, ﬁbroblasts, immune cells, adipocytes, and
vascular cells. The analysis of speciﬁc subsets of tumor cells is both
essential and challenging, since tumors contain diﬀerent cell types,
necrotic material and stroma. Diﬀerences between conventional cell
culture models and the metastatic microenvironment contribute to the
discrepancies observed in the literature, reinforcing the need for more
physiologically relevant approaches.
The implementation and standardization of in vivo techniques to
measure the levels of speciﬁc ROS and their sub-cellular distribution is
essential to dissect and conﬁrm several mechanisms by which ROS
impact cancer cell migration.
9.2.2. Role of NADPH oxidases in ﬁbrogenesis and cancer
The oxidative stress that takes place during chronic liver diseases is
due to increased ROS production, as well as to decreased activity of
antioxidant systems. It is not only a consequence of chronic liver injury,
but also a signiﬁcant contributor to excessive tissue remodeling and
ﬁbrogenesis. The main source of ROS implicated in liver ﬁbrosis is the
NOX family of proteins [523,660]. NOX proteins are also likely to act as
a persistent, endogenous source of ROS during Hepatitis C virus (HCV)-
induced pathogenesis [661]. These enzymes are expressed in diverse
cells and tissues, and their products are essential in several physiolo-
gical settings [662]. NOX1, NOX2 and NOX4 have been proposed to
play essential roles in liver ﬁbrogenesis. Transforming growth factor-
beta (TGF-β)-induced activation of hepatic stellate cells (HSC) to
myoﬁbroblasts (MFB) is mediated by NOX4-derived ROS [184]. More-
over, NOX1, activated either by TGF-β or other stimuli, promotes
myoﬁbroblast proliferation by PTEN inactivation to positively regulate
an AKT/FOXO4/p27 signaling pathway [663]. Furthermore, NOX1
activity might further contribute to the inﬂammatory process that
promotes COX-2 expression and prostaglandin synthesis in hepatocytes
[664]. Promotion of hepatocyte apoptosis is another crucial event
during ﬁbrogenesis since it triggers Kupﬀer cell and HSC activation by
secreting cytokines, chemokines and microparticles. NOX4 is necessary
to mediate apoptosis induced by TGF-β [177,184]. However, the pro-
apoptotic eﬀect of the cytokine can be attenuated when NOX1 is active
[179]. NOX2 is expressed in both endogenous liver cells and bone
marrow-derived cells, possibly acting in the process of phagocytosis of
dead hepatocytes [665]. The role of NOX in hepatocarcinogenesis is
more complex and is still a matter of study in diﬀerent laboratories.
NOX4 may play essential roles mediating TGF-β tumor suppressor
functions, in particular its eﬀects on cell death [177,528]. In this sense,
recent results indicate that silencing NOX4 in liver tumor cells increases
their proliferative and tumorigenic properties [185]. In contrast, NOX1
might control autocrine cell growth of liver tumor cells through
regulation of the EGFR pathway [179,666]. In fact, recent studies
indicate that NOX1 and NOX4 proteins have opposite prognostic eﬀects
in HCC. High NOX1 and low NOX4 expression were independent
predictors of both shorter recurrence-free survival and shorter overall
survival [667]. In view of the essential roles played by NOX4 in liver
ﬁbrosis, recent preclinical studies with a NOX4/1 inhibitor
(GKT137831) have demonstrated its eﬃciency as a potent inhibitor
of ﬁbrosis and hepatocyte apoptosis [668], thus paving the way for
future translational studies.
9.3. Neurological and psychiatric disorders
The following subsections were composed by Vincent Jaquet, Karl-
Heinz Krause, Francis Rousset, and Tamara Seredenin.
9.3.1. Redox imbalance in the pathogenesis of schizophrenia
The etiology of schizophrenia is unknown, but it is generally
thought that a combination of genetic and environmental factors
modulates the disease. A popular theory of schizophrenia involves an
imbalance between inhibitory and excitatory neurotransmission. This is
evidenced at the neuropathological level by a decrease in number of
parvalbumin-positive GABAergic interneurons (PV neurons) and altera-
tions of N-methyl-D-aspartate (NMDA) receptor subunits [669]. The
molecular mechanisms involved at onset, during psychotic episodes and
chronicity of schizophrenia are unknown, but numerous studies in both
humans and rodents point towards a contribution of neuroinﬂamma-
tion, increased reactive oxygen species (ROS) generation and dysfunc-
tion of redox signaling [670,671].
Most studies using post-mortem analysis of brains of schizophrenic
patients indicate (i) increased markers of oxidative modiﬁcations of
biomolecules, including lipids (4HNE), nucleic acids (8-hydroxydeox-
yguanosine) and proteins (carbonylation); (ii) decreased levels of
glutathione and enzymes involved in glutathione metabolism, (iii)
microgliosis and astrogliosis and increase of microglia activation
markers. Rodent models of social isolation and administration of
NMDA receptor antagonists recapitulate several neuropathological
features (loss of PV neurons and pro-oxidative phenotypes). Several
studies have proposed a key role of speciﬁc redox systems in the
pathogenesis of diseases of the central nervous system (CNS). Low
glutathione (GSH) levels are a hallmark of schizophrenia [672]. GSH is
a major regulator of intracellular redox homeostasis. Schizophrenic
patients show low levels of GSH in blood and in prefrontal cortex, and
mice deﬁcient in the Glutamate-Cysteine Ligase gene, the rate-limiting
enzyme for GSH synthesis, display behavioral and neurochemical
abnormalities commonly associated with schizophrenia [673]. Clinical
trials using the general antioxidant agent N-acetylcysteine (which can
act as a GSH precursor) show promise for treating some features of
schizophrenia. Behrens et al. observed an increase in NOX2 activity in
neurons following repeated administration of subanesthetic doses of the
NMDA receptor antagonist ketamine [674]. Importantly, ketamine
administration led to the loss of PV neurons, which could be pharma-
cologically reversed by administration of the antioxidant apocynin. The
eﬃcacy of apocynin was further conﬁrmed in another study using a
transgenic model of NMDA receptor hypofunction (Ppp1r2-Cre/fGluN1
knockout mice), which endured social isolation. However, the increase
of neuronal oxidation was not changed in NOX2-deﬁcient mice,
suggesting that NOX2 is not the main source of ROS in this model
[675]. Interestingly PGC-1α – a key regulator of mitochondrial biogen-
esis and antioxidant response – is enriched in GABAergic interneurons
[676]. In this social isolation model, PGC-1α downregulation correlates
with increased oxidation in PV interneurons, suggesting a role for
mitochondrial ROS [675]. Other studies failed to detect NOX2 in
mature neurons, but showed that NOX2 is mainly expressed in
microglia and adult neural stem cells in the CNS [677,678]. Microglia
are the CNS cell type that expresses the highest levels of proteins
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regulating redox dynamics suggesting a prominent role in the CNS
redox balance [679]. Further studies assessing microglial perturbations
in psychiatric diseases may highlight how redox genes are involved in
modulating neuronal activity by pruning synapses and regulating
neurogenesis. Altogether, there are strong arguments for redox imbal-
ance in schizophrenia; however, the sources of ROS, redox kinetics,
contribution of speciﬁc redox pathways and the cell types implicated
require further studies.
9.3.2. Role of NOX3 in inner ear pathologies
Research over the last decades has identiﬁed a major role for ROS in
hearing disorders, including overexposure to noise, ototoxic drugs (e.g.
cisplatin) and age-related hearing loss [680]. While the sources of ROS
are complex and only partially understood (e.g. mitochondria), there is
increasing evidence that activation of NOX enzymes, in particular
NOX3, plays a key role in hearing loss. High level and speciﬁc
expression in the inner ear identiﬁes NOX3 as a prime drug target to
combat hearing loss [681]. NOX3 is a multi-subunit NADPH oxidase,
functionally and structurally closely related to NOX1 and NOX2. NOX3
is active as a multiprotein complex including the membrane-bound
NOX3 and p22phox and the cytosolic subunits NOXO1 and NOXA1.
NOX3 is crucial for the formation of otoconia, small proteinaceous
carbonate crystals involved in balance [682]. Mice carrying a loss of
function mutation within the NOX3 complex – including the common
NOX1 to NOX4 subunit p22phox, or the cytosolic subunit NOXO1 – have
a vestibular phenotype similar to NOX3 mutant mice (referred to as
head-tilt mice). However, the role of NOXA1 is less clear and has mostly
been addressed in vitro. So far, the physiological relevance of NOX3
expression in the cochlea remains unclear as no hearing phenotype was
described for NOX3 loss of function mutant animals. The role of NOX3
in cisplatin induced hearing loss is actually the best documented. An
agonist eﬀect of the antineoplastic drug cisplatin on the NADPH oxidase
activity of NOX3 was observed in vitro, suggesting a potential role of
NOX3 in cochlear damage [683]. Moreover, an increased NOX3 mRNA
level has been described in the cochlea of cisplatin treated rats while
siRNA against NOX3 were able to prevent cisplatin-mediated hearing
loss in this model [684]. Together, it is now accepted that NOX3 is a
major source of ROS in the cochlea. However, the role of NOX3 may not
be limited to cisplatin-induced ototoxicity. Indeed, oxidative stress is
also a major component in other hearing pathologies such as presby-
cusis, Meniere's disease or noise-induced hearing loss. For these
conditions, further experimental conﬁrmation and a deeper conﬁrma-
tion and understanding of the role of NOX3 in hearing loss based on loss
of function mutant mice is required. Three mouse models of hearing
loss have been successfully developed in one of the laboratories of this
COST action – namely noise overexposure, cisplatin and age-related
hearing loss models and investigation of the role of NOX3 is currently
ongoing through both NOX3 and p22phox mutant mice. In parallel,
speciﬁc approaches allowing inhibition of pathological NOX3 activity
should be developed. At this point, it is diﬃcult to predict whether
classical pharmacological approaches, i.e. small molecule NOX3 in-
hibitors, or rather molecular biology-based therapies, i.e. siRNA-
mediated knock-down, will be the ultimate tools for NOX3-targeted
therapies.
9.4. Metabolic diseases and diabetes
The following subsections were composed by David Bernlohr, Bato
Korac, Irina Milisav, Tatjana Ruskovska, Shlomo Sasson, and Ana
Stancic.
9.4.1. Importance of setting superoxide/nitric oxide ratio in diabetes. Role
of L-arginine
A hallmark of the diabetic state is the increased level of O2•- in many
tissues as a result of hyperglycemia and hyperlipidemia. The high level
of O2•-, along with the reduced endogenous synthesis of NO, is
responsible for the low bioavailability of NO in diabetic conditions.
The product of O2•-/NO interaction, peroxynitrite (ONOO-) and more
potent oxidants, deriving from ONOO-, play a signiﬁcant role in the
metabolic complications that accompany diabetes including obesity
and insulin resistance. To increase NO bioavailability and/or to
simultaneously reduce the O2•- level in order to improve prediabetic
and diabetic states, supplementation with L-arginine, the substrate for
NO synthases, as well as mimics of superoxide dismutase (SOD) have
been proposed as a potential therapeutic strategy. Several beneﬁcial
eﬀects of L-arginine have been observed in diabetes. In the pancreas L-
arginine induces β-cell regeneration [685] and positively regulates
insulin synthesis and secretion [686]. The favorable eﬀects of L-arginine
in obesity and insulin resistance are well-established and could be
ascribed to the role of L-arginine in improving fat metabolism, by
increasing lipolysis and β-oxidation [687] as well as thermogenesis-
related energy expenditure [653,688,689] and insulin sensitivity [687].
It seems likely that all these eﬀects of L-arginine may be related to
improved NO bioavailability. An innovative mechanism-based ap-
proach for controlling NO and O2•- levels includes the use of redox-
modulating compounds such as selective functional mimics of SOD.
SOD mimics were initially designed to scavenge excessive O2•-, but
additional data suggest that a decreased formation of peroxynitrite and
nitr(os)ative stress and restoration of NO signaling underlie the
therapeutic beneﬁts of these agents [690–692]. These compounds show
positive eﬀects on insulin sensitivity and metabolic complications in
diabetes, in part through the recovery of mitochondrial function
[690,692,693]. Altogether, using speciﬁc potent redox-active agents
to adjust the O2•-/NO ratio seems to have potential in the treatment of
degradation by
proteolysis
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Fig. 9.3. Structure of the insulin degrading enzyme complex with amyloid-β, sites of redox regulation and major functions as a peptidase. The structure was displayed by the Visual
Molecular Dynamics program [698] from the structure PDB ID: 2G47 [699]. Yellow: the sulfur atoms of cysteines; orange: Glu111; red/gold: ATP, light green: amyloid-β fragment. We
acknowledge the help of Jure Stojan to prepare the crystal structure image.
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this widespread metabolic disorder. The fact that traditional antiox-
idants failed to show signiﬁcant beneﬁts in diabetes emphasizes the
importance of the aforementioned approaches.
9.4.2. Regulation of insulin degradation by redox-related pathways
S-Nitrosylation (the covalent addition of NO-related species to
cysteine residues of target proteins resulting in the formation of
nitrosothiols-SNOs) has recently emerged as a relevant mechanism that
activates or inhibits protein function, and alters protein conformation,
protein aggregation, protein localization and protein-protein interac-
tions [694]. S-nitrosylation can aﬀect other post-translational modiﬁca-
tions of cysteine thiol groups (like palmitoylation, which is important
for protein-membrane associations), bond formations and cellular
signal transduction pathways [695,696] Only speciﬁc cysteine residues
are S-nitrosylated, as this depends on the proximity to reactive species,
local hydrophobicity and is counterbalanced by denitrosylation en-
zymes, like the thioredoxin system and protein disulﬁde isomerases.
Insulin degrading enzyme (IDE) is a zinc metalloprotease that
degrades insulin, small peptides and amyloidogenic peptides, like
amyloid β peptides, α-synuclein, amylin, and atrial natriuretic peptide
(Fig. 9.3) [696]. IDE deﬁcit increases the abundance and signaling of
the pancreatic hormones insulin, amylin and glucagon. Increased
insulin improves glucose tolerance, increased amylin levels slow
postprandial gastric emptying. IDE deﬁcit increases levels of amylin,
α-synuclein, and Aβ monomers. These molecules impair the secretory
function and survival of pancreatic β cells and neurons through the
formation of toxic oligomers. Whereas IDE is expressed in all tissues,
the regulation of its levels is an intricate and still unclear process. Cell
stress, glucagon and free fatty acids have all been shown to participate
[696]. In cells IDE is mostly localized in the cytosol but its presence has
also been reported in peroxisomes, mitochondria, cell membranes and
extracellular ﬂuids, including cerebrospinal ﬂuid and plasma
[696,697].
IDE can be present as a monomer or multimer but it has been shown
that dimerization allosterically regulates its catalytic activity [697].
Dimerization and binding with cytoskeletal proteins and ATP enhances
the degradation of small peptides, like bradykinin. Aβ-bound IDE
structures reveal that the β-strand of amyloidogenic peptides interacts
with the door subdomain of IDE, which may explain the aﬃnity of IDE
for amyloidogenic peptides.
Exposure of IDE to S-nitrosoglutathione can result in the modiﬁca-
tion of IDE activity through S-nitrosylation of at least 5 of its 13
cysteine residues: Cys110, Cys178, Cys819, Cys789 and Cys966 [700].
S-nitrosylation of Cys819 promotes nitrosylation of Cys110, which is
near the catalytic site that is composed of two glutamates (residues 111
and 189) and a zinc ion coordinated by two histidines (residues 108 and
112). S-nitrosylation of Cys110 results in inactivation of IDE. Modiﬁca-
tion of Cys178 prevents the nitrosothiol formation on Cys110 and
buﬀers the enzyme inhibition. S-nitrosylations at Cys789 and Cys966
induce a conformational change that triggers the aggregation of IDE
and its inhibition. S-nitrosylation of Cys178 protects all of the above
mentioned cysteine residues from nitrosylation. The oxidative modiﬁ-
cations by H2O2 resulted in the modiﬁcations of the same residues with
equal eﬀects on IDE activity. Although these results are from in vitro
studies, IDE was exposed to 10–100 µM S-nitrosoglutathione or H2O2,
which is in the concentration range of ROS/RNS released under
pathophysiological conditions [700]. These modiﬁcations were tested
for inhibition of Aβ hydrolysis. It has been proposed that the cysteines
of IDE act as sensors of environmental ROS/RNS levels through subtle
alterations of the protein structure and that IDE function is modulated
by the levels of oxidative/nitrosative stress. It is likely that the
oxidation of cysteine 178 may result in the protection of the active
site under moderate amounts of ROS, while severe oxidative stress
inhibits the enzyme. The decreased activity of IDE through S-nitrosyla-
tion could also reduce the degradation of both insulin and Aβ and
contribute to pathological disease conditions in type 2 diabetes and AD.
This is supported by ﬁndings demonstrating an altered redox state of
hippocampal and cortical neurons in both diseases. Indeed, increased
levels of glucose result in a signiﬁcant rise in neuronal reactive nitrogen
species similar to the eﬀects of oligomeric Aβ peptides. The high
glucose and Aβ oligomers were shown to increase neuronal Ca2+ and
NO levels in cortico-hippocampal brain slices and in cortical cultures to
the •NO levels that could potentially promote S-nitrosylation of speciﬁc
protein thiols in IDE resulting in a reduction or inhibition of its activity
[701]. Therefore, increased oxidative/nitrosative stress can contribute
to increased Aβ levels, an important pathologic hallmark of AD through
the S-nitrosylation of IDE. Although IDE is the best characterized
enzyme that degrades insulin, reduction in IDE activity in various
experimental models does not consistently increase insulin concentra-
tions. Recently the study with the IDE inhibitor that binds to its exosite
resulted in increased plasma levels of amylin, but not of insulin [697].
Other regulatory mechanisms and/or IDE substrates may also contri-
bute to glucose homeostasis, development of insulin resistance and
diabetes mellitus type 2.
9.4.3. Lipohormesis and lipotoxicity in pancreatic beta cells
Monounsaturated and polyunsaturated fatty acids (MUFA and
PUFA, respectively) promote adaptive responses and enhance cell
tolerance to lipid overload through induction of cellular defense
mechanisms (lipohormesis) that protect cells against lipotoxic eﬀects.
Recent lipidomic analysis performed on pancreatic beta cells that were
exposed to increasing glucose and palmitic levels revealed extensive
remodeling of fatty acids in membrane phospholipids. Particularly, the
abundance of PUFA was decreased whereas the content of MUFA
increased. These changes were accompanied by non-enzymatic perox-
idation of the released PUFA and their transformation to bioactive 4-
hydroxyalkenals. This process in beta cells leads to the generation of 4-
hydroxynonenal, which activates PPARδ [702–704]. The latter aug-
ments the secretion of insulin, which promotes hepatic and peripheral
mechanisms that enhance glucose disposal and the incorporation of free
fatty acids into triglycerides and their storage in adipose tissues.
Excessive and prolonged nutrient overload often interferes with normal
cell functions and dysregulates hormonal-mediated inter- and intra-
organ metabolic communication networks. In beta cells, hyperglycemia
and hyperlipidemia synergistically compromise insulin synthesis, glu-
cose-stimulated insulin secretion and cell survival. The mechanisms
underlying these derangements, which characterize the etiology of type
2 diabetes and other manifestations of the metabolic syndrome, have
been thoroughly investigated [705]. A central hormetic mechanism is
redox-mediated release of KEAP1 from the KEAP1/NRF2 complex,
allowing nuclear translocation of NRF2 and its interaction with
Antioxidant Response Elements (ARE) in promoters of target genes
encoding antioxidant enzymes, ultimately resulting in their activated
transcription. Beyond the modiﬁcation of dietary habits and life style in
addition to treatment of the underlying condition, it would be
theoretically sound to propose pharmacological approaches with potent
oral antioxidants, which are eﬃciently absorbed, reach the circulation
and aﬀect cells, such as beta cells, and protect them against direct and
indirect eﬀects of free radicals and lipid peroxidation. However, the
prevailing knowledge favors the notion that these oral antioxidants are
only eﬀective when triggering intracellular physiological signals related
to endogenous protective pathways such as the aforementioned KEAP1/
NRF2-ARE axis.
9.4.4. Redox regulation of white adipose tissue remodeling
The white adipose organ features high metabolic activity and
endocrine function and regulates whole-body energy homeostasis
through the secretion of macronutrients (fatty acids) and adipokines
(e.g., adiponectin, resistin). White adipose tissue (WAT) can be
anatomically divided into visceral and subcutaneous. It is found
distributed broadly in the body and is subject to regulatory cues
throughout development and aging. Evolutionarily developed for
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eﬀective fat storage in the short periods of food access, as well as for
immune surveillance, dysfunctional obese WAT underlies metabolic
disorders in the modern era because food is readily and continuously
available [706].
In the fed state, insulin mediates the uptake of glucose by adipocytes
that is metabolized via the combined actions of glycolysis, TCA cycle
and fatty acid biosynthesis to produce precursors utilized for triglycer-
ide biosynthesis. Through these pathways, high nutrient oxidation
decreases the adipocyte NAD+/NADH ratio that attenuates the activity
of all NAD+ dependent enzymes, including the sirtuins. Sirtuins
deacetylate/deacylate both histone and non-histone target proteins
regulating their activity and cellular function. SIRT1 is the best studied
of all seven mammalian sirtuins. It provides a molecular link between
the cellular metabolic status and the adaptive transcriptional response.
In the WAT SIRT1 acts through repression of transcriptional activity of
the nuclear receptor PPARγ, the master regulator of both lipogenesis
and adipogenesis. Calorie restriction increases the adipocyte SIRT1
activity and promotes lipid mobilization, as well as insulin sensitivity
and glucose tolerance [707]. Therefore, the adipocyte NAD+/NADH
ratio, acts as an important indicator of cellular and whole body energy
status, and emerges as one of the key redox regulators of WAT function.
SIRT1 also has an important role in the browning of the WAT, a
metabolically beneﬁcial WAT remodeling that promotes energy expen-
diture to combat obesity and diabetes, which might serve as a novel
strategy to improve metabolic health. A very recent study reveals that
capsaicin (a bioactive compound of red pepper) has the potential to
induce increased expression and phosphorylation of SIRT1 in the
subcutaneous WAT of mice fed a high fat diet. Activated SIRT1
deacetylates both PPARγ and positive regulatory domain containing
16 (PRDM-16), promotes WAT browning and prevents weight gain. The
eﬀect of capsaicin on SIRT1 is mediated by the transient receptor
potential cation channel subfamily V 1 (TRPV1), Ca++/calmodulin
activated protein kinase II and adenosine monophosphate activated
kinase (AMPK). In parallel, an increased expression of mitochondrial
uncoupling protein 1 (UCP1) was found in the WAT of mice treated
with capsaicin, conﬁrming the key role of UCP1 in the browning of
WAT [708].
Evolutionarily designed for eﬀective fat storage (and release), the
WAT has developed an extraordinary ability for expansion, thus
preventing the metabolically detrimental ectopic fat accumulation. As
a consequence of nutrient overload, the existing adipocytes enlarge and
accumulate triglycerides (a process known as lipogenesis), and/or new
adipocytes diﬀerentiate from the multipotent mesenchymal stem cells
(MSC) to form mature adipocytes (adipogenesis). Adipogenesis, also
known as adipose tissue hyperplasia, leads to a metabolically healthy
obese WAT phenotype that is characterized by increased secretion of
adiponectin and insulin sensitivity, as well as decreased immune cell
recruitment, hypoxia and ﬁbrosis. Among the many factors that initiate
and regulate adipogenesis, the contribution of ROS has been recognized
in the face of NOX4-generated H2O2. Importantly, ROS depletion with
N-acetyl-L-cysteine results in abrogation of in vitro adipogenesis [709].
Whereas adipocytes have an extraordinary capacity for fat accumula-
tion (lipogenesis), their growth above the critical volume (hypertrophy)
leads to necrotic death and pro-inﬂammatory remodeling linked to
macrophage inﬁltration and their phenotypic change from M2 (inﬂam-
mation resolving) to M1 (pro-inﬂammatory), appearance of crown-like
structures, increased angiogenesis and extracellular matrix production,
hypoxia, unbalanced production of pro- and anti-inﬂammatory cyto-
kines, and insulin resistance. Dysfunctional obese WAT exhibits sig-
niﬁcantly increased protein carbonylation, indicating the central role of
excess ROS and oxidative stress in obesity induced insulin resistance
[710].
In contrast to the white adipocytes and their function for fat storage,
the adipocytes from the brown adipose tissue (BAT) are responsible for
energy dissipation in response to cold, exercise or excess calories. The
key player in energy dissipation is the inner mitochondrial membrane
protein UCP1 that uncouples the electron transport chain (ETC) from
ATP biosynthesis, thus dissipating the proton motive force, generating
heat, and increasing the rate of substrate oxidation. The recent
discovery of metabolically active BAT in human adults has attracted
much interest as a potential target for the development of anti-obesity
drugs. In addition to the classical white and brown adipocyte pheno-
type, beige adipocytes (also known as “brite” – short for brown in
white, or “brown-like”) have been identiﬁed as an inducible form of
thermogenic adipocytes. When induced they exhibit high UCP1 expres-
sion and energy expenditure. Beige adipocytes express unique genetic
signatures that distinguish them from both white and brown adipo-
cytes. In rodents, the brite adipocytes are most abundant in the
subcutaneous WAT and are responsible for its browning [711].
Intriguingly, a recent study reveals that UCP1-mediated thermo-
genesis depends on mitochondrial ROS production. It has been shown
in vivo that acute activation of BAT thermogenesis is associated with a
substantial increase in mitochondrial superoxide, lipid hydroperoxides
and hydrogen peroxide. Pharmacological depletion of mitochondrial
ROS inhibits the UCP1 dependent increase in whole-body energy
expenditure, conﬁrming the essential role of ROS in the regulation of
adipocyte function and metabolism. At the same time, a substantial
oxidation and depletion of the cellular and mitochondrial glutathione
pool has been demonstrated, as well as an increased global protein
sulfenylation, and sulfenylation of UCP1 Cys253 as a redox sensitive
site related to thermogenesis [712]. The possible dependence of WAT
UCP1 activity on the cellular pro-oxidant state was studied in Nrf2-/-
mice. The NRF2 transcription factor is a critical regulator of genes
involved in detoxiﬁcation and antioxidant defense. Therefore, Nrf2-/-
mice are more susceptible to toxicant- and oxidative stress-induced
diseases, as well as autoimmune diseases and cancer. Paradoxically,
they are also resistant to high fat diet-induced obesity, exhibit improved
metabolic proﬁles, and demonstrate increased energy expenditure in
comparison to the wild type mice fed a high fat diet. Such mice also
exhibit a concomitant decrease in the GSH/GSSG ratio and up-regula-
tion of UCP1 and other BAT markers in intra-abdominal fat pads [713].
Overall, balanced ROS levels are required for proper WAT function, and
both very high and very low levels impede its function and inﬂuence
whole-body energy homeostasis [714]. Therapeutic control of adipose
ROS therefore represents an attractive axis to regulate not only
adiposity, but also metabolic healthfulness.
9.5. Cardiovascular pathologies
The following subsections were composed by Andreas Daiber,
Vaclav Hampl, Jan Herget, Jaap Joles, Thomas Münzel, Isabel
Nguyen, and Olga Vajnerova.
9.5.1. Drug-induced oxidative stress – the case of nitroglycerin
Organic nitrate therapy is still a mainstay in the treatment of
patients with acute and chronic congestive heart failure, stable
coronary artery disease or acute coronary syndrome [715]. However,
despite the fact that members of this drug class have been clinically
used for more than a century, chronic organic nitrate therapy (espe-
cially in the case of nitroglycerin) is associated with a number of serious
side eﬀects, including induction of oxidative stress [716] and endothe-
lial and autonomic dysfunction [717], with incomplete understanding
of the underlying pathomechanisms. The induction of reactive oxygen
and nitrogen species formation by chronic nitroglycerin therapy was
shown to largely depend on mitochondrial oxidative metabolism since
partial deﬁciency in MnSOD aggravated nitrate-induced oxidative stress
and also the degree of tolerance to the vasodilator activity of
nitroglycerin [718]. This was later shown to rely on complex I
dysfunction in response to nitroglycerin therapy [719]. The initial
formation of mitochondrial reactive oxygen and nitrogen species can
also activate secondary sources of oxidants in a crosstalk fashion
involving mitochondrial KATP channels and the permeability transition
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pore [61]. This leads to the activation of speciﬁc enzymatic “redox
switches” in NOXs and eNOS, as recently reviewed [60]. The formation
of mitochondrial reactive oxygen and nitrogen species may lead to
endothelial dysfunction by the activation of the vascular and phagocy-
tic NOXs through protein kinase C [720] as well as to the uncoupling of
eNOS by increased S-glutathionylation, inhibitory phosphorylation and
oxidative depletion of the eNOS cofactor tetrahydrobiopterin [478].
eNOS uncoupling and oxidative desensitization of the soluble guanylyl
cyclase are probably the major enzymatic mechanisms contributing to
endothelial dysfunction observed under nitroglycerin therapy, the latter
also accounting for impaired nitroglycerin-dependent vasodilation
(nitrate tolerance), all of them corrected by co-administration of an
activator of soluble guanylyl cyclase [721]. Nitroglycerin-induced
endothelial dysfunction but also nitrate tolerance may also rely on
direct oxidative break-down of nitric oxide by superoxide leading to the
formation of peroxynitrite and signiﬁcantly increased levels of 3-
nitrotyrosine-positive proteins, an eﬀect prevented by the peroxynitrite
scavenger hydralazine [722]. Finally, the bioactivation of nitroglycerin
largely depends on enzymatic conversion by mitochondrial aldehyde
dehydrogenase (ALDH-2) [723], which is a highly redox-regulated
enzyme and inactivated by oxidative stress [716]. Hence, nitroglycerin-
induced reactive oxygen and nitrogen species formation will ultimately
lead to inactivation of the thiol-based enzymatic activity of ALDH-2
contributing to impaired nitroglycerin bioactivation, loss of its vasodi-
lator activity and nitrate tolerance [724]. There is also clinical evidence
for nitroglycerin-induced vascular oxidative stress [725] and oxidative
DNA damage in patients under chronic nitrate therapy [726]. Very
recently, we were able to demonstrate persistent oxidative modiﬁca-
tions of DNA and proteins in nitroglycerin-treated rats, even after a 3.5-
day nitrate-free interval, which was enough to normalize nitroglycerin
responsiveness but not endothelial dysfunction. The latter could be
related to endothelial cell death by pro-apoptotic stimuli such as 8-
oxoguanine lesions in DNA and 3-nitrotyrosine-positive proteins [727].
Other organic nitrates show similar side eﬀects, such as the activation
of NADPH oxidases, increased vascular oxidative stress and severe
endothelial dysfunction by chronic isosorbide-5-mononitrate therapy,
which was associated with augmented endothelin-1 signaling and eNOS
uncoupling [728]. The only exception among the clinically used
organic nitrates is pentaerythritol tetranitrate [715,716], which over-
comes the typical side eﬀects of nitrovasodilators by mechanisms that
are largely based on NRF2-dependent activation of antioxidant enzymes
such as heme oxygenase-1 and superoxide dismutase [729,730] as well
as beneﬁcial eﬀects on other transcription factor and epigenetic path-
ways [731,732].
In conclusion, the side eﬀects of chronic therapy with organic
nitrates, especially with nitroglycerin, are largely based on oxidative
stress and adverse redox regulation. Antioxidant therapy (e.g. by ACE
inhibitors or statins) represents a pharmacological tool to overcome
these side eﬀects [715–717]. These and other combination therapies
with speciﬁc antioxidants, inhibitors of relevant sources of oxidants
(e.g. inhibitors of NADPH oxidase isoforms) and drugs for repair of
oxidative damage (e.g. activators of soluble guanylyl cyclase) need to
be explored in the future to increase the therapeutic window of organic
nitrates, the oldest drug class in clinical use today.
9.5.2. Regulation of renal hemodynamics in chronic kidney disease
Hypertension and an increased renal vascular resistance (RVR) are
inherent to chronic kidney disease (CKD). There is accumulating
evidence that oxidative stress is involved in its pathogenesis [733].
Experimental induction of ROS (superoxide and H2O2) generation in
the renal medulla promotes hypertension [734]. Downregulation of the
antioxidant enzymes superoxide dismutase (SOD), catalase and glu-
tathione peroxidase in the kidney were found in experimental CKD
[735]. Hence, it has been suggested that antioxidant interventions may
have beneﬁcial eﬀects on renal hemodynamics in CKD.
Tempol, a SOD-mimetic, has been shown to reduce oxidative injury
in cells and animal models. It improved oxidative stress and lowered
arterial pressure and RVR in various models of hypertension. However
few studies have focused on the eﬀects of Tempol in CKD. Rats
undergoing 5/6 renal mass reduction to induce CKD showed an
elevated arterial pressure and nitrotyrosine abundance, while urinary
NOx excretion was depressed [736]. The administration of Tempol for
one week ameliorated hypertension, reduced the nitrotyrosine abun-
dance and increased NOx excretion. In spontaneously hypertensive rats
(SHR), two weeks of Tempol administration decreased the elevated
mean arterial pressure (MAP) and renal excretion of 8-iso-prostaglandin
F2α and increased the glomerular ﬁltration rate (GFR) [737], while it
had no signiﬁcant eﬀect on these variables in the normotensive Wistar-
Kyoto (WKY) control rats. These ﬁndings suggest that oxygen radicals
may be involved in the long-term maintenance of hypertension in SHR.
Another study found an elevated RVR in SHR compared to WKY rats
[738]. When SHR were treated with Tempol the baseline RVR was no
longer signiﬁcantly diﬀerent from the WKY rats. The additional use of
the NO-synthase inhibitor L-NAME did not inﬂuence the eﬀects of
Tempol on the RVR, suggesting that it has a renal vasodilator eﬀect and
that the elevated RVR is unlikely due to ROS-induced quenching of NO.
The two-kidney one-clip model showed an elevated MAP and 8-iso-
prostaglandin F2α excretion, which was signiﬁcantly reduced by the
acute administration of Tempol [739]. In the clipped kidney, adding
Tempol increased GFR and eﬀective renal plasma ﬂow and reduced
RVR compared to their controls. The latter was also found in the non-
clipped kidney. This indicates that Tempol is able to have a vasodilating
eﬀect via dismutation of the superoxide resulting from angiotensin
signaling that is independent of the local perfusion pressure. This
supports the role of superoxide during the early stage of renovascular
hypertension. In another study the acute eﬀects of the SOD-mimetic on
renal hemodynamics were investigated in rats with long-established
CKD induced by bilateral 2/3 nephrectomy [740]. Tempol was not able
to reduce the increased MAP in the CKD rats, but did lower MAP in age-
matched controls with normal kidneys, suggesting that the maintenance
of hypertension in this CKD model does not appear to depend on
superoxide. As expected, RVR was higher in the CKD rats compared to
controls, but the administration of Tempol did not have any signiﬁcant
eﬀect on RVR. This proposes that renal resistance vessels are not
sensitive to the renal vasoconstrictor eﬀects of ROS in this model.
These data suggest that although antioxidant therapy can reduce the
elevated arterial pressure in the early stages of experimental CKD, it
does not appear to be eﬀective once CKD is established. The same
concept could be applied to the eﬀects of Tempol on the RVR. In early
stages of experimental CKD, prior to the development of renal ﬁbrosis,
Tempol can have a vasodilating eﬀect independent of the local
perfusion pressure. However, when structural damage occurs to the
vascular beds and in their direct proximity, such as in established CKD,
the vasodilating eﬀects of Tempol are lost. This suggests that ROS may
not be a driving force in the maintenance of disturbed renal hemody-
namics in established CKD.
9.5.3. Vascular eﬀects related to chronic hypoxia of lungs and placenta
Oxidative tissue injury participates in the pathogenesis of chronic
hypoxic pulmonary hypertension (HPH) [741,742]. HPH is caused by
persistent lung hypoxia. It results in an increase in pulmonary vascular
resistance to blood ﬂow as a consequence of the sustained increase in
the tone of the pulmonary vascular smooth muscle, decreased com-
pliance of pulmonary blood vessels due to ﬁbrosis and muscularization
of prealveolar pulmonary arterioles. The severity of HPH is dose
dependent. After stabilization it does not progress further. It is fully
reversible after several weeks in normoxia. HPH typically appears in
residents at high altitudes. It is involved in the pathogenesis of
pulmonary hypertension in patients with various lung and heart
diseases with alveolar hypoxia.
Two basic mechanisms increase pulmonary vascular resistance in
HPH: structural remodeling of the peripheral pulmonary vessel walls
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and vasoconstriction. Vasoconstriction plays a pathogenetic role at the
onset of HPH and it is related to hypoxia-induced oxidant vascular
stress. Superoxide, hydroxyperoxide and peroxynitrite are important
vasoactive factors released at the beginning of exposure to chronic
hypoxia [743]. Oxidant tissue injury to the pulmonary vascular wall
induced by hypoxia is the primary mechanism that triggers vascular
remodeling in HPH. Antioxidant treatment at the beginning of hypoxia
is more eﬀective in reducing HPH than antioxidant therapy applied in
later stages of developed pulmonary hypertension.
For the fetus, the placenta plays a role similar to that of the
pulmonary circulation in postnatal life - blood oxygenation and CO2
removal. For this reason, we speculated that the regulatory and
pathophysiological mechanisms of the fetoplacental and pulmonary
vessels were similar. Indeed, we showed that both acute and chronic
hypoxia elevate vascular resistance in the fetoplacental vascular bed,
which is similar to pulmonary and in contrast to systemic vascular beds
[744]. We have also demonstrated that a well-known state of high
oxidative stress, maternal diabetes, causes an increase similar to
chronic hypoxia in fetoplacental vascular resistance (preliminary
observations). As is the case in the pulmonary circulation, oxidative
stress also appears to be a major mechanism of vascular resistance
elevation in the fetoplacental circulation.
9.6. Conclusions
Redox signaling and oxidative stress constitute fundamental reg-
ulatory mechanisms not only in highly prevalent pathologies but also in
less explored areas of biomedicine such as those related to ﬁbrosis, cell
migration and proliferation, hearing loss, schizophrenic disorders,
insulin resistance, drug metabolism, lung hypoxia or renal hemody-
namics. In some cases, the underlying molecular mechanisms of this
redox sensitivity have been deciphered, in others we are just beginning
to open the door. It is clear that the pervading nature of ROS reactivity
will continue to oﬀer surprises-and explanations- of complex patholo-
gies such as the ones covered in this section.
10. Toxin and bacteria-mediated ROS formation and antioxidant
strategies in ROS-related diseases
Thomas Kietzmann (E-mail: Thomas. Kietzmann@oulu.ﬁ) and
Kateryna Kubaichuk (E-mail: kateryna.kubaichuk@oulu.ﬁ).
10.1. Introduction
Research during the last decade has shown that ROS are important
regulators of physiological and pathophysiological processes and not
only simply detrimental due to their chemical nature or by causing
oxidative stress. This is further supported by ﬁndings indicating that
redox active compounds are essential components of living organisms.
Thereby, recent advances in genomics and proteomics have led to the
identiﬁcation of a “redoxome” consisting of hundreds of proteins
involved in redox systems. It comprises enzymes generating RONS such
as NADPH oxidases and nitric oxide synthases, redox relays such as
peroxiredoxins, thioredoxins and glutaredoxins, enzymes degrading
ROS such as superoxide dismutase or catalase, as well as numerous
proteins dependent on redox modiﬁcations, which are involved in the
defense against oxidant, inﬂammatory and/or proteotoxic stress [745].
Although a number of substances, factors, products of metabolism,
and nutrients are important for normal cell biology and redox signaling
of all species, toxins are rather important for causing deleterious eﬀects.
Since toxins act universally on almost all species, it is conceivable that
their action may, at least in part, involve ROS or oxidative stress and
that antioxidant defense mechanisms could help to avoid the deleter-
ious eﬀects of toxins.
10.2. A toxin and its action via ROS
João G. Costa and Nuno G. Oliveira, discuss how the well-known
nephrotoxic food contaminant and animal carcinogen, the mycotoxin
ochratoxin A (OTA), appears to act at least partially via ROS and
induction of oxidative stress, although diﬀerent mechanisms of its
toxicity have also been pointed out. Furthermore, the OTA actions can
be overcome by antioxidant based approaches [746–748] (Fig. 10.1).
OTA increased ROS appear to precede the loss of cell viability
particularly in renal cells, indicating that these ROS may contribute to
OTA cytotoxicity rather than being a consequence of cell death
processes [746,749]. Concomitant with ROS induction, OTA also
increased lipid peroxidation, depleted antioxidant enzymes
[746–751], induced oxidative stress-related proteins, and caused DNA
damage. The latter has also been associated with oxidative DNA
damage, as assessed by the formation of 8-oxoguanine or using
modiﬁed versions of the comet assay (e.g. with FPG) [749,750].
Mechanistically, recent studies propose a pathway in which electro-
philic species that directly bind to DNA bases are generated during OTA
metabolism [752]. Further, OTA was found to be able to cause
nitrosative stress due to stimulation of iNOS-mediated NO formation,
which may contribute to the formation of peroxynitrite, nitrogen
dioxide, and hydroxyl radicals [753]. Several in vitro and in vivo
studies assessed the impact of diﬀerent antioxidants on the OTA-
mediated toxicity and it was found that, in general, antioxidants
Fig. 10.1. Lines of evidence supporting the induction of oxidative stress by Ochratoxin A (OTA). Alterations in biomarkers related with oxidative stress and several antioxidant-based
approaches that provide protection against a plethora of OTA-induced toxic eﬀects are indicated. Abbreviations: SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; GST,
glutathione S-transferase; GPx, glutathione peroxidase; GR, Glutathione reductase; AP-1, activator protein 1; NRF2, nuclear factor E2-related factor 2; PRDX4, peroxiredoxin-4; VDAC1,
voltage-dependent anion channel 1; HO-1, heme-oxygenase 1; DDAH, dimethylarginine dimethylaminohydrolase; TBARS, thiobarbituric acid reactive substances; MDA, malondialde-
hyde; 4-HNE, 4-hydroxynonenal; FPG, formamidopyrimidine DNA glycosylase.
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exerted protective eﬀects [746,747,750,751,754].
10.3. Are ROS usage and antioxidant reactions conserved?
In order to avoid the life threatening eﬀects of toxins and toxin-
induced oxidative stress, both exogenously taken up antioxidants and
trace molecules as well as endogenous defense mechanisms contribut-
ing to redox regulation with which nature has equipped not only
eukaryotes but also prokaryotes and plants, are important to maintain
redox status. These systems appear to be quite conserved and, together
with the ROS generator sites, they largely contribute to the tightly
controlled redox balance.
For example Brandán Pedre and Joris Messens discuss that,
Actinomycetes, a genus of gram-positive Actinobacteria, possess a low
molecular weight thiol molecule, mycothiol (MSH), which serves as a
glutathione surrogate [755,756], and they express a mycothiol perox-
idase (Mpx) - a glutathione peroxidase-like enzyme. Both, MSH and
Mpx are involved in reversibly protecting cysteines from oxidation
[130] and controlling the level of ROS [131]. Further, MSH in concert
with mycoredoxin-1 [757] and the thioredoxin reduction pathways are
alternative routes for the reduction of the diﬀerent oxidative forms of
Mpx. Since thioredoxin can de-mycothiolate Mpx, this indicates the
interrelationship between the MSH/mycoredoxin-1 and thioredoxin
reduction pathways. Interestingly, this is also seen in the pathogenic
Actinobacteria family Corynebacterium diphtheriae (Cd), where MSH and
thioredoxin can deliver electrons to the methionine sulfoxide reductase
A (Cd-MsrA) which stereospeciﬁcally reduces Met-S-SO [132], thus
controlling sulfur oxidation repair. Thereby, the Cd-MsrA uses a unique
intramolecular mycothiol redox relay involving a MSH/mycoredoxin-1
monothiol mechanism, which keeps several MSH-dependent enzymes
on track [130–132,757,758]. Interestingly, Mycobacterium tuberculosis
1-Cys peroxiredoxin AhpE is reduced by a mycoredoxin-1 dithiol
mechanism in addition to the mycothiol/mycoredoxin-1 monothiol
mechanism, again indicating that mycothiol-dependent enzymes are
promiscuous in the pathway that they use for receiving electrons from
NADPH [758]. Overall, it appears that a number of conserved
mechanisms are in place to defend against oxidative stress.
Although a variety of microorganisms have well established defense
systems against oxidative stress, the gain of compartmentalization in
higher organisms created the need to develop an integrated system
allowing redox regulation and protection at the same time in each cell
compartment. As indicated by Afroditi Chatzi and Kostas Tokatlidis, an
excellent example of such cross-talk is the compartment‐speciﬁc import
and folding of proteins in the mitochondrial intermembrane space
(IMS) in Saccharomyces cerevisiae where potential antioxidant proteins
are involved.
The protein import and folding in the IMS relies on the Mia40
pathway [759–761] where Mia40 and Erv1 are key components.
Importantly these mechanisms are not restricted to yeast since Mia40
and Erv1 have homologs in almost all organisms including humans. In
that system Mia40 functions as a key import receptor in the IMS where
it exerts a chaperone-like role recognizing a speciﬁc hydrophobic signal
of Cys-rich IMS proteins and transfers a disulﬁde to the substrate [762].
Erv1, on the other hand, is a FAD-linked oxidoreductase that recycles
Mia40 to its oxidized state [763]. It was found that the Mia40 pathway
is inﬂuenced by hydrogen peroxide and that a fraction of Hyr1/Gpx3, a
thiol-peroxidase known to act as a redox-transducer in H2O2 signaling
via YAP1 in the cytosol, is localized in the IMS. Additional proteins
involved in the antioxidant response, like thioredoxin 1 and thioredoxin
reductase1, are also part of the IMS proteome in S. cerevisiae [764].
Although these data indicate that the Mia40 oxidative folding in the
IMS [765] is associated with antioxidant proteins, its putative links to
redox homeostasis and redox signaling are still elusive. However, it is
evident that a cross-talk between redox regulation and the oxidative
stress response and the IMS oxidative folding pathway exists in higher
eukaryotes.
10.4. Involvement of ROS and antioxidant mechanisms in human diseases
The existence of rather eﬃcient, and conserved systems involved in
both the defense and maintenance of cell, tissue, or organism function-
ality, indicates that an imbalance in ROS homeostasis is connected with
the pathogenesis of frequently occurring diseases.
Fig. 10.2. SODm in cancer therapy. A. Model proposed to describe the opposite eﬀects of intracellular H2O2 concentration on the proliferation of cancer and normal cells. B. SODm
generate additional intracellular H2O2, which leads to diﬀerential eﬀects in cancer and normal cells. C. Potential applications of SODm in cancer treatment. SODm may protect normal
tissues from the adverse side eﬀects of radio and chemotherapy and, conversely, increase the sensitivity of malignant cells to standard radio and chemotherapeutic agents. SODm have
also been used as mechanistic tools in the ﬁeld of redox biology to evaluate the impact of ROS in cancer therapy and in carcinogenesis. (Modiﬁed from [768] and book chapter Fernandes
et al. Springer International Publishing (2016), Switzerland. DOI 10.1007/978-3-319–30705-3_18).
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10.4.1. ROS and malignant disease
One example where ROS are considered to be involved is cancer.
However, ROS appear to have a dual role; they are often implicated in
being the cause of a carcinogenic process, but since the majority of
conventional therapies rely also on the increase of ROS they seem to be
also of therapeutical beneﬁt causing cancer cell death [766,767].
The intracellular H2O2 concentration is an important factor for the
diﬀerential proliferation often observed when comparing cancer and
non-cancer cells (Fig. 10.2A) [768]. In general, normal cells do not
show high levels of ROS. In contrast, cancer cells with a reduced
antioxidant defense and higher instability have usually a higher ROS
concentration. This fact can be at least partially be explained by the
occurrence of mitochondrial dysfunction, which is associated with an
imbalance of the antioxidant defense and an increased production of
ROS.
Among the ﬁrst defenses against ROS is the dismutation of super-
oxide radicals to hydrogen peroxide and molecular oxygen by SODs; in
mitochondria this task is carried out by MnSOD/SOD2. Since mito-
chondrial dysfunction is a hallmark of cancer, carcinogenesis may be
expected to be associated with a dysregulation in the expression of
MnSOD. Indeed, numerous reports show that reduced MnSOD con-
tributes to carcinogenesis in many solid tumors [769]. Kateryna
Kubaichuk and Thomas Kietzmann discuss the concept that loss of
MnSOD leads to a transformed cell type, which was recently supported
by ﬁndings from cells deﬁcient in MnSOD and in hepatocyte-speciﬁc
MnSOD knockout mice [770]. The loss of MnSOD in cells caused
increased proliferation, reduced apoptosis, decreased contact inhibition
and cell adhesion as well as enhanced migration. This was in line with
the in vivo ﬁndings showing that hepatocyte-speciﬁc loss of MnSOD in
mice caused liver failure, and initiation of malignant transformation
and tumor formation [770].
Mechanistically, these ﬁndings could be linked to two pathways: the
Wnt/β-catenin pathway and the hypoxia signaling pathway. The Wnt/
β-catenin pathway is one of the most important pathways associated
with cancer, in particular liver cancer. The Wnt pathway components β-
catenin and APC were decreased in MnSOD-deﬁcient HepG2 hepatoma
cells as well as in MnSOD deﬁcient mouse livers [770]. This is in line
with ﬁndings from hepatocyte-speciﬁc β-catenin knockout mice, which
displayed an increased susceptibility to diethylnitrosamine-induced
carcinogenesis [771]. Indeed, induction of HIF-1α, a major regulator
of the hypoxia response pathway, was disrupted both in vitro and in
vivo due to the loss of MnSOD [770]. Although those data do not
unravel all mechanistic aspects of the carcinogenic process in response
to MnSOD deﬁciency, they indicate an intricate interplay between HIF-
1α and β–catenin.
Moreover, MnSOD can be regulated by the transcription factor
Nuclear factor (erythroid-derived 2)-like 2 (NRF2). As indicated by
Natalia Robledinos-Antón and Antonio Cuadrado, NRF2 is of utmost
importance and regulates the expression of about 250 genes with
homeostatic functions such as those involved in NADPH, glutathione
and thioredoxin metabolism, phase II detoxiﬁcation reactions, inﬂam-
mation and proteostasis [772,773].
Considering the fact that cancer development is characterized by an
altered hypoxia response and malfunctioning of MnSOD, which both
can be aﬀected by NRF2, superoxide dismutase mimics (SODm), as well
as NRF2 inhibitors, can be considered to be useful in cancer treatment
and in other diseases associated with enhanced ROS including cardio-
vascular, inﬂammatory, and neurodegenerative disorders [774].
Ana S. Fernandes and Nuno G. Oliveira point out that SODm are
synthetic compounds with low molecular weight that mimic the
Direct determinants:
• Nature of RONS
• Cellular site / organ system
• Time: early vs. late, acute 
vs. chronic
RONS sources:
• Mitochondria
• NADPH oxidases
• Xanthine oxidase
• Uncoupled eNOS
Indirect determinants:
• Interacon with other signaling pathways (e.g. H2S, 
phosphorylaon, Ca2+)
• Acvaon of intrinsic anoxidant defense (e.g. Nrf2, HIF1)
• Acvaon of inﬂammatory signaling pathways (e.g. NFκB)
• Changes of epigenec proﬁles and long-term reprogramming
Eﬀects:
• Beneﬁcial/essenal: cellular redox signaling, (ischemic) 
precondioning, anpathogenic defense
• Detrimental/harmful: oxidave stress, vicious circles, cellular 
damage, cell death
Fig. 11.1. Who's the bad guy – or which biological source of RONS formation is the most detrimental one? Likely candidates are mitochondrial RONS formation (mitochondrial
superoxide/hydrogen peroxide), NADPH oxidases (Nox1, Nox2, Nox4, in humans also Nox3), uncoupled eNOS (uc-eNOS) or xanthine oxidase (XO). The most challenging task for the
future is the discrimination between beneﬁcial and detrimental eﬀects of RONS formation and signaling, which is largely determined by the nature of the involved RONS, as well as the
time and place they are formed. This concept was put forward previously [18,21,28,32].
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functional properties of SOD enzymes [774,775]. Most SODm are
considered polyfunctional antioxidants, rather than speciﬁc O2•- sca-
vengers [775–777]. Along with the disproportionation of O2•-, SODm
may react with other reactive species (RS), including peroxynitrite,
CO3•-, H2O2, •NO2 radicals, peroxyl radicals, and alkoxyl radicals
[775,776]. Although many compounds with SOD-like activity with
distinct chemical structures have been reported, the search for SOD
mimics has been mostly focused on complexes that contain a redox-
active metal center and rich coordination chemistry [776]. This is the
case of Mn(III) porphyrins (MnPs), Mn(II) complexes with cyclic
polyamines (aza crown ethers), Mn(III) salen derivatives, and diﬀerent
types of iron and copper complexes [775,776,778,779]. Some non-
metallic compounds, such as nitroxides and fullerenes have also been
explored as SODm [776,779].
The rationale underling the use of SODm as prospective drugs in
cancer treatment is presented in Fig. 10.2. SODm, which lead to an
additional amount of H2O2 (Fig. 10.2B), may reduce cell proliferation
and increase the eﬃcacy of chemo- and radiotherapy treatments in
cancer cells (pro-oxidative eﬀects).
Conversely, SODm may promote the survival/proliferation of
normal cells, protecting them against adverse side eﬀects observed in
standard medical treatments for cancer (antioxidant eﬀects)
[768,776,778,780]. Finally, SODm can be used to give further mechan-
istic insights namely to assess the involvement of ROS in carcinogenesis
or in cancer therapy (Fig. 10.2).
Mechanistically, SODm can aﬀect redox-based cellular transcrip-
tional activity by aﬀecting reactive thiols of transcription factors (e.g.
NF-κB or KEAP1/NRF2) [776,777,780]. In line with this and according
to Natalia Robledinos-Antón and Antonio Cuadrado, NRF2 inhibitors
are being developed for cancer therapy [781], though a wide range of
NRF2 activators is already known. Most activators identiﬁed so far
target KEAP1 by oxidation or adduct formation [782]. These molecules
include allyl sulﬁdes, dithiolethiones, ﬂavonoids, isothiocyanates,
polyphenols and terpenoids, etc. Moreover, many of these electrophilic
compounds may also react with redox sensitive cysteines located in the
catalytic center of several phosphatases, thus up-regulating signaling
pathways that further impinge on NRF2 activation. The most successful
case reported so far of a drug targeting NRF2 is the ester derivative of
fumaric acid, dimethyl fumarate, which is used for treatment of
multiple sclerosis.
Ana S. Fernandes and Nuno G. Oliveira explain that although the
development of SODm started long ago, none has reached clinical use
yet, however, some SODm have been entering phase I/II clinical trials,
especially in combination with chemotherapy or radiotherapy regi-
mens. Some examples include MnPs, which are currently being studied
for radioprotection in late-stage glioma patients treated with concur-
rent radiotherapy and temozolamide. In addition, both MnPs and Mn
macrocycles are being assessed as radioprotectors in head & neck cancer
patients. A diﬀerent SODm, Mangafodipir, was studied as a protector
against oxaliplatin neurotoxicity and FOLFOX6 side eﬀects, while its
analog calmangafodipir is being studied in combination with FOLFOX6
in advanced metastatic colorectal cancer [http://clinicaltrials.gov, as of
22nd June 2016].
In summary, there are several therapeutic opportunities for SODm
in oncology. These compounds can increase the therapeutic index of
chemo- and radiotherapy by boosting the eﬃcacy of such treatments in
cancer cells, while counteracting major drug and radiation toxicity
issues.
10.4.2. ROS and non-malignant disease
Although the above-mentioned SODm may be beneﬁcial in cancer
therapy, it is so far unknown whether their antioxidant eﬀect could be
of use in other diseases where oxidative stress occurs without proper
malignancy. As indicated by Marios Phylactides and Marina
Kleanthous, such a disease is β-thalassemia – an autosomal recessive
red blood cell disorder characterized by a reduction or complete
absence of β-globin chain production, globin chain imbalance and the
accumulation of α-globins.
Precipitation and autoxidation of excess α-globins lead to the
generation of high levels of ROS as well as the release of free heme
and iron. Hemolysis, secondary iron overload, often the result of
regular blood transfusions and increased absorption of dietary iron in
the gut, as well as ineﬀective erythropoiesis overwhelm the patients'
antioxidant defense systems, giving rise to severe oxidative stress,
anemia and secondary complications [783].
Overall, Marios Phylactides and Marina Kleanthous mention that
the recurring theme seen in most of the trials involving β-thalassemia
patients is an improvement of the oxidant-antioxidant imbalance for the
duration of the trial with a decrease of oxidative stress markers (e.g.
ROS levels, RBC malondialdehyde concentration, lipid peroxidation)
and enhancement of the patients’ antioxidant status (e.g. RBC SOD,
glutathione peroxidase, reduced glutathione). However, with some rare
exceptions [784,785], there is no improvement of the patients' anemia,
and no eﬀect on hemoglobin levels. Thus, antioxidant supplements
undoubtedly have a beneﬁcial role in the management of β-thalasse-
mia; however, they do not substitute for blood transfusions and iron
chelation in patients with the most severe anemia, but they can feature
more prominently in milder, transfusion-independent forms of the
disease.
Given the central role of ROS in the pathophysiology of the disease,
Lidija Milković, and Višnja Stepanić indicate that the use of antiox-
idants as a means of reducing oxidative damage is an attractive
therapeutic option. A wide variety of compounds have been tested in
this context without, however, becoming established as an indispen-
sable part of the patients’ treatment regime. Some of the antioxidant
compounds under investigation are food products or herbal extracts,
which are used as supplements or form part of the normal diet (e.g.
vitamin E [784,786,787], resveratrol [788], curcuminoids [784,789],
N-acetylcysteine [785]), CoQ10 [790], green tea [791], fermented
papaya preparation [792], or the thistle Silybum marianum (L.) extract
silymarin [793,794].
The latter appears to be one of the most interesting and, as discussed
by Vladimir Kren and Katerina Valentova, silymarin's major active
constituent silybin (CAS no. 22888-70-6; syn. silibinin) is a typical
radical scavenger per se [795,796]. However, in addition to its radical
scavenging activity, this compound selectively interacts with various
speciﬁc receptors and signaling molecules such as the estrogen receptor
[797]. This eﬀect was found to account for the proapoptotic activity of
silybin in MCF-7 breast cancer cells [798]. Silybin also targets p53, NF-
κB or Wnt/β-catenin signaling in various cancer cells, thus aﬀecting
mitogenesis, cell cycle, apoptosis, autophagy, and angiogenesis. Its
ability to reverse the P-glycoprotein mediated multi-drug resistance in
small lung carcinoma [799] partially explains its chemopreventive and
chemoprotective activity [800,801]. Moreover, the ability of silybin to
bind to the α-amanitin binding site of RNA polymerase II is probably
responsible for its antidote eﬀect in Amanita poisoning [802]. Alto-
gether, the role and the mode of action of this traditional and well
known chemoprotectant needs to be substantially revised in the future.
10.5. ROS, antioxidants and therapeutic options
In addition to the beneﬁcial eﬀects of antioxidant supplements in
mild β-thalassemia, their action may not always be a direct antiradical
(scavenging) action, as discussed by Lidija Milković and Višnja
Stepanić. Although the ability to reduce the amount of ROS in vitro
still remains to be an important stage in the evaluation of the
antioxidant potency of any new or known compounds [803], this
approach is challenged because: і) many known antioxidants do not
show direct antiradical activity in vivo and vice versa [31]; іі) proved
antioxidants (e.g. ﬂavonoids, PUFAs as part of ﬁsh/plant oils) exhibit a
dual role acting as antiradical and prooxidant agents simultaneously
[804]; and ііі) eﬀects of the known antioxidants are mostly related to
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their indirect action [31,805].
Hence, more speciﬁc therapeutic options need to be used and
accordingly ﬁrst generations of speciﬁc compounds (e.g. NOX inhibi-
tors, NRF2 activators, myeloperoxidase inhibitors) are being developed
for application in a wide range of diseases including metabolic, ﬁbrotic,
and neurodegenerative diseases as well as cancer [32]. The validation
of the speciﬁcity of these drugs is highly dependent on the availability
of speciﬁc target engagement and functional assays. Since the redox
reactions are complex and often redundant, the careful use of tools for
measuring ROS is important to select drugs, identify potential non-
speciﬁc eﬀects and evaluate their mode of action [806].
Tamara Seredenina and Vincent Jaquet indicate that currently,
countless chemical probes are used to detect ROS, all with advantages
and limitations; it is therefore advisable to use several of them and it is
critical to control the types of ROS with which they react [807]. On this
matter, it is worth mentioning the innovative use of the cell-permeable
small molecule dihydroethidine as it allows detection of speciﬁc
oxidants and their quantiﬁcation both in vitro [808] and in vivo
[809,810]. Genetically encoded probes are also great tools for detecting
intracellular H2O2 localization and real time monitoring [56] and may
prove essential for redox dynamics; they also allow visualization of the
redox state directly in paraformaldehyde ﬁxed tissues [811].
The more speciﬁc design of redox active compounds together with
the selection of appropriate druggable biological targets should en-
compass diﬀerent in silico approaches and in vitro assays for prediction
and measurement, respectively, of their various redox activities. In
addition to standard cell-free assays that allow evaluation of the
antioxidant properties of new compounds [e.g. DPPH scavenging
method, Trolox equivalent antioxidant capacity (TEAC) method,
ABTS radical cation decolorization assay, Ferric reducing-antioxidant
power (FRAP) assay or hydroxyl radical averting capacity (HORAC)
method], in vitro models of diﬀerent cancer and normal cells should be
used [812]. In vivo, KO mouse models are to be used to prove the
speciﬁcity of action of a drug on a given target. They may, according to
Danylo Kaminskyy, Khrystyna Semen, and Olha Yelisyeyeva, enable
evaluation of a compounds’ cytotoxicity and possible selectivity (e.g.
toxic to cancer but not to normal cells), pro-oxidative activity (mea-
sured as ROS generation), as well as endogenous antioxidative
response; whether they are added alone or in combination with known
drugs to evaluate any possible synergistic eﬀect.
Despite these advantages and a strong rationale for therapeutic
targeting of ROS and redox pathways, it is not known why the
antioxidants used so far in clinical trials/therapies did not exert the
expected eﬀects [216]. Dose and combination regimen, or duration of
treatment, may be partial reasons. Indeed, in those studies high
antioxidant doses were usually applied, and some actions such as the
prooxidant action of some antioxidants as discussed above have been
neglected. Moreover, patients were usually not tested for antioxidant
deﬁciencies and/or compliance as in the EPIC clinical trial [813].
10.6. Conclusion
Altogether, in almost all living organisms ROS cannot simply be
considered as detrimental since they contribute to signaling, as well as
to maintenance of integrity and homeostasis in diﬀerent organisms
ranging from bacteria to mammals. In the latter, disturbances of ROS
homeostasis can contribute to the pathogenesis of several chronic
diseases such as atherosclerosis, type II diabetes, and cancer via
modulation of diverse processes such as inﬂammation, and the immune
response. The common associated increase in ROS in these diseases
points to the therapeutic use of small molecules with antioxidant
function; however, so far little or no beneﬁt could be observed from
the large scale studies with antioxidant supplementation. Overall, these
ﬁndings signify that further improvement is needed in our knowledge
about ROS, ROS-targets, antioxidants, measurement techniques, and
their connection to homeostasis and diseases.
11. Concluding remarks
Andreas Daiber and Fabio Di Lisa.
The last decade has witnessed intense research related to the
implications of ROS in cellular pathology with special emphasis on
the identiﬁcation of sources, biochemical reactions and cellular eﬀec-
tors responsible for ﬁnal pathophysiological outcomes. The recognition
of RONS as conveyors of physiological signals has added a new level of
understanding to their function and has generated contradictory
observations regarding the eﬀects of antioxidant molecules, which we
are only beginning to unravel. Studies in the context of whole organs
both in their healthy and diseased state have expanded the importance
of RONS regulation in unpredicted settings. The previous sections
highlight some interesting examples of these aspects and also reﬂects
the major achievements of the EU-ROS consortium, evidencing how
redox biology is slowly but inexorably evolving towards redox medi-
cine, a concept also put forward in [30,814].
Unfortunately, conclusive and precise answers are still needed and
the world of redox biology and medicine still has challenges. The
notions on the relevant sources might look obvious, yet it is not clear
which are the most important ones under physiological and pathologi-
cal conditions. In addition, it is not clear how much the various RONS
are compartmentalized, especially within a given cell. Thirdly, it is still
diﬃcult to monitor RONS formation due to limitations that still aﬀect
their assessment. Fourthly, the discussion is open on why and how the
same molecules might mediate physiological and pathological events. It
is likely that a threshold of RONS levels exists separating beneﬁcial
eﬀects from contribution to cell injury. The deﬁnition of this threshold,
that is likely to be diﬀerent in healthy and diseased cells, requires
quantitative methods that are hardly available. The identiﬁcation of
beneﬁcial levels as opposed to detrimental ones should allow deﬁning
and/or predicting the consequences of changes in RONS levels, and
how “good” RONS can change into “bad” ones. This last issue is
obviously crucial and necessary for the proper translation of experi-
mental ﬁndings into clinical settings. This applies not only to the
development of focused, if not personalized, therapeutic approaches,
but also to diagnostic procedures and disease monitoring. Although
providing the correct answers to the above deﬁned questions seems
daunting, we hope that future studies and technological advances will
clarify the unsolved issues leading to an improved control of cardiac,
neurodegenerative, metabolic and inﬂammatory diseases. These con-
cepts have been laid down by members of the EU-ROS consortium
within 3 major coordinated collections of position papers, reviews and
original articles published by our members [1–4] (Fig. 11.1).
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Abstract——Systems medicine has a mechanism-based
ratherthanasymptom-ororgan-basedapproachtodisease
and identifies therapeutic targets in a nonhypothesis-
drivenmanner. In thiswork,we apply this to transcription
factor nuclear factor (erythroid-derived 2)–like 2 (NRF2)
by cross-validating its position in a protein–protein
interaction network (the NRF2 interactome) functionally
linked to cytoprotection in low-grade stress, chronic
inflammation, metabolic alterations, and reactive oxygen
species formation. Multiscale network analysis of these
molecularprofiles suggestsalterationsofNRF2expression
and activity as a common mechanism in a subnetwork
of diseases (the NRF2 diseasome). This network joins
apparently heterogeneous phenotypes such as autoimmune,
respiratory, digestive, cardiovascular, metabolic,
and neurodegenerative diseases, along with cancer.
Importantly, this approach matches and confirms
in silico several applications for NRF2-modulating
drugs validated in vivo at different phases of clinical
development. Pharmacologically, their profile is as
diverse as electrophilic dimethyl fumarate, synthetic
triterpenoids like bardoxolonemethyl and sulforaphane,
protein–protein or DNA–protein interaction inhibitors,
and even registered drugs such as metformin and
statins, which activate NRF2 and may be repurposed
for indications within the NRF2 cluster of disease
phenotypes. Thus, NRF2 represents one of the first
targets fully embraced by classic and systems medicine
approaches to facilitate both drug development and
drug repurposing by focusing on a set of disease
phenotypes that appear to be mechanistically linked.
The resulting NRF2 drugome may therefore rapidly
advance several surprising clinical options for this
subset of chronic diseases.
I. Introduction
Life span has almost doubled in the last century, and
aging-specific diseases are now becoming prevalent. How-
ever, the pathologic mechanisms underlying most of them
are poorly understood and treated rather by correcting
symptoms or risk factors. Moreover, contrary to a hitherto
linear approach that considered one disease, one medicine,
chronic diseases demonstrate a high degree of connected-
ness and a need formore precise,mechanism-based disease
definitions rather than the current organ- and symptom-
based. After the human genome sequencing and the devel-
opment of molecular networks, a new concept of disease is
thus emerging, in which diseases are diagnosed not only by
clinical symptoms, but mainly by the underlying molecular
signatures (Goh et al., 2007). The fact that different
pathophenotypes have a shared molecular mechanism
provides also a rationale toward a new concept of therapy
summarized as “several diseases, one medicine” and drug
repurposing. Network medicine, i.e., the application of
network concepts to the analysis of dynamic connections
among diseases and drugs, provides a new opportunity to
develop this new approach. Chronic diseases in the elderly
are most likely characterized by the loss of homeostasis
during aging or as a result of environmental factors, all of
them leading to low-grade stress by pathologic formation of
reactive oxygen species (ROS), chronic inflammation, and
metabolic unbalance. Based on a network medicine ap-
proach, in this review we will present extensive evidence
indicating that thenuclear factor (erythroid-derived 2)–like
ABBREVIATIONS: AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; AMPK, AMP-activated protein kinase; ARE, antioxidant response
element; b-TrCP, b-transducin repeat containing E3 ubiquitin protein ligase; bZip, basic region-leucine zipper; CDDO, 2-cyano-3,12-dioxo-oleana-1,9(11)-
dien-28-oate; CDDO-Me, CDDO-methyl ester; COPD, chronic obstructive pulmonary disease; CUL3, Cullin 3; DC, dendritic cell; DMF, dimethyl
fumarate; EAE, experimental autoimmune encephalomyelitis; ECH, erythroid cell–derived protein with Cap’n’collar homology; GCLC, g-glutamyl
cysteine ligase catalytic subunit; GCLM, g-glutamyl cysteine ligase modulator subunit; GI, gastrointestinal tract; GSH, glutathione; GSK-3, glycogen
synthase kinase 3; HFD, high-fat diet; HNSCC, head and neck squamous cell carcinoma; HO-1, heme oxygenase-1; IBD, inflammatory bowel disease;
IkB, k-B inhibitor; IKK, IkB kinase; IL, interleukin; KEAP1, kelch-like ECH-associated protein 1; LDL, low-density lipoprotein; LPS, lipopolysaccharide;
MAF, musculoaponeurotic fibrosarcoma protein; MMF, monomethyl fumarate; MS, multiple sclerosis; NASH, nonalcoholic steatohepatitis; NF-kB, p65
subunit of nuclear factor k-light-chain enhancer of activated B cells; NQO1, NADPH:quinone oxidoreductase; NRF2, nuclear factor (erythroid-derived 2)–
like 2; PD, Parkinson disease; PI3K, phosphatidylinositol 3-kinase; PPI, protein–protein interaction; PTEN, phosphatase and tensin homolog; RA,
rheumatoid arthritis; RBX1, RING-box protein 1; RNS, reactive nitrogen species; ROS, reactive oxygen species; SFN, sulforaphane; SLE, systemic lupus
erythematous; SNP, single-nucleotide polymorphism; SQSTM1, sequestosome 1; STAT, signal transducer and activator of transcription; T2DM, type
2 diabetes mellitus; TGF, transforming growth factor; Th, T helper; TNF, tumor necrosis factor; Treg, T regulatory.
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2 (NRF2), as the master regulator of multiple cytoprotec-
tive responsesandakeymolecularnodewithinaparticular
cluster of diseases, provides a new strategy for drug
development and repurposing.
II. From Nuclear Factor (Erythroid-Derived 2)–
Like 2 Interactome to Nuclear Factor (Erythroid-
Derived 2)–Like 2 Diseasome
A. Nuclear Factor (Erythroid-Derived 2)–Like 2 as a
Master Regulator of Cellular Homeostasis
NRF2 is a basic region-leucine zipper (bZip) tran-
scription factor (Fig. 1) that forms heterodimers with
small musculoaponeurotic fibrosarcoma protein (MAF)
K, G, and F in the nucleus. The heterodimer recognizes
an enhancer sequence termed antioxidant response
element (ARE) that is present in the regulatory regions
of over 250 genes (ARE genes) (Ma, 2013; Hayes and
Dinkova-Kostova, 2014). These ARE genes encode a
network of cooperating enzymes involved in phase I, II,
and III biotransformation reactions and antioxidant
mechanisms that generate NADPH, glutathione
(GSH), and thioredoxin reactions; lipid and iron ca-
tabolism; and interaction with other transcription
factors, etc. (Hayes and Dinkova-Kostova, 2014). Re-
cently, NRF2 was also found to regulate the expres-
sion of several proteasome subunits and autophagy
genes, providing additional interest for its control of
proteostasis (Pajares et al., 2015, 2016, 2017; de la
Vega et al., 2016).
The great significance of NRF2 from a clinical perspec-
tive is that it might be targeted pharmacologically with
patient benefit. The main mechanism regulating the
transcriptional activity of NRF2 is the control of protein
stabilization by the E3 ligase adapter Kelch-like erythroid
cell–derived protein with Cap’n’collar homology (ECH)-
associated protein 1 (KEAP1) (Fig. 2). KEAP1 is a
homodimeric protein that bridges NRF2 with the E3
ligase complex formed by Cullin 3 and RING-box protein
1 (CUL3/RBX1). Under homeostatic conditions, the
N-terminal domain of the KEAP1 homodimer binds
one molecule of NRF2 at two amino acid sequences
with low (aspartate, leucine, and glycine; DLG) and high
(glutamate, threonine, glycine, and glutamate; ETGE)
affinity, and hence presents NRF2 to ubiquitination by
CUL3/RBX1 (Tong et al., 2007) and subsequent degrada-
tion by the proteasome.KEAP1 is a redox and electrophile
sensor that uponmodification of critical cysteines loses its
ability to repress NRF2 (Fig. 2; Biomarkers as Nuclear
Factor (Erythroid-Derived 2)–Like 2 Signature and for
Monitoring Target Engagement). An alternative mecha-
nism of regulation of NRF2 stability is the phosphorylation
mediated by glycogen synthase kinase 3 (GSK-3) (Fig. 2).
This kinase phosphorylates a domain of NRF2 (aspartate,
serine, glycine, isoleucine, serine;DSGIS) andhence creates
a recognition motif for the E3 ligase adapter b-transducin
Fig. 1. NRF2 as a master regulator of cytoprotective responses. (A) NRF2 heterodimerizes with the members of MAF family through their bZip
domain. The heterodimer binds to an enhancer sequence termed ARE that is present in the regulatory regions of over 250 genes (ARE genes). (B) These
genes participate in the control of redox metabolism, inflammation, and proteostasis balance, as indicated. The existence of susceptibility SNPs in
NFE2L2, elevated levels of its target genes in brain necropsies, and positive data from preclinical studies suggests that the imbalance in proteostasis,
redox, and inflammatory control may be counterbalanced by NRF2 activation. ACl, ATP citrate lyase; ACC1, acetyl-coenzyme A carboxylase 1;
CALCOCO2, calcium binding and coiled-coil domain 2; cGS, c-glutamate cysteine synthetase; FAS, fatty acid synthase; G6PDH, glucose-6-phosphate
dehydrogenase; Gpx, glutathione peroxidase; Gpx8, gluthation peroxidase 8; GR, glutathione reductase; HMOX1, heme oxygenase-1; IDH1, isocitrate
dehydrogenase 1; ME, malic enzyme; MTHFD2, methylenetetrahydrofolate dehydrogenase 2; PGD, phosphogluconate dehydrogenase; PPAT,
phosphoribosyl pyrophosphate amidotransferase; PSMB7, proteasome subunit b type-7; SCD1, stearoyl-CoA desaturase; TrxR, thioredoxin reductase;
ULK1, unc-51 like autophagy activating kinase 1.
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repeat containing E3 ubiquitin protein ligase (b-TrCP) that
presents NRF2 to a CUL1/RBX1 complex, leading to an
alternative pathway for ubiquitin-dependent proteasome
degradation of NRF2. Therefore, KEAP1 and GSK-3/
b-TrCP tightly control NRF2 protein levels in the context
of redox homeostasis and cell signaling, respectively
(Cuadrado, 2015). Other mechanisms of NRF2 regulation
at protein, mRNA, or gene level have been reported
(Hayes and Dinkova-Kostova, 2014), but at least these
two are amenable to pharmacological regulation.
B. Positioning Nuclear Factor (Erythroid-Derived 2)–
Like 2 and Its Regulatory Pathway in the Human
Interactome and Diseasome
The gene encoding NRF2, termed NFE2L2, is highly
polymorphic and presents a mutagenic frequency of 1 per
every 72 bp. An excellent review on this topic reported in
2015 up to 18 single-nucleotide polymorphisms (SNPs),
most of them in the 59 regulatory region and in intron
1 (Cho et al., 2015). Several of these SNPs might
constitute functional haplotypes that are associated with
risk at onset or progressionof chronic diseases. Variations
in functional haplotypes may have a subtle impact on a
proportion of individualswho exhibit clinical symptoms of
specific diseases, yet they may have a profound effect at
the population level and may define specific strategies to
target this gene in precision medicine.
Recent advances in network medicine have provided
quantitative tools to characterize how the interplay
between genes and their interactions (interactome) is
related to pathology (Barabasi et al., 2011; Vidal et al.,
2011; Guney et al., 2016), how dysregulated molecular
networks are common to various diseases (Menche et al.,
2015), and how diseases manifest in particular tissues
(Kitsak et al., 2016). To understand the relevance of
NRF2 in pathology from the systems medicine perspec-
tive, first we have generated the human interactome
map. We have integrated and curated information on
physical interactions among proteins involved in the
NRF2-regulating pathway (Hayes andDinkova-Kostova,
2014; Cuadrado, 2015). The interaction data have been
taken from the recently published human interactome
that compiles data across several protein–protein in-
teraction (PPI) resources (Turei et al., 2013; Menche
et al., 2015). However, the currently available informa-
tion for development of the NRF2 interactome is limited
by the fact that, because NRF2 is a very short half-life
protein, some meaningful interactions may be unde-
tected. Nevertheless, some well-known proteins that
physically interact with NRF2 are found in the inter-
actome, including KEAP1, b-TrCP, and MAFs. Another
group of NRF2-interacting proteins corresponds to nu-
clear proteins with functions in regulation of gene
expression. These include proteins related with bZip
transcription factors, nuclear receptors or coactivators,
or proteins involved in histone acetylation. Therefore,
the NRF2 interactome evidences additional mechanisms
of gene regulation beyond those directly connected to this
Fig. 2. Regulation of NRF2 stability by KEAP1 and b-TrCP and its pharmacological targeting. (A) According to the dual regulation model (Rada et al.,
2011), two domains of NRF2, termed Neh2 and Neh6, participate in NRF2 degradation in response to redox and electrophile changes (KEAP1) and to
signaling kinases (b-TrCP), respectively. The Neh2 domain binds the E3 ligase adapter KEAP1 that presents NRF2 for ubiquitination to a CUL3/RBX1
complex. The Neh6 domain requires previous phosphorylation by GSK-3 to bind the E3 ligase adapter b-TrCP and subsequent ubiquitination by a
CUL1/RBX1 complex (see text for details). (B) Detail of the binding between NRF2 and KEAP1 and current strategies to target this interaction. The
KEAP1 homodimer binds NRF2 at two motifs of the Neh2 domain: the low-affinity (29-DLG-31) and the high-affinity (79-ETGE-82) binding sites.
Current strategies to disrupt this interaction include the following: electrophiles that alter sulfhydryl groups of cysteines C151, 273, and 288; PPI
inhibitors that alter the docking of NRF2 to the DC domain of KEAP1. (C) Hypothetical binding of NRF2 and b-TrCP and suggested strategies to target
this interaction. The b-TrCP homodimer binds to the Nhe6 domain at the phospho-motif 334-DSGIS-338 when it is phosphorylated by GSK-3 (Rada
et al., 2011, 2012) and at the phospho-motif 373-DSAPGS-378 independently of GSK-3 (Chowdhry et al., 2013). In this figure we postulate that, by
analogy with KEAP1, one b-TrCP homodimer interacts with one molecule of NRF2 at the two phospho-motifs, but experimental evidence is still
lacking. Two possible strategies to disrupt this interaction include the use of GSK-3 inhibitors and PPI inhibitors.
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transcription factor. NRF2 is phosphorylated at several
residues, and therefore it is expected to interact with
several kinases that include GSK-3 and several protein
kinase C isoforms. These kinases are downstream of
somemembrane receptors and adapter/scaffold proteins.
In addition to this physical interaction, we have identi-
fied several biologic functions that are enriched in the
NRF2 neighborhood, includingmetabolic processes, such
as biosynthesis of pentose, tetrapyrrole, heme, glucose
6-phospate, cysteine, GSH, glyceraldehyde-3-phosphate,
and NADPH. Most of these regulatory proteins do not
interact directly with each other but are connected
through proteins acting as mediators (Fig. 3; a more
detailed description of specific interacting molecules can
be found at http://sbi.imim.es/data/nrf2/).
Perturbations of the NRF2 interactome have been
reported in several diseases. We have developed a dis-
easomemapby curating a list of 37NRF2-related diseases
based on DisGeNET (Pinero et al., 2017) and GeneCards
(Stelzer et al., 2016) databases, as well as knowledge from
some studies in animal models. We have also retrieved
disease–gene associations for these pathologies using
DisGeNET, OMIM, and GWAS databases (Menche
et al., 2015) (Table 1). The interactome-based proximity
(Guney and Oliva, 2014) of NRF2 to known disease
genes for each of the NRF2-related disease phenotypes
is shown in Fig. 4. NRF2 is significantly closer to the
known disease genes of the digestive system and cancers,
such as prostate, liver, and lung neoplasms, compared
with randomly selected proteins, highlighting the key
functional role of NRF2 in these pathologies. Moreover,
NRF2was found to be proximal to various proteins related
to metabolic and cardiovascular diseases, such as di-
abetes, hyperglycemia, ischemia, middle cerebral artery
infarction, and atherosclerosis. Protein interactions of
NRF2 also connect it to genes associated to respiratory
disorders such as asthma, pulmonary fibrosis, and pul-
monary emphysema, as well as to neurodegenerative
conditions such as Alzheimer disease (AD), Parkinson
disease (PD), and amyotrophic lateral sclerosis (ALS).
The interactome-based proximity therefore offers a
perspective on how NRF2 can be linked to various
pathologic conditions. The relationships among diseases
have been previously summarized as a network, termed
diseasome, that is connecting them based on genetic (Goh
et al., 2007) and clinical (Hidalgo et al., 2009; Zhou et al.,
2014) commonalities. In Fig. 5, we have defined a network
of diseases, the NRF2 diseasome, based on shared genes,
symptom similarity, and comorbidities. NRF2 appears to
connect diseases governed substantially by inflammatory
processes, such as acute kidney injury, liver cirrhosis, and
atherosclerosis. Furthermore, neurodegenerative dis-
eases such as AD, PD, Huntington’s disease, and ALS
constitute a cluster consistent with recent studies impli-
cating also NRF2 in neuroinflammatory processes (Rojo
et al., 2010; Lastres-Becker et al., 2012, 2014; Jung et al.,
2017; Wang et al., 2017b). The regulation of NRF2 by
kinase-signaling cascades (Jung et al., 2017) could explain
the well-connected cluster of cancers, particularly sup-
porting the involvement of NRF2 in pathologic ROS
Fig. 3. Locating the NRF2 regulatory pathway in the human interactome. NRF2 plays a key role in pathologic ROS formation as well as inflammatory
and metabolic responses by coordinating the activity of various proteins. These interactions constitute a molecular interaction network, the NRF2
interactome. The known physical interactions between proteins involved in the NRF2 regulatory pathway (i.e., regulator proteins, brown circles) and
the proteins through which they are connected (i.e., mediator proteins, green circles) are shown with a gray link. The regulator proteins that involve
more than one mediator protein to connect to NRF2 are shown with a blue link. The regulator proteins are curated from literature, and their
interactions are retrieved from various resources, including IntAct, MINT, BioGRID, HPRD, KEGG, and PhosphoSite. The list of all the proteins that
interact with NRF2 in the human interactome is available online at http://sbi.imim.es/data/nrf2/.
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formation underlining colon (Gonzalez-Donquiles et al.,
2017) and breast (Lu et al., 2017) tumors.
III. Target Validation of Nuclear Factor
(Erythroid-Derived 2)–Like 2 in Human
Disease States
A. Key Role of Nuclear Factor (Erythroid-Derived 2)–
Like 2 in Resolution of Inflammation
Persistent inflammation is a hallmark of all patho-
phenotypes found in the NRF2 diseasome. This is
most likely because inflammation is associated with
increased local and systemic pathologic formation of
reactive oxygen species (ROS). In fact, ROS and reactive
nitrogen species (RNS) stimulate and aggravate in-
flammatory responses that are mechanistically related
to the activation of transcription factor, p65 subunit of
nuclear factor k-light-chain enhancer of activated
B cells (NF-kB) (Wenzel et al., 2017). Very simplified,
in resting immune cells, NF-kB is retained in the cytosol
through interaction with the nuclear k-B inhibitor
(IkBa). Pathogen-associated molecular pattern mole-
cules derived from microorganisms as well as damage-
associated molecular pattern molecules released in
TABLE 1
Cluster of diseases with evidence of NRF2 association
Disease phenotypes with evidence of genetic association with NRF2 were selected from the DisGeNet database. DisGeNet integrates disease–
gene association information from various resources, such as UniProt, ClinVar, GWAS Catalog, and Comparative Toxicogenomics Database and
scores disease–gene associations according to the number of resources and publications supporting these associations. The curation of the list was
based on the following criteria: 1) only pathophenotypes with more than one citation in Pubmed were selected; 2) the score of reliability was set to
a threshold of 0.001; and 3) disease entries with very similar names or overlapping terms were simplified to one single entry.
Pathophenotype Reliability Score Pathophenotype Reliability Score
Diabetic nephropathy 0.2016 Diabetic cardiomyopathy 0.0803
Liver cirrhosis 0.2005 Middle cerebral artery infraction 0.0800
Nonalcoholic steatohepatitis 0.2005 Breast neoplasms 0.0087
Acute kidney injury 0.2000 Vitiligo 0.0076
Pulmonary fibrosis 0.2000 Atherosclerosis 0.0067
Nonsmall cell lung carcinoma 0.1252 Asthma 0.0043
Squamous cell carcinoma 0.1243 Leukemia 0.0038
Liver neoplasms 0.1238 Colon neoplasm 0.0038
Hyperglycemia 0.1208 Gastrointestinal diseases 0.0029
Drug-induced liver injury 0.1200 Parkinson disease 0.0026
Prostatic neoplasms 0.1200 Systemic lupus erythematous nephritis 0.0026
Chronic obstructive pulmonary disease 0.0899 Glioma 0.0024
Colorectal neoplasms 0.0847 Amyotrophic lateral sclerosis 0.0022
Alzheimer disease 0.0837 Ischemia 0.0016
Type 2 diabetes mellitus 0.0814 Pulmonary emphysema 0.0013
Chronic kidney disease 0.0808 Pancreatic neoplasms 0.0013
Diabetic retinopathy 0.0805 Vascular diseases 0.0013
Huntington’s disease 0.0805 Sepsis 0.0013
Fig. 4. Systems medicine view of NRF2 from the perspective of the human interactome. Diseases are triggered by mutations that perturb proteins and
their interactions, affecting a certain neighborhood in the NRF2 interactome. Interactome-based proximity measures the distance of genes to those
disease neighborhoods. The bars show the proximity of NRF2 gene (NFE2L2) to known disease genes that participate in NRF2-related
pathophenotypes. These bars highlight the role of NRF2 in digestive system diseases and cancers. For a given disease, the proximity first calculates the
distance from NRF2 to the closest known disease gene and then compares that distance to a random expectation that is estimated using average
distances between randomly selected proteins in the interactome. The z-score reported by interactome-based proximity corresponds to the significance
of the observed distance between NRF2 and the disease genes. A negative value indicates that the observed distance is lower than what would be
expected by chance. The bars are colored in varying tones of orange based on the z-score: significantly proximal (dark orange), proximal (orange), not
proximal (light orange), respectively. The known disease genes are taken from DisGeNet, OMIM, and GWAS Catalog.
Systems Medicine Approach to NRF2 in Chronic Diseases 353
response to tissue damage stimulate cognate receptors
expressed by immune cells that lead to activation of IkB
kinase (IKK)b. This kinase phosphorylates IkBa, tar-
geting it for degradation and allowing nuclear trans-
location and activation of NF-kB (Napetschnig and Wu,
2013). These events are submitted to redox control
through several modes of regulation of IkBa (Bowie
and O’Neill, 2000; Morgan and Liu, 2011; Siomek,
2012), but one that has been described recently involves
the regulation of IKKb stability by KEAP1. Just like
NRF2, IKKb possesses an ETGE motif that enables its
binding to KEAP for ubiquitination and proteasomal
degradation. Therefore, under basal redox conditions,
active KEAP1 targets IKKb for degradation and then
IkBa inhibits NF-kB. By contrast, in the presence of
ROS, KEAP1 is inhibited and IKKb is stabilized,
phosphorylating IkBa and leading to its degradation
and therefore to upregulation of NF-kB (Lee et al.,
2009).
Because NRF2 is a master regulator of redox homeo-
stasis, it exerts an indirect control on NF-kB activity.
Lipopolysaccharide (LPS) activates simultaneously a
fast, proinflammatory NF-kB response and a slow
NRF2 response. The NF-kB response is subsequently
inhibited when NRF2 is maximally active (Cuadrado
et al., 2014). For instance, Ras-related C3 botulinum
toxin substrate 1, a small G protein of the Rho family,
activated the NF-kB pathway and NRF2 overexpres-
sion blocked, whereas NRF2 knockdown enhanced
NF-kB–dependent transcription (Cuadrado et al.,
Fig. 5. Current status of the NRF2 diseasome. The relationships between diseases are represented as a network in which pathophenotypes are linked
by common genetic and clinical descriptors. In the figure, nodes (red hexagons) represent diseases, and the edges are similarities among them based on
shared genes, common symptoms, and comorbidities (gray, orange, and blue lines, respectively). The genes and symptoms associated with the diseases
are used to identify disease pairs that have a significant genetic and symptomatic overlap calculated using the Jaccard index. Among significant
disease–disease connections (P , 0.05, assessed by Fisher’s exact test based on the observed gene or symptom overlap), only the links that have an
elevated overlap and comorbidity are shown to eliminate potentially spurious connections. Accordingly, the diseases that share at least 10% of the
disease-associated genes and more than half of the associated symptoms are included in the figure. The comorbidity information is extracted from
medical insurance claims, representing disease pairs that tend to occur together in the population (relative risk .2).
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2014). Consistently, in NRF2-deficient (Nrf22/2) mice
challenged with LPS or tumor necrosis factor (TNF)-a,
the activity of IKKwas exacerbated and led to increased
phosphorylation and degradation of IkB (Thimmulappa
et al., 2006a).
NRF2 also induces an anti-inflammatory phenotype
thatmodulates the functions of CD8+ T cells (Sha et al.,
2015) as well as in macrophages and microglia ( Rojo
et al., 2010, 2014a; Brune et al., 2013). This is because
NRF2 increases cysteine and GSH levels in macro-
phages through regulation of the cystine/glutamate
transporter and the GSH-synthesizing enzyme
g-glutamyl cysteine ligase modulator and catalytic
subunits [g-glutamyl cysteine ligase modulator sub-
unit (GCLM) and g-glutamyl cysteine ligase catalytic
subunit (GCLC)]. Conversely, GSH depletion sensi-
tizes macrophages to NRF2 activation by LPS
(Diotallevi et al., 2017). All of these studies point to
NRF2 as an anti-inflammatory factor, crucial in con-
trolling the intensity and duration of inflammatory
responses (Fig. 6).
NRF2 and NF-kB crosstalk through feed forward and
feedback mechanisms (Fig. 7). At the transcriptional
level, NF-kB activates NRF2 expression due to the
existence of several functional binding sites in the
promoter region of the NFE2L2 gene, thus inducing a
negative feedback loop (Rushworth et al., 2012). More-
over, both NF-kB and NRF2 transcription factors re-
quire the coactivator CBP/p300, which is a histone
acetyltransferase that acetylates and increases the
DNA-binding capacity. As such, NF-kB overexpression
hampers the availability of CBP/p300 for NRF2, hence
reducing its transcriptional capacity, whereas NF-kB
knockdown shows the opposite effect (Liu et al., 2008).
Additionally, NF-kBmay promote interaction of histone
deacetylase-3 with MAF proteins, therefore preventing
their dimerization with NRF2 (Liu et al., 2008). NF-kB
binds and translocates KEAP1 to the nucleus, thus
favoring NRF2 ubiquitination and degradation in this
cellular compartment (Yu et al., 2011). The E3 ligase
adapter b-TrCP tags both IkBa (Winston et al., 1999)
and NRF2 (Rada et al., 2011, 2012; Cuadrado, 2015) for
proteasomal degradation, and therefore it can lead to
increased NF-kB activity.
The anti-inflammatory activity of NRF2 was thought
to rely only on modulation of redox metabolism or
crosstalk with NF-kB. However, NRF2 can also directly
block the transcription of the proinflammatory genes
interleukin (IL)-6 and IL-1b in macrophages upon
exposure to LPS (Kobayashi et al., 2016). LPS exposure
or pharmacological activation of NRF2 leads to its
binding to the proximal promoters of these proinflam-
matory genes and blocks the recruitment of RNA pol II.
The mechanism appears to be independent of the
binding of NRF2 to its well-established ARE enhancer.
In other studies, NRF2 could directly regulate the
expression of several other macrophage-specific genes,
such as macrophage receptor with collagenous struc-
ture, a receptor required for bacterial phagocytosis, or
CD36, a scavenger receptor for oxidized low-density
Fig. 6. Direct and indirect regulation of inflammation by NRF2. Direct mechanisms of action include transcriptional induction of anti-inflammatory
genes as well as transcriptional repression of proinflammatory genes. In the second case, the quotation mark indicates that further work is required to
identify the bZip partner of NRF2 in this function, if any. Indirect mechanisms to counteract inflammation involve ROS/RNS modulation and inhibition
of migration/infiltration of immune cells. Overall, these pathways lead to an anti-inflammatory response that helps to properly resolve inflammation.
The existence of polymorphisms in NFE2L2 associated with reduced transcriptional activity, the altered levels of target genes in patients, and
promising data from preclinical studies support a relevant role of NRF2 in inflammation resolution.
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lipoprotein (Harvey et al., 2011; Ishii and Mann, 2014).
Similarly, the gene encoding the proinflammatory
cytokine, IL-17D, contains AREs, and this NRF2–T
helper (Th)17 axis seems to confer protection against
tumorigenesis and viral infections (Saddawi-Konefka
et al., 2016).
Chronic inflammatory processes involve adhesion of
leukocytes to the vascular endothelium and infiltration
into the damaged tissue. Both processes appear to be
modulated by NRF2 together with at least one of its
target genesHMOX1, coding heme oxygenase-1 (HO-1).
The NRF2/HO-1 axis inhibits adhesion of inflammatory
Fig. 7. Crosstalk between NF-kB and NRF2 occurs at different levels. (A) Responsive elements have been identified in the promoter region ofNFE2L2.
(B) Both NRF2 and NF-kB transcription factors compete for binding to the transcriptional coactivator CREB-binding protein (CBP/p300). (C) The
NF-kB activating kinase IKKb contains an ETGE motif allowing KEAP1 binding and subsequent ubiquitin–proteasome degradation. (D) NF-kB was
reported to bind and translocate KEAP1 to the nucleus, thereby promoting NRF2 degradation. (E) ROS produced during inflammation activate NF-kB
and NRF2; finally, NRF2 attenuates ROS and consequently NF-kB activity. (F) Different proinflammatory signals activate the Rho GTPase RAC1,
which leads to NF-kB and NRF2 activation. Then NRF2 inhibits RAC1-mediated activation of NF-kB.
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cells to the endotheliumbymodulating the expression of
several cell adhesion molecules such as vascular cell
adhesion molecule 1 (Banning and Brigelius-Flohe,
2005; Wenzel et al., 2015). Additionally, NRF2/HO-1
inhibits metalloproteinase-9 in macrophages that are
necessary for migration of immune cells within tissues
(Bourdonnay et al., 2009).
Numerous preclinical studies have reported that
activation of NRF2 by natural compounds (Satoh
et al., 2013) or by disrupting its negative regulator
KEAP1 leads to potent anti-inflammatory effects in
myeloid leukocytes (Kong et al., 2011) andmacrophages
(Lin et al., 2008). In observational studies, a poly-
morphism in NFE2L2 was associated with reduced
transcriptional activity correlating with increased risk
of inflammatory bowel disease (Arisawa et al., 2008b)
and chronic gastritis (Arisawa et al., 2007). One exam-
ple of the immune modulatory action of NRF2 is
provided in the central nervous system. Injured neu-
rons release fractalkine, a chemokine that specifi-
cally activates the phosphatidylinositol 3 kinase/AKT
(PI3K/AKT) pathway in microglia, resulting in inhibi-
tion of GSK-3b and upregulation of NRF2 (Lastres-
Becker et al., 2014). In this study, necropsies from AD
and progressive supranuclear palsy patients exhibited a
compensatory increase in fractalkine levels together
with upregulated NRF2 protein, suggesting that this
pathway contributes to limiting the inflammatory re-
sponse in the diseased brain.
B. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Autoimmune Diseases
At the periphery of the NRF2 diseasome cluster, we
found several autoimmune disease phenotypes, such as
vitiligo, asthma, multiple sclerosis (MS), and systemic
lupus erythematosus (SLE). Indeed, extensive work in
animal models of experimental autoimmune encepha-
lomyelitis (EAE) and rheumatoid arthritis (RA), as well
as clinical evidence inMS and psoriasis further points to
a role of NRF2 in autoimmune diseases. Oxidative
tissue damage and apoptosis may increase the genera-
tion of autoantigens, leading to activation of T cells and
production of autoantibodies by B cells, e.g., as observed
for 3-nitrotyrosine–positive proteins (Thomson et al.,
2012). In addition, loss of phase II detoxification
enzymes, many of which are transcriptionally regulated
by NRF2, results in increased production of reactive
intermediates that contribute to formation of haptens or
damaged macromolecules that sometimes become im-
munogenic, increasing hence the pool of autoantigens
that trigger autoimmune reactions. Because NRF2-
regulated enzymes play a critical role in the detoxifica-
tion of many chemicals, it is conceivable that NRF2
may be a protective mechanism against the environ-
mental contribution to autoimmune pathogenesis (Ma,
2013). Potential mechanisms for NRF2-mediated regu-
lation of autoimmunity also involve suppression of
proinflammatory Th1 and Th17 responses and activa-
tion of immunosuppressive T regulatory (Treg) and Th2
ones. There is also increasing evidence that NRF2 may
control the differentiation and function of dendritic cells
(DCs) and macrophages involved in antigen presenta-
tion and regulation of adaptive immune responses. In
fact, NRF2 deficiency was shown to alter the function
and phenotype of DCs by increasing the expression of
costimulatory molecules and consequently the antigen-
specific T cell reactivity (Al-Huseini et al., 2013).
MS is a chronic inflammatory disease characterized
by infiltration of autoreactive immune cells into the
central nervous system. The absence of NRF2 exacer-
bates the development of EAE, which is a mouse model
of MS (Johnson et al., 2010). Part of the effects
associated with NRF2 deficiency may be related to the
reduced levels of HO-1. Thus, mice with a myeloid-
specific HO-1 deficiency exhibited higher incidence of
lesions, accompanied by activation of antigen-
presenting cells and infiltration of inflammatory Th17
and myelin-specific T cells (Tzima et al., 2009). Knock-
down of KEAP1 (Kobayashi et al., 2016) or treatment
with a wide range of small molecules that activate
NRF2 (Buendia et al., 2016) inhibited the development
and severity of disease. NRF2 is strongly upregulated
in active MS lesions, and the expression of NRF2-
responsive genes is predominantly found in areas of
initial myelin destruction (Licht-Mayer et al., 2015). In
MS brains, NRF2 and its targets NADPH:quinone
oxidoreductase (NQO1) and HO-1 are mainly expressed
in infiltrating macrophages and to a lesser extent in
astrocytes, most likely as a compensatory response
against pathologic ROS formation. In contrast, there
is a lack of NRF2 and antioxidant gene expression in
oligodendrocytes, and this may underlie their damage
and loss in MS (van Horssen et al., 2010). As a
consequence of the altered immune and redox homeo-
stasis, HO-1 expression is reduced in peripheral blood
mononuclear cells of MS patients and is downregulated
during exacerbation of the disease (Fagone et al., 2013).
Of note, gene expression profiling in interferon-b–treated
patients identified NRF2 as a potential mediator of long-
term antioxidant response and neuronal preservation
(Croze et al., 2013).
SLE is underlined by high oxidative environment,
deregulated cell death, and defects in removal of dead
cells, which leads to cell necrosis as source of autoan-
tigens. Female mice deficient in NRF2 develop with
age amultiorgan autoimmune disorder similar to SLE,
characterized by increased DNA oxidation, lipid per-
oxidation, splenocyte apoptosis, presence of antibodies
against double-strand DNA and the Smith antigen,
along with important tissue damage (vasculitis, glo-
merulonephritis, hepatitis, and myocarditis) (Li et al.,
2004). The fact that only female mice show progression
to SLE suggests that female-specific factors may
contribute to break immune tolerance to self-antigens
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(Li et al., 2004). NRF2 deficiency also results in
enhanced proliferative responses of CD4+ T cells,
altered CD4+/CD8+ ratio, and promotion of proinflam-
matory Th17 in SLE (Ma et al., 2006; Zhao et al., 2016).
In fact, NRF2 depletion has been associated with Th17
differentiation and function during development of
lupus nephritis, which seems to be mediated by regu-
lation of the suppressor of cytokine signaling 3/phos-
phorylated signal transducer and activator of
transcription (STAT)3 pathway and IL-1b signaling
(Zhao et al., 2016). In addition, the salivary glands of
Nrf22/2 mice show intense lymphocyte infiltration,
reminiscent of the Sjögren syndrome, which is often
associated with SLE (Ma et al., 2006). SLE patients
exhibit alterations in repair mechanisms of oxidative
DNA damage (Evans et al., 2000), high serum levels of
oxidized proteins, apolipoprotein C3 (Morgan et al.,
2007), oxidized phospholipids, and autoantibodies
against oxidatively modified lipoproteins (Frostegard
et al., 2005). NRF2 polymorphisms have not been
associated with SLE susceptibility, although the SNP
rs35652124 was related to increased risk of nephritis
in childhood onset of Mexican females (Cordova et al.,
2010).
Rheumatoid arthritis (RA) is a systemic inflamma-
tory disease with a complex but still elusive autoim-
mune profile, in which neutrophils, macrophages,
and lymphocytes are actively recruited and activated
in the inflamed joints. This results in increased secre-
tion of proinflammatory mediators such as ROS/RNS,
eicosanoids, cytokines (IL-17, TNF-a, interferon-g, IL-6,
and IL-1b), and catabolic enzymes that trigger hyper-
proliferation of synovial fibroblasts, joint swelling, and
progressive destruction of cartilage and bone (Roberts
et al., 2015). Deletion of the NRF2 gene increases
vulnerability to joint alterations in experimental RA
models. For instance, in mice expressing the T cell
receptor KRN and themajor histocompatibility complex
class IImolecule A(g7) (theK/BNarthritismodel), and
in antibody-induced arthritis, NRF2 deficiency acceler-
ates the incidence and aggravates the disease course
(Maicas et al., 2011; Wu et al., 2016b). NRF2 deficiency
dramatically upregulates migration of inflammatory
cells, expression of cyclooxygenase-2 and inducible
nitric oxide synthase, production of ROS and RNS,
and release of proinflammatory cytokines and chemo-
kines. Moreover, NRF2 may be a protective factor for
bone metabolism in arthritis (Maicas et al., 2011), and
NRF2/HO-1 activation exerts anti-inflammatory and
antioxidant effects in animal models of RA and in
human synovial fibroblasts (Wu et al., 2016b). It is
interesting that antirheumatic gold(I)-containing com-
pounds that stimulate the antioxidant response
through activation of NRF2 and upregulation of HO-1
and GCLC proved clinical efficacy in RA (Kobayashi
et al., 2016). Moreover, NRF2/HO-1 activationmediates
the induction of synovial cell apoptosis and inhibition of
proinflammatory cytokine production by cilostazol
(Park et al., 2010) as well as the anti-inflammatory
effects of H2S and related compounds, which are able to
modify by sulfhydration the cysteine residues of KEAP1
(Wu et al., 2016b). Other drugs that induce NRF2 and
HO-1 signaling, such as rebamipide, can divert the
differentiation of human and murine CD4+ T cells
toward an immunosuppressive Treg phenotype and
inhibit the differentiation of TCD4+ cells toward in-
flammatory Th17 cells through specific inhibition of
STAT3 (Moon et al., 2014). Excessive ROS generation
within the inflamed synovium appears to contribute to
the pathogenesis of RA because patients show amarked
increase in ROS formation, lipid peroxidation, protein
oxidation, DNA damage, and decrease in the activity of
the antioxidant defense mechanisms, all of these con-
tributing to tissue damage and disease progression
(Datta et al., 2014). In response to pathologic ROS
formation, the NRF2 pathway is activated in synovial
cells of RA patients and in joints of antibody-induced
arthritic mice, but this response is apparently insuffi-
cient to counteract the disease progression (Wu et al.,
2016b).
Vitiligo is a skin inflammatory disorder characterized
by the accumulation of ROS in the epidermis, which
participates in the death of melanocytes. These mole-
cules modify DNA and melanosomal proteins with
formation of autoantigens and activation of an autoim-
mune response against melanocytes (Xie et al., 2016).
Genetic studies have revealed associations of NRF2
promoter SNPs with susceptibility to develop vitiligo,
such as the SNP at 2650 position (Guan et al., 2008),
whereas the C allele of rs35652124 was shown to be
associated with protective effects in a Han Chinese
population (Song et al., 2016). NRF2 and its down-
stream detoxification target genes NQO1, GCLC, and
GCLM are upregulated in the epidermis of vitiligo
patients, suggesting insufficient activation of this de-
fensive mechanism (Natarajan et al., 2010).
C. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Chronic Respiratory Diseases
The relevance of NRF2 in respiratory diseases was
reviewed in 2010 (Cho and Kleeberger, 2010), and in
this work we will highlight only the most relevant
findings (Fig. 8). Cigarette smoke is a main risk factor
for chronic obstructive pulmonary disease (COPD).
COPD patients have dysfunctional alveolar macro-
phages that lead to uncontrolled ROS production,
proinflammatory mediators, defective phagocytosis,
and an array of metalloproteinases that participate in
tissue damage. In fact, the emphysematous lung tissue
shows a direct correlation between alveolarmacrophage
density in the parenchyma and severity of lung de-
struction (Finkelstein et al., 1995). Impaired phagocytic
activity of alveolar macrophages is a major cause of
recurrent bacterial and viral infections that cause acute
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exacerbations of COPD and are a major source of
morbidity and mortality. Nrf22/2 mice exhibit en-
hanced susceptibility to cigarette smoke-induced em-
physema (Rangasamy et al., 2004). Importantly,
activation of NRF2 with the isothiocyanate sulfora-
phane (SFN) restores bacteria recognition and phago-
cytosis, enhances pulmonary bacterial clearance by
alveolar macrophages, and reduces inflammation in
wild-type mice, but not in Nrf22/2 mice exposed to
cigarette smoke (Harvey et al., 2011). In humans, the
transcriptional signature of NRF2 is decreased in
alveolar macrophages from patients with smoking-
related lung emphysema as compared with smoking
and nonsmoking patients without emphysema (Goven
et al., 2008). Decreased NRF2 expression is associ-
ated with increased macrophage expression of the
lipid peroxidation product 4-hydroxynonenal. In the
NFE2L2 promoter, a functional haplotype constituted
by three SNPs and one triplet repeat, polymorphism
that produces low to medium NRF2 expression
(Yamamoto et al., 2004), was associated with in-
creased risk to develop COPD (Hua et al., 2010). The
low-expressing haplotypes were significant predictors
for developing respiratory failure. Thus, the 2617A
allele of SNP rs6721961 had a significantly higher risk
for developing acute lung injury (Marzec et al., 2007).
Pathologic ROS formation may play a role in the
pathogenesis of chronic lung fibrosis. An early study
demonstrated that pulmonary fibrosis induced by bleo-
mycin is more severe in Nrf22/2 than in wild-type mice
(Cho et al., 2004). In fact, wild-type mice induced an
antioxidant and anti-inflammatory response by upre-
gulating NRF2, and this could not be achieved in the
Nrf22/2 mice. Later, it was verified that patients with
idiopathic pulmonary fibrosis or chronic sarcoidosis/hy-
persensitivity pneumonitis exhibit increased expres-
sion of NRF2 and augmented levels of low-mol. wt.
antioxidants in bronchoalveolar lavage fluids, such as
uric acid, ascorbic acid, retinol, and a-tocopherol,
suggesting an unsuccessful adaptive response to the
ROS challenge (Markart et al., 2009). Mechanistically,
NRF2 deficiency increases myofibroblast differentia-
tion, whereas pharmacological induction of NRF2 with
SFN results in lower number of myofibroblasts and
Fig. 8. Role of NRF2 in common mechanisms and pathophenotypes of chronic diseases. The picture provides some examples extracted from the NRF2
diseasome cluster of Fig. 5. Common pathomechanisms of these diseases include abnormally high ROS levels and low-grade chronic inflammation that
participate in tissue damage. NRF2 provides a cytoprotective signature against these and other tissue-specific alterations by regulating the expression
of numerous cytoprotective genes.
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attenuation of the profibrotic effects of transforming
growth factor-b (TGF-b) (Artaud-Macari et al., 2013).
D. Nuclear Factor (Erythroid-Derived 2)–Like 2 in the
Digestive System
The prominent position of pathophenotypes of the
digestive system in the NRF2 diseasome highlights the
relevance of the transcriptional signature of NRF2 as a
potent adaptive mechanism to chronic oxidative dam-
age and inflammatory stress triggered by xenobiotics.
In the gastrointestinal tract (GI), chronic exposure to
xenobiotics triggers dysfunctional interactions between
the microbiota of the intestinal lumen and the immune
system (Aviello and Knaus, 2017). This can lead to
chronic diseases of the GI tract, like the inflammatory
bowel disease (IBD) phenotypes comprising Crohn’s
disease and ulcerative colitis, in which there is evidence
of activation of a protective NRF2 response. For in-
stance, in colonic tissues from IBD patients, colon
epithelial cells responded to inflammatory signals
through a NRF2-dependent adaptation that was asso-
ciated with increased proteasome protein expression
(Kruse et al., 2016). Monocyte-derived macrophages
from IBD patients evidenced a specific NRF2-
dependent gene expression profile that was exacerbated
in response to LPS, further suggesting an attempt to
attenuate the inflammatory challenge (Baillie et al.,
2017). At the genetic level, a particular genotype of the
NFE2L2 gene (26862684) was associated with the
development of ulcerative colitis, especially in females,
in a Japanese cohort (Arisawa et al., 2008a). In fact,
pathologic processes in the GI are highly dependent on
the genetic background of the host in relation with
dysfunctional interaction between the microbiota of the
intestinal lumen and the immune system (Aviello and
Knaus, 2017).
One of the symbiotic effects of themicrobiota of theGI is
to release moderate amounts of ROS that elicit a cytopro-
tective response mediated by NRF2 in epithelial colono-
cytes and infiltrating immune cells (Jones et al., 2015).
Moreover, cytoprotective molecules that are under the
transcriptional control of NRF2 in eukaryotes can also be
produced by commensal bacteria. For instance, the HO-1
homologs in the microbiota may greatly contribute to GI
homeostasis, and this can be therapeutically exploited for
local delivery of carbonmonoxide to the intestine (Onyiah
et al., 2014).
The proven involvement of NRF2 in maintaining GI
homeostasis makes this transcription factor a promising
therapeutic target in IBD. Thus, several chemical com-
pounds and dietary supplementsmight exhibit beneficial
effects, like melatonin, 3-(3-pyridylmethylidene)-2-
indolinone, butyrate, Lactobacillus casei, L-carnitine,
4-vinyl-2,6-dimethoxyphenol (canolol), lacto-wolfberry
(formulated product of wolfberries in skimmed milk),
etc. (Orena et al., 2015). Therefore, it is of utmost
importance to define the involvement of NRF2 in chronic
and acute diseases of the GI tract for better guidance on
the therapeutic approach for modulating the NRF2
pathway.
The liver is also a first line of defense against food
xenobiotics. Therefore, it is not surprising that the
NRF2 diseasome highlights the relevance of this tran-
scription factor in pathophenotypes associated with liver
damage. Early work with the Nrf22/2 mouse model
demonstrated its protective effect against acetaminophen-
induced hepatocellular injury, benzo[a]pyrene-induced
tumor formation, and Fas- and TNF-a–mediated hepato-
cellular apoptosis (Aleksunes and Manautou, 2007). The
higher sensitivity of Nrf22/2 mice to chemical toxicity
correlated with reduced basal and inducible expression of
detoxification enzymes. In humans, the functional haplo-
type of three NRF2 promoter SNPs that result in reduced
NRF2 expression was significantly associated with devel-
opment of gastric mucosal inflammation, either indepen-
dently or by interacting with Helicobacter pylori infection
(Arisawa et al., 2007). Analysis of the transcriptional
signature of NRF2 in patients with primary biliary
cholangitis indicated that these patients exhibit reduced
NRF2 expression together with low levels of HO-1 and
GCLCproteins, and these impairments aremore advanced
in patients with cirrhosis (Wasik et al., 2017).
Pathologic ROS formation is a key mechanism of
hepatocellular injury and disease progression in pa-
tients with nonalcoholic steatohepatitis (NASH) (Fig.
8). This disease evolves in two phases, one of progressive
accumulation of fatty acids in hepatocytes and a second
that involves liver injury and inflammatory pathologic
ROS formation (Wang et al., 2018). Accordingly, mice
fed with a high-fat diet (HFD) developed a simple
steatosis, characterized by increased hepatic fat de-
position without inflammation or fibrosis, but Nrf22/2
mice presented exacerbated hepatic steatosis and sub-
stantial inflammation, consistent with NASH (Reccia
et al., 2017). It is interesting, however, that the
hepatocyte-specific KEAP1 deletion, while reducing
liver steatosis, did not alter inflammation during devel-
opment of NASH, suggesting a compensatory mecha-
nism (Ramadori et al., 2016). At least in the rat model of
NASH, dietary NRF2 activators attenuate the progres-
sion of liver fibrosis (Shimozono et al., 2013). Markers of
pathologic ROS formation were increased in liver bi-
opsies of NASH patients, and the NRF2 signature was
increased, suggesting an attempt to reduce the oxidant
and inflammatory burden (Takahashi et al., 2014).
E. Nuclear Factor (Erythroid-Derived 2)–Like 2 in the
Cardiovascular System
The NRF2 diseasome cluster points to the high
susceptibility of the cardiovascular system to changes
in the cellular redox balance and the development of
well-known comorbidities like atherosclerosis, hyper-
tension, and diabetes (Griendling and FitzGerald,
2003a,b; Harrison et al., 2003; Jay et al., 2006)
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(Fig. 8). A role of NRF2 in preventing these pathophe-
notypes has been demonstrated inNrf22/2mice, which
exhibit impaired cardiac structure (more remodeling
events) and function (less fractional shortening) in
response to chronic endurance exercise (Shanmugam
et al., 2017a). They are also more susceptible to develop
heart failure after myocardial infarction (Strom and
Chen, 2017). In contrast, constitutive activation of
NRF2 creates a reductive state, characterized by in-
creased cardiac GSH/glutathione disulfide ratio and
decreased ROS formation and malondialdehyde levels
(Shanmugam et al., 2017b). In humans, microarray
analysis in Tako–Tsubo cardiomyopathy indicated an
increase in pathologic ROS levels and a compensatory
upregulation of NRF2 during the acute phase of this
contractile dysfunction (Nef et al., 2008). Recently,
systemic inflammation and pathologic ROS formation
in hemodialysis patients were associated with down-
regulation of NRF2 (Pedruzzi et al., 2015), and two
promoter polymorphisms (rs35652124 and rs6721961)
were associatedwith increased risk ofmortality in these
patients (Shimoyama et al., 2014).
One of the most relevant targets of NRF2 in endothe-
lial homeostasis is HO-1, which is usually paralleled by
upregulation of ferritin, hence decreasing free iron
levels and preventing Fenton-type reactions. Bilirubin,
which is generated from the combined activity of HO-1
and biliverdin reductase, is one of the most powerful
endogenous antioxidants that scavenges ROS/RNS
(Jansen et al., 2010), and is highly efficient in prevent-
ing lipid peroxidation in vitro (Stocker et al., 1987).
Hmox12/2 mice show increased pulmonary hyperten-
sion in response to chronic hypoxia (Christou et al.,
2000), and pharmacological HO-1 induction improves
diabetic complications (Kruger et al., 2006), as well as
nitroglycerin-induced vascular dysfunction (nitrate tol-
erance) (Wenzel et al., 2007). Recently,Hmox12/2mice
were shown to display upregulated NADPH oxidase-2,
vascular pathologic ROS formation, markers of inflam-
mation, endothelial dysfunction, and higher blood pres-
sure in response to angiotensin-II (Wenzel et al., 2015).
In fact, high serum levels of bilirubin are inversely
correlated with the incidence of coronary artery disease
(Hopkins et al., 1996). Bilirubin prevents the activation
of the vascular NADPH oxidase (Kwak et al., 1991),
involved in the development of cardiovascular diseases
(Griendling and FitzGerald, 2003a,b; Harrison et al.,
2003; Jay et al., 2006). Patients suffering from periph-
eral artery disease, which is a common manifestation
of atherosclerosis, present reduced levels of HO-1
(Signorelli et al., 2016).
F. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Metabolic Diseases
Type 2 diabetes mellitus (T2DM) is one of the most
common chronicmetabolic diseases and is highly under-
lined in theNRF2 diseasome. Pathologic ROS formation
in insulin-sensitive tissues, as well as in pancreas, has
been found in T2DM patients, resulting in severe
impairment of both insulin secretion by pancreatic b
cells and insulin action in peripheral tissues (Uruno
et al., 2015) (Fig. 8). Likewise, pathologic ROS levels
also contribute to the pathogenesis of diabetic compli-
cations due to nonenzymatic glycation of proteins. This
has been evidenced in diabetic nephropathy, in which
the glomeruli exhibit pathologic ROS levels and a
compensatory elevation of NRF2 (Jiang et al., 2010).
Since 2007, several studies have addressed the role of
NRF2 in T2DM and its complications using animal
models and cell lines. In vitro studies in human cells
reported that NRF2 activation is achieved with acute
exposure to high glucose, whereas longer incubation
times or oscillating glucose concentration failed to
activate NRF2 (Ungvari et al., 2011; Liu et al., 2014).
Accordingly, these studies pointed out that NRF2
activation is dependent on glucose concentration and
dynamics. In contrast, NRF2 is downregulated in
peripheral blood mononuclear cells of prediabetic and
diabetic patients, suggesting that NRF2 could be an
important therapeutic target (Jimenez-Osorio et al.,
2014).
The impact of NRF2 deficiency on hyperglycemia was
first shown in Nrf22/2mice, where oxidative and nitro-
sative alterations were enhanced and led to early-stage
renal injury (Yoh et al., 2008). In a subsequent study,
streptozotocin-induced diabetic Nrf22/2 mice exhibited
exacerbated glomerular injury, together with high ROS
production and increased expression of the profibrotic
markers TGF-b and fibronectin (Jiang et al., 2010).
In this diabetic model, NRF2 protected against dys-
function of the blood–retina barrier and the progres-
sion of diabetic retinopathy (Xu et al., 2014). Likewise,
HFD-induced increase in vascular ROS levels was signif-
icantly exacerbated inNrf22/2mice andwas accompanied
by a severe endothelial dysfunction, as shown by
diminished acetylcholine-induced relaxation of aorta
and increased expression of intercellular adhesion
molecule-1 and TNF-a (Ungvari et al., 2011).
NRF2 plays a complex role in tissue-specific insulin
resistance. Thus, HFD-fed Nrf22/2 mice displayed
better insulin sensitivity due to enhanced insulin
signaling in liver and skeletal muscle than their wild-
type counterparts, but conversely, these mice developed
a severe NASH due to excessive hepatic lipotoxicity
linked to pathologic ROS formation (Meakin et al.,
2014). Accordingly, this study dissociated hepatic in-
sulin resistance from the development of NASH. In light
of these data, a subsequent study demonstrated that the
livers of HFD-fed Nrf22/2 mice exhibited higher path-
ologic ROS formation by a significant depletion of GSH
due to attenuated expression of the CYP2A5 enzyme
(Cui et al., 2013). The knockdown of NRF2 in hepato-
cytes enhanced the apoptosis induced by palmitate, a
fatty acid that is highly elevated in insulin-resistant
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obese patients. This effect was correlated with in-
creased production of pathologic ROS, again reinforcing
the key role of NRF2 in the progression of NASH (Pilar
Valdecantos et al., 2015).
To further examine the role of NRF2 in the metabolic
syndrome, NRF2 was ablated in leptin-deficient (ob/ob)
mice, a model with an extremely positive energy balance
(Xue et al., 2013). Interestingly, global ob/ob/Nrf22/2mice
or adipocyte-specific ob/ob/Nrf22/2micedisplayed reduced
white fat mass, revealing NRF2 as a key player in
adipogenesis. These mice had an even more severe
metabolic syndrome that was characterized by hyper-
lipidemia, aggravated insulin resistance, and hyper-
glycemia, suggesting a mechanistic linkage between
the metabolic syndrome and pathologic ROS formation.
Another subset of studies has evaluated the effects of
persistent induction of NRF2 in glucose metabolism.
Genetic NRF2 induction making use of a hypomorphic
allele of Keap1 (Keap1flox/- mutant) decreased blood
glucose in the obese diabetic db/db mice by suppressing
hepatic glucose 6 phosphatase through the repression of
cAMP-CREB signaling in hepatocytes, as well as other
gluconeogenic genes, such as peroxisome proliferator-
activated receptor coactivator-1a (Uruno et al., 2013).
Additionally, enhancement of NRF2 activity in Keap11-
knocked down mice increased the phosphorylation of
AMP-activated protein kinase (AMPK) in the liver, as
well as insulin signaling in skeletal muscle, resulting in
a substantial improvement of glucose tolerance (Xu
et al., 2013). Due to the pleiotropic activities of NRF2 in
the context of T2DM, the results of all these and other
studies have evidenced the need to design multiple
genetic and pharmacological strategies to elucidate the
full array of NRF2 functions in tissues involved in the
control of whole-body glucose homeostasis.
In addition to diabetic factors like age, body weight,
and blood glucose, genetic factors that are linked to
NRF2 have been poorly studied in humans. In aChinese
population, the SNP rs6721961 has been associated
with pathologic ROS formation and risk of newly di-
agnosed T2DM and may also contribute to impaired
insulin secretory capacity and increased insulin re-
sistance (Wang et al., 2015). The same SNP was
associated with diabetes in Mexican mestizo men
(Jimenez-Osorio et al., 2017). In a case-control study
performed with Han volunteers, a significant difference
in genotypic and allelic frequencies of four SNPs of the
NFE2L2 gene was found between T2DM patients with
and without complications, including peripheral neu-
ropathy, nephropathy, retinopathy, foot ulcers, and
microangiopathy (Xu et al., 2016b).
G. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Neurodegenerative Diseases
The NRF2 diseasome provides evidence of NRF2
involvement in several neurodegenerative diseases,
including AD and PD, which represent the most
prevalent cognitive and motor disorders of the elderly.
In neurodegenerative diseases, the connection be-
tween low-grade pathologic ROS formation and proteo-
stasis is particularly relevant because most of these
pathophenotypes are characterized by abnormal ag-
gregation of specific proteins (Fig. 8). Evidence point-
ing to pathologic ROS formation in proteinopathy, as
well as NRF2 as regulator of proteasome and auto-
phagy was provided in cellular and animal models
(Pajares et al., 2017). Initially, it was reported that the
autophagy cargo protein sequestosome 1 (SQSTM1)
competes with NRF2 for binding to KEAP1. SQSTM1
takes KEAP1 to the autophagosome degradative path-
way, therefore upregulating NRF2 (Komatsu et al.,
2010). More recently, it was found that NRF2 regulates
the expression of autophagy genes involved in auto-
phagy initiation, cargo recognition, elongation, and
autolysosome clearance (Pajares et al., 2016). In this
study, amyloidopathy and tauopathy induced by trans-
gene overexpression of human mutant amyloid pre-
cursor protein and tau were aggravated in Nrf22/2
mice. A connection between NRF2 deficiency and
neurodegeneration is supported by a growing body of
evidence in animal models (Johnson and Johnson,
2015). The general point of view is that damaged
neurons try to activate NRF2-dependent transcription,
presumably to increase their own survival. Addition-
ally, upregulation of NRF2 in astrocytes participates
in metabolic compensations, including increased sup-
ply of GSH for augmenting their proliferative capacity
(Bolanos, 2016), whereas NRF2 upregulation in micro-
glia returns this immune cell to a resting state (Rojo
et al., 2014a).
Ramsey et al. (2007) evidenced the nuclear localiza-
tion of NRF2 in dopaminergic neurons of patients with
PD. Other studies found that amyloid precursor
protein– and tau-injured neurons expressed increased
levels of NRF2 and its target SQSTM1, probably as
compensatory mechanism to clear these toxic proteins
through autophagy (Lastres-Becker et al., 2014; Pajares
et al., 2016). In agreement with these results, the levels
of HO-1, NQO1, GCLM, and SQSTM1 are increased in
AD and PD brains (van Muiswinkel et al., 2004;
Cuadrado et al., 2009; Schipper et al., 2009; Lastres-
Becker et al., 2016). However, there is some controversy
in the field, as Ramsey’s study described the accumula-
tion of NRF2 in the cytosol of AD-injured neurons,
suggesting an impaired capacity of these neurons to
upregulate NRF2 transcriptional activity. In addition,
the cytoprotective proteins associated with NRF2 ex-
pression, such as NQO1 and SQSTM1, were partly
sequestered in Lewy bodies, suggesting impaired neuro-
protective capacity of the NRF2 signature in PD
patients (Lastres-Becker et al., 2016). One possible
explanation for this discrepancy could be that the levels
of NRF2 and its target genes might change during
ageing and disease progression.
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Some SNP haplotypes of NFE2L2 were associated
with decreased risk or delayed onset of ALS, AD, or PD.
The onset of ALS was analyzed in two studies regarding
three functional promoter SNPs that were previously
linked to high gene expression. Interestingly, this
haplotype was associated with a 4-year delay in onset
of ALS (Bergstrom et al., 2014), but another study did
not find a clear association (LoGerfo et al., 2014).
Regarding AD, one haplotype allele was associated with
2-year earlier age onset of AD, suggesting that variants
of the NFE2L2 gene may affect AD progression (von
Otter et al., 2010b). Genetic association ofNFE2L2with
PD has been analyzed in more detail. Three SNPs in
the NFE2L2 promoter (rs6721961, rs6706649, and
rs35652124) were evidenced as protective haplotype in
a case-control study (von Otter et al., 2010a). Such
haplotype delayed the onset of disease in a Swedish
cohort or even reduced the risk of PD in a Polish cohort.
These results were supported by four new independent
European case-control studies (von Otter et al., 2014),
but were not replicated in a Taiwanese population
(Chen et al., 2013), suggesting disparity in ethnicities
and environmental factors. As an alternative approach,
PD cells derived from olfactory mucosa were exposed to
smoke extract or pesticide to assess gene–environment
interaction, and several SNPs were identified that
affect the susceptibility to these toxins (Todorovic
et al., 2015). Altogether, it is possible that a slight
activation of NRF2, such as that found for some
functional haplotypes of the NFE2L2 gene, should be
enough to trigger protective mechanisms in the brain.
IV. The Kelch-Like ECH-Associated Protein
1 Paradox in Cancer
An apparent dichotomy appears to exist in the role of
NRF2 in tumorigenesis and further tumor progression.
On one hand, by activating biotransformation reactions,
NRF2 protects against chemically induced carcinogen-
esis. Preclinical studies have demonstrated complete
protection against aflatoxin B(1)-induced liver cancer
after pharmacological activation of NRF2 in rats
(Johnson et al., 2014). In contrast, the protective
responses elicited by NRF2 provide a growth advantage
in established cancers, and this will be the focus of this
section.
Constantly increased levels of ROS can sustain
tumorigenesis through alteration of genomic stability,
along with activation of specific redox signaling circuits
and inflammatory processes that favor survival and
proliferation of tumor cells (Reuter et al., 2010). There-
fore, upregulation of NRF2 represents a mechanism of
adaptation of cancer cells to tolerate high ROS levels
that propel tumor progression (Schumacker, 2006) as
well as to maintain cancer stem cells that are respon-
sible for tumor relapse and formation of distant metas-
tases (Ryoo et al., 2016). For instance, the NRF2
signature in cancer stem cells from human colorectal
tumors pointed out protective mechanisms mediated by
high levels of GCLC, glutathione peroxidase, and
thioredoxin reductase-1 that underlie the ability of
these cells to counteract stressors and chemotherapeu-
tics (Emmink et al., 2013). From this perspective, NRF2
behaves in cancer cells like an oncogene that by in-
ducing chronic activation of ARE-mediated cytoprotec-
tive responses affords adaptation to their oxidative
environment (Panieri and Santoro, 2016). Several
mechanisms of malignant activation of NRF2 have been
reported, including somatic mutations, epigenetics, and
oncogenic signaling alterations.
Close to 600 somatic mutations have been reported
in cancer along the coding sequence of NFE2L2 (Gao
et al., 2017). In Fig. 9, we show the results from a
dataset of 10,000 cancer patients (Zehir et al., 2017). In
most cases, these mutations alter the interaction of the
DLG and ETGE motifs of NRF2 with KEAP1, hence
inducing hyperactivation of NRF2 in several solid
tumors, including esophagus, skin, lung, and larynx
carcinomas (Kim et al., 2010b; Taguchi and Yama-
moto, 2017). For instance, in advanced esophageal
squamous cancer, gain-of-function mutations of
NRF2 were associated with tumor recurrence and poor
prognosis due to increased proliferation, attachment-
independent survival, and resistance to chemo- and
radiotherapy (Shibata et al., 2011). Loss-of-function
mutations in the KEAP1 gene are also frequent in some
solid tumors such as lung cancer (Singh et al., 2006).
Based on the strong evidence that this pathway regu-
lates b-TrCP/NRF2, it is strange that disrupting so-
matic mutations have not been found at the interface
between NRF2 and b-TrCP. This fact suggests that
such mutations are not viable for unknown reasons or
that the increase in NRF2 levels that would result
from the escape of b-TrCP is not sufficient to drive
oncogenicity.
Nonetheless, somatic mutations account for chronic
NRF2 activation only in a fraction of cancer patients. At
the level of gene expression, it is interesting that an
allele of the SNP rs6721961 (2617C. A) located at the
ARE enhancer of the human NRF2 gene abolished self-
induction of NRF2, and this correlated with remarkable
survival of these cancer patients (Okano et al., 2013).
Epigenetic changes due to promoter hypermethylation
of three CpG sites ofKEAP1 have been described in lung
tumors, resulting in consequent NRF2 activation that
could be reversed by 5-aza-29-deoxycitydine treatment
(Wang et al., 2008). The role of miRNAs in the post-
transcriptional regulation of NRF2 levels has been
reviewed recently (Kurinna and Werner, 2015). Briefly,
miR200a targets the KEAP1 mRNA in human breast
cancer cells, leading to its degradation and consequent
activation of NRF2 (Eades et al., 2011). In turn, miR28
facilitates the degradation of the NRF2 mRNA (Yang
et al., 2011).
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Oncogenes or mutated tumor suppressors may en-
hance the activation of NRF2 in cancer. Endogenous
oncogenic alleles of KRAS, BRAF, or c-MYC upregulate
NRF2, presumably through oncogene-mediated ROS
generation and consequent chronic inactivation of
KEAP1 (DeNicola et al., 2011). The mutated form of
the tumor suppressor p53, which sustains the growth of
cancer cells by enhancing nutrient uptake and synthesis
of building blocks, can also upregulate NRF2, possibly
through the crosstalk with the Sp1 transcription factor
that binds to the NRF2 promoter (Tung et al., 2015).
The phosphorylation of NRF2 (phospho-NRF2) by
various protein kinases is a potential mechanism of
activation in 107 hepatocellular carcinomas. Increased
levels of phospho-NRF2 were associated with reduced
KEAP1 expression and poor 5-year overall survival of
patients exhibiting this distinctive phenotype (Chen
et al., 2016). Additionally, mutations in the phosphatase
and tensin homolog (PTEN) tumor suppressor sustain
hyperactive and oncogenic phosphatidylinositol-3-kinase
(PI3K)–AKT signaling and consequent increase in NRF2
activity due to the downregulation of the PTEN/GSK-3/
b-TrCP pathway for the proteasomal degradation of
NRF2 (Rada et al., 2011, 2012; Cuadrado, 2015). Thera-
peutic interventions targeting the PTEN/GSK-3/b-TrCP
pathway should take into consideration that GSK-3 may
act both as tumor suppressor and tumor promoter, and is
also implicated in the generation of cancer stem cells
(McCubrey et al., 2014).
Some stress-induced proteins interact with KEAP1
and thus compete with its NRF2 binding in cancer cells.
Consequently, NRF2 escapes KEAP1-mediated degra-
dation. One of theNRF2 competitors for KEAP1 binding
is the phosphorylated form of the autophagy-adaptor
protein SQSTM1 that occurs during selective auto-
phagy used by cancer cells for sustaining their own
growth (Shimizu et al., 2016). The cyclin-dependent
kinase inhibitor p21 that promotes cell cycle arrest in
cancer stem cells was also demonstrated to inhibit the
association of NRF2 with KEAP1 through the interac-
tion of its KRR motif with DLG and ETGE motifs in
NRF2 (Chen et al., 2009). Recently, it was shown that
dipeptidyl-peptidase 3, which bears an ETGE motif,
may compete with NRF2 for binding to KEAP1 (Hast
et al., 2013). Overexpression of dipeptidyl-peptidase 3,
possibly induced by chronic alteration of the redox
status, correlates with increased expression of ARE
genes and poor prognosis, particularly in estrogen
receptor–positive breast cancer (Lu et al., 2017).
NRF2 induces metabolic changes that contribute to
cancer progression. For instance, a multiplatform non-
targeted metabolomics study identified patterns of
metabolite changes in breast tumor samples (Tang
et al., 2014). They found that GSH and 3-(4-
hydroxyphenyl)lactate were positively correlated with
the involvement of BRCA1 in redox homeostasis
through interaction with NRF2. Metabolomics studies
also indicate that NRF2 can increase aerobic glycolysis
in cancer cells to support their high-energy require-
ments. This occurs through NRF2-mediated induction
of Mn-superoxide dismutase expression, leading to
elevatedmitochondrial production of hydrogen peroxide
Fig. 9. Somatic mutations found in tumors of the MSK-IMPACT Clinical Sequencing Cohort (MSKCC) study (Zehir et al., 2017) and pharmacologic
strategies to inhibit NRF2. (A) Percentage of tumors with NRF2 mutations. (B) Distribution of mutations along the NRF2 polypeptide. (C) PyMOL
representation of the interaction between the NRF2/MAFF heterodimer and the ARE element. Blue, NRF2; pink, MAFF. The red arrows indicate
possible mechanisms of inhibition of NRF2 by small molecules that could target the bZip domains of interaction between NRF2 and MAF proteins (PPI
inhibitors) or the interface of interaction of the NRF2-MAF heterodimer with the ARE [DNA–protein interaction (DPI)].
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and to activation of AMPK. The process is regulated by
caveolin-1, which binds directly to both NRF2 and
KEAP1, and impedes on NRF2 activation and hence
on the glycolytic shift. This is apparently one explana-
tion why glycolytic tumors, which are generally more
aggressive, have a caveolin-1low/Mn-superoxide dismu-
tasehigh phenotype (Hart et al., 2016). NRF2 can also
drive glucose and glutamine toward anabolic pathways
required for tumor cell proliferation (Mitsuishi et al.,
2012). In the presence of active PI3K–AKT signaling
and loss of KEAP1 activity, NRF2 was shown to induce
the shift of glucose metabolism from glycolysis toward
anabolic pathways (purine synthesis) in cancer
(Mitsuishi et al., 2012; Xu et al., 2016a). This is under-
lined byNRF2-mediated transcription of genes involved
in the pentose phosphate pathway and generation of
NADPH (glucose 6 phosphate dehydrogenase; phospho-
gluconate dehydrogenase, malic enzyme 1, isocitrate
dehydrogenase 1, transketolase, and transaldolase),
along with genes involved in purine nucleotide synthe-
sis (phosphoribosyl pyrophosphate amidotransferase,
methylenetetrahydrofolate dehydrogenase 2).
The fact that activation of NRF2 confers a growth
advantage to cancer cells might argue that its pharma-
cologic activation in chronic diseases presented in this
work might imply a high risk of developing cancer.
However, it must be considered that the oncogenic
activity of NRF2 requires mutations in its gene or in
KEAP1, which results in very high and persistent
induction of NRF2 signaling. This is not the case in
pharmacological therapy, in which it is possible to
modulate drug dosing and NRF2 activity. Moreover,
empirical evidence indicates that subjects enrolled in
clinical trials with NRF2 activators do not exhibit
increased cancer risk. This is best exemplified in the
case of patients with MS, who have been taking the
NRF2 activator dimethyl fumarate for several years
since it was approved by the regulatory agencies in
2013. Conversely, the use of NRF2 inhibitors in cancer
patients might lead to manifestation of the pathophe-
notypes described in the NRF2 diseasome. This is a
possibility that will need further investigation when
NRF2 inhibitors reach the clinic.
V. Nuclear Factor (Erythroid-Derived 2)–
Like 2 Drugome
This section attempts to develop a NRF2 drugome
that might be useful for future clinical directions to
target therapeutically NRF2 centered on the pathophe-
notypes of the NRF2 diseasome. As stated in Fig. 2B,
the pharmacological activation of NRF2 is being pur-
sued for increasing its stability by targeting KEAP1.
These strategies are based on the discovery of either
electrophile compounds that alter the KEAP1 structure
or small molecules that prevent the docking of NRF2 to
KEAP1. Although not yet demonstrated empirically,
the GSK-3 inhibitors should prevent the recognition of
NRF2 by b-TrCP and some compounds could be discov-
ered to prevent binding of NRF2 to b-TrCP. The
inhibition of NRF2 is being analyzed with compounds
that target the bZip dimerization domain to prevent
formation of the active NRF2/MAF heterodimer. By
comparison with other transcription factors, it might be
possible to find small molecules that impede binding
of the NRF2/MAF heterodimer to the ARE (Fig. 9C).
This section summarizes the most important findings
from a translational point of view in both de novo drug
discovery and repurposing.
A. Electrophilic Nuclear Factor (Erythroid-Derived 2)–
Like 2 Inducers
Themajority of known physiologic or pharmacological
NRF2 inducers are electrophilic molecules that cova-
lently modify, by oxidation or alkylation, cysteine
residues present in the thiol-rich KEAP1 protein (Hur
and Gray, 2011; Satoh et al., 2013). KEAP1 is one of the
best-suited proteins to act as electrophilic or redox
sensor, as it contains 27 cysteine residues in humans
and functions as an electrophile trap. The cysteines
C151, C273, and C288 of KEAP1 appear to be the most
prone to electrophile reaction (Fig. 2B), although there
are some specificities (Yamamoto et al., 2008; Saito
et al., 2015). Electrophile adducts inhibit KEAP1 in two
different ways. One is induction of a conformational
change in KEAP1 that will result in loss of its binding
capacity to NRF2. The other is the blockade of the
interaction between KEAP1 and CUL3/RBX1, resulting
in sequestration of KEAP1 with NRF2 and further
stabilization of newly synthetized NRF2 (Rachakonda
et al., 2008; Baird and Dinkova-Kostova, 2013; Cleasby
et al., 2014; Saito et al., 2015).
At least 30 recent patents for NRF2 modulators are
indexed in the World International Property Organiza-
tion. These patents are protecting chalcone derivatives,
novel amide triterpenoid derivatives, deuterium-
substituted fumarate derivatives, 3-alkylamino-1H-
indolyl acrylate derivatives, withanolide, a benzyl
derivative containing an activated vinyl group, androgra-
pholide or [S]+apomorphine, and sesquiterpene lactone
derivative (Sun et al., 2017). Although most of these
compounds proved to be useful to some degree from a
preclinical proof-of-concept perspective, their clinical
value is to date generally very limited. Only a few of
them have entered clinical trials, and regulatory bodies,
such as Food and Drug Administration or European
Medicines Agency, have approved even fewer. We in
this study discuss the most developed NRF2 activators
along the translational pipeline.
Fumaric acid esters are the most prominent example
of a KEAP1 modifier, and dimethyl fumarate (DMF) is
to date the only Food and Drug Administration– and
European Medicines Agency–approved drug registered
as NRF2 activator. The monoester form of DMF,
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monomethyl fumarate (MMF), was described as its
active metabolite. DMF and MMF are Michael accep-
tors that directly react with cysteine residues present in
KEAP1 (Lin et al., 2011).
DMF and other fumaric acid esters have been used for
treating psoriasis for over 50 years, starting at a time
when the function of NRF2 was still unknown. This
compoundwas licensed in Europe under the commercial
name of Fumaderm. Clinical trials showed a decrease in
the psoriasis area and severity index to 50%–80% after
12–16 weeks of DMF therapy (Altmeyer et al., 1994;
Mrowietz et al., 1998). More recently, DMF has demon-
strated its efficacy in the treatment of adults with
moderate to severe chronic plaque psoriasis in a phase
III trial (BRIDGE) (Mrowietz et al., 2017). The mecha-
nism of action underlying fumarates in remission of
psoriatic lesions includes the decrease in the number of
peripheral T cells along with a shift from a Th1 toward a
Th2 immune response (Ghoreschi et al., 2011; Tahvili
et al., 2015). In another autoimmune disease, SLE,
fumaric acid esters have been used as systemic combi-
nation therapy in the treatment of severe, extensive,
and refractory cutaneous manifestations (Saracino and
Orteu, 2017).
DMF was approved in 2013 for the treatment of MS
under the commercial name Tecfidera (Xu et al., 2015).
The use of DMF in MS patients was propelled by
positive results obtained in the MS mouse model of
EAE. Significant therapeutic effects on the disease
course and histology were associated with a markedly
reduced macrophage-mediated inflammation in the
spinal cord. Multiplex cytokine analysis in blood evi-
denced an increase of the anti-inflammatory cytokine
IL-10 in DMF-treated animals (Schilling et al., 2006).
Moreover, DMF also improved preservation of myelin,
axons, and neurons inwild-type, but not inNrf22/2mice
(Ellrichmann et al., 2011). In humans, DMF demon-
strated a significant reduction of lesions and annualized
relapse rate in MS (Schimrigk et al., 2006). Two phase
III clinical trials, DEFINE and CONFIRM, substanti-
ated these results (Fox et al., 2012; Gold et al., 2012).
Therefore, DMF is currently used as the first line of
treatment of relapsing-remitting MS that cannot be
treated by traditional therapies. New formulations of
DMF are being tested and patented to improve drug
bioavailability and efficacy (Sun et al., 2017). For
instance, MMF has been used to develop a second
generation of NRF2 inducers as prodrugs (Zeidan
et al., 2014). The lead compound ALKS-8700, a 2-(2,5-
dioxo-1-pyrrolidinyl)ethyl ester derivative of MMF, is
rapidly converted into MMF in the body, hence in-
creasing its bioavailability and reducing gastrointesti-
nal side effects. ALKS-8700 is currently under phase III
clinical trial (EVOLVE MS).
DMF and MMF modulate the immune response. For
example, they inhibit the maturation of DCs by re-
ducing the release of inflammatory cytokines and hence
the ability of DCs to process antigens. Moreover, DMF
and MMF activate natural killer cells to lyse DCs and
enhance apoptosis of both DCs and T cells (Ghoreschi
et al., 2011; Al-Jaderi and Maghazachi, 2015). As such,
DMF and MMF impede T cell–mediated autoreactivity.
Some studies indicate that DMF also induces type II
DCs by triggering GSH depletion, which results in
enhanced HO-1 activity and suppression of STAT1
phosphorylation. These classic type II DCs suppress
Th1- and Th17-mediated responses in favor of Th2 ones.
Furthermore, the increased production of IL-10 by DCs
favors the differentiation of CD4+ T cells toward a
suppressive Treg phenotype (Ockenfels et al., 1998;
Ghoreschi et al., 2011). DMF also inhibits the nuclear
translocation of NF-kB (Peng et al., 2012) and conse-
quently the production of inflammatorymediators, such
as TNF-a, IL-1b, IL-6, chemokines, adhesionmolecules,
and nitric oxide in microglia and astrocytes (Brennan
et al., 2017), as well as in peripheral blood mononuclear
cells (Eminel et al., 2017). In addition, DMF exerts
antiangiogenic effects that are dependent on the down-
regulation of vascular endothelial growth factor
receptor-2 expression in endothelial cells (Meissner
et al., 2011). Recent findings indicated that DMF
reduced the number of CD4+, CD8+, Th1, and Th17
cells, whereas the CD4+/CD8+ ratio and the Th2 subset
were increased in the blood of these patients. Interest-
ingly, the inhibitory effects of DMF/MMF on T cell
activation were confined mainly to memory T cells (Wu
et al., 2017). These immunomodulatory activities of
DMF or MMF are important for the protection of
oligodendrocytes against ROS-induced cytotoxicity
(Scannevin et al., 2012).
Additional mechanisms might explain the inhibition
of NF-kB independently of NRF2 activation. Thus, DMF
may interact with cysteine residues in several proteins
that regulate NF-kB signaling (Blewett et al., 2016). In
addition, DMF inhibits ubiquitin-conjugating enzymes
and thus prevents the degradation of the IkB repressor
of NF-kB in response to IL-1b or Toll-like receptor
agonists (McGuire et al., 2016). Moreover, DMF binds
directly to specific cysteine residues in protein kinase
C-u, a key kinase involved in signaling by the T cell
receptor (Blewett et al., 2016). In addition, MMF and
DMF activate the hydroxycarboxylic acid receptor-2,
resulting in inhibition of NF-kB and downregulation of
proinflammatory cytokines and adhesion molecules
(Chen et al., 2014; Gillard et al., 2015) and leading to
decreased neutrophil infiltration (Chen et al., 2014).
Although these NRF2-independent effects would
be relevant in the acute inflammatory phase of EAE,
the neuroprotective efficacy of DMF during chronic
autoimmune demyelination depends on NRF2 activa-
tion (Linker et al., 2011). The clinical benefit of
DMF treatment in both Nrf22/2 and wild-type mice
was associated with a reduction of inflammatory
Th1 and Th17 cells, as well as with induction of
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anti-inflammatory M2 monocytes. At the same time,
decreased expression of CD80 and CD86 costimulatory
molecules was observed in wild-type, but not inNrf22/2
mice, indicating that at least these effects were NRF2-
dependent (Schulze-Topphoff et al., 2016).
The success of DMF for the treatment of autoimmune
diseases indicates that other diseases that share com-
mon pathomechanisms underlined by chronic, low-
grade inflammation and pathologic ROS formation
might benefit from the repositioning of this drug. In a
mouse model of Huntington’s disease, the survival rate,
muscle function, and body weight were preserved with
DMF treatment, and this was associated with an
increased number of intact neurons (Ellrichmann
et al., 2011). Also, in a recent preclinical study of PD,
using the a-synucleinopathymodel of this disease, DMF
was neuroprotective in wild-type, but not in Nrf22/2
mice due to impaired autophagy induction (Lastres-
Becker et al., 2016).
DMF was shown to prevent endothelial dysfunction
and cardiovascular pathologic ROS formation and in-
flammation in diabetic mice (Sharma et al., 2017), and
decreased atherosclerosis, kidney dysfunction, and
other diabetic complications were reported in apolipo-
protein E–deficient mice after streptozotocin injection
(Tan et al., 2014). Additionally, several studies in-
dicated that DMF might exert antitumor activity by
inhibiting the NF-kB pathway, hence adding therapeu-
tic value in the treatment of aggressive cancers
(Kastrati et al., 2016). DMF is a relevant example of
the drug-repurposing concept within the network phar-
macology approach.
Synthetic triterpenoids are derivatives of 2-cyano-
3,12-dioxo-oleana-1,9(11)-dien-28-oate (CDDO; bardox-
olone, RTA401) that resemble the natural product
oleanolic acid. They exhibit Michael acceptor activity
through its a-b unsaturated scaffold and represent the
most potent inducers of NRF2 (Sun et al., 2017). They
interact with C151 of KEAP1 and impede its interaction
with CUL3, hence leading to NRF2 activation (Cleasby
et al., 2014). Proof-of-principle studies strongly support
the use of synthetic triterpenoids for degenerative
diseases and are being the focus of intensive research
as antioxidant modulators of inflammation by Reata/
Abbott. For instance, CDDO-imidazole (CDDO-Im
RTA403) induced in peritoneal neutrophils of wild-
type but not Nrf22/2 mice the expression of various
antioxidant genes (Hmox1, Gclc, Gclm, and Nqo1) and
attenuated LPS-induced ROS generation and produc-
tion of proinflammatory cytokines, consequently de-
creasing mortality (Thimmulappa et al., 2006b).
CDDO-ethyl amide (RTA405) and CDDO-CDDO-
trifluoethyl amide (RTA 404) had significant effects
across all endpoints measured in a toxin-induced PD
model (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
(Kaidery et al., 2013). In the EAE model of MS, CDDO-
CDDO-trifluoethyl amide suppressed inflammation,
pathologic ROS formation, and myelin degeneration
(Pareek et al., 2011).
CDDO-methyl ester (CDDO-Me, RTA 402) was the
first CDDO that reached in clinical trials for the
treatment of diabetic nephropathy (Pergola et al.,
2011). Although the results of the phase II were very
encouraging, CDDO-Me was later withdrawn at phase
III (BEACON trial) due to cardiovascular safety issues
(Zhang, 2013) that were not related to NRF2 but most
likely to an off-target alteration of endothelin signaling
(de Zeeuw et al., 2013; Chin et al., 2014). Currently,
CDDO-Me is under clinical study as potential treatment
of Alport syndrome and pulmonary hypertension
(Table 2). In an effort to improve its safety profile,
further studies have led to the development of CDDO-
difluoropropionamide (RTA-408, omaveloxone), which
is currently in phase II trial for the treatment of
Friedreich’s ataxia, ocular inflammation, and pain after
ocular surgery.
Oltipraz is an organosulfur compound that is used as
an antischistosomal agent and is currently in phase III
trial for the treatment of nonalcoholic steatohepatitis.
Advanced clinical trials for the treatment of Hunting-
ton’s disease are under development with minocycline,
an antibiotic that has demonstrated neuroprotective
properties due to NRF2 activation (Kuang et al., 2009).
Another NRF2 inducer in phase I clinical study for the
treatment of acute kidney disease is CXA-10, a nitro
fatty acid with anti-inflammatory properties through
the activation of NRF2 (Batthyany and Lopez, 2015).
Many other NRF2 inducers with the same mechanism
of action have been described in the last years (Buendia
et al., 2015a,b, 2016), and some are in preclinical
studies, such as the compound VEDA-1209, a chalcone
derivative with a good anti-inflammatory profile for the
treatment of ulcerative colitis.
SFN is an isothiocyanate produced from enzymatic
cleavage of the organosulfur compound glucoraphanin,
which is present in sprouts of broccoli, cabbage, and
other Brassicacea plants. The catalytic reaction is
driven by the enzymemyrosinase that is found in plants
and microbiota of the GI tract (Kensler et al., 2013).
More recently, SFN has been obtained by chemical
synthesis (Kim et al., 2015). Translation of SFN to the
clinic has been achieved by administration of SFN-
containing broccoli sprout powder to patients with
T2DM (Bahadoran et al., 2012). Broccoli powder de-
creased plasma malondialdehyde and oxidized low-
density lipoprotein (LDL) and increased the total
antioxidant capacity. Cardiovascular risk factors such
as serum triglycerides, oxidized LDL/LDL ratio, and
atherogenic index of plasma (log of triglycerides/high-
density lipoprotein ratio) were also reduced. Further-
more, proinflammatory markers such as C-reactive
protein and IL-6 were decreased. In a more recent
study, SFN administered as concentrated broccoli
sprout extract suppressed glucose production from
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TABLE 2
Selected NRF2 inducers acting as electrophilic modifiers of KEAP1
The reference corresponds to the code in ClinicalTrials.gov.
Compound Disease Clinical Trial Reference
Multiple sclerosis Approved
Psoriasis Approved
Rheumatoid arthritis Phase II NCT00810836
Adult brain glioblastoma Phase I NCT02337426
Cutaneous T cell lymphoma Phase II NCT02546440
Obstructive sleep apnea Phase II NCT02438137
Chronic lymphocytic leukemia small lymphocytic lymphoma Phase I NCT02784834
Multiple sclerosis Phase III NCT02634307
Diabetic nephropathy Phase II NCT00811889
Chronic kidney disease, T2DM, diabetic nephropathy Phase III NCT01351675
Liver disease Phase I/II NCT00550849
Hepatic impairment Phase I NCT01563562
Advanced solid tumors
Lymphoid malignancies
Phase I NCT00529438
NCT00508807
Alport syndrome PhaseII/III NCT03019185
Pulmonary hypertension Phase III NCT03068130
Pulmonary arterial hypertension Phase III NCT02657356
Renal insufficiency, T2DM Phase II NCT01053936
Mitochondrial myopathy Phase II NCT02255422
Friedreich’s ataxia Phase II NCT02255435
Inflammation and pain following ocular surgery Phase II NCT02065375
Corneal endothelial cell loss, ocular pain and inflammation,
cataract surgery
Phase II NCT02128113
Melanoma Phase I/II NCT02259231
Breast cancer Phase II NCT02142959
Non-small cell lung cancer, melanoma Phase I NCT02029729
Acute kidney injury Phase I NCT02248051
HD Phase II/III NCT00277355
Intracerebral hemorrhage Phase I/II NCT01805895
Retinitis pigmentosa Phase I/II NCT02140164
Intracerebral hemorrhage Phase I/II NCT03040128
NASH Phase III NCT02068339
Schistosomiasis Approved
Lung cancer Phase I NCT00006457
(continued )
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TABLE 2—Continued
Compound Disease Clinical Trial Reference
Ulcerative colitis Preclinical PK ——
Cystic fibrosis Phase II NCT01315665
Schizophrenia Phase II/III NCT02880462
Phase II NCT02810964
Phase II NCT01716858
COPD Phase II NCT01335971
Atopic asthmatics Phase I NCT01845493
Autism Phase II NCT01474993
Phase II NCT02909959
Phase II NCT02677051
Phase II NCT02654743
Phase I/II NCT02561481
Healthy Phase I NCT01008826
Phase I NCT02023931
Melanoma Phase I NCT01568996
Asthma Phase I NCT01845493
Phase I/II NCT01183923
Prostate cancer Phase II NCT01228084
Breast cancer Phase II NCT00843167
Lung cancer Phase II NCT03232138
Environmental carcinogenesis Phase II NCT01437501
Alcohol sensitivity Phase II NCT01845220
Aging Phase II NCT03126539
Allergic rhinitis Phase II NCT02885025
Helicobacter pylori infection Phase IV NCT03220542
T2DM Phase II NCT02801448
Head and neck squamous cell carcinoma, head and neck
cancer, tobacco-related carcinoma
Phase I NCT03182959
Subarachnoid hemorrhage Phase II NCT02614742
Breast neoplasm Phase I/II NCT02970682
Prostate cancer Phase I NCT02055716
NCT01948362
Brain ischemia Preclinical PK —
Alzheimer disease Phase II NCT02711683
Acute ischemic stroke Phase I/II NCT02149875
Vascular cognitive impairment Phase II/III NCT02993367
Cerebrovascular occlusion, collateral blood circulation, anterior
cerebral circulation infarction
Phase IV NCT02594995
(continued )
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hepatocytes by nuclear translocation of NRF2 and
decreased expression of key enzymes involved in gluco-
neogenesis. Moreover, SFN reduced fasting blood glu-
cose and glycated hemoglobin in obese patients with
T2DM (Axelsson et al., 2017). SFN-induced activation of
NRF2 protected renal cells against lupus nephritis by
reducing the ROS burden and by inhibiting the NF-kB
and TGF-b1 signaling pathways (Jiang et al., 2014a).
In regard to neurodegenerative diseases, it has been
shown that SFN crosses the blood brain barrier and
provides sufficient cerebral bioavailability to activate
the NRF2 signature and to reduce LPS-elicited neuro-
inflammation, as reflected in the reduction of proin-
flammatory markers (inducible nitric oxide synthase,
IL-6, TNF-a) and microgliosis in the hippocampus
(Innamorato et al., 2008). SFN also safeguarded dopa-
minergic neurons against the parkinsonian toxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and at-
tenuated astrogliosis and microgliosis (Jazwa et al.,
2011). In line with these findings, SFN reduced the
levels of phosphorylated tau and increased Beclin-1 and
LC3-II, suggesting that NRF2 activation might facili-
tate degradation of this toxic protein through auto-
phagy in the brain (Jo et al., 2014). SFN-treated rats
subjected to spinal cord injury had significantly
decreased levels of inflammatory cytokines, reduced
contusion volume, and improved coordination (Wang
et al., 2012). This drug also ameliorated EAE by
preserving the blood-brain barrier and by reducing
pathologic ROS formation and the number of inflam-
matory cells (Li et al., 2013). SFN has been used to date
in at least 32 clinical studies addressing chronic dis-
eases such as cancer, asthma, chronic kidney disease,
T2DM, cystic fibrosis, autism, and schizophrenia
(Duran et al., 2016; Houghton et al., 2016) (Table 2).
Altogether, these observations paved the way for the
development of other SFN-derived compounds exhibit-
ing an improved pharmacokinetic profile. SFN is an oily
substance with low stability in hydrophilic media. Its
physicochemical profile prompted Evgen Pharma
(Wilmslow, Cheshire, England) to develop a cyclodex-
trin complex formulation, Sulforadex, which is under
phase II clinical trial for the treatment of subarachnoid
hemorrhage. SFN was also hybridized with melatonin
to generate the ITH12674, a compound that was designed
to have a dual drug–prodrug mechanism of action for
treatment of brain ischemia (Egea et al., 2015).
Curcumin is the main curcuminoid found in turmeric
and has been used for the treatment of obesity, meta-
bolic syndrome, and prediabetes. A nontargeted
TABLE 2—Continued
Compound Disease Clinical Trial Reference
Cholestasis Phase II/III NCT00846963
HD Phase I NCT00514774
Barrett esophagus, low-grade dysplasia Phase II NCT01097304
Chronic hepatitis C Phase III NCT00200343
T2DM Phase II NCT02033876
T2DM Phase I NCT01677611
Colon cancer Phase I NCT00256334
COPD Phase III NCT02245932
Friedreich ataxia Phase I/II NCT01339884
NASH Phase II/III NCT02030977
Non-ischemic cardiomyopathy Phase III NCT01914081
Endometriosis Phase IV NCT02475564
Chronic renal insufficiency Phase III NCT02433925
Metabolic syndrome X Phase II NCT02114892
Chronic subclinic inflammation Phase III NCT01492114
AD Phase II NCT01504854
Phase III NCT00743743
Colorectal cancer Phase I NCT00433576
HD Phase III NCT02336633
T2DM, cardiovascular risk Phase IV NCT01052025
Schizophrenia, cognition, psychosis Phase I/II NCT02104752
Acute kidney injury, abdominal aortic aneurysm Phase II/III NCT01225094
Chronic kidney diseases, T2DM Phase II/III NCT03262363
AD Phase I/II NCT00164749
Neoplasms Phase II NCT02944578
Crohn’s disease Phase III NCT02255370
Chronic schizophrenia Phase IV NCT02298985
Mild cognitive impairment Phase II NCT01811381
Prostate cancer Phase III NCT02064673
Major depression Phase IV NCT01750359
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metabolomics study to investigate the effects of curcu-
min on rat liver was conducted by means of gas
chromatography with electron impact mass spectrome-
try. The intermittent intake of curcumin upregulated
NRF2 and displayed antioxidant and anti-inflammatory
roles in the protection against liver damage (Qiu et al.,
2016). Oral consumption of curcumin is effective in
lowering serum triglycerides, IL-1b, IL-4, and vascular
endothelial growth factor, and in increasing adiponectin
levels in blood. In T2DM patients, curcumin decreases
the levels of fasting blood glucose, glycated hemoglobin,
serum free fatty acids, triglycerides, and uric acid, and
increases the levels of lipoprotein lipase (Na et al., 2013;
Chuengsamarn et al., 2014).
Resveratrol is a polyphenol that protects plants
against fungal infection and is found in the skin of
grapes, red wine, berries, and many other plants.
Resveratrol exerts antioxidant properties through acti-
vation of NRF2 signaling by downregulating KEAP1
expression and by activating the protein deacetylase
sirtuin-1 (Ungvari et al., 2010). In healthy subjects, the
dietary administration of resveratrol prevented the
elevation in plasma of cholesterol, endotoxins, pro-
oxidants, and inflammatorymarkers (p47phox, KEAP1,
IL-1b, and TNF-a). These events correlated with the
elevation of NRF2 activity as determined by enhanced
expression of its targets NQO1 and glutathione
S-transferase (Ghanim et al., 2011). In T2DM patients,
insulin sensitivity was improved after 4 weeks of
treatment, as determined by enhanced insulin signaling
via AKT, decreased pathologic ROS formation, and
reduced levels of glycated hemoglobin (Brasnyo et al.,
2011; Bhatt et al., 2012). Overall, resveratrol was
reported to prevent major cardiovascular, inflamma-
tory, oxidative, and metabolic complications in hyper-
tension, hypercholesterolemia, atherosclerosis, ischemic
heart disease, diabetes, and metabolic syndrome in
animal models and patients (Xia et al., 2017).
A problem that is frequently overlooked is the lack of
selectivity of electrophilic KEAP1 inhibitors. Electro-
philes react with different nucleophiles present in the
cell, thus exhibiting off-target and nondesired side
effects. For instance, CDDO-Im can interact with more
than 500 different targets (Yore et al., 2011). In general,
several protein phosphatases contain redox-sensitive
cysteines in their catalytic center, and some KEAP1
inhibitors may modify and inactivate these phospha-
tases, hence disturbing signaling networks. One of
these phosphatases is PTEN (Lee et al., 2002;
Kitagishi and Matsuda, 2013; Han et al., 2015). The
catalytic C124 residue of PTEN can bemodified through
adduct formation with strong electrophiles such as
CDDO-Im (Pitha-Rowe et al., 2009) and tert-
butylhydroquinone (Rojo et al., 2014b). Then, the in-
creased activation of the PI3K/AKT pathway involves
inhibition of GSK-3 and subsequent stabilization of
NRF2 (Fig. 2C) (Rada et al., 2011, 2012). Moreover,
KEAP1 interacts with other proteins that also contain
the high-affinity bindingmotif ETGE (Hast et al., 2013),
such as Bcl-2 and IKKb (Kim et al., 2010a; Cazanave
et al., 2014). Therefore, some results obtained from
KEAP1-deficient cells may not necessarily be related to
NRF2 activation.
B. Protein–Protein Interaction Inhibitors for Nuclear
Factor (Erythroid-Derived 2)–Like 2 Activation
To overcome the pitfall of selectivity, a new class of
NRF2 inducers that prevent the docking of NRF2 to
KEAP1 has emerged (Richardson et al., 2015). The use
of PPI inhibitors has been achieved by the prior
elucidation of the X-ray crystal structure of KEAP1
(Padmanabhan et al., 2006) bound to a peptide contain-
ing the high-affinity binding ETGE motif of NRF2 (Lo
et al., 2006). KEAP1 contains a six-bladed b-propeller
with specific hydrophobic and hydrophilic residues that
participate in the docking of theETGEmotif that adopts
a b-hairpin structure. Docking is mainly favored by
electrostatic interactions between several arginines of
KEAP1 and the two glutamates in the ETGE motif (Lo
et al., 2006; Padmanabhan et al., 2006). The docking to
KEAP1 of the low-affinity DLG motif of NRF2 has also
been characterized (Tong et al., 2007). Based on these
interactions, peptidomimetic compounds were the first
example of PPI inhibitors with significantly improved
selectivity over electrophiles (Hu et al., 2013; Marcotte
et al., 2013; Winkel et al., 2015). These inhibitors show
weak activity in cells, and a new provocative strategy
has now been reported based on the use of cyclic
peptides. One of these peptides exhibited high-binding
affinity for KEAP1 and activation of NRF2 and elicited
anti-inflammatory effects in mouse macrophages (Lu
et al., 2018).
The discovery of new peptides and small-molecule
inhibitors of the KEAP1/NRF2 interaction has been
reviewed recently (Abed et al., 2015; Jiang et al., 2016).
Briefly, a series of truncated NRF2 peptides was
initially evaluated as direct inhibitors of PPI using
surface plasmon resonance and fluorescence polariza-
tion assays (Hu et al., 2013). The minimal peptide
sequence with inhibitory capacity was the 9-mer se-
quence of LDE-ETGE-FL (Chen et al., 2011; Inoyama
et al., 2012). In parallel, Wells and collaborators
(Hancock et al., 2013) searched for new putative peptide
ligands using a phage display library combined with
high-throughput fluorescence polarization assay. They
found that hybrid peptides based upon the ETGE motif
of NRF2 and SQSTM1 have superior binding activity to
KEAP1 compared with either native peptide alone. To
facilitate cellular uptake, a peptide was designed with
the ETGEmotif fused to the cell transduction domain of
the HIV-Tat protein and the cleavage sequence of
calpain (DEETGE-Cal-Tat). This peptide showed neu-
roprotective and cognitive-preserving effects in amouse
model of cerebral ischemia (Tu et al., 2015).
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TABLE 3
Selected NRF2 inducers acting as NRF2–KEAP1 protein–protein interaction inhibitors
Compound Patent Title Applicant
WO2017060855 Arylcyclohexyl pyrazoles as NRF2
regulators
GlaxoSmithKline Astex
Therapeutics
WO2016/202253 NRF2 regulators GlaxoSmithKline Astex
Therapeutics, GlaxoSmithKline
(China), R&D
WO2014/197818 Small-molecule activators of NRF2
pathway
General Hospital, Regents of the
University of California
WO2013/067036 Direct inhibitors of KEAP1–NRF2
interaction as antioxidant
inflammation modulators
Rutgers, The State University of
New Jersey, Broad Institute
WO2011/156889 Novel modulators of NRF2 and
uses thereof
TRT Pharma Gerald Batist, Jian
Hui Wu
JP2011/0167537 KEAP1 protein-binding compound,
crystal of complex between the
same and KEAP1 protein, and
method for producing the same
Toray Industries
(continued )
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Five families of PPI inhibitors have been described:
tetrahydroisoquinoline (Jnoff et al., 2014; Richardson
et al., 2015), thiopyrimidine (Marcotte et al., 2013),
naphthalene (Jiang et al., 2014b), carbazone (Ranjan
et al., 2014), and urea derivatives (Sato et al., 2013).
Table 3 compiles recent patents addressing these
small molecules. Although these compounds are very
promising, it is still needed to demonstrate that they are
selective for the KEAP1/NRF2 interaction, because
KEAP1 also targets at least Bcl2 and IKK (Kim et al.,
2010a; Hast et al., 2013; Cazanave et al., 2014).
From the large number of compounds indexed in the
available libraries, the compounds LH601, benzenesulfonyl-
pyrimidone 2, N-phenyl-benzenesulfonamide, and a series
TABLE 3—Continued
Compound Patent Title Applicant
WO2017124835 1-sulfonamido-4-aryloxy
compound, and preparation
method and medicinal
application thereof
China Pharmaceutical University
WO2015/092713 NRF2 regulators GlaxoSmithKline Astex
Therapeutics Limited
WO2011156889A1 Novel regulators of NRF2 and uses
thereof
TRT Pharma Gerald Batist, Jian
Hui Wu
WO2016/202253 NRF2 regulators GlaxoSmithKline Astex
Therapeutics, GlaxoSmithKline
(China), R&D CO., LTD
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of 1,4-diphenyl-1,2,3-triazoles might be very well-suited
candidates to inhibit the PPI with KEAP1 (Hu et al.,
2013; Jnoff et al., 2014; Bertrand et al., 2015; Wen
et al., 2015; Nasiri et al., 2016). These studies de-
scribed in detail the atomic interaction with KEAP1,
the affinity, and the thermodynamics parameters of
binding. The therapeutic efficacy of these compounds
is to be analyzed in future work in which safety,
potency, and blood brain barrier permeability should
be addressed.
C. Drug Targets Other Than Kelch-Like
ECH-Associated Protein 1 for Nuclear Factor
(Erythroid-Derived 2)–Like 2 Activation
Protein kinase GSK-3 phosphorylates the two serine
residues in the DSGIS sequence of NRF2 to generate a
phosphorylation-dependent degradation motif or phos-
phodegron (Fig. 2). This phosphodegron is recognized by
the E3 ligase adapter b-TrCP, leading to ubiquitin-
dependent proteasomal degradation of NRF2. There-
fore, GSK-3 inhibitors should stopNRF2 degradation by
preventing the generation of this phosphodegron. GSK-3
is an important kinase in AD and other pathophenotypes.
It phosphorylates the cytoskeletal protein tau, facilitating
the formation of neurofibrillary tangles, which are path-
ologic intracellular aggregates that disturb axonal trans-
port and lead to neuronal death (Silva et al., 2014).
Therefore, it has been speculated that GSK-3 inhibition
might have the double benefit of preventing neurofibril-
lary tangle formation and NRF2 degradation. Unfortu-
nately, most pipelines for the development of GSK-3
inhibitors have been discontinued due to futility, although
in most cases there was not good evidence of target
modulation (Palomo and Martinez, 2017).
Conceptually, inhibitors of the b-TrCP-phosphoNRF2
interaction should also lead to NRF2 activation as they
should disrupt this branch ofNRF2 degradation (Fig. 2).
The molecular interactions between the b-propeller of
b-TrCP and a peptide containing the NRF2 phosphode-
gron have been resolved by NMR (Rada et al., 2012). As
it happens for KEAP1/EGTE, the most relevant amino
acids appear to be several arginine residues of b-TrCP
that interact with the two phosphoserines of the
DpSGIpS motif. However, the discovery of small mole-
cules that could inhibit the b-TrCP-phosphoNRF2 in-
teraction is still to come.
Additional strategies have been developed to inhibit
the NRF2 repressor BACH1, a bZip protein that makes
heterodimers with MAF proteins and blocks expression
of ARE genes. Efficient inhibition of BACH1 by the
HPP-4382 compound has been described in vitro
(Attucks et al., 2014), but, prior to a full clinical trial,
the safety and efficacy profile of HPP-4382 will have to
be demonstrated in vivo. Considering that other path-
ways may also influence NRF2 activity, it is reasonable
to speculate that a combinatorial approach will be the
best way to activate this transcription factor.
D. Nuclear Factor (Erythroid-Derived 2)–
Like 2 Inhibitors
NRF2 has a “dark side” related to its oncogenic
activity when constitutively and highly overexpressed.
Therefore, NRF2 inhibition has been proposed as a
mechanism to sensitize cancer cells to chemotherapeu-
tic drugs or radiotherapy (Milkovic et al., 2017). Two
strategies can be envisioned to inhibit NRF2 with small
molecules: PPI inhibitors that disrupt the bZip interac-
tion between NRF2 and MAFs, and DNA–protein in-
teraction inhibitors that block binding of NRF2-MAF to
the ARE (Fig. 9C). Both strategies are hampered by the
need by such drugs to overcome the large free energy of
association between protein–protein and, to a lesser
extent, protein–DNA interfaces. Nevertheless, such
drugs have been found for other bZip transcription
factors such as STAT3-STAT3, MYC-MAX, and JUN-
FOS (Yap et al., 2011), and new small molecules are
being described for NRF2-MAF. For instance, malabar-
icone-A is a pro-oxidant compound that overcomes
leukemia resistance by targeting NRF2 (Manna et al.,
2015). Ascorbic acid (vitamin C), a well-known ROS
scavenger, was found to sensitize imatinib-resistant
cancer cells by decreasing the levels of the NRF2/ARE
complex, reducing the expression of theGCLC gene and
dropping GSH levels (Tarumoto et al., 2004). All-trans-
retinoic acid is another example of NRF2 inhibitor that
significantly decreases NRF2 activation by potent elec-
trophilic NRF2 inducers in vitro and in vivo. It activates
the retinoic acid receptor a, which forms a complex with
NRF2, hence impeding the binding of the transcription
factor to ARE genes (Wang et al., 2007).
Natural products such as brusatol (Ren et al., 2011;
Olayanju et al., 2015), ochratoxin A (Tarumoto et al., 2004;
Limonciel andJennings, 2014), and trigonelline (Arlt et al.,
2013) have also been found to inhibit NRF2. However,
theirmechanism of action is not fully understood. In fact, a
significant issue related to currently available compounds
is the profound off-target effect that they might have. For
instance, promising results with brusatol were recently
discouraged by the finding that this drug exerts a general
and unspecific inhibition of protein synthesis, resulting in
the drop of NRF2 levels, but also of many other proteins
with rapid turnover (Harder et al., 2017). Similarly, the
antiprotozoal agent halofuginone, used in veterinary
practice, enhances the chemosensitivity of cancer cells by
suppressingNRF2accumulation, but this effect appears to
be indirect by inhibiting prolyl–transfer RNA synthesis
that is strongly required for ribosomal translation ofNRF2
as well as many other proline-containing proteins
(Tsuchida et al., 2017).
A novel approach to identify selective NRF2 inhibitors
has been reported recently by the use of quantitative high-
throughput screen of small-molecule inhibitors (Singh
et al., 2016). The authors identified a first-in class
compound, termed ML385, which most likely prevented
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the binding of NRF2 to other bZip coactivators. This
compound blocked NRF2 transcriptional activity and
sensitized KEAP1-deficient cells to carboplatin and other
chemotherapeutic drugs. Additional studies are needed to
confirm whether ML385 is selective for NRF2 or if it also
inhibits other bZip transcription factors.
In light of the highly favorable systemic effects of
NRF2 in various tumor pathophenotypes, a specific
targeting of NRF2with small-molecule inhibitors seems
to provide an excellent clinical approach. However, it is
necessary to determine whether cancer treatment with
NRF2 inhibitors increases the risk of other pathophe-
notypes of the NRF2 diseasome.
E. Repurposing Instead of De Novo Drug Discovery
and Development
As previously discussed, numerous compounds are
under development to provide a benefit for the patho-
phenotypes associated with the NRF2 diseasome. An
alternative approach is to give drugs that are already in
clinical use for a certain pathomechanism a new use for
the treatment of other pathomechanisms that are
connected to NRF2. This section provides the basis for
repositioning some commonly used drugs based on their
role in NRF2 regulation.
Metformin is the first-line monotherapy for the
T2DM. According to Fig. 6, it provides therapeutic
benefit to the NRF2 subcluster of pathophenotypes
related to glucose metabolism. In fact, SFN reduces
hepatic glucose production and improves glucose con-
trol in patients with T2DM (Axelsson et al., 2017).
Interestingly, some evidence suggests that metformin
may be effective in preventing other nonglycemic
pathophenotypes of the NRF2 diseasome, including
cardiovascular (Nesti and Natali, 2017), respiratory
(Sato et al., 2016), digestive (Bauer and Duca, 2016),
neurodegenerative (Markowicz-Piasecka et al., 2017),
autoimmune (Schuiveling et al., 2017), and neoplastic
(Heckman-Stoddard et al., 2017) disorders. The mech-
anism of action of metformin is not completely clear, but
it involves inhibition of mitochondrial complex I, thus
increasing the AMP/ATP ratio (El-Mir et al., 2000;
Owen et al., 2000) and leading to activation of the
energy sensor AMPK (Hardie, 2004; Rena et al., 2017).
Importantly, AMPK activates NRF2 (Wang et al.,
2017a; Zhao et al., 2017), and pharmacological targeting
of this axis attenuates inflammation after stroke (Wang
et al., 2017c) or endotoxin exposure (Ci et al., 2017; Lv
et al., 2017). Indeed, metformin activates NRF2 in an
AMPK-dependent manner, resulting in inhibition of
inflammatory responses in preclinical rodent models of
transient global cerebral ischemia (Ashabi et al., 2015;
Kaisar et al., 2017). Glucose metabolism and inflam-
mation may not be the only pathomechanisms affected
by metformin/NRF2. In fact, other salutary effects have
been described for redox (Kocer et al., 2014; Kelleni
et al., 2015) and protein homeostasis (Tsai et al., 2017).
Statins prevent and reduce cardiovascular patho-
phenotypes. In addition to a lipid-lowering effect,
statins appear to protect against pathomechanisms
associated with the NRF2 network such as inflamma-
tory (Pantan et al., 2016; Wu et al., 2016a; Hwang
et al., 2017) and pathologic ROS formation
(Abdanipour et al., 2014). They are competitive inhib-
itors of 3-hydroxy-3-methyl-glutaryl-CoA reductase,
which catalyzes the rate-limiting reaction in cholesterol
synthesis. Other pleiotropic effects include the upregu-
lation of transcription factor Krüppel-like factor 2,
which is induced early during progression of cirrhosis
and lessens the development of hepatic vascular dys-
function (Marrone et al., 2015). Recent evidence indi-
cates that at least some statins activate NRF2. In a
proteomic study conducted in isolated hepatocytes, high
concentrations of simvastatin activatedNRF2, probably
as a defensive mechanism (Cho et al., 2013). The
pretreatment of neural stem cells with lovastatin
activated the NRF2 pathway and elicited protection
against hydrogen peroxide–induced cell death
(Abdanipour et al., 2014). In liver cirrhosis, simvastatin
activates an axis formed by Krüppel-like factor 2 and
NRF2 to reduce the oxidative burden and inflammatory
response of stellate cells, improving liver fibrosis,
endothelial dysfunction, and portal hypertension. The
mechanism of activation of NRF2 by simvastatin is not
completely clear, but it appears to involve elements
found in the NRF2 interactome, such as mitogen-
activated protein kinase, PI3K/AKT pathways (Jang
et al., 2016), and GSK-3 (Lin et al., 2016).
Other cases for drug repurposing can be inferred from
the NRF2 interactome of Fig. 4, in particular with
signaling kinases. As indicated in Fig. 2C, GSK-3
phosphorylates the Neh6 domain of NRF2, leading to
the recognition by b-TrCP and further ubiquitin-
dependent proteasomal degradation. GSK-3 is active
in the absence of stimuli and inactive when signaling
cascades that activate AKT and other kinases lead to
phosphorylation of GSK-3 at its N-terminal pseudosub-
strate domain. It follows that medications known to
target signaling kinases may be used to upregulate
(GSK-3 inhibitors) or downregulate (PI3K/AKT inhibi-
tors) the NRF2 signature.
GSK-3 participates in at least some pathophenotypes
found in the NRF2 diseasome such as diabetes and
neurodegeneration (Beurel et al., 2015; Maqbool and
Hoda, 2017). A broad spectrum of GSK-3 inhibitors has
been discovered from natural and synthetic origins
(Khan et al., 2017), but probably the best evidence for
repurposing a GSK-3 inhibitor to increase NRF2 activ-
ity stems from the clinical use of lithium as mood
stabilizer (Chiu et al., 2013). Although bipolar disorder
and depression are not found at this time in the NRF2
diseasome, it is becoming evident that they exhibit
neuroinflammatory and degenerative pathophenotypes
that at least in mouse models imply deregulation of
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NRF2 (Martin-de-Saavedra et al., 2013; Freitas et al.,
2016; Yao et al., 2016).
The NRF2 interactome also provides a justification
for the inhibition of NRF2 by cancer drugs that block
signaling kinases, thus activating GSK-3. For example,
the epidermal growth factor receptor inhibitor erlotinib
leads to NRF2 inhibition, participating in tumor cell
sensation in nonsmall cell lung cancer (Xiaobo et al.,
2016). The kinase cascade inhibitor sorafenib, used in
therapy of hepatocellular carcinoma, also leads to in-
hibition of NRF2 and its downstream targets
metallothionein-1 (Houessinon et al., 2016) and meth-
ylenetetrahydrofolate dehydrogenase 1 (Lee et al.,
2017).
Finally, search for repurposing drugs that might
impinge on NRF2 regulation has been done to date in
two relevant studies. Using a fluorescence correlation
spectroscopy-based screening system, two of 1633 drugs
significantly increased NRF2 protein levels in HepG2
cells: chlorophyllin and bonaphton (Yoshizaki et al.,
2017). In another study, the connectivity map database
that comprises gene expression profiles for human cell
lines treated with 1309 agents (Lamb et al., 2006; Iorio
et al., 2010) was analyzed (Zhang et al., 2017) in search
for potential redox regulators through activation of
NRF2 (Xiong et al., 2014). This study found astemizole,
a potent antihistamine drug, used in allergic conditions,
as a novel NRF2 activator.
VI. Biomarkers as Nuclear Factor (Erythroid-
Derived 2)–Like 2 Signature and for Monitoring
Target Engagement
The evaluation of the redox status in patients or
population studies is hampered by the short half-life of
ROS, in the range of milliseconds or nanoseconds
(Ghezzi et al., 2017b). Therefore, biomarkers of patho-
logic ROS formation are based on measuring the traces
left by ROS, which are normally terminal oxidation
products of cellular molecules, many of them being
nonspecific (Frijhoff et al., 2015). On the contrary,
activation of NRF2 and subsequent expression of its
target genes is an indirect but reliable estimation of the
total exposure of the organism to pathologic ROS
formation. Because NRF2 activation is a well-
established cellular response to environmental stres-
sors, it has been considered as biomarker of exposure to
xenobiotics. In lung, a data mining of several transcrip-
tion studies followed by Ingenuity pathway analysis
reported that the NRF2 signature is upregulated in
healthy smokers, therefore suggesting that NRF2-
regulated antioxidant genes play a central role in
protection against toxic effects of tobacco smoke
(Comandini et al., 2010). Similarly, the levels of
NQO1, an enzyme regulated by NRF2, were 15-fold
higher in liver tissue obtained from acetaminophen-
overdosed patients (Aleksunes et al., 2006). The
association between disease and nutrition is frequently
based on unreliable self-reporting (Archer et al., 2015).
Measuring biomarkers of response to nutrients, sup-
posedly having beneficial effects by activating NRF2,
could provide a reliable method to validate nutritional
studies. However, this possibility is still unexplored.
The changes associated with NRF2 transcription
could be useful as biomarker for monitoring the efficacy
of drugs aimed at reducing pathologic ROS formation by
inhibitors of xanthine oxidase and NADPH oxidase.
Similarly, exposure to environmental chemicals could
be detected and monitored by defining a global protein
and gene expression profile (Ghezzi et al., 2017a). This
approach is similar to the use of phase I drug-
metabolizing enzymes, in which cytochrome P450,
which is induced by various xenobiotics through the
Ah receptor, can be used as indicator ofmarine pollution
(Cajaraville et al., 2000). Daily oral administration of
fumaric acid esters over 12 weeks was associated with
the increased expression of NRF2 target genes in the
skin of patients with psoriasis (Onderdijk et al., 2014).
Similarly, a fivefold increase in the mRNA level of
NQO1 has been reported in peripheral blood mono-
nuclear cells obtained from cancer patients that re-
ceived a daily dose of CDDO-Me for 3 weeks (Hong et al.,
2012).
The use of the transcriptional signature of NRF2 as a
biomarker requires a good knowledge of the mecha-
nisms involved in activation of ARE genes, as most of
the NRF2 targets are regulated by additional transcrip-
tion factors. It is therefore important to analyze the
expression of several ARE genes. For instance, a study
using NRF2 as predictor for response to treatment in
lung squamous cell carcinoma has proposed the use of
28 genes to define a NRF2 activation profile (Cescon
et al., 2015).
VII. Conclusions
Systems medicine together with network pharmacol-
ogy highlights a cluster of chronic disease pathopheno-
types in which NRF2 plays a fundamental role. These
diseases share common mechanisms, including oxida-
tive, inflammatory, and metabolic alterations. The
NRF2 interactome, the NRF2 diseasome, and the
NRF2 drugome presented in this work are still in an
early stage of development, but they represent a first
attempt to structure NRF2 as a common therapeutic
and systems medicine approach. The forthcoming re-
finement of current databases and upcoming clinical
outcome data will further improve the accuracy of this
new approach to pharmacology and mechanism-based
drug repurposing. This paper provides a road map for a
comprehensive strategy for drug discovery to activate or
inhibit NRF2 and highlights the need of translational
efforts toward the development of de novo drugs or the
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repurposing of drugs that target NRF2 as a common
element in chronic diseases.
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The transcription factor NRF2 (nuclear factor erythroid 2-related factor 2) triggers the ﬁrst line of homeostatic responses against
a plethora of environmental or endogenous deviations in redox metabolism, proteostasis, inﬂammation, etc. Therefore,
pharmacological activation of NRF2 is a promising therapeutic approach for several chronic diseases that are underlined by
oxidative stress and inﬂammation, such as neurodegenerative, cardiovascular, and metabolic diseases. A particular case is
cancer, where NRF2 confers a survival advantage to constituted tumors, and therefore, NRF2 inhibition is desired. This
review describes the electrophilic and nonelectrophilic NRF2 activators with clinical projection in various chronic diseases.
We also analyze the status of NRF2 inhibitors, which at this time provide proof of concept for blocking NRF2 activity in
cancer therapy.
1. Introduction
Nuclear factor erythroid 2-related factor 2 (NRF2) is the
product of the NFE2L2 gene and belongs to the cap′n′col-
lar transcription factor family. By sequence homology with
other orthologs, the domains termed Neh1-7 have been tra-
ditionally allocated in this protein (Figure 1(a)). At the C-ter-
minus, NRF2 contains a basic leucine-zipper (bZip) domain
that participates in the formation of heterodimers with other
bZip proteins, like small muscle aponeurosis ﬁbromatosis
(MAF) K, G, and F [1, 2]. These heterodimers regulate the
expression of about 250 human genes that present a regulatory
enhancer sequence termed Antioxidant Response Element
(ARE; 5′-TGACNNNGC-3′) and participate in multiple
homeostatic functions including regulation of inﬂammation,
redox metabolism, and proteostasis [3–6].
From a clinical perspective, it is of utmost importance
that NRF2 can be targeted pharmacologically in diseases
underlined by oxidative stress and inﬂammation, such as
neurodegenerative, vascular, and metabolic diseases as well
as cancer [7, 8]. In models of most chronic diseases, a rein-
forcement of homeostasis through NRF2 activators provides
a beneﬁcial therapeutic eﬀect. In cancer, the pharmacological
regulation of NRF2 appears to be context dependent. It is
generally accepted that NRF2 inhibitors not only reduce the
survival and proliferative advantage of cancer cells but also
sensitize tumors to chemo- and radiotherapy [9]. In this
review, we describe the pharmacological activators of NRF2
that are in several stages of pharmacological development
for the treatment of several chronic diseases. The most devel-
oped compounds activate NRF2 by preventing its degrada-
tion by KEAP1-dependent mechanisms. We also discuss
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the current state of NRF2 inhibitors which may be highly
relevant for cancer therapeutics although at this time they
are still in early phases of development.
2. Physiologic Regulation of NRF2
NRF2 is ubiquitously and constitutively expressed by cells,
thus ensuring their prompt protective response to oxidative,
inﬂammatory, and metabolic stresses. Under normal physio-
logical conditions, NRF2 has a rapid turnover and presents a
half-life of about 20-30min due to its constant degradation
by the ubiquitin proteasome system [10, 11]. Therefore,
under nonstressed conditions, low NRF2 levels provide basal
expression of its target genes.
The main control of NRF2 stability is exerted by the E3
ligase adapter Kelch-like ECH-associated protein 1 (KEAP1).
KEAP1 is a homodimer protein that comprises three func-
tional domains (Figure 1(b)): a broad complex, tramtrack,
bric-a-brac (BTB) homodimerization domain, an interven-
ing region (IVR), and a C-terminal Kelch domain with a dou-
ble glycine repeat (DGR). The Kelch domain binds to the
Neh2 domain of NRF2 at two amino acid sequences: DLG
and ETGE. Experiments based on isothermal calorimetry
have led to the conclusion that the ETGE motif exhibits
about one hundred times higher aﬃnity for KEAP1 than
the DLG motif [12]. KEAP1 presents NRF2 for ubiquitina-
tion by the E3 ligase complex formed by Cullin3 and RBX1
proteins (CUL3/RBX1) [13], resulting in subsequent NRF2
degradation by the proteasome 26S [2, 14].
KEAP1 contains 27 cysteine residues in humans, con-
verting this protein in a redox sensor for endogenous and
environmental oxidative signals as well as for electrophilic
reactions [15]. Under redox-challenging conditions, the cel-
lular redox buﬀers comprising glutathione (GSH), thiore-
doxin, etc. maintain low intracellular levels of reactive
oxygen species (ROS) and glutathionylated proteins. How-
ever, ROS oxidize thiols and induce glutathionylation and
alkylation of macromolecules, therefore having the capacity
to modify KEAP1 cysteines [16]. From a pharmacological
perspective, electrophile reaction with some cysteines of
KEAP1 leads to the formation of adducts that prevent the
ubiquitination NRF2, resulting in its stabilization, nuclear
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Figure 1: Domain structures of NRF2 and KEAP1. (a) Domain structure of NRF2. NRF2 possesses six highly conserved domains called
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translocation, and transcriptional induction of NRF2-target
genes [7, 8].
An alternative mechanism for proteasomal degradation
of NRF2 is mediated by the glycogen synthase kinase 3
(GSK-3) and the E3 ligase adapter β-TrCP. GSK-3α and β
are serine/threonine protein kinases involved in several sig-
naling pathways such as receptor tyrosine kinase, WNT,
and Hedgehog that inﬂuence cell division, survival, and
development [17, 18]. GSK-3α and β are maintained in an
inactive state under normal conditions due to their inhibition
by AKT-mediated phosphorylation at their N-terminal pseu-
dosubstrate domain or by sequestration in protein complexes.
However, in the absence of receptor signaling, active GSK-3
phosphorylates NRF2 at the Neh6 domain (DSGIS). This
phosphodomain recruits β-TrCP, which recognizes pSGIpS,
and the CUL1/RBX1 complex for ubiquitin-proteasome
degradation [19]. β-TrCP also recognizes another motif in
the Neh6 domain of NRF2 (DSAPGS) which appears to be
constitutively phosphorylated in a GSK-3-independent
manner [20]. Additional degradative systems are able to reg-
ulate NRF2 at posttranscriptional level, such as the inositol-
requiring enzyme (IRE1)/E3 ubiquitin ligase synoviolin
(HRD1) [21].
NRF2 can be regulated at the transcriptional level. The
NFE2L2 gene promoter presents several regulatory sequences:
(a) one xenobiotic response element (XRE; 5′-TA/TGCG
TGA/C-3′) at -712 and two XRE-like sequences at +755
and +850 that are recognized by the transcription factor Aryl
Hydrocarbon Receptor (AHR) [22]; (b) two ARE-like
sequences at -492 (AREL1; TGACTCCGC) and -754 pb
(AREL2; TGACTGTGGC), which allow NRF2 autoregula-
tion [23]; (c) one 12-O-tetradecanoylphorbol-13-acetate-
response element (TRE) (TGCGTCA) at +267 to +273 pb
that is activated by the oncogenic KRAS [24], BRAF, and
MYC [25] hence being critically involved in carcinogenesis;
(d) one NF-κB binding site that responds to inﬂammatory
stimuli [26]; and (e) epigenetic changes such as promoter
methylation, microRNAs including miR-144 [27], miR-28
[28], miR-98-5p [29], and long noncoding RNA deregulation
[30] that contribute to changes in expression of the NRF2-
coding gene.
3. Pharmacologic Activators of NRF2
The so-called “NRF2 activators” should be more precisely
termed “KEAP1 inhibitors” as their molecular target is in fact
KEAP1 [31]. These compounds can be classiﬁed as electro-
philes, protein-protein interaction (PPI) inhibitors, and mul-
titarget drugs (Figure 2).
3.1. Electrophilic Compounds. Most pharmacological NRF2
activators are electrophilic molecules that covalently modify
cysteine residues present in the thiol-rich KEAP1 protein
by oxidation or alkylation [32–34]. Many cysteines of KEAP1
are modiﬁed by diﬀerent electrophiles [35–37]. Cysteines
Cys-151, Cys-273, and Cys-288 [38, 39] appear to be the
most susceptible to electrophile reaction [40, 41]. Other sen-
sitive cysteines are Cys-226, Cys-434, and Cys-613. This
“cysteine-code” controls KEAP1 activity when the protective
response mediated by NRF2 is needed. Selected electrophilic
activators of NRF2 that are in various stages of clinical devel-
opment are presented in Table 1.
One mechanism of KEAP1 inhibition is the sequestra-
tion in complexes with NRF2 that cannot be ubiquitinated.
Modiﬁcations of several cysteines in KEAP1 generate a non-
functional closed state with both Neh2 motifs (DLG and
ETGE) of NRF2 interacting with the KEAP1 dimer but
not leading to ubiquitination. As a result, free KEAP1 is
not regenerated at a suﬃcient rate and newly synthesized
NRF2 escapes KEAP1-mediated ubiquitination and subse-
quent degradation [42].
Another mechanism of KEAP1 inhibition is related to
its interaction with the CUL3/RBX1 complex, required for
NRF2 ubiquitination. Cys-151 located at the BTB domain
inﬂuences the interaction of KEAP1 with CUL3. The crystal
structure of the BTB domain bound to the pentacyclic tri-
terpenoid 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oate
(bardoxolone, CDDO, RTA401) indicates that adduct for-
mation with Cys-151 most likely disrupts the interaction
between KEAP1 and CUL3 [43–45]. As a result, KEAP1 is
clogged in a NRF2 bound conformation, and newly formed
NRF2 escapes ubiquitination. Synthetic triterpenoids have
been derived from the natural compound oleanolic acid to
provide them with strong Michael acceptor reactivity. This
is achieved mainly through the addition of enone and ciano
groups to the A ring and another enone group to the C ring
[46, 47]. Bardoxolone methyl (CDDO-Me or RTA 402)
reached clinical trials for the treatment of advanced chronic
kidney disease (CKD) and type 2 diabetes mellitus [48].
Although phase II clinical trials demonstrated long-term
increment in glomerular ﬁltration, CDDO-Me was halted
at phase III due to cardiovascular safety issues [49]. A
new phase II clinical trial has recently started recruiting
patients with rare chronic kidney diseases to better deﬁne
the safety and eﬃcacy proﬁles of CDDO-Me. Currently,
CDDO-Me is also under clinical study for the Alport syn-
drome and pulmonary hypertension. In an eﬀort to improve
the safety proﬁle, a second-generation diﬂuoromethyl acet-
amide derivative of bardoxolone methyl, called RTA-408
(Omaveloxone), is now under clinical investigation in phase
II clinical trials for Friedreich’s ataxia, ocular inﬂammation,
and pain after ocular surgery [50]. Recently, a preclinical
study evaluated RTA-408 for diabetic wound recovery and
pointed NRF2 upregulation as responsible for the observed
improvement in regenerative capacity [51].
The most successful NRF2 activator to date is the fuma-
ric acid ester dimethyl fumarate (DMF) (BG-12 or Tecﬁdera,
from Biogen) that has been approved in 2013 by FDA for
relapsing-remitting multiple sclerosis (MS) [52–55]. Previ-
ously, DMF was authorized for the treatment of psoriasis
[56]. DMF was shown to reduce the number of peripheral
T cells, CD8+ cells being more sensitive to DMF than
CD4+ cells [57, 58]. DMF also reduces total B lymphocyte
counts, especially memory B cells, along with a decrease in
granulocyte-macrophage colony-stimulating factor, IL-6,
and TNF-α production, leading to an anti-inﬂammatory
shift in B cell responses [59, 60]. The DMF-induced activa-
tion of NRF2 in the central nervous system was described
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in the MS mice model of experimental allergic encephalomy-
elitis [61]. In this model, DMF-dependent NRF2 activation
correlated with an improvement in the clinical course of
MS, favored axon preservation, and increased astrocyte acti-
vation. These beneﬁcial eﬀects of DMF did not occur in
NRF2-null mice, hence indicating that DMF was acting
mainly by targeting the NRF2 pathway. DMF is mostly con-
verted to monomethyl fumarate (MMF) by intestinal ester-
ases, and only a small fraction is found in blood conjugated
with glutathione [62]. Therefore, an oral formulation of a
monomethyl fumarate (MMF) derivative, diroximel fuma-
rate (2-(2,5-dioxo-1-pyrrolidinyl)ethyl ester; ALKS-8700;
Alkermes) which exhibits improved bioavailability and eﬃ-
cacy, is currently under phase III trial for MS [63, 64]. How-
ever, the biological eﬀects of these fumaric acid esters are not
fully characterized and KEAP1/NRF2-independent eﬀects
are being described. For instance, it has been reported that
DMF and MMF activate the nicotinic receptor hydroxycar-
boxylic acid receptor 2, which is expressed in immune cells
and gut epithelial cells, resulting in NRF2-independent
anti-inﬂammatory responses [65].
Oltipraz (4-methyl-5(pyrazinyl-2)-1-2-dithiole-3-thione)
is a NRF2 inducer that enhances GSH biosynthesis and phase
II detoxiﬁcation enzymes, such as NQO1. Oltipraz is a prom-
ising chemopreventive agent [66] under phase III clinical
trial for the treatment of nonalcoholic fatty liver disease.
Ursodiol (ursodeoxycholic acid) is anFDA-approveddrug
for the treatment of primary biliary cirrhosis. Although its
cytoprotective mechanisms have not been elucidated yet, sev-
eral research groups suggested that the upregulation of NRF2
by ursodiol induces detoxiﬁcation and antioxidant mecha-
nisms that play a role in its therapeutic eﬃcacy [67, 68].
Several natural compounds have been identiﬁed as elec-
trophilic NRF2 inducers, including sulforaphane, curcumin,
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resveratrol, quercetin, genistein, and more recently andro-
grapholide [69]. For instance, sulforaphane (SFN), an iso-
thiocyanate found in cruciferous vegetables, has been
successfully used for the treatment of patients with type II
diabetes mellitus [70, 71]. Due to the capacity of SFN to cross
the blood-brain barrier, it protects against neurodegenerative
disorders as demonstrated in murine models of disease.
Regarding acute brain damage, SFN was shown to exert
protective eﬀects in hypoxic-ischemic injury in rats by reduc-
ing the infarct ratio and by upregulating NRF2 and HO-1
[72, 73]. In neurodegenerative disease models, SFN proved
protective capacity against the neurotoxic Aβ1-42 peptide in
neuronal cells [74]. In vivo, SFN ameliorated cognitive
impairment in an acute mouse model of Alzheimer disease
(AD) [75]. In Parkinson disease (PD), SFN protected
dopaminergic cells against the cytotoxic eﬀects of 6-
hydroxydopamine [76]. In the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine mouse model of PD, SFN counteracted
astrogliosis and microgliosis and reduced the death of dopa-
minergic neurons [77–79]. To improve the stability of SFN,
Evgen Pharma has developed a cyclodextrin formulation,
SFX-01, which is under phase II clinical trial for the treat-
ment of subarachnoid haemorrhage. A hybrid molecule of
SFN and melatonin (ITH12674) was designed to have a dual
“drug-prodrug” mechanism of action for the treatment of
brain ischemia [80].
Another natural compound that modiﬁes Cys-151 in
KEAP1 and has also ROS-scavenging activity is curcumin, a
linear diarylheptanoid present in turmeric (Curcuma longa)
[81]. It has been used for the treatment of obesity, metabolic
syndrome, and prediabetes [82–84]. Furthermore, curcumin
has been shown to suppress the deleterious action of carcin-
ogens by activating NRF2 [85, 86].
9-Nitro-octadec-9-enoic acid (OA-NO2) is a nitro-fatty
acid with anti-inﬂammatory properties. OA-NO2 reacts with
several cysteine residues of KEAP1, but mainly with Cys-273
and Cys-288, and its activity seems to be independent
of Cys-151 [36]. CXA-10 (10-nitro-9(E)-octadec-9-enoic
acid) is an isomer of OA-NO2 which has proven eﬃcacy
the uni-nephrectomized deoxycorticosterone acetate-high
salt mouse model of CKD [87] and is under several phase I
clinical trials for the treatment of this disease [88] and under
phase II trials for the treatment of pulmonary arterial hyper-
tension and primary focal segmental glomerulosclerosis.
The list of electrophilic compounds able to interact with
KEAP1 is continuously growing. For instance, some com-
pounds like 15-deoxy-Δ12,14-prostaglandin J2 interact with
Cys-273 and Cys-288 of the KEAP1 homodimer [40]. This
prostaglandin has a cyclopentenone core that is able to
modify covalently Cys-273 and induce NRF2 in models of
ureteral obstruction [89], hepatic ischemia-reperfusion
injury [90], and atherosclerosis [91]. However, its clinical
use is still far from being demonstrated. In a recent study,
the metabolite itaconate was described as a NRF2 activator
that alkylates cysteines 151, 257, 288, 273, and 297 of KEAP1.
A cell-permeable itaconate derivate, 4-octyl itaconate, pro-
tects against lipopolysaccharide cytotoxicity, thus providing
an anti-inﬂammatory response. Furthermore, this com-
pound is a more potent NRF2 activator than DMF [92]. Some
other examples are tert-butylhydroquinone [93], diethyl
maleate [94], TFM-735 [95], and nitric oxide [96]. However,
most of these compounds have not evolved beyond proof-of-
concept experiments, and a long way needs to be covered to
characterize their pharmacodynamic properties, clinical safety
proﬁle, and eﬃcacy in noncommunicable diseases.
3.2. Protein-Protein Interaction Inhibitors of the KEAP1-
NRF2 System. Protein-protein interaction (PPI) inhibitors
interfere with the docking of NRF2 to the Kelch propeller
of KEAP1 and provide more selectivity over electrophilic
compounds which may eventually form adducts with
redox-sensitive cysteines other than those in KEAP1 [97].
Based on the X-ray crystal structure of KEAP1 [98], small
PPI inhibitors have been designed to impede the binding of
the ETGE motif to KEAP1 [99]. The ETGE motif adopts a
β-hairpin structure that docks to the Kelch propeller of
KEAP1 through speciﬁc hydrophobic and electrostatic inter-
actions [98, 99]. A similar strategy is devised to prevent the
interaction of the low-aﬃnity DLG motif which is required
for correct lysine ubiquitination in NRF2 [13].
The ﬁrst PPI inhibitors of KEAP1 were designed from a
series of truncated NRF2 peptides [100, 101]. Some selected
peptides are shown in Table 2. It was found that the minimal
binding sequence of NRF2 required for docking to KEAP1 is
the 9-mer sequence LDEETGEFL [100–102]. A related
peptide was designed to increase cell penetrance by adding
the Tat sequence of the human immunodeﬁciency virus
and the cleavage sequence of calpain (-Cal-Tat). This peptide
demonstrated neuroprotection and cognition-preserving
eﬀects in a mouse model of cerebral ischemia [103].
Moreover, hybrid peptides based on both the region of
interaction between KEAP1 and NRF2 (ETGE motif)
and with the region of interaction between KEAP1 and
p62/Sequestosome-1 (SQSTM1) exhibited superior binding
activity compared to either native peptide alone [104]. Due
to unfavorable drug-like properties, such as low oral bioavail-
ability and cellular permeability of peptides, research has
been lately focused on the development of small molecules.
However, a cyclic peptide was used recently to improve
KEAP1 binding and NRF2 accumulation in cells [105].
Current PPI inhibitors are tetrahydroisoquinoline
[97, 106], thiopyrimidine [107], naphthalene [108], carba-
zone [109], and urea derivatives [110]. Recently, the
naphthalene-based nonelectrophilic PPI inhibitors were
modiﬁed to develop nonnaphthalene heterocyclic scaﬀold
based on 1,4-isoquinoline that avoids the carcinogenic and
mutagenic properties of naphthalenes [111]. Some patents
addressing these small molecules are presented in Table 3.
Several PPI inhibitors with improved selectivity over
electrophiles have been identiﬁed through screening of
small molecule libraries. These compounds include SRS-5,
benzenesulfonyl-pyrimidone 2, N-phenyl-benzenesulfonamide,
and a series of 1,4-diphenyl-1,2,3-triazole [106, 112–115].
Recently, a new protocol for identifying reversible modiﬁers
of the NRF2/KEAP1 interaction was proposed [116]. The
biochemical assays comprised time-resolved ﬂuorescence
resonance energy transfer as primary screening tool, surface
plasmon resonance to evaluate the aﬃnity of KEAP1
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binders, and 1H-15N heteronuclear single-quantum coherence
nuclear magnetic resonance assay to further analyze the bind-
ingmode. This protocol will help in identifying and improving
the properties of reversible binders to KEAP1.
3.3. Other Mechanism of NRF2 Activation. The phosphoryla-
tion of NRF2 by GSK-3 leads to its ubiquitination by the E3
ligase β-TrCP and subsequent proteasomal degradation. An
aberrant activity of GSK-3 is linked with several pathologies
such as AD, cardiovascular diseases, or cancer among others
[117–120]. Therefore, several clinical trials are now focused
on GSK-3 inhibitors for the treatment of several pathologies
[121]. For instance, the GSK-3-inhibitor Tideglusib, a thia-
diazolidinone compound, was studied in phase II trials for
AD in the ARGO study [122]. Another inhibitor is Enzas-
taurin which is intended for the treatment of solid and hema-
tological cancers. Although Enzastaurin provided promising
results at the preclinical level, treatment failed in phase II and
III trials [123, 124]. GSK-3-dependent NRF2 phosphoryla-
tion was shown to be inhibited by nordihydroguaiaretic acid
[125]. This compound and its derivative terameprocol are in
phase I and II clinical trials for the treatment of several types
of cancers, such as gliomas and leukemias (Table 4) [126].
Focusing on E3 ubiquitin ligase β-TrCP, it would be pos-
sible to develop small molecules able to disrupt the docking
of NRF2 to β-TrCP, hence opening a new way regarding
KEAP1-independent activators of NRF2 [127]. A novel E3
ubiquitin ligase linked to KEAP1-independent NRF2 degra-
dation is HRD1 [21]. HRD1-dependent NRF2 degradation
has been described in the context of cirrhotic liver. HRD1 is
a transcriptional target of X-box-binding protein 1 (XBP1)
that is upregulated upon activation of the inositol-requiring
enzyme 1 (IRE1) during endoplasmic reticulum (ER) stress
related to cirrhotic conditions. Inhibitors of HRD1 and
IRE1 restore the NRF2 response in liver cirrhosis [21].
Several proteins contain a (E/S)TGE motif that resembles
the high-aﬃnity ETGE motif of NRF2. The motif confers to
these proteins the ability to compete with NRF2 for KEAP1
binding, leading to a noncanonical mechanism of NRF2 sta-
bilization [128]. Proteins containing the (E/S)TGE motif are
dipeptidyl peptidase 3, Partner and Localizer of BRCA2, and
SQSTM1/p62. SQSTM1/p62, a protein that transports spe-
ciﬁc cargos to the autophagosome, including KEAP1, sus-
tains NRF2 stabilization and translocation to the nucleus
[129–131]. Compounds which elevate SQSTM1/p62 levels,
like rapamycin [132] and trehalose [133], are being therefore
studied in several phase II and III trials in connection with
diabetes mellitus, systemic lupus erythematosus, and autoso-
mal dominant polycystic kidney disease.
Another way to inhibit the transcriptional activity of
NRF2 is to impede its interaction with critical components
in the nucleus. BTB domain and CNC homolog 1 (BACH1)
is a transcriptional repressor which belongs to the cap′n′
collar, b-Zip family. BACH1 competes in the nucleus with
NRF2 to form heterodimers with small MAF proteins and
blocks therefore the expression of ARE genes [134]. A recent
study characterized the HPP-4382 compound as an inhibitor
of BACH1 repression activity in vitro [135].
All these alternative mechanisms for NRF2 stabilization
and activation suggest that a combinatorial pharmaceutical
approach will be the best way to activate the cytoprotective
responses mediated by NRF2.
4. Pharmacologic Inhibitors of NRF2
The implication of NRF2 in cancer is still controversial.
Several studies described that NRF2 knockout mice are more
susceptible to chemically induced carcinogenesis, pointing
NRF2 as a potential tumor suppressor that limits carcinogen-
esis [136, 137]. On the other hand, NRF2 is overexpressed in
many types of tumors, and it has been related to poor disease
prognosis because it confers a survival and growth advantage
to cancer cells, along with resistance to chemo- and radio-
therapy [138–140]. Altogether, these results suggest a protec-
tive role of NRF2 in the ﬁrst steps of cancer, but in advanced
stages, NRF2 overexpression helps cancer cells to adapt to the
tumorigenic demands. Cancer cells are “addicted” to NRF2
and resist treatment with chemotherapy or radiotherapy
[141, 142]. Therefore, it is reasonable to assume that NRF2
inhibitors should sensitize tumor cells to anticancer thera-
pies. In all cases, the mechanism of inhibition is either
unknown or not speciﬁc, and therefore, NRF2 inhibitors
are still far from being translated from bench to bedside.
4.1. Agonists of Nuclear Receptors. Ligands of the glucocorti-
coid receptor such as dexamethasone [143] and clobetasol
propionate [144] inhibit NRF2 by blocking its transcriptional
activity or preventing its nuclear translocation. All-trans-
retinoic acid and bexarotene, agonists of the retinoic acid
receptor-α and retinoid X receptor-α, inhibit the transcrip-
tional activity of NRF2 [145, 146]. Retinoid X receptor-α
Table 2: Selected peptides acting as NRF2-KEAP1 protein-protein
interaction inhibitors.
Sequence
Mechanism
of action
Reference
LDEETGEFL-NH2
Binding to
KEAP1-Kelch
domain
[100, 101]
DEETGE-CAL-Tat (NH2-
RKKRRQRRR-
PLFAERLDEETGEFLPNH2)
[103]
Ac-DPETGEL-OH [102]
FITCβ-DEETGEF-OH [102]
FITC-β-LDEETGEFL-OH [102]
Ac-DEETGEF-OH [102]
Ac-DPETGEL-OH [102]
FITC-LDEETGEFL-NH2 [100]
FAM-LDEETGEFL-NH2 [108]
LQLDEETGEFLPIQGK(MR121)-OH [107]
Ac-LDEETGEFL-NH2 [100, 101]
Ac-DPETGEL-NH2 [104]
Ac-NPETGEL-OH [104]
St-DPETGEL-OH [104]
YGRKKRRQRRRLQLDEETGEFLPIQ [162]
c[GQLDPETGEFL] [105]
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appears to bind to the Neh7 domain of NRF2 preventing
binding to the ARE enhancer [146]. The pharmacological
value of this mechanism of NRF2 inhibition is limited by
the multiple eﬀects that are expected through the regulation
of these nuclear receptors.
4.2. Natural Compounds. Several compounds of natural
origin have been reported to inhibit NRF2. The quassinoid
brusatol, extracted from Brucea javanica, inhibits the NRF2
transcriptional signature and sensitizes tumors and cancer
cell lines to several chemotherapeutics [147]. However, its
mechanism of action is not speciﬁc as it blocks protein
translation, hence aﬀecting other short-lived proteins as
well [148–150].
The ﬂavonoids luteolin [151] and wogonin [152] were
reported to inhibit NRF2 and sensitize cells to anticancer
drugs by increasing the instability to its transcript. However,
later studies also indicated that these compounds may elicit
NRF2 activation [153]. Therefore, their value as NRF2
inhibitor is highly controversial.
Table 3: Selected small molecule activators of NRF2 acting as NRF2-KEAP1 protein-protein interaction inhibitors.
Compound Type Ref. Patent
(SRS)-5
O
O
O
O OHN
S N RS
1,2,3,4-Tetrahydroisoquinoline core [112] WO2013/067036
Cpd 15
O
O
S
O
H
N
N
H
F
F
F
N
S
O
Benzenesulfonyl-pyrimidone [107] WO2016/202253
Cpd 16
O
O
S
HN
HN
O
S
O
O
O
1,4-Diaminonaphthalene core [107] WO2016/202253
Compound 2
O
O
O
S
N
OO
O
O
O
N
S
HO OH
1,4-Diaminonaphthalene core [163] CN105566241A
3-(Pyridin-3-ylsulfonyl)-5-(triﬂuoromethyl)-2H-chromen-2-one (PSTC)
F
F
F
OO
O
S
N
O
Sulfonyl coumarins [164] WO2015/092713
AN-465/144580
O
O
O
OO
NN
N
H
N
H OH
Other structure classes [165] JP2011/0167537
Compound 7
N N
N
NN
N
O
O Arylcyclohexyl pyrazoles [166] WO2017060855
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Table 4: Selected KEAP1-independent activators of NRF2.
Compound Mechanism of action Disease Clinical trial
ClinicalTrials.gov
identiﬁer
Tideglusib
O
O
N
N
S
GSK-3 inhibition
Autism spectrum disorders Phase II NCT02586935
Myotonic dystrophy 1 Phase II NCT02858908
Alzheimer’s disease Phase II NCT01350362
Nordihydroguaiaretic acid (NDGA)
HO OH
OH
HO
GSK-3 inhibition
Prostate cancer
Phase II NCT00678015
Phase I NCT00313534
Brain and central nervous
system tumors
Phase I/II NCT00404248
Terameprocol (NDGA derivative)
O
O
O
O
GSK-3 inhibition
High-grade glioma Phase I NCT02575794
Leukemias
Acute myeloid leukemia (AML)
Acute lymphocytic leukemia (ALL)
Phase I NCT00664677
Refractory solid tumors
Lymphoma
Phase I NCT00664586
Enzastaurin
N
N
N
N
NH
O
O
GSK-3 inhibition
Diﬀuse large B cell lymphoma Phase III NCT03263026
Solid tumor
Lymphoma, malignant
Phase I NCT01432951
LS-102
O
N
N N
N N
N
N
H
H
HRD1 inhibition — —
No clinical trials
available
Rapamycin
O
O
O O
O
O
O HO
O O
N
HO
O
OH
p62/SQSTM1 activation
Diabetes mellitus, type 1 Phase III NCT01060605
Systemic lupus erythematosus (SLE) Phase II NCT00779194
Autosomal dominant polycystic
kidney disease
Phase II/III NCT00920309
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Other natural compounds such the mycotoxin ochra-
toxin A [154] and the coﬀee alkaloid trigonelline [155]
prevent the nuclear translocation of NRF2. In leukemic cells,
malabaricone-A, a plant-derived prooxidant, eﬀectively
inhibits NRF2 transcriptional activity as reﬂected by a reduc-
tion in HO-1 protein levels and leads to ROS accumulation
and subsequent cell apoptosis [156]. Ascorbic acid, a well-
known ROS scavenger, was found to sensitize imatinib-
resistant cancer cells by decreasing the levels of the
NRF2/ARE complex, hence reducing the expression of
Glutamate-Cysteine Ligase Catalytic Subunit and dropping
GSH levels [157]. In general, the main concern with these
compounds is that their selectivity for NRF2 inhibition has
not been conclusively demonstrated.
4.3. Other Approaches. The lack of knowledge about the ﬁne
structure of NRF2 hampers a straightforward strategy for the
in silico analysis of small molecules that might dock to
relevant domains of interaction with MAF proteins, ARE
enhancer, etc. Therefore, a high-throughput screening was
used which is helping in the identiﬁcation of NRF2 inhibitors
but still not providing selectivity [158]. A ﬁrst-in-class com-
pound, termed ML385, was found after the screening of a
chemical library of 400,000 molecules. ML385 blocks NRF2
transcriptional activity and sensitizes KEAP1-deﬁcient cells
to carboplatin and other chemotherapeutics. ML385 inter-
acts with the DNA-binding domain of NRF2 and most likely
prevents the binding of NRF2 to AREs. However, given the
similarity between AREs and other enhancers such as AP1,
additional studies are needed to clearly establish if ML385
is selective for NRF2 or if it also inhibits other bZip transcrip-
tion factors involved in chemoresistance.
Halofuginone, a synthetic derivate of febrifugine that is
used in veterinary medicine, blocked the chemoresistance
and radioresistance of cancer cells in parallel to the decrease
of NRF2 protein levels [159]. It was found that halofuginone
induces amino acid starvation resulting in global inhibition
of protein synthesis.
Another compound, AEM1, decreased the expression of
NRF2-controlled genes and sensitized KEAP1-deﬁcient
A549 lung tumor cells to various chemotherapeutic agents
[160]. Although it seems that the anticancer eﬀect of AEM1
is restricted to cell lines harboring mutations which render
NRF2 constitutively active, the selectivity for NRF2 inhibi-
tion is not demonstrated yet.
In HeLa cells transfected with an ARE-driven luciferase
reporter, a pyrazolyl hydroxamic acid, termed 4f, inhibited
NRF2, reduced cell proliferation of myeloid cell lines, and
increased apoptosis of acute myeloid leukemia cells [161].
Most likely, 4f altered the BCL2/BAX ratio and induced
mitochondria-dependent apoptosis.
5. Conclusions
The NRF2/KEAP1 system represents a very promising phar-
macological target to control common pathologic mecha-
nisms of many chronic diseases characterized by low-grade
oxidative stress and inﬂammation. A plethora of NRF2 acti-
vators, mostly of electrophilic nature, have been identiﬁed
and a few are under clinical development. The pleiotropic
eﬀects of NRF2 on cell physiology together with potential
oﬀ-target eﬀects exerted by some NRF2 activators explain
why drug development is moving slowly. The ﬁeld of NRF2
inhibitors that may have a huge impact on cancer ther-
apy is less advanced. Future work should be directed
towards ﬁnding compounds with a good pharmacokinetic/
pharmacodynamic proﬁle for speciﬁc diseases.
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Table 4: Continued.
Compound Mechanism of action Disease Clinical trial
ClinicalTrials.gov
identiﬁer
HPP-4382
S
N
N
N
O
H
O
N
OH
O
N
NH
Cl
BACH1 inhibition — —
No clinical trials
available
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ABSTRACT: The adult subventricular zone (SVZ)
is a highly organizedmicroenvironment established during
the first postnatal days when radial glia cells begin to trans-
form into type B-cells and ependymal cells, all of which
will form regenerative units, pinwheels, along the lateral
wall of the lateral ventricle. Here, we identify p73, a p53
homologue, as a critical factor controlling both cell-type
specification and structural organization of the developing
mouse SVZ.We describe that p73 deficiency halts the tran-
sition of the radial glia into ependymal cells, leading to the
emergence of immature cells with abnormal identities
in the ventricle and resulting in loss of the ventricular
integrity. p73-deficient ependymal cells have noticeably
impaired ciliogenesis and they fail to organize into pin-
wheels, disrupting SVZ niche structure and function.
Therefore, p73 is essential for appropriate ependymal cell
maturation and the establishment of the neurogenic niche
architecture. Accordingly, lack of p73 results in impaired
neurogenesis. Moreover, p73 is required for translational
planar cell polarity establishment, since p73 deficiency
results in profound defects in cilia organization in individ-
ual cells and in intercellular patch orientation. Thus, our
data reveal a completely new function of p73, independent
of p53, in the neurogenic architecture of the SVZ of rodent
brain and in the establishment of ependymal planar cell
polarity with important implications in neurogenesis.
VC 2015 Wiley Periodicals, Inc. Develop Neurobiol 76: 730–747, 2016
Keywords: p73; ciliogenesis; ependymal cells; neuro-
genic pinwheel; planar cell polarity
INTRODUCTION
Maintenance of neural stem cell (NSC) capacity to
self-renew is dependent upon intrinsic regulatory net-
works and extrinsic cues within the NSC niches
(Miller and Gauthier-Fisher, 2009). The members of
the p53 family of tumor suppressor genes, TP53,
TP63, and TP73, are important players in NSC biol-
ogy (Killick et al., 2011). In particular, TP73
is deeply involved in NSC maintenance and organiza-
tion of the sub-ventricular zone (SVZ) germinal
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center (Agostini et al., 2010; Fujitani et al., 2010;
Gonzalez-Cano et al., 2010; Talos et al., 2010) and
regulates the balance between symmetric and asym-
metric cell divisions of NSC (Gonzalez-Cano et al.,
2013). The hydrocephalus phenotype of Trp732/2
mice (p73KO from now on) (Yang et al., 2000) sug-
gested a possible p73 role in ependymal ciliary func-
tion that might be linked to its regulation of the
neurogenic environment. However, this has never
been addressed.
The architecture of the SVZ is established during
the first postnatal days when a select group of radial
glia cells (RGCs) begins to transform into NSC (Mer-
kle et al., 2004), while other subpopulation gives rise
to ependymal cells (ECs). ECs will form pinwheel
structures with B-cells (NSC) intercalated among
them. B-cells have a small apical surface with a sin-
gle primary cilium contacting the ventricle and large
basal process contacting blood vessels, and exhibit
ultrastructural characteristics and markers of astro-
glial cells, including GFAP and GLAST expression
(Ihrie and Alvarez-Buylla, 2011). The apical proc-
esses of the B-cells form the core of the pinwheel,
which itself is formed by multi and bi-ciliated ECs
(Mirzadeh et al., 2008). This highly organized micro-
environment is necessary for maintaining NSC self-
renewal and differentiation capacity as well as the
neurogenic niche homeostasis (Lim et al., 2000;
Chmielnicki et al., 2004; Ramirez-Castillejo et al.,
2006; Andreu-Agullo et al., 2009).
Multiciliated ECs have a prominent role in the
maintenance of the neurogenic niche, since they
induce neurogenesis and suppress gliogenesis by
secreting the bone morphogenetic protein (BMP)
inhibitor, Noggin (Lim et al., 2000; Chmielnicki
et al., 2004). ECs are defined as large-apical surface
multiciliated cells that express S100ß and Vimentin
(Spassky et al., 2005; Raponi et al., 2007; Mirzadeh
et al., 2008; Pastrana et al., 2009). ECs are generated
from RG in a multistep process orchestrated by the
primary cilium and its basal body apparatus (Spassky
et al., 2005). RG planar cell polarity (PCP) is first
established during perinatal development when the
primary cilium migrates toward the rostral end. Later
on, from P5 until P20, cilia clusters in maturing ECs
become densely packed, with basal bodies aligned
and positioned as a patch on the downstream side of
the EC apical surface with respect to the direction of
cerebrospinal fluid (CSF) flow (Bayly and Axelrod,
2011). Thus, EC cilia display two types of PCP: rota-
tional PCP (rPCP) which refers to the parallel align-
ment of the basal bodies within each multi-ciliated
cell and translational PCP (tPCP), defined by the
basal body cluster anterior position on the cell apical
surface (Mirzadeh et al., 2010). Both forms of polar-
ity correlate with the onset of coordinated cilia beat-
ing in a uniform direction (Hirota et al., 2010).
Defects in cilia are associated with a range of
human diseases, such as primary ciliary dyskinesia or
hydrocephaly (Badano et al., 2006; Kishimoto and
Sawamoto, 2012). In the brain, EC cilia are required
for CSF circulation and neurogenesis (Boutin et al.,
2014). Disruption in PCP establishment results in
dysfunctions of ependymal cilia and their directional
beating. Thus, the identification of the main players
in EC maturation and PCP establishment might have
important therapeutic implications.
Here we describe that p73 deficiency impairs epen-
dymal cell maturation and ciliogenesis, as well as
their organization in neurogenic pinwheel structures.
Moreover, lack of p73 dramatically alters the estab-
lishment of PCP and affects the neurogenic capacity
of the germinal center, independently of p53.
MATERIAL AND METHODS
Mice Husbandry, Genotyping, and BrdU
Treatment
Housing and animal experiments were conducted in
agreement with European and Spanish regulations on the
protection of animals used for scientific purposes (Coun-
cil Directive 2010/63/UE and RD 53/2013, respectively)
with the appropriate institutional committee approval.
Mice heterozygous for Trp73 on a mixed background
C57BL/6 x 129/svJae (Yang et al., 2000) were back-
crossed to C57BL/6, at least five times, to enrich for
C57BL/6 background. Heterozygous animals were
crossed to obtain the p73KO mice. C57BL/6 p53 knock-
out mice (p53KO) were previously described (Done-
hower et al., 1992). To generate the double p73;p53
knock-out mice (DKO), heterozygous Trp731/2 animals
were crossed with p53KO mice, obtaining the double
heterozygous mice, Trp731/2; Tp531/2. Then, double
heterozygous were inter-crossed to originate the DKO
animals. Genotyping of adult animals was performed by
PCR analysis as described before (Yang et al., 2000;
Flores et al., 2005). The thymidine analogue BrdU
(Sigma, St. Louis, MO) was administered intraperitoneal
(90 mg kg21) in pulse injections every 2 h, during 8 h.
Male and female mice were used in the experiments.
Immunohistochemistry
Animals were fully anesthetized using an analgesic/anes-
thetic mixture of medetomidine hydrochloride (Domtor
VR
,
Orion Corporation, Espoo, Finlandia) and ketamine
(Imalgene
VR
500, Merial, Duluth, GA). Medetomidine
(1 mg kg21)/ketamine (75 mg kg21) euthanasic mixture
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was prepared in phosphate buffer saline (PBS) and injected
intraperitoneally. Animals were euthanized in agreement
with European and Spanish regulations by transcardial per-
fusion with 0.1M PBS supplemented with 1% heparin until
the drained blood became clear, and then with 20–40 mL
of fresh 4% paraformaldehyde (PFA) in 0.1M PBS, depend-
ing of the age of the animal.
After perfusion, brains were dissected and post-fixed
overnight (o/n) in fresh 4% PFA in PBS solution at 48C.
For cryopreservation, samples were incubated for 24 h in
30% sucrose/PBS solution. Samples were then frozen in
dry ice and stored at 2808C. A 30-mm-thick coronal sec-
tions were prepared using a Microm HM450 sliding micro-
tome (Thermo Scientific, Walthman, MA) and stored in
PBS supplemented with 0.05% sodium azide at 48C. BrdU
and Ki67 staining required antigen retrieval for which sec-
tions were incubated in 2N HCl for 15 min at 378C. Then,
sections were washed and stained according to the pub-
lished protocol (Gonzalez-Cano et al., 2010). Sections were
incubated with the indicated antibodies (Table 1). Confocal
microscopy images were obtained with Nikon Eclipse
TE2000 confocal microscope (Nikon, Chiyoda-Tokyo,
Japan) and Olympus FluoView FV10i Confocal Laser
Scanning Microscope (Olympus, Shinjuku-Tokyo, Japan).
Figures show single level representative pictures.
Isolation and Immunostaining of SVZ
Wholemounts
Wholemounts of the lateral wall of the ventricles were dis-
sected from 7, 15, and 160 postnatal day mice. Animals
were anesthetized and euthanized in agreement with Euro-
pean and Spanish regulations and the brain was dissected
and placed in cold 0.1M PBS. Dissection of the WMs was
made under the stereomicroscope as described (Mirzadeh
et al., 2010). WMs were transferred ventricle side up to a
24-well plate with 4%PFA/0.1% Triton-X100 (Tx100),
fixed o/n at 48C and stored in 0.1M PBS at 48C.
WMs were incubated for 2 h at room temperature in
blocking buffer (0.1M PBS/10% NDS/0.5% Tx100). Then,
sections were incubated for 48 h at 48C with the appropri-
ate primary antibodies (Table 1) diluted in blocking buffer.
Immunofluorescent detections were carried out with Alexa
Fluor (Invitrogen, Carlsbad, CA) or DyLight (Pierce,
Whaltman, MA) and Cy2, Cy3, and Cy5 (Jackson Immu-
noResearch Laboratories, West Grove, PA) conjugated
secondary antibodies. DAPI (1 mg mL21) was used for
nuclear counterstaining. Samples were analysed in an
Olympus FluoView FV10i confocal laser scanning micro-
scope (Olympus, Shinjuku-Tokyo, Japan). Images were
acquired and processed using FV10-ASW 2.1 viewer
software.
Scanning Electron Microscopy (SEM)
Lateral wall isolated from P7 and P15 mice were fixed with
0.1M PBS/2% glutaraldehyde, pH 7.2–7.4 at 48C. Then,
samples were dehydrated through a series of aqueous etha-
nol solutions (30, 70, 90, 96, and 100% ethanol) and finally
dried with liquid CO2 (critical point at 88C). To obtain
SEM images, samples were covered with a cycle of evapo-
ration of gold atoms induced by argon in vacuum condi-
tions (0.05–0.07 mbar). SEM images were obtained using a
JEOL Scanning Electron Microscope (JEOL, Akishima-
Tokyo, Japan). Images of the wholemounts were acquired
every 0.5 mm and maximum projection of three to five con-
secutive Z levels are shown.
Image Data Quantification and
Statistical Analyses
For all the analyses, at least three independent mice from
each genotype were considered. Analysis of SVZ coronal
sections was performed considering anterior, medial and
posterior sections. For each section, Z-stacks (20 mm) from
at least six dorso-ventral regions along the wall of the ven-
tricle were acquired. To determine the numbers of positive
Table 1 Primary Antibodies Used for Immunohistochemistry
Antibody Host Dilution Manufacturer, Catalog Number
BrdU Mouse 1:200 Dako,M0744
BrdU Mouse 1:500 BD Biosciences,347583
ß-Catenin Rabbit 1:100 Cell signaling,9587
ß-Catenin Mouse 1:100 BD Biosciences, 610153
Dcx Goat 1:150 Santa Cruz Biotech,SC8066
GFAP Chicken 1:500 Chemicon,Ab5541
GLAST Rabbit 1:100 Tocris, 2064
IB4 Mouse 1:20 Sigma,L2140
Ki67 Rabbit 1:100 Abcam,ab15580
s100ß Rabbit 1:100 Dako,Z0311
Ac-Tubulin Mouse 1:1000 Sigma,T6793
c-Tubulin Goat 1:200 Santa Cruz Biotech,SC7396
Vimentin Guinea Pig 1:500 Fitzgerald,20R-VP004
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cells, images were counted approximately every 7 mm
ensuring that different cells were considered. The percent-
age of positive or double positive cells was calculated rela-
tive to the total number of nuclei (DAPI staining) at each Z
level. When comparing the number of B cells versus GFAP
positive cells, the number of GFAP and positive cells was
first determined independently. Then, the percentage of
GFAP/Ki67 cells out of the GFAP positive was calculated.
Quantification of GLAST cells refers to the number of posi-
tive cells touching the ventricle relative to the analyzed lat-
eral wall length (linear measurement5 130 lm).
Wholemount image analysis was performed counting four
non overlapping fields (130 lm 3 130 lm) of every speci-
fied region and genotype. Images of the WM were acquired
every 0.5 mm and maximum projections of three to five con-
secutive Z levels are shown. In some cases, due to the cell
heterogeneity depending on the region and the genotype,
data are presented relative to the total surface analysed.
A customized software developed by Wimasis (Wimasis
GmbH, Munich, Germany) was used to determine cell
areas, percentage of cell polarization and angle displace-
ment. Ten independent representative images per genotype
were analyzed. For cell polarization analysis, the contours
of ependymal cells and BB patches were defined and the
relative distance between the geometric center of the apical
cell surface and the BB cluster centroid was determined
and divided by the cell radio. Angle displacement was
determined relative to a reference angle for each micros-
copy field by drawing a vector from the cell center to the
cluster centroid (Boutin et al., 2014).
Comparison of the cellular populations that constitute
the SVZ was carried out using a Kruskal–Wallis test
together with Dunn’s multiple comparisons test. For all the
other analyses, Mann–Whitney non-parametric tests were
performed. Angle displacements were compared by circular
statistical analysis. Data were graphically represented using
Oriana software (Kovach Computing Services, Anglesey,
Wales) and Watson’s U2 test was performed. Differences
were considered significant when P< 0.05 (*P< 0.05,
**P< 0.01, ***P< 0.001) and all data are reported as
mean6 standard deviation of the mean (SD).
RESULTS
p73 Deficiency Alters RG Cells Transition
into ECs, Generating Immature Cells with
Abnormal Identities and Resulting in
Loss of Ventricular Integrity
ECs are generated from RGCs during perinatal devel-
opment. This ependymal layer is crucial for the SVZ
germinal center organization and function. Thus, to
address whether p73 deficiency affected the matura-
tion and organization of the EC layer, we analyzed
P7 and P15 coronal sections using EC markers
(Vimentin and S100b) together with GFAP. In P7-
wild type (WT) mice [Fig. 1(A)], most of the
ependymal-Vimentin1/S100b1 cells already formed
a mono-stratified epithelium lining the ventricle,
although there were areas that remained pseudo-
stratified at this stage (white arrows). In the absence
of p73, formation of the monostratified epithelium
looked halted and chains of S100b1/Vimentin1 cells
appeared to progress inwards with remarkable sepa-
rations between the cells [Fig. 1(A), white arrows]. In
WT ECs Vimentin and S100b proteins did not have
the same cellular localization, with S100b being
expressed mostly at the apical surface (white arrow-
heads). On the contrary, in p73KO ECs these proteins
co-localized (white arrowhead) also coinciding with
GFAP expression around the cell soma and radial
extensions [Fig. 1(B), yellow arrowheads].
Many of these triple positive cells (S100b/Vimen-
tin/GFAP) were contacting the ventricle and could
Figure 1 Lack of p73 results in a defective ependymal cell layer and loss of ventricular integrity. (A,B) Expression of
Vimentin (A,B, red), S100b (A, B, green), and GFAP (B, blue) in confocal images of brain coronal sections from P7 WT and
p73KO mice. Mono- or pseudo-stratified ependymal layers are indicated by white arrows. Colocalization of S100b1/
Vimentin1 is indicated by white arrowheads (A) and S100ß1/Vimentin1/GAFP1 by yellow arrowheads (B). (C) Analysis of
GLAST (green), Vimentin (red), and GFAP (blue) expression in P15 mice after RGC transition into ependymal cells.
Vimentin1 cells are indicated by white arrowheads. Different stages of RGCs transition were detected: immature GLAST1-
RGCs (white arrows), RGCs in transition GLAST1/Vimentin1 (yellow arrows) and aberrant GLAST1/Vimentin1/GFAP1
cells (yellow arrowheads). (D) Quantification of GLAST1 cells touching the lateral wall of the ventricule of SVZ. (E) Coronal
sections of P15 WT, p73KO, p53KO, and DKO mice were stained with the indicated antibodies and the LW of the lateral ven-
tricle was analyzed by confocal microscopy. WT LW showed a mono-stratified epithelium of ependymal S100b1/IB41 cells
(red/green, white arrows), with some S100ß1/GFAP1 positive mature astrocytes in the striatum (yellow arrows) and a few
GFAP1/S100b2 B-cells (white arrowheads). TP73 defective cells formed a pseudo-stratified and discontinuous layer (yellow
arrowheads) with S100b1/GFAP1 cells (pink arrows) with periventricular soma and long RG-like striatal processes. Some
S100b1 ependymal cells were IB42 (blue arrows). Tile scan of coronal sections images (310) from WT, p73KO, p5KO, and
DKO mice. Scale bars: 20 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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correspond with immature cells in a transitional state
from RGCs to ECs [Fig. 1(B)]. To address this, we
analyzed expression and localization of the RGC
marker GLAST, together with Vimentin, at a stage
were RG transition into ECs has just been completed
(P15) (Lavado and Oliver, 2011). As previously
described (Mirzadeh et al., 2008), GLAST1-RGCs
were mostly absent from the ventricle wall in P15
WT brains and Vimentin1-ECs lacked GLAST
expression [Fig. 1(C), white arrowheads]. However,
p73KO brains had significantly more GLAST1-
RGCs that remained in contact with the ventricle
[Fig. 1(C,D), white arrows]. Moreover, many of these
cells expressed Vimentin in their processes
(Vimentin1/GLAST1 cells, yellow arrows). This pat-
tern of marker expression strongly suggests an imma-
ture phenotype in the p73KO brains. We also
detected an aberrant triple positive population
(Vimentin1/GLAST1/GFAP1) in P15-p73KO mice
[Fig. 1(C), yellow arrowheads]. This population most
likely represent an intermediate cellular state during
RG transformation into GFAP1 astrocytes and B
cells (Spassky et al., 2005), indicating that p73 might
be required for RGCs cell fate determination.
To further study the effect of p73 deficiency on
ependymal cell maturation and morphology, P15 cor-
onal sections were stained with antibodies against
S100ß (also expressed by mature GFAP-astrocytes)
and isolectin B4 (IB4), which also labels endothelial
cells. At this stage, WT mice already exhibited an
Figure 2 p73 deficiency affects proliferating neuroblasts and neural stem cells, even in the absence of p53. Coronal sections
of P15 WT, p73KO, p53KO, and DKO mice were stained with the indicated antibodies and the LW of the lateral ventricle
was analyzed by confocal microscopy (A, B) and cellular populations were quantified (C, D). (A, C) p73 loss resulted in less
proliferating neuroblasts [Doublecortin (Dcx1)/BrdU1 (red/green)], even in the absence of p53. (B, D) Mice lacking p73 had
more non proliferating astrocytes indicated by white arrows (GFAP1, red), but a reduced proportion of B-cells, indicated by
white arrowheads (GFAP1/Ki671, red/green). Scale bars: 20 lm. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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organized and continuous mono-stratified epithelium
of mature ECs (S100b1/IB41) [Fig. 1(E), white
arrows] with few B-cells (GFAP1/S100b2) contact-
ing the ventricle (white arrowheads) and some mature
GFAP1/S100b1/IB42 astrocytes only in the striatum
(yellow arrows). In contrast, lack of p73, resulted in a
pseudo-stratified and discontinuous ependyma with
scattered S100b1-ECs [Fig. 1(E), yellow arrow-
heads]. It is worth noticing that not all S100b1-ECs
were positive for IB4 (blue arrow) but, in turn,
p73KO brains had abundant GFAP1/S100b1 cells,
some of which were in contact with the ventricle
(pink arrow), suggesting either an incomplete matura-
tion or an astrocytic nature. p73-deficient ependymal
layer had gaps, invaginations, and “bumps” [Fig.
1(E), yellow arrowheads and Supporting Information
Fig. 1], indicating that lack of p73 compromises
ependymal barrier integrity. Defects in the ependy-
mal barrier have been associated to hydrocephalus
(Jimenez et al, 2014), a condition observed in the
p73KO mice (Yang et al., 2000). However, it has
been proposed that hydrocephalus in p73KO could be
the result of induced apoptosis associated to an exa-
cerbated p53 activity, due to the lack of the prosur-
vival DNp73 isoform (Pozniak et al., 2002; Lee et al.,
2004). To address this possibility, even though the
number of S100b1 cells was not lower in p73KO
SVZ than in WT brains (data not shown), we ana-
lyzed coronal sections from p53 knock-out (p53KO)
and double mutant p73KO/p53KO (DKO) brains.
DKO, like p73KO, showed severe hydrocephalus and
enlarged ventricles [Fig. 1(E)], suggesting that p73-
loss has a dominant effect. Consistently, DKO also
had numerous S100b1 ECs, some of which were
IB41, but these ECs did not form a monostratified epi-
thelium [Fig. 1(E)] demonstrating that p53 abolish-
ment did not restore the phenotype. Moreover, DKO
mice, but not the single p53KO, displayed defective
ependymal layers [Fig. 1(E), yellow arrowheads].
It has been reported that disruption of the mature
ependyma disturbs neurogenic activity (Jimenez
et al., 2014). Mature ECs create a permissive neuro-
genic environment by secreting Noggin (Lim et al.,
2000). Noggin and S100ß expression co-localized
within the ependymal layer in WT mice (Supporting
Information Fig. 1). However, in the p73KO, Noggin
was detected throughout the SVZ and did not com-
pletely match the S100b1 expressing cells, highlight-
ing the lack of appropriate organization and
maturation of ECs (Supporting Information Fig. 1).
This finding not only was consistent with the idea
that p73 is required for the transition of RG into the
different cell types that comprise the SVZ but, more
importantly, it also suggested possible defects in the
neurogenic environment of this region in p73-
defective mice. To address this, we analyzed the dif-
ferent cellular populations that constitute the SVZ.
P15 brain coronal sections were first stained against
Doublecortin (Dcx), combined with the proliferation
markers Ki67 or BrdU to quantify the proliferating
neuroblasts [Fig. 2(A–C)]. It has been published that
p53KO mice had more proliferating neuroblasts than
WT (Ferron et al., 2009). However, we observed that,
lack of p73, alone or in the context of p53KO (DKO),
resulted in a significant reduction of the proliferating
neuroblasts compared to WT or p53KO, respectively
[Fig. 2(C)], indicating that p73 deficiency leads to a
reduction in neurogenesis in the SVZ, despite p53
absence. However, p53 ablation in the context of p73
deficiency (DKO) did not elevate the number of pro-
liferating neuroblasts, indicating that p73 effect was
not due to enhanced neuroblast cell death resultant
from p53 compensatory activation.
RGC will also give raise to neural stem cells (B-
cell) and astrocytes. Thus, we next analyzed these
populations: astrocytes (non-proliferative GFAP
cells) and B-cells, identified as the subpopulation of
proliferating astrocytes (GFAP/Ki67 double positive)
in the SVZ (Merkle et al., 2004). Strikingly, lack of
p73 gave raise to GFAP1 cells that had a periventric-
ular cell soma in contact with the ventricle, GFAP1
filaments that formed tangles surrounding the
nucleus, and long GFAP1 processes that extended
across the striatum towards the pial surface, alto-
gether resembling the morphology of RG cells [Fig.
2(B), white arrows]. However, most of these GFAP1
cells were non-proliferating cells [Fig. 2(B,D), white
arrows], discarding their possible identity as B-cells.
While 43.86% of GFAP1 cells represented B-cells in
the WT, only 17.56% of GFAP1 cells were B-cells in
p73KO. Moreover, p73 deficiency, alone or in the
context of p53 ablation (DKO), resulted in significant
reduction in the proportion of B-cells in the SVZ
compared to WT and p53KO, respectively [Fig.
2(D)], suggesting a p73 requirement for adult neural
stem cells establishment and maintenance.
Altogether the alterations in the p73KO SVZ indi-
cate that p73 loss results in an aberrant maturation of
the ECs, affecting the SVZ environment, which might
cause, at least in part, the impaired neurogenic
capacity of the germinal centers, independently of p53.
p73 is Essential for the Ependymal Cell
Assembly into Neurogenic SVZ
Pinwheels
EC generation involves the transformation of mono-
ciliated RGCs into multiciliated ECs during the first
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postnatal days (P0-P15) (Spassky et al., 2005).
Within the first postnatal week, RGCs gradually
increase their apical surfaces and upon reaching cer-
tain size, multiply the number of basal bodies (BB) to
develop clusters of motile cilia (Mirzadeh et al.,
2010). To analyze this maturation, P7-WT and
p73KO mice wholemounts dissections were stained
with c-tubulin to label the cilia basal bodies (BBs),
and b-catenin to delimit the cell membrane, and the
apical cell surface size was quantified [Fig. 3(A)].
Most of the mono-BB cells in WT mice were small
cells with an apical surface 25 mm2 corresponding
to B-cells and RGCs according to Mirzadeh et al.
(2010). WT mice also had mono-BB cells with
expanded apical surface, between 30 and 60 mm2,
which are RGCs in transition (Mirzadeh et al., 2010),
but we rarely detected mono-BB cells with an apical
surface bigger than 60 mm2. However, in p73KO
mice the percentages of mono-BB cells with interme-
diate size or with apical surfaces bigger than 60 mm2
were significantly higher [Fig. 3(A)]. The later cells
correspond, most likely, to abnormal stages of RGC
transitioning into ECs.
The neurogenic capacity of the rodents SVZ is
dependent upon ependymal cells integrity and their
capacity to assemble into the unique structures that
define this region: the pinwheels (Kuo et al., 2006;
Paez-Gonzalez 2011). Multi and bi-ciliated ECs sur-
round mono-ciliated GFAP1-B-cells forming pin-
wheels in which the apical processes of the neural
stem cells constitute the core of the structure (Mirza-
deh et al., 2008). To address whether p73-deficiency
affected SVZ cytoarchitecture, P7 and P15 whole-
mounts were stained with c-tubulin, b-catenin and
GFAP antibodies to identify ventricle-contacting
monociliated GFAP1-neural stem cells (B-cells) and
multiciliated GFAP- ECs [Fig. 3(B–D)].
P7-WT AV region showed mono-BB cells which
do not express GFAP and correspond to RGCs [Fig.
3(B, B’)], blue arrows] and RGCs with extended api-
cal surface and c-tubulin stainings marks like dense
punctuated deposits known as deuterosomes (Spassky
et al., 2005) [Fig. 3(B, B’), yellow arrows]. There
were also cells with multiple BBs, which are sparse
and randomly oriented in the apical surface, that
correspond to immature multiciliated cells [Fig. 3(B),
white arrowheads].
Toward posterior regions, WT-ECs seemed to be
organizing into pinwheel structures, with immature
large GFAP1-multi BB cells surrounding groups of
small mono-BB cells (pre-pinwheels) [Fig. 3(B),
white lines], confirming the gradual transformation of
the lateral ventricle wall in WT mice. The maturing
p73KO-ECs were arranged into aberrant structures,
with many intermediate-size mono-BB cells in the
core, but without a pre-pinwheel organization [Fig.
3(B), white lines]. Moreover, while in the WT brains
neighbors cells have begun to coordinate their BB
clusters [Fig. 3(B’) white arrowheads], in p73KO the
cells do not show any coordinated orientation at this
stage (white arrowheads). Nevertheless, p73 deficient
mice did not show significant differences in the num-
ber of total mono-BB cells [Fig. 3(D)], neither in
multi-BB cells (WT 32.836 12.45 vs. p73KO
22.026 8.086; p5 0.0734).
P15-WT mice [Fig. 3(C)] showed a progressive
maturation with pre-pinwheel patterns (white lines)
at AV zone and pinwheels (yellow lines) in PD
regions, very similar to those described in the adult
mice (Mirzadeh et al., 2008). The monociliated cells
at the pinwheel core had a small apical surface with
long GFAP1 processes oriented tangentially to the
epithelial surface, what identified them as B-cells
[Fig. 3(C), pink arrows]. Surprisingly, P15-p73KO
SVZ lacked this cytoarchitecture [Fig. 3(C)]. First,
the number of total monociliated cells was signifi-
cantly higher in p73KO than in the WT [Fig. 3(D)].
However, 62.9%6 15.4% of monociliated cells in
WT were GFAP1 B-cells, while in p73KO only
17.0%6 3.8% (AV region) and 31.4%6 6.1% (PD
region) expressed this marker [Fig. 3(E)], indicating
that p73 deficient monociliated cells were not bona-
fide B-cells. As we progressed toward the posterior
regions, a more organized distribution was observed,
Figure 3 Lack of p73 delays the establishment of the lateral ventricle wall cytoarchitecture and the organization of ependy-
mal cells into pinwheels. Confocal Z-stacks images of lateral ventricle wall whole-mounts from the indicated age and pheno-
type immunostained for b-catenin (green), c-tubulin (red), and GFAP (blue). (A) Confocal images of P7 WT and p73KO SVZ
with trace of the cell contour (green) and quantification of mono- basal body (BB) cell size. (B, B’) In P7 mice, RGCs are
identified by the presence of a single BB and small apical surface (blue arrows). Immature multiciliated cells are shown by
either yellow arrows (cells with deuterosomes) or by white arrowheads (cells with multiple BB covering the apical surface).
The orientation of RGCs and multi-BB cells is indicated by white arrows and white arrowheads, respectively. (B, C) In P7
and P15 mice white and yellow lines mark pre-pinwheels and pinwheels respectively, and pink arrows indicate pinwheel core
cells. (D–F) Quantification of the indicated populations at anterior-ventral (AV) and posterior-dorsal (PD) regions in P7 and
P15 mice. The images represent Z-stacks (20 mm) from at least 6 dorso-ventral regions. Scale bars: 20 lm. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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but structures resembling pinwheel patterns were sel-
dom detected [yellow lines and pink arrows]. In the
absence of p73, it is noteworthy that, a significant
number of large-surface multi-BB cells touching the
ventricle, which by definition are ECs (Spassky et al.,
2005), were GFAP1, even at P15 [Fig. 3(C,F), white
arrowheads]. These large multiciliated-GFAP1 cells
[Fig. 4(A), white arrowheads] seemed to correspond
with the previously described cells contacting the
ventricle that coexpressed S100b, Vimentin and
GFAP, some of which were also GLAST1 [Fig.
1(B,C), yellow arrowheads]. These cells had an aber-
rant membrane morphology with waves and pleats
[Fig. 4(A), yellow arrowheads], suggesting that the
intercellular junctions at the apical surface of these
cells might be affected.
It has been reported that p73KO brains suffer
ependymal denudation (Medina-Bolivar et al.,
2014). This process triggers neighboring astrocytes
to proliferate and form a superficial cell layer cover-
ing the denuded ventricular surface (Roales-Bujan
et al., 2012). The reactive astrocytes found at the
denuded ventricular walls resemble the ependymal
cells in several aspects, like the expression of vimen-
tin, but maintain specific differences like lack of N-
cadherin expression and absence of cilia (Roales-
Bujan et al., 2012). Thus, we sought to determine
whether the GFAP-expressing cells in p73KO VZ/
SVZ were indeed, reactive astrocytes. We analyzed
the proliferation capacity of S100b1/GFAP1 cells,
since remodeling astrocytes have been shown to
express proliferative markers (Kuo et al., 2006; Luo
et al., 2008), and found that most of the S100b1/
GFAP1 cells in the p73KO SVZ were nonproliferat-
ing BrdU2-cells [Fig. 4(B), yellow arrows]. Further-
more, the cells lining the ventricles in p73 deficient
mice, including the GFAP1 cells, expressed N-
cadherin at the lateral plasma membrane [Fig. 4(C),
white arrows]. A similar phenotype was observed in
DKO mice (Supporting Information Fig.2). More-
over, the presence of BB clusters in these GFAP1
cells revealed their fate as multicilliated ependymal
cells [Fig. 4(A), white arrowheads]. Altogether, our
data is consistent with a defect in RGC maturation
and the presence of aberrant and immature
multiciliated-ECs in p73KO VZ/SVZ, rather than
with the presence of remodeling astrocytes. It is
meaningful that adult p73KO maintained the
observed phenotype in adulthood with the presence
of multiple large-surface ependymal cells with BBs
clusters and altered membrane junctions [Fig. 4(D)].
Adult p73KO multiciliated cells had strong GFAP
expression and very condensed basal bodies clusters
forming mainly pre-pinwheel structures [Fig. 4(D)
white lines] and only a small number of pinwheels
(yellow line). Thus, in the absence of p73, EC matu-
ration is halted, with the immature ECs remaining in
the lateral ventricle. These data confirm that p73
deficiency results in a deregulation of the transition
process from RGC to ependymal and B-cells, lead-
ing to the emergence of aberrant cells not capable of
assemble into neurogenic structures.
To further address whether p53 function played a
relevant role on neurogenic pinwheel organization,
we performed a comparative study of wholemounts
from the four genotypes at P15, since the DKO mice
do not survive any longer. p53 deficient brains dis-
played an organized VZ with mature multiciliated
ECs and monociliated GFAP1-B cells forming pin-
wheels [Fig. 4(E), yellow lines]. Thus, lack of p53
did not affect the cytoarchitecture of the lateral ven-
tricle wall, despite the numerous B-cells touching the
ventricle [Fig. 4(E), white arrows]. Strikingly, DKO
mice were very similar to p73KO, with numerous
monociliated cells with expanded apical surface,
some of them GFAP1 [Fig. 4(E), white arrowhead].
Figure 4 p73 deficiency results in immature and aberrant multiciliated ependymal cells that persist in adulthood, independ-
ently of p53. (A) Magnification of confocal WMs Z-stacks micrographs (left) and coronal section (right) from P15 p73KO
mice immunostained for b-catenin (green), c-tubulin (red), and GFAP (blue). Yellow arrowheads indicate multiciliated cells
with aberrant membrane morphology, while multiciliated cells with abnormal identities (GFAP1) are marked by white arrow-
heads. (B) Confocal images of brain coronal section from WT and p73KO mice. Inmunostaining for BrdU (green), S100b
(red), and GFAP (blue) indicate that most of the S100b1/GFAP1 cells in the p73KO SVZ were non-proliferating cells
(BrdU2) (yellow arrows). (C) Confocal images and magnifications of P15 coronal sections immunostained for N-Cadherin
(red), and GFAP (blue). White arrows indicate N-cadherin1/GFAP1 cell touching the ventricle. (D) Analysis of lateral ventri-
cle wall whole-mounts of the indicated phenotypes at P160 (D) and P15 (E) immunostained for b-catenin (green), c-tubulin
(red), and GFAP (blue). Pinwheel structures are marked by white lines and pre-pinwheel structures by yellow lines. (E)
Wholemount analysis of P15 mice from the four genotypes. While p53KO mice presented pinwheel structures (yellow lines)
with B cells (white arrows), DKO mice showed aberrant expanded apical surface monociliated GFAP1 cells (white arrow-
heads) and cells with deuterosomes (yellow arrowheads), but not organized structures. Yellow arrows follow basal body polar-
ization of ependymal cells. Scale bars: 20 lm. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Moreover, many multiciliated cells still had deutero-
somes, with no detectable polarization, characteristic
of immature ECs [yellow arrowheads]. These results
demonstrate that while p73 function is required for
the establishment of SVZ architecture while p53 is
not essential for these processes.
Lack of p73 Impairs Ciliogenesis and
Planar Cell Polarity Establishment
To address whether lack of p73 affected the genesis
and organization of ependymal cilia, we performed a
comparative study of P7 and P15 WT and p73KO
mice using SEM. It has been described that cilia tufts
appear around P5 and reach their mature density by
P10 (Tissir et al., 2010). Accordingly, P7-WT AV
regions displayed some monociliated cells [Support-
ing Information Fig. 3(A), black arrows; Fig. 5(A),]
and abundant multiciliated cells [Supporting Infor-
mation Fig. 3(A,B)] covering most of the ventricular
surface. At the same stage, p73KO showed an imma-
ture phenotype with many monociliated cells [Sup-
porting Information Fig. 3(A,B), black arrows] and
less cilia tufts [Supporting Information Fig. 3(A,B)].
Moreover, it is noteworthy the presence of cells with
cilia of different sizes distributed through the whole
apical surface [Fig. 5(A), double line]. As reported
(Spassky et al., 2005), we observed that by P15
mature ECs dominate the VZ displaying compacted
cilia clusters on the apical surface which have begun
to be coordinately oriented [Fig. 5(B)]. In contrast,
cilia tufts in p73KO cells displayed an abnormal
organization and, in some cases, the individual cilia
within a given cell did not point to the same direction
and some cilia seem to be angled or even truncated
[Fig. 5(B), black triangles]. This data suggests that in
the p73KO mice the cilia fail to form normally.
We found intriguing that while the SEM analysis
revealed less cilia covered area in p73KO lateral ven-
tricle wall [Fig. 5(B)], our previous en-face whole-
mount staining of the walls of the lateral ventricle
(Fig. 3) demonstrated that there were no differences
in the number of total multiciliated cells in the
p73KO, as accounted by the presence of BB clusters.
Thus, we hypothesized that p73-deficient VZ ependy-
mal cells had BB clusters, but lacked cilia due to a
defect in the ciliogenesis process. To address this, we
analyzed wholemounts of P7 and P15 SVZ stained
for acetylated tubulin (Ac-tubulin) which marks
ependymal long motile cilia and RGCs short primary
cilia. At P7 anterior regions, WT mice displayed
RGCs with a primary cilium associated to a single
basal body [Fig. 5(C), white arrows], while at poste-
rior regions, ECs have long cilia tufts emanating
from BBs patches (yellow arrowheads). The major-
ity, although not all, p73-deficient RGCs had a pri-
mary cilium associated to a basal body [Fig.5(C),
white arrows]. However, many ECs had BB clusters
that lacked cilia (white arrowheads). Few p73KO
ECs had BB patches with associated cilia, but in
these cases, the EC displayed disorganized cilia of
different lengths [Fig.5(C), yellow arrowheads], simi-
lar to those observed by SEM [Fig. 5(A), double
lines].
P15 WT ECs displayed densely packed BB clus-
ters, all associated to cilia tufts [Fig. 5(D,E), white
arrows]. The cilia dysfunction was patent in p73KO
at this stage where many of the large surface cells
had disorganized BB clusters that were not associated
with cilia [Fig. 5(D,E), white arrowheads]. Ac-
tubulin antibodies also stained some long and slender
processes with varicosities [Fig. 5(C–F), yellow
arrows], corresponding with supra-ependymal axons
(Tong et al., 2014). Supra-ependymal axons run par-
allel to the anterior–posterior axis (PD!AD) of the
lateral ventricle on the dorsal V-SVZ and along the
dorso-ventral axis (PD!PV) of the WT mice. Sur-
prisingly, the lateral ventricular wall of the P7-
p73KO mice had a less dense network of supra-
ependymal axons which lack direction [Fig. 5(F) and
Figure 5 Lack of p73 alters motile cilia generation and planar cell polarity establishment during the transformation of mono-
ciliated RG into ependymal cells. SEM analysis of WT and p73KO lateral ventricle wall wholemounts at P7 (A) and P15 (B).
(A) P7-p73KO mice displayed aberrant groups of cilia of different length (double lines). Scale bar: 5 lm (B) P15 WT PD
region showed organized multiciliated cells while in p73KO the cells had angled and truncated cilia (black triangles). Scale
bar: 5 and 10 lm. (C–F) Confocal Z-stacks images of WMs immunostained for c-tubulin (red), b-catenin (blue) and Ac-
tubulin (green) from P7 (C, F) and P15 (D–F) mice. (C) At P7 RGCs had a primary cilium associated to a single basal body
(white arrows) and immature ECs had long cilia emanating from basal bodies patches (yellow arrowheads). Most p73KO ECs
had multiple basal bodies but lacked motile cilia (white arrowheads) and only few displayed cilia, but disorganized and of dif-
ferent lengths (yellow arrowheads). (D,E) Mature WT-EC showed characteristic oriented basal bodies patches associated to
cilia tufts (white arrows). ECs in p73KO had non oriented BB clusters either associated to disorganized cilia (pink arrowhead)
or without cilia (white arrowheads). (F) Comparison of the supra-ependymal axons (C-F, yellow arrows) network between
WT and p73KO mice. AV: anterior-ventral; PD: posterior-dorsal. PD!AD: anterior-posterior axis. PD!PV: dorso-ventral
axis. Scale bar: 20 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Supporting Information Fig.4(A), yellow arrows].
This was also evident at P15 stage where a fine and
organized network of supra-ependymal axons run-
ning on a dorso-ventral direction was observed in the
WT mice [Fig. 5(F) and Supporting Information Fig.
4(B), yellow arrows]), whereas p73-deficient mice
showed a less dense and disorganized network, pre-
sumably contributing to their neurogenic deficiency.
Our results confirmed that p73 deficiency results in
defective ciliogenesis during the transition from
monociliated RGCs into multiciliated ECs. A correla-
tion between defective ciliogenesis and alterations in
ependymal planar polarization has been previously
reported (Mirzadeh et al., 2010). In agreement,
throughout this work we had detected, in p73KO
cells, irregularities in the position of BBs on the api-
cal surface of the cells, i.e., defects in translational
cell polarity (tPCP). For example, while neighboring
RGCs in P7-WT mice had their cilia BB displaced to
the same side of the apical surface [Fig. 3(B’), blue
arrows], neighboring p73KO-RGCs had their cilia
positioned on opposite sides [Fig. 3(B’), white
arrows], suggesting that p73 deficiency affected
RGCs primary cilium polarization. Most multiciliated
P15 WT ECs were polarized at tissue level (tPCP
established), since they had their BB patches com-
pacted and clustered on the “downstream” side of the
apical cell surface, with respect to the direction of
CSF flow, and cilia tufts following the same orienta-
tion [Fig. 5(D,E), white arrows]. However, in p73-
deficient cells most BB clusters were not polarized
[Fig. 5(D), white arrowheads), independently of the
presence of cilia tufts [Fig. 5(E), white arrows, pink
arrowhead] or its absence [white arrowheads], sug-
gesting that p73 effect on tPCP was upstream of
ciliogenesis.
Moreover, WT ECs that conform a pinwheel struc-
ture had their BB clusters polarized with a similar
orientation [Fig. 6(A), yellow lines and white
arrows,]. That was not the case in p73KO ECs, which
had their BBs either distributed throughout the apical
surface, or oriented following different directions
[Fig.6 (A,B), white arrows). Moreover, they display
different arrays of cilia cluster distribution: some
cells had very tightly compacted basal bodies [Fig.
6(B), yellow arrows], others formed more than one
cluster located on one side of the apical surface, or
even in two opposing poles [white lines]. Altogether,
suggesting that p73 is essential to organize BB in
individual cells and also for intercellular BB patch
orientation. To further address p73 requirement for
the establishment of tPCP we quantify the degree of
cluster polarization relative to the apical surface. For
this purpose we use a program generated by
Wimasis
VR
to calculate the polarization ratio [Fig.
6(C,D)]. We measured the relative distance between
the geometric center of the apical surface and the BB
cluster centroid (Boutin et al., 2014). We observed
significant differences between WT ECs, with a
mean polarization ratio of 77.726 19.77, and p73KO
cells with a ratio of 25.996 12.13 [Fig. 6(D)], indi-
cating that p73 is essential to organize translational
polarity at single cell level. Furthermore, we asked
whether p73 deficiency affected the coordination of
BB patches displacement at tissue level by drawing a
vector from the cell center to the cluster centroid
(Boutin et al., 2014). Vectors of neighbor WT ECs
had similar direction, but in p73KO ECs they were
more divergent [Fig. 6(C), white lines]. Calculation
of the angle of displacement [Fig. 6(E)] indicated
that the angular deviation of individual vectors from
the mean was6 35.768 in the WT while the p73 defi-
cient cells displayed a significantly higher deviation,
with a mean of6 57.838 (Watson’s U2 test
p< 0.005). Altogether, our data strongly support the
hypothesis that p73 is essential to translational PCP.
DISCUSSION
The appropriate functioning of ependymal cells is
fundamental to create and maintain the neurogenic
Figure 6 Lack of p73 impairs translational planar cell polarity in ependymal cells. Confocal Z-stacks images of lateral ven-
tricle wall wholemounts from the indicated age and phenotype immunostained for b-catenin (green, A, B or blue, C) and c-
tubulin (red). (A) P15-WT ECs, but not the p73KO, were organized in pinwheel structures (yellow lines) and displayed trans-
lational PCP with cilia patches clustered on the “downstream” side of the apical cell surfaces, and oriented with respect to the
direction of CSF flow (white arrows). (B) p73KO multiciliated ECs had the basal bodies distributed throughout the apical sur-
face (white arrows) and showed different cilia clusters distribution: e.g. BB patches compacted very tightly (yellow arrows) or
multiple clusters (white lines). (C) Trace of the cell contour (green) and magnifications of the white line inserts (right panels).
Lines from the cell center to the BB centroid show BB cluster’s angle displacement. Scale bar: 20 lm. (D) Quantification of
BB polarization (the relative distance between the geometric center of the apical surface and the BB cluster centroid) (E)
Angular distribution of vectors of BB displacement around the mean. In WT, the majority of vectors were closely distributed
showing the coordination of BB displacement among neighbor cells. In the absence of p73, this coordination is lost, leading
to a broader distribution. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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milieu of the germinal niche in the SVZ of rodent
brain (Lledo et al., 2008). In this regard, since p73 is
expressed in the ependymal cells (Hernandez-Acosta
et al., 2011; Medina-Bolivar et al., 2014), we
hypothesized that p73 had a possible role in EC biol-
ogy. In agreement with our hypothesis, ependymal
cell denudation in p73 deficient mice has recently
been described (Medina-Bolivar et al 2014), although
the nature of the ECs defects have not been
described.
Our results indicated that p73 ablation did not
result in less S100b1 cells, but rather in ECs imma-
turity with the consequent cellular disorganization in
the VZ and loss of brain ventricular integrity. One of
the hallmarks of the p73 deficient brain is the pres-
ence of immature ECs that express GFAP and had
the basal bodies clustered in deuterosomes. These
immature ECs fail to organize into neurogenic pin-
wheels, disrupting p73KO-SVZ cytoarchitecture and
thus, niche structure and function (Kokovay et al.,
2012). These features are maintained in the adult
p73KO VZ, suggesting that the EC maturation was
halted and confirming that p73 deficiency results in a
deregulation of the transition process from RGC to
ependymal and B-cells, leading to the emergence of
aberrant cells with abnormal intermediate identities
within the lateral wall of the ventricle. p73 deficient
ependymal cells had an aberrant membrane morphol-
ogy with pleats and invaginations that could be the
cause of their failure in establishing appropriate cell
to cell adhesions. This p73KO phenotype was also
detected in the absence of p53 (DKO mice), suggest-
ing that p73-deficient effect is not due to an enhanced
cell death resultant from p53 compensatory activation
in the absence of the anti-apoptotic DNp73. Indeed,
the ependymal layer in the absence of p73, including
in DKO, is pseudostratified and discontinuous indi-
cating p73 requirement for brain ventricular integrity.
In this regard, studies have demonstrated that epen-
dymal cell–cell adhesion regulates NSC activation
under physiological and regenerative conditions (Por-
lan et al., 2014). Thus, lack of cellular contacts in the
p73KO SVZ could lead to activation and subsequent
depletion of the normally quiescent NSCs.
In P15 p73KO mice we detect monociliated cells
(accounted by BB staining) that cannot be identified
as bona fide B1-cells (neural stem cells). These cells
resemble the monociliated-small apical surface radial
glial cells observed in WT brains at early immature
stages (P7) that did not yet display GFAP expression.
It is possible that in the absence of p73, only few
RGC are capable to progress into functional neural
stem cells (GFAP expressing B1-cells), leading to a
diminished neural stem cell population in the SVZ.
This lack of an appropriate pool of neural stem cells
could be the underlying mechanism of the impaired
neurogenic capacity in p73KO mice brain. This sug-
gests that p73 is not only essential for neural stem
cell maintenance (Agostini et al., 2010; Fujitani
et al., 2010; Gonzalez-Cano et al., 2010; Talos et al.,
2010), but also for the de novo generation of neural
stem cells during the postnatal generation of the
neurogenic niche in mice SVZ. In agreement with
impaired neurogenic function, p73KO lateral wall
had a less dense network of supra-ependymal axons,
known to directly interact with NSCs to regulate neu-
rogenesis (Tong et al., 2014). These axons normally
encircle the base of ependymal cilia tufts; therefore,
their reduction could be secondary to abnormal cilia
generation and growth. It has been proposed that glu-
tamate provided by these axons may supplement met-
abolic pathways in multiciliated ECs in order to fuel
the energy demand of the ciliary beating (Robinson
et al., 1996). Consistent with p73 requirement for the
maintenance of the neurogenic niche function, our
analysis revealed that p73KO mice had significantly
less proliferating neuroblasts and B cells than WT
mice. This effect it not due to p53-induced cell death
since DKO mice also showed a significant reduction
in these cellular populations in the SVZ. These results
support an impairment of neurogenesis and probably a
decrease in the number of new neurons that migrate to
the OB. Thus, p73 deficiency has a profound effect on
SVZ maintenance and neurogenesis.
The most striking alteration of the p73KO brain is
the profound defects in ECs planar cell polarity. Our
data strongly suggest that p73 is necessary for the pri-
mary cilia organization in RGCs, which orchestrates
the planar polarized architecture of both radial glia
and their progeny ependymal cells (Mirzadeh et al.,
2010), and also for the establishment of ependymal
tPCP. Moreover, in the absence of p73 many ECs
had basal body clusters but lacked cilia, or the num-
ber of total cilia tufts was lower, indicating that p73
deficiency alters or delays ciliogenesis.
We demonstrate that p73 function is necessary to
organize the basal bodies within individual cells and,
even though it is not required for basal body cluster
displacement from the center, it is essential for inter-
cellular patch orientation, since the p73KO cells did
not have a common direction of displacement. Lack of
basal body cluster orientation in p73KO ECs was inde-
pendent of the presence of cilia tufts, suggesting that
p73 effect on PCP is upstream of ciliogenesis. This is
in agreement with reported observations that support
the notion that PCP signaling influences cilium, while
definitive evidence for regulation of PCP signaling by
cilium is still missing (Gray et al., 2011). Many PCP
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core regulator genes like Cadherin EGF LAG Seven-
Pass G-Type 1-3 (Celsr 1-3), Frizzled Class Receptor
3 (Fzd3), Van Gogh like1-2 (Vangl1-2) and Dishev-
eled1-3 (Dvl1-3) or Non-Muscle Myosin II (NMII)
have also been implicated in cilia development and
function (Iba~nez-Tallon, et al. 2004; Lechtreck et al.,
2008; Guirao et al., 2010; Hirota et al., 2010; Ohata
et al., 2014). However, the mechanism of p73 regula-
tion of PCP remains elusive.
Our results show that lack of p73 results in pro-
found defects in the timing of ependymal cell matura-
tion, and in the establishment of planar cell polarity,
altogether affecting the correct assembly of the neu-
rogenic cytoarchitecture of the SVZ germinal center.
These alterations could be the subjacent mechanisms
that lead to the hydrocephalus and defective neuro-
genic capacity of the p73 deficient mice, highlighting
the important role of p73 in brain development and
brain homeostasis.
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A B S T R A C T
There is emerging evidence for the involvement of reactive oxygen species (ROS) in the regulation of stem cells
and cellular diﬀerentiation. Absence of the ROS-generating NADPH oxidase NOX2 in chronic granulomatous
disease (CGD) patients, predominantly manifests as immune deﬁciency, but has also been associated with
decreased cognition. Here, we investigate the role of NOX enzymes in neuronal homeostasis in adult mouse brain
and in neural cells derived from human induced pluripotent stem cells (iPSC). High levels of NOX2 were found in
mouse adult neurogenic regions. In NOX2-deﬁcient mice, neurogenic regions showed diminished redox
modiﬁcations, as well as decrease in neuroprecursor numbers and in expression of genes involved in neural
diﬀerentiation including NES, BDNF and OTX2. iPSC from healthy subjects and patients with CGD were used to
study the role of NOX2 in human in vitro neuronal development. Expression of NOX2 was low in
undiﬀerentiated iPSC, upregulated upon neural induction, and disappeared during neuronal diﬀerentiation. In
human neurospheres, NOX2 protein and ROS generation were polarized within the inner cell layer of rosette
structures. NOX2 deﬁciency in CGD-iPSCs resulted in an abnormal neural induction in vitro, as revealed by a
reduced expression of neuroprogenitor markers (NES, BDNF, OTX2, NRSF/REST), and a decreased generation of
mature neurons. Vector-mediated NOX2 expression in NOX2-deﬁcient iPSCs rescued neurogenesis. Taken
together, our study provides novel evidence for a regulatory role of NOX2 during early stages of neurogenesis in
mouse and human.
1. Introduction
There is increasing evidence for the role of reactive oxygen species
(ROS) in developmental processes, such as cardiomyogenesis [33,7,8],
hematopoiesis [48,49], and neurogenesis [14,30,42,54,59,66,67]. This
role of ROS might at least in part be due to a regulatory role in stem cell
homeostasis and diﬀerentiation. Several redox-sensitive signaling path-
ways have been described, including H2O2-dependent protein phos-
phatase inhibition, as well as redox-regulation of transcription factors
and ion channels [19].
There is a wide range of possible cellular sources of ROS, including
mitochondria, xanthine oxidase, lipoxygenase, cyclooxygenases, cyto-
chrome P450, nitric oxide synthase and peroxisomes [23]. In addition
to these systems that produce ROS as a side reaction, there is the NOX
family of NADPH oxidases (NOXs), for which production of ROS is the
main biological function [3,32]. Enzymes of the NOX family include the
phagocyte NAPDH oxidase NOX2, as well as more recently discovered
isoforms (NOX1, NOX3-5, and DUOX1-2). NOXs are highly regulated
enzymes, with some of the isoforms (NOX1-NOX4) functioning in a
subunit-dependent manner. For example, NOX2 functions as a complex
containing at least ﬁve subunits (p22phox, p47phox, p67phox and p40phox,
and small Rac GTPases) [29]. Loss of function mutations in any of the
constituents of the NOX2 complex leads to the genetic disorder chronic
granulomatous disease (CGD). CGD patients predominantly show an
http://dx.doi.org/10.1016/j.redox.2017.04.026
Received 8 February 2017; Received in revised form 19 April 2017; Accepted 20 April 2017
⁎ Correspondence to: Dept. of Pathology and Immunology, Centre Médical Universitaire, 1, rue Michel-Servet, CH-1211 Geneva 4, Switzerland.
E-mail address: Karl-Heinz.Krause@unige.ch (K.-H. Krause).
Redox Biology 13 (2017) 82–93
Available online 24 April 2017
2213-2317/ © 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
immunological phenotype, including susceptibility to infection, hyper
inﬂammation and autoimmunity [55]. However, there is also evidence
for a role of NOX2 in the physiological function of the central nervous
system (CNS): NOX2-deﬁcient mice [26] and CGD patients [45] have a
discreet, but consistently observed cognitive impairment. Thus, the
question to which extent NOX2 plays a role in the physiological
function of the CNS is pertinent.
Basically there are two main concepts to explain how ROS might be
involved in the physiological function of the CNS: modulation of the
function of mature neurons [12,24,25,27,31,43,4,52,58,61] versus
impact on neural development and neurogenesis [14,30,31,59]. These
two concepts are not mutually exclusive and the nature of ROS
regulation might depend on the brain area and neural cell types. For
instance, RNAseq studies in the murine cerebral cortex demonstrate
that under physiological conditions, NOX2 is mostly expressed in
microglia, while NOX4 is mostly found in endothelial cells [68].
However, several recent publications suggest that NOX2 is highly
expressed in neural progenitor cells (NPCs) in murine adult neurogenic
regions: the subventricular zone (SVZ) of the lateral ventricle and the
dentate gyrus (DG) of the mouse hippocampus [30,60,67]. These
regions contain adult neural stem cells (NSCs) and diﬀerentiate into
neural progenitors which migrate, mature and are ﬁnally integrated
into various brain regions. Adult neurogenesis is not only involved in
brain repair, but regulates several physiological functions, in particular
memory [13].
A recent review on the role of redox environment in neurogenic
development [44] summarized the present knowledge as follows. The
cellular redox state during neurogenesis and neural diﬀerentiation
controls speciﬁc mechanism of lineage progression through control of
signal transduction and transcriptional regulation. More speciﬁcally,
redox-dependent mechanisms regulate NSC proliferation, cell cycle
exit, and diﬀerentiation into mature neurons and glia. Oxidizing species
accumulate during early stages of diﬀerentiation, while a reductive
environment persists during terminally diﬀerentiated neural cells. The
Fig. 1. NOX2 and subunits, but not microglia markers, are expressed in neurogenic regions of the mouse brain. (A) Schematic representation of micro-dissected adult mouse brain areas
(dashed blue lines) including the neurogenic regions dentate gyrus (DG) and subventricular zone (SVZ) and the non-neurogenic regions olfactory bulb (OB) and prefrontal cortex (PFC).
CBM: cerebellum, Hi: hippocampus, St: striatum, RMS: rostral migratory stream. (B-D, F-I) mRNA expression of NOX isoforms and NOX subunits in micro-dissected brain regions. The
following murine tissues were used as positive control; colon (Nox1), spleen (Nox2), and kidney (Nox4). (E) Schematic representation of the Nox2 complex including its subunits Cyba
(p22phox), Ncf1 (p47phox), Ncf2 (p67phox), Ncf4 (p40phox) and Rac. (J, L): expression of microglia markers Aif-1 (IBA-1) and Spi-1 (PU.1), in diﬀerent brain regions as assessed by RT-qPCR
(J, L) or by immunoﬂuorescence (K, M). ALS = spinal cord of mice overexpressing SOD1G93A mutant (a model for amyotrophic lateral sclerosis, ALS) served as a positive control for high
levels of microglial gene expression [51]. For RT-qPCR, expression values were normalized to housekeeping genes and data are shown as mean±SEM. Statistics were done by Student's t-
test from n =6. *P<0.05, **P<0.01, ***<0.001.
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generation of certain neurotrophic growth factors also appears to be
under redox control [47]. For example, there is a redox-regulation of
brain-derived neurotrophic factor BDNF [39,53], which contributes to
the self-renewal and survival of neural stem/progenitor cells during
neurogenesis, inﬂuencing memory and cognition [46,5,64]. These
ﬁndings on the role of redox-dependent processes in neurogenesis raise
the question whether NOX enzymes play a role during early stages of
neural diﬀerentiation.
While hitherto the study of neurodevelopmental processes was
mostly restricted to animal models, the availability of human pluripo-
tent stem cells provides now powerful tools to study the mechanisms
underlying cellular decisions during neural diﬀerentiation in a human
Fig. 2. Decreased oxidative modiﬁcations and proliferating neuroprecursor cells in neurogenic brain regions of NOX2-deﬁcient mice. Oxidative modiﬁcations of DNA (8-
hydroxydeoxyguanosine, 8-OHdG in Figure A, C) and lipids (4-hydroxynonenal; 4-HNE in Figure E, G) were detected using DAB immunohistochemistry in sections of the neurogenic
mouse brain regions. The SVZ and DG from wild type (WT) and NOX2-knock-out mice were analyzed. Arrows in panel A and E indicate intensely stained cells in the subgranular zone
(SGZ) of the dentate gyrus. (B, D, F and H) Quantiﬁcation of 8-OHdG and 4-HNE DAB staining are shown as bar graphs as % of positive cells per analyzed area as analyzed by Metamorph
software (see Material and Methods). Immunoﬂuorescence staining of proliferating progenitor cells in DG (I) and SVZ (K) of wild type and NOX2 KO mice. IF markers: Nestin (red); Ki67
(green); DAPI (blue). Quantiﬁcation of immunoﬂuorescence staining (% of double-positive cells/total cells) in the DG (J) and SVZ (L). Data are shown as mean± SEM. Statistics were
performed using Student's t-test from 8 animals per condition. (M) RT-qPCR analysis of Nes (nestin), neuroblast marker Dcx (doublecortin), Bdnf (brain derived neurotrophic factor) and
Otx2 transcription factor in neural stem/progenitor cells of DG and SVZ. Data are shown as mean± SEM. Statistics done by Student's t-test from n =7. *P< 0.05, **P< 0.01,
***< 0.001.
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system [15,56]. And, while there are many fundamental developmental
mechanisms shared between mice and humans, there are also consider-
able diﬀerences. For example, preclinical mouse studies did not predict
the teratogenicity of thalidomide while transcriptomic and proteomic
investigation of the compound using human embryonic stem cells
(hESCs) clearly indicated that thalidomide impacts several key devel-
opmental human genes at clinically relevant concentrations [40]. This
could be due to diﬀerences in the metabolism of the compounds.
In this study we have investigated the role of NOX2 during
neurogenesis in mice and in human induced pluripotent stem cells
(hiPSCs). For this purpose, we investigated brains from NOX2-deﬁcient
mice, as well as in NPCs and neurons diﬀerentiated from iPSCs derived
from NOX2-deﬁcient and p22phox-deﬁcient CGD patients. We show that
NOX2 is highly expressed in neurogenic regions of the mouse brain, as
well as in NPCs derived from hiPSCs. NOX2 deﬁciency or inhibition
decreases oxidative modiﬁcations in neural stem/precursor cells,
reduces the size of the neuroprogenitor pool, and impacts down-stream
neural diﬀerentiation. Correction of NOX2 expression in CGD-hiPSCs
was associated with the restoration of the expression to near normal
levels of crucial genes involved in neurogenesis. Our results provide
further evidence for a role of NOX2 in neurogenesis, unrelated to the
well-known function of the enzyme in inﬂammation and host defense.
2. Results
2.1. NOX expression and activity in neurogenic regions of the adult mouse
brain
To examine the expression and function of NOX enzymes and their
subunits in neurogenic regions [1], we ﬁrst investigated the subven-
tricular zone (SVZ) and the dentate gyrus (DG) isolated from adult
mouse brain (see Material and methods). In the SVZ, proliferating NPCs
are lining the lateral ventricles from where they migrate towards the
olfactory bulb and diﬀerentiate into granular interneuron cells
[35,36,38]. In the DG of the hippocampus, the sub-granular zone
(SGZ) contains precursor cells, which proliferate and migrate along the
granular cell layer to diﬀerentiate into hippocampal granule cells
[9,2,28] (Fig. 1A).
We studied the expression of the diﬀerent NOX isoforms in micro-
dissected neurogenic regions (see Methods) (Fig. 1B-D and Fig. S1D and
S1E). NOX1 and NOX4 expression was relatively low in neurogenic
brain regions, but showed higher levels in the prefrontal cortex (PFC)
and the olfactory bulb (OB). No relevant expression in neurogenic
regions was observed for Nox3 and the two Duox genes (Fig. S1D). In
contrast, Cybb (NOX2) was markedly higher in both neurogenic regions
as compared to PFC and OB (Fig. 1C). Similarly, Cyba (p22phox) and
Ncf1 (p47phox) as well as GTPase Rac1were signiﬁcantly higher
expressed in DG, SVZ and the olfactory bulb (Figs. 1F, 1G and 1H),
while there was no distinct pattern for Ncf4 (p40phox) and Ncf2
(p67phox) or for other GTPase Rac isoforms including Rac2 and Rac3
(Figs. 1H and 1I, and Fig. S1E). Note that the NOX2 enrichment in the
neurogenic regions is considerable as it approaches levels comparable
to those observed in spleen.
The CNS phagocyte microglia is the most relevant NOX2 expressing
cells in the brain and its presence might provide an explanation for the
high NOX2 levels observed in neurogenic regions [50]. We therefore
investigated microglia markers in the SVZ and the DG. The microglia
marker Aif1 (IBA-1) was expressed only at very low levels in neurogenic
regions (Figs. 1J and 1K). Similarly, the transcription factor Spi1 (PU.1)
which is highly expressed in microglia and other types of phagocytes
[3] was found at only very low levels in neurogenic regions (Figs. 1L
and 1M).
To assess the relative contribution of NOX2-derived ROS in murine
neurogenic areas, we investigated the levels and localization of
oxidative modiﬁcations of DNA (8-OHdG; 8-hydroxyguanosine) and
of lipids (4-HNE; 4-hydroxynonenal). Analysis of both markers revealed
elevated staining localizing to cells within SVZ and DG (Fig. 2A-H). In
the granular cell layer of the DG, the staining intensity of 8-OHdG was
strongest in the lower layer, i.e. the SGZ, which is enriched in
proliferating NPCs (Figs. 2A and 2B, arrow heads).
Staining for 8-OHdG and 4-HNE was markedly decreased in NOX2-
deﬁcient mice as compared to wild-type DG (Figs. 2A and 2E, left vs.
right panels) and SVZ (Figs. 2C and 2G, left vs. right panels).
Quantiﬁcation of staining showed lower levels of 8-OHdG (Figs. 2B
and 2D) and 4-HNE (Figs. 2F and 2H) in NOX2-deﬁcient mice
suggesting that NOX2 contributes to oxidative modiﬁcations in speciﬁc
subsets of cells of SVZ and DG. Thus, a signiﬁcant fraction of oxidative
modiﬁcations in the neurogenic areas can most likely be attributed to
NOX2-derived ROS. The residual oxidative modiﬁcations might be due
to low levels of other NOX isoforms (see Fig. S1D) or to distinct cellular
sources, such as mitochondria and xanthine oxidase.
In order to assess proliferation in NOX2 deﬁcient mice, we analyzed
the proportion of nestin and Ki-67 double positive cells in the DG
(Figs. 2I and 2J) and the SVZ (Figs. 2K and 2L). As shown in Fig. 2I-L,
the proportion of nestin-Ki67 positive cells is signiﬁcantly lower in the
DG and the SVZ from NOX2-deﬁcient mice suggesting that NOX2
deﬁciency is associated with a reduced proliferation of NPCs in adult
neurogenic regions.
We next analyzed mRNA levels of a panel of neuronal and neural
stem/progenitor markers [41] using qPCR in the two neurogenic
regions as well as in the OB, which is the projection zone of SVZ.
These results showed a clear impact of NOX2-deﬁciency: mRNA levels
for nestin (expressed in NSCs and NPCs), doublecortin (Dcx) (expressed
in young migrating neurons), BDNF (a soluble factor regulating
neurogenesis), Otx2 (neurogenesis transcription factor), as well as
NeuN (marker of mature neurons) were signiﬁcantly decreased in
NOX2-deﬁcient regions (Fig. 2M and S1F)[34]. Note, however, that
there were regional diﬀerences. While Otx2 was massively decreased in
the SVZ of NOX2-deﬁcient mice, there was no impact on expression in
the DG. Conversely, while there was a signiﬁcant decrease of BDNF in
the DG of NOX2-deﬁcient mice, BDNF was below detection levels in the
SVZ (as described previously [20] (Fig. 2M). No impact of NOX2
deﬁciency was observed on mRNA levels of the glutamatergic marker
mGluR, as well as the GABAergic markers Calb1 (Calbindin) and Gad67
(Fig. 2G). Interestingly, in the OB global neuronal and NPC markers
(Nestin, Otx2, Dcx, NeuN) were also decreased, despite the fact that
NOX2 levels in this region are low (Fig. 2M and S1F). Taken together
these results demonstrate a functional impact of NOX2 deﬁciency not
only on neural stem/precursor cells as well but also on the olfactory
bulb, a mature neural region.
2.2. Proliferation deﬁcit of NPCs derived from the neurogenic niche of
NOX2 deﬁcient mice
To asses further whether NOX2 aﬀects the stemness of NPCs, we
isolated NPCs from the neurogenic niches of WT and NOX2-deﬁcient
pups (P0 to P4). Relatively high level expression of NOX2 was observed
in the dissected regions (Fig. S2A) but, unlike the adult neurogenic
niches, the microglia markers IBA-1 and PU.1 were present (Fig. S2B;
note, however, that the microglia markers disappeared during neuro-
sphere formation, Fig. S2C). The dissected tissues were dissociated into
single cells and allowed to proliferate and form primary neurospheres
[33] (Fig. 3A, B). A serial dilution assay [11] indicated a decrease in the
number of formed neurospheres after 7 days at every dilution tested in
the NOX2-deﬁcient cultures, (Fig. 3C). To analyze the cellular composi-
tion of the neurospheres, we performed immunocytochemical staining
for nestin. The number of nestin-positive cells was strikingly reduced in
NOX2-deﬁcient neurospheres (Fig. 3D, E), strengthening the idea of a
decreased NSC pool in the absence of NOX2. The proliferation rate of
NSCs was evaluated using EdU pulse labeling assay. A decrease in the
percentage of EdU-positive cells in NOX2-deﬁcient neurospheres was
observed at 2, 4 and 8 h after incubation with EdU compared to WT
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neurospheres (Figs. 3F and 3G). The decreased number of proliferative
cells could be caused by an imbalance in the symmetric/asymmetric
divisions. An increase of asymmetric divisions would lead to a decrease
in the pool of undiﬀerentiated NSCs and to an increase in the number of
diﬀerentiated cells. To analyze this, we performed the cell-pair assay,
showing that asymmetric divisions (Fig. 3H-J) are more prominent in
NOX2-deﬁcient cultures suggesting that lack of NOX2 leads to a bias
towards asymmetric cell divisions.
Taken together, these results suggest that NOX2 deﬁciency di-
minishes self-renewal of NPCs through symmetric divisions, aﬀecting
the maintenance of stem cells pool.
2.3. Immunolocalization of NOX2 in Macaca fascicularis brain
To our knowledge, there are no useful antibodies to perform
immunohistochemistry of NOX2 in mouse tissues (available antibodies
lack speciﬁcity and sensitivity). However, there are very good immu-
nohistochemistry-compatible antibodies against human NOX2. In par-
ticular, there is the monoclonal 7D5 antibody, which has also been
shown to speciﬁcally recognize NOX2 in other primates [65]. We
therefore performed immunohistochemistry of the DG in the Macaca
fascicularis (macaque) brain (Fig. S3). DCX immunostaining (young
migrating neurons) showed a moderately intense, but clearly discern-
able staining in the DG, with a preferential staining of the SGZ (Fig.
S3A). Immunostaining of NOX2 revealed a remarkably intense staining
throughout the granular cell layer (GCL). A weaker staining of NOX2
could also be found in some adjacent areas. Although the exact nature
of these NOX2-expressing cells is unknown, immunohistochemistry in
the macaque brain conﬁrms that the high expression of NOX2 in the DG
is not limited to rodents, but is also observed in primates.
2.4. Role of NOX2 during neural diﬀerentiation of human iPSCs
To study the eﬀect of NOX2 deﬁciency on human neurogenesis, we
generated iPSCs from two diﬀerent types of CGD patients, X-linked
NOX2-deﬁcient patient (X°-CGD) and an autosomal-recessive p22phox-
deﬁcient patient (AR-22°-CGD) [6]. Two iPSC lines from healthy donors
(control-iPSCs) and the human ESC line H1 (H1-hESCs) were used as
control lines. As expected for cells that have acquired a pluripotent
state, these iPSCs showed typical morphology of hPSC colonies,
expressed markers of pluripotent cells and diﬀerentiated in vivo and
in vitro into the lineages derived from three embryonic germ-layers
mesoderm, ectoderm and endoderm (Fig. S4). We also conﬁrmed that,
like the parental ﬁbroblasts, the X°-CGD-iPSCs harbored the nonsense
Fig. 3. Impaired proliferation and altered balance in symmetric/asymmetric divisions of NSCs from NOX2-deﬁcient mice. (A) Schematic representation of generation of neurospheres
from subventricular zone (SVZ) and dentate gyrus (DG). (B) Light microscope pictures of the neurospheres derived from the SVZ of WT and NOX2-deﬁcient mice (NOX2-KO). (C) Dilution
assay and quantiﬁcation of neurosphere generation as a function of the initial number of seeded cells demonstrates decreased proliferation of NOX2-deﬁcient neural stem/precursor cells.
(D) Immunostaining of nestin within neurospheres. (E) Quantiﬁcation of nestin-staining in neurospheres (n=6) from D. (F) Representative image of EdU-labeled cells in neurospheres
after 8 h of incubation from WT and NOX-deﬁcient mice; (G) Quantiﬁcation of EdU incorporation after incubation of neurospheres during 2, 4 and 8 h. (H) Cell pair assay with SOX2
staining allows visualizing symmetric and asymmetric division of the cells; (I) representative image of SOX2 staining of WT and NOX2-deﬁcient neurospheres (J). Quantiﬁcation of
symmetric and asymmetric divisions in neurospheres from WT and NOX2-KO as percentage of dividing cells. Data were analyzed by Student's t-test and shown as mean
values± SEM.*P< 0.05, **P< 0.01, ***< 0.001.
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mutation (CgA→TgA) at the position 469 of exon 5 of the CYBB (NOX2)
gene leading to the absence of NOX2 mRNA and protein. The mutation
was absent in the iPSC control lines and present in all the X°CGD-iPSC
lines (Fig. S6A). Among the three CGD iPSC lines, one had large copy
number variations detected by CGH array and was therefore excluded
from further experiments (Fig. S5).
Based on the mouse data obtained in the ﬁrst part of this study, we
examined a possible role of NOX2 in neural diﬀerentiation of the
Fig. 4. NOX2 impacts early human neural diﬀerentiation in vitro. (A) Schematic representation of in vitro neural diﬀerentiation of human PSCs: undiﬀerentiated pluripotent stage (blue),
neural induction in neurosphere culture (pink) neural maturation on poly L-ornithine/laminin (green). DIV= days of in vitro. (B) Expression of CYBB (NOX2; B) and its subunit CYBA
(p22phox; C) was assessed in control hiPSCs (C3, C4 lines) and human ESC line H1 (H1-hESCs) at the undiﬀerentiated pluripotent stage (blue bar: day 0), after neural induction (red bar:
day 7) and during neuronal maturation (green bar: day 7–60). (D) Immunostaining demonstrates the absence of NOX2 protein in the pluripotent stage (day 0), the presence of NOX2
protein during the neural induction phase (day 7), and the absence of NOX2 protein in beta 3 tubulin-positive neurons (day 60). (E) Quantitative RT-PCR expression of a NPC marker
nestin (NES), transcription factors involved in neural fate and diﬀerentiation (OTX2 and NRSF/REST1) and a gene involved in neurodevelopment (DCX) in neurospheres derived from
control-iPSCs, X°-CGD-iPSCs and AR-22°-iPSCs (n=8). (F) Schematic representation of NOX2 rescue in the X°-CGD-iPSC line using a lentiviral vector expressing NOX2 and GFP. (G) High
expression of GFP in pluripotent colonies (day 0) and in neurospheres (day 7) derived from X°-CGD+NOX2-GFP-iPSC lines. (H) In neurospheres derived from the X°-CGD+NOX2-GFP-
iPSC line (day 7), the GFP ﬂuorescence (green) and positive NOX2 immunostaining (red) are observed. (I) Expression of NES, OTX2, NRSF/REST and DCX in neurospheres derived from
X°-CGD+NOX2-GFP-iPSCs. Data are shown as mean± SEM, n =9. Statistical analyses were done by one-way ANOVA followed by multiple comparisons Tukey's test. *P<0.05,
**P<0.01, ***< 0.001, ****< 0.0001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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described iPSC lines, as well as the human embryonic pluripotent stem
cell line H1-hESCs (for protocol see Fig. 4A). We ﬁrst investigated the
temporal expression pattern of CYBB (NOX2) and CYBA (p22phox) by
quantitative RT-PCR (qRT-PCR) upon neural induction and neuronal
diﬀerentiation of control-iPSCs and H1-hESCs (Figs. 4B and 4C). As
shown in Fig. 4B, CYBB and CYBA expression was very low in
undiﬀerentiated control-iPSCs and H1-hESCs. Upon neural induction
into NPCs, the expression of both genes was strongly increased. In
contrast to CYBB which expression returns to baseline levels in neurons
(Fig. 4B), CYBA expression remains high (Fig. 4C). These results were
also conﬁrmed at the protein level showing (i) high expression of NOX2
in the NPCs and (ii) t absence of NOX2 protein in undiﬀerentiated iPSC
and in neurons. As expected, NOX2 protein was undetectable in X°-
CGD-iPSC-derived NPCs (Fig. 4D).
2.5. Neurogenesis impairment in NPCs derived from X°-CGD-iPSCs and AR-
22°-iPSCs
To investigate a possible functional impact of NOX2 deﬁciency on
early stage of neural induction, we measured by q-RT-PCR the expres-
sion of neural progenitor markers in neurospheres derived from control-
iPSCs, X°-CGD-iPSCs and AR-22°-iPSCs. Corroborating our observations
in the mouse brain, NOX2 deﬁciency was associated with a 4-fold
decrease of NES (Nestin) in NPCs (Fig. 4E). This was associated with a
decrease of the expression of transcription factors involved in neural
fate and diﬀerentiation such as OTX2 and NRSF/REST1 (Fig. 4E).
However, no diﬀerence in the expression of DCX was found between
NPCs derived from control-iPSCs, X°-CGD-iPSCs and AR-22°-iPSCs
(Fig. 4E).
To provide additional support for NOX2 involvement in the
defective neurogenesis of X°-CGD-iPSCs, we performed a rescue of
NOX2 expression in X°-CGD-iPSCs providing an isogenic iPSC-based
model. For this, X°-CGD-iPSCs were transduced with a lentiviral vector
carrying human CYBB (NOX2) cDNA and GFP as selection marker (Fig.
S6A). GFP-positive cells were selected by ﬂow cytometry sorting and
induced to diﬀerentiate into neurospheres (Fig. 4G). The obtained
rescue line will be referred to as X°-CGD+hNOX2. At the undiﬀer-
entiated pluripotent stage, X°-CGD+hNOX2 expressed mRNA for CYBB
(NOX2) (Fig. S6B), but no NOX2 immunoreactivity was observed (not
shown). This is possibly explained by the absence of p22phox in
undiﬀerentiated human PSCs (Fig. 4C), and the fact that NOX2 requires
p22phox for protein stability. However, upon diﬀerentiation of PSCs
towards neurospheres, p22phox expression increases (Fig. 4C), which
stabilizes the NOX2 protein and hence allows its detection (Fig. 4D).
Accordingly, a clear NOX2 staining could be observed in neurospheres
derived from the X°-CGD +hNOX2-iPSCs (Fig. 4H). Importantly, NOX2
rescue in neurospheres derived from X°-CGD-C6+hNOX2-iPSCs in-
creased the expression of the neural markers NES, OTX2, and NRSF/
REST1 (Fig. 4I), indicative of an improved neurogenesis.
2.6. Localization and activity of NOX2 in neural rosettes derived from PSCs
In order to identify which type of cells are expressing NOX2 during
neural induction, we used a co-immunostaining for NOX2 and the NPC
marker nestin in neurospheres derived from control and X°-CGD-iPSCs
[21]. Within neurospheres, we observed a clear population of cells with
nuclei-rich regions positive for both nestin and NOX2 (Fig. 5A), with
NOX2 staining occurring mostly in cell bodies, and nestin staining
extending to neurites (Fig. 5A, right panel). As expected, NOX2 was not
expressed in the X°-CGD neurospheres (Fig. 4A, lower panel, and
Fig. 5B). Interestingly, the number of nestin and Ki67 double positive
cells was lower in X°-CGD than in control neurospheres (Figs. 5C and
5D) while the fraction of young migratory -DCX-positive neurons was
similar in both groups (Figs. 5E and 5F).
To further investigate cellular localization of NOX2, we generated
neurospheres from H1-hESCs. Basically we observed two diﬀerent types
of rosettes in neurospheres derived from H1-hESCs: poly-rosette neuro-
spheres (Fig. 5G) and mono-rosette neurospheres (Fig. 5I). NOX2
staining was observed in inner cell layers of these rosettes (Figs. 5H
and 5J), which represent the in vitro analogue of the neural tube, where
neurogenesis is initiated [10,16]. To verify whether NOX2 is functional,
we used two diﬀerent probes to detect ROS, namely CellROX and
nitroblue tetrazolium (NBT). Fig. 5K shows an example of CellROX
visualization in a poly-rosette neurosphere. Intense red ﬂuorescence
indicates ROS generation, which was observed in the center of the
rosettes (Fig. 5K, left panel). After addition of the NOX inhibitor
diphenyleneiodonium (DPI), the red ﬂuorescence of CellROX decreased
(Figs. 5K and 5L), compatible with the concept that NOX2 is the source
of ROS generation. A blue formazan precipitate corresponding to NBT
reduction was observed in two diﬀerent mono-rosette neurospheres,
and was absent in rosettes pre-treated with DPI (Figs. 5M and 5N). Note
that addition of DPI to neurospheres would not remove already
established NBT precipitates.
2.7. Altered maturation of NPCs derived from NOX2-deﬁcient iPSCs into
neurons
Given the impact of NOX2 deﬁciency on diﬀerentiation of iPSCs into
NPCs, we further studied the eﬀect of NOX2 deﬁciency on later stages
of neural diﬀerentiation (Fig. 6). For this purpose, NPCs were plated on
polyornithin/laminin-coated dishes (at day 0) and allowed to mature
for 60 days. The expression of neuronal markers (TUBB3, MAP2 and
BDNF) was analyzed by RT-qPCR at diﬀerent time points of neural
diﬀerentiation (Figs. 6A, 6C and 6E) and by immunoﬂuorescence
staining at day 60 of neuronal diﬀerentiation (Figs. 6F, 6J, 6M, and
6P). Interestingly, neurons derived from X°-CGD-iPSCs and AR-22°-
CGD-iPSCs expressed lower levels of neuronal markers (TUBB3, MAP2
and BDNF) than those derived from control-iPSCs (Figs. 6A, 6C and 6E).
Consistent with these results, upon neuronal diﬀerentiation, X°-CGD-
iPSCs and AR-22°-CGD-iPSCs generated less β3-tubulin positive cells
and MAP2-positive cells (Figs. 6B and 6D). Quantiﬁcation of neurite
branching from soma of MAP2-positive neurons at day 60 of diﬀer-
entiation showed that the mean number of branches was lower in
neurons derived from X°-CGD-iPSCs and AR-22°-CGD-iPSCs compared
to those derived from control-iPSCs (Figs. 6F and 6G), which translates
into a reduced length of neurites in neurons derived from X°-CGD-iPSCs
and AR-22°-CGD-iPSCs (Fig. 6H).
Considering that an impaired maturation could explain the cogni-
tive impairment observed in CGD patients, we investigated the expres-
sion of both pre- and post-synaptic markers of neurons by RT-qPCR and
by immunoﬂuorescence analysis. As shown, no diﬀerence in SYN1,
SNAP25 and PSD95 expression was found in neurons derived from X°-
CGD-iPSCs, AR-22°-CGD-iPSCs and control-iPSCs (Fig. 6I). In line with
this, the density of synapsin punctae was similar in neurons derived
from X°-CGD-iPSCs, AR-22°-CGD-iPSCs and control-iPSCs (Figs. 6J and
6K).
In order to determine if the reduced number of neurons generated
from X°-CGD-iPSCs, AR-22°-CGD-iPSCs is associated with a gliogenic
shift, we analyzed the expression of astroglial (S100B and GFAP) and
oligodendroglial markers (OLIG1 and OLIG2) by RT-qPCR upon neuro-
nal diﬀerentiation of these iPSCs. Interestingly, no diﬀerence in the
expression of GFAP and S100B as well as in the number of GFAP-
positive cells was observed upon neuronal diﬀerentiation of X°-CGD-
and AR-22°-CGD-iPSCs (Figs. 6L, 6M and 6N). By contrast, upon
neuronal diﬀerentiation both X°-CGD- and AR-22°-CGD-iPSCs showed
a reduced expression of OLIG1 and OLIG2 as well as a reduced number
of OLIG2-positive cells (Figs. 6O, 6P and 6Q). Collectively, our results
suggest that NOX2 deﬁciency is associated with a reduced generation of
neurons and oligodendroglial cells with no impact in the number of
astroglial cells.
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3. Discussion
In this study, we show that the ROS-generating enzyme NOX2 is
highly expressed in neurogenic regions of the mouse and macaque
brain, as well as in neurally diﬀerentiated human iPS cells. Using
NOX2-deﬁcient mice and iPSC from NOX2-deﬁcient patients, we
demonstrate that NOX2 is functionally relevant in nestin positive
NPCs and their proliferation.
To our knowledge, this is the ﬁrst article that presents the role of
NOX2 during neural diﬀerentiation by using human NOX2 deﬁcient-
iPSC lines. Two previous studies have investigated the role of ROS, and
to some extent NOX, in NPCs. Le belle et al. has described the presence
of NOX2 in the SVZ and a role of ROS in the self-renewal and
multipotency of mouse NSCs. However, the conclusions of this study
was mostly based on the use of non-speciﬁc inhibitors [14,30]. have
shown NOX2-dependent regulation of proliferation and signaling in
adult mouse hippocampal precursor (AHP) cells and decrease NPC
proliferation NOX2-deﬁcient adult mouse dentate gyrus [14,30].
Our study provides several novel and relevant elements: i) we
investigated all NOX isoforms and demonstrate that only NOX2 mRNA
is speciﬁcally enriched in the DG and SVZ; ii) we excluded the
possibility that the presence of NOX2 in neurogenic regions is due to
microglia; iii) by demonstrating decreased oxidative modiﬁcations in
neurogenic regions of NOX2-deﬁcient animals, we demonstrated that
NOX2 is functional in neurogenic regions; iv) we detected region-
speciﬁc role of NOX2, which mediates BDNF generation in the dentate
gyrus, but Otx2 expression in the subventricular zone and olfactory
bulb.
The role of human NOX2 was studied using iPSC from two diﬀerent
patients, one with X-linked CYBB (NOX2) deﬁciency, and one with
autosomal CYBA (p22phox) deﬁciency. As discussed in the introduction,
p22phox is an obligatory subunit of the NOX2 complex, but in addition,
it is also part of the NOX1, NOX3, and NOX4 complex [3]. Globally
speaking, the results obtained with the two diﬀerent types of CGD iPSCs
were similar. However, the results obtained with the p22phox deﬁcient
cells (AR-22°) were more pronounced than the one observed with the
NOX2-deﬁcient cells. Thus, we cannot exclude a small contribution of
NOX1, NOX3, or NOX4 to ROS generation in neurogenesis. Note, that in
Fig. 5. NOX2 localization and activity in NPCs derived from iPSCs Immunoﬂuorescence images (A) and quantiﬁcation (B) of NOX2 (red) and the NPC marker nestin (green) in
neurospheres (day7) of control and X°-CGD-iPSCs. Images in panel (A) are shown at lower (left) and higher (right) magniﬁcations. (C) Co-staining of neurospheres with the proliferation
marker Ki-67 and the NPC marker nestin. (D) Quantiﬁcation of percentage of Ki67-nestin double positive cells. Immunostaining images (E) and quantiﬁcation (F) of the early neuronal
marker DCX (n=6). Formation of multiple small rosettes (G) and single large rosettes (I) in neurospheres (day 7) derived from H1-hESCs (light microscopy). (H, J) NOX2 immunostaining
in the two distinct types of rosette structures (right panels: higher magniﬁcation). (K, M) ROS production was visualized in neural rosette structures by using CellROX and NBT (yellow
arrows). Generation of ROS was decreased in presence of 10uM DPI (ﬂavoprotein inhibitor), arrows in yellow, suggesting NOX2 as a main source of ROS generation in rosettes (right
panels in K and M). (L and M) Dot plot graph demonstrating ROS measurement in neural rosettes using DPI (ﬂavoprotein inhibitor) (n=5). Statistics were done Student's t-test. *P<0.05,
**P<0.01, ***< 0.001, ****< 0.0001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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contrast to the rapid down-regulation of NOX2 during neuronal
diﬀerentiation of human ESCs and iPSCs, there was a persistence of
p22phox expression, possibly compatible with a role of other NOX
enzymes during later stages of neuronal diﬀerentiation.
Also, a role for microglia during neurogenesis is emerging [50].
Thus a likely explanation for the presence of NOX2 in neurogenic zones
would be the presence of microglia, a CNS phagocyte which typically
expresses the phagocyte NADPH oxidase NOX2 [12,18,31,42,54,63].
However, the following arguments plead against a microglial localiza-
tion of NOX2 in neurogenic regions: i) NOX2-rich neurogenic regions of
the adult mouse brain contained only very low amounts of microglia; ii)
in vitro neuroectodermal diﬀerentiation of iPSCs is NOX2-regulated,
but no microglia (of mesodermal origin) is present under these
conditions; and iii) immunoﬂuorescence staining shows NOX2 within
rosette-like structures, which are analogous to the neural tube [16,17],
and it co-localization with the NPC marker nestin. Interestingly, the
presence of NOX2 appears to be required for symmetric divisions,
which might not be an independent eﬀect, but rather a mechanism that
contributes to the maintenance of the physiological number of prolif-
erating NSC. In the absence of this NOX2-driven oxidizing environment
there is a decrease in the neuroprecursor pool.
Eventually, at the ﬁnal stage of neural maturation, NOX2 appears to
be strongly down-regulated. This corroborates RNAseq data from a
mature neuronal region (cortex) where NOX2 is almost exclusively
detected in microglia and completely absent in mature neurons [68].
However our data do not formally exclude the possibility that low level
NOX2 expression may be present in neuronal subpopulations or at
speciﬁc developmental stages (for review see [42].
We observed particularities associated with the NOX2 expression in
neurogenic regions which merit discussion: i) NOX2 expression is not
accompanied by a detectable expression of the transcription factors
PU.1, which is one of the main known transcription factors driving
NOX2 expression in leukocytic cells [57]. This suggests a PU.1-
independent NOX2 expression in NPCs and the presence of alternative
transcriptional regulation of NOX2. ii) The expression levels of several
cytoplasmic NOX2 subunits (in particular p67phox, p40phox) were below
detection threshold. Yet, our data show that NOX2 is functional in
mouse and human NSCs/NPCs: NOX2 deﬁciency has a marked impact
on NSC/NPC proliferation and gene expression and NOX2 expression is
associated with ROS generation in neurogenic regions. Based on our
present knowledge of NOX2 biochemistry, it seems unlikely that NSCs/
NPCs exhibit a subunit-independent ROS generation by NOX2, but
rather that low level and/or intermittent expression of subunits suﬃces
to activate NOX2 in NSCs/NPCs; iii) the expression of the Rac GTPase
isoforms in the neurogenic regions of the mouse brain is also unique as
compared with other NOX2 expressing tissues. As expected, the
neutrophil-typical Rac2 is virtually absent. However, in addition to
Rac1, which is typically associated with NOX2 in macrophages,
neurogenic regions also express high levels of the neuronal Rac3
[37]. Thus, it is tempting to speculate that Rac3 might be implicated
in NOX2 activity in NSC/NPC.
In human phagocytes, activation of NOX2 is a tightly regulated
system which responds to speciﬁc stimuli and rapidly deactivates once
the relevant stimulus has disappeared. For the time being, we do not
have evidence that NOX2 in NSCs behaves in a similar way. Indeed,
under our experimental conditions, NOX2 appears to be active without
addition of a speciﬁc stimulus (data not shown). However, we observed
NOX2 activity in NSCs/NPCs within the neurogenic niche, where
various growth factors are released which contributes to the control
of the NSC/NPC system. Indeed, there is evidence for activation and/or
enhanced expression of NOX2 by neural growth factors such as FGF2
[14], BDNF [53] and VEGF [31]. For example, NOX2 expression is
decreased in neurogenic regions of VEGF-deﬁcient mice [31]. In
addition, there appears to be a feed-forward mechanism through a
redox-sensitive activation of the respective growth factor receptors by
NOX2 [62]. Thus, although we do not have experimental evidence for a
receptor-dependent activation of NOX2 in neural precursors, our data
certainly do not exclude this possibility.
Deﬁciency of NOX2 leads to a moderate decrease in cognitive
function in man [45] and mice [26]. Given recent results that connect
adult neurogenesis and learning [46,5,64], it is possible that the
defective neurogenesis caused by NOX2 deﬁciency plays a causal role
in the decreased cognition observed in CGD. This is also particularly
relevant with respect to BDNF, which is thought to play a role in
learning [22] and was found in our study to be decreased in human and
mouse carrying NOX2-loss of function mutations. Future studies are
needed to address whether learning associated neurogenesis is indeed
decreased in CGD mice.
These results likely explain a hitherto poorly understood phenotype
of NOX2-deﬁcient CGD patients. It also adds a new level of complexity
to the concept of NOX2 as a drug target for the treatment of oxidative
stress diseases of the CNS.
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The transcription factor NRF2 is a master regulator of cellular antioxidant and detoxification responses, 
but it also regulates other processes such as autophagy and pluripotency. In human embryonic stem cells 
(hESCs), NRF2 antagonizes neuroectoderm differentiation, which only occurs after NRF2 is repressed 
via a Primary Cilia-Autophagy-NRF2 (PAN) axis. However, the functional connections between NRF2 
and primary cilia, microtubule-based plasma membrane protrusions that function as cellular antennae, 
remain poorly understood. For instance, nothing is known about whether NRF2 affects cilia, or whether 
cilia regulation of NRF2 extends beyond hESCs. Here, we show that NRF2 and primary cilia 
reciprocally regulate each other. First, we demonstrate that fibroblasts lacking primary cilia have higher 
NRF2 activity, which is rescued by autophagy-activating mTOR inhibitors, indicating that the PAN axis 
also operates in differentiated cells. Furthermore, we show that NRF2 controls cilia formation and 
function. NRF2-null cells grow fewer and shorter cilia and display impaired Hedgehog signaling, a cilia-
dependent pathway. These defects are not due to increased oxidative stress or ciliophagy, but rather to 
NRF2 promoting expression of multiple ciliogenic and Hedgehog pathway genes. Among these, we 
focused on GLI2 and GLI3, the transcription factors controlling Hh pathway output. Both their mRNA 
and protein levels are reduced in NRF2-null cells, consistent with their gene promoters containing 
consensus ARE sequences predicted to bind NRF2. Moreover, GLI2 and GLI3 fail to accumulate at the 
ciliary tip of NRF2-null cells upon Hh pathway activation. Given the importance of NRF2 and ciliary 
signaling in human disease, our data may have important biomedical implications. 
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INTRODUCTION  
Primary cilia are microtubule-based plasma membrane protrusions that function as cell type-specific 
antennae by accumulating signal receptors and transducers. Structurally, the ciliary membrane is 
undergirded by the ciliary shaft, or axoneme, consisting of nine microtubule pairs emanating from the 
basal body, a membrane-anchored centriole1,2.  
The presence of primary cilia is cell cycle and cell type-dependent3,4. In the cell cycle, cilia form during 
G1/G0 and disassemble before mitosis3. Moreover, specific transcription factors (e.g. RFX1-4, FOXJ1) 
promote ciliogenic gene expression in a cell type-specific manner4,5. Ciliogenesis and ciliary 
maintenance critically depend on a bidirectional trafficking system, known as intraflagellar transport 
(IFT), that moves cargoes up and down the axoneme1,2. To do this, cargoes bind adaptors such as IFT-
B and IFT-A complexes, which in turn associate to microtubule motors moving toward (heterotrimeric 
kinesin-2) or from (cytoplasmic dynein-2) the ciliary tip.  
In mammals, the complete absence of cilia is embryonic lethal, as seen in mice lacking essential 
ciliogenic genes such as Ift88 and Kif3a 6,7. Less severe congenital ciliary defects lead to ciliopathies, a 
diverse group of human diseases causing blindness, cystic kidneys, obesity, sterility, polydactyly and 
brain malformations, among other symptoms1. Cilia defects acquired later in life are associated with 
ailments such as cancer and neurodegeneration8-11. 
Disruption of Hedgehog (Hh) signaling, a cilia-dependent pathway controlling multiple aspects of 
embryogenesis and adult stem cell function7, explains many (but not all) ciliopathy symptoms and cilia-
dependent cancers. Hh ligands, such as Sonic Hedgehog (SHH), act in paracrine fashion by binding to 
Patched (PTCH1), a ciliary transmembrane protein. Ligand binding prevents PTCH1 from opposing the 
ciliary accumulation of Smoothened (SMO), a seven transmembrane protein whose activation displaces 
another G protein-coupled receptor, GPR161, from cilia. This in turn lowers cAMP levels and PKA 
activity at the basal body, affecting phosphorylation of GLI2 and GLI3, the zinc finger transcription 
factors mediating Hh pathway output. This promotes GLI2 and GLI3 accumulation at the ciliary tip, 
where they dissociate from SUFU, a pathway repressor. From the ciliary tip, GLI2 and GLI3 travel to 
the ciliary base to meet different fates: GLI2 is processed into a transcriptional activator and translocates 
to the nucleus to activate target genes, whereas GLI3 is fully degraded in the proteasome, abolishing its 
basal activity as a transcriptional repressor. Thus, by promoting GLI2 activation and GLI3 non-
repression, Hh ligands stimulate expression of target genes, including Ptch1 and Gli1, another activating 
GLI 7. 
Primary cilia also modulate mTOR signaling and autophagy12-17. In the kidney, mechanosensory cilia in 
tubular epithelial cells respond to fluid flow by repressing mTOR, thereby promoting autophagy and 
reducing cell volume, a homeostatic mechanism perturbed in polycystic kidney disease13,15,18,19. Similar 
pathways occur in other cell types, such as fibroblasts and radial glia16,17. During human embryonic stem 
cell (hESC) differentiation, cell fate choice between mesendoderm and neuroectoderm is also controlled 
by cilium-dependent autophagy12. In the first stages of neuroectoderm progenitor specification, cell 
cycle lengthening allows cilia to emerge during G1. Cilia in turn activate autophagy, resulting in the 
inactivation of NRF2, which antagonizes neuroectoderm differentiation. Whether this so-called Primary 
Cilium-Autophagy-NRF2 (PAN) axis is conserved in other cell types, and whether mTOR is involved 
in it, has not been addressed12. 
NRF2 (nuclear factor erythroid 2-related factor 2), encoded by the Nfe2l2 gene, is a basic region-leucine 
zipper (bZip) transcription factor best known as a master regulator of cellular antioxidant and 
detoxification responses20. Under normal conditions, NRF2 binding to KEAP1 targets the former for 
ubiquitin-dependent proteasome degradation. By modifying cysteine residues in KEAP1, oxidative 
stress, or electrophilic compounds like dimethyl fumarate (DMF), an FDA-approved drug for treatment 
of multiple sclerosis, disrupt KEAP1-NRF2 binding, leading to NRF2 accumulation20. NRF2 then 
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translocates to the nucleus and activates expression of its multiple target genes by binding to antioxidant 
response elements (AREs) in their enhancer regions20. Many of these genes encode detoxification 
enzymes, such as heme oxygenase-1 (Hmox1) or the catalytic (Gclc) and modulatory (Gclm) subunits 
of glutamate-cysteine ligase, which catalyzes the first step in the biosynthesis of glutathione, a major 
cellular scavenger of reactive oxygen species (ROS)20. NRF2 also targets autophagy genes, which 
contribute to stress tolerance. Hence, NRF2 is both a regulator of autophagy and an autophagy-regulated 
protein12,21,22.  
Likewise, primary cilia both control and are controlled by autophagy12,14,23,24. A cilia-specific form of 
autophagy, termed ciliophagy, plays a key role in lung damage caused by cigarette smoke. HDAC6, a 
histone deacetylase and ubiquitin-binding autophagy receptor, plays a key role in both ciliophagy and 
aggrephagy, the autophagic clearance of protein aggregates23,25,26. Moreover, autophagy promotes 
ciliogenesis and lengthens cilia by removing an inhibitory protein, OFD1, from the basal body vicinity 
24. 
In view of these reciprocal cilia-autophagy and NRF2-autophagy connections, we wondered whether 
analogous reciprocal relationships exist between cilia and NRF2. Indeed, we find that fibroblasts lacking 
cilia have increased NRF2 activity, which we rescue with mTOR inhibitors. Conversely, NRF2-null 
cells have defects in ciliogenesis and Hh signaling. These defects, rather than being caused by changes 
in redox stress or ciliophagy, are due to NRF2 promoting expression of multiple ciliogenic and Hh 
pathway genes. 
RESULTS 
Primary cilia downregulate NRF2 transcriptional activity via mTOR 
Cells lacking KIF3A, a kinesin-2 subunit, or IFT88, an IFT-B complex component, are completely 
incapable of growing cilia and are commonly used to study the effects of cilia ablation1,6,7,27. We 
confirmed this using both Kif3a−/− and Ift88−/− mouse embryonic fibroblasts (MEFs). After 24 hours of 
starvation, most wild type MEFs displayed primary cilia, in which both axoneme (acetylated α-tubulin, 
AcTub) and ciliary membrane (ARL13B) markers are seen to emerge from the -tubulin-positive basal 
bodies. In contrast, Kif3a−/− and Ift88−/− MEFs failed to grow any cilia under the same conditions 
(Fig.1a). 
To test whether cilia regulate NRF2 activity in MEFs, we measured mRNA levels of heme oxygenase-
1 (Hmox1) and glutamate-cysteine ligase catalytic subunit (Gclc), two well-established transcriptional 
NRF2 targets20, in Kif3a−/−, Ift88−/− and their respective littermate control MEFs (Fig.1b-c). We tested 
this in presence or absence of DMF, a known NRF2 activator20. Both with and without DMF, cilia-null 
MEFs displayed consistently higher Hmox1 and Gclc mRNA levels, an effect that was more obvious 
and significant in presence of DMF (Fig.1b-c). As expected, DMF raised Hmox1 and Gclc, but to a 
lesser extent in cilia-null MEFs (Fig.1b-c). Since these results were observed for both Kif3a and Ift88 
MEFs, this suggests that cilia downregulate NRF2 transcriptional activity. Accordingly, another NRF2 
target gene, NADPH quinone oxidoreductase-1 (Nqo1), was also upregulated, together with Hmox1, in 
both Kif3a−/− and Ift88−/− MEFs, and this upregulation was enhanced by another NRF2 activator, 
sulforaphane (Supplementary Fig.S1a-b)20. Furthermore, Hmox1 protein levels were also increased in 
Ift88−/− MEFs, and the effect was clearer in sulforaphane-treated cells (Supplementary Fig.S1c). 
To see if this increase in NRF2 activity was due to increased NRF2 protein levels, we analyzed the latter 
by Western blot in Kif3a+/+ and Kif3a−/− MEFs treated or not with DMF. Relative to α-tubulin, NRF2 
protein levels were strongly upregulated by DMF in both Kif3a+/+ and Kif3a−/− MEFs, without obvious 
differences between cell types (Fig.1d). Hence, the effect of KIF3A on NRF2 activity is not due to 
changes in NRF2 protein levels. 
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Since primary cilia downregulation of NRF2 during neuroectoderm differentiation is mediated by 
autophagy, we next tested whether mTOR inhibitors, which are widely used to activate autophagy, could 
restore normal NRF2 activity in Kif3a−/− MEFs12,28. For this, we used both Torin-1 and rapamycin, an 
ATP-competitive and an allosteric mTOR inhibitor, respectively29. Indeed, gene expression of both 
Hmox1 and Gclc returned to wild type levels upon treatment of Kif3a−/− MEFs with either Torin-1 or 
rapamycin (Fig.1e-f).  
To assess whether changes in autophagic flux may explain the mTOR-dependent effects of cilia on 
NRF2 activity, we used Western blot to look at the relative levels of LC3-I and LC3-II in presence or 
absence of chloroquine, an autophagolysosome blocker. It is well-established that, during autophagy, 
LC3-I is conjugated to phosphatidylethanolamine, thus generating LC3-II and tethering it to 
autophagosomes, which evolve into autophagolysosomes where LC3-II is degraded. Based on this, the 
chloroquine-induced increase in LC3-II levels (normalized as LC3-II/LC3-I ratio) is a widely accepted 
measure of autophagic flux. In starved and DMF-treated Kif3a+/+ MEFs, we saw a clear chloroquine-
induced increase in the LC3-II/LC3-I ratio, indicating active autophagy (Fig.1g). Under the same 
conditions, autophagic flux in Kif3a−/− MEFs was reduced by more than 30% relative to the Kif3a+/+ 
control. This reduction, however, was rescued by both Torin-1 and rapamycin, in whose presence 
autophagic flux in Kif3a−/− MEFs was even higher than that in Kif3a+/+ cells (Fig.1g). Since autophagy 
flux in these cells shows a strong inverse correlation with NRF2 target expression, these data are 
consistent with primary cilia downregulating NRF2 by promoting autophagy.  
Intriguingly, this correlation did not clearly extend to NRF2 protein levels, even though quantitation of 
NRF2/Tubulin ratios showed a slight increase in Kif3a−/− relative to Kif3a+/+ MEFs, an increase that was 
no longer seen when Kif3a−/− MEFs were treated with mTOR inhibitors (Fig.1h). However, to what 
extent this modest increase in NRF2 protein might explain the observed increase in NRF2 transcriptional 
activity remains unclear. 
Altogether, these data suggest that the PAN axis described in differentiating hESCs is also operative in 
more differentiated cell types, such as MEFs. 
Ciliary repression of NRF2 does not involve Hh signaling  
Since primary cilia are required for vertebrate Hh signaling, we also tested whether Hh pathway 
alterations might be involved in the higher NRF2 activity of Kif3a−/− MEFs. In these cells, lack of cilia 
prevents proteolytic processing of GLI transcription factors7. Since GLI3 is processed into a 
transcriptional repressor (GLI3R) in a constitutive and cilia-dependent manner, Kif3a−/− MEFs fail to 
form GLI3R, leading to higher unstimulated expression of Hh target genes Gli1 and Ptch1 
(Supplementary Fig.S2a). 
KIF3A and cilia are also required for GLI2 processing, which forms a transcriptional activator (GLI2A) 
only upon Hh pathway stimulation. Hence, Kif3a−/− MEFs fail to form GLI2A and do not induce target 
gene expression in response to Hh pathway agonists. Nevertheless, Hh target gene expression can be 
stimulated in these cells by transfecting them with a constitutively active, oncogenic allele of GLI2 
known as GLI2N 27. Indeed, transient expression of GLI2N activated Hh target expression in Kif3a+/+ 
and, even more so, in Kif3a−/− MEFs, where GLI3R does not counteract its effect (Supplementary 
Fig.S2a). 
However, despite strongly activating Hh signaling in Kif3a+/+ and Kif3a−/− MEFs, GLI2N had no effect 
on Hmox1 and Gclc gene expression, indicating that NRF2 activity is not affected by GLI2N-induced 
Hh pathway activation (Supplementary Fig.S2b).  
Thus, GLI2 activation does not mediate the effects of cilia on NRF2. Nor does GLI2 inhibition, as GLI2 
is transcriptionally inactive in unstimulated MEFs, as confirmed by our observation that GLI2 inhibitor 
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GANT61 does not lower Hh target expression in MEFs not treated with Hh pathway agonists (data not 
shown)30. 
Having ruled out GLI2, it was still possible that cilia repress NRF2 activity by promoting GLI3R 
synthesis. If this were the case, then GLI3R expression in Kif3a−/− MEFs should lower NRF2 activity, 
restoring it to normal. However, this is not the case (Supplementary Fig.S2c-d). 
Overall, these data indicate that the negative impact of cilia on NRF2 activity is not related to Hh 
signaling.  
Ciliogenesis is reduced in NRF2-null cells  
We next wondered whether NRF2 affects cilia in addition to being affected by them. To test this, we 
first looked at ciliogenesis in Nfe2l2+/+ and Nfe2l2−/− MEFs. Although Nfe2l2−/− MEFs generated cilia 
that appeared normal by ARL13B, AcTub and γ-tubulin staining (Fig.2a), the percentage of such cells 
displaying primary cilia was reduced in half relative to Nfe2l2+/+ cells (Fig.2b). Moreover, cilia in 
Nfe2l2−/− MEFs were on average 15-20% shorter than control cilia (Fig.2c). Primary Nfe2l2−/− MEFs 
displayed similar ciliogenic defects, excluding MEF immortalization as their cause (Supplementary 
Fig.S3). 
We then examined whether NRF2 affects ciliogenesis in vivo. Since NRF2-null mice are viable and 
develop normally, we reasoned their embryonic cilia cannot be strongly perturbed31. In contrast, adult 
NRF2-null mice have phenotypes that could potentially be explained by ciliogenic defects. In particular, 
both NRF2 and cilia play important roles in the hippocampus, affecting cognitive functions11,32,33. Thus, 
we decided to look at hippocampal cilia in coronal sections of three month-old Nfe2l2+/+ and Nfe2l2−/− 
mouse brains. Moreover, since NRF2 plays a prominent role in astrocytes34-36, and ARL13B specifically 
labels astrocytic cilia in adult mouse brain37,38, we focused our study on this cell type, which can be 
readily identified with the GFAP marker38. In both Nfe2l2+/+ and Nfe2l2−/− hippocampus, ARL13B+ cilia 
were indeed only seen in close association with GFAP+ astrocytes, confirming the above reports 
(Fig.2c)37,38. In control sections, about 50% of such GFAP+ cells contained a primary cilium, but this 
percentage was reduced to about 10% in equivalent Nfe2l2−/− sections (Fig.2c-d). 
Thus, our data suggest that NRF2 is required for optimal ciliogenesis both in vitro and in vivo. 
Hh signaling is reduced in NRF2-null cells  
Since Hh signaling is cilia-dependent, we next examined Hh pathway responsiveness in Nfe2l2−/− MEFs. 
To do this, we used Smoothened agonist (SAG), a well-established Hh pathway activator39. While SAG 
strongly induced Hh target genes Gli1 and Ptch1 in Nfe2l2+/+ cells, this response was much attenuated 
in Nfe2l2−/− MEFs, even if still significant (Fig.3a). Very similar results were obtained in primary MEFs, 
confirming defective Hh responsiveness is not related to MEF immortalization (Supplementary Fig.S4). 
Moreover, differences in SAG responsiveness were also seen by Western blot of GLI1, whose protein 
levels were strongly upregulated by SAG in Nfe2l2+/+ MEFs but much less so in Nfe2l2−/− MEFs (Fig.3b). 
Thus, NRF2-null cells display defects in both ciliogenesis and Hh signaling. 
ROS, HDAC6, mTOR and PKA inhibitors do not rescue Hh signaling in NRF2-null cells  
We then asked whether increased oxidative stress in absence of NRF2 was the cause for the sharp 
decrease in Hh signaling. To address this, we used N-acetyl-cysteine (NAC), a glutathione precursor 
that promotes ROS scavenging, thereby reducing oxidative stress40. NAC treatment of Nfe2l2−/− MEFs 
did not affect their poor SAG responsiveness relative to wild type cells, indicating that the antioxidant 
functions of NRF2 are not the main reason why it promotes Hh signaling (Fig.4). 
Another possible explanation for the effect of NRF2 on cilia and Hh signaling is that NRF2 affects 
ciliophagy, which critically depends on HDAC6, a protein that is upregulated in Nfe2l2−/− cells and 
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functions as both a protein deacetylase and a ubiquitin-binding autophagy receptor23,25,26. If increased 
HDAC6-dependent ciliophagy was the cause of Nfe2l2−/− MEFs displaying ciliogenic and Hh signaling 
defects, then Tubastatin A, an HDAC6 inhibitor that blocks ciliophagy, should improve Hh responses 
in these cells23,41. However, this is not the case (Fig.4). 
Since PKA, by promoting generation of GLI repressors at the expense of GLI activators, is a negative 
regulator of Hh signaling, we also tested whether a PKA inhibitor, H89, restored high Hh responsiveness 
in Nfe2l2−/− MEFs42. The lack of such restoration indicates that NRF2 is required downstream of PKA 
in the Hh pathway (Fig.4). 
Lastly, given that NRF2 promotes autophagy21,22, we tested whether autophagy stimulation with mTOR 
inhibitor Torin-1 improved Hh signaling in Nfe2l2−/− MEFs, but it did not (Fig.4). 
Hence, oxidative stress, HDAC6-dependent ciliophagy, overactive PKA or reduced autophagy do not 
appear to explain the cilia and Hh phenotypes of Nfe2l2−/− MEFs. 
Ciliogenic and Hh pathway gene expression is reduced in NRF2-null cells 
NRF2 is a transcription factor with hundreds of known target genes, so we reasoned that its effects on 
cilia and Hh signaling might be mediated by changes in gene expression. To test this, we first looked at 
mRNA levels of ciliogenic genes in Nfe2l2+/+ and Nfe2l2−/− MEFs. These genes encode proteins such as 
ciliary microtubule motors (Dync2h1) and components of intraflagellar transport complexes IFT-B 
(Ift74, Ift88, Ift172) and IFT-A (Ift140). Interestingly, expression of all IFT and motor genes analyzed 
was significantly lower in Nfe2l2−/− relative to Nfe2l2+/+ MEFs, regardless of whether or not cells were 
treated with SAG (Fig.5a). Similar results were obtained in primary MEFs (Supplementary Fig.S5a). 
Nfe2l2−/− MEFs show a two-fold reduction in ciliogenesis (Fig.2b), yet their Hh responsiveness is lower 
by at least 4-fold (Fig.3a). This suggested that the remaining cilia in Nfe2l2−/− MEFs are not fully 
functional regarding Hh signal transduction. This, we hypothesized, might be due to defects in gene 
expression of Hh pathway components. To test this, we measured mRNA levels for several Hh pathway 
mediators, including positive regulators SMO, GLI2 and IFT27, and negative regulators GLI3, SUFU 
and GPR1617. All of them were significantly downregulated in Nfe2l2−/− MEFs independently of Hh 
pathway activation (Fig.5b). Similar reductions in Hh pathway gene expression were observed in 
primary MEFs (Supplementary Fig.S5b). 
Additionally, we measured gene expression of RFX transcription factors, some of which promote 
ciliogenesis by binding to X-box motifs in the regulatory regions of many ciliary genes1,4,5. Interestingly, 
two of them were significantly reduced (Rfx5 and Rfx7), one was strongly upregulated (Rfx8) and three 
were unaffected (Rfx1, Rfx2, Rfx3) in Nfe2l2−/− MEFs (Supplementary Fig.S6a). For Rfx4, absence of 
NRF2 made no difference in immortalized MEFs, yet it upregulated expression about 100-fold in 
primary MEFs (Supplementary Fig.S6b). However, as interesting as these changes may be, they seem 
to bear little or no relationship with our observed ciliogenic and Hh defects, as will be discussed later. 
In contrast, the widespread reduction in ciliogenic and Hh pathway gene expression shown in Fig.5a-b 
is likely to be a major cause of the ciliogenic and Hh signaling defects of Nfe2l2−/− MEFs. 
DMF does not increase basal levels of ciliogenesis and Hh responsiveness 
Since NRF2 loss in Nfe2l2−/− MEFs causes a reduction in ciliogenesis and Hh signaling, we wondered 
whether higher NRF2 levels would have the opposite effect, increasing ciliogenesis and Hh pathway 
output. To test this, we treated Nfe2l2+/+ MEFs (and Nfe2l2−/− MEFs as a negative control) with DMF, 
which raises NRF2 protein levels (Fig.1c)20. DMF treatment did not significantly increase ciliogenesis 
in either Nfe2l2+/+ or Nfe2l2−/− MEFs, nor did it affect ciliary length (Supplementary Fig.S7a-b). 
Likewise, Hh responsiveness was not enhanced by DMF (Supplementary Fig.S7c). Thus, it appears that 
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basal NRF2 levels are not limiting for ciliogenesis or Hh signaling in MEFs, at least under our study 
conditions. 
DMF stimulates ciliogenic gene expression 
Even though DMF did not enhance ciliogenesis or Hh signaling, its upregulation of NRF2 protein levels 
might still cause an increase in NRF2-dependent gene expression. We therefore tested if DMF affects 
expression of some of the ciliogenic and Hh pathway genes from Fig.S5. Interestingly, DMF caused a 
significant increase in Dync2h1 and Ift88 mRNA levels in Nfe2l2+/+ but not Nfe2l2−/− MEFs, indicating 
that the effect depends on NRF2 (Supplementary Fig.S8a). As for Hh pathway genes, we checked 
mRNA levels of Smo, Gli2 and Gli3. Although we did not see any significant DMF-induced increase 
for any of these genes in control or NRF2-null MEFs, in the former there was a consistent upward trend, 
which might merit further study (Supplementary Fig.S8b). Altogether, these experiments suggest that 
NRF2 levels in control cells may be limiting for the expression of some genes but not for others. 
Identification of putative AREs in ciliogenic and Hh pathway genes  
Given the effects of NRF2 upon ciliogenic and Hh pathway gene expression, we reasoned that some of 
these genes might be direct targets of NRF2. If so, they should contain ARE sequences in their regulatory 
regions. To assess this possibility, we analyzed the promoter regions of all ciliogenic and Hh pathway 
genes whose expression we found reduced in NRF2-null cells. Promoter sequences of the human genes 
were compared with consensus ARE sequences from the JASPAR database, as previously described22. 
Remarkably, many of these genes contain putative ARE sequences with high scores relative to the 
consensus (Fig.5c). In particular, two genes (GLI2 and GLI3) contain putative AREs with relative scores 
higher than 0.99, indicating a virtually perfect match with the consensus. Six other genes (IFT172, 
IFT140, IFT88, GPR161, PTCH1, and IFT27) contain putative AREs with scores above 0.9, whereas 
IFT74 has one above 0.8. In contrast, no putative AREs with scores above 0.8 were found in the 
promoter regions of DYNC2H1, GLI1, SUFU and SMO.  
Altogether, our bioinformatic analysis supports the idea that some ciliogenic and/or Hh pathway genes  
are direct NRF2 transcriptional targets.    
GLI2 and GLI3 ciliary localization and protein levels are reduced in NRF2-null cells  
Of all the Hh pathway genes whose expression is reduced in NRF2-null cells, GLI2 and GLI3 are 
potentially the most significant, as they act downstream of all others, directly controlling Hh target gene 
expression7. We therefore looked at GLI2 and GLI3 proteins in Nfe2l2−/− MEFs. Both GLI2 and GLI3 
are known to accumulate at the ciliary tip upon Hh pathway activation7,43. This accumulation is 
important for GLI2 to be processed into the transcriptionally active GLI2A, and for GLI3 to stop being 
processed into a repressor, GLI3R, and undergo full proteasomal degradation instead7,44-46. Thus, failure 
of GLI2 and/or GLI3 to accumulate at the ciliary tip might well explain the low Hh responsiveness of 
Nfe2l2−/− MEFs. To test this hypothesis, we performed immunofluorescence for GLI2 and GLI3 in 
Nfe2l2 MEFs treated with either vehicle or SAG. In Nfe2l2+/+ MEFs, SAG induced a strong 
accumulation of both GLI2 and GLI3 at the ciliary tip. By contrast, their accumulation in SAG-treated 
Nfe2l2−/− MEFs was strongly and significantly reduced (Fig.6a-d).        
Western blot analysis of GLI2 and GLI3 confirmed a strong reduction in the overall basal levels of these 
proteins, especially of their proteolytically processed lower molecular weight forms (Fig.6e-f). 
Moreover, Nfe2l2−/− MEFs appeared to react differently to SAG than Nfe2l2+/+ MEFs. In control cells, 
as previously shown, SAG did not affect the pattern of GLI2 bands47, but caused a marked reduction in 
GLI3 levels48. On the other hand, Nfe2l2−/− MEFs responded to SAG by reducing the processed forms 
of GLI2 while having only a modest effect on GLI3 (Fig.6e-f). Together with the immunofluorescence 
data, these results suggest that GLI2 and GLI3 ciliary accumulation, processing and protein levels are 
abnormal in NRF2-null cells.  
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Finally, we also carried out immunofluorescence and Western blot with IFT88 and SMO antibodies. 
Despite the observed lower mRNA levels in Nfe2l2−/− MEFs relative to control (Fig.5a-b), we saw no 
such differences in either ciliary IFT88 intensity (Supplementary Fig.S9a-b), ciliary SMO intensity with 
or without SAG (Supplementary Fig.S9c-d), or total levels of these proteins as seen by Western blot in 
presence or absence of DMF (Supplementary Fig.S9e). This might reflect compensatory mechanisms 
that maintain protein homeostasis despite altered mRNA levels.  
DISCUSSION 
In pluripotent hESCs, cell fate choice between mesendoderm and ectoderm lineages depends on the 
PAN axis, whereby early emergence of cilia in some cells stimulates autophagy, thereby downregulating 
NRF2 activity and committing those cells to neuroectoderm12. Here, we have shown data suggesting 
that the PAN axis is also at work in more differentiated cell types, including fibroblasts. In support of 
this, NRF2 transcriptional activity is higher in cells unable to grow cilia (Fig.1a-c), whose autophagic 
flux is reduced (Fig.1g). Moreover, mTOR inhibitors, which raise autophagic flux in cilia-null cells 
(Fig.1g), fully rescue the abnormal NRF2 activity of these cells (Fig.1e-f). 
If the PAN axis is not restricted to hESCs, then what is its biological role beyond early embryogenesis? 
In stem cells, it may control cell fate choices in a similar way to what it does in hESCs, except that the 
relevant NRF2 target genes would differ in each case (in hESCs it promotes expression of pluripotency 
genes OCT4 and NANOG, which are epigenetically silenced in more differentiated cells12).  
In terminally differentiated cells, the PAN axis might convey information about ciliary integrity or 
stress. Since genetic deletion of cilia reduces autophagy and raises NRF2 activity, something similar 
might occur by accidental or stress-induced cilia ablation or damage. If so, this would trigger NRF2-
dependent cytoprotective responses, which might include cilia regeneration, consistent with our data 
that NRF2 promotes ciliogenic gene expression. Consistent with this, NRF2 plays a protective role in 
cigarette smoke-induced harm to airway cilia23. Also, flow sensation in renal mechanosensory cilia 
represses mTOR to promote autophagy and reduce cell size13,15. Thus, it would be interesting to test 
whether mechanical stress in renal cilia also modulates NRF2 activity. If so, this could have important 
implications, as disruption of this ciliary pathway causes polycystic kidney disease (PKD), the most 
common ciliopathy19. The fact that NRF2 dysregulation is involved in kidney cystogenesis in a mouse 
cancer model supports a potential connection between NRF2 and PKD49.  
Mechanistically, many questions remain concerning how the PAN axis works. Our data indicate that 
GLI-dependent Hh signaling is not involved (Supplementary Fig.S2), but how cilia control autophagy 
and NRF2 remains poorly understood. For instance, our evidence shows cilia downregulate NRF2 
activity but not its protein levels (Fig.1d,h). Since NRF2 is often regulated through protein stability50, 
this raises the question of how cilia affect NRF2 in MEFs, and whether this mechanism also applies to 
hESCs, where NRF2 protein levels were not assessed12. 
We have also found that NRF2-null cells grow fewer and shorter cilia than normal (Fig.2), and display 
poor Hh signaling, a cilia-dependent pathway (Fig.3). We investigated several possible causes for these 
effects. Hh responsiveness in Nfe2l2−/− MEFs was not improved by NAC, which acts in oxidatively 
stressed cells by replenishing their levels of glutathione, a major cellular antioxidant and ROS scavenger 
(Fig.4)40. This largely rules out oxidative stress as a significant cause of Hh signaling defects in our 
model. And since Hh defects arise, at least partly, from ciliogenic defects, the lack of Hh signaling 
rescue by NAC also suggests, indirectly, that oxidative stress does not explain reduced ciliation in 
Nfe2l2−/− MEFs. Tubastatin A, an HDAC6 inhibitor, also failed to even partially rescue Hh signaling 
(Fig.4). Thus, ciliophagy, the HDAC6-dependent autophagic resorption of cilia, does not account for 
the Hh defects either23. Likewise, lack of rescue by Torin-1 shows that mTOR is not involved in poor 
Hh responsiveness in Nfe2l2−/− MEFs, indicating that NRF2 affects cilia through mechanisms distinct 
from how cilia affect NRF2 (Fig.4). We also failed to rescue Hh signaling with H89, a PKA inhibitor 
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(Fig.4). Since PKA acts as a Hh pathway repressor downstream of SMO but upstream of GLI2 and 
GLI3, these data pointed to Hh signaling disruption downstream of SMO and PKA7. 
We then discovered that multiple ciliogenic and Hh pathway mRNAs are expressed at lower levels in 
Nfe2l2−/− MEFs (Fig.5a-b). These moderate but highly significant reductions in gene expression, when 
combined, likely account for the ciliogenic and Hh defects of Nfe2l2−/− cells.  
The evidence for this is particularly strong for the Hh pathway. GLI2 and GLI3 transcription factors are 
the main controllers of Hh target gene expression (as GLI1 is a Hh target gene whose expression is 
almost negligible before pathway stimulation)7. Hh pathway stimulation alters the transcriptional 
activities of GLI2 and GLI3, turning the former into an activator (GLI2A) and preventing the latter from 
turning into a repressor (GLI3R), its fate under basal conditions7. For these changes to occur, GLI2 and 
GLI3 need to accumulate at the ciliary tip, but this accumulation is strongly reduced in Nfe2l2−/− MEFs 
(Fig.6a-d)7,44-46. In addition, GLI2 and GLI3 protein levels are strongly reduced in these mutants (Fig.6e-
f), as are their mRNAs (Fig.5b). These changes in GLI2 and GLI3 can readily explain the observed Hh 
defects. And since GLI2 and GLI3 act downstream from SMO, GPR161, IFT27 and SUFU in the Hh 
pathway7, the lower mRNA expression observed for the latter genes is likely to be of little consequence 
in terms of Hh pathway output (Fig.5b). In fact, despite the lower mRNA levels in Nfe2l2−/− MEFs, 
SMO protein levels and SAG-induced cilia translocation appear unaffected in these cells 
(Supplementary Fig.S9c-e). 
Regarding ciliogenesis, it is less clear which genes and their products are responsible for the observed 
defects. In principle, each of the genes studied in Fig.5a might account for these defects, as they are all 
important in the process. Moreover, since our analysis was far from exhaustive, many other ciliogenic 
genes might be affected in NRF2-null cells. Since IFT88 is absolutely required for ciliogenesis (Fig.1a), 
we tested the role of IFT88 protein in the ciliogenic defects of Nfe2l2−/− MEFs. Intriguingly, neither total 
nor ciliary IFT88 protein levels were visibly affected in mutant relative to control MEFs (Supplementary 
Fig.S9a-b). This might indicate that compensatory mechanisms operate in Nfe2l2−/− MEFs to keep IFT88 
and SMO protein levels constant, despite lowered mRNA levels. 
Some RFX transcription factors promote ciliogenesis by stimulating expression of ciliogenic genes such 
as the ones in Fig.5a, so a reduction in one or more pro-ciliogenic RFX factors could neatly explain why 
NRF2-null MEFs grow fewer and shorter cilia. RFX1-4 are well established pro-ciliogenic factors4, but 
none of them was reduced in Nfe2l2−/− MEFs. Instead, we found reductions in Rfx5 and Rfx7 
(Supplementary Fig.S6). RFX5 and RFX7 constitute a distinct RFX subfamily and both play important 
roles in immunity4,5,51, yet only RFX7 has recently been linked to ciliogenesis in the neural tube52. 
Whether RFX7 contributes to the ciliogenic phenotype of NRF2-null cells remains unaddressed. 
Unlike Rfx5 and Rfx7, we found elevated levels of Rfx4 and Rfx8 in NRF2-null MEFs. This, however, 
cannot explain the ciliogenic defects, which were seen in both primary and immortalized Nfe2l2−/− MEFs 
(Fig.2a-c and Supplementary Fig.S3), whereas Rfx4 upregulation only occurred in the former 
(Supplementary Fig.S6b). Additionally, higher RFX4 levels would be expected to upregulate ciliogenic 
genes, not reduce them. Virtually nothing is known about RFX8, except that it belongs to the same RFX 
subfamily as RFX4 4,5.  
Since NRF2 stimulates its target genes by binding to ARE sequences in their promoters, we performed 
a bioinformatic search for putative ARE sequences in the human promoters of the ciliogenic and Hh 
pathway genes whose expression we found reduced in Nfe2l2−/− MEFs (Fig.5c). Remarkably, the top 
two hits from this analysis were GLI2 and GLI3, whose promoters each contain a perfect match with the 
consensus ARE sequence (relative score = 0.997). Together with the data presented above, this suggests 
that GLI2 and GLI3 may be direct NRF2 targets, although this awaits experimental demonstration. 
Putative ARE sequences with relative scores in the 0.81-0.98 range were also found in IFT172, IFT140, 
IFT88, IFT74, GPR161, PTCH1 and IFT27. Consistent with these data, Ift74, Ift27 and Gpr161 
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promoter sequences were pulled down with NRF2 in a ChIP-seq study in sulforaphane-treated cells53. 
The presence of putative AREs in PTCH1 (but not GLI1) promoter raises the possibility that NRF2 
directly upregulates Hh targets. If so, we would expect lower basal PTCH1 levels in unstimulated NRF2-
null MEFs, which we did not detect. However, since basal PTCH1 levels are very low, detecting such a 
reduction, if it exists, could be very challenging. Using cells with higher basal PTCH1 levels could 
clarify this issue. 
Since genetic deletion of NRF2 reduces ciliogenic and Hh pathway gene expression, we also tested 
whether NRF2 stabilization by DMF had the opposite effect. Interestingly, ciliogenic genes Dync2h1 
and Ift88 were both significantly upregulated in DMF-treated Nfe2l2+/+ but not Nfe2l2−/− MEFs 
(Supplementary Fig.S8a). This confirms that these genes are positively regulated by NRF2. In these 
experiments, we also tested expression of Gli2, Gli3 and Smo. Although the data pointed in the same 
direction, DMF did not cause any statistically significant changes in the expression of these genes 
(Supplementary Fig.S8b). Likewise, DMF did not increase ciliogenesis or Hh responsiveness above 
basal levels, indicating that NRF2 levels in these cells are not limiting for these processes 
(Supplementary Fig.S7). 
Beyond the mechanistic details, our work raises an important question: what is the biological 
significance of NRF2 affecting ciliogenesis and Hh signaling? Severe ciliogenesis and Hh signaling 
disruptions in mouse embryos lead to embryonic lethality and malformations7,54. In contrast, Nfe2l2−/− 
mice are viable, have no malformations, and do fairly well unless exposed to stress31,55. Hence, cilia and 
Hh signaling cannot be severely perturbed in Nfe2l2−/− mouse embryos. Together with our data, this 
suggests that NRF2 affects ciliogenesis and Hh signaling in a manner dependent on cell type, tissue and 
developmental stage. Comprehensive spatiotemporal studies can shed light on this issue.  
Our data so far show that NRF2 affects ciliogenesis in both embryonic fibroblasts and hippocampal 
astrocytes, so one might expect NRF2-null mice to have cilia or Hh-dependent phenotypes related to 
these cell types. In this regard, we have recently reported defects in hippocampal neurogenesis in NRF2-
null mice, a process where cilia and Hh signaling also play important roles32,56-58. Thus, neurogenesis 
defects in the NRF2-null hippocampus may well be related to defective ciliation. If so, this might involve 
astrocyte cilia, but maybe also neuronal cilia, which are not labeled by ARL13B and thus were not 
visualized in our study37,38. 
The reasons why NRF2 affects ciliogenesis in some cell types more than others remain a mystery. Cell 
type-specific compensatory mechanisms may exist, which could act at many levels, such as gene 
expression, protein stability or enzyme activity, to name a few. Redundancy is another possibility: 
NFE2L1/NRF1, an NRF2-related transcription factor, acts redundantly with NRF2 during mouse 
development59. Thus, our data might be explained by NRF1 compensating for NRF2 loss in some cell 
types but not others. If so, one would expect Nfe2l1-Nfe2l2 double knockout mice to display cilia and 
Hh-related phenotypes. These embryos are delayed, show signs of massive oxidative stress and 
apoptosis, and die at midgestation, too early to assess for all but the most drastic defects in cilia and Hh 
signaling1,7,59. On the other hand, NRF1 is expressed ubiquitously, and Nfe2l1-Nfe2l2 double mutant 
MEFs show markedly higher apoptosis and stress sensitivity than Nfe2l2−/− MEFs, demonstrating that 
NRF1 is present and functional in the latter59,60. Therefore, cilia and Hh defects in Nfe2l2−/− MEFs are 
unlikely to be explained by lack of NRF1 function in these cells. Still, factors other than NRF1 might 
act redundantly with NRF2. 
Another possible in vivo meaning of the NRF2-Hh connection is that Hh signaling participates in NRF2-
dependent cytoprotective responses. Since NRF2 promotes Hh signaling, stress-induced NRF2 
stabilization might enhance Hh signaling, which might protect cells from damage in some way. 
Although Hh signaling stimulation by oxidative stress and cytoprotective effects of Hh signaling are 
both reported in the literature61-66, our data showed no enhancement of Hh responsiveness by DMF, as 
mentioned above (Supplementary Fig.S7c). This, however, does not rule out that Hh responses play 
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cytoprotective roles in vivo, particularly in cell types where basal NRF2 protein levels are low relative 
to what cells need for optimal Hh responsiveness. 
Here, we have established a clear connection between NRF2, expression of ciliogenic and Hh pathway 
genes, and the processes controlled by these genes. The physiopathological contexts where changes in 
NRF2 activity affect cilia and Hh signaling remain to be elucidated. 
METHODS 
Reagents, plasmids and antibodies 
Reagents: Torin-1 (ApexBio, 250nM), Rapamycin (Fisher Bioreagents, 200nM), dimethyl fumarate 
(Sigma, 20µM), Chloroquine (Acros Organics, 10 µM), SAG (Cayman, 200nM), R,S-Sulforaphane 
(LKT Laboratories, 15µM), N-acetyl-L-cysteine (Alfa Aesar, 3mM), H89 dihydrochloride (BioVision, 
10µM) and Tubastatin A (Cayman, 10µM). Plasmids: pcDNA3.1-mGli2ΔN and pcDNA3.1-hGLI3R 
were kind gifts of Drs. Victor L. Ruiz-Perez and Elisa Martí, respectively67. Antibodies: Acetylated α-
Tubulin (Sigma, T7451, 1:10,000), GLI1 (Cell Signaling, L42B10, 1:1,000), GFAP (Sigma, G3893, 
1:200), HMOX1 (Enzo Life Sciences, 1:2,000), SMO (Proteintech 66851-1-Ig, WB: 1:1000) GAPDH 
(Proteintech, 60004-1-Ig, 1:1,000), β-Actin (Proteintech, 66009-1-Ig, 1:5,000)  and α-Tubulin 
(Proteintech, 66031-1-Ig, 1:1,000) were from mouse. GLI2 (R&D systems, AF3635, WB: 0.1µg/ml, IF: 
1µg/ml), GLI3 (R&D systems, AF3690, WB: 1µg/ml, IF: 5µg/ml), Lamin B (Santa Cruz, sc-6217, 
1:5,000) and γ-Tubulin (Santa Cruz, sc-7396, 1:200) were from goat. ARL13B (Proteintech, 17711-1-
AP, 1:200), LC3B (Cell Signaling Technology, #2775, 1:2000), SMO (Abcam, ab38686, IF: 1:1000), 
IFT88 (Proteintech, 13967-1-AP, WB: 1:1000, IF: 1/100) and NRF2 (described in 21, 1:5,000) were from 
rabbit. Due to their initial low specificity (see Fig.3b and Supplementary Fig.S11), NRF2 antibodies 
were repeatedly incubated with membranes from NRF2-null cells, which led to greater specificity 
towards NRF2, as seen in Fig.1d, Fig.1h and Supplementary Fig.S11. Secondary antibodies were from 
donkey (Thermofisher, AlexaFluor 488, 555 or 647-conjugated) or from goat (Thermofisher, HRP-
conjugated).  
Animals  
Colonies of Nfe2l2+/+ and Nfe2l2−/− C57BL/6 mice were established from funders kindly provided by 
Prof. Masayuki Yamamoto68. Animal procedures were performed according to protocols approved by 
the Ethical Committee for Research of the Spanish National Research Council (CSIC), in accordance 
with institutional, Spanish and European guidelines (Boletín Oficial del Estado, 18 March 1988; and 
European Council Directives 86/609/EEC and 2003/65/EC). 
Cell culture 
Kif3a+/+, Kif3a−/−, Ift88+/+ and Ift88−/− MEFs have been reported elsewhere69. Nfe2l2+/+ and Nfe2l2−/− 
littermate MEFs were derived from E11.5 mouse embryos and immortalized with SV40 large T antigen 
using previously described protocols43. All MEFs were grown in DMEM medium supplemented with 
10% fetal bovine serum at 37ºC and 5% CO2 in a humidified atmosphere. All cell lines were 
mycoplasma-free, as ascertained by regular tests. To induce ciliogenesis and for drug treatments, MEFs 
were starved for 24 hours in OptiMEM medium (Thermofisher). For autophagy flux analysis, cells were 
starved for 4 hours in Earle’s Balanced Salts Solution (EBSS, Sigma). 
RT-qPCR 
Total cellular RNA was extracted using GeneJET RNA purification kit (Thermofisher) and reverse 
transcribed with MMLV Reverse Transcriptase (Promega) using oligo-dT18. Quantitative real time PCR 
was performed using PowerUp SYBR Green Master Mix (Thermofisher) and the primer pairs listed in 
Supplementary Fig.S10. Reactions were run on an Applied Biosystems StepOne Real Time PCR System 
and data analyzed using ΔΔCt method with -Actin as control gene. 
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Western blot and quantitation 
Total cell lysates were prepared in buffer containing 50mM Tris-HCl pH 7.5, 150mM NaCl, 1% 
IGEPAL CA-630 and protease inhibitor cocktail (Thermofisher). Lysates were centrifuged at 20,000 x 
g for 10 min at 4ºC to obtain postnuclear supernatants, whose protein concentrations were equalized 
after measuring them with Pierce BCA Protein Assay kit. Samples were then processed for SDS-PAGE, 
run in 4-20% Novex Tris-Glycine gels (Thermofisher) and transferred to nitrocellulose membranes for 
immunostaining. Results were visualized using ECL chemiluminescence reagents and captured on either 
X-ray film or using an MF-ChemiBIS 3.2 system (DNR Bio-Imaging Systems). Images were then 
cropped and their brightness and contrast adjusted using Adobe Photoshop. Uncropped and unadjusted 
images are shown in Supplementary Fig. S11. For band quantitation, Fiji (Image J) software was used. 
Briefly, 8-bit grayscale images of blots were inverted and average pixel intensity measured for all bands 
of interest and their corresponding backgrounds. Total pixel intensity of each band was then obtained 
by multiplying average pixel intensity by pixel number. To this value, total pixel intensity of an equally-
sized background area was subtracted in order to obtain the specific band signal, which was expressed 
as a ratio to the control band. For autophagy flux calculation, basal LC3B-II/I ratio was subtracted from 
the same ratio in presence of chloroquine, and the resulting difference was normalized relative to control 
sample.       
Immunofluorescence and quantitation 
Cultured cells were grown on coverslips, fixed 5 min at RT in PBS with 4% paraformaldehyde, then 3 
min at -20ºC in freezer-cold methanol. Cells were blocked and permeabilized in blocking solution (PBS 
+ 0.1% Triton X100 + 2% donkey serum + 0.02% sodium azide) for 30-60 min at RT before proceeding 
with standard immunostaining procedures and imaging with a Nikon 90i fluorescence microscope. All 
cilia quantitations were performed with the aid of Fiji (Image J) software. For percent ciliation, one or 
more coverslips per condition were examined in each independent experiment. For each coverslip, seven 
representative cell fields were used to count cilia (identified by ARL13B and γ-Tubulin costaining), 
whose number was divided by total cells (DAPI-labeled nuclei). For length measurements, cilia were 
identified as above and their length measured in the ARL13B channel. For ciliary intensity 
measurements, unsaturated 8-bit images were used. Total signal in the region of interest (ciliary tip 
region for GLI2-3 or whole cilium for IFT88 and SMO) was obtained for the relevant channel as the 
product of average pixel intensity and pixel number in the region. Background signal was likewise 
measured near each region of interest and subtracted from total signal to obtain the specific signal. For 
in vivo studies, 30 µm-thick coronal brain sections of 3-month-old mice were obtained and processed as 
previously described32. Five hippocampal sections were imaged for each mouse using a Leica TCS SP5 
confocal microscope. For quantitation, Fiji was used to count cilia, identified as rod-shaped ARL13B+ 
structures, and GFAP+ astrocytes. Since ARL13B+ cilia were only seen in close association with 
astrocytes, which is consistent with reports indicating that ARL13B is an astrocytic ciliary marker in 
adult brain37,38, we plotted data as percentage of  GFAP+ astrocytes carrying ARL13B+ cilia. 
Bioinformatics 
Putative ARE sequence identification was performed as previously described22. Briefly, we first 
identified putative AREs in the promoter regions of our genes of interest using the Encyclopedia of 
DNA Elements at UCSC (ENCODE) of the human genome (Feb. 2009), based on the ChIP data 
available for ARE-binding transcription factors BACH1 and MAFK. Subsequently, using a Python-
based script, these putative AREs were compared with the position-specific scoring matrix (PSSM) 
derived from the frequency matrix of the consensus ARE sequence recognized by NRF2, obtained from 
JASPAR database. We considered only putative AREs with a relative score higher than 80% 22. 
Statistical analysis 
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GraphPad Prism 7 software was used to graph and statistically analyze data. The specific details of each 
experiment are provided in the corresponding figure legends. 
Data availability 
The datasets generated during the current study are available from the corresponding author on 
reasonable request. 
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Figure 1. Primary cilia downregulate NRF2 activity via mTOR. (a) Representative immunofluorescence images of ARL13B, 
acetylated α-Tubulin (AcTub) and γ-Tubulin (γTub) in control (Kif3a+/+, WT), Kif3a-/- and Ift88-/- MEFs starved 24h to induce 
ciliogenesis. Nuclei were counterstained with DAPI. Scale bar, 5µm. (b) Expression of NRF2 target genes Hmox1 and Gclc was 
analyzed by RT-qPCR in Kif3a+/+ and Kif3a-/- MEFs starved for 24h and then treated for 6h in starvation medium with vehicle 
(DMSO) or 20mM dimethyl fumarate (DMF), as indicated. Data are β-Actin (Actb)-normalized relative mRNA levels (mean ± SEM, 
n=4 independent experiments). (c) Same as in b using Ift88+/+ and Ift88-/- MEFs (mean ± SEM, n=3 independent experiments). 
(d) Kif3a MEFs treated as in b were analyzed by Western blot with antibodies against NRF2 and α-Tubulin, as loading control. 
Molecular weight markers in kilodaltons are on the right. Quantitation of NRF2/Tubulin band intensity ratio is shown below. The 
compared bands were both in the same gel and blot. See methods for details. Uncropped blots are shown in Supplementary 
Fig.S11. (e-f) Hmox1 and Gclc were analyzed as in b in Kif3a MEFs treated with DMF (20mM), Torin-1  (250nM) or Rapamycin 
(200nM), as indicated. Data shown as in b (mean ± SEM, n=6 independent experiments). (g) Kif3a MEFs were serum-starved for 
24h and then incubated for 4h in Earle’s balanced salt solution (EBSS)  with or without 10µM Chloroquine and analyzed by 
Western blot with anti-LC3 antibodies. Each sample’s LC3-II/LC3-I ratio is shown below, together with relative autophagy flux 
(LC3 ratio increase by Chloroquine, normalized to control). (h) Kif3a MEFs treated as in e-f were analyzed by Western blot and 
quantitated as in d. ------Statistical analysis in b-c and e-f: two-way ANOVA followed by Tukey’s multiple comparisons test. Aste-
risks indicate p<0.05 (*), p<0.01 (**) or p<0.001 (***). 
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Figure 2. Ciliogenesis is reduced in NRF2-null cells. (a) Representative immunofluorescence images for ARL13B, 
acetylated α-tubulin (AcTub) and γ-tubulin (γTub) in Nfe2l2+/+ and Nfe2l2-/- littermate MEFs starved 24h to induce 
ciliogenesis. Nuclei were counterstained with DAPI. Scale bar, 10µm. (b) Quantitation of percentage of ciliated cells in 
a (mean ± SEM of n=3 independent experiments). (c) Quantitation of cilia length in a (mean ± SEM of n=81-85 cilia 
measured per condition). (d) Representative immunofluorescence images for ARL13B, γ-tubulin and astrocyte marker 
GFAP in hippocampus of 3-month old Nfe2l2+/+ and Nfe2l2-/- mice. Nuclei were counterstained with DAPI. Boxed 
region in left is magnified on the right. Arrowheads point to cilia. Scale bars, 25µm (left) and 10µm (right).(d) Quantita-
tion of percentage of ciliated cells from c (mean ± SEM, n=3 mice). Asterisks in b, c and e: statistical significance in 
unpaired two-tailed t-tests with p<0.01(**), p<0.001 (***) or p<0.0001 (****).
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Figure 3. Hh signaling is reduced in NRF2-null cells. (a) Nfe2l2 +/+ and Nfe2l2 –/– MEFs were starved 24h in 
presence of DMSO or SAG (200nM) and expression of Hh target genes Gli1 (top) and Ptch1 (bottom) was analyzed 
by RT-qPCR. Data shown as β-actin (Actb)-normalized relative mRNA levels (mean ± SEM, n=8-9). Statistical analy-
sis: two-way ANOVA followed by Tukey’s multiple comparisons tests. Asterisks: p<0.05 (*) or p<0.0001 (****). (b) 
Nfe2l2 MEFs treated as in a were analyzed by Western blot with antibodies for GLI1, NRF2 and Lamin-B as loading 
control. Molecular weight markers in kilodaltons are shown on the right. Asterisk denotes non-specific band. Uncro-
pped blots are shown in Supplementary Fig.S11.
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Figure 4. Hh signaling defects in NRF2-null cells are not rescued by HDAC6, PKA, mTOR or ROS inhibitors. 
Nfe2l2 +/+ and Nfe2l2 –/– MEFs were starved 24h in presence of DMSO (vehicle), SAG (200nM), Tubastatin A 
(10µM), H89 (10µM), Torin-1 (250nM) or NAC (3mM), as indicated, and expression of Hh target genes Gli1 and Ptch1 
was analyzed by RT-qPCR. Data displayed as β-actin-normalized relative mRNA levels (mean ± SEM of n=5 indepen-
dent experiments). Statistical analysis: one-way ANOVA followed by Tukey’s multiple comparisons tests. Significance: 
p<0.05 (*), p<0.0001 (****) or not significant (n.s.).
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Figure 5. Ciliogenic and Hh pathway gene expression is reduced in NRF2-null cells. (a) Nfe2l2 +/+ and Nfe2l2 
–/–  MEFs were starved 24h in presence of DMSO or SAG (200nM) and expression of the indicated ciliogenic genes 
was analyzed by RT-qPCR. (b) Expression of the indicated Hh pathway genes was analyzed as in a. All data in a-b 
shown as β-actin-normalized relative mRNA levels (mean ± SEM of n=3-5 independent experiments). Statistical 
analysis: two-way ANOVA. Significance between genotypes: p<0.01 (**) or p<0.0001 (****). SAG treatment did not 
cause significant differences. (c) Putative ARE sequences were identified for the human ciliogenic and Hh pathway 
genes indicated on the left. Table shows genomic location and sequences of these putative AREs, as well as maxi-
mum and relative scores (see methods for details). Only sequences with relative score above 0.8 were considered as 
hits. No such hits were found for for DYNC2H1, SMO, SUFU or GLI1.
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IFT140 chr16:1609650-1609639 18.2 0.978 GTGACACAGCA 
IFT88 chr13:21140720-21140731 15.68 0.918 GTGACTAAGCG 
 chr13:21190459-21190470 12.17 0.833 GTGACTCATCC 
IFT74 chr9:26976638-26976627 11.53 0.818 ATGCCACAGCC 
GLI2 chr2:121697382-121697371 18.97 0.997 GTGACTCAGCA 
 chr2:121621394-121621383 15.97 0.925 GTGACTCAGCT 
 chr2:121672424-121672435 15.8 0.921 GTGAGTCAGCA 
GLI3 chr7-42250128-42250139 18.97 0.997 GTGACTCAGCA 
 chr7:42107843-42107832 12.51 0.842 CTGACTTAGCT 
GPR161 chr1:168054318-168054307 18.33 0.981 ATGACACAGCA 
PTCH1 chr9:98224655-98224644 17.97 0.973 ATGACTTAGCA 
 chr9:98271654-98271665 15.79 0.920 ATTACTCAGCA 
 chr9:98215348-98215337 13.47 0.865 GTGACTCTGCT 
 chr9:98214704-98214693 13.37 0.862 ATGACAGGGCA 
 chr9:98225033-98225044 13.07 0.855 ATGACAAACCA 
IFT27 chr22:37170122-37170133 15.92 0.923 ATGACACAGCC 
 
Figure 6. GLI2 and GLI3 ciliary tip accumulation and protein levels are reduced in NRF2-null cells. (a-b) Repre-
sentative immunofluorescence images for ARL13B, γ-tubulin and GLI2 (a) or GLI3 (b) in Nfe2l2+/+ and Nfe2l2-/- 
littermate MEFs starved 24h in presence of DMSO (vehicle) or SAG (200nM). Nuclei were counterstained with DAPI. 
Top right of each image shows magnification of boxed area. Scale bars, 10µm. (c-d) Quantification of GLI2 (c) or GLI3 
(d) signal intensity at ciliary tip from a-b. Data are mean ± SEM of at least 40 cilia per condition (A.U.: arbitrary units). 
Statistical analysis: two-way ANOVA followed by Tukey’s multiple comparisons tests. Asterisks: p<0.05 (*), p<0.01 (**), 
p<0.001 (***) or p<0.0001 (****). (e-f) Nfe2l2 +/+ and Nfe2l2 –/– MEFs were treated as in a-b and analyzed by Wes-
tern blot with GLI2 (e) and GLI3 (f) antibodies. Most GLI2 and GLI3 are found in their processed forms (arrows), 
whose levels are reduced in mutant MEFs (and by SAG treatment for GLI3, as expected). Lamin B was used as 
loading control. Molecular weight markers in kDa are on the right. 
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